niacinamide and sorafenib
niacinamide has been researched along with sorafenib in 4071 studies
Research
Studies (4,071)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 671 (16.48) | 29.6817 |
2010's | 3328 (81.75) | 24.3611 |
2020's | 72 (1.77) | 2.80 |
Authors
Authors | Studies |
---|---|
Hirte, HW; Hotte, SJ | 1 |
Chien, DS; Wilhelm, S | 1 |
Bauer, RJ; Hedley, D; Hilger, RA; Kredke, S; Moeller, JG; Scheulen, ME; Seeber, S; Stellberg, W; Strumberg, D | 1 |
Beling, C; Hilger, RA; Kredtke, S; Moeller, JG; Richly, H; Scheulen, ME; Seeber, S; Strumberg, D; Voliotis, D | 1 |
Beeram, M; Patnaik, A | 1 |
Lee, JT; McCubrey, JA | 1 |
Bauer, S; Díaz-Carballo, D; Hilger, RA; Kredtke, S; Scheulen, ME; Seeber, S; Strumberg, D | 1 |
Heim, M; Hilger, RA; Scheulen, ME; Seeber, S; Sharifi, M; Strumberg, D | 1 |
Baas, F; Brendel, E; Buss, P; Mersmann, S; Mross, K; Reil, M; Schwartz, B; Steinbild, S; Voliotis, D | 1 |
Grubert, M; Hilger, RA; Kredtke, S; Kupsch, P; Passage, K; Richly, H; Scheulen, ME; Seeber, S; Strumberg, D; Voliotis, D | 1 |
Bollag, G; Freeman, S; Lyons, JF; Post, LE | 1 |
Götz, R; Kramer, BW; Rapp, UR | 1 |
Chiloeches, A; Friedlos, F; Hayward, R; Hedley, D; Karasarides, M; Marais, R; Marshall, CJ; Martin, J; Niculescu-Duvaz, D; Ogilvie, L; Scanlon, I; Springer, CJ | 1 |
Afify, S; Högger, P; Rapp, UR | 1 |
Ahmad, T; Eisen, T | 1 |
Adnane, L; Auclair, D; Bollag, G; Cao, Y; Carter, C; Chen, C; Eveleigh, D; Gawlak, S; Gedrich, R; Liu, L; Lynch, M; McHugh, M; McNabola, A; Post, LE; Riedl, B; Rong, H; Rowley, B; Shujath, J; Tang, L; Taylor, I; Trail, PA; Vincent, P; Voznesensky, A; Wilhelm, SM; Wilkie, D; Zhang, X | 1 |
Fagin, JA | 1 |
Hilger, RA; Kredtke, S; Scheulen, ME; Seeber, S; Strumberg, D | 1 |
Brendel, E; Christensen, O; Grubert, M; Haase, CG; Hilger, RA; Kupsch, P; Passage, K; Richly, H; Schwartz, B; Strumberg, D; Voigtmann, R | 1 |
Awada, A; Brendel, E; Faghih, M; Haase, CG; Hilger, RA; Korfee, S; Richly, H; Scheulen, ME; Schleucher, N; Schwartz, B; Seeber, S; Strumberg, D; Tewes, M; Voigtmann, R; Voliotis, D | 1 |
Heim, M; Jaehde, U; Scharifi, M; Seeber, S; Strumberg, D; Voliotis, D; Zisowsky, J | 1 |
Seeber, S; Strumberg, D | 1 |
Desai, AA; Stadler, WM | 1 |
Robertson, GP; Sharma, A; Smith, CD; Trivedi, NR; Tuveson, DA; Zimmerman, MA | 1 |
Hedley, D; Siu, LL; Sridhar, SS | 1 |
Awada, A; Bartholomeus, S; Brendel, E; de Valeriola, D; Gil, T; Haase, CG; Hendlisz, A; Mano, M; Piccart, M; Schwartz, B; Strumberg, D | 1 |
Herbst, RS; Onn, A; Sandler, A | 1 |
Marx, J | 1 |
Gravell, A; Wright, JJ; Zerivitz, K | 2 |
Branca, MA | 1 |
Lyons, J; Thompson, N | 1 |
Armand, JP; Boige, V; Escudier, B; Le Cesne, A; Le Chevalier, T; Lhomme, C; Malka, D; Pautier, P; Robert, C; Soria, JC; Spatz, A; Wechsler, J | 1 |
Cihon, F; Hirte, HW; Hotte, SJ; Lathia, C; Moore, M; Oza, A; Petrenciuc, O; Schwartz, B; Siu, L | 1 |
Adjei, AA; Bruzek, LM; Carter, CA; Gores, GJ; Kaufmann, SH; Meng, XW; Yu, C | 1 |
Motzer, RJ; Rini, BI; Sosman, JA | 1 |
Clark, JW; Eder, JP; Lathia, C; Lenz, HJ; Ryan, D | 1 |
Armand, JP; Escudier, B; Faivre, S; Raymond, E; Robert, C | 1 |
Cooney, MM; Remick, SC; Vogelzang, NJ | 2 |
Bauer, C; Davis, EM; Dent, P; Grant, S; Rahmani, M | 1 |
Cihon, F; Gallentine, M; Lathia, C; Lettieri, J; Radtke, M; Sundaresan, P | 1 |
Schiller, JH; Wakelee, HA | 1 |
Beeram, M; Patnaik, A; Rowinsky, EK | 2 |
Baek, WS; Pytel, P; Rubeiz, H; Undevia, SD | 1 |
Brendel, E; Christensen, O; Henning, BF; Hilger, RA; Hofstra, E; Kupsch, P; Passarge, K; Richly, H; Scheulen, ME; Schwartz, B; Seeber, S; Strumberg, D; Voigtmann, R; Wiesemann, K | 1 |
Soff, G; Zakarija, A | 1 |
Awada, A; Giannaris, T; Lathia, C; Moore, MJ; Petrenciuc, O; Piccart, M; Schwartz, B; Siu, LL; Takimoto, CH | 1 |
Bürckstümmer, T; Hildt, E; Kriegs, M; Lupberger, J; Pauli, EK; Schmittel, S | 1 |
Gollob, JA | 1 |
Awada, A; Brueckner, A; Christensen, O; Clark, JW; Hirte, H; Hofstra, E; Piccart, P; Schwartz, B; Seeber, S; Strumberg, D; Voliotis, D | 1 |
Flaherty, KT; Gallagher, M; Mosenkis, A; O'Dwyer, PJ; Stevenson, JP; Townsend, RR; Veronese, ML | 1 |
Atkins, MB; Mier, JW; Panka, DJ; Wang, W | 1 |
Chaganti, RS; Motzer, RJ; Patel, PH | 1 |
Strumberg, D | 3 |
Kanetake, H; Koga, S | 1 |
Chow, S; Hedley, D; Tong, FK | 1 |
Brendel, E; Christensen, O; Flashar, C; Grubert, M; Henning, BF; Hilger, RA; Kupsch, P; Ludwig, M; Passarge, K; Richly, H; Scheulen, ME; Schwartz, B; Seeber, S; Strumberg, D; Voigtmann, R | 1 |
Rini, BI | 7 |
Anaganti, S; Carlomagno, F; Guida, T; Salvatore, G; Santoro, M; Troncone, G; Wilhelm, SM | 1 |
Frantz, S | 1 |
Carlomagno, F; De Falco, V; Melillo, RM; Nappi, TC; Pepe, S; Salerno, P; Salvatore, G; Santoro, M; Troncone, G; Wilhelm, SM | 1 |
Von Hoff, DD | 1 |
Ardizzoni, A; Franciosi, V; Tiseo, M | 1 |
Abbruzzese, JL; Desai, AA; Eisen, T; Flaherty, KT; Gore, M; Kaye, SB; O'Dwyer, PJ; Patnaik, A; Ratain, MJ; Rosner, GL; Rowinsky, E; Schwartz, B; Simantov, R; Stadler, WM; Xia, C; Xiong, HQ | 1 |
Boogaerts, M; Cools, J; Folens, C; Lierman, E; Marynen, P; Mentens, N; Scheers, W; Stover, EH; Van Miegroet, H; Vandenberghe, P | 1 |
Colombi, M; Kiser, KF; Moroni, C | 1 |
Brink, C; Carter, CA; Chen, C; Gilbert, KS; Maxuitenko, YY; Vincent, P; Waud, WR; Zhang, X | 1 |
Bukowski, RM; Reddy, GK | 1 |
Adnane, L; Taylor, I; Trail, PA; Wilhelm, SM | 1 |
Budillon, A; Caraglia, M; Marra, M; Tagliaferri, P; Tassone, P; Venuta, S | 1 |
Escudier, B; Gore, ME | 1 |
Bukowski, RM | 3 |
Baker, SD; Hafner, FT; He, P; Hidalgo, M; Messersmith, WA; Radtke, M; Rudek, MA; Smith, BD; Wright, JJ; Zhao, M | 1 |
Desai, A; Lacouture, ME; Laumann, AE; Petronic-Rosic, V; Ratain, MJ; Soltani, K; Stadler, WM | 1 |
Hampton, T | 2 |
Eto, M; Naito, S | 1 |
Bukowski, RM; Rini, BI; Shaheen, PE | 1 |
McCormick, F; Oda, K; Okada, J; Rauen, K; Rodriguez-Viciana, P; Tetsu, O | 1 |
Ahmad, T; Eisen, T; Flaherty, KT; Gibbens, I; Gore, M; Hackett, S; James, M; Kaye, S; Marais, R; Nathanson, KL; O'Dwyer, PJ; Poulin-Costello, M; Ratain, MJ; Schuchter, LM; Schwartz, B; Simantov, R; Xia, C | 1 |
Carter, C; Gollob, JA; Kelley, SL; Wilhelm, S | 1 |
Rapp, UR; Schreck, R | 1 |
Mancuso, A; Sternberg, CN | 1 |
Abou-Alfa, GK; Amadori, D; De Greve, J; Douillard, JY; Figer, A; Lathia, C; Moscovici, M; Ricci, S; Saltz, LB; Santoro, A; Schwartz, B; Schwartz, L; Taylor, I | 1 |
Biedrzycki, BA | 1 |
King, CR | 1 |
Jane, EP; Pollack, IF; Premkumar, DR | 1 |
Chami, L; Escudier, B; Lamuraglia, M; Lassau, N; Leclère, J; Roche, A; Schwartz, B | 1 |
Figg, WD; Jain, L; Venitz, J | 1 |
Stadler, W | 1 |
Curtiss, FR | 1 |
Adjei, AA; Carter, CA; Friday, BB; Kaufmann, SH; Kay, NE; Lai, JP; Roberts, LR; Sarkaria, J; Yang, L; Yu, C | 1 |
Hahn, O; Stadler, W | 1 |
Adusumilli, J; Baxter, DL; El-Khoueiry, A; Govindarajan, R; Harik, SI | 1 |
Berry, WR; Galsky, MD; Hutson, TE; Sonpavde, G | 1 |
Carter, C; Dumas, J; Kelley, S; Lowinger, T; Lynch, M; Schwartz, B; Simantov, R; Smith, RA; Wilhelm, S | 1 |
Haseke, N; Heinemann, G; Schöppler, G; Stadler, T; Staehler, M; Stief, CG | 1 |
Burton, A | 1 |
Carter, C; Feldman, MD; Lassoued, W; Lee, WM; Makonnen, S; Murphy, DA | 1 |
Gascón, P; Mellado, B | 1 |
Baas, F; Brendel, E; Christensen, O; Gmehling, D; Mross, K; Radtke, M; Steinbild, S; Unger, C; Voliotis, D | 1 |
Blanke, C | 1 |
Arslan, MA; Basaga, H; Kutuk, O | 1 |
Chung, NM; Gutierrez, M; Turner, ML | 1 |
Wetherbee, SL | 1 |
Bukowski, RM; Motzer, RJ | 1 |
Adnane, J; Bortolon, E; Carter, CA; Chang, YS; Chen, C; Henderson, A; Ichetovkin, M; Levy, J; Lynch, M; McNabola, A; Taylor, IC; Trail, PA; Wilhelm, S; Wilkie, D; Xue, D | 1 |
Fesik, SW; Huang, X; Li, L; Lin, X; Morgan-Lappe, S; Shen, Y; Vernetti, LA; Zakula, DM | 1 |
Cao, Y; Carter, C; Chen, C; Liu, L; Lynch, M; McNabola, A; Wilhelm, S; Wilkie, D; Zhang, X | 1 |
Culine, S; Pouessel, D | 3 |
Chadalavada, RS; Chaganti, RS; Motzer, RJ; Patel, PH | 1 |
Booth, B; Chidambaram, N; Farrell, AT; Garvey, P; Jee, JM; Justice, R; Kane, RC; Liang, C; Morse, D; Pazdur, R; Saber, H; Sridhara, R; Tang, S; Williams, G | 1 |
Azad, NS; Cowen, EW; Dahut, W; Gutierrez, M; Kong, HH; Turner, ML | 1 |
Abriola, L; Auclair, D; Burd, A; Carter, C; Chang, Y; Dumas, J; Gedrich, R; Lynch, M; Miller, D; Pickett, W; Rocks, S; Shi, H; Trail, PA; Vasavada, H; Wilhelm, SM; Wilkie, D; Yatsula, V; Zhang, X | 1 |
Bukowski, RM; Chevreau, C; Demkow, T; Desai, AA; Eisen, T; Escudier, B; Freeman, S; Gore, M; Hutson, TE; Negrier, S; Oudard, S; Rolland, F; Schwartz, B; Shan, M; Siebels, M; Simantov, R; Solska, E; Stadler, WM; Szczylik, C | 1 |
Brugarolas, J | 1 |
Cools, J; Lahortiga, I; Lierman, E; Marynen, P; Mentens, N; Van Miegroet, H | 1 |
Kuzel, T; Lacouture, ME; Lai, SE | 1 |
Dreicer, R | 1 |
Creel, P; George, D; Speca, J; Yenser, S | 1 |
Herbst, RS | 1 |
Grossman, ME; MacGregor, JL; Sherman, WH; Silvers, DN | 1 |
Flaherty, KT | 3 |
Baradari, V; Höpfner, M; Huether, A; Scherübl, H; Schuppan, D | 2 |
Hussar, DA | 1 |
Clemetson, KJ | 1 |
Miller, K | 1 |
Colantuoni, G; Comunale, D; De Vita, A; Del Gaizo, F; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
Schneider, BP; Sledge, GW | 1 |
McKeage, K; Wagstaff, AJ | 1 |
Figlin, RA | 1 |
Arnold, R; Bartsch, DK; Fendrich, V; Hörsch, D; Karhoff, D; Sauer, S; Schrader, J | 1 |
Angevin, E; Armand, JP; Brendel, E; Chami, L; Escudier, B; Lamuraglia, M; Landreau, V; Lassau, N; Robert, C; Schwartz, B; Soria, JC; Zafarana, E | 1 |
Michaelson, MD | 1 |
Miroglu, C; Silay, MS | 1 |
Hauschild, A | 1 |
Busch, S; Garbe, C; Herlyn, M; Kulms, D; Lasithiotakis, K; Maczey, E; Meier, F; Schittek, B | 1 |
Alexandrescu, DT; Dasanu, CA; Dutcher, J | 1 |
Acs, G; Brafford, P; Chen, L; Edwards, R; Herlyn, M; Kazianis, S; Kumar, SM; Xu, X; Yu, H | 1 |
Dudek, AZ; Mulamalla, K; Truskinovsky, AM | 1 |
Hanna, N | 1 |
Amar, S; Tan, WW; Wu, KJ | 1 |
Autran Gomez, AM; Di Silverio, F; Gentile, V; Gentilucci, A; Parente, U; Salciccia, S; Sciarra, A | 1 |
Kruck, S; Kuczyk, M; Merseburger, AS | 1 |
Linehan, WM; Novakovic, KR; Pinto, PA; Vira, MA | 1 |
Ardizzoni, A; Tiseo, M | 1 |
Force, T; Krause, DS; Van Etten, RA | 1 |
Angele, MK; Bruns, CJ; Eichhorn, ME; Jauch, KW; Kleespies, A | 1 |
De Mulder, PH; Mulder, SF; van Spronsen, DJ | 1 |
Brocheriou, I; Deray, G; Izzedine, H; Rixe, O | 1 |
Awada, A; Clark, JW; Eder, JP; Hendlisz, A; Hirte, HW; Lenz, HJ; Moore, MJ; Richly, H; Schwartz, B; Strumberg, D | 1 |
Senan, S; Smit, EF | 1 |
Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C | 1 |
Kamba, T; McDonald, DM | 1 |
Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P | 1 |
Anaganti, S; Carlomagno, F; Gedrich, R; Guida, T; Provitera, L; Santoro, M; Sullivan, E; Wilhelm, SM | 1 |
Crabtree, TR; Davis, EM; Dent, P; Grant, S; Habibi, JR; Nguyen, TK; Rahmani, M | 1 |
Bukowski, R; Cella, D; Escudier, B; Gondek, K | 1 |
Ernstoff, MS; George, DJ; Kasibhatla, M; Meyer, J; Steinberg, P | 1 |
Bareschino, M; Ciardiello, F; Gridelli, C; Maione, P; Mongillo, F; Rossi, A | 1 |
Escudier, B | 3 |
Di Lorenzo, G | 1 |
Calzada, G; El-Naggar, AK; Jasser, SA; Kim, S; Myers, JN; Wang, ZY; Yazici, YD; Younes, MN | 1 |
Baz, RC; Bukowski, RM; Choueiri, TK; Elson, P; Garcia, JA; Golshayan, AR; Khasawneh, M; Rini, BI; Usman, S; Wood, L | 1 |
Bracarda, S; Caserta, C; Crinò, L; Hamzay, A; Rossi, M; Sordini, L | 1 |
Hobday, TJ; McWilliams, RR; Morris, JC; Robinson, SI; Sathananthan, A | 1 |
Dent, P; Grant, S; Nguyen, TK; Rahmani, M | 1 |
Flaherty, KT; Stein, MN | 1 |
Atkins, MB | 1 |
Chiao, PJ; Dicker, DT; El-Deiry, WS; Flaherty, KT; Jin, Z; Kim, SH; Ling, J; Liu, YY; Ogi, K; Plastaras, JP; Ricci, MS; Smith, CD; Wang, W | 1 |
Rini, BI; Unnithan, J | 1 |
Batt, D; Li, N; Warmuth, M | 1 |
Dai, Y; Dasmahapatra, G; Dent, P; Grant, S; Yerram, N | 1 |
Cabebe, E; Wakelee, H | 1 |
Blansfield, JA; Kachala, S; Libutti, SK; Lorang, D; Mangiameli, DP; Muller, GW; Schafer, PH; Stirling, DI | 1 |
Atkins, MB; Goldberg, SN; Hakimé, A; Hines-Peralta, A; Peddi, H; Regan, M; Signoretti, S; Sukhatme, VP | 1 |
Albers, P; Bergmann, L; Geschwend, JE; Jäger, E; Jakse, G; Marschner, N; Miller, K | 1 |
Goldspiel, BR; Grandinetti, CA | 1 |
Bodrogi, I | 1 |
Barford, D; Gambacorti-Passerini, C; Hofstra, RM; Isacke, CM; Links, TP; Magee, AI; Mologni, L; Plaza-Menacho, I; Sala, E | 1 |
Gollob, JA; Grigson, G; Gu, L; Marino, CB; Miller, EK; Peterson, BL; Rathmell, WK; Richmond, TM; Watkins, C; Wright, JJ | 1 |
Beer, TM; Crawford, ED; Drabkin, HA; Goldman, BH; Lara, PN; Lemmon, D; Mack, PC; Pan, CX; Ryan, CW; Tangen, CM | 1 |
Kibble, A; Shumoogam, J | 1 |
Buer, J; Hegele, A; Hofmann, R; Jeron, A; Olbert, P; Schrader, AJ | 1 |
Adjei, AA; Dai, H; Dai, NT; Flatten, K; Karp, JE; Kaufmann, SH; Kumar, SK; Lee, SH; Loegering, D; Meng, XW; Schneider, P; Smith, BD; Yu, C | 1 |
Chen, EX; Dancey, J; Duan, L; Duran, I; Hirte, H; Hotté, SJ; Lathia, C; MacLean, M; Pond, GR; Siu, LL; Turner, S; Walsh, S; Wright, JJ | 1 |
Agaram, NP; Antonescu, CR; Besmer, P; Clarkson, BD; D'Adamo, D; DeMatteo, RP; Guo, T; Hom, G; Maki, RG; Schwartz, GK; Singer, S; Veach, D; Wong, GC | 1 |
Agulnik, M; Cheiken, R; Chen, EX; Chin, SF; Elser, C; Elting, J; Francis, P; McNabola, A; Petrenciuc, O; Pond, GR; Siu, LL; Wilkie, D; Winquist, E | 1 |
Raspollini, MR | 1 |
Blum, HE; Mohr, L; Spangenberg, HC; Thimme, R | 1 |
George, D; Medioni, J; Motzer, R; Oudard, S | 1 |
Armand, JP; Mir, O; Ropert, S | 1 |
Billemont, B; Izzedine, H; Méric, JB; Rixe, O; Sultan-Amar, V; Taillade, L | 1 |
Robert, C | 1 |
Distelrath, A; Hoeffkes, HG; Hofmann, E; Ranze, O | 1 |
Duyster, J; Grundler, R; Kancha, RK; Peschel, C | 1 |
Fiedler, W; Grünwald, V; Heinzer, H | 1 |
Hutson, TE | 2 |
Karrison, TG; Maitland, ML; Ratain, MJ; Stadler, WM | 1 |
Tan, W | 1 |
Li, M; Srinivas, S | 1 |
Kampik, A; Kernt, M; Neubauer, AS; Staehler, M; Stief, C | 1 |
Cerniglia, G; Dicker, DT; Diehl, JA; Dorsey, JF; El-Deiry, WS; Flaherty, KT; Gupta, A; Kim, SH; Liu, YY; McDonough, J; Plastaras, JP; Rajendran, RR; Rustgi, AK; Smith, CD | 1 |
Almenara, JA; Coe, S; Grant, S; Rosato, RR | 1 |
Almhanna, K; Kalmadi, S; Kim, R; Pelley, R | 1 |
Alba, E; Medina, MA; Quesada, AR | 1 |
Bjelogrlic, SK; Radulovic, S | 1 |
Akaza, H; Murai, M; Naito, S; Nakajima, K; Tsukamoto, T | 1 |
Furuse, J; Ishii, H; Nakachi, K; Nakajima, K; Shimizu, S; Suzuki, E | 1 |
Manchen, B; Wood, LS | 1 |
Bukowski, R; Dreicer, R; Elson, P; Garcia, J; Ioachimescu, AG; Mekhail, T; Rini, BI; Tamaskar, I; Wood, L | 1 |
Beldner, M; Burges, GE; Chaudhary, UB; Dewaay, D; Jacobson, M; Maize, JC | 1 |
Thomas, X | 1 |
Albanell, J; Bellmunt, J; Climent, MA; González-Larriba, JL; López-Vivanco, G; Urruticoechea, L | 1 |
Easson, AM; Eng, FC; Knox, JJ; Szentgyorgyi, E | 1 |
Faivre, S; Le Tourneau, C; Raymond, E | 1 |
Atkins, MB; Cho, DC; Mier, JW; Panka, DJ | 1 |
Brozmanova, K; Mardiak, J; Mego, M; Obertova, J; Reckova, M; Sycova-Mila, Z | 1 |
Bukowski, RM; Dreicer, R; Elson, P; Garcia, JA; Mekhail, T; Rini, BI; Tamaskar, I; Wood, L | 1 |
Awada, A; Takimoto, CH | 1 |
Culine, S; Patard, JJ; Pouessel, D; Verhoest, G | 1 |
Burkholder, I; Dittrich, C; Edler, L; Frost, A; Gillessen, S; Hanauske, AR; Hochhaus, A; Morant, R; Mross, K; Scheulen, M; Steinbild, S; Strumberg, D | 1 |
Zhu, AX | 5 |
Bhojani, N; Hutterer, G; Jeldres, C; Karakiewicz, PI; Oudard, S; Patard, JJ; Patenaude, F; Perrotte, P; Suardi, N | 1 |
Chi, KN; Czaykowski, P; Ellard, SL; Gauthier, I; Hansen, C; Hotte, SJ; Moore, M; Ruether, JD; Schell, AJ; Seymour, L; Taylor, S; Walsh, W | 1 |
Chang, JW; Chang, YC; Chuang, CK; Hsieh, JJ; Kuo, TT; Lin, WC; Lin, YC; Pang, ST; Yang, CH | 1 |
Imarisio, I; Paglino, C; Porta, C | 2 |
O'Neil, BH; Venook, AP | 1 |
Bukowski, RM; Choueiri, TK; Elson, P; Escudier, B; Negrier, S; Oudard, S; Plantade, A; Ravaud, A; Rini, BI; Zhou, M | 1 |
Aragon-Ching, JB; Arlen, PM; Cao, L; Chen, CC; Dahut, WL; Figg, WD; Gulley, JL; Jain, L; Jones, E; Posadas, E; Scripture, C; Steinberg, SM; Venitz, J; Wright, JJ; Yu, Y | 1 |
Bonomi, L; Imarisio, I; Paglino, C; Porta, C | 1 |
Hiles, JJ; Kolesar, JM | 1 |
Keating, GM; Simpson, D | 1 |
Andreeff, M; Bornmann, WG; Cortes, J; Evans, RL; Konopleva, M; McCubrey, J; McQueen, T; Ruvolo, VR; Zhang, W | 1 |
Claflin, JE; Crean, S; Lahn, M; Linz, H; Noel, JK; Ranganathan, G | 1 |
Chu, D; Fillos, T; Lacouture, ME; Wu, S | 1 |
Flaherty, KT; Gallagher, ML; Heitjan, DF; O'Dwyer, PJ; Rosen, MA; Schnall, MD; Schwartz, B | 1 |
Chen, JJ; Kudelka, A; Lu, J; Wu, S; Zhu, X | 1 |
Bui, B; Italiano, A | 1 |
Di Fiore, F; Michel, P | 1 |
Tuma, RS | 2 |
Andreeff, M; Cortes, J; Estrov, Z; Harris, D; Konopleva, M; Ling, X; McQueen, T; Quintás-Cardama, A; Shi, YX; Small, D; Zhang, W | 1 |
Collett, LC; Diago, T; Link, TP; Molina, JR; Pulido, JS; Ryan, EH | 1 |
Lang, L | 1 |
Cohen, AF; Dubois, EA; Osanto, S; van Bronswijk, H | 1 |
Miki, T; Mizuno, M; Mizutani, Y; Nakanishi, H; Yoshida, J | 1 |
Demetri, GD; George, S; Humphreys, BD; Maki, RG; Morgan, JA; Patel, TV; Quigley, M | 1 |
Ehninger, G; Illmer, T | 1 |
Giordano, S; Petrelli, A | 1 |
Annunziata, CM; Azad, NS; Chow, C; Kohn, EC; Kotz, HL; Minasian, L; Premkumar, A; Steinberg, SM | 1 |
Desai, AA; Garcia, JG; Gomberg-Maitland, M; Husain, AN; Lang, RM; Liu, Y; Lussier, YA; Maitland, ML; Moreno-Vinasco, L; Ratain, MJ; Sam, L; Sammani, S; Singleton, PA | 1 |
Bruix, J; Llovet, JM | 4 |
Dahut, W; Figg, WD; Gardner, ER; Jain, L; Venitz, J | 1 |
Brauer, KM; Brossart, P; Hilf, N; Hipp, MM; Radsak, MP; Singh-Jasuja, H; Walter, S; Weinschenk, T; Werth, D | 1 |
Angelotti, U; Antonaci, S; Fransvea, E; Giannelli, G | 1 |
Allison, RR; Cavalieri, R; Finley, J; Gay, HA; Quan, WD | 1 |
Flaherty, KT; Garbe, C; Kulms, D; Lasithiotakis, KG; Maczey, E; Meier, FE; Schittek, B; Sinnberg, TW | 1 |
Stewart, DJ | 1 |
Chow, S; Goolsby, C; Hedley, DW; Shankey, TV | 1 |
Hersey, P; Hong, A; Moncrieff, M; Shannon, K; Thompson, J | 1 |
Gu, YH; Qu, BQ; Song, R; Xu, Q; Zhao, W | 1 |
Barbare, JC; Boige, V; Rosmorduc, O | 1 |
Autier, J; Mateus, C; Robert, C; Spatz, A; Wechsler, J | 1 |
Chevreau, C; Delord, JP; Deslandres, M; Sibaud, V | 1 |
Burgin, S; Heidary, N; Naik, H | 1 |
Bellersen, L | 1 |
Fenning, R; Gudena, V; Kizziah, M; Montero, AJ; Post, G; Verma, N | 1 |
Burris, H; Rocha-Lima, C | 1 |
de Mulder, PH; Gietema, JA; Groenewegen, G; Haanen, JB; Jansen, RL; Kruit, WH; Mulders, PF; Osanto, S; Richel, DJ; Sleijfer, S; van den Eertwegh, AJ; Voest, EE | 1 |
El-Deiry, WS; Kim, SH; Ricci, MS | 1 |
Berthold, DR; Chin, S; Knox, JJ; Moore, MJ; Riechelmann, RP; Tannock, IF; Wang, L | 1 |
Godley, P; Rathmell, WK; Rini, BI | 1 |
Athar, U; Gentile, TC | 1 |
Avakian, R; Belldegrun, AS; Kabbinavar, FF; LaRochelle, JC; Pantuck, AJ; Patard, JJ; Riggs, SB; Shuch, B | 1 |
Ambrosini, G; Cheema, HS; Sambol, EB; Schwartz, GK; Seelman, S; Singer, S; Teed, A | 1 |
Bajetta, E; Catena, L; Gevorgyan, A; Guadalupi, V; Mancin, M; Martinetti, A; Platania, M; Procopio, G; Pusceddu, S; Verzoni, E | 1 |
Chintala, L; El Naggar, AK; Gagel, R; Hong, D; Kurzrock, R; Wright, J; Ye, L | 1 |
Agarwala, S; Beeram, M; Cranmer, L; Frenette, G; Gonzalez, R; Hersh, E; Hodi, FS; Jakub, JW; Kirkwood, J; Lewis, K; Linette, GP; McDermott, DF; Patel, K; Puzanov, I; Richards, J; Sosman, JA; Tarantolo, S; White, JM; Xia, C | 1 |
Peters, NA; Richel, DJ; Stalpers, LJ; Verhoeff, JJ | 1 |
Lee, CB; Socinski, MA | 1 |
Araki, K; Ebi, H; Kawada, K; Kim, YI; Kitagawa, K; Minami, H; Mukai, H; Nakajima, H; Nakajima, K; Tahara, M | 1 |
Baker, SD; Dahl, GV; Hu, S; Inaba, H; Minkin, P; Niu, H; Orwick, S; Rubnitz, J; Shimada, A | 1 |
Buhl, R; Fischer, B | 1 |
Jonasch, E; Margulis, V; Matin, SF; Swanson, DA; Tamboli, P; Tannir, N; Wood, CG | 1 |
Cui, YZ; Luo, RC; Wu, J; Zhang, H | 1 |
Sherman, SI | 2 |
Gettinger, S | 1 |
Bissonnette, M; Cerda, S; Chumsangsri, A; Delgado, JS; Dougherty, U; Fichera, A; Lichtenstein, L; Mustafi, R; Yee, J | 1 |
Kester, M; Robertson, GP; Smith, CD; Tran, MA | 1 |
Blumenschein, G | 1 |
Adjei, AA | 1 |
Heinemann, V; Stemmler, HJ | 1 |
Brose, MS; Flaherty, KT; Gupta-Abramson, V; Loevner, LA; Mandel, SJ; Nellore, A; O'Dwyer, PJ; Puttaswamy, K; Ransone, K; Redlinger, M; Troxel, AB | 1 |
Gerami, P; Guitart, J; Lacouture, ME; Reilly, LM | 1 |
Chung, CY; Wu, SS; Yen, HH | 1 |
Cohen, PR; Diwan, AH; Evans, HL; Hong, DS; Kurzrock, R; Prieto, VG; Reddy, SB; Tannir, NM; Wright, JJ | 1 |
Chanco Turner, ML; Chevreau, C; Fojo, T; Hornyak, TJ; Kong, HH; Sibaud, V | 1 |
Del Conte, G; Guibal, A; Rüegg, C; Sessa, C | 1 |
Lountzis, NI; Maroon, MS | 1 |
Atkins, MB; Goldberg, SN; Kruskal, JB; Rahmanuddin, S; Raptopoulos, VD; Sabir, A; Schor-Bardach, R; Signoretti, S; Wilcox, CJ | 1 |
Clark, M | 1 |
Bruns, I; Czibere, A; Dienst, A; Fenk, R; Haas, R; Kobbe, G; Reinecke, P; Safaian, NN | 1 |
Brouwers, AH; Hospers, GA; Mulder, NH; Siemerink, EJ | 1 |
Andrea, A; Di Silverio, F; Panebianco, V; Parente, U; Passariello, R; Sciarra, A; Von Heland, M | 1 |
Hakenberg, OW | 1 |
Becker, M; Börgermann, C; Rose, A; Rübben, H; Vom Dorp, F | 1 |
Kuczyk, MA; Merseburger, AS | 1 |
Figlin, R; Moldawer, NP | 1 |
Bierer, S; Bolenz, C; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C | 1 |
Egberts, F; Hauschild, A; Kahler, KC; Livingstone, E | 1 |
Bart, S; Billemont, B; Bitker, MO; Izzedine, H; Rixe, O; Sultan, V; Thibault, F | 1 |
Bouffard, D; Joncas, V; Krasny, M; Provost, N; Sammour, R | 1 |
Gakis, G; Kramer, MW; Kruck, S; Kuczyk, MA; Merseburger, AS; Stenzl, A | 1 |
Bauer, S; Bode, B; Knuth, A; Liewen, H; Renner, C; Samaras, P; Stenner, F; Tchinda, J; Weber, A; Zweifel, M | 1 |
Pár, A; Pár, G | 1 |
Bukowski, RM; Choueiri, TK; Cotta, C; Dreicer, R; Elson, P; Garcia, J; Khasawneh, MK; Mekhail, T; Rini, BI; Unnithan, J; Wood, L | 1 |
Bhalla, IP; Bukowski, RM; Choueiri, TK; Elson, P; Ganapathi, R; Golshayan, AR; Jaeger, E; Rini, BI; Sein, N; Sercia, L; Simko, J; Small, EJ; Vaziri, SA; Waldman, FM; Weinberg, V; Wood, L; Zhou, M | 1 |
Autier, J; Escudier, B; Robert, C; Spatz, A; Wechsler, J | 1 |
Ardavanis, A; Doufexis, D; Kountourakis, P; Rigatos, G | 1 |
Blanc, JF; Bolondi, L; Borbath, I; Bruix, J; de Oliveira, AC; Forner, A; Galle, PR; Gane, E; Giannaris, T; Greten, TF; Häussinger, D; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Porta, C; Raoul, JL; Ricci, S; Santoro, A; Schwartz, M; Seitz, JF; Shan, M; Voliotis, D; Zeuzem, S | 1 |
Roberts, LR | 1 |
Dykens, JA; Hirakawa, B; Hynes, J; Jamieson, J; Jessen, BA; Marroquin, LD; Nadanaciva, S; Patyna, S; Will, Y | 1 |
Chen, EX; Ng, R | 1 |
Cannistra, SA | 1 |
Annunziata, CM; Azad, NS; Cao, L; Chen, HX; Chow, C; Figg, WD; Jain, L; Kohn, EC; Kotz, HL; Kwitkowski, VE; McNally, D; Minasian, L; Posadas, EM; Premkumar, A; Sarosy, G; Steinberg, SM; Wright, JJ | 1 |
Rini, BI; Vakkalanka, BK | 1 |
Albertini, MR; Brose, MS; Elder, D; Flaherty, KT; Hingorani, SR; Jacobetz, MA; Lathia, C; Liu, G; O'Dwyer, PJ; Petrenciuc, O; Redlinger, M; Schiller, J; Schuchter, LM; Tuveson, DA; Van Belle, PA; Weber, BL; Xia, C | 1 |
Ahn, SH; Clayman, GL; Henderson, YC; Kang, Y | 1 |
Chang, CJ; Chen, YJ; Ding, Q; Hsu, JM; Hung, MC; Huo, L; Kuo, HP; Lai, CC; Lee, DF; Li, LY; Liao, Y; Lin, CY; Tsai, CH; Tsai, FJ; Wei, Y; Xia, W; Yang, JY; Yang, Y; Yen, CJ | 1 |
Agulnik, M; Wang, LX | 1 |
Rübben, H | 1 |
Amin, C; Calvo, BF; Godley, PA; Pruthi, RS; Rathmell, WK; Wallen, E | 1 |
Culine, S; Patard, JJ; Pouessel, D | 2 |
Checcaglini, F; Colloca, G; Venturino, A | 1 |
Chun, FK; Eichelberg, C; Heinzer, H; Heuer, R; Hinrichs, K; Huland, H; Zacharias, M | 1 |
Awada, A; D'Hondt, V; Dal Lago, L | 1 |
Fan, J; Huang, XW; Qiu, SJ; Tang, ZY; Wang, Z; Yu, Y; Zhou, J | 1 |
O'Dowd, A | 1 |
Bierer, S; Hertle, L; Nitschmann, S | 1 |
Bensalah, K; Cornu, JN; Oudard, S; Patard, JJ; Rouprêt, M | 1 |
Amaravadi, R; Fecher, LA; Schuchter, LM | 1 |
Alexandrescu, DT; Dasanu, CA; Farzanmehr, H; McClure, R | 1 |
Amoroso, V; Ferrari, V; Grisanti, S; Marini, G; Marpicati, P; Rangoni, G; Simoncini, E; Valcamonico, F; Vassalli, L | 1 |
Bar-Eli, M; Melnikova, VO | 1 |
Bierer, S; Gerss, J; Herrmann, E; Hertle, L; Köpke, T; Wülfing, C | 1 |
Rey, PM; Villavicencio, H | 1 |
Billemont, B; Boudou-Rouquette, P; Goldwasser, F; Loriot, Y; Ropert, S | 1 |
Palmer, D | 1 |
Moch, H | 1 |
Curiel, DT; Dent, P; Fisher, PB; Graf, M; Grant, S; Hamed, H; Lee, R; Martin, AP; Mitchell, C; Park, MA; Rahmani, M; Roberts, JD; Yacoub, A; Zhang, G | 1 |
Alexandrescu, DT; Anderson, RT; Atkins, MB; Dutcher, JP; Garbe, C; Guitart, J; Hauschild, A; Kong, HH; Lacouture, ME; Puzanov, I; Robert, C; Wood, L; Wu, S | 1 |
Jorda, E; Lopez, V; Marti, N; Monteagudo, C; Pinazo, I | 1 |
Dent, P; Fisher, PB; Graf, M; Grant, S; Hamed, H; Hylemon, PB; Liu, X; Martin, AP; Mitchell, C; Norris, J; Park, MA; Rahmani, M; Ryan, K; Spiegel, S; Zhang, G | 1 |
Elder, DE; Flaherty, KT; Herlyn, M; Letrero, R; Nathanson, KL; Nguyen, TK; Smalley, KS; Van Belle, P; Villanueva, J; Wang, Y; Xiao, M | 1 |
Lohse, AW; Schramm, C; Schuch, G | 1 |
Fujioka, T; Obara, W | 1 |
Kakehi, Y | 1 |
Aguilar-Ponce, JL; Buzaid, AC; de la Garza, J; Fernandes, Gdos S; Kann, AG; Maluf, FC | 1 |
Bukowski, RM; Vakkalanka, BK | 1 |
Chaparro, M; González Moreno, L; Medina, J; Moreno-Otero, R; Trapero-Marugán, M | 1 |
Chen, FS; Cui, YZ; Luo, RC; Wu, J; Zhang, H | 1 |
Clynes, M; Crown, J; Eustace, AJ; O'Donovan, N | 1 |
Hahn, OM; Karczmar, G; Karrison, T; Kistner, E; Manchen, E; Medved, M; Mitchell, M; Ratain, MJ; Stadler, WM; Yang, C | 1 |
Haseke, N; Karl, A; Stadler, T; Staehler, M; Stief, CG; Zilinberg, K | 1 |
Chowdhury, S; Gore, ME; Larkin, JM | 1 |
Ferrière, JM; Grenier, N; Kilkoski, F; Ravaud, A; Sire, M; Wallerand, H | 1 |
Gish, R; Marrero, JB; Tong, MJ | 1 |
Figlin, RA; Hutson, TE; Kuhn, JG; Motzer, RJ | 1 |
Lenihan, DJ | 1 |
Bojic, A; Bojic, M; Hejna, M; Ruhsam, M; Schmidinger, H; Schmidinger, M; Schukro, C; Vogl, UM; Zielinski, CC | 1 |
Bissonnette, M; Chumsangsri, A; Cohen, EE; Delgado, J; Keswani, RN; Mustafi, R | 1 |
Anderson, S; Bukowski, R; Cihon, F; Eisen, T; Escudier, B; Gravis, G; Heinzer, H; Middleton, R; Oudard, S; Shah, S; Szczylik, C | 1 |
Brautigan, DL; McSkimming, CC; Molhoek, KR; Olson, WC; Slingluff, CL | 1 |
Döme, B; Magyar, M | 1 |
Choi, JI; Kim, CM; Park, BJ; Park, JW; Shim, JH | 1 |
Chen, Q; Huang, WX; Li, XF; Ye, YB | 1 |
Adnane, L; Llovet, JM; Lynch, M; Newell, P; Villanueva, A; Wilhelm, SM | 1 |
Daher, IN; Yeh, ET | 1 |
Bekaii-Saab, T; Bloomston, MA; Patel, T; So, BJ | 1 |
Bennani-Lahlou, M; Escudier, B; Massard, C; Mateus, C; Robert, C; Soria, JC; Spatz, A | 1 |
Hwu, P; Kim, K; Lazar, AJ; Quintás-Cardama, A; Ross, M; Woodman, SE | 1 |
Bamias, A | 1 |
Bex, A; Cosentino, M; Ficarra, V; Flörcken, A; Grünwald, V; Johannsen, M; Kloeters, C; Miller, K; Rief, M; Rogalla, P; Roigas, J | 1 |
Busch, AE; Dony, E; Ellinghaus, P; Ghofrani, HA; Grimminger, F; Klein, M; Milting, H; Nikolova, S; Pullamsetti, SS; Riedl, B; Savai, R; Schäfer, S; Schermuly, RT; Weissmann, N | 1 |
Evans, TR; Roxburgh, P | 1 |
Cicek, D; Dagli, FA; Haligur, BD; Kandi, B; Karaoglu, A | 1 |
Kroog, GS; Motzer, RJ | 1 |
Arena, S; Bardelli, A; De Dosso, S; Di Nicolantonio, F; Frattini, M; Martini, M; Mazzucchelli, L; Molinari, F; Saletti, P; Sartore-Bianchi, A; Siena, S | 1 |
Buettner, R; Chen, MY; Hedvat, M; Jove, R; Kirschbaum, M; Kowolik, CM; Liang, W; Mepani, N; Mirosevich, J; Nam, S; Tye, G; Van Meter, TE; Yang, F | 1 |
Bauer, C; Przybilla, B; Ruëff, F | 1 |
Hakenberg, OW; Klebingat, KJ; Protzel, C; Ruppin, S | 1 |
Greten, TF; Korangy, F; Malek, NP; Manns, MP | 1 |
Azizi, M; Bobrie, G; Bouché, O; Deray, G; des Guetz, G; Halimi, JM; Lecomte, T; Levy, B; Mourad, JJ; Nochy, D; Oudard, S; Rieu, P; Sahali, D | 1 |
Escudier, B; Mateus, C; Robert, C; Spatz, A; Wechsler, J | 1 |
Byeon, SH; Chung, EJ; Koh, HJ; Lee, JH; Lim, HJ; Yoo, S | 1 |
Kelley, RK; Venook, AP | 1 |
Chan, P; Epstein, R; Poon, RT; Yau, T | 2 |
Carroll, S; Dale, P; Knox, J; Maroun, J; McDonald, H; Muszbek, N; Shah, S | 1 |
Büchler, MW; Glimm, H; Heining, C; Hoffmann, K; Jaeger, D; Radeleff, B; Richter, G; Schemmer, P; Schenkel, I; Schirrmacher, P; Schmidt, J; von Kalle, C; Zahlten-Hinguranage, A | 1 |
Iwata, C; Kano, MR; Kataoka, K; Komuta, Y; Miyazono, K; Morishita, Y; Oka, M; Ouchi, Y; Shirai, YT | 1 |
Aburatani, H; Hamakubo, T; Ishiguro, T; Kinoshita, Y; Kodama, T; Miyazaki, Y; Nakano, K; Ohizumi, I; Sugimoto, M; Sugo, I; Tsuchiya, M; Tsunoda, H; Yamada-Okabe, H | 1 |
Fitch, TR; Flynn, PJ; Hillman, DW; Lingle, WL; Moreno-Aspitia, A; Morton, RF; Perez, EA; Rowland, KM; Wiesenfeld, M | 1 |
Bergh, J | 1 |
Dham, A; Dudek, AZ; Lindgren, BR; Szczylik, C; Zolnierek, J | 1 |
Paggi, S; Spinzi, G | 1 |
Poust, J | 1 |
Andreef, M; Cortes, J; Kantarjian, H; Mori, S; Ravandi, F; Zhang, W | 1 |
Aydin, H; Bukowski, RM; Elson, P; Garcia, JA; George, S; Golshayan, AR; Heng, DY; Mekhail, TM; Rini, BI; Wood, LS; Zhou, M | 1 |
Copur, MS | 1 |
Palmer, DH | 1 |
Chen, CK; Chen, YJ; Hsieh, CH; Jeng, KS; Lin, CC; Lin, CP; Liu, CY; Shueng, PW; Tai, HC; Wang, CH | 1 |
Borrás-Blasco, J; Casterá, ME; Galán Brotons, A; Rosique-Robles, JD; Vicent Verge, JM | 1 |
Bair, SM; Cherpelis, BS; Fenske, NA; Glass, LF; Marquez, CB; Smithberger, EE; Wenham, RM | 1 |
Foreman, B; Hicks, MD; LaRocca, RV; Mull, L | 1 |
Burock, K; Chen, Z; Cheng, AL; Feng, J; Guan, Z; Kang, YK; Kim, JS; Liang, H; Liu, J; Luo, R; Pan, H; Qin, S; Sun, Y; Tak, WY; Tsao, CJ; Voliotis, D; Wang, J; Xu, J; Yang, TS; Ye, S; Zou, J | 1 |
Bellot, P; Llanos, L; Pérez-Mateo, M; Such, J; Zapater, P | 1 |
Adamietz, IA; Brendel, E; Christensen, O; Grubert, M; Hilger, RA; Kupsch, P; Ludwig, M; Richly, H; Schultheis, B; Strumberg, D | 1 |
Chan, P; Cheung, TT; Chok, SH; Fan, ST; Ng, KK; Poon, RT; Yau, T | 1 |
Billingham, L; Johnson, P | 1 |
Kung, EF; Maddox, JS; Petronic-Rosic, V; Sethi, A | 1 |
Beijnen, JH; Lagas, JS; Schellens, JH; Schinkel, AH; Sparidans, RW; Vlaming, ML | 1 |
Masumori, N; Ohmoto, Y; Tochizawa, S; Tsukamoto, T; Yabuuchi, Y; Yanai, Y | 1 |
Bosch, J; Fernandez, M; Garcia-Pras, E; Mejias, M; Miquel, R; Tiani, C | 1 |
Chow, PK; Chung, A; Huynh, H; Lam, IW; Lee, JW; Lew, GB; Ngo, VC; Ong, HS; Soo, KC | 1 |
Booth, B; Chattopadhyay, S; Farrell, AT; Justice, R; Kane, RC; Madabushi, R; Pazdur, R; Sridhara, R | 1 |
Abou-Alfa, GK | 3 |
Graziadei, I; Königsberg, R; Kornek, G; Maieron, A; Peck-Radosavljevic, M; Pinter, M; Plank, C; Sieghart, W; Vogel, W; Weissmann, A | 1 |
Clark, JW; Zhu, AX | 1 |
Aragon-Ching, JB; Arlen, PM; Chen, CC; Dahut, WL; Draper, D; Figg, WD; Gulley, JL; Jain, L; Jones, E; Steinberg, SM; Venitz, J; Wright, JJ | 1 |
Greten, TF; Malek, N; Manns, MP | 1 |
Befeler, AS; Gogia, S | 1 |
Berger, W; Lamm, W; Micksche, M; Pichelmeyer, O; Pirker, C; Schmidinger, M; Vogl, UM; Zielinski, CC | 1 |
Bukowski, RM; Cella, D; Demkow, T; Escudier, B; Hutson, TE; Laferriere, N; Negrier, S; Rolland, F; Scheuring, UJ; Shah, S; Staehler, M; Szczylik, C | 1 |
Mills, EJ; O'Regan, C; Perri, D; Rachlis, B; Thabane, L | 1 |
Bergmann, L; Jäger, E; Jakse, G; Keilholz, U; Miller, K; Wirth, M | 1 |
Alken, P; Bolenz, C; Häcker, A; Herrmann, E; Honeck, P; Michel, MS; Schöppler, G; Trojan, L | 1 |
Schneeberger, A; Tatzreiter, G; Udvardi, A; Volc-Platzer, B; Wolber, C | 1 |
Camp, RL; Flaherty, KT; Jilaveanu, L; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Zito, C | 1 |
Becker, JC; Hofmeister, V; Houben, R; Noelke, C; Schrama, D; Voigt, H | 1 |
Antonucci, M; Cabibbo, G; Craxì, A; Latteri, F | 1 |
Hill, KL; Lipson, AC; Sheehan, JM | 1 |
Eberhardt, W; Grubert, M; Hense, J; Hilger, RA; Kredtke, S; Richly, H; Scheulen, ME; Schuler, M; Thyssen, D | 1 |
Boucher, E; Bruix, J; Forner, A; Reig, M | 1 |
Ansari, J; Bhatt, RI; Chaudhri, S; Fatima, A; James, ND; Wallace, M | 1 |
Apostolidis, L; Horstmann, S; Jäger, D; Kahlert, C; Lordick, F; Siegmund, A; Thom, R | 1 |
Arbiser, JL | 1 |
Moretti, L; Salemi, S; Scapozza, L; Schmid, I; Simon, D; Simon, HU; Yousefi, S | 1 |
Basso, U; Bertuzzi, A; Brunello, A; Santoro, A | 1 |
Beullens, E; Cools, J; Lierman, E; Marynen, P; Michaux, L; Pierre, P; Vandenberghe, P | 1 |
Dubauskas, Z; Hwu, P; Jonasch, E; Kunishige, J; Prieto, VG; Tannir, NM | 1 |
Choo, SP; Chow, P; Chung, A; Huynh, H; Koong, HN; Ngo, VC; Ong, HS; Poon, D; Soo, KC; Thng, CH | 1 |
Keating, GM; Santoro, A | 1 |
Aragon-Ching, JB; Azad, NS; Dahut, WL; Figg, WD; Gutierrez, M; Jain, L; Kohn, EC; Kong, HH; Steinberg, SM; Turner, ML | 1 |
Ayuso, C; Bru, C; Bruix, J; Buti, M; de la Mata, M; Forner, A; Isabel Real, M; Llovet, JM; Martí-Bonmatí, L; Robles, R; Sangro, B; Sastre, J; Tabernero, J; Varela, M | 1 |
Abou-Alfa, G; Dees, EC; Desai, A; Edelman, MJ; Fakih, MG; Frank, RC; Hohl, RJ; Hollis, DR; Hwang, J; Kennedy, EB; Lewis, LD; Millard, F; Miller, AA; Murry, DJ; Owzar, K; Ratain, MJ; Villalona-Calero, MA | 1 |
Arbogast, D; Collamore, M; Grever, M; Hall, NC; King, M; Kloos, RT; Knopp, MV; Liang, J; Ringel, MD; Rittenberry, J; Saji, M; Shah, MH; Stevens, R; Vasko, VV; Wakely, PE; Wei, L; Wright, JJ | 1 |
Desmedt, E; Digue, L; Milano, G; Mortier, L; Ravaud, A | 1 |
Bellmunt, J; Calvo, E; Castellano, D; Climent, MA; Esteban, E; García del Muro, X; González-Larriba, JL; Maroto, P; Trigo, JM | 1 |
Choueiri, TK; Chowdhury, S | 1 |
Lee, F; Richmond, A; Smykla, R; Thu, YM; Yang, J; Zaja-Milatovic, S | 1 |
Lee, WM; Tsai, JH | 1 |
Alfaro, C; Dubrot, J; Erro, L; Gonzalez, A; Grande-Pulido, E; Gurpide, A; Hervas-Stubbs, S; Lopez-Picazo, JM; Melero, I; Palazon, A; Perez-Gracia, JL; Solano, S; Suarez, N | 1 |
Benichou, AS; Billemont, B; Blanchet, B; Chhun, S; Cramard, J; Dauphin, A; Goldwasser, F; Harcouet, L; Ropert, S; Tod, M | 1 |
Amadori, D; Arienti, C; Carloni, S; Fabbri, F; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
Mizutani, Y | 1 |
Dreyer, C; Faivre, S; Raymond, E | 1 |
Di Micoli, A; Frigerio, M; Santi, V; Trevisani, F | 1 |
Bhat-Nakshatri, P; Maluccio, MA; Nakshatri, H; Saxena, R; Sheng, H; Skill, NJ; Wu, JM; Yu, M | 1 |
El-Serag, HB; Hussain, K | 1 |
Eskens, FA; Verheul, HM; Verhoef, C; Witjes, CD | 1 |
Bakken, GA; Yu, N | 1 |
Aberg, E; Duyster, J; Engh, RA; Peschel, C; Sänger, J; von Bubnoff, N | 1 |
Rosmorduc, O | 1 |
Asemissen, AM; Keilholz, U; Knoedler, M; Miller, K; Schmittel, A; Steiner, U; Thiel, E; Zimmermann, K | 1 |
Jarkowski, A; Wong, MK | 1 |
Bruix, J; Shah, VH | 1 |
Barnabei, A; Corsello, SM; Gasparini, G; Longo, R; Torino, F | 2 |
Oseini, AM; Roberts, LR | 1 |
Elfiky, AA; Rosenberg, JE | 1 |
Abe, K; Arimura, A; Hojo, K; Iguchi, M; Matsumoto, M; Matsuo, Y; Wada, T | 1 |
Bastien, L; Culine, S; de la Taille, A; Ledbai, S; Patard, JJ; Paule, B | 1 |
Heller, J; Hennenberg, M; Kohistani, AZ; Sauerbruch, T; Stark, C; Trebicka, J | 1 |
Carrie, C; Diaz, O; Martin, E; Mazeron, R | 1 |
Cao, MR; Li, AM; Lü, CW; Luo, RC; Su, N; Wei, L; Yan, X; Zheng, DY | 1 |
Aburatani, H; Hirakawa, K; Iwata, C; Johansson, E; Kano, MR; Kiyono, K; Komuro, A; Matsumoto, Y; Miyazono, K; Miyoshi, H; Morishita, Y; Shirai, YT; Suzuki, HI; Watanabe, A; Yashiro, M | 1 |
Armand, JP; Domont, J; Lassau, N; Le Cesne, A; Massard, C; Soria, JC | 1 |
Clayman, GL; Herzog, CE; Sherman, SI; Waguespack, SG; Williams, MD | 1 |
Goldfarb, M; Hodin, R; Nucera, C; Parangi, S | 1 |
Horn, L; Sandler, AB | 1 |
Kagechika, H; Kurosu, T; Miura, O; Ohki, M; Wu, N | 1 |
Dabora, SL; Lee, N; Messina, MP; Nobil, AM; Rauktys, AE; Woodrum, CL | 1 |
Bregman, H; Marmorstein, R; Meggers, E; Pagano, N; Qin, J; Streu, C; Xie, P | 1 |
Maitland, ML; Snider, KL | 1 |
Chen, MH | 1 |
Ball, SA; Plowman, PN; Reznek, R; Richards, TM | 1 |
Jonkers, IJAM; van Buren, M | 1 |
Cheung, YK | 1 |
Chiang, D; Llovet, JM; Mínguez, B; Tovar, V; Villanueva, A | 1 |
Burchert, A; Chaturvedi, A; Eilers, M; Enghofer, E; Metzelder, S; Neubauer, A; Teichler, S; Wang, Y; Wanzel, M; Wollmer, E | 1 |
Ye, SL | 2 |
Barreiros, AP; Galle, PR; Krupp, M; Maass, T; Strand, S; Teufel, A; Thieringer, F; Wang, C; Wörns, MA | 1 |
Ravaud, A; Sire, M | 1 |
Secasan, CC | 1 |
De Roover, A; Delwaide, J; Detry, O; Honoré, P; Lamproye, A; Meunier, P; Polus, M; Van Daele, D | 1 |
Billemont, B; Kelly, RJ; Rixe, O | 1 |
Jansen, PL; Kuiken, SD; Richel, DJ; van Delden, OM | 1 |
Ferraris, E; Imarisio, I; Paglino, C; Porta, C | 1 |
Drummond, M; Evans, B; Karakiewicz, P; LeLorier, J; MacLeod, S; Martin, D; Tugwell, P | 1 |
Balleyguier, C; Celier, C; Escudier, B; Gautier, J; Medioni, J; Negrier, S; Oudard, S; Ravaud, A; Sablin, MP | 1 |
Molina, AM; Motzer, RJ | 1 |
Antonescu, CR; Blachère, NE; Brockstein, B; Cooney, MM; D'Adamo, DR; Edgar, MA; Elias, AD; Hensley, ML; Keohan, ML; Kraft, AS; Livingston, MB; Maki, RG; Mita, MM; Qin, LX; Saulle, M; Schuetze, SM; Schwartz, GK; Schwartz, LH; Takimoto, CH; Undevia, SD | 1 |
Anderson, S; Bukowski, RM; Chevreau, C; Demkow, T; Desai, AA; Eisen, T; Escudier, B; Gore, M; Hofilena, G; Hutson, TE; Lathia, C; Negrier, S; Oudard, S; Pena, C; Rolland, F; Shan, M; Stadler, WM; Staehler, M; Szczylik, C | 1 |
Desar, IM; Mulder, SF; Mulders, PF; Stillebroer, AB; van der Graaf, WT; van Herpen, CM; van Spronsen, DJ | 1 |
Cui, YZ; Huang, N; Li, AM; Lü, CW; Luo, RC; Wei, L; Yang, L; Zheng, DY; Zheng, H | 1 |
Bisagni, G; Boni, C; Cavazza, A; Gardini, G; Rossi, G; Sartori, G | 1 |
Dhomen, N; Marais, R | 1 |
Alsop, DC; Atkins, MB; Goldberg, SN; Lenkinski, RE; Marquis, RP; Pedrosa, I; Regan, M; Schor-Bardach, R; Signoretti, S; Solazzo, SA; Wang, X | 1 |
Dent, P; Graf, M; Grant, S; Houghton, PJ; Mitchell, C; Park, MA; Rahmani, M; Voelkel-Johnson, C; Walker, T; Yacoub, A | 1 |
Dent, P; Grant, S; Häussinger, D; Martin, AP; Mitchell, C; Park, MA; Rahmani, M; Reinehr, R; Thorburn, A; Walker, T | 1 |
Shibuya, M | 1 |
English, BC; Figg, WD; Price, DK | 1 |
Feito Rodríguez, M; Feltes, RA; González-Beato, MJ | 1 |
Rimassa, L; Santoro, A | 2 |
Decosterd, LA; Duchosal, MA; Haouala, A; Leyvraz, S; Montemurro, M; Ris, HB; Rochat, B; Widmer, N; Zaman, K; Zanolari, B | 1 |
Brower, V | 2 |
Berchem, G; Dewilde, S; Mahassen, P | 1 |
Bilaç, C; Ermertcan, AT; Kayhan, TC; Müezzinoğlu, T; Oztürkcan, S; Temeltaş, G; Temiz, P | 1 |
Boijsen, M; Lundstam, S; Lyrdal, D; Stierner, U; Suurküla, M | 1 |
Alasker, A; Guevremont, C; Karakiewicz, PI | 1 |
Abel, EJ; Wood, CG | 1 |
Cortés-Funes, H | 1 |
DiPaola, R; Dreicer, R; Eleff, M; Li, H; Roth, BJ; Stein, M; Wilding, G | 1 |
Burkemper, NM; Chappell, JA; Semchyshyn, N | 1 |
Chen, MS; Li, P; Lin, XJ; Xu, L; Yuan, YF; Zhang, YQ | 1 |
Akaza, H; Miyanaga, N | 1 |
Crowley, J; Leblanc, M; Rankin, C | 1 |
Brüning, A; Burger, P; Burges, A; Friese, K; Gingelmaier, A; Vogel, M | 1 |
Chang, SE; Choi, JH; Kang, YK; Koh, JK; Lee, JL; Lee, MW; Lee, WJ; Moon, KC | 1 |
Berg, CP; Bitzer, M; Claussen, CD; Gregor, M; Horger, M; Koppenhöfer, U; Lauer, UM; Schraml, C | 1 |
Dai, Z; Fan, J; Yu, L; Zhou, J | 1 |
Braun, M; Buness, A; Conrad, J; Falk, CS; Krapfenbauer, U; Kuner, R; Lund, P; Mang-Fatehi, S; Poustka, A; Ruschhaupt, M; Schäfer, R; Sers, C; Stelniec, I; Sueltmann, H | 1 |
Frieling, T; Heise, J; Wassilew, SW | 1 |
Getlik, M; Grütter, C; Pawar, V; Rabiller, M; Rauh, D; Simard, JR; Wulfert, S | 1 |
Barbaro, B; Gasbarrini, A; Lauritano, EC; Novi, M; Piscaglia, AC; Pompili, M; Zocco, MA | 1 |
Mendizabal, M; Reddy, KR | 1 |
Chen, HX; Cleck, JN | 1 |
Abe, H; Fukabori, Y; Furuya, N; Kamai, T; Tokui, N; Yoshida, K | 1 |
Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
Aractingi, S; Arnault, JP; Escudier, B; Grange, JD; Malka, D; Mateus, C; Poirier-Colame, V; Robert, C; Sibaud, V; Soria, JC; Spatz, A; Tomasic, G; Wechsler, J | 1 |
Kong, HH; Turner, ML | 1 |
Campbell, SC; Fergany, A; Garcia, JA; Gill, IS; Klein, EA; Krishnamurthi, V; Novick, AC; Rini, BI; Stephenson, AJ; Thomas, AA; Zhou, M | 1 |
Aragon-Ching, JB; Dahut, WL | 2 |
Dai, B; Dong, B; Huang, Y; Lu, JJ; Shen, Y; Yao, X; Ye, D; Zhang, H; Zhang, S; Zhu, Y | 1 |
Awasthi, S; Rao Lelsani, PC; Sahu, M; Sehrawat, A; Singhal, P; Singhal, SS; Vatsyayan, R; Yadav, S | 1 |
Bil, J; Golab, J; Jakobisiak, M; Nowis, D; Zapala, L | 1 |
Guo, W; Ji, T; Li, DS; Li, X; Peng, CL; Qu, HY; Ren, T; Tang, S; Tang, XD; Yan, TQ; Yang, Y | 1 |
Dudley, AC; Klagsbrun, M | 1 |
Qin, LX; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xiong, YQ; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
Fukuoka, M; Hatashita, E; Nakagawa, K; Okamoto, I; Takezawa, K; Yamada, Y; Yonesaka, K | 1 |
Walker, JG | 1 |
Balis, FM; Kim, A; Widemann, BC | 1 |
Aieta, M; Autorino, R; Bruni, G; Cartenì, G; De Laurentiis, M; De Placido, S; Di Lorenzo, G; Ficorella, C; Giannarini, G; Gonnella, A; Imbimbo, C; Longo, N; Mirone, V; Palmieri, G; Perdonà, S; Pignata, S; Rescigno, P; Rizzo, M; Tudini, M | 1 |
Blumenschein, GR; Cihon, F; Cupit, L; Fossella, F; Gatzemeier, U; O'Leary, J; Reck, M; Stewart, DJ | 1 |
Dutcher, JP; Hudes, G; Kim, S; Rini, BI; Rosbrook, B; Stadler, WM; Tarazi, J; Trask, PC; Wilding, G; Wood, L | 1 |
Carlo-Stella, C; Giacomini, A; Gianni, AM; Lavazza, C; Righi, M; Sia, D | 1 |
Armstrong, RC; Belli, B; Bhagwat, SS; Brigham, D; Chao, Q; Cramer, MD; Gardner, MF; Gunawardane, RN; James, J; Karaman, MW; Levis, M; Pallares, G; Patel, HK; Pratz, KW; Sprankle, KG; Zarrinkar, PP | 1 |
Haley, H; Hamza, S; Skelton, HG; Smith, KJ | 1 |
Flaherty, KT; Smalley, KS | 1 |
Li, M; Li, N; Wu, T; Zhang, Y | 1 |
Egerbacher, M; Gerner, W; Heiduschka, G; Skalicky, M; Thalhammer, JG; Tonar, Z; Walter, I; Wolfesberger, B | 1 |
Alsinet, C; Bruix, J; Cabellos, L; Chiang, DY; Deniz, K; Fiel, MI; Friedman, SL; Hoshida, Y; Lim, KH; Llovet, JM; Mazzaferro, V; Melgar-Lesmes, P; Minguez, B; Newell, P; Peix, J; Roayaie, S; Savic, R; Schwartz, M; Thung, S; Toffanin, S; Tovar, V; Villanueva, A; Yea, S | 1 |
Samlowski, W; Vogelzang, NJ; Weissman, A | 1 |
Hammock, BD; Hwang, SH; Liu, JY; Morisseau, C; Park, SH; Weiss, RH | 1 |
Christensen, O; Chu, QS; Das, S; Meza-Junco, J; Rajagopalan, P; Sawyer, MB; Stefanyschyn, R | 1 |
Gopal, LD; Heller, T; Kohn, EC; von Rosenvinge, EC; Yao, MD | 1 |
Heilbrun, L; Parsa, V; Sethi, A; Smith, D; Vaishampayan, U | 1 |
Benghiat, H; Collins, S; James, N; Karina, M; Oldroyd, A; Parry, H; Pascoe, J; Porfiri, E; Ray, D; Zachariah, A | 1 |
Shen, H; Wang, D; Wang, Y; Zhang, Z; Zhou, X | 1 |
Cella, D | 2 |
Cascinu, S | 1 |
Jaworsky, C; Kish, LS; Kwon, EJ | 1 |
Daniele, B; Di Maio, M; Perrone, F | 1 |
Baumert, TF; Blum, HE; Hildt, E; Himmelsbach, K; Ludwig, L; Sauter, D | 1 |
Kuszatal, E; Langiewicz, P; Nurzyński, P; Oborska, S; Obrocka, B; Szczylik, C; Waśko-Grabowska, A; Zołnierek, J | 1 |
Dudek, AZ; Franklin, MJ; Spector, E; Truskinovsky, AM | 1 |
Pappo, A; Paulino, AC | 1 |
Lee, SH; Paietta, E; Racevskis, J; Wiernik, PH | 1 |
Subbiah, V; Wolff, JE | 1 |
Chong, LW; Chow, P; Chung, A; Huynh, H; Koong, HN; Lam, WL; Lee, J; Lee, SS; Lew, GB; Ngo, VC; Ong, HS; Ong, WJ; Soo, KC; Thng, CH; Yang, S | 1 |
Balabanov, S; Benten, D; Braig, M; Brummendorf, TH; Gontarewicz, A; Keller, G; Lohse, AW; Moll, J; Quaas, A; Schrader, J; Wege, H | 1 |
Angermayr, B; Gangl, A; Mitterhauser, M; Peck-Radosavljevic, M; Reiberger, T; Rohr-Udilova, N; Schwabl, P | 1 |
Bai, S; Datta, J; Ghoshal, K; Hsu, SH; Kumar, P; Kutay, H; Nasser, MW; Nuovo, G; Wang, B; Yadav, A | 1 |
Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
Ivy, SP; Kaufman, BM; Wick, JY | 1 |
Aziz, SA; Camp, RL; Conrad, PJ; Jilaveanu, LB; Kluger, HM; Rimm, DL; Schmitz, JC; Sznol, M; Zito, CR | 1 |
Cheng, AL; Fan, HH; Hsu, C; Liang, JD; Liou, JY; Lu, YS; Ou, DL; Shen, YC; Wang, DS; Yu, SL | 1 |
Bergamini, L; Bianchi, G; Gianni, L; Laferriere, N; Lathia, C; Loibl, S; Peña, C; Raab, G; Salvagni, S; Siena, S; Zamagni, C | 1 |
Carbonell, CE; Coleman, TA; Davis, CH; Davis, WB; La Vine, DB | 1 |
Anderson, S; Bellmunt, J; Bukowski, R; Cihon, F; Escudier, B; Jäger, E; Lewis, J; McDermott, D; Moore, M; Negrier, S; Porta, C | 1 |
Fukino, K; Fukuoka, M; Hasegawa, Y; Kaneda, H; Kawada, A; Miyazaki, M; Morinaga, R; Nakagawa, K; Okamoto, I; Satoh, T; Tanigawa, T; Ueda, S | 1 |
Huang, WS; Yang, CH | 1 |
Choueiri, TK; Je, Y; Schutz, FA | 1 |
Beynat, C; Coudert, B; Diaz, P; Favier, L; Ghiringhelli, F; Ladoire, S | 1 |
Bitzer, M; Claussen, CD; Horger, M; Lauer, U; Martirosian, P; Schraml, C; Schwenzer, NF | 1 |
Chiou, JF; Jen, YM; Liu, TZ; Shiau, CY; Tai, CJ; Wang, YH | 1 |
Corssmit, EP; Gelderblom, H; Heemstra, KA; Hoftijzer, H; Huijberts, M; Kapiteijn, E; Morreau, H; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP; Weijers, K | 1 |
Black, HR; Elliott, WJ; Karrison, T; Kasza, KE; Maitland, ML; Moshier, K; Ratain, MJ; Sit, L; Stadler, WM; Undevia, SD | 1 |
Baker, SD; Chen, Z; Franke, R; Hu, S; Orwick, S; Rudek, MA; Sparreboom, A; Zhao, M | 1 |
Botella-Estrada, R; Echeverría, B; Guillén, C; Llombart, B | 1 |
Banik, NL; Karmakar, S; Ray, SK; Roy Choudhury, S | 1 |
Fujino, H; Kawashima, T; Kiuchi, Y; Matsumoto, I; Matsuzawa, Y; Murayama, T; Nakamura, H; Toyomura, K | 1 |
Song, IH | 1 |
Atkins, MB; Humphreys, BD | 1 |
Garnock-Jones, KP; Keating, GM | 1 |
Bruera, G; Giordano, AV; Lapecorella, M; Lucchesi, A; Mariani, G; Napolitano, M; Ricevuto, E; Tudini, M | 1 |
Printz, C | 1 |
Gil, R; Grueso, J; Hernandez-Losa, J; López-Fauqued, M; Moliné, T; Pujol, A; Recio, JA | 1 |
Blechacz, BR; Bronk, SF; Gores, GJ; Sirica, AE; Smoot, RL; Werneburg, NW | 1 |
Atkins, MB; Bukowski, RM; Cheng, T; Chi, KN; Choueiri, TK; Eigl, BJ; Golshayan, AR; Heng, DY; Knox, JJ; Kollmannsberger, C; McDermott, DF; North, S; Oh, WK; Regan, MM; Rini, BI; Ruether, JD; Sahi, C; Venner, P; Warren, MA; Xie, W | 1 |
Kuczyk, MA; Merseburger, AS; Simon, A; Waalkes, S | 1 |
An, J; Chang, YJ; Chiou, JF; Huang, MT; Liu, TZ; Tai, CJ; Wang, YH; Wei, PL; Wu, CH | 1 |
Crouthamel, MC; Gontarek, RR; King, AG; Kumar, R; Levin, RA; Rominger, DH; Tummino, PJ | 1 |
Escudier, B; Fizazi, K; Gross-Goupil, M; Massard, C; Szczylik, C; Zonierek, J | 1 |
Hasegawa, Y; Matsubara, A; Mita, K; Ohdan, H | 1 |
Wilkes, GM | 1 |
Andreu, J; Carles, J; Serrano, C; Suárez, C | 1 |
Boere, IA; Hamberg, P; Sleijfer, S | 1 |
Coupe, P; Fournier, P; Gautier, S; Gerard, R; Marks, AB | 1 |
Aparicio, A; Ashe, RG; Corn, P; Johnson, MM; Jonasch, E; Ng, C; Pagliaro, LC; Tamboli, P; Tannir, NM; Warneke, CL; Wright, JJ | 1 |
Angeli, P; Burra, P; Cillo, U; Farinati, F; Lonardi, S; Pastorelli, D; Vitale, A; Volk, ML | 1 |
Figueiredo, J; Gonçalves, J; Meireles, AM; Preto, A; Rebocho, AP; Rocha, AS; Seca, H; Seruca, R; Soares, P; Sobrinho-Simões, M; Vasconcelos, HM | 1 |
Dumortier, J; Guillet, M; Lombard-Bohas, C; Scoazec, JY; Vial, T; Walter, T | 1 |
Goldschmeding, R; Overkleeft, EN; van Reekum, F; Verheul, HM; Voest, EE | 1 |
Breau, RH; Leibovich, BC | 1 |
Bruix, J; Reig, M | 1 |
Chevreau, C; Delord, JP; Sibaud, V | 1 |
Akita, H | 1 |
Furukawa, M; Hakariya, T; Ide, S; Ishimoto, H; Kohno, S; Nagashima, S; Nakamura, Y; Sawai, T; Soda, H; Takemoto, S; Tomari, S | 1 |
Cho, JH; Choi, JH; El-Gamal, MI; Hah, JM; Hong, JH; Jung, MH; Kim, H; Kim, HJ; Lee, SH; Oh, CH; Sim, TB; Yoo, KH | 1 |
Blaskovich, MA; El Naggar, AK; Gagel, RF; Hong, DS; Khan, R; Kurzrock, R; Moulder, S; Naing, A; Newman, RA; Ng, CS; Sebti, SM; Sherman, SI; Tannir, NM; Trent, J; Wheler, JJ; Wright, JJ; Ye, L | 1 |
Choo, SP; Chow, P; Chung, A; Goh, BC; Huynh, H; Koong, HN; Ngo, VC; Ong, HS; Poon, D; Smith, PD; Soo, KC; Thng, CH; Toh, HC | 1 |
Johnston, KW; Walid, MS | 1 |
Cheng, CL; Dahm, P; Ou, YC; Wang, SS | 1 |
Chen, KF; Chen, PJ; Cheng, AL; Lee, SS; Liu, TH; Yu, HC | 1 |
Hasinoff, BB; Patel, D | 1 |
DeNicola, GM; Karreth, FA; Tuveson, DA; Winter, SP | 1 |
Montalvo, RO; Moretti, LV | 1 |
Lipworth, AD; Robert, C; Zhu, AX | 1 |
Tai, CJ | 1 |
Cabrera, R; Nelson, DR | 1 |
Cowey, CL; Fielding, JR; Rathmell, WK | 1 |
Mayor, S | 1 |
Adjei, AA; Haug, JL; Kimlinger, TK; Kumar, S; Rajkumar, SV; Ramakrishnan, V; Timm, M; Wellik, LE; Witzig, TE | 1 |
Aitini, E; Bengala, C; Bertolini, F; Boni, C; Conte, P; Dealis, C; Del Giovane, C; Depenni, R; Fontana, A; Luppi, G; Malavasi, N; Zironi, S | 1 |
Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Staehler, M; Varga, Z | 1 |
Bolondi, L; Greten, TF; Lammer, J; Peck-Radosavljevic, M; Rosmorduc, O; Sangro, B; Santoro, A | 1 |
Ajani, JA; Cheng, H; Gusani, NJ; Jiang, Y; Kimchi, ET; Staveley-O'Carroll, KF | 1 |
Arima, Y; Fukushima, H; Nakamura, S; Noda, K; Ogawa, H; Oshima, S; Shono, M; Taniguchi, I | 1 |
Ahmed, A; Balfe, P; Bicknell, R; Farquhar, MJ; Harris, HJ; Hu, K; Maurel, P; McKeating, JA; Mee, CJ; Ramma, W | 1 |
Digue, L; Ravaud, A; Smith, D; Trufflandier, N | 1 |
Thompson, JA | 1 |
Wood, LS | 1 |
Brade, AM; Chung, C; Dawson, LA; Joshua, AM | 1 |
Gore, M; Larkin, J | 1 |
Saif, MW | 2 |
Polliack, A; Tadmor, T; Tallman, MS | 1 |
Aglietta, M; Alberghini, M; Bottos, A; Bruno, S; Bussolino, F; Camussi, G; Cavalloni, G; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Migliardi, G; Motta, M; Picci, P; Pignochino, Y; Tapparo, M; Torchio, B | 1 |
Dupre-Goetghebeur, D; Jantzem, H; Merrer, J; Spindler, P | 1 |
Baessler, T; Kampa, KM; Krusch, M; Mayer, F; Salih, HR; Salih, J; Schlicke, M | 1 |
Levis, M; Murphy, KM; Pratz, KW; Rajkhowa, T; Sato, T; Stine, A | 1 |
Archer, SL; Barst, RJ; Bond, L; Coslet, S; Gomberg-Maitland, M; Lacouture, ME; Maitland, ML; Perrino, TJ; Ratain, MJ; Sugeng, L | 1 |
Broxterman, HJ; de Haas, RR; Lind, JS; Smit, EF; van Hinsbergh, VW; Verheul, HM; Vroling, L | 1 |
Aksoy, S; Altundag, K; Arslan, C; Dede, DS; Dogan, E | 1 |
Dudek, AZ; Kamada, P | 1 |
Amadori, D; Arienti, C; Brigliadori, G; Fabbri, F; Leonetti, C; Passardi, A; Scarsella, M; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W; Zupi, G | 1 |
Cheng, P; Ding, X; Gao, H; Liu, H; Su, X; Wang, D; Wei, D; Zhang, T | 1 |
Cupit, L; Flaherty, KT; Judson, IR; Kaye, SB; O'Dwyer, PJ; Pacey, S; Ratain, MJ; Rowinsky, EK; Xia, C | 1 |
Finn, RS; Saab, S; Yeganeh, M | 1 |
Wang, ZY | 1 |
Liu, ZZ; Piao, Y; Xie, XD | 1 |
Duan, F; Liu, FY; Song, P; Wang, MQ; Wang, ZJ | 1 |
Autorino, R; Di Lorenzo, G | 1 |
Green, C; Hoyle, M; Liu, Z; Moxham, T; Stein, K; Thompson Coon, J; Welch, K | 1 |
Bitzer, M; Claussen, CD; Hartmann, JT; Horger, M; Maksimovic, O; Pintoffl, J; Schraml, C | 1 |
Lieber, ML; Shah, SN; Smith, AD | 1 |
Chernick, MS; Figg, WD; Gardner, ER; Jain, L; Kong, HH | 1 |
Cozzio, A; Donghi, D; Dummer, R | 1 |
Bayer, M; Berdel, WE; Kessler, T; Liersch, R; Mesters, RM; Schwöppe, C | 1 |
Bruix, J; Navasa, M | 1 |
Le Moulec, S; Loriot, Y; Soria, JC | 1 |
Aracil, C; Bruix, J; Bustamante, J; de la Mata, M; Del Val, A; Matilla, A; Pascasio, JM; Pascual, S; Reig, M; Rodríguez, M; Turnes, J; Varela, M | 1 |
Chao, G; Dicker, DT; El-Deiry, WS; Ferrara, T; Katz, SI; Smith, CD; Wang, W; Zhou, L | 1 |
Addeo, R; Bianco, M; Capasso, E; Caraglia, M; Cennamo, G; D'Agostino, A; Faiola, V; Febbraro, A; Guarrasi, R; Maiorino, L; Mamone, R; Montella, L; Montesarchio, V; Palmieri, G; Piai, G; Pisano, A; Prete, SD; Sabia, A; Savastano, C; Tarantino, L; Vincenzi, B | 1 |
Braillon, A | 1 |
Bellmunt, J; Dutcher, JP; Escudier, B; Tannir, N | 1 |
De Greve, J; Decoster, L; Fontaine, C; Schallier, D; Trullemans, F | 1 |
Addeo, R; Caraglia, M; Colucci, G; Del Prete, S; Frezza, AM; Giuliani, F; Montella, L; Rizzo, S; Russo, A; Santini, D; Tonini, G; Venditti, O; Vincenzi, B | 1 |
Annunziata, CM; Azad, N; Houston, N; Kohn, EC; Kotz, H; Lee, JM; Minasian, L; Sarosy, GA; Squires, J | 1 |
Alfano, RW; Bugge, TH; Duesbery, NS; Frankel, AE; Lairmore, TC; Leppla, SH; Liu, S; Mitchell, IC; Nwariaku, F; Ortiz, JM | 1 |
Alfieri, RR; Belletti, S; Bonelli, MA; Bottini, A; Cavazzoni, A; Dowsett, M; Evans, DB; Fox, SB; Fumarola, C; Galetti, M; Gatti, R; Generali, D; Harris, AL; La Monica, S; Martin, LA; Petronini, PG | 1 |
Forner, A; Llovet, JM; Minguez, B; Reig, M; Villanueva, A | 1 |
Büchner, T; Krug, U; Lübbert, M | 1 |
Finn, RS | 4 |
Dolcet, X; Domingo, M; Eritja, N; Gonzalez-Tallada, FJ; Llobet, D; Matias-Guiu, X; Pallares, J; Santacana, M; Sorolla, A; Yeramian, A | 1 |
Hasskarl, J | 2 |
Shoemaker, RH | 1 |
Altorki, NK; Alvarez, H; Beer, DG; Boonstra, JJ; Chaves, P; Darnton, SJ; Dinjens, WN; Eshleman, JR; Klimstra, DS; Lin, L; Pereira, AD; Ribeiro, C; Roque, L; Schrump, DS; Shimada, Y; Tang, LH; Tilanus, HW; van Dekken, H; van Marion, R | 1 |
Adham, M; Boschetti, G; Cassier, P; Dumortier, J; Hervieu, V; Lombard-Bohas, C; Scoazec, JY; Walter, T | 1 |
Barete, S; Billemont, B; Blanchet, B; Cabanes, L; Coriat, R; Francès, C; Garrigue, H; Goldwasser, F; Knebelmann, B | 1 |
Bukowski, RM; Chu, L; Cupit, L; Curti, BD; Drabkin, HA; Dutcher, JP; Ernstoff, MS; Figlin, RA; George, JR; Hainsworth, JD; Hajdenberg, J; Henderson, CA; Hotte, SJ; Kindwall-Keller, TL; Knox, JJ; McDermott, DF; Miller, WH; Ryan, CW; Stadler, WM; Xia, C | 1 |
Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB; Venner, P | 1 |
Antoun, S; Baracos, VE; Birdsell, L; Escudier, B; Sawyer, MB | 1 |
Bukowski, R; Elson, P; Garcia, J; Golshayan, A; Khan, G; Rini, B; Wood, L | 1 |
Peter, S; Rohde, D; Tong, TQ | 1 |
Hayashi, N; Hosui, A; Ishida, H; Kohga, K; Miyagi, T; Takehara, T; Tatsumi, T | 1 |
Beijnen, JH; Lagas, JS; Schinkel, AH; Sparidans, RW; van Waterschoot, RA; Wagenaar, E | 1 |
Brose, MS; Cohen, MA; Keefe, SM | 1 |
Braconi, C; Croce, CM; Gasparini, P; Huang, N; Nuovo, G; Patel, T; Suzuki, T; Taccioli, C; Valeri, N | 1 |
Smilde, T; Toonen, F | 1 |
Brüning, A; Friese, K; Gingelmaier, A; Rahmeh, M | 1 |
Abe, K; Amagai, Y; Hojo, K; Ide, N; Iguchi, M; Kato, A; Matsumoto, M; Shichijo, M; Tanaka, H; Wada, T | 1 |
Brandwein, J; Buckstein, R; Crump, M; Eisenhauer, E; Hedley, D; Kamel-Reid, S; Kassis, J; Leber, B; Matthews, J; McIntosh, L; Minden, M; Robinson, S; Seymour, L; Turner, R; Wells, R | 1 |
Akriviadis, E; Dedes, I; Drevelegas, A; Papalavrentios, L; Sinakos, E | 1 |
Agamah, E; Elit, L; Fleming, GF; Huo, D; Knost, JA; Morgan, RJ; Nimeiri, HS; Oza, AM; Vokes, EE; Wade, JL | 1 |
Dent, P; Fisher, RI; Friedberg, J; Grant, S; Jordan, N; Nguyen, TK | 1 |
Yen, Y; Zhou, W | 1 |
Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P | 1 |
Kurzrock, R; Lenihan, D; Tsimberidou, AM; Vaklavas, C | 1 |
Oya, M | 1 |
Aitini, E; Cengarle, R; Costa, P; Fibbia, GC; Morandini, B; Perboni, G; Scalzini, A; Tagliani, A | 1 |
Chen, Z; Gu, K; Jiang, GL; Li, WT; Liu, J; Liu, LM; Ren, ZG; Xu, ZY; Zhao, JD; Zhou, ZH | 1 |
Chung, JY; Hah, JM; Kim, H; Lee, J; Oh, CH; Sim, T; Yoo, KH; Yu, H | 1 |
Kurashige, Y; Otani, A; Yoshimura, N | 1 |
Minor, DR | 2 |
Billemont, B; Boccon-Gibod, L; Bompas, E; Camparo, P; Couturier, J; Dutcher, J; Escudier, B; Guillot, A; Malouf, GG; Molinié, V; Oudard, S; Rixe, O; Rustine, A; Schleiermacher, G; Theodore, C | 1 |
Amin, C; Cowey, CL; Crane, J; Fielding, JR; Godley, PA; Grigson, G; Jalkut, M; Kim, WY; Moore, DT; Nance, KV; Nielsen, ME; Pruthi, RS; Rathmell, WK; Wallen, EM; Watkins, C; Whang, YE | 1 |
Albanell, J; Bellmunt, J; Calvo, E; Carles, J; Lázaro, M; López, R; Pérez-Gracia, JL; Rubió, J; Trigo, JM; Virizuela, JA | 1 |
Gschwend, JE | 1 |
Eibl, KH; Haritoglou, C; Kampik, A; Kernt, M; Lackerbauer, CA; Liegl, RG; Neubauer, AS; Rueping, J; Ulbig, MW | 1 |
Bose, D; Ellis, LM; Flaherty, KT; Hofstetter, W; Meric-Bernstam, F; Reardon, DA | 1 |
Bruix, J; de Lope, CR; Forner, A; Reig, ME | 1 |
Fournier, C; Tisman, G | 1 |
Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Klar, U; Merk, J; Rolff, J; Sommer, A | 1 |
Bierer, S; Herrmann, E; Wülfing, C | 1 |
Chevreau, C; Dielenseger, P; Ederhy, S; Goldwasser, F; Grange, JD; Mortier, L; Neidhardt-Berard, ME; Robert, C; Rosmorduc, O; Scotté, F; Seitz, JF | 1 |
Blattler, C; Eisen, A; Hotte, SJ; McWhirter, E; Moore, MJ; Mukherjee, SD; Sridhar, SS; Tannock, IF; Wang, L; Winquist, E; Wright, JJ | 1 |
Bandarchi-Chamkhaleh, B; Chen, EX; Do, T; Duran, I; Le Tourneau, C; MacLean, M; Mak, TW; Metser, U; Nayyar, R; Pham, NA; Quintela-Fandino, M; Siu, LL; Tsao, M; Tusche, MW; Wang, L; Wright, JJ | 1 |
Huang, S; Sinicrope, FA | 1 |
Bertsch, A; Henneges, C; Jung, S; Kohlbacher, O; Nahnsen, S; Nordheim, A; Pfeifer, N; Zerck, A | 1 |
Burgess, S; Echeverria, V | 1 |
Coch, C; Eckhardt, M; Hartmann, G; Kübler, K; Kuhn, W; Pölcher, M; Rudlowski, C; Wolfgarten, M | 1 |
Garcia, JG; Moreno-Vinasco, L | 1 |
Abrão Miziara, JE; Albert, I; Arén, O; Balint, B; Barrios, CH; Cihon, F; Csollak, M; Cupit, L; De Marinis, F; Dimatteo, S; Grossi, F; Hanna, N; Keller, A; Krzakowski, M; Novello, S; Pereira, JR; Reck, M; Scagliotti, G; Thomas, M; von Pawel, J | 1 |
Andreeff, M; Bekele, BN; Borthakur, G; Brandt, M; Byrd, A; Cortes, JE; Estrov, Z; Faderl, S; Garcia-Manero, G; Jones, D; Kantarjian, HM; Konopleva, MY; Levis, M; Luthra, R; O'Brien, S; Pierce, SR; Pratz, K; Ravandi, F; Thomas, D | 1 |
Chon, SY; Diamantis, ML | 1 |
Amato, AM; Atkins, MB; Cho, DC; Choueiri, TK; Clement, J; McDermott, D; Oh, WK; Regan, MM; Rosenberg, JE; Signoretti, S | 1 |
Kerbel, RS; Lee, CR; Man, S; Tang, TC; Xu, P | 1 |
Bouattour, M; Castelnau, C; Degos, F; Farges, O; Ozenne, V; Paradis, V; Pernot, S; Valla, D; Vullierme, MP | 1 |
Fujimoto, T; Itatani, H; Kamoto, A; Kanemitu, T; Kobayashi, Y; Mori, N; Satoh, M; Sekii, K; Yoshioka, T | 1 |
Carr, BI; Wang, M; Wei, G | 1 |
Bang, YJ; Han, SW; Im, SA; Kim, JW; Kim, TY; Lee, JO; Oh, DY | 1 |
Byrnes, A; Pancoast, JR; Rixe, O; Verma, S; Wang, SX | 1 |
Bali, MA; Devière, J; Maréchal, R; Van Laethem, JL; Verset, G | 1 |
Ikeda, M; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Ueno, H | 1 |
Hutson, T | 1 |
Bukhtiyarova, M; Karpusas, M; Lee, Y; Namboodiri, HV; Ramcharan, J; Springman, EB | 1 |
Inui, K; Kamba, T; Mizuno, T; Nakamura, E; Ogawa, O; Shinsako, K; Terada, T; Watanabe, J | 1 |
Barbastefano, J; Campbell, SC; Dreicer, R; Elson, P; Garcia, JA; Lane, BR; Rini, BI; Wood, LS | 1 |
Kats-Ugurlu, G; Kiemeney, LA; Leenders, WP; Mulders, PF; Old, LJ; Oosterwijk, E; Oosterwijk-Wakka, JC | 1 |
Doki, Y; Hayashi, N; Hikita, H; Hosui, A; Ishida, H; Kodama, T; Miyagi, T; Mori, M; Nagano, H; Noda, T; Shimizu, S; Takehara, T; Tatsumi, T | 1 |
Bhoori, S; Germini, A; Lampis, A; Mazzaferro, V; Pellegrinelli, A; Sposito, C; Toffanin, S | 1 |
Hurlstone, A; Wellbrock, C | 1 |
Bellmunt, J; Choueiri, TK; Je, Y; Rosenberg, JE; Schutz, FA | 1 |
Grossgoupil, M; Ravaud, A | 1 |
Arbogast, D; Collamore, M; Hall, NC; Kloos, RT; Knopp, MV; Lam, ET; Liang, J; Moley, JF; Prior, TW; Ringel, MD; Saji, M; Sammet, S; Shah, MH; Snyder, PJ; Vasko, VV; Villalona-Calero, MA; Wakely, PE; Wei, L; Wright, JJ | 1 |
Kudo, M | 8 |
Brown, C; Buettner, R; Hedvat, M; Jensen, M; Jove, R; Schroeder, A; Scuto, A; Starr, R; Yang, F | 1 |
Dobrovic, A; Hamilton, AL; Handolias, D; Kerr, L; McArthur, GA; Moodie, K; Salemi, R; Tan, A | 1 |
Galle, PR; Wörns, MA | 2 |
Grothey, A; Hubbard, J | 1 |
Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Ulivi, P; Zoli, W | 1 |
Greten, TF; Manns, MP; Plentz, RR | 1 |
Choueiri, TK | 1 |
Bronstein, Y; Busaidy, NL; Cabanillas, ME; Feng, L; Hernandez, M; Lopez, A; Sherman, SI; Waguespack, SG; Williams, MD | 1 |
Bekers, O; Dingemans, AM; Giovannetti, E; Groen, HJ; Heideman, DA; Honeywell, RJ; Lind, JS; Peters, GJ; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ | 1 |
Kriener, S; Mönch, C; Trojan, J; Welker, MW; Zangos, S; Zeuzem, S | 1 |
Bellmunt, J; Eisen, T; Fishman, M; Quinn, D | 2 |
Cuesta Alcalá, JA; De Pablo Cárdenas, A; Millán Serrano, JA; Sánchez Zalabardo, D | 1 |
Hara, T; Hatano, K; Inoue, H; Kinoshita, T; Kinouchi, T; Kobayashi, M; Nonomura, N; Takada, T | 1 |
Engel, K; Gnoth, MJ; Radtke, M; Sandmann, S | 1 |
Chen, PJ; Cheng, AL; Ding, YH; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC | 1 |
Fesler, MJ; Petruska, PJ; Richart, JM | 1 |
Albouy, B; Escudier, B; Gross Goupil, M; Massard, C | 1 |
Ayllon, J; Barrascout, E; Cuenod, CA; Elaidi, R; Medioni, J; Mejean, A; Oudard, S; Scotte, F; Tartour, E | 1 |
Escudier, B; Gross-Goupil, M | 1 |
Boyle, H; Fléchon, A; Négrier, S | 1 |
Dingemans, AM; Hochstenbach, MM; Postmus, PE; Smit, EF; Thunnissen, FB; van Suylen, RJ | 1 |
Balsom, SM; Bekaii-Saab, TS; Bloomston, M; Li, X; Patel, T; Rose, J; Trolli, E | 1 |
Eto, M; Inokuchi, J; Kuroiwa, K; Masubuchi, D; Naito, S; Seki, N; Shiota, M; Tada, Y; Takeuchi, A; Tatsugami, K; Uchiumi, T; Yokomizo, A | 1 |
Carr, BI; Wang, M; Wang, Z | 1 |
Kondo, M; Nieder, C; Norum, J | 1 |
Saadati, H; Saif, MW | 1 |
Hirose, R; Vagefi, PA | 2 |
Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Janney, D; Marcello, J; McLendon, RE; Peters, K; Reardon, DA; Sampson, JH; Vredenburgh, JJ | 1 |
Gao, J; Jiang, H; Ma, J; Wang, Y; Zhang, D; Zhang, J | 1 |
Vaishampayan, U | 1 |
Rini, BI; Shah, SN | 1 |
Ansari, RH; Benson, AB; Catalano, P; O'Dwyer, PJ; Powell, M; Sun, W | 1 |
Karakiewicz, PI; Lughezzani, G; Perrotte, P; Sun, M | 1 |
Guha-Thakurta, N; Korshunov, A; Pfister, S; Remke, M; Rokes, CA; Witt, O; Wolff, JE | 1 |
Moreno-Aspitia, A | 1 |
Altieri, DC; Gilbert, CA; Raskett, CM; Ross, AH; Siegelin, MD | 1 |
Chen, N; Chen, XQ; Huang, R; Huang, Y; Zeng, H | 1 |
Beljanski, V; Knaak, C; Smith, CD; Zhuang, Y | 1 |
Crea, F; Landolfi, R; Leo, A; Miele, L; Pompili, M; Porto, I | 1 |
Alter, M; Degen, A; Gutzmer, R; Kapp, A; Satzger, I; Schenck, F; Völker, B | 1 |
Deville, JL; Duffaud, F; Huynh, T; Salas, S | 1 |
Bonvalot, S; Cioffi, A; Dômont, J; Le Cesne, A; Tardieu, M | 1 |
Abdulrahman, RM; Corssmit, EP; Gelderblom, H; Hoftijzer, H; Hovens, GC; Kapiteijn, E; Pereira, AM; Reiners, C; Romijn, JA; Smit, JW; Verburg, E; Verloop, H; Visser, TJ | 1 |
Albers, P; Bergmann, L; Gschwend, J; Jäger, E; Keilholz, U; Miller, K | 1 |
Lieber, ML; Remer, EM; Rini, BI; Shah, SN; Smith, AD | 2 |
Brown, RE; Chai, H; Luo, AZ; Weerasinghe, P | 1 |
Amadori, D; Arienti, C; Carloni, S; Chiadini, E; Fabbri, F; Leonetti, C; Milandri, C; Orlandi, A; Passeri, D; Scarsella, M; Silvestrini, R; Tesei, A; Ulivi, P; Zoli, W; Zupi, G | 1 |
Fehér, J; Lengyel, G | 1 |
Ahn, CS; Hwang, S; Kang, YK; Kim, KH; Kim, TW; Lee, HC; Lee, SG; Moon, DB; Ryoo, BY; Ryu, MH; Suh, DJ; Yoon, DH | 1 |
Demers, A; Green, MR; Li, L; Moser, RP; Ross, AH; Sheng, Z; Smith, TW; Zhu, LJ | 1 |
Lee, YC; Park, YH; Roh, SY | 1 |
Guaglianone, PP; Huang, CH; LeBlanc, M; Moon, J; Urba, SG; Williamson, SK; Wolf, GT | 1 |
Baumbusch, T; Hastka, J; Metzgeroth, G; Reiter, A; Ströbel, P | 1 |
Bayliss, S; Connock, M; Greenheld, W; Moore, D; Round, J; Tubeuf, S | 1 |
Farnebo, M; Grandér, D; Kharaziha, P; Lennartsson, L; Mahmoudi, S; Nilsson, S; Panaretakis, T; Thyrell, L; Ullén, A | 1 |
Akisik, MF; Bu, G; Chiorean, EG; Hutchins, GD; Lin, C; Sandrasegaran, K | 1 |
Ichijo, T; Joshita, S; Kamijo, A; Kobayashi, S; Komatsu, M; Matsumoto, A; Morita, S; Sano, K; Sekiguchi, T; Tanaka, E; Umemura, T; Yoshizawa, K | 1 |
Duyster, J; Menzel, H; Peschel, C; Rummelt, C; Sigl, M; von Bubnoff, N | 1 |
Appleman, LJ; Cihon, F; Mazzu, A; Mita, AC; Shapiro, GI; Sundaresan, PR; Tolcher, AW | 1 |
Billemont, B; Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Massault, PP; Mir, O; Ropert, S; Vignaux, O | 1 |
Burger, AM; Egorin, MJ; Heilbrun, LK; Horiba, MN; Ivy, P; Li, J; Lorusso, PM; Pacey, S; Sausville, EA; Vaishampayan, UN | 1 |
Fagin, JA; Pfister, DG; Tuttle, RM | 1 |
Amoh, Y; Eto, H; Iwamura, M; Katsuoka, K; Mii, S; Tanabe, K | 1 |
Baumann, B; Büchler, MW; Gladkich, J; Herr, I; Kallifatidis, G; Liu, L; Mattern, J; Rausch, V; Salnikov, AV; Schemmer, P; Wirth, T; Zöller, M | 1 |
Baker, SD; Carducci, MA; Cho, E; Gore, SD; Karp, JE; Levis, MJ; McDevitt, M; Pratz, KW; Rudek, MA; Smith, BD; Stine, A; Wright, JJ; Zhao, M | 1 |
Sato, Y | 1 |
Ikeda, K | 1 |
Brandes, AA; Franceschi, E; Girardi, F | 1 |
Balvay, D; Banu, E; Chatellier, G; Cuenod, CA; Fournier, LS; Frija, G; Medioni, J; Oudard, S; Thiam, R; Trinquart, L | 1 |
Bigatti, GL; Castagneto, B; Cosimi, MF; Giorcelli, L; Montefiore, F; Pisacco, P; Stevani, I | 1 |
Fujisawa, M; Inoue, TA; Kondo, Y; Kurahashi, T; Miyake, H; Takenaka, A; Yamanaka, K | 1 |
Iordanov, MS; Magun, BE; Magun, EA; Sauter, KA | 1 |
Chen, Y; He, CM; Lin, DJ; Ruan, XX; Wang, LL; Xiao, RZ | 1 |
Clark, BL; Ervin, T; Friedman, E; Hainsworth, JD; Lamar, RE; Murphy, PB; Priego, V | 1 |
Bechstein, WO; Engels, K; Gog, C; Herrmann, E; Lubomierski, N; Trojan, J; Vogl, TJ; Welker, MW; Zeuzem, S | 1 |
Cheng, AL; Hsu, C; Shen, YC | 1 |
Auberdiac, P; Chargari, C; Magné, N; Merrouche, Y; Moncharmont, C; Spano, JP | 1 |
Kong, LQ; Sun, HC; Tang, ZY; Wang, L; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
Ali-Osman, F; Augustine, CK; Beasley, GM; Burchette, J; Jung, SH; McMahon, N; Padussis, J; Pruitt, SK; Selim, MA; Toshimitsu, H; Tyler, DS; Yoo, JS; Yoshimoto, Y; Zipfel, PA | 1 |
Fukui, I; Hatake, K; Kodaira, M; Saotome, T; Takahashi, S; Takeuchi, K; Yonese, J; Yuasa, T | 1 |
Brown, RS; Magun, A; Olsen, SK; Siegel, AB | 1 |
Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM | 1 |
Fetterly, G; Iyer, R; Lugade, A; Thanavala, Y | 1 |
Abou-Alfa, GK; Geschwind, JF; Krishnan, S; Salem, R; Schwarz, RE; Venook, AP | 1 |
Burak, KW; Thomas, MB; Zhu, AX | 1 |
Beck, J; Bellmunt, J; Escudier, B | 1 |
Barbare, JC; Belghiti, J; Castaing, D; Chirica, M; Farges, O; Paradis, V; Soubrane, O; Vullierme, MP | 1 |
Eto, M; Itsumi, M; Naito, S; Shiota, M; Tada, Y; Takeuchi, A; Tatsugami, K; Uchiumi, T; Yokomizo, A | 1 |
Davies, L; Hedley, D; Kirk, R; Lopes, F; Manne, HA; Marais, R; Ménard, D; Niculescu-Duvaz, D; Niculescu-Duvaz, I; Nourry, A; Ogilvie, LM; Preece, N; Springer, CJ; Suijkerbuijk, BM; Whittaker, S; Zambon, A | 1 |
Fischer, L; Herden, U; Nashan, B; Schäfer, H; Sterneck, M; von Baehr, V | 1 |
Antón-Torres, A; Bellmunt, J; Carles, J; Guillem, V; López-Martín, JA; Maroto-Rey, P; Trigo, JM; Urruticoechea, L | 1 |
Chen, E; Coatney, RW; Davis, CB; Frazier, KS; French, KJ; Gales, TL; Hu, CX; McSurdy-Freed, J; Renninger, JP; Storck, LM; Zhao, S | 1 |
Kudo, M; Ueshima, K | 2 |
Han, KH; Lee, JM | 1 |
Dietrich, J; Hulme, C; Hurley, LH | 1 |
de Ruysscher, D; Dingemans, AM; Lind, JS; Meijerink, MR; Ollers, MC; Postmus, PE; Smit, EF; van Kuijk, C | 1 |
Kallert, S; Mackensen, A; Meidenbauer, N; Rech, D; Rech, J; Roesler, W; Winkler, J | 1 |
Baum, CE; Dahut, WL; Danesi, R; English, BC; Figg, WD; Giaccone, G; Jain, L; Kohn, EC; Kummar, S; Liewehr, D; Price, DK; Sissung, TM; Venitz, J; Venzon, D; Yarchoan, R | 1 |
Allegood, J; Dent, P; Fisher, PB; Grant, S; Häussinger, D; Larner, A; Mitchell, C; Ogretmen, B; Park, MA; Reinehr, R; Spiegel, S; Voelkel-Johnson, C; Yacoub, A; Zhang, G | 1 |
Barbaro, D | 1 |
Eames, T; Staehler, M; Wollenberg, A | 1 |
Aucejo, F; Kim, R; Menon, N | 1 |
Chang, JW; Chang, NJ; Chuang, CK; Hou, MM; Hsieh, JJ; Hsu, T; Huang, HY; Wang, HM | 1 |
Herrmann, TR; Kramer, M; Kuczyk, MA; Merseburger, AS; Schrader, AJ; Waalkes, S | 1 |
Bureik, M; Drăgan, CA; Maurer, HH; Neunzig, I; Peters, FT; Schwaninger, AE; Widjaja, M | 1 |
Edwards, JP; Emens, LA | 1 |
Udagawa, T; Wood, M | 1 |
Ambrosini, V; D'Errico-Grigioni, A; Fanti, S; Fini, M; Franchi, R; Giavaresi, G; Malvi, D; Nanni, C; Quarta, C; Torricelli, P; Zinzani, PL | 1 |
Kudo, M; Lencioni, R; Marrero, J; Venook, A; Ye, SL | 1 |
Najarian, DJ; Packianathan, V; Zeitouni, NC | 1 |
Barbare, JC; Chatelain, D; Descamps, V; Duverlie, G; Ezzoukhry, Z; François, C; Galmiche, A; Godin, C; Joly, JP; Louandre, C; Mazière, JC; Nguyen-Khac, E; Regimbeau, JM; Sabbagh, C; Trouillet, N | 1 |
Fischer, JW; Grandoch, M; Rose, A; Rosenkranz, A; Rübben, H; vom Dorp, F; Weber, AA | 1 |
Fukasawa, S; Ichikawa, T; Imamura, Y; Komaru, A; Maruoka, M; Naya, Y; Nihei, N; Sazuka, T; Suyama, T; Ueda, T | 1 |
Bukowski, RM; Escudier, B; Lathia, C; Peña, C; Shan, M | 1 |
Fricke, HJ; Hochhaus, A; Klink, A; Muegge, LO; Scholl, S; Spies-Weisshart, B | 1 |
Agaimy, A; Hartmann, A; Ocker, M; Strobel, D; Wich, C; Wissniowski, TT | 1 |
Anderson, S; Bellmunt, J; Bukowski, R; Eisen, T; Escudier, B; Hutson, TE; Nadel, A; Porta, C; Staehler, M; Szczylik, C | 1 |
Dann, F; Kelly, K; Laquer, V; Saedi, N | 1 |
Carol, H; Gorlick, R; Houghton, PJ; Kang, MH; Keir, ST; Kolb, EA; Lock, R; Maris, JM; Morton, CL; Reynolds, CP; Smith, MA; Watkins, A | 1 |
Spinzi, G; Terreni, N | 1 |
Armstrong, C; Hull, D | 1 |
Dent, P; Grant, S; Häussinger, D; Ogretmen, B; Park, MA; Reinehr, R; Voelkel-Johnson, C; Yacoub, A | 1 |
Arrivé, L; Fartoux, L; Lewin, M; Menu, Y; Rosmorduc, O; Vignaud, A | 1 |
Dawson, LA; Horgan, AM; Knox, JJ; Swaminath, A | 1 |
Lekili, M; Muezzinoglu, T; Nese, N; Temeltas, G | 1 |
Agostino, NM; Chinchilli, VM; Drabick, JJ; Gingrich, R; Koszyk-Szewczyk, A; Lynch, CJ; Sivik, J | 1 |
An, J; Bilenky, M; Birol, I; Butterfield, YS; Cezard, T; Chuah, E; Corbett, R; Fejes, AP; Griffith, M; Griffith, OL; Hirst, M; Holt, RA; Huntsman, DG; Jones, SJ; Laskin, J; Li, YY; Marra, MA; Martin, M; Mayo, M; Melnyk, N; Moore, RA; Morin, RD; Pugh, TJ; Severson, T; Shah, SP; Sutcliffe, M; Tam, A; Terry, J; Thiessen, N; Thomson, T; Varhol, R; Yee, J; Zeng, T; Zhao, Y | 1 |
Bader, M; Haseke, N; Karl, A; Roosen, A; Siebels, M; Stadler, T; Staehler, M; Stief, CG | 1 |
Hashimoto, Y; Iizuka, J; Kobayashi, H; Kondo, T; Nakano, M; Nishikawa, T; Tanabe, K | 1 |
Bono, AV; Cheng, L; Cunico, SC; Iezzi, M; Liberatore, M; Montironi, R; Musiani, P; Pannellini, T; Sasso, F | 1 |
Duerden, M | 1 |
Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Tod, M | 1 |
Chan, P; Pang, R; Poon, RT; Yau, T | 1 |
Downing, L; Galoforo, S; Marples, B; Martinez, AA; McGonagle, M; Robertson, JM; Suen, AW; Wilson, GD | 1 |
Berros, JP; Blay, P; Corral, N; Esteban, E; Estrada, E; Fernández, Y; Fonseca, PJ; Fra, J; Izquierdo, M; Lacave, ÁJ; Luque, M; Muriel, C; Pardo, P; Sanmamed, M; Vieitez, JM; Villanueva, N | 1 |
Dralle, H; Machens, A | 1 |
Crea, F; Danesi, R; Del Tacca, M; Mey, V; Nannizzi, S; Pasqualetti, G; Ricciardi, S | 1 |
Aucejo, F; Kim, R | 1 |
Degen, A; Gutzmer, R; Hauschild, A; Kapp, A; Satzger, I; Voelker, B | 1 |
Cools, J | 1 |
Tomita, Y | 1 |
Castelo, B; Espinosa, E; Pinto, A; Redondo, A; Zamora, P | 1 |
Eschenhagen, T; Hansen, A | 1 |
Bukowski, RM; Chu, L; Cupit, L; Curti, BD; Drabkin, HA; Dutcher, JP; Ernstoff, MS; Figlin, RA; Hainsworth, JD; Hajdenberg, J; Henderson, CA; Hotte, SJ; Kindwall-Keller, TL; Knox, JJ; McDermott, DF; Miller, WH; Ryan, CW; Stadler, WM; Xia, C | 1 |
Crawford, J; Dubey, S; Heinze, R; Jänne, PA; Kindler, HL; Kratzke, R; Krug, L; Pang, H; Vokes, E; Wang, X; Watt, C | 1 |
Merle, P; Mornex, F | 1 |
Dank, M | 1 |
Antoniu, SA | 1 |
Burchert, A; Metzelder, SK; Neubauer, A; Wollmer, E | 1 |
Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Ishida, H; Iwase, K; Kanto, T; Kodama, T; Li, W; Miyagi, T; Shigekawa, M; Shimizu, S; Takehara, T; Tatsumi, T | 1 |
Berardi, R; Cascinu, S; Del Prete, M; Di Pietro Paolo, M; Faloppi, L; Maccaroni, E; Scartozzi, M | 1 |
Agamah, E; Hall, MJ; Kindler, HL; Locker, G; Nattam, S; Stadler, WM; Vokes, EE; Wallace, JA; Wroblewski, K | 1 |
Cinatl, J; Dauth, S; Doerr, HW; Löschmann, N; Michaelis, M; Nevels, M; Paulus, C; Stange, E | 1 |
Bukowski, RM; Cowey, CL; Dreicer, R; Elson, P; Garcia, JA; Gilligan, T; Hutson, TE; Nemec, C; Rini, BI | 1 |
Büchler, T | 1 |
Chamalidou, E; Chelis, L; Deftereos, S; Kakolyris, S; Maltezos, E; Ntinos, N; Souftas, V; Xenidis, N | 1 |
Guo, K; He, Y; Huang, Y; Li, Y; Wang, Y | 1 |
Berrino, L; Capasso, A; Ciardiello, F; De Vita, F; Eckhardt, SG; Martinelli, E; Morelli, MP; Morgillo, F; Orditura, M; Rodolico, G; Santoro, M; Troiani, T; Tuccillo, C; Vecchione, L; Vitagliano, D | 1 |
Calvet, JP; Reif, GA; Wallace, DP; Yamaguchi, T | 1 |
Sas, KM | 1 |
Cawkwell, L; Little, SJ; Maraveyas, A; Murray, A; Stanley, P | 1 |
Guo, W; Lu, X; Ren, T; Tang, X; Zhao, H | 1 |
Rowe, IA | 1 |
Kan, HP; Tan, YF; Wang, Y; Zhou, J | 1 |
Chen, H; Chen, HJ; Huang, Y; Li, X; Wei, Q; Wu, YJ; Xie, X; Yang, YR; Zeng, H; Zhou, Q; Zhu, YC | 1 |
Armand, JP; Brendel, E; Lathia, C; Ludwig, M; Robert, C; Ropert, S; Soria, JC | 1 |
Breaker, K; Costa, LJ; Crighton, F; Drabkin, H; Flaig, TW; Gustafson, DL; Kim, FJ; Schultz, MK | 1 |
Beck-Peccoz, P; Fugazzola, L; Iavarone, M; Perrino, M; Viganò, M | 1 |
Frank-Raue, K; Ganten, M; Kreissl, MC; Raue, F | 1 |
Barbier, EL; Bouchet, A; Coquery, N; Le Duc, G; Lemasson, B; Maisin, C; Rémy, C; Robert, P; Serduc, R; Troprès, I | 1 |
Chang, HM; Choi, YH; Kang, BW; Kang, YK; Kim, C; Kim, TW; Lee, JL; Ryu, MH | 1 |
Adema, GJ; de Vries, IJ; Desar, IM; Hulsbergen-vandeKaa, CA; Jacobs, JH; Mulders, PF; Oyen, WJ; van der Graaf, WT; van Herpen, CM | 1 |
Banerji, U; Berns, B; de Boer, C; Edmonds, K; Ferguson, TR; Gore, ME; James, MG; Larkin, JM; Pickering, LM; Thomas, K | 1 |
Baba, S; Kinoshita, M; Kurita, Y; Kyono, Y; Mugiya, S; Ozono, S; Takayama, T | 1 |
Bojic, M; Clodi, M; Haitel, A; Heinzl, H; Kramer, G; Lamm, W; Schmidinger, M; Vogl, UM; Zielinski, CC | 1 |
Elit, L; Hirte, HW; Macalpine, K; Oza, AM; Schilder, RJ; Wang, L; Welch, SA; Wright, JJ | 1 |
Bustamante, J; Castells, L; de La Mata, M; Delgado, M; Forner, A; Matilla, A; Moreno, JM; Reig, M; Varela, M | 1 |
Josephs, DH; Ross, PJ | 1 |
Avril, MF; Barete, S; Billemont, B; Blanchet, B; Carlotti, A; Francès, C; Franck, N; Goldwasser, F; Moguelet, P; Ropert, S | 1 |
Bäuerle, T; Komljenovic, D; Merz, M; Semmler, W; Zwick, S | 1 |
Huang, Z; Li, C; Wu, P; Zhang, F; Zhang, L; Zhang, W | 1 |
Baker, SD; Li, L; Navid, F; Pratz, K; Rudek, MA; Smith, BD; Zhao, M | 1 |
Jeske, S; Kung, S; Lehrer, D; Matulich, D; Mazumdar, M; Milowsky, MI; Nanus, DM; Selzer, J; Sung, M; Tagawa, ST; Wright, JJ | 1 |
Gu, Y; Meng, F; Qu, B; Shen, Y; Shu, Y; Sun, Y; Wu, X; Xu, Q; Zhang, T; Zhao, W; Zhu, X | 1 |
Bury, MJ; Floyd, JD; Gandara, DR; Gitlitz, BJ; Glisson, BS; Ho, C; Moon, J; Reimers, HJ; Schulz, TK; Sundaram, PK | 1 |
Iiduka, H; Ishida-Yamamoto, A; Komatsu, S; Minami-Hori, M | 1 |
Sahai, S; Swick, BL | 1 |
De Onzoño, LI; García-Arpa, M; Martinez-Martínez, ML; Rodríguez-Vázquez, M | 1 |
Aglietta, M; Aieta, M; Buonerba, C; D'Aniello, C; De Placido, S; Di Lorenzo, G; Federico, P; Felici, A; Imbimbo, C; Longo, N; Milella, M; Mirone, V; Ortega, C; Palmieri, G; Rescigno, P; Ruggeri, EM | 1 |
Chen, KF; Chen, PJ; Cheng, AL; Huang, HP; Li, PK; Lin, YC; Liu, TH; Shiau, CW; Tai, WT | 1 |
Fischer, HP; Granzow, M; Heller, J; Hennenberg, M; Klein, S; Kohistani, Z; Körner, C; Krämer, B; Nischalke, HD; Sauerbruch, T; Stark, C; Trebicka, J | 1 |
Bawa, O; Benatsou, B; Koscielny, S; Lassau, N; Leguerney, I; Massard, C; Opolon, P; Peronneau, P; Roche, A; Rodrigues, M; Rouffiac, V; Thalmensi, J | 1 |
Bitzer, M; Claussen, CD; Fenchel, M; Gregor, M; Horger, M; Lauer, UM; Spira, D | 1 |
De Falco, V; Jo, YS; Kim, DW; Kim, JM; Kim, SJ; Kim, YK; Kweon, GR; Lee, JU; Lee, MH; Lee, SE; Park, JH; Ryu, MJ; Shong, M | 1 |
Heinz, WJ; Helle-Beyersdorf, A; Kahle, K; Keller, D; Klinker, H; Langmann, P; Lenker, U; Schirmer, D | 1 |
Frederick, RT; Frenette, CT; Gish, RG | 1 |
Duffy, A; Greten, T | 1 |
Audrain, O; Boucher, E; Leroux, C; Pracht, M; Raoul, JL; Vauléon, E; Zoheir, Y | 1 |
Bruns, I; Czibere, A; Fenk, R; Haas, R; Kobbe, G; Safaian, NN; Saure, C; Schroeder, T; Zohren, F | 1 |
Malek, NP; Manns, MP; Vogel, A | 1 |
Hagymási, K; Tulassay, Z | 1 |
Beck, D; Berger, A; Flaherty, K; Garbe, C; Gogel, J; Kulms, D; Lasithiotakis, K; Maczey, E; Mauthe, M; Meier, F; Niessner, H; Proikas-Cezanne, T; Schadendorf, D; Schaller, M; Schittek, B; Sinnberg, T; Toulany, M; Venturelli, S | 1 |
Childs, R; Lundqvist, A; Su, S; Yokoyama, H | 1 |
Homma, Y; Kaneko, T; Matsushima, H; Morimoto, H; Tsuzaka, Y | 1 |
Cruikshanks, N; Curiel, DT; Dent, P; Dmitriev, IP; Eulitt, PJ; Fisher, PB; Hossein, H; Park, MA; Yacoub, A; Yang, C | 1 |
Amoroso, F; Boldt, S; Dahlhaus, M; Etro, D; Freund, M; Fuellen, G; Glass, A; Junghanss, C; Lange, S; Neri, LM; Ruck, S; Sawitzky, M; Schult, C; Wolkenhauer, O | 1 |
Agarwal, S; Elmquist, WF; Ohlfest, JR; Sane, R | 1 |
Andreeff, M; Borthakur, G; Cortes, JE; Faderl, S; Kantarjian, H; Konopleva, M; Mathews, S; Ravandi, F; Verstovsek, S; Wright, JJ; Zhang, W | 1 |
Arai, K; Kaneko, S; Yamashita, T | 1 |
Fujisawa, M; Miyake, H | 1 |
Bernardini, R; Duntas, LH | 1 |
Figlin, RA; Pal, SK | 1 |
Hoshida, Y; Newell, P; Villanueva, A | 1 |
Boerman, OC; Desar, IM; Leenders, WP; Mulders, PF; Oosterwijk, E; Oyen, WJ; Stillebroer, AB; van der Graaf, WT; van Herpen, CM | 1 |
Alge, CS; Hirneiss, C; Kampik, A; Kernt, M; Liegl, RG; Neubauer, AS; Ulbig, MW; Wolf, A | 1 |
Abalı, H; Beşen, AA; Dişel, U; Karadeniz, C; Köse, F; Nursal, GN; Oztuzcu, S; Ozyılkan, O; Sezer, A; Sümbül, AT | 1 |
Aberg, E; Duyster, J; Engh, RA; Gorantla, SP; Oliveira, TM; Peschel, C; Thöne, S; von Bubnoff, N | 1 |
Rosen, N; Solit, D | 1 |
Chung, GG; Cohen, P; Creswell, K; Eng-Wong, J; Herbolsheimer, P; Isaacs, C; Liu, MC; Novielli, A; Ottaviano, Y; Slack, R; Smith, KL; Warren, R; Wilkinson, M | 1 |
Li, H; Shi, GH; Wang, CF; Yang, LF; Yang, ZY; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y | 1 |
Hu, BS; Huang, GM; Huang, JW; Li, Y; Lu, LG; Shao, PJ; Wei, ZG; Zhang, L | 1 |
Eto, M; Kiyoshima, K; Naito, S; Oki, T; Takeuchi, A; Tatsugami, K; Yamada, H; Yoshikai, Y | 1 |
Borner, M; Candinas, D; Dufour, JF; Heim, MH; Helbling, B; Hoppe, H; Kickuth, R; Maurhofer, O; Saar, B; Szucs-Farkas, Z | 1 |
Carr, BI; Carroll, S; Gondek, K; Muszbek, N | 1 |
Baba, T; Hamanishi, J; Kang, HS; Konishi, I; Mandai, M; Matsui, S; Matsumura, N; Mori, S; Murphy, SK; Okamoto, T; Oura, T; Yamaguchi, K; Yamamura, S | 1 |
Burger, DM; Desar, IM; Timmer-Bonte, JN; van der Graaf, WT; van Herpen, CM | 1 |
Bednaríková, D; Kocák, I | 1 |
Chen, KF; Cheng, AL; Fan, HH; Feng, WC; Hsu, C; Lin, LI; Ou, DL; Shen, YC; Wang, CT; Yeh, PY; Yu, SL | 1 |
Schaab, C | 1 |
Andersen, JL; Andersson, M; Kamby, C; Nielsen, DL | 1 |
Izumi, N; Kuzuya, T; Tsuchiya, K | 1 |
Aucejo, F; Byrne, M; Chang, YD; El-Gazzaz, G; Elson, P; Kim, R; Tan, A | 1 |
Düber, C; Galle, PR; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA | 1 |
Balis, FM; Cole, DE; Cruz, R; Fox, E; Kim, A; McCully, C; Widemann, BC | 1 |
Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; Lampard, JG; McDermott, DF; North, S; Rini, BI; Xie, W | 1 |
Emmenegger, U; Francia, G; Hashimoto, K; Kerbel, RS; Man, S; Tang, TC; Xu, P | 1 |
Bellmunt, J; Eisen, T; Mulders, P; Porta, C; Szczylik, C | 1 |
Bharati, IS; Fecteau, JF; Handel, TM; Kipps, TJ; Messmer, D; O'Hayre, M | 2 |
Abou-Alfa, GK; Capanu, M; Davidenko, I; Gansukh, B; Johnson, P; Knox, JJ; Lacava, J; Leung, T; Saltz, LB | 1 |
Halff, G; Speeg, KV; Wang, Y; Washburn, WK | 1 |
Sulkes, A | 1 |
Ausoni, G; Bayer, AJ; Bellesi, S; Chiusolo, P; Giammarco, S; Laurenti, L; Leone, G; Mario, B; Metafuni, E; Sica, S; Sorà, F; Zini, G | 1 |
Birrer, MJ; Bristow, RE; Calvert, V; Cohn, D; DeGeest, K; Farley, J; Lankes, HA; Matei, D; Mutch, D; Petricoin, EF; Sill, MW; Yamada, SD | 1 |
Jung, O; Kang, M; Kim, H; Kim, HJ; Kwak, TK; Lee, JW; Lee, MS; Lee, SA; Park, KH; Ryu, HW | 1 |
FENG, FL; JIANG, XQ; LAU, WY; LIU, C; LUO, XJ; QIU, YH; Qiu, ZQ; RAN, RZ; TAN, WF; WANG, JH; WU, MC; YAN, PN; YI, B; YU, Y; ZHANG, BH | 1 |
Hofmann, WP; Trojan, J; Waidmann, O; Zeuzem, S | 1 |
Chen, XP; Dagher, L; Lencioni, R; Venook, AP | 1 |
Büchler, MW; Franz, C; Hoffmann, K; Mohr, E; Schemmer, P; Serba, S; Xiao, Z | 1 |
Rini, B | 1 |
Chen, H; Chen, Z; Lin, JH; Liu, LM; Meng, ZQ; Xu, LT; Zhou, ZH | 1 |
Chen, Y; Gan, YH; Ge, NL; Ren, ZG; Wang, YH; Xie, XY; Ye, SL; Zhang, BH; Zhang, L | 1 |
Biglietto, M; Buonerba, C; Cartenì, G; Chiurazzi, B; Di Lorenzo, G; Riccardi, F; Scognamiglio, F | 1 |
Busuttil, RW; Finn, RS; McTigue, M; Saab, S | 1 |
Fesler, MJ | 1 |
Catalano, O; De Giuli, L; Della Porta, MG; Eleuteri, E; Riccardi, A; Tondini, C; Zambelli, A | 1 |
Asemissen, A; Braun, F; Busse, A; Fusi, A; Keilholz, U; Miller, K; Nonnenmacher, A; Ochsenreither, S; Schmittel, A; Stather, D; Thiel, E | 1 |
Aglietta, M; Capellero, S; Cavalloni, G; Gammaitoni, L; Giordano, S; Migliardi, G; Milani, A; Moggio, A; Montemurro, F; Pecchioni, C; Peraldo-Neia, C; Petrelli, A; Sapino, A; Valabrega, G; Zaccarello, G | 1 |
Bierer, S; Herrmann, E; Hertle, L; Hoffmeister, I; Köpke, T; Papavassilis, P; Riesenbeck, LM; Thielen, B | 1 |
Di Stefano, G; Fiume, L; Manerba, M; Vettraino, M | 2 |
Bozorgzadeh, A; Grossman, S; Piperdi, B; Rawson, AP; Saidi, RF; Shah, SA | 1 |
Nelson, KC; Puri, PK; Raymond, AK; Selim, MA; Tyler, DS | 1 |
Chung, YH; Jin, YJ; Kang, YK; Kim, KM; Ko, GY; Lee, HC; Lee, JL; Lee, YS; Lim, YS; Shim, JH; Suh, DJ; Sung, KB; Yoo, DJ; Yoon, HK | 1 |
Jungmeechoke, K; Kanjanapayak, B; Ruangkanchanasetr, P | 1 |
Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R | 1 |
Angulo, P; Chen, C; Daily, MF; Evers, BM; Gedaly, R; Hundley, J; Koch, A | 1 |
Oudard, S | 1 |
Lolkema, MP; van Hillegersberg, R; Verheul, HM; Voest, EE; Walraven, M; Witteveen, PO | 1 |
Boulton, ME; Cai, J; Han, S; Law, B; Liao, D; Qing, R | 1 |
Azzariti, A; Colucci, G; Fratto, ME; Galluzzo, S; Maiello, E; Santini, D; Silvestris, N; Tommasi, S; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
Carroll, AR; Coleman, RL; Sood, AK | 1 |
Aburto, MR; Magariños, M; Muñoz-Agudo, C; Rapp, UR; Sánchez-Calderón, H; Varela-Nieto, I | 1 |
Colombo, M; Sangiovanni, A | 3 |
Bouattour, M; Faivre, S; Raymond, E | 1 |
Chen, HL; Chen, KF; Chen, PJ; Cheng, AL; Feng, WC; Hsu, CH; Tai, WT | 1 |
Bhujanga Rao, AK; Pulla Reddy, M; Ravikumar, K; Sridhar, B | 1 |
Buckley, M; Christos, PJ; Goldberg, L; Hamilton, A; Liebes, L; Min, C; Osman, I; Ott, PA; Pavlick, AC; Polsky, D; Safarzadeh-Amiri, S; Wright, JJ; Yee, H; Yoon, J | 1 |
Awada, A; Besse-Hammer, T; Brendel, E; Delesen, H; Gil, T; Hendlisz, A; Joosten, MC; Lathia, CD; Loembé, BA; Piccart-Ghebart, M; Van Hamme, J; Whenham, N | 1 |
Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
Asemissen, AM; Braun, F; Busse, A; Fusi, A; Keilholz, U; Miller, K; Nonnenmacher, A; Ochsenreither, S; Schmittel, A; Stather, D; Thiel, E | 1 |
Chang, CJ; Chao, CH; Chen, CT; Hortobagyi, GN; Hsu, JM; Hung, MC; Woodward, WA; Xia, W; Xie, X; Yang, JY | 1 |
Aramendi, T; Balbin, E; Diaz-Sanchez, A; Rodriguez-Salas, N | 1 |
Adjei, AA; Dy, GK; Hillman, SL; Mandrekar, S; Molina, JR; Nair, S; Rowland, KM; Schild, SE; Steen, PD; Wender, DB | 1 |
Aomatsu, K; Arao, T; Fujita, Y; Furuta, K; Kaneda, H; Kimura, H; Kudo, K; Kudo, M; Matsumoto, K; Nagai, T; Nishio, K; Saijo, N; Sakai, K; Tamura, D | 1 |
Becker, JC; Berking, C; Degen, A; Egberts, F; Frey, L; Garbe, C; Gutzmer, R; Hassel, JC; Hauschild, A; Kaehler, KC; Livingstone, E; Mauch, C; Mohr, P; Rass, K; Schadendorf, D; Schenck, F; Trefzer, U; Ugurel, S; Weichenthal, M; Wilhelm, T | 1 |
Huang, FK; Shi, Z | 1 |
Cao, L; Choyke, P; Force, J; Giaccone, G; Gutierrez, M; Keen, C; Kelly, RJ; Kummar, S; Lopez-Chavez, A; Raffeld, M; Rajan, A; Steinberg, SM; Turkbey, B; Wright, JJ; Xi, L; Yu, Y | 1 |
Amano, R; Hirakawa, K; Ishikawa, T; Kubo, N; Maeda, K; Muguruma, K; Nakata, B; Noda, E; Ohira, M; Onoda, N; Sawada, T; Takashima, T; Tanaka, H; Yamada, N; Yashiro, M | 1 |
Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Nakatake, R; Yanagimoto, Y | 1 |
Guan, YS; He, Q | 1 |
Lord, R; Ross, PJ; Suddle, A | 1 |
Girard, N; Mornex, F | 1 |
Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W; Wrba, F | 1 |
Altomare, E; Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bertoni, M; Bozzi, E; Bresci, G; Capria, A; Gianluigi, G; Romano, A; Sacco, R | 1 |
Donaldson, MR; Smith, JL; Stetson, CL | 1 |
Baek, YH; Cho, JH; Han, JS; Han, SY; Kim, BG; Kim, SO; Lee, SW; Nam, KJ | 1 |
Fujii, H; Fukino, K; Hamamoto, Y; Hashine, K; Niwakawa, M; Sumiyoshi, Y; Tanigawa, T; Yamaguchi, R | 1 |
Ahn, SH; Choi, HJ; Han, KH; Kim, DY; Lee, S; Park, JY; Yoon, SH | 1 |
Eibl, KH; Haritoglou, C; Hirneiss, C; Kampik, A; Kernt, M; Lackerbauer, CA; Neubauer, AS; Thiele, S; Ulbig, MW; Wolf, A | 1 |
Dunn, RL; Filson, CP; Miller, DC; Redman, BG | 1 |
Beljanski, V; Lewis, CS; Smith, CD | 1 |
Borg, C; Curtit, E; Di Martino, V; Heyd, B; Nguyen, T; Pivot, X; Thiery-Vuillemin, A | 1 |
Burnett, A; Galkin, S; Knapper, S; Levis, M; Sato, T; Small, D; Smith, BD; White, P; Yang, X | 1 |
Benedict, A; Charbonneau, C; Figlin, RA; Hariharan, S; Harmenberg, U; Négrier, S; Remák, E; Sandin, R; Sandström, P; Ullén, A | 1 |
Akiyama, Y; Fujita, K; Murayama, N; Sasaki, Y; Sugiyama, M; Yamazaki, H | 1 |
Brion, N; Paule, B | 1 |
Cheng, SQ; Deng, YZ; Feng, YX; Guan, DX; Li, JJ; Li, N; Qin, Y; Wang, H; Wang, HY; Wang, T; Wang, XF; Wu, MC; Xie, D; Yang, P; Yao, F; Zhu, YQ | 1 |
Dufour, JF; Hora, C; Romanque, P | 1 |
Eskens, FA; Mathijssen, RH; Peeters, RP; van der Lugt, A; van Doorn, L; Visser, TJ | 1 |
Choi, BI; Kim, KW; Lee, JM | 1 |
Andreadis, C; Bamias, A; Dimopoulos, M; Karadimou, A; Kontovinis, L; Laschos, K; Papazisis, K; Paraskevopoulos, P | 1 |
Bornschein, J; Csepregi, A; Malfertheiner, P; Ricke, J; Rühl, R; Schütte, K; Zimmermann, L | 1 |
Lowe, SW; Pardee, TS; Zuber, J | 1 |
Bidyasar, S; Busaidy, NL; Cabanillas, ME; El Naggar, AK; Hernandez, M; Hong, DS; Kurzrock, R; Naing, A; Sherman, SI; Tsimberidou, AM; Waguespack, SG; Wheler, J; Wright, J; Ye, L | 1 |
Decker, T; Huber, S; Kuhnt, T; Lutzny, G; Oelsner, M; Oostendorp, RA; Peschel, C; Ringshausen, I; Schmidt, B; Wagner, M; zum Büschenfelde, CM | 1 |
Atkins, MB; Choueiri, TK; Guo, M; Heng, DY; Jagannathan, J; Krajewski, KM; McDermott, DF; Pedrosa, I; Ramaiya, N; Schutz, FA; Van den Abbeele, AD; Yap, J | 1 |
Poller, B; Schinkel, AH; Tang, SC; Wagenaar, E | 1 |
Fukui, I; Hatake, K; Inamura, K; Ishikwa, Y; Kodaira, M; Nakano, K; Takahashi, S; Urakami, S; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
Cripe, TP; Dombi, E; Jousma, E; Kim, A; Kim, MO; Lindquist, D; Ratner, N; Schnell, BM; Scott Dunn, R; Widemann, BC; Wu, J | 1 |
Bellini, E; Berruti, A; Brizzi, MP; Dogliotti, L; Pia, A; Tampellini, M; Terzolo, M; Torta, M | 1 |
Cabrera, R; Cao, M; Gabrilovich, D; Liu, C; Nelson, DR; Xu, Y; Youn, JI; Zhang, X | 1 |
Bajetta, E; Beck, J; Bokemeyer, C; Bracarda, S; Burock, K; Escudier, B; Keilholz, U; Mersmann, S; Negrier, S; Procopio, G; Richel, DJ; Staehler, M; Strauss, UP; Szczylik, C | 1 |
Amaravadi, RK; Li, LZ; Lum, JJ; Ma, XH; McAfee, QW; Nathanson, KL; Piao, S; Wang, D | 1 |
Baba, N; Hyodo, I; Ishige, K; Matsuda, S; Nakanuma, Y; Onodera, M; Onuki, K; Shoda, J; Sugiyama, H; Takeuchi, K; Ueda, T; Yamamoto, M; Yamato, M | 1 |
Cano Megías, M; Carrasco De La Fuente, M; González Albarrán, O; Menacho Román, M; Pérez López, G | 1 |
Adnot-Desanlis, L; Bernard, P; Reguiaï, Z | 1 |
Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Hsu, CY; Hu, FC; Shen, YC; Shih, TT; Wei, SY; Yu, CW | 1 |
Prasad, SR; Sahani, DV; Shanbhogue, AK; Takahashi, N; Vikram, R | 1 |
Blanchet, B; Chaussade, S; Coriat, R; Goldwasser, F; Gouya, H; Legmann, P; Mir, O; Pol, S; Ropert, S; Sogni, P; Vignaux, O | 1 |
Adachi, M; Akaza, H; Fukino, K; Furuse, J; Iijima, M; Minami, H; Murai, M; Naito, S; Tsukamoto, T | 1 |
Lanzuela, M; Lao, J; Pazo Cid, RA | 1 |
Katsahian, S; O'Quigley, J; Zohar, S | 1 |
Borentain, P; Durieux, O; Garcia, S; Gérolami, R; Gregoire, E; Hardwigsen, J; Le Treut, YP | 1 |
Fliegel, L; Karki, P; Li, X; Schrama, D | 1 |
Ravaud, A | 1 |
Flaherty, KT; Frye, RF; Lathia, C; O'Dwyer, PJ; Redlinger, M; Rosen, M; Schuchter, L | 1 |
Abe, H; Fukuda, T; Furuya, N; Kamai, T; Kambara, T; Mizuno, T; Nakamura, F; Nakanishi, K; Shirataki, H; Yanai, Y; Yoshida, K | 1 |
Carr, BI; Hyslop, T; Wang, M; Wang, Z; Wei, G | 1 |
Demlová, R; Komínek, J; Ondrácková, B | 1 |
Alpini, G; Cleary, JP; DeMorrow, S; Francis, H; Glaser, SS; Han, Y; Hubble, L; Kumar, P; Liu, CG; Liu, X; Meng, F; Passarini, JD; Priester, S; Sharma, J; Staloch, D; Stokes, A; Venter, J | 1 |
Hah, JM; Kim, H; Kim, M; Kim, MH; Sim, T; Yoo, KH; Yu, H | 1 |
Allen, GI; Chung, BI; Gill, HS; Harshman, LC; Srinivas, S; Yu, RJ | 1 |
Chen, KF; Chen, PJ; Cheng, AL; Huang, HP; Huang, JW; Shiau, CW; Tai, WT | 1 |
Friedrich, MJ | 1 |
Chen, YL; Ding, X; Li, HP; Liu, CH; Liu, P; Lv, J; Min, LH; Sun, MY; Xu, Q; Ye, XL | 1 |
Barbara, C; Barni, S; Cabiddu, M; Colombo, S; Corti, D; Elia, S; Ghilardi, M; Petrelli, F; Stringhi, E | 1 |
Hashimoto, Y; Iizuka, J; Ishimori, I; Kennoki, T; Kimata, N; Kobayashi, H; Kondo, T; Murakami, J; Nakazawa, H; Takagi, T; Tanabe, K; Yoshida, K | 1 |
Aster, J; Christie, AL; DePinho, RA; Gao, D; Gutierrez, A; Gygi, SP; Inuzuka, H; Kung, AL; Lau, AW; Look, T; Maser, RS; Nakayama, KI; Onoyama, I; Settleman, J; Shaik, S; Tseng, A; Wan, L; Wei, W; Xiao, Y; Zhai, B | 1 |
Adams, DR; Lynch, MC; Straub, R | 1 |
Choi, JI; Kim, MJ; Lee, JS; Park, JW | 1 |
Ikeda, R; Iseki, K; Maeda, H; Nakano, K; Shibayama, Y; Sugawara, M; Taguchi, M; Takeda, Y; Yamada, K | 1 |
Bruix, J; Sherman, M | 1 |
Jin-hui, T; Ke-hu, Y; Li, M; Ling-lin, Z | 1 |
Abe, K; Alzoubi, A; Fagan, KA; Gairhe, S; Gerthoffer, WT; Ito, M; Koubsky, K; McMurtry, IF; Oka, M; Ota, H; Toba, M | 1 |
Akladios, CY; Aprahamian, M; Balboni, G; Bour, G; Marescaux, J; Mutter, D | 1 |
Takami, HE | 1 |
Bousquet, G; Faugeron, I; Hindie, E; Lussato, D; Toubert, ME; Vercellino, L | 1 |
Oberstein, PE; Saif, MW | 1 |
Brocks, DR; Fong, L; Harzstark, AL; Lin, AM; Rosenberg, JE; Ryan, CJ; Small, EJ; Sun, J; Weinberg, VK | 1 |
Dahut, WL; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kohn, EC; Kummar, S; Mould, DR; Venitz, J; Woo, S; Yarchoan, R | 1 |
Behnsawy, HM; Fujisawa, M; Fukuhara, T; Inoue, TA; Kusuda, Y; Miyake, H | 1 |
Cheng, CW; Chong, TW; Huynh, H; Lau, WK; Sim, MY; Siml, HG; Yuen, JS | 1 |
Cohen, PR; Stewart, DJ; Williams, VL | 1 |
Kim, DY | 1 |
Asakawa, C; Fujinaga, M; Fukumura, T; Hatori, A; Kato, K; Kawamura, K; Kumata, K; Ogawa, M; Yamasaki, T; Yui, J; Zhang, MR | 1 |
Arranz, JÁ; Climent, MÁ; González-Larriba, JL; León, L; Maroto, JP | 1 |
El-Khoueiry, AB; Gandara, D; Lenz, HJ; Ramanathan, RK; Shibata, S; Wright, JJ; Yang, DY; Zhang, W | 1 |
Liu, Y; Shi, Y; Sun, Y; Wang, L; Wang, Y; Yu, S; Zhang, X | 1 |
Bell, JC; Breitbach, CJ; Falls, T; Heo, J; Hickman, T; Hwang, TH; Kim, CW; Kim, MK; Kirn, DH; Lee, YK; Moon, A; Oh, SY; Parato, K; Patt, R; Rhee, BG; Rintoul, J; Woo, HY | 1 |
Li, QH; Liu, BC; Liu, KQ; Mi, YC; Wang, JX; Wei, H; Wei, SN; Zhou, CL | 1 |
Gong, P; Li, G; Li, W; Pu, Y; Zhai, X; Zhong, Z | 1 |
Canipari, C; Chen, K; Duh, MS; Imarisio, I; Neary, M; Paglino, C; Porta, C | 1 |
Chang, HM; Kang, YK; Kim, JE; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Suh, DJ | 2 |
Cohen, EE; Fleming, GF; Gangadhar, TC; Geary, D; House, LK; Janisch, L; Kocherginsky, M; Maitland, ML; Ramirez, J; Ratain, MJ; Undevia, SD; Wu, K | 1 |
Ahn, L; Antonescu, CR; D'Adamo, DR; Gounder, MM; Hameed, M; Keohan, ML; Lefkowitz, RA; Maki, RG; Singer, S; Stout, K | 1 |
Bajetta, E; Bracarda, S; Miceli, R; Porta, C; Procopio, G; Ricci, S; Ridolfi, L; Sacco, C; Verzoni, E; Zilembo, N | 2 |
Amri, A; Arguello, M; Borden, K; Cormack, G; Kraljacic, BC | 1 |
Belghiti, J; Chopin-Laly, X; Faivre, S; Irtan, S; Paradis, V; Ronot, M | 1 |
Blumenstengel, K; Grimm, MO; Groschek, M; Herrmann, E; Hutzschenreuter, U; Marschner, N; Ohlmann, CH; Overkamp, F; Pühse, G; Steiner, T | 1 |
Maráz, A | 1 |
Du, DZ; Herynk, MH; Heymach, JV; Jonasch, E; Khajavi, M; Logothetis, CJ; McKee, KS; Tannir, NM; Tran, HT; Wang, X; Xu, L; Yan, S; Zurita, AJ | 1 |
Abbass, K; Baumann, MA; Dewani, S; Kaplon, MK; Markert, R | 1 |
Bushmakin, AG; Bycott, P; Cappelleri, JC; Kim, S; Rini, B; Rosbrook, B; Stadler, WM; Tarazi, J; Trask, PC | 1 |
Duh, MS; Feinberg, BA; Fortner, B; Gilmore, J; Jolly, P; Neary, MP; Scott, J; Wang, ST | 1 |
Tanji, N; Yokoyama, M | 1 |
Dai, B; Shen, YJ; Shi, GH; Wang, CF; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
Akaza, H; Fukino, K; Murai, M; Naito, S; Tsukamoto, T | 1 |
Clerc, J; Coriat, R; Goldwasser, F; Mir, O; Ropert, S | 1 |
Karakiewicz, PI; Maurin, C; Perrotte, P; Sun, M; Thuret, R | 1 |
Allen, P; Jonasch, E; Mahajan, A; Tannir, N; Verma, J | 1 |
Afthinos, M; Djonov, V; Dufour, JF; Hlushchuk, R; McSheehy, PM; Piguet, AC; Radojevic, V; Saar, B; St-Pierre, MV; Terracciano, L | 1 |
Baker, SD; Calabrese, C; Campana, D; Fan, Y; Hu, S; Inaba, H; Niu, H; Orwick, S; Panetta, JC; Pounds, S; Rehg, JE; Rose, C; Rubnitz, JE; Yang, S | 1 |
Chen, YJ; Liang, CP; Shen, JL; Yang, CS | 1 |
Ma, L; Wang, Y; Wu, Z; Zhang, L; Zhou, Q | 1 |
Busch, J; Flörcken, A; Grünwald, V; Johannsen, M; Keilholz, U; Kempkensteffen, C; Miller, K; Weikert, S; Weinkauf, L; Westermann, J; Zimmermann, K | 1 |
Boeykens, E; Rutsaert, R; Stappaerts, I; Van Loo, S | 1 |
Dörken, B; Engert, A; Janz, M; Köchert, K; Lamprecht, B; Mathas, S; Ullrich, K; Wurster, KD | 1 |
Choi, JI; Kim, CM; Kim, HB; Kim, HK; Kim, HY; Kim, TH; Nam, BH; Park, JW | 1 |
Chen, Y; He, CM; Lin, DJ; Ruan, XX; Wang, LL; Xiao, RZ; Xiong, MJ | 2 |
Abbruzzese, A; Addeo, R; Caraglia, M; Giuberti, G; Marra, M; Montella, L; Murolo, M; Naviglio, S; Prete, SD; Sperlongano, P; Stiuso, P; Vincenzi, B | 1 |
Fernández-Contreras, ME; Hinojar-Gutiérrez, A; Mendoza, J; Mera-Menéndez, F; Moreno, R; Nieto-Llanos, S | 1 |
Aglietta, M; Asaftei, SD; Casali, PG; D'Ambrosio, L; Dileo, P; Fagioli, F; Ferrari, S; Grignani, G; Mercuri, M; Palmerini, E; Picci, P; Pignochino, Y | 1 |
Danesi, R; Del Tacca, M; Mey, V; Pasqualetti, G; Ricciardi, S | 1 |
Hua, SC; Li, Y; Liu, J; Liu, L; Ma, CY; Yang, M; Yuan, Q; Zhang, X; Zhou, C | 1 |
Chen, KF; Chen, PJ; Chen, WL; Cheng, AL; Hsu, CY; Huang, JW; Shiau, CW; Tai, WT | 1 |
Abrahamova, J; Brabec, P; Buchler, T; Dusek, L; Klapka, R; Melichar, B; Vyzula, R | 1 |
El-Deiry, WS; Ferrara, TA; Katz, SI; Mayes, PA; Smith, CD; Wang, W; Zhou, L | 1 |
Eto, M; Inokuchi, J; Kiyoshima, K; Kuroiwa, K; Naito, S; Shiota, M; Takeuchi, A; Tatsugami, K; Yokomizo, A | 1 |
Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
Aucejo, F; Byrne, MT; Kim, R; Tan, A | 1 |
Burak, KW | 1 |
Gores, GJ; Razumilava, N | 1 |
Chao, CC; Kuo, TC; Lu, HP | 1 |
Arai, Y; Imazu, T; Inoue, H; Kajikawa, J; Kawashima, A; Kinoshita, T; Nin, M; Nishimura, K; Nonomura, N; Takada, S; Takayama, H; Tanigawa, G; Tsujimura, A; Yasunaga, Y | 1 |
Couto, JP; Martins, TC; Prazeres, H; Rodrigues, F; Soares, P; Sobrinho-Simões, M; Torres, J; Trovisco, V; Vinagre, J | 1 |
Kumar, B; Kumar, P; Teknos, TN; Yadav, A | 1 |
Boldrini, R; Cortesi, E; De Pasquale, MD; Donfrancesco, A; Ilari, I; Jenkner, A; Pessolano, R | 1 |
Chong, LW; Huynh, H; Jong, CT; Lam, IW; Lee, SS; Li, PY; Luu, DA; Ong, RW; Yang, S | 1 |
Burris, HA; Greco, FA; Hainsworth, JD; Kommor, M; Molthrop, DC; Peacock, N; Spigel, DR; Vazquez, ER; Yardley, DA | 1 |
Block, MS; Kohli, M | 1 |
Alsop, DC; Atkins, MB; Bhasin, M; Bhatt, RS; Collins, MP; Goldberg, SN; Libermann, T; Mier, JW; Panka, D; Putheti, P; Schor-Bardach, R; Signoretti, S; Wang, X; Zhang, L | 1 |
Doehn, C; Hegele, A; Heinzer, H; Oberneder, R; Siebels, M; Varga, Z | 1 |
Ahmed, M; Barbachano, Y; Harrington, KJ; Hickey, J; Marais, R; Newbold, KL; Nutting, CM; Riddell, A; Viros, A | 1 |
Hashemolhosseini, S; Hellerbrand, C; Klinger, N; Neureiter, D; Ocker, M; Sass, G; Sirma, H; Tiegs, G; Wege, H | 1 |
Blechacz, B; Ehman, R; Glaser, K; Huebert, R; Lomberk, G; Masyuk, T; Patel, L; Ritman, E; Routray, C; Shah, V; Shergill, U; Thabut, D; Urrutia, R; Vercnocke, A | 1 |
Chen, M; Orsini, LS; Qiao, YL; Therneau, T | 1 |
Flaig, MJ; Prinz, JC; Rübsam, K; Ruzicka, T | 1 |
Bass, JD; Burris, HA; Daniel, DB; Friedman, EK; Greco, FA; Hainsworth, JD; Mitchell, RB; Shipley, DL; Spigel, DR; Waterhouse, DM; Whorf, RC; Zangmeister, J | 1 |
Chen, CL; Naib, T; Steingart, RM | 1 |
El-Gamal, MI; Jung, MH; Lee, WS; Oh, CH; Sim, T; Yoo, KH | 1 |
Bruners, P; Frei, P; Geier, A; Herweg, C; Mahnken, AH; Martin, IV; Mertens, JC; Müllhaupt, B; Schmitt, J | 1 |
Bertolotto, C; Bourcier, C; Grépin, R; Griseri, P; Mazure, N; Pagès, G | 1 |
Abou-Alfa, GK; Carter, WD; Chan, SL; Chiorean, EG; Gutheil, JC; Holcombe, RF; Lin, CC; Melink, TJ; Mulcahy, MF; Patel, K; Tsao, CJ; Wilson, WR | 1 |
Geoerger, B; Leblond, P | 1 |
Abou-Alfa, GK; Gish, RG; Tong, MJ | 1 |
Buonerba, C; Casciano, R; De Placido, S; Di Lorenzo, G; Liu, Z; Malangone, E; Sherman, S; Wang, X; Willet, J | 1 |
Wu, Y; Zhao, Y | 1 |
Bajetta, E; Bearz, A; Calcagno, A; Cartenì, G; Chiappino, I; Guadalupi, V; Imarisio, I; Landi, L; Paglino, C; Porta, C; Procopio, G; Re, GL; Ricotta, R; Rizzo, M; Ruggeri, EM; Sabbatini, R; Verzoni, E; Zustovich, F | 1 |
Espinosa, E; González, R; Merino, M; Pinto, A | 1 |
An, S; Choe, TB; Hong, SI; Jin, HO; Kim, YS; Lee, KH; Lee, SJ; Park, IC; Seo, SK; Woo, SH | 1 |
Caja, L; Campbell, JS; Fabregat, I; Fausto, N; Fernández-Rodriguez, CM; Fernando, J; Lledó, JL; Sancho, P | 1 |
Cramer, T; Daskalow, K; Decker, G; Gonzalez-Carmona, MA; Hirt, S; Raskopf, E; Sauerbruch, T; Schmitz, V; Standop, J; Vogt, A | 1 |
Cabrera, R; Caridi, J; Clark, V; Firpi, RJ; George, TJ; Morelli, G; Nelson, DR; Pannu, DS; Soldevila-Pico, C; Suman, A | 1 |
Greil, R; Grundbichler, M; Kappacher, A; Mlineritsch, B; Moik, M; Ressler, S; Rosenlechner, S | 1 |
Dombi, E; Force, J; Giaccone, G; Rajan, A; Steinberg, SM | 1 |
Fassnacht, M; Kreissl, MC; Schott, M; Spitzweg, C; Willhauck, MJ | 1 |
Cohen, L; Gao, Y; Gu, K; Li, HX; Meng, ZQ; Wang, P; Xu, LT; Xu, LY; Yang, PY | 1 |
Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Eulitt, P; Fisher, PB; Grant, S; Hamed, HA; Hubbard, N; Moran, RG; Nephew, KP; Park, MA; Tang, Y; Tye, G; Yacoub, A | 1 |
Allen, E; Hanahan, D; Walters, IB | 1 |
Bendell, JC; Burris, HA; Greco, FA; Hainsworth, JD; Infante, JR; Jones, SF; Lane, CM; Spigel, DR; Yardley, DA | 1 |
Chen, W; Collins, R; Tirado, CA; Wakim, JJ | 1 |
Cunningham, D; Okines, AF; Reynolds, AR | 1 |
Belghiti, J; Botti, M; Boussaha, T; Dubreuil, O; Housset, M; Landi, B; Rougier, P; Taieb, J; Trouilloud, I; Williet, N | 1 |
Abbadessa, G; Carrillo-Infante, C; Cucchi, E; Pressiani, T; Rimassa, L; Santoro, A | 1 |
Betlloch, I; Cuesta, L; Latorre, N; Monteagudo, A; Toledo, F | 1 |
Boers-Doets, C; Chrysou, M; Edmonds, K; Hull, D; Koldenhof, J; Molassiotis, A; Spencer-Shaw, A | 1 |
Airoldi, A; Mancuso, A; Pinzello, G; Vigano, R | 1 |
He, JT; Zhang, D | 1 |
Chida, N; Furuse, J; Hayashi, N; Hori, T; Imanaka, K; Kaneko, S; Kudo, M; Kumada, H; Matsui, O; Meinhardt, G; Nakachi, K; Ohya, T; Okita, K; Okusaka, T; Suh, DJ; Tak, WY; Takayama, T; Tanaka, K; Tsubouchi, H; Wada, M; Yamaguchi, I; Yoon, JH | 1 |
Blay, JY; Chaigneau, L; Curtit, E; Dobi, E; Kalbacher, E; Mansi, L; Nguyen, T; Pivot, X; Viel, E | 1 |
Dai, Z; Fan, J; Hu, J; Huang, XW; Qiu, SJ; Tan, CJ; Wang, Z; Zhou, J | 1 |
Barbier, EL; Christen, T; Duchamp, O; Farion, R; Fondraz, N; Genne, P; Lemasson, B; Provent, P; Remy, C; Segebarth, C; Tizon, X | 1 |
Caponigro, F; Ciarmiello, A; Milano, A; Perri, F | 1 |
Chapuy, B; Dohm, A; Hand, E; Panse, M; Schroers, R; Schuelper, N; Truemper, L; Wulf, GG | 1 |
Dai, Z; Ding, ZB; Fan, J; Gu, CY; Hui, B; Ke, AW; Peng, YF; Qiu, SJ; Shi, GM; Shi, YH; Wang, XY; Zhou, J | 1 |
Abbas, H; Bancelin, N; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dauphin, A; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Ropert, S; Taieb, F; Thomas-Schoemann, A; Tod, M; Vidal, M | 1 |
Cohen, JD; Gallegos, AC; Lau, SS; Mastrandrea, NJ; Monks, TJ; Tham, KY | 1 |
Kang, WK; Lee, J; Lee, SJ; Lim, HY; Park, JO; Park, SH; Park, YS; Yim, DS | 1 |
Spicák, J; Suchánková, G | 1 |
Baek, KK; Kang, WK; Kim, JH; Lee, J; Lim, HY; Park, JO; Park, SH; Park, YS; Uhm, JE | 1 |
Cui, Z; He, B; Qu, W; Wang, JC; Wang, YB; Zhang, H; Zhang, JY; Zhang, Q | 1 |
Boulinguez, S | 1 |
Chan, AL; Leung, HW | 1 |
Bloor, A; Cross, NC; Erben, P; Gesk, S; Haferlach, C; Haferlach, T; Hochhaus, A; Hofmann, WK; Metzgeroth, G; Reiter, A; Ritter, M; Score, J; Telford, N; Walz, C | 1 |
Chang, YI; Chao, YS; Chen, CP; Chen, CT; Chen, CW; Cheng, AH; Chou, LH; Hsieh, SY; Hsu, JT; Hsu, T; Huang, YL; Jiaang, WT; Lin, WH; Lu, CT; Tseng, YJ; Yeh, TK; Yen, KR; Yen, SC | 1 |
de Vries, IJ; Desar, IM; Galama, JM; Jacobs, JF; Mulder, SF; Mulders, PF; Olde Nordkamp, MA; Punt, CJ; Teerenstra, S; Torensma, R; van Herpen, CM; Vissers, KC | 1 |
Boucher, E; Edeline, J; Le Roux, C; Perrin, C; Pracht, M; Raoul, JL; Rolland, Y; Vauléon, E | 1 |
Curtit, E; Le Tourneau, C; Mansi, L; Medioni, J; Viel, E | 1 |
Desbois-Mouthon, C; Rosmorduc, O | 1 |
Ahn, HK; Kang, WK; Lee, J; Lee, S; Lim, HY; Park, JO; Park, SH; Park, YS; Sun, JM | 1 |
Bergmann, L; Gschwend, J; Keilholz, U; Miller, K | 1 |
Aller, S; Gosiengfiao, Y; Morgan, E; Popescu, A; Rao, S | 1 |
Bodnar, L; Górnas, M; Szczylik, C | 1 |
Fujii, M; Fujisawa, M; Kitajima, K; Maeda, T; Miyake, H; Ohno, Y; Sugimura, K; Takahashi, S; Yoshikawa, T | 1 |
Abdulghani, J; Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Hong, B; Katz, SI; Navaraj, A; Smith, CD; Wang, W | 1 |
Allen, JE; Dicker, DT; Dolloff, NG; El-Deiry, WS; Gallant, JN; Navaraj, A; Smith, CD; Wang, W | 1 |
Adjei, AA; Blumenschein, GR; Gatzemeier, U; Heigener, D; Hillman, S; Mandrekar, S | 1 |
Shen, YF; Zhang, SJ; Zhou, XJ | 1 |
Baumann, M; Cerny, T; Koeberle, D; Sommacal, A | 1 |
Carr, BI; Cavallini, A; D'Alessandro, R; Refolo, MG; Wang, M; Wang, Z | 1 |
Huang, C; Nan, K; Suo, A; Yao, Y; Zhang, L; Zhang, M; Zhang, W | 1 |
Brendel, E; Kornacker, M; Kummer, G; Schultheis, B; Strumberg, D; Xia, C; Zeth, M | 1 |
Hong, SH; Jeon, EK; Jeong, HK; Ko, YH; Lee, SL; Roh, SY; Shin, OR; Won, HS | 1 |
Bechelli, J; Ifthikharuddin, JJ; Jordan, CT; Liesveld, JL; Lu, C; Messina, P; Mulford, D; Phillips Ii, GL; Rosell, KE | 1 |
Keresztes, RS; Wu, S | 1 |
Ahn, SH; Choi, HJ; Han, KH; Kim, DY; Lee, JD; Lee, JH; Park, JY; Seo, HJ | 1 |
Ben-Josef, E; Blanke, CD; El-Khoueiry, AB; Eng, C; Gold, PJ; Govindarajan, R; Hamilton, RD; Lenz, HJ; Rankin, CJ | 1 |
Affolter, A; Ahmad, T; Chao, D; Chevreau, C; Corrie, P; Eisen, T; Gibbens, I; Gore, ME; Harries, M; James, MG; Jouary, T; Lorigan, P; Marais, R; Montegriffo, E; Nathan, PD; Negrier, S; Ottensmeier, C; Prendergast, S; Robert, C; Strauss, UP | 1 |
Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C | 1 |
Borden, E; Bramwell, V; Demetri, GD; Goldblum, JR; Rankin, C; Ryan, CW; von Mehren, M | 1 |
Bedeir, A; Berger, W; Ghassemi, S; Grasl-Kraupp, B; Grusch, M; Heffeter, P; Heinzle, C; Held, G; Holzmann, K; Marian, B; Metzner, T; Micksche, M; Peter-Vörösmarty, B; Pirker, C; Spiegl-Kreinecker, S | 1 |
Busch, J; Grünwald, V; Hinz, S; Kempkensteffen, C; Magheli, A; Miller, K; Seidel, C; Weikert, S; Weinkauf, L; Wolff, I | 1 |
Aubourg, A; Bacq, Y; Lucas, E; Perarnau, JM | 1 |
Paz, C; Querfeld, C; Shea, CR | 1 |
Albiges, L; Escudier, B; Rini, B; Salem, M | 1 |
Atkinson, B; Choueiri, TK; Chowdhury, S; Matrana, MR; Tannir, NM; Tsang, C | 1 |
Andreeff, M; Bashir, Q; Bayraktar, UD; Champlin, RE; Chen, J; Chiattone, A; Cortes, J; de Lima, M; Giralt, S; Kantarjian, H; Kebriaei, P; Konopleva, M; McCue, D; Qazilbash, M; Ravandi, F; Sharma, M | 1 |
Caldwell, GA; Caldwell, KA; Dawson, TM; Dawson, VL; Hamamichi, S; Lee, BD; Liu, Z; Ray, A; Smith, WW; Yang, D | 1 |
Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA | 1 |
Connock, M; Hyde, C; Moore, D | 1 |
Al-Osaimi, AM; Argo, CK; Caldwell, SH; Northup, PG; Schmitt, TM; Shah, NL; Truesdale, AE | 1 |
Beardsley, EK; Chi, KN; Ellard, SL; Hotte, SJ; Kollmannsberger, C; Mukherjee, SD; North, S; Winquist, E | 1 |
Broneshter, R; Iancu, TC; Manov, I; Pollak, Y | 1 |
Demartines, N; Dormond, O; Dormond-Meuwly, A; Dufour, M; Roulin, D; Waselle, L | 1 |
Budak, K; Pestalozzi, B; Weisshaupt, Ch | 1 |
Ballarin, R; Berretta, M; D'Amico, G; De Ruvo, N; Di Benedetto, F; Gerunda, GE; Iemmolo, RM; Tarantino, G | 1 |
Busch, J; Grünwald, V; Hinz, S; Johannsen, M; Kempkensteffen, C; Magheli, A; Miller, K; Seidel, C; Weikert, S; Wolff, I | 1 |
Bollag, G | 1 |
Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Moran, RG; Nephew, KP; Tang, Y | 1 |
Abril, C; Al-Kali, A; Brandt, M; Cortes, J; Faderl, S; Jones, D; Kantarjian, H; Pierce, S; Ravandi, F | 1 |
Cross, NC; Erben, P; Hochhaus, A; Hofmann, WK; Klippstein, T; Martin, H; Metzgeroth, G; Mousset, S; Reiter, A; Teichmann, M; Walz, C | 1 |
Cunningham, D; Yim, KL | 1 |
Hu, ML; Huang, CS; Lyu, SC | 1 |
Atkins, M; Bukowski, R; Choueiri, TK; Dutcher, J; Eisen, T; Elson, P; Escudier, B; Heng, DY; Manola, J; Mazumdar, M; McCormack, JB; Motzer, R; Négrier, S; Royston, P | 1 |
Kim, HY; Park, JW | 1 |
Chung, H; Hagiwara, S; Inoue, T; Ishikawa, E; Kitai, S; Kudo, M; Minami, Y; Nagai, T; Sakurai, T; Takita, M; Tatsumi, C; Ueda, T; Ueshima, K; Yada, N | 1 |
Geliebter, J; Moscatello, AL; Nowicki, TS; Schantz, S; Shin, E; Tiwari, RK | 1 |
Choo, SP; Chow, PK; Chung, AY; Huynh, H; Ong, R; Soo, KC; Tai, WM; Toh, HC | 1 |
Brose, MS; Chung, J; Kalmus, J; Kappeler, C; Nutting, CM; Reike, G; Schlumberger, M; Sherman, SI; Shong, YK; Smit, JW | 1 |
Aguillo Gutiérrez, E; Altemir Trallero, J; Cabrejas Gómez, Mdel C; Lázaro Sierra, J; Ocón Bretón, J | 1 |
Fan, JM; Jia, ZR; Liu, YO; Wang, XQ; Zhang, Q; Zhao, B | 1 |
Chan, JL; Chen, S; Goydos, JS; Lee, HJ; Namkoong, J; Rosenberg, S; Shin, SS; Wall, BA; Wangari-Talbot, J | 1 |
Crespo, O; Daneman, R; Ho, PP; Kang, SC; Lindstrom, TM; Robinson, WH; Sobel, RA; Steinman, L | 1 |
Calvani, N; Cinefra, M; Cinieri, S; Gnoni, A; Leo, S; Lombardi, L; Lorusso, V; Maiello, E; Morelli, F; Orlando, L | 1 |
Fujita, N; Hayashi, N; Hikita, H; Hiramatsu, N; Hosui, A; Ishida, H; Kanto, T; Kodama, T; Miyagi, T; Shimizu, S; Takehara, T; Tatsumi, T; Tsunematsu, H; Yoshimori, T | 1 |
Becker, C; Berger, F; Hittinger, M; Reiser, M; Schramm, N; Staehler, M; Ubleis, C | 1 |
Anders, RA; Bai, H; Chenna, V; Fan, J; Hu, C; Khan, M; Maitra, A; Sun, HX; Sun, YF; Xu, Y; Yang, XR; Zhu, QF | 1 |
Hammock, BD; Hwang, SH; Inoue, H; Wecksler, AT; Weiss, RH | 1 |
Ballini, JP; Griffioen, AW; Lovisa, B; Nowak-Sliwinska, P; van Beijnum, JR; van den Bergh, H; Weiss, A; Wong, TJ | 1 |
Akita, K; Fujii, I; Gouda, M; Ishihama, Y; Kirii, Y; Kitagawa, D; Narumi, Y; Sugiyama, N; Yokota, K | 1 |
Buder, R; Graziadei, I; Grünberger, B; Hucke, F; Königsberg, R; Kornek, G; Maieron, A; Matejka, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Schöniger-Hekele, M; Sieghart, W; Stauber, R; Vogel, W; Weissmann, A | 1 |
Fukui, I; Habuchi, T; Hatake, K; Horikawa, Y; Inoue, T; Nakano, K; Narita, S; Saito, M; Takahashi, S; Tsuchiya, N; Urakami, S; Yamamoto, S; Yonese, J; Yuasa, T | 1 |
Chan, P; Fan, ST; Pang, R; Poon, RT; Wong, H; Yao, TJ; Yau, T | 1 |
Cabibbo, G; Cammà, C; Colombo, M; Grieco, A; Iavarone, M; Piscaglia, F; Villa, E; Zavaglia, C | 1 |
Caronia, LM; Phay, JE; Shah, MH | 1 |
Hasegawa, Y; Itou, N; Nitta, H; Takahara, T; Takahashi, M; Wakabayashi, G | 1 |
Adamus, G; Anitori, R; Golchet, P; Jampol, LM; Mets, RB; Shaw, J; Wilson, D | 1 |
Bhagat, N; Cosgrove, D; Geschwind, JF; Kamel, IR; Pawlik, TM; Reyes, DK | 1 |
Joly, F | 1 |
Fukumoto, M; Ichida, T; Matsuda, Y | 1 |
Albert, MH; Corbacioglu, S; Fröhlich, B; Graf, N; Häberle, B; Kammer, B; Kontny, U; Leuschner, I; Scheel-Walter, HG; Scheurlen, W; Schmid, I; von Schweinitz, D; Werner, S; Wiesel, T | 1 |
Bellesi, S; Chiusolo, P; Giammarco, S; Laurenti, L; Leone, G; Metafuni, E; Sica, S; Sorà, F; Za, T | 1 |
Liu, Q; Mier, JW; Panka, DJ | 1 |
Borbujo, JM; Córdoba, S; Espinosa, P; Martínez-Morán, C; Meseguer-Yebra, C; Nájera, L; Romero-Maté, A; Ruiz-Casado, AI | 1 |
Bustamante, J; Castroagudin, JF; Garralda, E; Gomez-Martin, C; Herrero, I; Matilla, A; Salcedo, M; Sangro, B; Testillano, M | 1 |
Anderson, KC; Podar, K | 1 |
Bruns, CJ; Clevert, DA; Cyran, CC; Dietrich, O; Eschbach, R; Hinkel, R; Ingrisch, M; Nikolaou, K; Paprottka, PM; Reiser, MF; Schwarz, B; von Einem, JC; Wintersperger, BJ | 1 |
Ciampi Dopazo, JJ; de Artaza Varasa, T; de la Cruz Perez, G; Gómez Moreno, AZ; Gómez Rodríguez, R; González de Frutos, C; Lanciego Pérez, C; Romero Gutiérrez, M | 1 |
Kong, D; Ma, W; Song, T; Wu, Q; Zhang, W | 1 |
Bracarda, S; Cortesi, E; D'Angelo, A; Ferraù, F; Merlano, M; Monti, M; Ruggeri, EM; Santoro, A | 1 |
Li, XH; Liu, Y; Yang, DH; Zhong, KB; Zhou, J | 1 |
Grünberger, B | 1 |
Cho, HG; Choi, HS; El-Gamal, MI; Hong, JH; Oh, CH; Yoo, KH | 1 |
Batchelor, T; Chamberlain, M; Desideri, S; Grossman, SA; Gujar, S; Nabors, LB; Phuphanich, S; Rosenfeld, M; Supko, JG; Wright, J; Ye, X | 1 |
Callahan, M; Johnson, CS; Jones, T; Matei, D; Perkins, SM; Ramasubbaiah, R; Schilder, J; Sutton, G; Whalen, C | 1 |
Boleslawski, E; Cattan, S; Dharancy, S; Ernst, O; Hebbar, M; Hollebecque, A; Louvet, A; Mathurin, P; Mourad, A; Pruvot, FR; Romano, O; Sergent, G; Truant, S | 1 |
Giménez-Bachs, JM; Nam Cha, S; Salinas-Sánchez, AS; Sánchez-Prieto, R; Serrano-Oviedo, L | 1 |
Bihari, C; Gupta, NL; Jain, D; Rastogi, A; Sarin, SK | 1 |
Hara, T; Kajikawa, J; Kawashima, A; Meguro, N; Miyoshi, S; Nishimura, K; Nonomura, N; Oka, T; Takayama, H; Tanigawa, G; Yamaguchi, S; Yosioka, T | 1 |
Doudican, NA; Orlow, SJ; Quay, E; Zhang, S | 1 |
Asghar, U; Meyer, T | 1 |
Altomare, E; Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bozzi, E; Bresci, G; Di Biase, M; Ginanni, B; Romano, A; Sacco, R; Tumino, E | 1 |
Rexer, H | 3 |
Jirillo, A; Mazurek, M; Palozzo, AC; Trojniak, MP | 1 |
Galle, PR; Gamstätter, T; Niederle, IM; Schadmand-Fischer, S; Schuchmann, M; Spies, PR; Weinmann, A; Wörns, MA | 1 |
Chen, TJ; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Shao, YY; Shen, YC | 1 |
Mori, M; Sprague, J | 1 |
Hara, F; Hirano, N; Iida, K; Ishii, K; Kikuchi, Y; Shiozawa, K; Sumino, Y; Wakui, N; Watanabe, M | 1 |
Cheng, H; Dicker, AP; Force, T; Kari, G; Koch, WJ; Rodeck, U | 1 |
Fiedler, W; Wellbrock, J | 1 |
Chevreau, C; Cottura, E; Garrido-Stowhas, I; Sibaud, V | 1 |
Abbas, H; Billemont, B; Blanchet, B; Coriat, R; Dauphin, A; Goldwasser, F; Harcouet, L; Hornecker, M; Mir, O; Ropert, S; Sassi, H; Taieb, F; Tod, M | 1 |
Awasthi, S; Nagaprashantha, LD; Singhal, J; Singhal, SS; Vatsyayan, R | 1 |
Fukushima, H; Gao, D; Inuzuka, H; Lau, AW; Liu, P; Wan, L; Wang, Z; Wei, W | 1 |
Han, KH; Kim, DY | 2 |
Hagihara, H; Ikeda, F; Kobayashi, S; Kuwaki, K; Miyahara, K; Miyake, Y; Nakamura, S; Nouso, K; Onishi, H; Shiraha, H; Takaki, A; Tomoda, T; Toshimori, J; Yamamoto, K | 1 |
Beckett, L; Eddings, C; Gandara, D; Lara, PN; Lau, DH; Pan, CX; Semrad, TJ | 1 |
Gomez, P; Lacouture, ME | 1 |
Berger, DM; Collins, K; Frommer, E; Hu, Y; Powell, D; Salaski, EJ; Wang, X; Wojciechowicz, D | 1 |
Fan, J; Gao, Q; Gu, FM; Huang, XY; Jiang, JH; Li, QL; Pan, JF; Zhou, J | 1 |
Cheng, S; Moslehi, J; Uraizee, I | 1 |
Ferlitsch, A; Peck-Radosavljevic, M; Pinter, M; Reiberger, T; Rohr-Udilova, N; Sieghart, W | 1 |
El-Gamal, MI; Lee, YS; Oh, CH; Park, JH | 1 |
Busch, J; Fenner, M; Ganser, A; Grünwald, V; Seidel, C; Weikert, S | 1 |
Bartolozzi, C; Iannopollo, M; Lencioni, M; Oliveri, F; Orlandini, C; Petrini, I; Ricasoli, M; Ricci, S | 1 |
de Waal, R; Hulsbergen-van de Kaa, C; Kats-Ugurlu, G; Leenders, W; Maass, C; Mulders, P; Oosterwijk, E; van Herpen, C | 1 |
Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dumas, G; Goldwasser, F; Mir, O; Rodrigues, MJ; Ropert, S; Rousseau, B | 1 |
Lachenmayer, A; Mínguez, B | 1 |
Cabibbo, G; De Giorgio, M; Genco, C; Pressiani, T; Rolle, E; Sacco, R; Spada, F | 1 |
Procopio, G | 1 |
How, GF; Linn, YC; Loh, Y; Mohan, BP | 1 |
Hughes, M; Pickert, A; Wells, M | 1 |
Cooper, T; Watt, TC | 1 |
Berdel, WE; Brandts, C; Ehninger, G; Haibach, M; Hentrich, M; Junghanß, C; Krämer, A; Kramer, M; Krause, SW; Müller-Tidow, C; Pflüger, KH; Ritter, B; Röllig, C; Schleyer, E; Serve, H; Shaid, S | 1 |
Bex, A; Haanen, J | 1 |
Castellano, D; Cella, D; Chen, C; Escudier, B; Gorbunova, VA; Gore, ME; Hutson, TE; Kaprin, A; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Negrier, S; Ou, YC; Rini, BI; Rosbrook, B; Rusakov, IG; Szczylik, C; Tarazi, J; Tomczak, P; Uemura, H | 1 |
Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Mackenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wang, Y; Wood, L | 1 |
Adenis, A; Antonescu, CR; Blay, JY; Bompas, E; Bui, B; Casali, P; Cioffi, A; Coco, P; Coindre, JM; Debiec-Rychter, M; Duffaud, F; Isambert, N; Italiano, A; Keohan, ML; Le Cesne, A; Maki, RG; Rutkowski, P; Schöffski, P; Toulmonde, M | 1 |
Ardlie, K; Chalk, CJ; Dziunycz, P; Garraway, LA; Hofbauer, GF; Jones, R; Kamsukom, N; Kee, D; MacConaill, LE; McArthur, GA; Oberholzer, PA; Palescandolo, E; Piris, A; Robert, C; Roden, C; Schadendorf, D; Sucker, A | 1 |
Reed, MW; Young, RJ | 1 |
Baba, S; Bessho, H; Fujita, T; Ishikawa, W; Iwamura, M; Maeyama, R; Sugita, A; Tabata, K; Tokuyama, Y; Yoshida, K | 1 |
Pratz, KW; Rudek, MA; Smith, BD; Villarroel, MC; Wright, JJ; Xu, L | 1 |
Allegra, M; Bahadoran, P; Ballotti, R; Bertolotto, C; Deville, A; Giacchero, D; Lacour, JP; Ortonne, JP; Passeron, T; Ségalen, C; Thyss, A | 1 |
Di Fiore, F; Ménager, C; Michel, P; Pfister, C; Rigal, O | 1 |
Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H; Sakai, I | 1 |
André, J; Arnault, JP; Boussemart, L; Druillennec, S; Dumaz, N; Eggermont, AM; Escudier, B; Eychène, A; Hollville, E; Kamsu-Kom, N; Lacroix, L; Larcher, M; Malka, D; Mateus, C; Robert, C; Sarasin, A; Soria, JC; Spatz, A; Tomasic, G; Vagner, S; Wechsler, J | 1 |
Liu, H; Shen, Y; Yang, Y; Yao, X | 1 |
Chen, R; Curley, SA; Liu, H; McConkey, DJ; Ward, JF; Zhang, T | 1 |
Amiand, MB; Bard, JM; Bobin-Dubigeon, C; Bouché, O; Heurgue-Berlot, A; Le Guellec, C | 1 |
Agarwal, K; Brendel, VJ; Jarjoura, D; Koh, YW; Koo, BS; McCarty, SK; Porter, K; Ringel, MD; Saji, M; Shah, MH; Wang, C | 1 |
Bernardo, G; Cornalba, G; Delmonte, A; Di Cesare, P; Greco, G; Melchiorre, F; Montagna, B; Poggi, G; Quaretti, P; Riccardi, A; Sottotetti, F; Stella, MG; Tagliaferri, B; Villani, L; Zorzetto, M | 1 |
Asahina, Y; Hoshioka, T; Hosokawa, T; Itakura, J; Izumi, N; Kato, T; Kurosaki, M; Kuzuya, T; Nakanishi, H; Suzuki, Y; Takahashi, Y; Tamaki, S; Tanaka, K; Tsuchiya, K; Ueda, K; Yasui, Y | 1 |
Fang, Z; Wang, ZX; Wei, P; Yang, Z | 1 |
Calvo Aller, E; Castellano, D; Díaz Cerezo, S; González Larriba, JL; Kreif, N; López-Brea, M; Maroto, P; Martí, B | 1 |
Farley-Loftus, R; Lewin, J; Pomeranz, MK | 1 |
Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, RW; Poon, R; Tang, YF; Wong, H; Yao, TJ; Yau, T | 1 |
Lencioni, R | 1 |
Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J | 1 |
Chen, HC; Chen, YL; Hsu, HC; Jeng, YM; Yuan, RH | 1 |
Chlenski, A; Cohn, SL; Guerrero, LJ; Kakodkar, NC; Maitland, ML; Peddinti, RR; Salwen, HR; Tian, Y; Yang, Q | 1 |
Kim, H; Lim, HY | 1 |
Dörken, B; Flörcken, A; Hopfenmüller, W; Pezzutto, A; Singh, A; Takvorian, A; Van Lessen, A; Westermann, J | 1 |
Brown, RE; Buryanek, J; Pfister, S; Rytting, ME; Vats, TS; Wolff, JE | 1 |
Amato, RJ; Flaherty, AL; Stepankiw, M | 1 |
Chen, X; Guan, W; Hu, Z; Li, Y; Liu, F; Peng, E; Ye, Z; Zhuang, Q | 1 |
Ciardiello, F; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T | 1 |
Armeanu-Ebinger, S; Dewerth, A; Eicher, C; Fuchs, J; Kirchner, B; Warmann, SW | 1 |
Fukumoto, M; Matsuda, Y | 1 |
Gotoh, M; Kashiwagi, Y; Nakano, Y; Takeda, H; Yoshino, Y | 1 |
Chen, KF; Chen, PJ; Cheng, AL; Ko, CH; Lin, MW; Liu, CY; Shiau, CW; Tai, WT | 1 |
Aymerich, M; Campo, E; Colomer, D; López-Guerra, M; Montserrat, E; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Villamor, N; Xargay-Torrent, S | 1 |
Hatano, E; Iida, T; Ishii, T; Isoda, H; Kitamura, K; Machimito, T; Shibata, T; Taura, K; Uemoto, S; Yamanaka, K; Yasuchika, K | 1 |
Dai, X; He, F; Lian, J; Ni, Z; Smith, AR; Su, C; Xu, L | 1 |
Alsop, DC; Atkins, MB; Bhasin, M; Bhatt, RS; Brown, V; Goldberg, SN; Mier, JW; Signoretti, S; Wang, X; Zhang, L | 1 |
Ardito, A; Baudin, E; Berruti, A; Daffara, F; De Francia, S; Ferrero, A; Generali, D; Germano, A; Leboulleux, S; Papotti, M; Perotti, P; Priola, AM; Sperone, P; Terzolo, M; Volante, M | 1 |
Adjei, AA; Halling, T; Haug, JL; Kimlinger, TK; Kumar, S; Rajkumar, SV; Ramakrishnan, V; Timm, M; Wellik, LE; Witzig, TE | 1 |
Heuer, V; Kummer, G; Neumann, H; Roy, R; Schultheis, B; Strumberg, D | 1 |
Ishizaki, M; Kaibori, M; Kwon, AH; Matsui, K; Matsushima, H; Nakatake, R; Sakaguchi, T | 2 |
Egawa, C; Kato, T; Miki, H; Nakahira, S; Nakata, K; Okamura, S; Okishiro, M; Suzuki, R; Takatsuka, Y; Takeda, Y; Takeno, A; Tamura, S | 1 |
Baba, H; Beppu, T; Chikamoto, A; Horino, K; Ishiko, T; Masuda, T; Mima, K; Nakahara, O; Okabe, H; Takamori, H; Tanaka, H | 1 |
Hamilton, J; Hong, DS; Ketonen, LM; Kurzrock, R; McCutcheon, IE; Slopis, J; Subbiah, V | 1 |
Alonso, S; Calabrò, F; Caristo, R; Catalano, A; Cerbone, L; Di Paola, ED; Leone, A; Mancuso, A; Messina, C; Sternberg, CN; Vigna, L; Zivi, A | 1 |
Sia, D; Villanueva, A | 1 |
Lee, IJ; Seong, J | 1 |
Bae, SH; Guan, S; Lim, HY; Park, HC; Seong, J; Tak, WY; Tanaka, M; Zeng, ZC | 1 |
Choi, JY | 1 |
Henmi, S; Inuzuka, T; Kimura, T; Kita, R; Kudo, M; Nishikawa, H; Osaki, Y; Saito, S; Sakamoto, A; Sekikawa, A; Takeda, H | 1 |
Gadaleta, CD; Gadaleta-Caldarola, G; Goffredo, V; Mangia, A; Patruno, R; Ranieri, G; Rizzo, A; Sciorsci, RL | 1 |
Ba-Ssalamah, A; Lammer, J; Müller, C; Peck-Radosavljevic, M; Pinter, M; Reisegger, M; Sieghart, W | 1 |
Bassett, RL; Bedikian, AY; Culotta, KS; Dancey, JE; Davies, MA; Deng, W; Fox, PS; Gupta, S; Huang, S; Hwu, P; Hwu, WJ; Kim, KB; Lazar, AJ; Liu, W; Madden, TL; Ng, CS; Papadopoulos, NE; Prieto, VG; Wright, JJ; Xu, Q | 1 |
Lanocita, R; Procopio, G; Verzoni, E | 1 |
Dranitsaris, G; Fang, F; Huang, L; Lacouture, ME; Vincent, MD; Yu, J | 1 |
Akerley, WL; Flaherty, LE; Kirkwood, JM; Lao, CD; Margolin, KA; Moon, J; Othus, M; Sondak, VK; Sosman, JA | 1 |
Albiges, L; Caty, A; Dietrich, PY; Duclos, B; Escudier, B; Geoffrois, L; Gravis, G; Guillot, A; Joly, F; Kohser, F; Laguerre, B; Legouffe, E; Negrier, S; Oudard, S; Rolland, F; Theodore, CA | 1 |
Atsmon, J; Brendel, E; Bulocinic, S; Figer, A; Geva, R; Nalbandyan, K; Shacham-Shmueli, E; Shpigel, S | 1 |
Eisen, T; Escudier, B; Izzedine, H; Mulders, P; Pyle, L; Robert, C; Sternberg, CN; Zbinden, S | 1 |
Allavena, P; Mantovani, A | 1 |
Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Kim, TW; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
Chen, Z; Cheng, AL; Fang, F; Guan, Z; Kang, YK; Kim, JS; Lentini, G; Pan, H; Qin, S; Tak, WY; Tsao, CJ; Voliotis, D; Xu, J; Yang, TS; Yu, S; Zou, J | 1 |
Bruix, J; Dominguez, S; Germanidis, G; Greten, TF; Hilgard, P; Llovet, JM; Mazzaferro, V; Moscovici, M; Nadel, A; Raoul, JL; Ricci, S; Scherubl, H; Scheulen, ME; Sherman, M; Voliotis, D | 1 |
Galle, PR; Marquardt, JU; Teufel, A; Wörns, M | 1 |
Angulo, P; Chen, C; Daily, MF; Evers, BM; Gedaly, R; Hundley, J | 1 |
Brentani, RR; Cooke, VG; Damascena, A; Duncan, MB; Kalluri, R; Keskin, D; Khan, Z; LeBleu, VS; Maeda, G; O'Connell, JT; Rocha, RM; Sugimoto, H; Teng, Y; Vong, S; Xie, L | 1 |
Chang, YF; Chen, CL; Chen, CW; Chiang, IT; Hwang, JJ; Kuo, YC; Lin, WC; Su, SH | 1 |
Düber, C; Galle, PR; Heise, M; Hoppe-Lotichius, M; Koch, S; Niederle, IM; Otto, G; Schuchmann, M; Weinmann, A; Wörns, MA | 1 |
Aoyagi, Y; Fujimaki, S; Kubota, M; Matsuda, Y; Ohkoshi, S; Sanpei, A; Takamura, M; Wakai, T; Yamagiwa, S; Yano, M | 1 |
Bruns, CJ; Cyran, CC; Dietrich, O; Hinkel, R; Ingrisch, M; Nikolaou, K; Paprottka, PM; Pietsch, H; Reiser, MF; Schwarz, B; Sourbron, S; von Einem, J; Wintersperger, BJ | 1 |
Bull, VH; Rajalingam, K; Thiede, B | 1 |
Babić, Z; Balzarini, J; Crkvenčić, M; Kralj, M; Mikecin, AM; Petrova, M; Rajić, Z; Vanderleyden, J; Zorc, B | 1 |
Im, SA; Kang, BY; Kang, YK; Kwon, HC; Lee, SS; Park, SH; Park, SR; Ryoo, BY; Ryu, MH | 1 |
Anract, P; Babinet, A; Boudou-Rouquette, P; Dumaine, V; Goldwasser, F; Larousserie, F; Mir, O | 1 |
Augsten, M; Björklund, AC; Egevad, L; Grander, D; Kharaziha, P; Kroemer, G; Li, Q; Nilsson, S; Panaretakis, T; Rodriguez, P; Rundqvist, H; Ullén, A; Wiklund, P | 1 |
Colecchia, M; Iacovelli, R; Mariani, L; Procopio, G; Torelli, T; Verzoni, E | 1 |
Caravetta, A; Guarino, R; Mollo, F; Peluso, L; Rombolà, F; Spinoso, A | 1 |
Awada, A; Bartholomeus, S; Brendel, E; Christensen, O; de Valeriola, D; Delaunoit, T; Gil, T; Hendlisz, A; Lathia, CD; Lebrun, F; Piccart-Gebhart, M; Radtke, M | 1 |
Gong, RY; Li, XF; Shi, LH; Wang, K; Wang, M; Yan, ZL; Yuan, B | 1 |
Capdevila, J; Corral, J; Grande, E; Grau, JJ; Halperin, I; Iglesias, L; Martínez-Trufero, J; Obiols, G; Segura, A; Tabernero, J; Vaz, MÁ | 1 |
Bay, JO; Blay, JY; Bompas, E; Bousquet, G; Chevreau, C; Clisant, S; Collard, O; Cupissol, D; Fournier, C; Gauthier, E; Isambert, N; Italiano, A; Le Cesne, A; Lemaitre, L; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Robin, YM | 1 |
Sleijfer, S | 1 |
Dudgeon, C; Peng, R; Sebastiani, A; Wang, P; Yu, J; Zhang, L | 1 |
Bies, RR; Jin, Y; Karrison, TG; Maitland, ML; Ratain, MJ; Sharma, MR; Stadler, WM | 1 |
Kondo, M; Maeda, S; Morimoto, M; Morioka, Y; Moriya, S; Nozaki, A; Numata, K; Tanaka, K | 1 |
Bruyere, F; Carmier, D; Combe, P; D'Arcier, BF; Linassier, C; Narciso, B | 1 |
Han, SH; Kang, H; Park, H; Park, K | 1 |
Bui, B; Coindre, JM; Italiano, A; Kind, M; Maki, RG; Roubaud, G | 1 |
Meyer, P; Missana, A | 1 |
Corey, SJ; Park, BJ; Whichard, ZL | 1 |
Dahut, W; English, BC; Federspiel, J; Figg, WD; Gardner, ER; Giaccone, G; Jain, L; Kim, A; Kirkland, CT; Kohn, E; Kummar, S; Peer, CJ; Richardson, ED; Sissung, TM; Troutman, SM; Venzon, D; Widemann, B; Woo, S; Yarchoan, R | 1 |
Choueiri, TK; Je, Y; Richards, CJ; Schutz, FA | 1 |
Celeghini, C; Melloni, E; Norcio, A; Secchiero, P; Voltan, R; Zauli, G | 1 |
Buettner, R; Chang, S; Hedvat, M; Jove, R; Jove, V; Liu, L; Scuto, A; Tian, Y; Van Meter, T; Wen, W; Yang, F; Yen, Y; Yip, ML | 1 |
An, S; Choi, JI; Kim, HB; Kim, HY; Koh, YH; Nam, BH; Park, JW; Woo, SM | 1 |
Ayuso, C; Barrufet, M; Bruix, J; Burrel, M; de Lope, CR; Forner, A; Llovet, JM; Real, MI; Reig, M; Tremosini, S | 1 |
Faris, JE; Zhu, AX | 1 |
Chang, C; Hsu, CL; Huang, CK; Hung, YC; Jeng, LB; Lin, TY; Ma, WL; Wu, MH; Yeh, CC; Yeh, S | 1 |
Du, H; He, L; Lv, N; Ren, J; Wang, S | 1 |
Alsinet, C; Cabellos, L; Friedman, SL; Hoshida, Y; Lachenmayer, A; Llovet, JM; Minguez, B; Thung, S; Toffanin, S; Tsai, HW; Villanueva, A; Ward, SC | 1 |
Boulanger, G; Edeline, J; Jouan, F; Martin, B; Oger, E; Patard, JJ; Rioux-Leclercq, N; Vigneau, C; Zerrouki, S | 1 |
Ibrahim, N; Walsh, WR; Yang, JL; Yu, Y | 1 |
Hatanaka, Y; Minami, T; Nozawa, M; Shimizu, N; Tsuji, H; Uemura, H; Yamamoto, Y | 1 |
Conteduca, V; Dammacco, F; Lauletta, G; Russi, S; Sansonno, D; Sansonno, L | 1 |
Agarwal, S; Elmquist, WF | 1 |
Chang, KH; Chen, YJ; Cheng, SB; Hwang, WL; Teng, CL | 1 |
Bellail, AC; Ding, L; Hao, C; Liu, Y; Lu, G; Olson, JJ; Sun, SY; Wang, G; Wei, F; Yuan, C | 1 |
Gupta, GN; Singer, EA; Srinivasan, R | 1 |
Ancukiewicz, M; Boucher, Y; Demetri, GD; Duda, DG; Eder, JP; Jain, RK; Lahdenranta, J; Morgan, JA; Quek, R; Raut, CP | 1 |
Bruix, J; Forner, A; Llovet, JM | 1 |
Atrash, B; Avery, S; Bavetsias, V; Blagg, J; de Haven Brandon, A; Eccles, SA; Faisal, A; Gonzalez de Castro, D; Linardopoulos, S; Mair, D; Mirabella, F; Moore, AS; Pearson, AD; Raynaud, FI; Sun, C; Swansbury, J; Valenti, M; Workman, P | 1 |
Deblois, F; Devic, S; Heravi, M; Holmes, J; Liang, L; Muanza, T; Radzioch, D; Tomic, N | 1 |
Buti, S; Buttitta, F; Calabrese, F; Cavazza, A; Di Chiara, F; Felicioni, L; Garagnani, L; Marchetti, A; Mengoli, MC; Migaldi, M; Nannini, N; Nicoli, D; Rea, F; Rossi, G; Sartori, G; Schirosi, L; Valli, R | 1 |
Choi, JS; Chung, SH; Joo, CK; Seo, JW | 1 |
Aste, MG; Buti, S; Conte, PF; Cosmai, L; Del Giovane, C; Di Lorenzo, G; Grosso, F; Iacovelli, R; Invernizzi, R; Lucia Manenti, A; Masini, C; Moscetti, L; Onofri, A; Ortega, C; Pagano, M; Porta, C; Procopio, G; Sabbatini, R | 1 |
Cheung, AM; Choi, WW; Chow, HC; Eaves, C; Fung, TK; Han, HH; Ho, C; Kwong, YL; Leung, AY; Lok, S; Ma, AC; Man, CH | 1 |
Ishii, M; Kamo, R; Kobayashi, H; Kumei, A; Tamiya, H; Yanagihara, S | 1 |
Chiang, IT; Hsu, FT; Hwang, JJ; Liu, YC | 1 |
George, S; Hornick, JL; Jagannathan, JP; Ramaiya, NH; Shinagare, AB | 1 |
Liu, BX; Ying, JE; Zhu, LM | 1 |
Bruix, J; Lathia, CD; Llovet, JM; Meinhardt, G; Peña, CE; Shan, M | 1 |
George, J; Nguyen, V; van der Poorten, D | 1 |
Czeche, S; Feldt, S; Franzmann, A; Ludwig, WD; Quinzler, R; Schulz, M; Schüssel, K | 1 |
Culig, Z; Erb, HH; Hobisch, A; Oh, SJ; Santer, FR | 1 |
Dummer, R; Karpova, MB; Levesque, MP; Mangana, J | 1 |
Abrams, SL; Andreeff, M; Bergamo, P; Chiaretti, S; Ciuffreda, L; Cognetti, F; Del Bufalo, D; Foà, R; Konopleva, M; Marchetti, A; Mascolo, MG; McCubrey, JA; Milella, M; Petrucci, MT; Ricciardi, MR; Scerpa, MC; Steelman, LS; Tafuri, A; Tavolaro, S; Tsao, T | 1 |
Dufour, JF | 1 |
Hidaka, H; Kaneko, T; Koizumi, W; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M | 1 |
Chan, P; Cheung, TT; Fan, ST; Pang, R; Poon, RT; Wong, H; Yao, TJ; Yau, T | 1 |
Döme, B; Török, S | 1 |
Abraldes, JG; Bosch, J; D'Amico, M; Fernández, M; García-Pagán, JC; García-Pras, E; Mejías, M | 1 |
Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tang, Y; Tye, G; Yacoub, A | 1 |
Ara, T; Buettner, R; DeClerck, YA; Jove, R; Jove, V; Nam, S; Seeger, R; Wang, Y; Wu, J; Xin, H; Xu, Y; Yang, F; Yu, H | 1 |
LeBlanc, M; Tangen, C | 1 |
Baselga, J; Bermejo, B; Ciruelos, EM; Costa, F; de Moraes, AA; Del Giglio, A; Durán, MÁ; Espié, M; Filho, SC; Garicochea, B; Gil Gil, M; Gómez, P; Hoff, PM; Kwon Ro, S; Li, S; Llombart, A; Mathias, C; Morales, J; Ojeda, B; Pinczowski, H; Ribeiro, RA; Roché, H; Segalla, JG; Van Eyll, B | 1 |
Bozzarelli, S; Carnaghi, C; Giordano, L; Pedicini, V; Personeni, N; Pressiani, T; Rimassa, L; Santoro, A; Sclafani, F; Tronconi, MC | 1 |
Aoudjehane, L; Barbu, V; Blivet-Van Eggelpoël, MJ; Chettouh, H; Desbois-Mouthon, C; Fartoux, L; Housset, C; Priam, S; Rey, C; Rosmorduc, O | 1 |
Camidge, DR; Dasari, A; Diab, S; Drabkin, HA; Flaig, TW; Gore, L; Jimeno, A; Lewis, KD; Messersmith, WA; Weekes, CD | 1 |
Cillo, U; Lombardi, G; Ramirez Morales, R; Vitale, A | 1 |
Artéaga, C; Brardjanian, S; Coton, T; Fabries, P; Guisset, M; Pauleau, G | 1 |
Boudou-Rouquette, P; Cessot, A; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Mallet, V; Mir, O; Pol, S; Ropert, S; Sogni, P | 1 |
Mudur, G | 1 |
Jung, CK; Kang, JH; Kim, JO; Oh, JE; Shin, JY; Yoon, SA; Zhang, XH | 1 |
Chan, SL; Ma, BB; Mok, T | 1 |
Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS | 1 |
Graziadei, I; Grünberger, B; Hucke, F; Kölblinger, C; Königsberg, R; Maieron, A; Müller, C; Peck-Radosavljevic, M; Pinter, M; Sieghart, W; Stauber, R; Vogel, W | 1 |
Hye Khan, MA; Imig, JD; Nagasawa, T | 1 |
Attkisson, E; Aust, MM; Ferreira-Gonzalez, A; Grant, S; Rahmani, M; Williams, DC | 1 |
Spechler, SJ; Wang, DH; Xie, B | 1 |
Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Lee, JL; Park, I; Park, K; Park, S; Song, C | 1 |
Li, ZD; Liao, Y; Liu, Y; Zuo, GQ | 1 |
Haritoglou, C; Hirneiss, C; Kampik, A; Kernt, M; Koenig, S; Neubauer, AS; Thiele, S; Ulbig, MW | 1 |
An, L; Bai, W; Chang, X; Chen, Y; Lou, M; Lu, Y; Lv, J; Qu, J; Wang, C; Yang, Y; Zeng, Z; Zhou, L | 1 |
Akli, S; Duong, MT; Hunt, KK; Keyomarsi, K; Liu, W; Lu, Y; Mills, GB; Wei, C; Wingate, HF; Yi, M | 1 |
Espat, NJ; Falanga, V; Katz, SC; Kurniali, PC; O'Gara, K; Somasundar, P; Wang, LJ; Wang, X | 1 |
Chen, J; He, Z; Sun, W; Xu, W; Yao, J | 1 |
Cohen, RA; Feusner, JH; Lo, L; Marsh, AM | 1 |
Abell, AN; Chen, X; Darr, DB; Duncan, JS; Earp, HS; Frye, SV; Gomez, SM; Granger, DA; Graves, LM; He, X; Hoadley, KA; Jin, J; Johnson, GL; Johnson, NL; Jordan, NV; Kim, WY; Kuan, PF; Major, B; Midland, AA; Nakamura, K; Perou, CM; Sharpless, NE; Smalley, DM; Usary, J; Whittle, MC; Zawistowski, JS; Zhou, B | 1 |
Baldus, C; Basara, N; Brugger, W; Burchert, A; Dreger, P; Fey, M; Finck, A; Giagounidis, A; Götze, K; Heinicke, T; Kröger, M; Linn, YC; Metzelder, SK; Meyer, RG; Mori, M; Müller, L; Neubauer, A; Reiter, A; Salih, HR; Schäfer-Eckart, K; Scholl, S; Schroeder, T; Schultheis, B; Stuhlmann, R; Vöhringer, M | 1 |
Cortes, J; Daver, N | 1 |
Chan, E; Deng, H; Friberg, G; Gilbert, J; Hwang, YC; Mahalingam, D; McCaffery, I; Michael, SA; Mita, AC; Mita, MM; Mulay, M; Puzanov, I; Rosen, LS; Sarantopoulos, J; Shubhakar, P; Zhu, M | 1 |
Braun, S; Brummer, T; Capper, D; Eisenhardt, AE; Fiala, GJ; Halbach, S; Heilmann, K; Herr, R; Röring, M; Saunders, DN; Schamel, WW; von Deimling, A | 1 |
Cui, PH; Doddareddy, MR; Edwards, RJ; Ghassabian, S; Hibbs, DE; Murray, M; Rawling, T; Tattam, BN; Zhou, F | 1 |
Barbare, JC; Chauffert, B; Diouf, M; Dupont, S; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC; Trécherel, E | 1 |
Chan, AC; Chan, P; Cheung, TT; Chiu, J; Fan, ST; Leung, R; Pang, R; Poon, R; Tang, YF; Wong, A; Wong, H; Yao, TJ; Yau, T | 1 |
Heo, J; Woo, HY | 2 |
Du, W; Gong, K; Wang, DL; Zhang, QJ; Zhou, JR | 1 |
Chan, SL; Johnson, P | 1 |
Duan, F; Liu, FY; Song, P; Wang, MQ; Wang, Y; Wang, ZJ | 1 |
Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, KH; Kim, SG; Kim, YJ; Kim, YS; Lee, JE; Lee, SH | 1 |
Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, EH; Kim, SU; Lee, DY; Park, JY; Park, MS; Seong, J | 1 |
Byun, SS; Hong, SK; Jeong, CW; Jeong, SJ; Kwak, C; Lee, SE; Yoon, CY | 1 |
Byrne, M; Estfan, B; Kim, R | 1 |
Basu, B; Kaye, SB; Molife, LR; Moreno Garcia, V | 1 |
Augustine, C; Beasley, GM; Brady, MS; Coleman, AP; Davies, MA; Peterson, BL; Raymond, A; Sanders, G; Selim, MA; Tyler, DS | 1 |
Hayashi, N; Ikeda, I; Inoue, T; Kishida, T; Kobayashi, K; Kubota, Y; Makiyama, K; Minamimoto, R; Miura, T; Murakami, T; Nakaigawa, N; Noguchi, S; Ohgo, Y; Sano, F; Tateishi, U; Ueno, D; Yao, M | 1 |
Amato, R; DeFoe, M; Saxena, S; Willis, J; Zhai, J | 1 |
Bai, XZ; Han, XR; Sun, Y | 1 |
Aktürk, M; Baloş Törüner, F; Coşkun, U; Demirci, U; Konca Degertekin, C | 1 |
Cho, M; Heo, J; Kang, DH; Kim, GH; Song, GA; Woo, HY; Yoon, KT | 1 |
Escobar-Jiménez, F; García-Martín, A; López-Ibarra Lozano, PJ; Triviño-Ibáñez, EM | 1 |
Dong, Z; Nör, JE; Zeitlin, BD | 1 |
Anichini, A; Barbati, C; Carlo-Stella, C; Corradini, P; Devizzi, L; Di Nicola, M; Dodero, A; Farina, L; Gianni, AM; Guidetti, A; Lanocita, R; Locatelli, SL; Malorni, W; Marchianò, A; Matteucci, P; Mortarini, R; Pierdominici, M; Tarella, C | 1 |
Lucas, LM | 1 |
De Luca, M; Di Costanzo, GG; Iodice, L; Lampasi, F; Lanza, AG; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R | 1 |
Anderson, BE; Mackay, D; Svoboda, RM; Welsch, MJ | 1 |
Fujisawa, M; Gleave, ME; Kususda, Y; Miyake, H | 1 |
Hou, T; Li, Y; Ma, Y; Peng, H; Ren, Z; Wei, Y; Zhao, Q | 1 |
Hagiwara, S; Inoue, T; Kudo, M; Nagai, T; Nishida, N; Sakurai, T; Ueshima, K; Watanabe, T | 1 |
Powles, T | 1 |
Chung, AS; Ferrara, N; Finkle, D; Komuves, L; Kowanetz, M; Ngu, H; Peale, F; Wu, X; Zhuang, G | 1 |
Freeman, C; Giles, F; Swords, R | 1 |
Arcaroli, J; Azad, N; Carducci, MA; Dasari, A; Diaz, LA; Donehower, RC; Hidalgo, M; Laheru, DA; McManus, M; Messersmith, WA; Quackenbush, K; Rudek, MA; Taylor, GE; Wright, JJ; Zhao, M | 1 |
Gradishar, WJ | 1 |
Cheng, AL; Hsu, CH; Huang, CC; Lin, SD; Shao, YY | 1 |
Daimon, M; Kaino, W; Kameda, W; Karasawa, S; Kato, T; Oizumi, T; Susa, S; Takase, K; Tomita, Y; Wada, K | 1 |
Duan, F; Gu, J; Jia, D; Liu, X; Ren, S; Ruan, Y; Sun, L; Sun, Z; Wang, L; Zhou, L | 1 |
Dauser, B; Dienes, HP; Dufour, JF; Hayden, H; Peck-Radosavljevic, M; Piguet, AC; Pinter, M; Prager, G; Rohr-Udilova, N; Sieghart, W | 1 |
Kuczyk, MA; Schnoeller, TJ; Schrader, AJ; Schrader, M; Steffens, S | 1 |
Cheng, CW; Chong, TW; Huynh, H; Lau, WK; Ong, RW; Sim, HG; Sim, MY; Yuen, JS | 1 |
Aiello, RA; Alì, M; Caruso, M; La Rocca, R; Licciardello, P; Sanò, MV; Scandurra, G; Taibi, E; Todaro, FM | 1 |
Fabris, L; Ferrero, C; Fiorotto, R; Kim, AK; Locatelli, L; Morell, CM; Okolicsanyi, S; Spirli, C; Strazzabosco, M | 1 |
He, H; Shen, Z; Wang, H; Wang, X; Wu, Y; Zhang, C; Zhao, J; Zhou, W; Zhu, Y | 1 |
Donsky, RS; Fletcher, JA; Griffith, DJ; Heinrich, MC; Liang, CW; Marino-Enriquez, A; McKinley, A; Patterson, J; Presnell, A; Taguchi, T | 1 |
Igarashi, Y; Iida, K; Ishii, K; Kanayama, M; Kanekawa, T; Matsui, D; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N | 1 |
Blanchet, B; Boudou-Rouquette, P; Chaussade, S; Coriat, R; Durand, JP; Goldwasser, F; Michels, J; Mir, O; Pol, S; Ropert, S; Vidal, M | 1 |
Cicala, MV; Fassina, A; Finco, I; Frigo, AC; Iacobone, M; Mantero, F; Mariniello, B; Pezzani, R; Rosato, A; Rubin, B; Zuccolotto, G | 1 |
Allegood, J; Bareford, MD; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Ogretmen, B; Park, MA; Poklepovic, A; Spiegel, S | 1 |
Spârchez, Z | 1 |
Chatzimichail, K; Gkoutzios, P; Kalokairinou, M; Karagiannis, E; Kiltenis, M; Kornezos, I; Malagari, K; Moschouris, H; Papadaki, MG; Stamatiou, K | 1 |
Buchler, T; Cathomas, R; Chastonay, R; Haile, SR; Knuth, A; Liewen, H; Porta, C; Renner, C; Rothermundt, C; Samaras, P; Siciliano, RD; Stenner, F; Stoll, S | 1 |
Cagan, RL; Dar, AC; Das, TK; Shokat, KM | 1 |
Du, H; Li, H; Lin, A; Peng, C; Qiu, W; Seewoo, V; Shen, B; Wang, J; Yang, W | 1 |
Bouzin, C; Calderon, PB; Charette, N; Danhier, P; Feron, O; Gallez, B; Grégoire, V; Jordan, BF; Karroum, O; Kengen, J; Magat, J; Mignion, L; Sonveaux, P; Starkel, P; Verrax, J | 1 |
Agarwala, SS; Chen, CC; Garay, CC; Gesme, DH; Guo, A; Hess, GP; Hill, JW; Liu, Z | 1 |
Bilim, VN; Kato, T; Kawazoe, H; Nagaoka, A; Naito, S; Tomita, Y; Ugolkov, AV; Yuuki, K | 1 |
Ayala, R; Canal, A; Castro, N; Grande, C; Martínez-López, J; Rueda, D | 1 |
Andrews, DW; Camphausen, K; Den, RB; Dicker, AP; Dougherty, E; Friedman, DP; Glass, J; Green, MR; Hegarty, S; Hyslop, T; Kamrava, M; Lawrence, YR; Marinucchi, M; Sheng, Z; Werner-Wasik, M | 1 |
Biasco, G; Erente, G; Lolli, C; Mandrioli, A; Nannini, M; Pantaleo, MA; Saponara, M | 1 |
Filipiak, KJ; Nurzyński, P; Opolski, G; Szczylik, C; Szmit, S; Waśko-Grabowska, A; Zaborowska, M; Żołnierek, J | 1 |
Celeghini, C; di Iasio, MG; Lanza, F; Melloni, E; Ongari, M; Secchiero, P; Tiribelli, M; Voltan, R; Zauli, G | 1 |
Bass, MB; Deptala, A; Dirix, LY; Escudier, B; Fishman, M; Koralewski, P; Kracht, K; Puhlmann, M; Ramlau, R; Ravaud, A; Rini, B; Rogowski, W; Sun, YN; Szczylik, C; Tannir, NM; Tomczak, P | 1 |
Chen, G; Huang, N; Huang, XP; Lin, X; Peng, S; Roth, BL; Wang, S; Wang, SX; Wang, Y; Whaley, R; Zhang, G | 1 |
Dong, J; Evers, BM; Gao, T; Gulhati, P; Kim, JT; Lee, EY; Sasazuki, T; Shirasawa, S; Stevens, PD; Valentino, JD; Weiss, HL; Zaytseva, YY | 1 |
Bronowicki, JP; Chen, XP; Cihon, F; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK | 1 |
Abrahamova, J; Bortlicek, Z; Buchler, T; Dusek, L; Melichar, B; Pavlik, T; Poprach, A; Puzanov, I; Vyzula, R | 1 |
Endo, Y; Kai, K; Kawai, T; Koujima, T; Matsumoto, Y; Miyamoto, M; Nobuhisa, T; Sato, S; Toda, K; Watanabe, N; Watanabe, T; Watanabe, Y | 1 |
Fujisawa, A; Matsumura, Y; Miyachi, Y; Ono, S; Tanioka, M; Tanizaki, H | 1 |
Cowey, CL; Gohil, H; Khandani, AH; Moore, DT; Rathmell, WK | 1 |
Bockisch, A; Ertle, J; Lauenstein, TC; Müller, S; Schlaak, JF; Schlosser, TW; Theysohn, JM | 1 |
Chen, CS; Chen, JM; Gong, GQ; Liu, LX; Liu, QX; Liu, R; Luo, JJ; Qian, S; Qu, XD; Wang, JH; Yan, ZP | 1 |
Huang, W; Jiang, F; Li, S; Li, Y; Yao, S; Yao, Z; Yu, S; Yuan, S; Zhan, W; Zhao, Y | 1 |
Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
Chiang, CP; Hung, CT; Wu, BY | 1 |
Gold, KA; Kim, E; Zhang, J | 1 |
Beaugrand, M; Bolondi, L; Bruix, J; Craxi, A; Galle, PR; Gerken, G; Llovet, JM; Marrero, JA; Mazzaferro, V; Moscovici, M; Nadel, A; Porta, C; Raoul, JL; Sangiovanni, A; Santoro, A; Shan, M; Sherman, M; Voliotis, D | 1 |
Bae, SH; Chung, YH; Kim, BI; Kim, JA; Koh, KC; Lee, D; Lee, HC; Lee, JH; Park, NH; Shim, JH; Shin, ES; Yoon, JH | 1 |
Billemont, B; Blanchet, B; Boudou-Rouquette, P; Cabanes, L; Coriat, R; Franck, N; Goldwasser, F; Mir, O; Ropert, S; Tod, M | 1 |
Canon, JL; Clausse, M; D'Hondt, L; Duck, L; Kerger, J; Machiels, JP; Mardjuadi, F; Medioni, J; Moxhon, A; Musuamba, F; Oudard, S | 1 |
Fujimoto, K; Gemma, A; Horiuchi-Yamamoto, Y; Inoue, Y; Johkoh, T; Kudoh, S; Sakai, F; Taniguchi, H | 1 |
Geisberg, C; Pentassuglia, L; Sawyer, DB | 1 |
Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bertoni, M; Bozzi, E; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Neri, E; Parisi, G; Romano, A; Sacco, R; Sodini, E; Tumino, E | 1 |
Abrahamova, J; Bortlicek, Z; Buchler, T; Melichar, B; Pavlik, T; Poprach, A; Vyzula, R | 1 |
Fuziwara, CS; Hirokawa, M; Matsuse, M; Mitsutake, N; Miyauchi, A; Nishihara, E; Ogi, T; Saenko, VA; Suzuki, K; Tanimura, S; Yamashita, S | 1 |
Angulo, P; Chen, C; Creasy, KT; Daily, MF; Evers, BM; Gedaly, R; Hundley, J; Shah, M; Spear, BT | 1 |
Avril, MF; Billemont, B; Blanchet, B; Coriat, R; Franck, N; Goldwasser, F; Lebbe, C; Mir, O; Pécuchet, N; Tod, M; Viguier, M | 1 |
Dahan, L; Delpero, JR; Esterni, B; François, E; Gasmi, M; Genre, D; Gilabert, M; Giovannini, M; Gonçalves, A; Lamy, R; Largillier, R; Moureau-Zabotto, L; Perrier, H; Raoul, JL; Re, D; Seitz, JF; Tchiknavorian, X; Turrini, O; Viens, P | 1 |
He, X; Hu, BS; Li, Y; Lu, LG; Luo, XN; Shao, PJ; Yu, XY | 1 |
Bornfeld, N; Freistuehler, M; Hilger, RA; Scheulen, M; Steuhl, KP; Westekemper, H | 1 |
Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S; Satoh, T; Tabata, K; Tanabe, K | 1 |
Chen, J; Chen, L; Jiang, Y; Li, C; Li, Y; Ma, Y | 1 |
Cao, L; Li, B; Li, YM; Sui, CJ; Yin, ZF; Zhang, XF; Zhou, YM | 1 |
Yan, SJ; Zhang, FM; Zhang, H | 1 |
Gao, H; Hu, S; Jiang, H; Kong, J; Li, Z; Shi, B; Yang, Y; Yao, M; Zhang, P | 1 |
Kashima, T; Ohno, Y; Tachibana, M | 1 |
Hidaka, H; Kobayashi, S; Kondo, M; Matsunaga, K; Morimoto, M; Numata, K; Ohkawa, S; Okuse, C; Okuwaki, Y; Shibuya, A; Suzuki, M; Takada, J; Tanaka, K | 1 |
Chen, L; Lu, H; Luo, Q; Ruan, M; Shen, Y; Yu, Y; Zhu, R | 1 |
Hatano, E; Iwaisako, K; Koyama, Y; Miyagawa-Hayashino, A; Nagata, H; Nakamura, K; Narita, M; Taura, K; Uemoto, S | 1 |
Halfdanarson, TR; Naraev, BG; Strosberg, JR | 1 |
Bria, E; Pilotto, S; Tortora, G | 1 |
Azzolina, A; Bachvarov, D; Cervello, M; Cusimano, A; Lampiasi, N; McCubrey, JA; Montalto, G | 2 |
Beumer, JH; Bitran, JD; Christner, SM; Egorin, MJ; Lestingi, TM; Nabhan, C; Tolzien, K; Valdez, TV; Villines, D | 1 |
Alsinet, C; Barretina, J; Bruix, J; Cabellos, L; Friedman, SL; Hoshida, Y; Lachenmayer, A; Llovet, JM; Mazzaferro, V; Minguez, B; Newell, P; Savic, R; Schwartz, M; Thung, S; Toffanin, S; Tsai, HW; Villanueva, A; Ward, SC | 1 |
Singal, AG; Subramanian, M; Yopp, AC | 1 |
Giaccone, G; Killian, KJ; Lee, C; Lee, HS; Luo, J; Meltzer, PS; Petrini, I; Roncalli, M; Santoro, A; Steinberg, SM; Tsokos, M; Wang, Y; Zucali, PA | 1 |
Bhaumik, S; Biswas, T | 1 |
Feng, M; Liu, X; Wang, Q; Wang, Z; Yu, T; Yuan, Y; Zhuang, H | 1 |
Barbero, C; Campisi, P; Centofanti, P; Giorgi, M; Molino, F; Rinaldi, M; Salizzoni, S | 1 |
Kaklamani, V; Raffin, M; Reddy, S | 1 |
Banerjee, P; Basu, A; Choi, AM; Gasser, M; Mizumura, K; Otterbein, LE; Pal, S; Waaga-Gasser, AM; Wegiel, B | 1 |
Choi, J; Hwang, JJ; Jang, S; Jeong, IG; Kim, CS; Kim, DE; Kim, MJ; Lee, JH; Ro, S | 1 |
Altomare, E; Bargellini, I; Bartolozzi, C; Bertini, M; Bertoni, M; Bresci, G; Faggioni, L; Federici, G; Ginanni, B; Metrangolo, S; Parisi, G; Romano, A; Sacco, R; Scaramuzzino, A; Tumino, E | 1 |
Claasen, J; Frenzel, LP; Gehrke, I; Hallek, M; Krause, G; Kuckertz, M; Patz, M; Veldurthy, A; Wendtner, CM | 1 |
Chan, CC; Huang, YT; Lee, KC; Lee, TY; Lin, HC; Yang, YY; Yeh, YC | 1 |
Alberola, V; Bennouna, J; Biesma, B; Eisen, T; Gans, S; Gottfried, M; Heigener, D; Le Marie, E; Liao, M; Montegriffo, E; Ong, TJ; Paz-Ares, LG; Santoro, A; Strauss, UP; Sun, Y; Syrigos, K; Vansteenkiste, J; von Pawel, J; Zhang, L | 1 |
Baumann, C; Dahal, BK; Davie, N; Evans, S; Fairman, D; Ghofrani, HA; Grimminger, F; Kilty, I; Kojonazarov, B; Kosanovic, D; Luitel, H; Majewski, M; Phillips, P; Pullamsetti, SS; Schermuly, RT; Seeger, W; Sydykov, A; Tian, X; Wayman, C; Weissmann, N | 1 |
Amigo, G; Antón, A; Esquerdo, G; García-Otín, AL; Lanzuela, M; Martín-Duque, P; Pazo-Cid, RA; Pérez-Gracia, JL; Trufero, JM | 1 |
Fukuda, K; Kataoka, M; Ono, T; Sano, M; Satoh, T; Tamura, Y | 1 |
Brown, P; Leahy, D; Levis, M; Li, L; Nguyen, B; Small, D; Williams, AB | 1 |
Arai, Y; Kawashima, A; Nakai, Y; Nin, M; Nishimura, K; Nonomura, N; Takayama, H; Tanigawa, G; Tsujimura, A; Uemura, M | 1 |
Kaneko, S; Yamashita, T | 1 |
Ikeda, M; Kuwahara, A; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Shimizu, S; Takahashi, H | 2 |
Chen, KF; Chen, PJ; Hsu, CY; Huang, JW; Kim, I; Liu, CY; Shiau, CW; Tai, WT | 1 |
Matsui, O | 1 |
Yamashita, T | 1 |
Hatano, E; Kokudo, N; Nakajima, J; Numata, K | 1 |
Furuse, J; Ikeda, K; Ikeda, M; Izumi, N; Kokudo, N; Kudo, M; Matsui, O; Tateishi, R; Yamashita, T | 1 |
Díaz-Rubio, E; Ladero, JM; Manzano, A; Puente, J; Sastre, J; Zugazagoitia, J | 1 |
Fischer, L; Nashan, B; Seegers, B; Staufer, K; Sterneck, M; Vettorazzi, E | 1 |
He, XS; Hu, AB; Huang, JF; Ju, WQ; Ma, Y; Tai, Q; Wang, DP; Wang, GD; Wu, LW; Zhu, XF | 1 |
Fukui, I; Kitsukawa, S; Saito, K; Takahashi, S; Urakami, S; Yamamoto, S; Yasuda, Y; Yonese, J; Yuasa, T | 1 |
Aikata, H; Chayama, K; Hiramatsu, A; Honda, Y; Kawaoka, T; Miyaki, D; Murakami, E; Naeshiro, N; Nagaoki, Y; Nakahara, T; Takahashi, S; Takaki, S; Tanaka, M; Waki, K | 1 |
Arao, T; Arii, S; Hagiwara, S; Haji, S; Hakamada, K; Hiasa, Y; Hidaka, H; Hirooka, M; Hisai, H; Iso, Y; Izumi, N; Kanazawa, A; Kimura, H; Kubota, K; Kudo, M; Kumada, T; Kuzuya, T; Matsumoto, K; Nagai, T; Nishio, K; Sakurai, T; Sato, S; Shimada, M; Toyoda, H; Toyoki, Y; Tsuchiya, K; Ueshima, K; Utsunomiya, T; Yasui, K | 1 |
Caccialanza, R; Ganini, C; Imarisio, I; Magnani, L; Paglino, C; Porta, C | 1 |
Açmaz, G; Akkar, OB; Atilgan, R; Boztosun, A; Kosar, MI; Ozer, H | 1 |
Alexandre, J; Batteux, F; Chaussade, S; Chéreau, C; Coriat, R; Goldwasser, F; Mir, O; Nicco, C; Ropert, S; Weill, B | 1 |
Fan, X; Haney, CR; Karczmar, GS; Markiewicz, E; Mustafi, D; Stadler, WM | 1 |
Inoue, T; Kawa, G; Kawabata, T; Kinoshita, H; Komai, Y; Matsuda, T; Uemura, Y | 1 |
Bitzer, M; Föller, M; Jilani, K; Lang, E; Lang, F; Lupescu, A; Pasham, V; Plate, A; Qadri, SM; Shaik, N; Zbidah, M; Zelenak, C | 1 |
Blanchet, B; Boudou-Rouquette, P; Coriat, R; Dauphin, A; Durand, JP; Goldwasser, F; Golmard, JL; Loriot, MA; Mir, O; Narjoz, C; Taieb, F; Thomas-Schoemann, A; Tod, M; Vidal, M | 1 |
Abdulrahman, RM; Corssmit, EP; Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JW | 1 |
Chou, H; Fiel, MI; Friedman, SL; Hong, F | 1 |
Fínek, J | 1 |
Kong, LQ; Li, Q; Song, TQ; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xiong, YQ; Xu, HX; Zhang, QB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
Friedman, SL | 1 |
Chung, HC; Jeong, I; Jeung, HC; Kim, GE; Kim, YB; Lee, K; Rha, SY | 1 |
Saito, K | 1 |
Anmarkrud, JA; Huitfeldt, HS; Line, PD; Liu, SZ; Scholz, H; Shi, JH; Wierød, L; Zhang, SJ | 1 |
Baker, SD; Chaudhry, AS; Finkelstein, D; Gibson, A; Inaba, H; Li, L; Roberts, JL; Rubnitz, JE; Schuetz, EG; Zimmerman, EI | 1 |
Balakrishnar, B; Clements, A; Gao, B; Gurney, H; Wong, M; Yeap, S | 1 |
Chen, GG; Ho, RL; Lai, PB; Liu, LP | 1 |
Krzemieniecki, K; Sowa-Staszczak, A; Zygulska, AL | 1 |
Secchiero, P; Tisato, V; Voltan, R; Zauli, G | 1 |
Dogan, E; Koca, D; Olmez, A; Yalcin, S | 1 |
Abou-Alfa, GK; Ang, C; O'Reilly, EM | 1 |
Ahn, SK; Eum, KH; Kang, H; Lee, M | 1 |
Gao, PT; Han, BH; Li, GL; Li, HJ; Ma, J; Mao, WF; Shao, MH; Yuan, CG | 1 |
Chen, D; Chen, W; Liang, LJ; Yang, D; Yin, XY; Zhao, P | 1 |
Björkholm, M; Celsing, F; De Raeve, H; Fristedt, C; Grandér, D; Gruber, A; Jernberg-Wiklund, H; Johnsson, P; Kharaziha, P; Kokaraki, G; Laane, E; Li, Q; Osterborg, A; Panaretakis, T; Panzar, M; Vanderkerken, K; Zhivotovsky, B | 1 |
Bondarde, S; Gradishar, WJ; Jain, M; Kaklamani, V; Lokanatha, D; Lokker, NA; Raina, V; Ro, SK; Sahoo, TP; Schwartzberg, L | 1 |
Maly, DJ; Ranjitkar, P | 1 |
Arie, S | 1 |
Chu, SH; Civin, C; Collector, M; Heiser, D; Huso, D; Kaplan, I; Li, L; Sharkis, SJ; Small, D | 1 |
Abraham, J; Carew, JS; Chua, YX; Druker, BJ; Giles, FJ; Glover, JM; Keller, C; Kilcoyne, A; Loriaux, MM; Michalek, JE; Nelon, LD; Ouyang, Y; Pal, R; Rubin, BP; Tyner, JW | 1 |
Balis, FM; Choyke, PL; Dombi, E; Fox, E; Jayaprakash, N; Kim, A; Korf, B; Martin, S; Muradyan, N; Reddy, A; Tepas, K; Turkbey, B; Widemann, BC; Wolters, P | 1 |
Brümmendorf, TH; Gambacorti-Passerini, C; Wege, H | 1 |
Axelrod, M; Capaldo, BJ; Gioeli, D; Jensen, K; Mackey, A; Roller, DG; Weber, MJ | 1 |
Adamson, PC; Balis, FM; Baruchel, S; Blaney, SM; Burke, M; Fox, E; Glade Bender, J; Ingle, AM; Kim, A; Stempak, D; Weigel, B; Widemann, BC | 1 |
Allensworth, JL; Devi, GR; Diehl, AM; Lyerly, HK; Morse, MA; Rangwala, F; Smith, GR; Thomas, Z; Williams, KP | 1 |
Boni, C; Bracarda, S; Caserta, C; Cinquini, M; Cortesi, E; De Angelis, V; Di Costanzo, F; Falcone, A; Gasparro, D; Labianca, R; Mucciarini, C; Paglino, C; Pazzola, A; Porta, C; Santoro, A | 1 |
Chowdhury, NF; Kuge, Y; Murakami, M; Nishijima, K; Takiguchi, M; Tamaki, N; Yu, W; Zhao, S; Zhao, Y | 1 |
Ebert, MP; Schott, E; Trojan, J | 1 |
Hanumanthu, PL; Keechilat, P; Koyakutty, M; Malarvizhi, GL; Menon, D; Menon, K; Mony, U; Nair, S; Prabhu, R; Retnakumari, AP; Sidharthan, N; Thampi, MV | 1 |
Ma, YT; Palmer, DH | 1 |
Bottai, G; Santarpia, L | 1 |
Dekker, H; Galvani, E; Giovannetti, E; Honeywell, R; Labots, M; Lind, JS; Peters, GJ; Sciarrillo, R; Smit, EF; Verheul, HM | 1 |
Boccagni, P; Burra, P; Cillo, U; D'Amico, F; Kertusha, X; Lodo, E; Lombardi, G; Pastorelli, D; Ramirez Morales, R; Senzolo, M; Vitale, A; Zanus, G | 1 |
Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ | 1 |
Chen, HL; Chen, KF; Chen, PJ; Cheng, AL; Chu, PY; Ichikawa, K; Liu, CY; Shiau, CW; Tai, WT | 1 |
Bussolati, B; Cassoni, P; Marchino, GL; Moggio, A; Pittatore, G; Revelli, A | 1 |
Carbone, DP; Hanna, NH; Lee, JW; Schiller, JH; Traynor, AM; Wakelee, HA | 1 |
Boedi, P; Ganggaiswari, A; Gani, RA; Hasan, I; Lesmana, LA; Luwia, MS; Waspodo, A | 1 |
Berger, MR; Galle, PR; Gockel, I; Graf, C; Hainz, M; Hamdi, S; Maderer, A; Moehler, M; Schimanski, CC; Schmidtmann, I; Theobald, M; Wehler, TC | 1 |
Del Rio, A; Grossi, V; Ingravallo, G; Liuzzi, M; Martelli, N; Murzilli, S; Napoli, A; Simone, C | 1 |
Tan, P; Wei, A | 1 |
Kondo, T | 1 |
Anai, H; Kichikawa, K; Maeda, S; Masada, T; Nishiofuku, H; Sueyoshi, S; Tanaka, T | 1 |
Bechstein, WO; Trojan, J; Welker, MW; Zeuzem, S | 1 |
Barbier, EL; Bouchet, A; Christen, T; Le Duc, G; Lemasson, B; Maisin, C; Rémy, C; Serduc, R | 1 |
Puche-Sanz, I; Vázquez-Alonso, F | 1 |
O'Connor, TM; O'Reilly, SP; Power, DG; Teo, M | 1 |
Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
Camera, L; Colao, A; Del Prete, M; Esposito, R; Faggiano, A; Fonti, R; Marotta, V; Palmieri, G; Ramundo, V; Salvatore, M; Vitale, M | 1 |
Breaker, K; Clemons, J; Flaig, TW; Gao, D; Garfield, D; Naam, M | 1 |
Fang, D; Gao, J; Liu, J; Rao, Z; Zhang, A; Zhang, B; Zhang, Y; Zhao, J; Zhao, Y | 1 |
Chen, J; Fang, H; He, Z; Sun, W; Xu, W; Yao, J | 1 |
Benekli, M; Buyukberber, S; Cetin, B; Guz, G; Inal, S; Memis, L; Ozturk, SC; Turan, N | 1 |
Atkinson, B; Chen, A; Sevin, A | 1 |
Andreeff, M; Borthakur, G; Jin, L; Kantarjian, H; Konopleva, M; Lu, H; Miida, T; Tabe, Y | 1 |
Arma, D; Balabaud, C; Bexiga, MG; Bioulac-Sage, P; Blanc, JF; Castain, C; Chevet, E; Higa, A; Le Bail, B; Marza, E; Rosenbaum, J; Simpson, JC; Taouji, S; Yi, P | 1 |
Banzi, M; Boni, C; Carnaghi, C; Ceriani, R; Cortesi, E; Covini, G; De Giorgio, M; Fagiuoli, S; Fanello, S; Ferrari, D; Giordano, L; Labianca, R; Latini, L; Locopo, N; Lutman, FR; Mucciarini, C; Naimo, S; Porta, C; Pressiani, T; Rimassa, L; Salvagni, S; Santoro, A; Tommasini, MA; Torzilli, G; Tronconi, MC | 1 |
Chang, CC; Chuang, CL; Hsieh, HG; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Teng, TH; Wang, SS | 1 |
Airoldi, A; Belli, LS; Cordone, G; Gentiluomo, M; Mancuso, A; Vangeli, M; Viganò, R; Zavaglia, C | 1 |
Allemeersch, J; Carmeliet, P; Casteleyn, C; Colle, I; Coulon, S; Geerts, A; Heindryckx, F; Libbrecht, L; Stassen, JM; Terrie, E; Van Vlierberghe, H | 1 |
Kimura, T; Miyagawa, T; Suetomi, T; Tsutsumi, M | 1 |
Bandeali, S; Brammer, JE; Lulla, PD; Lynch, GR | 1 |
Fetterly, GJ; Jusko, WJ; Ma, WW; Pawaskar, DK; Straubinger, RM | 2 |
Dai, B; Qin, XJ; Shi, GH; Wang, CF; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
Alden, C; Blumenschein, G; Davis, SE; Herbst, R; Hong, WK; Kim, E; Lee, JJ; Lippman, S; Liu, S; Stewart, D; Tang, XM; Tsao, AS; Wistuba, I | 1 |
Fan, J; Huang, XW; Qiu, SJ; Shi, RY; Wang, WM; Wang, Z; Xu, Y; Yang, XR; Zhang, X; Zhou, J | 1 |
Assouline, SE; Brandwein, J; Caplan, S; Couban, S; Eisenhauer, EA; Foo, A; Kamel-Reid, S; Leber, B; Macdonald, DA; Walsh, W | 1 |
Banzato, A; Bertorelle, R; Ciccarino, P; Della Puppa, A; Denaro, L; Farina, P; Fiduccia, P; Gardiman, MP; Lombardi, G; Polo, V; Zagonel, V; Zustovich, F | 1 |
Ganten, TM; Gotthardt, D; Jaeger, D; Koehler, C; Koschny, R; Stremmel, W | 1 |
Chang, CC; Chen, YC; Hsin, IF; Hsu, SJ; Huang, HC; Lee, FY; Lee, SD; Lin, HC; Lin, YL | 1 |
Dingemans, AM; Grigorieva, J; Groen, HJ; Kuiper, JL; Lind, JS; Roder, H; Roder, J; Smit, EF | 1 |
He, L; Hu, Y; Li, Q; Liu, M; Xi, M; Zhao, L | 1 |
Bühler, A; Döhner, H; Jebaraj, BM; Kienle, D; Stilgenbauer, S; Winkler, D; Zenz, T | 1 |
Luyken, J; Neuhaus, T | 1 |
Addeo, R; Calvieri, A; Caraglia, M; Del Prete, S; Montella, L; Picardi, A; Santini, D; Silletta, M; Tonini, G; Vespasiani, U; Vincenzi, B | 1 |
Cabrera, R; Clark, V; Firpi, R; Horne, P; Limaye, AR; Mills, R; Morelli, G; Nelson, DR; Soldevila-Pico, C | 1 |
Abrey, L; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, JE; DeAngelis, LM; Drappatz, J; Gilbert, MR; Kuhn, J; Lamborn, KR; Lee, EQ; Levin, VA; Lieberman, F; Mehta, MP; Prados, MD; Robins, HI; Wen, PY; Wright, JJ; Yung, WK | 1 |
Rosenthal, H; von Falck, C; Wacker, F | 1 |
Albiges, L; Escudier, B; Iacovelli, R; Lanoy, E | 1 |
Hildt, E; Himmelsbach, K | 1 |
Cabrera, R; Cao, M; Liu, C; Nelson, DR; Ogunwobi, OO; Puszyk, WM; Tian, C; Wang, T; Zhao, X | 1 |
Cronauer, MV; Höpfner, M; Nitzsche, B; Schrader, AJ; Schrader, M; Streicher, W; Zengerling, F | 1 |
Dekervel, J; Nevens, F; Van Cutsem, E; van Malenstein, H; van Pelt, J; Verslype, C; Windmolders, P | 1 |
Duffy, A; Greten, TF; Wilkerson, J | 1 |
Chapman, R; Dowlati, A; Fu, P; Lavertu, P; Nagaiah, G; Remick, SC; Savvides, P; Wasman, J; Wright, JJ | 1 |
Karakiewicz, PI; Sun, M; Trinh, QD | 1 |
Cabibbo, G; Campisi, G; Compilato, D; Genco, C | 1 |
Inagaki, Y; Ito, M; Kasai, C; Kusagawa, S; Nobori, T; Nojiri, K; Ogura, S; Shiraki, K; Sugimoto, K; Takei, Y; Tameda, M; Yamamoto, N; Yoneda, M | 1 |
Sattler, M; Weisberg, E | 1 |
Dekkers, OM; Smit, JW; Verloop, H | 1 |
Fukuda, K; Kataoka, M; Satoh, T; Yanagisawa, R; Yoshino, H | 1 |
Chao, Y; Chung, YH; Han, G; Kim, BI; Lee, TY; Shao, GL; Wang, J; Yang, J; Yoon, JH | 2 |
Boersma-van Ek, W; de Jong, S; de Vries, EG; Hollema, H; Kleibeuker, JH; Kruyt, FA; Pennarun, B | 1 |
Berkers, J; Beuselinck, B; Body, JJ; Debruyne, P; Dumez, H; Elaidi, R; Karadimou, A; Lerut, E; Paridaens, R; Rogiers, A; Schöffski, P; Van Cann, T; Van Poppel, H; Willems, L; Wolter, P | 1 |
Hensley, JR; Kulik, L; Lacouture, ME; Mulcahy, M; Nardone, B; Rademaker, A; West, DP | 1 |
Bauer, S; Bitz, U; Blay, JY; Duffaud, F; Gelderblom, H; Joensuu, H; Montemurro, M; Pink, D; Rutkowski, P; Schütte, J; Trent, J | 1 |
Atkins, MB; Cheng, S; Choueiri, TK; Pastorek, J; Qu, AQ; Signoretti, S | 1 |
Gu, K; He, M; Jiang, GL; Lai, S; Ma, N; Ren, Z; Shao, C; Yu, W; Yu, Z; Yuan, D; Zhang, X; Zhao, J | 1 |
Baker, SD; Billups, CA; Davidoff, AM; Fofana, D; Furman, WL; Hu, S; Leung, W; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Reddick, WE; Santana, VM; Spunt, SL; Stewart, CF; Turner, D; Wu, J | 1 |
Fouzas, I; Klein, CG; Kykalos, S; Nowak, KW; Paul, A; Sotiropoulos, GC; Vernadakis, S | 1 |
Bertossi, M; De Sanctis, R; De Vincenzo, F; Di Tommaso, L; Fattuzzo, G; Giordano, L; Lorenzi, E; Mancini, L; Masci, G; Perrino, M; Rimassa, L; Roncalli, MG; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA; Zuradelli, M | 1 |
Aino, H; Fukuizumi, K; Iwamoto, H; Kajiwara, M; Koga, H; Kurogi, J; Kuromatsu, R; Matsugaki, S; Matsukuma, N; Nagamatsu, H; Nakano, M; Niizeki, T; Ono, N; Sakai, T; Sakata, K; Sata, M; Satani, M; Sumie, S; Tajiri, N; Takata, A; Tanaka, M; Torimura, T; Yamada, S; Yano, Y | 1 |
Hernandez-Gea, V; Llovet, JM; Villanueva, A | 1 |
Adachi, M; Akaza, H; Hyodo, I; Murai, M; Naito, S; Tsukamoto, T | 1 |
Bex, A; de Bruijn, R; Horenblas, S; Kroon, BK; Powles, T; Prevoo, W | 1 |
Grill, V; Melloni, E; Rimondi, E; Secchiero, P; Zauli, G | 1 |
Kikuchi, Y; Kudo, T; Maruyama, K; Shiozawa, K; Sumino, Y; Watanabe, M | 1 |
Altun, A; Boztosun, A; Gulturk, S; Kiliçkap, S; Müderris, II; Ozer, H; Yanik, A | 1 |
Al-Riyami, AZ; Forrest, D; Hudoba, M; Young, S | 1 |
Dei Tos, AP; Del Vescovo, R; Frezza, AM; Santini, D; Schiavon, G; Silletta, M; Tonini, G; Vincenzi, B; Zobel, BB | 1 |
Lin, CI; Lorch, JH; Ruan, DT; Whang, EE | 1 |
Carr, BI; Cavallini, A; Correale, M; D'Alessandro, R; Di Carlo, A; Iacovazzi, PA; Lippolis, C; Messa, C; Refolo, MG | 1 |
Huang, GL; Liu, GJ; Lü, MD; Wang, W; Xie, XH; Xie, XY; Xu, M; Xu, ZF; Zheng, SG; Zheng, YL | 1 |
Hu, ZH; Huang, PY; Huang, Y; Lin, SJ; Liu, JL; Liu, LZ; Ma, YX; Pan, JJ; Song, XQ; Wu, JX; Wu, X; Xu, F; Xue, C; Yu, QT; Zhang, J; Zhang, JW; Zhang, L; Zhao, HY; Zhao, LP; Zhao, YY | 1 |
Arkadopoulos, N; Dimitriadis, G; Psyrri, A; Smyrniotis, V; Vassilakopoulou, M | 1 |
Galle, PR; Gamstätter, T; Koch, S; Marquardt, JU; Nguyen-Tat, M; Niederle, IM; Schuchmann, M; Schulze-Bergkamen, H; Weinmann, A; Wörns, MA | 1 |
Hoekstra, R; Honeywell, RJ; Peters, GJ; van Erp, NP; Verheul, HM; Westgeest, HM | 1 |
Ceder, S; Kharaziha, P; Panaretakis, T; Sanchez, C | 1 |
Hegde, U; Kaloudis, E; Patel, V | 1 |
Chang, AY; Wang, M | 1 |
Guo, H; Lv, Y; Nan, KJ; Ruan, ZP; Tian, T; Wang, WJ; Xu, R | 1 |
Bearz, A; Berretta, M; Cacopardo, B; Dal Maso, L; De Re, V; Di Benedetto, F; Facchini, G; Fiorica, F; Garlassi, E; Lleshi, A; Nasti, G; Spina, M; Tirelli, U | 1 |
Chen, CL; Cheng, YF; Hsu, HC; Kuo, YH; Lu, SN; Wang, CC; Wang, JH | 1 |
Adenis, A; Alt, M; Caty, A; Fumagalli, I; Penel, N; Vanhuyse, M; Zini, L | 1 |
Ararat, M; Atkinson, MA; Brusko, T; Cabrera, R; Chang, LJ; Liu, C; Nelson, DR; Wasserfall, C; Xu, Y | 1 |
Burgers, SA; Dingemans, AM; Groen, HJ; Heideman, DA; Kunst, PW; Mellema, WW; Smit, EF; Thunnissen, E; van Wijk, A | 1 |
Aparicio, AM; Bhatia, S; Lao, CD; Margolin, KA; Moon, J; Othus, M; Ribas, A; Sondak, VK; Weber, JS | 1 |
Chen, J; Sun, W; Xu, WF; Yao, JW | 1 |
Benitez, A; Bowen, T; Lokeshwar, VB; Shamaldevi, N; Yates, TJ | 1 |
Basso, U; Bertuzzi, A; Boglione, A; Comandone, A; De Sanctis, R; Giordano, L; Lutman, FR; Marcon, I; Santoro, A; Soto Parra, H; Stroppa, E | 1 |
Collier, J; Eisen, T; Fairfax, BP; Kaplan, R; Macaulay, VM; Meade, AM; Pratap, S; Protheroe, A; Ritchie, AW; Roberts, IS | 1 |
Cohen, MS; Cohen, SM; Mukerji, R; Samadi, AK; Timmermann, BN | 1 |
Campo, E; Colomer, D; López-Guerra, M; Montraveta, A; Navarro, A; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Xargay-Torrent, S | 1 |
Hu, GY; Yang, L; Yu, SY | 1 |
Fujishima, N; Habuchi, T; Hasunuma, N; Hatakeyama, S; Horikawa, Y; Inoue, T; Narita, S; Notoya, T; Numakura, K; Ohyama, C; Satoh, S; Tsuchiya, N | 1 |
Shlomai, A | 1 |
Bräuninger, A; Gattenlöhner, S; Holz, MS; Janning, A; Renné, C; Spieker, T | 1 |
Dai, X; Ganten, MK; Ganten, TM; Höh, K; Schlemmer, HP; Schmidt, B; Xu, K | 1 |
Bardet, V; Boudou Rouquette, P; Bouscary, D; Chapuis, N; Chesnais, V; Coriat, R; Fontenay, M; Kaltenbach, S; Kosmider, O; Mayeux, P; Radford-Weiss, I; Tamburini, J; Willems, L | 1 |
Acierno, R; Alberti, S; del Boccio, P; Giannelli, G; Maffia, M; Pieragostino, D; Sacchetta, P; Salzet, M; Simeone, P; Tinelli, A; Toto, C; Vergara, D | 1 |
Atkins, MB; Flaherty, KT; Flaherty, L; Kefford, R; Kirkwood, JM; Lee, SJ; Leming, P; Schuchter, LM; Zhao, F | 1 |
Arai, Y; Nakayama, M; Nishimura, K | 1 |
Ambring, A; Björholt, I; Lesén, E; Odén, A; Stierner, U | 1 |
Flaherty, KT; Heitjan, DF; Kang, HC; Keefe, SM; O'Dwyer, PJ; Rosen, MA; Siegelman, ES; Tan, KS | 1 |
Cappelleri, JC; Chen, C; Foley, G; Healey, PJ; Kroes, M; Larkin, J; Mitchell, S; Paine, A; Tumur, I | 1 |
Goertz, RS; Knieling, F; Strobel, D; Waldner, MJ | 1 |
Hayasaka, K; Kanno, M; Kawakami, T; Mitsui, T; Onoda, T; Sato, H; Takahashi, N | 1 |
Armeanu-Ebinger, S; Dewerth, A; Eicher, C; Ellerkamp, V; Fuchs, J; Hildenbrand, S; Thomale, J; Warmann, SW | 1 |
Chang, CY; Cheng, AL; Hsu, C; Lin, CY; Lin, KL; Liu, SH; Ou, DL; Shen, YC | 1 |
Arizumi, T; Kudo, M; Ueshima, K | 1 |
Bernatik, T; Goertz, RS; Knieling, F; Neurath, MF; Strobel, D; Waldner, MJ; Wildner, D; Zopf, S | 1 |
Chen, CS; Chen, WM; Cheng, CL; Chiu, KY; Ho, HC; Li, JR; Ou, YC; Su, CK; Wang, SS; Yang, CK; Yang, CR | 1 |
Brunello, F; Brunocilla, PR; Cantamessa, A; Carucci, P; Castiglione, A; Ciccone, G; Gaia, S; Rizzetto, M; Rolle, E | 1 |
Deming, DA; Goggins, T; Groteluschen, D; Hernan, HR; Holen, KD; LoConte, NK; Lubner, SJ; Mulkerin, DL; Oettel, K; Robinson, E; Schelman, WR; Traynor, AM | 1 |
Agarwal, S; Chi, M; Dudek, AZ; Elmquist, WF; Mittapalli, RK; Oberoi, R; Raza, A; Singhal, M | 1 |
Bogot, N; Grenader, T; Rosenbaum, E; Shavit, L; Zilber, S | 1 |
Borker, R; Fonseca, E; Hess, G | 1 |
Hara, J; Hasegawa, A; Kametaka, H; Koyama, T; Makino, H; Seike, K; Takagi, Y | 1 |
Frampas, E; Koscielny, S; Lassau, N; Vilgrain, V; Vullierme, MP; Zappa, M | 1 |
Pal, SK; Vogelzang, NJ | 1 |
Levra, MG; Novello, S; Pelosi, E; Scagliotti, GV; Solitro, F; Vavalà, T; Veltri, A | 1 |
Beijnen, JH; Harmsen, S; Maas-Bakker, RF; Meijerman, I; Schellens, JH | 1 |
He, ZY; Hua, XD | 1 |
Hammock, BD; Hee Hwang, S; Li, C; Shiu, EY; Wecksler, AT; Weiss, RH; Wettersten, HI | 1 |
Bruno, R; Cabibbo, G; Cammà, C; Colombo, M; Craxì, A; Enea, M; Gasbarrini, A; Grieco, A; Iavarone, M; Petta, S; Villa, E; Zavaglia, C | 1 |
Bar-Yehuda, S; Benjaminov, O; Ciuraru, NB; Cohen, S; Farbstein, M; Fishman, P; Fishman, S; Harpaz, Z; Kerns, WD; Medalia, G; Patoka, R; Silverman, MH; Singer, B; Stemmer, SM | 1 |
Fang, X; Jiang, H; Liang, Y; Liu, H; Liu, J; Liu, L; Meng, X; Song, R; Tian, L; Wang, J; Wang, L; Yin, D; Zheng, T | 1 |
Brandt, R; Dredge, K; Hammond, E | 1 |
An, CM; Han, ZK; Li, ZJ; Ma, J; Tang, PZ; Wang, Z | 1 |
Furuichi, Y; Imai, Y; Kamiyama, N; Moriyasu, F; Rognin, N; Saito, K; Sugimoto, K | 1 |
Ahn, SY; Kweon, YO; Lee, HS; Park, SY; Tak, WY | 1 |
Ascione, A; Cordone, G; De Luca, M; Di Costanzo, GG; Galeota Lanza, A; Imparato, M; Lampasi, F; Mattera, S; Picciotto, FP; Tartaglione, MT; Tortora, R | 1 |
Choi, YJ; Heo, K; Lee, JH; Shim, JW; Yang, K | 1 |
Duan, X; Wang, J; Ye, W; Zhang, M; Zhou, S | 1 |
Ding, ZB; Fan, J; Huang, XY; Ke, AW; Qiu, SJ; Shi, GM; Shi, YH; Wang, XY; Xiao, YS; Yan, J; Zhang, C; Zhang, X; Zhou, J | 1 |
Alasker, A; Bianchi, M; Hanna, N; Hansen, J; Ismail, S; Karakiewicz, PI; Meskawi, M; Perrotte, P; Sun, M; Tian, Z | 1 |
Bellmunt, J; Bracarda, S; Brueckner, A; Dutcher, J; Escudier, B; Hutson, TE; Knox, J; Molnar, I; Procopio, G | 1 |
Bai, W; Fan, DM; Han, GH; He, CY; Li, RJ; Qi, XS; Wang, YJ; Wu, KC; Xia, JL; Yin, ZX; Zhao, Y | 1 |
Chen, B; Chen, W; Huang, YH; Li, JP; Yang, JY | 1 |
Barbieri, F; Carra, E; Daga, A; Favoni, RE; Florio, T; Marubbi, D; Pattarozzi, A | 1 |
Fang, F; Feng, G; Huang, H; Li, G; Pu, C; Ye, X | 1 |
Chi, ZH; Cui, CL; Guo, J; Lian, B; Mao, LL; Sheng, XN; Si, L; Yang, SY | 1 |
Ahluwalia, MS; Grossman, SA; Hilderbrand, SL; Mikkelsen, T; Nabors, LB; Peereboom, DM; Phuphanich, S; Rosenfeld, MR; Supko, JG; Ye, X | 1 |
Amarapurkar, D; Chao, Y; Chen, PJ; Cheng, AL; Geschwind, JF; Goh, KL; Han, KH; Kudo, M; Lee, HC; Lee, RC; Lesmana, LA; Lim, HY; Paik, SW; Park, JW; Poon, RT; Tan, CK; Tanwandee, T; Teng, G | 1 |
Beuselinck, B; Blesius, A; Chevreau, C; Escudier, B; Oudard, S; Ravaud, A; Rolland, F | 1 |
Chen, YJ; Huang, YC; Ko, WC; Lee, JJ; Lin, JC; Liu, CL; Liu, TP; Wu, CH | 1 |
Angevin, E; Castellano, D; Chang, J; Escudier, B; Gschwend, JE; Harzstark, A; Kay, A; Lin, CC; Lopez-Martin, JA; Sen, P; Shi, M; Soria, JC | 1 |
Hong, S; Hong, SS; Jung, KH; Lee, H; Park, BH; Seo, JH; Son, MK; Yan, HH; Yun, SM | 1 |
Baker, SD; Gibson, AA; Hu, S; Li, L; Orwick, SJ; Roberts, JL; Sparreboom, A; Zimmerman, EI | 1 |
Bihan, H; Cohen, R; Coindre, JM; Des Guetz, G; Le Jeune, S; Mourad, JJ | 1 |
Fukamachi, S; Hosokai, H; Matsuzaki, Y; Mizuguchi, Y; Saya, H; Shimizu, A | 1 |
Ashikari, A; Kobayashi, H; Kohno, Y; Namitome, R; Nishiyama, T; Saito, S; Yagi, Y | 1 |
Bartsch, DK; Buchholz, M; Fendrich, V; Holler, JP; Maschuw, K; Rehm, J; Slater, EP; Waldmann, J | 1 |
Chen, YJ; Hsu, ML; Huang, WP; Huang, YC; Ko, WC; Lee, JJ; Lin, JC; Liu, CL; Liu, TP; Wu, CH | 1 |
Andrés, R; Arranz, JA; Cruz, J; del Muro, XG; Domenech, M; Gallardo, E; Maroto, JP; Meana, JA; Mellado, B; Perez-Gracia, JL | 1 |
Anichini, A; Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Mortarini, R | 1 |
Choi, HN; Hong, SE; Jin, HO; Kim, EK; Kim, HA; Kim, JH; Lee, JK; Noh, WC; Park, IC | 1 |
Ashida, S; Fukuhara, H; Inoue, K; Kamada, M; Karashima, T; Kuroda, N; Shuin, T; Taguchi, T; Tamura, K | 1 |
Catusse, J; Engelhardt, M; Follo, M; Ihorst, G; Schnerch, D; Schüler, J; Udi, J; Waldschmidt, J; Wäsch, R; Wider, D | 1 |
Cortesi, E; Iacovelli, R; Mezi, S; Naso, G; Palazzo, A; Pellegrino, D; Trenta, P | 1 |
Chen, HL; Chen, KF; Chen, PJ; Cheng, AL; Lin, CS; Liu, CY; Shiau, CW; Tai, WT | 1 |
Hidaka, H; Koizumi, W; Kokubu, S; Minamino, T; Nakazawa, T; Okuwaki, Y; Shibuya, A; Takada, J; Tanaka, Y; Watanabe, M | 2 |
Bolondi, L; Burroughs, A; Dufour, JF; Galle, PR; Mazzaferro, V; Piscaglia, F; Raoul, JL; Sangro, B | 1 |
Komine, M; Maekawa, T; Maki, N; Murata, S; Ohtsuki, M; Takatsuka, Y | 1 |
Rose, S | 1 |
Afonso, FJ; Anido, U; Antón-Aparicio, L; Fernández-Calvo, O; Lázaro, M; León, L; Ramos, M; Vázquez-Estévez, S | 1 |
Biasco, G; Brandi, G; Calzà, L; Caraceni, P; Cirignotta, F; de Rosa, F; Girolamo, SD; Ricci, CS; Tufoni, M | 1 |
Agris, PF; Fanning, KD; Francis, SP; Harris, KA; Katz, J; Lacy, M; Nicholas, BD; Pagana, J; Shin, JB | 1 |
Dai, Z; Fan, J; Gu, F; Huang, X; Jiang, J; Tan, C; Wang, Z; Xu, M; Yan, J; Zhou, J | 1 |
Bu, Y; Chai, ZT; Jia, QA; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, M; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhu, XD | 1 |
Ambe, CM; Anderson, AJ; Avital, I; Burka, D; Chen, JQ; Goldsmith, PK; Hari, DM; Herrmann, MA; Koizumi, T; Langan, RC; Miller, TC; Mullinax, JE; Ray, S; Rudloff, U; Stojadinovic, A; Thorgeirsson, SS; Wiegand, GW; Xin, HW | 1 |
Chen, EX; Colomer, R; Duncan, G; Grewal, M; Krzyzanowska, M; Moore, MJ; Petronis, J; Quintela-Fandino, M; Siu, LL; Stathis, A; Wang, L; Webster, S; Young, A | 1 |
Conroy, MD; Liu, AX; Liu, C; Schmidt, ES; Sviripa, V; Truong, J; Watt, DS; Zhang, W | 1 |
Chen, L; Gu, J; He, H; Liu, H; Liu, J; Liu, W; Liu, Y; Pan, D; Wang, S; Wu, Q; Xu, J; Xu, L; Zhang, H; Zhu, Y | 1 |
Ackermann, K; Friess, H; Galle, PR; Hartmann, D; Heikenwalder, M; Otto, G; Protzer, U; Puschnik, A; Reisinger, F; Ringelhan, M; Schiemann, M; Schuchmann, M; Sprinzl, MF; Weinmann, A | 1 |
He, K; Yu, J; Zhang, L; Zheng, X | 1 |
Addeo, R; Cennamo, G; Del Prete, S; Iodice, P; Montella, L; Palmieri, R; Russo, P; Sperlongano, P; Sperlongano, R; Vincenzi, B | 1 |
Kim, DY; Kim, YH | 1 |
Jiang, W; Zeng, ZC | 1 |
Damon, LE; Lasater, EA; Lin, KC; Salerno, S; Shah, NP; Smith, CC; Stewart, WK; Zhu, X | 1 |
Grønbæk, H; Køstner, AH; Ladekarl, M; Lassen, U; Olesen, RK; Sorensen, M | 1 |
Aglietta, M; Alberghini, M; Basiricò, M; Bruno, S; Capozzi, F; D'Ambrosio, L; Dell'Aglio, C; Fagioli, F; Ferrari, S; Gammaitoni, L; Grignani, G; Marchiò, S; Picci, P; Pignochino, Y; Sangiolo, D; Soster, M; Torchiaro, E | 1 |
Che, X; Chen, F; Chen, X; Fan, B; Song, X; Wang, J; Wang, X; Yang, D; Zhang, Z | 1 |
Cai, JP; Hao, XY; Hou, X; Lai, YR; Liang, LJ; Yin, XY; Zhai, JM; Zhang, LJ | 1 |
Bies, RR; Jin, Y; Kang, SP; Karrison, TG; Maitland, ML; Ratain, MJ; Sharma, MR; Stadler, WM; Wu, K | 1 |
Beck, JT; Bell-McGuinn, K; Eisenberg, P; Emanuelson, R; Hermann, RC; Hudis, CA; Isaacs, C; Kaklamani, V; Keaton, M; Kirshner, JJ; Levine, E; Lokker, NA; Makari-Judson, G; Medgyesy, DC; Qamar, R; Ro, SK; Rugo, HS; Schwartzberg, LS; Starr, A; Stepanski, EJ; Tauer, KW; Wang, W | 1 |
Abadie-Lacourtoisie, S; Azzouzi, AR; Bigot, P; Chautard, D; Delva, R; Hoarau, N; Latteux, G; Lebdai, S | 1 |
Annunziata, CM; Azad, N; Calvo, K; Chen, CC; Choyke, P; Davidson, B; Edelman, DC; Henning, R; Kohn, EC; Meltzer, P; Minasian, L; Steinberg, SM; Venkatesan, A; Wood, BJ; Yu, M | 1 |
Fetterly, GJ; Hylander, BH; Jusko, WJ; Ma, WW; Pawaskar, DK; Repasky, EA; Straubinger, RM | 2 |
Vogel, W | 1 |
Chen, XG; Feng, ZQ; Huo, LC; Jin, XF; Li, Y; Qin, AF; Song, HR; Wang, K; Zhang, LJ | 1 |
Andersen, KJ; Hamilton-Dutoit, S; Kannerup, AS; Knudsen, AR; Ladekarl, M; Mortensen, FV; Nyengaard, JR; Sasanuma, H | 1 |
Chang, TC; Chao, CC; Huang, SL; Sun, NK | 1 |
Breaker, K; Flaig, IP; Flaig, TW; La Rosa, FG; Naam, M | 1 |
Kim, BK; Kim, DY; Kim, EH; Kim, SU | 1 |
Ding, ZB; Fan, J; Gu, CY; Hui, B; Liu, WR; Peng, YF; Qiu, SJ; Shi, YH; Yang, H; Zhou, J | 1 |
Chao, Y; Feng, G; Han, G; Liu, Z; Lu, L; Shao, G; Teng, G; Wang, J; Wang, M; Yang, J; Yang, R | 1 |
Hui, KM; Ooi, LL; Xia, H | 1 |
Chen, KF; Cheng, AL; Hsieh, CY; Huang, CY; Lin, CS; Shiau, CW; Tai, WT | 1 |
Chan, JA; Jackson, N; Kulke, MH; Malinowski, P; Mayer, RJ; Regan, E | 1 |
de Gramont, A; Dos Santos, C; Faivre, S; Raymond, E; Riveiro, ME; Serova, M; Slimane, K; Tijeras-Raballand, A | 1 |
Berasain, C | 1 |
Brouwer, KL; Gnoth, MJ; Han, T; Lang, D; Lee, JK; Nebot, N; Proctor, WR; Radtke, M; Swift, B; Thakker, DR | 1 |
Albiges, L; Di Palma, M; Escudier, B; Fizazi, K; Levy, A; Loriot, Y; Menard, J | 1 |
Goldschmidt, H; Gütgemann, I; Hose, D; Moehler, T; Neben, K; Raab, MS; Schmidt-Wolf, IG; Witzens-Harig, M; Yordanova, A | 1 |
Awasthi, N; Hinz, S; Schwarz, MA; Schwarz, RE; Zhang, C | 1 |
Bhoori, S; Bongini, M; Flores Reyes, M; Germini, A; Grossi, G; Mariani, L; Mazzaferro, V; Sposito, C | 1 |
Barbare, JC; Chauffert, B; Ezzoukhry, Z; Galmiche, A; Godin, C; Louandre, C; Mazière, JC | 1 |
Eibl, K; Haritoglou, C; Kampik, A; Kernt, M; König, S; Langer, J; Liegl, RG; Siedlecki, J; Thiele, S | 1 |
Bai, W; Fan, DM; Guan, S; Han, GH; Li, HL; Li, HP; Liu, JS; Wang, WJ; Wu, JB; Xu, RC; Yin, ZX; Zhang, ZL; Zhao, Y | 1 |
Gaba, RC; Guzman, G; Kumar, N; Li, Y; Martinez, EM; Parvinian, A; van Breemen, RB; Yap, FY | 1 |
Omrčen, T; Rini, B; Schmidinger, M; Sella, A; Szczylik, C; Torday, L; Vrdoljak, E | 1 |
Bruno, R; Claret, L; Mercier, F | 1 |
Benson, AB; Bergsland, EK; Grabowsky, JA; Huang, Y; Hwang, J; Kelley, RK; Ko, AH; Korn, WM; Kuhn, P; Li, CM; Luttgen, MS; Mulcahy, MF; Munster, PN; Nimeiri, HS; Stucky-Marshall, L; Venook, AP; Vergo, MT; Yeh, BM | 1 |
Eriksson, J; Hendrikse, NH; Poot, AJ; Rongen, M; Schuit, RC; Stigter-van Walsum, M; van der Wildt, B; van Dongen, GA; Windhorst, AD | 1 |
Fuse, N; Hashizume, K; Ito, Y; Kato, K; Kiyota, N; Kuroki, Y; Minami, H; Ohtsu, A; Yamada, Y | 1 |
Banales, JM; Briz, O; Bujanda, L; Herraez, E; Lozano, E; Macias, RI; Marin, JJ; Vaquero, J | 1 |
Bulavina, I; Burdaeva, O; Cassidy, J; Chang, YL; Cheporov, S; Davidenko, I; Garcia-Carbonero, R; Gladkov, O; Köhne, CH; Lokker, NA; O'Dwyer, PJ; Potter, V; Rivera, F; Salazar, R; Samuel, L; Sobrero, A; Tabernero, J; Tejpar, S; Van Cutsem, E; Vladimirova, L | 1 |
Grybäck, P; Kanter, L; Lewensohn, R; Nilsson, S; Sandström, P; Shah, CH; Sherif, A; Ullén, A; Viktorsson, K | 1 |
Harada, M; Honma, Y; Shimizu, S; Takehara, T | 1 |
Ewig, JM; Iyer, P; Mayer, JL | 1 |
Villanueva, A | 1 |
Ahn, H; Ahn, JH; Ahn, S; Ahn, Y; Hong, JH; Kim, CS; Lee, DH; Lee, JL; Park, I; Park, K; Park, SJ; Song, C | 1 |
D'Angelo, S; De Cristofano, R; Secondulfo, M; Sorrentino, P | 2 |
Albizua, E; Arenas, A; Ayala, R; Barrio, S; Burgaleta, C; Gallardo, M; Gilsanz, F; Jiménez-Ubieto, A; Martinez-Lopez, J; Rapado, I; Rueda, D | 1 |
Salem, R; Weintraub, JL | 1 |
Piscaglia, F; Salvatore, V; Venerandi, L | 1 |
Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
Kearns, PR; Knapper, S; Moore, AS; Pearson, AD; Zwaan, CM | 1 |
Banerjee, SK; Hashmi, M; Huang, CH; Leblanc, M; Mehta, S; Moon, J; Rinehart, E; Urba, SG; Williamson, S; Wolf, GT | 1 |
Banzo, I; Carril, JM; Martínez-Rodríguez, I | 1 |
Katano, M; Kiyota, A; Koya, N; Morisaki, T; Onishi, H; Tanaka, H; Umebayashi, M | 1 |
Barbare, JC; Chatelain, D; Chauffert, B; Dupont, S; Ezzoukhry, Z; Galmiche, A; Godin, C; Henaut, L; Louandre, C; Maziere, JC; Regimbeau, JM; Sabbagh, C | 1 |
Grözinger, G; Horger, M; Plentz, R | 1 |
Majno, P; Mentha, G; Toso, C | 1 |
Robert, C; Sibaud, V | 1 |
Bozzarelli, S; Carnaghi, C; Destro, A; Di Tommaso, L; Giordano, L; Ligorio, C; Personeni, N; Pressiani, T; Rimassa, L; Roncalli, M; Santoro, A; Tronconi, MC | 1 |
Pavlick, AC | 1 |
Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z | 1 |
Suh, SJ; Yim, HJ | 1 |
O'Neil, B; Sampat, KR | 1 |
Bargellini, I; Bartolozzi, C; Battaglia, V; Bertini, M; Bresci, G; Faggioni, L; Ginanni, B; Romano, A; Sacco, R | 1 |
Bhattacharyya, H; Cella, D; Chen, C; Escudier, B; Kim, S; Motzer, R; Rini, B; Rosbrook, B; Tarazi, J | 1 |
Boni, C; Bozzarelli, S; Carnaghi, C; Chiara Banzi, M; Chiara Tronconi, M; Cortesi, E; Fagiuoli, S; Fanello, S; Foa, P; Giordano, L; Personeni, N; Pressiani, T; Rimassa, L; Romano Lutman, F; Rota Caremoli, E; Salvagni, S; Santoro, A | 1 |
Akiba, J; Kusano, H; Nakayama, M; Ogasawara, S; Ueda, K; Yano, H | 1 |
Bay, JO; Blay, JY; Bompas, E; Chaigneau, L; Chevreau, C; Cioffi, A; Clisant, S; Fournier, C; Gauthier, E; Isambert, N; Italiano, A; Le Cesne, A; Penel, N; Ray-Coquard, I; Robin, YM | 1 |
Chong, DQ; Choo, SP; Tan, IB; Toh, HC | 1 |
Colombo, N; Herzog, TJ; Kim, BG; Lhommé, C; Markowska, J; Oza, A; Petrenciuc, O; Ray-Coquard, I; Scambia, G; Sehouli, J; Shan, M | 1 |
Bex, A | 1 |
Chen, C; Escudier, B; Gore, ME; Hariharan, S; Hutson, TE; Kim, S; Michaelson, MD; Motzer, RJ; Negrier, S; Oudard, S; Rini, BI; Rosbrook, B; Tarazi, J; Tomczak, P | 1 |
Cho, JY; Choi, MS; Gwak, GY; Kim, YG; Koh, KC; Lee, JH; Lim, HK; Lim, HY; Min, YW; Paik, SW; Paik, YH; Yoo, BC | 1 |
Haraldsdottir, S; Ing, SW; Kendra, K; Li, Q; Olencki, TE; Villalona-Calero, MA | 1 |
Calvani, N; Chiuri, V; Cinieri, S; Fedele, P; Gnoni, A; Lorusso, V; Maiello, E; Morelli, F; Orlando, L; Scavelli, C | 1 |
Alattar, ML; Andreeff, M; Borthakur, G; Burger, J; Cortes, J; Daver, N; Dellasala, S; Faderl, S; Garcia-Manero, G; Grunwald, MR; Kadia, T; Kantarjian, H; Konopleva, M; Levis, M; Nazha, A; Pierce, S; Rajkhowa, T; Ravandi, F; Richie, MA; Rudek, MA | 1 |
Anthony Greco, F; Hainsworth, JD; Penley, WC; Shipley, DL; Thompson, DS; Waterhouse, DM; Webb, CD | 1 |
Gong, F; Ma, J; Shen, J; Zhang, F; Zhang, L; Zhang, P | 1 |
Carlo-Stella, C; Cleris, L; Giacomini, A; Gianni, AM; Guidetti, A; Locatelli, SL; Righi, M; Saba, E | 1 |
Hou, JN; Jiang, MD; Wang, Z; Weng, M; Wu, XL; Xu, GS; Xu, H; Zeng, WZ | 1 |
Ammi, M; Azzouzi, AR; Baumert, H; Beauval, JB; Bensalah, K; Berger, J; Bernhard, JC; Bigot, P; Escudier, B; Fardoun, T; Grenier, N; Hétet, JF; Lagabrielle, S; Lebdai, S; Long, JA; Paparel, P; Patard, JJ; Rioux-Leclercq, N; Rouprêt, M; Soulié, M; Xylinas, E | 1 |
Akaza, H; Chen, C; Kanayama, H; Kim, S; Naito, S; Ozono, S; Shinohara, N; Tarazi, J; Tomita, Y; Tsukamoto, T; Ueda, T; Uemura, H | 1 |
Waxman, DJ; Zhang, K | 1 |
Funakoshi, T; Galsky, MD; Latif, A | 1 |
Duan, W; George, J; Hu, Z; Lam, V; McLeod, D; Qiao, L; Tian, A; Wang, XM; Wilson, GS | 1 |
Agerbaek, M; Donskov, F; Fode, K; Folkmar, TB; Smidt-Hansen, T | 1 |
Aparo, S; Bakalarski, P; Berz, D; Charpentier, KP; Dubel, G; Eng, Y; Espat, J; Faricy-Anderson, K; Kaubisch, A; Luppe, D; Mantripragada, K; Martel, D; Miner, T; Perez, K; Plette, A; Rosati, K; Safran, H; Victor, J; Wingate, P | 1 |
Chung, CW; Jeong, YI; Kang, DH; Kim, CH; Kim, DH; Kwak, TW; Lee, HM | 1 |
Chandran, P; Gupta, N; Keechilat, P; Koyakutty, M; Malarvizhi, GL; Nair, S; Retnakumari, AP | 1 |
Fujiyama, Y; Hira, D; Morita, SY; Noda, S; Shioya, M; Terada, T | 1 |
Dent, P; Fisher, PB; Grant, S; Hamed, HA; Yamaguchi, Y | 1 |
Ferrero, S; Leone Roberti Maggiore, U; Valenzano Menada, M; Venturini, PL | 1 |
El Tal, AK; Ganger, LK; Mehregan, DA; Remichofsky, CJ | 1 |
Atkins, J; Busaidy, N; Fu, S; Hong, D; Kurzrock, R; Naing, A; Sherman, S; Wheler, J | 1 |
Dekervel, J; van Pelt, J; Verslype, C | 1 |
Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H | 1 |
Dai, XF; Ding, J; Ma, CM; Ren, JH; Wu, G; Zhang, RG | 1 |
Al-Harbi, H; Choueiri, TK; Heng, DY; Knox, JJ; Kollmannsberger, C; MacKenzie, M; North, S; Rini, BI; Vickers, MM | 1 |
Gong, R; Liu, LR; Nie, LH; Song, TR; Wang, JZ; Wazir, R; Wei, Q; Zhao, RN | 1 |
Aloia, TA; Boktour, M; Burroughs, SG; Frenette, CT; Gaber, AO; Galati, J; Ghobrial, RM; Kaseb, A; Monsour, H | 1 |
Abecassis, M; Atassi, R; Baker, T; Ganger, D; Hickey, R; Kulik, L; Lewandowski, RJ; Memon, K; Miller, FH; Mulcahy, M; Nayar, R; Salem, R; Vouche, M; Yaghmai, V | 1 |
Bioulac-Sage, P; Blanc, JF; Carteret, T; Laumonier, H; Poullenot, F; Saric, J | 1 |
Shen, HJ; Wang, YH; Xu, J | 1 |
Allegra, M; Bahadoran, P; Ballotti, R; Giacchero, D; Hofman, P; Lacour, JP; Le Duff, F; Long-Mira, E; Passeron, T | 1 |
Bargellini, I; De Maria, N; De Simone, P; Dufour, JF; Goulis, I; Marinho, RT | 1 |
De Vita, F; Di Marco, V; Koskinas, J; Semela, D; Toniutto, P; Verslype, C | 1 |
Barbier, L; Belghiti, J; Faivre, S; Fuks, D; Le Treut, YP; Muscari, F; Pessaux, P | 1 |
Chai, ZT; Gao, DM; Kong, LQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Xu, HX; Zhang, JB; Zhang, W; Zhu, XD; Zhuang, PY | 1 |
Al Ghazal, A; Arndt, A; Cronauer, MV; Kraft, K; Müller, J; Schrader, AJ; Schrader, M; Skowronek, P; Steinestel, J; Steinestel, K | 1 |
Fiel, I; He, X; Savić, R; Schuchman, EH | 1 |
Fu, SH; Hammock, BD; Hwang, SH; Morisseau, C; Nguyen, LV; Wecksler, AT; Zhang, G | 1 |
Augsten, M; Eriksson, LC; Hultcrantz, R; Mollbrink, A; Stål, P | 1 |
Harada, M; Honma, Y | 2 |
Bourget, K; Cui, PH; Gillani, TB; Murray, M; Rawling, T; Wang, XS; Zhou, F | 1 |
Chen, YL; Ding, X; Fang, W; Gao, F; Gao, Z; Ji, G; Liu, Y; Wang, J; Zhang, J | 1 |
Ao, JY; Chai, ZT; Kong, LQ; Li, JQ; Lu, L; Sun, HC; Tang, ZY; Wang, L; Wang, WQ; Wu, WZ; Zhang, KZ; Zhang, QB; Zhang, W; Zhang, YY; Zhu, XD | 1 |
Carithers, R; Halldorson, J; Jia, N; Lin, EH; Liou, I; Perkins, J; Rao, S; Reyes, J; Stohr, E; Yeh, M | 1 |
Chen, JW; Guo, YJ; Huang, WS; Meng, XC; Pang, PF; Shan, H; Zhou, B; Zhu, KS | 1 |
Stein, SM | 1 |
Lu, J; Qiu, Y; Shen, N; Wang, Z; Wei, Y; Yang, G; Yang, N; Yi, B | 1 |
Bedikian, AY; Falchook, G; Fu, S; Ganesan, P; Hong, DS; Janku, F; Kies, M; Kurzrock, R; Laday, S; Naing, A; Piha-Paul, S; Tsimberidou, AM; Wheler, J; Wolff, RA | 1 |
Fischer, T; Heidel, FH; Jentsch-Ullrich, K; Krogel, C; Luehr, H; Schalk, E; Schnoeder, TM; Wolleschak, D | 1 |
Aziz, K; Cades, JA; Chettiar, ST; Cosgrove, D; Gajula, RP; Gandhi, N; Geschwind, JF; Hales, RK; Herman, JM; Kumar, R; Maitra, A; Menon, S; Pawlik, TM; Taparra, K; Torbenson, MS; Tran, PT; Velarde, E; Wild, AT; Williams, RD; Wong, J; Zeng, J | 1 |
Bai, J; Chen, YL; Ding, X; Gai, L; Li, HP; Xu, L; Xu, Q; Ye, XL; Zhang, L; Zhang, X; Zhang, YX | 1 |
Angulo, P; Chen, C; Cohen, DA; Daily, MF; Evers, BM; Galuppo, R; Gedaly, R; Hundley, J; Musgrave, Y; Shah, M; Spear, BT | 1 |
Eisner, F; Gerger, A; Pichler, M; Samonigg, H; Schaberl-Moser, R | 1 |
Rombolà, F; Spinoso, A | 1 |
Helft, PR | 1 |
Choi, KY; Joh, JW; Kang, KJ; Kim, DS; Kim, G; Kim, JP; Kwon, JH; Lee, N; Moon, YH; Park, JY; Shin, JH; Wang, HJ; Yu, YS | 1 |
Ayuso, C; Bruix, J; Darnell, A; Forner, A; Llarch, N; Reig, M; Rimola, J; Ríos, J; Rodriguez-Lope, C; Torres, F | 2 |
Baker, SD; Cai, X; Chen, Z; Christensen, R; Inaba, H; Li, L; Navid, F; Regel, J | 1 |
Atil, B; Berger, W; Groza, D; Heffeter, P; Jungwirth, U; Keppler, BK; Koellensperger, G; Körner, W; Kryeziu, K; Mohr, T | 1 |
Al-Marrawi, MY; Brennan, MC; Dykes, TM; El-Deiry, WS; Saroya, BS; Yang, Z | 1 |
Arai, Y; Ikeda, M; Kondo, S; Kuwahara, A; Mitsunaga, S; Morizane, C; Ohno, I; Okusaka, T; Okuyama, H; Satake, M; Shimizu, S; Takahashi, H; Ueno, H | 1 |
Chan, C; Felsher, DW; Gamrekelashvili, J; Greten, TF; Hewitt, S; Kapanadze, T; Kapoor, V; Korangy, F; Ma, C; Manns, MP; Zender, L; Zhao, F | 1 |
Prado, CM | 1 |
Joo, J; Kim, CM; Kim, H; Kim, HY; Lee, WJ; Park, JW; Woo, SM | 1 |
Albiges-Sauvin, L; Antoun, S; Baracos, VE; di Palma, M; Escudier, B; Fizazi, K; Iacovelli, R; Lanoy, E; Loriot, Y; Merad-Taoufik, M | 1 |
Fukunishi, S; Higuchi, K; Nishikawa, T; Nouda, S; Sanomura, M; Sasaki, Y; Takahashi, Y; Umegaki, E | 1 |
Brendel, E; Broto, JM; Cubedo, R; del Muro, XG; Gallego, O; López-Pousa, A; Martín-Liberal, J; Tirado, OM | 1 |
Cao, D; Chen, C; Chen, SZ; Ding, J; Feng, GS; Han, T; Huang, L; Sun, W; Tang, L; Wang, HY; Wang, X; Wen, W; Wu, MC; Xiang, DM | 1 |
Andersen, NJ; Baker, LH; Boguslawski, EA; Dawes, MJ; Duesbery, NS; Dykema, KJ; Froman, RE; Furge, KA; Kamstock, DA; Kitchell, BE; Krivochenitser, RI; Nickoloff, BJ; Thomas, DG | 1 |
Itoh, K; Komai, Y; Matsubara, N; Mukai, H; Naito, Y; Sakai, Y | 1 |
Gong, K; Li, J; Li, W; Liu, T; Mei, L; Wan, J; Yu, C | 1 |
Aikata, H; Awai, K; Chayama, K; Fujino, H; Fukuhara, T; Hiramatsu, A; Ishikawa, M; Kakizawa, H; Kan, H; Kawaoka, T; Kobayashi, T; Masaki, K; Miyaki, D; Naeshiro, N; Nakahara, T; Takahashi, S; Urabe, A | 1 |
Ainora, ME; Annicchiarico, BE; Caracciolo, G; Di Stasio, E; Garcovich, M; Gasbarrini, A; Landolfi, R; Lupascu, A; Pompili, M; Ponziani, F; Rapaccini, GL; Riccardi, L; Roccarina, D; Siciliano, M; Zocco, MA | 1 |
Cho, HJ; Choi, HS; Choi, JH; El-Gamal, MI; Kim, G; Lee, SH; Oh, CH; Sim, T; Yoo, KH | 1 |
Dokduang, H; Juntana, S; Khuntikeo, N; Loilome, W; Namwat, N; Riggins, GJ; Techasen, A; Yongvanit, P | 1 |
Burkhardt, C; Johnson, C; Miller, KD; Mina, LA; Yu, M; Zon, R | 1 |
Biolato, M; Grieco, A; Lombardo, A | 1 |
Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Santini, F; Ulisse, S | 1 |
Chen, MH; Chen, ML; Cheng, AL; Lu, WC; Yan, BS; Yang, PC; Yu, SL | 1 |
Chang, YC; Cheng, AL; Hsu, C; Lee, BS; Lin, LI; Liou, JY; Ou, DL | 1 |
Dufour, JF; Erös de Bethlenfalva-Hora, C; Geier, A; Kettenbach, J; Mertens, JC; Piguet, AC; Schmitt, J; Terracciano, L; Weimann, R | 1 |
Abdel-Rahman, O; Abdel-Wahab, M; Abdel-Wahab, S; Elbassiony, M; Ellithy, M; Shaker, M | 1 |
Ikehata, Y; Kitamura, H; Masumori, N; Takahashi, S; Tsukamoto, T | 1 |
Gascoyne, RD; Go, RS; Greenwald, DR; Horning, S; Kahl, BS; King, D; Kolesar, J; Li, H; Luger, SM; Patel, T | 1 |
Anderson, SK; Buckner, JC; Flynn, PJ; Galanis, E; Giannini, C; Jaeckle, KA; Kaufmann, TJ; Kimlinger, TK; Kumar, SK; Lafky, JM; Northfelt, DW; Uhm, JH | 1 |
Bianco, R; Damiano, V; Formisano, L; Martignoni, G; Massari, F; Nappi, L; Rosa, R; Scarpa, A; Tortora, G | 1 |
Beijnen, JH; de Vries, N; Schinkel, AH; Sparidans, RW; Tang, SC; Wagenaar, E | 1 |
Beil, W; Holstein, A; Kovacs, P | 1 |
Chen, D; Li, SQ; Liang, LJ; Peng, BG; Xiao, WK; Yin, XY; Zhao, P | 1 |
Bartsch, DK; Doll, D; Greene, BH; Hoffmann, S; Khoruzhyk, M; Ramaswamy, A; Roth, S; Wunderlich, A | 1 |
Hashida, T; Inokuma, T; Kanamori, K; Kitada, N; Konishi, A; Suginoshita, Y; Tanaka, S | 1 |
Banerjee, P; Begum, S; Castellanos, MR; Debata, PR; Genzer, O; Kleiner, MJ; Mata, A | 1 |
Abernethy, AP; Chen, C; George, DJ; Harrison, MR; Kirkendall, DT; Korytowsky, B; Stepanski, EJ; Walker, MS | 1 |
Enomoto, M; Fujii, H; Hagihara, A; Iwai, S; Kawada, N; Kawamura, E; Morikawa, H; Tamori, A; Teranishi, Y | 1 |
Donnellan, F; Gill, S; Haque, M; Hashim, AM; Shingina, A; Suen, M; Weiss, AA; Yoshida, EM | 1 |
An, JZ; Dou, KF; Gong, ZB; He, Y; Li, JJ; Li, QJ; Li, XL; Wang, DS; Wang, S; Yang, F; You, N; Zhou, L | 1 |
Natori, T; Yamaguchi, M | 1 |
Choi, GH; Kang, YK; Kim, KM; Kim, MJ; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Shin, YM | 1 |
Baselga, J; Costa, F; Gomez, H; Gradishar, WJ; Hudis, CA; Petrenciuc, O; Rapoport, B; Roche, H; Schwartzberg, LS; Shan, M | 1 |
Booth, L; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Sajithlal, GB; Syed, J; Tavallai, S | 1 |
Degen, A; Egberts, F; Garbe, C; Gutzmer, R; Hauschild, A; Kilian, K; Poppe, LM; Trefzer, U; Ugurel, S; Weichenthal, M | 1 |
Bian, X; Bie, P; Cui, Y; Liu, C; Liu, L; Qian, C; Shan, J; Shen, J; Wu, L; Xia, F; Xu, Y; Yang, Z; Zhang, Q; Zhang, X | 1 |
Hargreaves, S; Hull, D; Hussain, SA; Johnson, PJ; Ma, YT; Palmer, DH; Ross, PJ; Smith, AJ | 1 |
Finn, RS; Gish, RG; Marrero, JA | 1 |
Fan, WZ; Huang, YH; Li, JP; Wang, Y; Yang, JY; Zhang, YQ | 1 |
Adjei, AA; Bible, KC; Croghan, G; Erlichman, C; Jett, J; Kaufmann, SH; Kumar, SK; Markovic, SN; Marks, R; Molina, J; Moynihan, T; Qin, R; Quevedo, F; Richardson, R; Tan, A | 1 |
Chen, XG; Huang, HH; Jin, B; Li, Y; Lu, CS; Ma, C; Tang, K; Yin, DL | 1 |
Allegra, M; Bahadoran, P; Ballotti, R; Bastian, BC; Bollag, G; Botton, T; Burton, EA; Garrido, MC; LeBoit, PE; McCalmont, TH; Nelson, T; Rocchi, S; Sparatta, A; Vemula, SS; Yeh, I | 1 |
Aljubran, A; Maraiki, F | 1 |
Deng, L; Jia, Q; Ren, Z; Shen, H; Wang, Y; Wu, W | 1 |
Aulitzky, W; Berdel, WE; Blau, I; Brandts, C; Brunnberg, U; Duyster, J; Ehninger, G; Fischer, T; Giagounidis, A; Heinecke, A; Krämer, A; Kreuzer, KA; Krug, U; Kunzmann, V; Müller-Tidow, C; Neubauer, A; Noppeney, R; Ottmann, O; Reichle, A; Sauerland, MC; Schaich, M; Serve, H; Steffen, B; Stuhlmann, R; Thiede, C; Wagner, R; Wandt, H | 1 |
Amoroso, D; Andreuccetti, M; Falcone, A; Fontana, A; Galli, C; Galli, L; Landi, L; Lombardi, G; Porta, C; Zagonel, V; Zustovich, F | 1 |
Agarwal, KL; Bakris, GL; Bhatta, SS; Cohen, EE; Karrison, T; Maitland, ML; Ratain, MJ; Seiwert, TY; Sit, L; Vokes, EE; Wroblewski, KE | 1 |
Abou-Alfa, GK; Capanu, M; Chou, JF; Chung, KY; Gansukh, B; Katz, SS; Lee, JK; Ma, J; O'Reilly, EM; Reidy-Lagunes, D; Saltz, LB; Segal, NH; Shia, J; Yu, KH | 1 |
Moroni, M; Zanlorenzi, L | 1 |
Chen, KF; Chen, PJ; Chu, PY; Huang, HP; Huang, JW; Liu, CY; Shiau, CW; Tai, WT | 1 |
Greer, PA; Leduc, C; Nagaria, TS; Sangrar, W; Squire, JA; Williams, JL | 1 |
Di Fiore, A; Di Fiore, F; Drieux, F; François, A; Kermiche-Rahali, S; Scotté, M | 1 |
Cha, J; Han, KH; Kim, JW; Lee, IJ; Seong, J | 1 |
Baracos, VE; Maia, YL; Ormsbee, M; Prado, CM; Sawyer, MB | 1 |
Barney, BM; Bauer, HJ; Laack, NN; Macdonald, OK; Markovic, SN; Miller, RC; Olivier, KR; Sarkaria, JN | 1 |
Chen, CL; Dooley, S; Feldman, D; French, SW; Jeong, JH; Kashiwabara, C; Liu, JC; Machida, K; Mishra, L; Petrovic, L; Sher, L; Tsukamoto, H | 1 |
Brandt, U; Bruix, J; Chen, LT; Finn, RS; Gomez-Martin, C; Kang, YK; Kim, TY; Klümpen, HJ; Kunz, T; Paquet, T; Poon, RT; Rodriguez-Lope, C; Sellami, D; Yau, T | 1 |
Cucchetti, A; Dietrich, CF; Piscaglia, F; Salvatore, V | 1 |
Feng, M; Li, G; Lu, L; Qian, X; Rao, J; Wang, X; Zhang, F | 1 |
D'Andrea, K; Flaherty, KT; Jilaveanu, LB; Kirkwood, JM; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Wilson, M; Zhao, F; Zito, CR | 1 |
Chang, KC; Chen, KF; Chu, PY; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, LM | 1 |
Escudero-Ortiz, V; Pérez-Ruixo, JJ; Valenzuela, B | 2 |
Lang, H; Ricke, J; Schlaak, J | 1 |
Deng, YR; Diehl, AM; Gershwin, ME; He, XS; Lian, ZX; Liu, CH; Liu, P; Lu, FT; Ma, HD; Tsuneyama, K; Wang, YH; Yang, W | 1 |
Dikomey, E; Gal, A; Gleißner, L; Grénman, R; Grob, TJ; Knecht, R; Kriegs, M; Laban, S; Petersen, C; Steinmeister, L | 1 |
Kobayashi, M; Komatsu, K; Kubo, T; Kurokawa, S; Morita, T; Nakano, K; Natsui, S; Nukui, A | 1 |
Cormode, DP; Farokhzad, OC; Fayad, ZA; Gianella, A; Kim, Y; Labarre, MP; Langer, R; Mieszawska, AJ; Mulder, WJ; Ozcan, C; Petrov, A; Priem, B; van Rooy, I | 1 |
Assenat, E; Causse, A; Del Rio, M; Evrard, A; Gongora, C; Jarlier, M; Leconet, W; Martineau, P; Mazard, T; Robert, B; Simony, J; Torro, A; Vezzio-Vie, N; Ychou, M | 1 |
Alfieri, RR; Bonelli, MA; Caffarra, C; Cavazzoni, A; Fumarola, C; Galetti, M; Galvani, E; Generali, D; La Monica, S; Petronini, PG | 1 |
Amoh, Y; Fujita, T; Ikeda, M; Iwamura, M; Matsumoto, K; Mii, S | 1 |
Baker, SD; Buaboonnam, J; Enemark, EJ; Inaba, H; Mullighan, CG; Neale, GA; Olsen, SR; Orwick, S; Rubnitz, JE; Shurtleff, S; Wang, YD; Zatechka, DS; Zimmerman, EI | 1 |
Hiyama, Y; Kato, S; Matsuda, Y; Shibamori, K; Tabata, H; Takei, F; Yanase, M | 1 |
Ichiyanagi, N; Kamata, S; Yoshinaga, A | 1 |
Garcia-Donas, J; Jonasch, E; Rodriguez-Antona, C | 1 |
Feng, FE; Jiang, ZH; Lin, XQ; Lu, J | 1 |
Armand, JP; de Baere, T; Dessen, P; Lassau, N; Lazar, V; Le Berre, MA; Loriot, Y; Massard, C; Meurice, G; Peña, C; Robert, C; Robert, T; Soria, JC | 1 |
Boucher, E; Chao, Y; Cheng, AL; Decaens, T; Ezzeddine, R; Han, KH; Heo, J; Hsu, CH; Hu, TH; Jeng, LB; Johnson, PJ; Komov, D; Kudo, M; Liu, D; Lu, L; Paik, SW; Park, JW; Philip, PA; Poon, RT; Qin, S; Raoul, JL; Robles-Aviña, J; Sobhonslidsuk, A; Tak, WY; Walters, I; Xu, J; Yan, L | 1 |
Kelley, RK | 1 |
Assenat, E; Blanc, JF; Boige, V; Boucher, E; Bruix, J; Chang, C; Chao, Y; Decaens, T; Ezzeddine, R; Fartoux, L; Finn, RS; Kang, YK; Kudo, M; Lim, HY; Lin, DY; Liu, D; Llovet, JM; Mathurin, P; Park, JW; Poon, RT; Raoul, JL; Sherman, M; Tak, WY; Walters, I | 1 |
Ding, LM; Guo, J; Kang, XS; Li, LJ; Qiu, YQ; Shen-Tu, JZ; Tan, FL; Zhou, J | 1 |
He, X; Zhang, T | 1 |
Angarano, G; Bronte, E; Bronte, F; Bronte, G; Cicero, G; Cusenza, S; Di Marco, V; Fiorentino, E; Firenze, A; Fontana, T; Rolfo, C; Russo, A | 1 |
Albiges, L; Escudier, B; Ferté, C; Fizazi, K; Iacovelli, R; Koscielny, S; Loriot, Y; Rocher, L; Soria, JC | 1 |
Kubota, Y; Makiyama, K; Nakaigawa, N; Nakamura, M; Sakata, R; Sano, F; Tatenuma, T; Yao, M | 1 |
Hosoya, N; Iwaba, A; Kanno, H; Kato, T; Kawazoe, H; Mashima, E; Nagaoka, A; Naito, S; Nishida, H; Sakurai, T; Tomita, Y; Yamakawa, M | 1 |
Büning, H; Decker, G; Gonzalez-Carmona, MA; Lukacs-Kornek, V; Meumann, N; Raskopf, E; Sauerbruch, T; Schmidt-Wolf, IG; Sievers, E; Strassburg, CP; Vogt, A | 1 |
Hsieh, YC; Huang, YT; Lee, FY; Lee, KC; Lee, PC; Lee, WP; Lin, HC; Liu, RS; Tan, TW; Yang, YY; Yeh, YC | 1 |
Bompas, E; Chaigneau, L; Chevreau, C; Fournier, C; Isambert, N; Penel, N; Valentin, T | 1 |
Paglino, C; Porta, C; Vercelli, A | 1 |
Cai, J; Mallick, R; Wogen, J | 1 |
Aronson, P; Uhlenhake, EE; Watson, AC | 1 |
Alonso, V; Capdevila, J; Castellano, D; Durán, I; García-Carbonero, R; Llanos, M; Manzano Mozo, JL; Salazar, R; Sastre, J; Sevilla, I | 1 |
Garnick, MB | 1 |
Alekseev, BY; Alyasova, A; Berkenblit, A; Bondarenko, I; Cella, D; Eisen, T; Esteves, B; Harza, M; Hutson, TE; Ivanescu, C; Kogan, M; Krivoshik, A; Lesovoy, V; Lipatov, O; Lyulko, O; Motzer, RJ; Nosov, D; Sternberg, CN; Strahs, A; Szczylik, C; Tomczak, P | 1 |
Ardisson, V; Audrain, O; Boucher, E; Clement, B; Edeline, J; Garin, E; Lenoir, L; Lepareur, N; Pracht, M; Raoul, JL | 1 |
Broom, RJ; Dranitsaris, G; Schmitz, S | 1 |
Bergot, E; Godinas, L; Guignabert, C; Humbert, M; Montani, D; Perros, F; Seferian, A; Sibille, Y | 1 |
Benedetto, C; Bussolati, B; Moggio, A; Pittatore, G; Revelli, A | 1 |
Aplenc, R; Caparas, M; Cullen, P; Johnston, DL; Nagarajan, R; Schulte, F; Sung, L | 1 |
Tan-Shalaby, J | 1 |
Columbano, A; Giordano, S | 1 |
Byun, KS; Kang, K; Kang, SH; Kim, JH; Lee, HJ; Lee, SJ; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL | 1 |
Hagihara, H; Honda, M; Ikeda, F; Iwadou, S; Kaneko, S; Kariyama, K; Kobayashi, Y; Kuwaki, K; Miyahara, K; Miyake, Y; Morimoto, Y; Nakamura, S; Nouso, K; Obi, S; Onishi, H; Sato, S; Sato, T; Shiraha, H; Takabatake, H; Takaguchi, K; Takaki, A; Takeuchi, Y; Takuma, Y; Yamamoto, K | 1 |
Baker, SD; Buaboonnam, J; Hu, S; Inaba, H; Janke, LJ; Orwick, S; Ramachandran, A; Roberts, MS; Stewart, CF; Turner, DC; Zimmerman, EI | 1 |
Abdel-Rahman, O; Elsayed, ZA | 1 |
He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhao, W; Zheng, YB | 2 |
Albers, P; de Geeter, P; Fenner, M; Feyerabend, S; Hakenberg, O; Heidenreich, A; Heinzer, H; Kamradt, J; Klotz, T; Krege, S; Kühn, M; Retz, M; Rexer, H; Roigas, J; Schrader, M; vom Dorp, F; Wülfing, C; Zastrow, S | 1 |
Agrogiannis, G; Chatziioannou, AN; Fokas, D; Kavatzas, N; Kostomitsopoulos, NG; Loxas, D; Malagari, K; Siskos, AP; Tamvakopoulos, C; Tsigkou, O | 1 |
Audard, V; Bahleda, R; Baumelou, A; Bouachi, K; Bourry, E; Izzedine, H; Khayat, D; Lang, P; Mangier, M; Massard, C; Ollero, M; Ory, V; Pawlak, A; Péchoux, C; Sahali, D; Sendeyo, K; Soria, JC; Zhang, SY | 1 |
Derbel Miled, O; Dionne, C; Droz, JP; Flechon, A; Negrier, S; Neidhart, EM; Segura-Ferlay, C; Terret, C | 1 |
Alesini, D; Cascinu, S; Cortesi, E; De Marchis, L; Iacovelli, R; Naso, G; Palazzo, A; Santoni, M; Trenta, P | 1 |
Bartz-Schmidt, KU; Bayyoud, T; Hofmann, J; Spitzer, M; Yoeruek, E | 1 |
Dermeche, S; Gravis, G; Guerin, M; Salem, N; Walz, J | 1 |
Lee, YJ; Shin, SY | 1 |
Barnadas, A; Barriuso, J; Casado, E; Gallego, R; Garcia Foncillas, J; Garcia-Albeniz, X; Iranzo, V; Juez, I; Martin-Richard, M; Maurel, J; Pericay, C; Queralt, B; Saigi, E; Visa, L | 1 |
Cheng, AL; Chung, HC; Kang, YK; Kudo, M; Lanzalone, S; Lechuga, MJ; Lin, DY; Omata, M; Park, JW; Pitman Lowenthal, S; Poggi, G; Qin, S; Raymond, E; Song, X; Xu, J; Yang, L | 1 |
Aucejo, F; Menon, KV; Murali, AR; Romero-Marrero, C | 1 |
Abdulghani, J; Allen, JE; Dicker, DT; El-Deiry, WS; Goldenberg, D; Humphreys, R; Liu, YY; Smith, CD | 1 |
Bolon, B; Grever, MR; Kinghorn, AD; Kogure, T; Lucas, DM; Patel, T; Yan, I | 1 |
Ishizuka, O; Nishizawa, O; Suzuki, H; Suzuki, T; Ueno, M | 1 |
Ganten, TM; Hoffmann, K; Koschny, R; Mehrabi, A; Pfeiffenberger, J; Radeleff, B; Schemmer, P; Schmitz, A; Stremmel, W | 1 |
Baba, T; Konishi, I; Koshiyama, M; Matsumura, N; Yamaguchi, K; Yoshioka, Y | 1 |
Barletta, E; Cannella, L; Daniele, B; Germano, D; Tinessa, V | 1 |
Goldwasser, F; Hescot, S; Vignaux, O | 1 |
Baglioni, M; Baron Toaldo, M; Bolondi, L; Chieco, P; Cipone, M; D'Adamo, S; Giovannini, C; Gramantieri, L; Ventrucci, C | 1 |
Fu, B; Gong, P; Gu, Y; Liao, W; Qin, M; Ren, J; Xu, C | 1 |
Asahina, Y; Enomoto, N; Hosokawa, T; Itakura, J; Izumi, N; Kurosaki, M; Kuzuya, T; Matsuda, S; Muraoka, M; Nakanishi, H; Nakata, T; Nishimura, T; Suzuki, S; Suzuki, Y; Takahashi, Y; Tamaki, N; Tsuchiya, K; Ueda, K; Yasui, Y | 1 |
Huang, T; Song, XS; Zhang, ZW | 1 |
Chen, L; Guo, Z; He, S; Wang, G; Wei, Y; Wu, Y; Zhang, Y; Zhou, J | 1 |
Berardi, R; Burattini, L; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Muzzonigro, G; Pantano, F; Santini, D; Santoni, M | 1 |
Baron Toaldo, M; Bolondi, L; Cipone, M; Marinelli, S; Milazzo, M; Palamà, C; Piscaglia, F; Salvatore, V; Venerandi, L | 1 |
Afzal, A; Beckett, BR; Doung, YC; Hayden, JB; Holtorf, ML; Huang, W; Hung, AY; Jones, RL; Mansoor, A; Meyer, JM; Mori, M; Perlewitz, KS; Pommier, RF; Rodler, ET; Ryan, CW; Tudorica, A; Vetto, JT; Woodward, WJ | 1 |
Ding, JF; Zhong, DF | 1 |
Chiba, T; Fukudo, M; Hatano, E; Ito, T; Kamba, T; Matsubara, K; Mizuno, T; Ogawa, O; Seno, H; Shinsako, K; Uemoto, S; Yamasaki, T | 1 |
Amos, S; Hussaini, IM; Kirzner, J; Sherman, JH; Siu, A | 1 |
Azzarà, A; Benedetti, E; Buda, G; Caracciolo, F; Carulli, G; Fontanelli, G; Galimberti, S; Orciuolo, E; Petrini, M; Rocco, M | 1 |
Fan, L; Han, TT; Li, JY; Xu, W | 1 |
Boyer, M; Davis, ID; Guo, Y; Liew, MS; Quaggiotto, M; Tafreshi, A; Thientosapol, E | 1 |
Chen, Z; Chowdry, RP; Khuri, FR; Kim, S; Owonikoko, TK; Saba, NF; Shin, DM | 1 |
Ahn, SH; Chang, S; Chon, CY; Han, KH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY; Park, Y | 1 |
Alden, C; Blumenschein, GR; Davis, SE; Diao, L; Erasmus, J; Fossella, FV; Girard, L; Gupta, S; Herbst, RS; Heymach, JV; Hicks, ME; Hong, WK; Kies, MS; Kim, ES; Lee, JJ; Lippman, SM; Liu, S; Mao, L; Minna, JD; Peyton, M; Saintigny, P; Stewart, DJ; Tang, X; Tran, HT; Tsao, AS; Wang, J; Wistuba, I | 1 |
Bitran, JD; Cygan, P; Galvez, AG; Lestingi, TM; Meyer, A; Nabhan, C; Tolzien, K | 1 |
Adelmann, CH; Baccarini, M; Busaidy, NL; Ching, G; Chitsazzadeh, V; Ciurea, AM; Curry, JL; Duvic, M; Dwyer, DW; Ehrenreiter, K; Ma, H; Ojeda, SS; Ruggieri, R; Tannir, NM; Tsai, KY; Vin, H | 1 |
Bae, JS; Chung, MJ; Jang, KY; Kim, DG; Kim, KM; Moon, WS; Noh, SJ | 1 |
Bastide, C; Bay, JO; Bruyere, F; Guy, L; Karsenty, G; Mahammedi, H | 1 |
Chang, CY; Huang, YS; Su, BH; Tseng, YJ; Tu, YS | 1 |
Aitini, E; Barni, S; Berardi, R; Bidoli, P; Boni, C; Caprioni, F; Cascinu, S; Cinquini, M; Conte, P; Di Costanzo, F; Faloppi, L; Ferrari, D; Labianca, R; Mosconi, S; Siena, S; Sobrero, A; Tonini, G; Villa, F; Zagonel, V | 1 |
Chen, L; Qin, J; Wang, GL; Wei, YZ; Xu, YY; Zhang, YX; Zhou, JM; Zhu, YY | 1 |
Aupérin, A; Ayyoub, M; Caignard, A; Caillat-Zucman, S; Chaba, K; Chaput, N; Dessen, P; Eggermont, A; Flament, C; Jacquelot, N; Jacques, Y; Mateus, C; Messaoudene, M; Mortier, E; Poirier-Colame, V; Porta, C; Robert, C; Romero, AI; Rusakiewicz, S; Valmori, D; Vielh, P; Zitvogel, L | 1 |
Aihara, Y; Douhara, A; Fukui, H; Kawaratani, H; Kitade, M; Moriya, K; Namisaki, T; Nishimura, N; Noguchi, R; Yoshiji, H | 1 |
Alpini, G; Fallon, MB; Hu, B; Venter, J; Wu, W; Yang, W; Zhang, J | 1 |
Liu, YL; Wang, JL; Wang, ZH; Xi, Y; Zhang, Q | 1 |
Adjei, AA; Kissel, M; Miner, JN; Mumberg, D; Neuhaus, R; Puehler, F; Schmieder, R; Scholz, A; Ziegelbauer, K | 1 |
Bai, F; Belli, LS; Mancuso, A; Puoti, M; Zavaglia, C | 1 |
Al-Shukri, S; Bair, AH; Chen, C; Hutson, TE; Kim, S; Lesovoy, V; Lipatov, ON; Rosbrook, B; Stus, VP; Vogelzang, NJ | 1 |
Larkin, J; Yousaf, N | 1 |
Airaksinen, AJ; Hirvonen, JT; Kaasalainen, MH; Liu, D; Mäkilä, EM; Salonen, JJ; Santos, HA; Sarparanta, MP; Wang, CF | 1 |
Gao, B; Lu, M; Qiao, X; Wang, X; Xue, D; Zhang, Y | 1 |
Chen, W; Deng, J; Li, X; Wu, XY; Zhang, L; Zhang, YN; Zhong, CJ; Zhong, N | 1 |
Chen, K; Li, B; Shen, J; Wang, G; Wang, H; Xu, Z; Yang, M; Zeng, B; Zhu, W | 1 |
Chang, YL; Cheng, AL; Hsu, CH; Huang, CY; Shao, YY | 1 |
Bal-Mahieu, C; Baldeyrou, B; Bay, JO; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Fournier, C; Italiano, A; Lansiaux, A; Le Cesne, A; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Robin, YM | 1 |
Igarashi, Y; Ishii, K; Kanayama, M; Kanekawa, T; Kobayashi, K; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Shinohara, M; Sumino, Y; Wakui, N | 1 |
Bamias, A; Bearz, A; Bellmunt, J; Imarisio, I; Melichar, B; Paglino, C; Porta, C; Procopio, G; Sabbatini, R; Schmidinger, M; Tinelli, C | 1 |
Fischer, JW; Freudenberger, T; Kretschmer, I; Nagy, N; Niedworok, C; Reis, H; Röck, K; Rübben, H; Szarvas, T; Vom Dorp, F | 1 |
Novara, G; Zustovich, F | 1 |
Cabibbo, G; Cammà, C; Craxì, A; Maida, M | 1 |
Agostini, V; Andreone, P; Biasco, G; Bolondi, L; Brandi, G; Cucchetti, A; de Rosa, F; di Girolamo, S; Golfieri, R; Gramenzi, A; Pinna, AD; Sama, C; Serra, C; Trevisani, F | 1 |
Stirner, B; Thangaraj, H | 1 |
Hu, BS; Li, Y; Liang, HY; Lu, LG; Shao, PJ | 1 |
Li, W; Lu, Y; Qin, Y; Qu, X; Wang, R | 1 |
Chen, Y; Duda, DG; Duyverman, AM; Hiddingh, L; Huang, P; Huang, Y; Jain, RK; Koppel, C; Lauwers, GY; Reiberger, T; Roberge, S; Samuel, R; Zhu, AX | 1 |
Cheng, NS; Chow, AK; Lam, CS; Ng, L; Pang, RW; Poon, RT; Wan, TM; Wong, SK; Yau, TC | 1 |
Ahn, JH; Bellmunt, J; Castellano, D; Chang, YH; Chiang, PH; Chuang, CK; Diaz, JR; Donnellan, P; Duh, MS; Elaidi, R; Feinberg, BA; Hawkins, R; Huang, CY; Korves, C; Levy, A; McCaffrey, J; McDermott, D; McDermott, R; Mehmud, F; Nathan, P; Neary, MP; Oh, WK; Ou, YC; Porta, C; Rha, SY; Scott, J; Scotte, F; Sun, JM; Wagstaff, J | 1 |
Blanchet, B; Boudou-Rouquette, P; Freyer, G; Goldwasser, F; Hénin, E; Thomas-Schoemann, A; Tod, M; Vidal, M | 1 |
Hatano, E; Ishii, T; Seo, S; Taura, K; Uemoto, S; Yasuchika, K | 1 |
Fukatsu, A; Gotoh, M; Hattori, R; Kuroda, M; Kuwahara, K; Morikawa, T; Sassa, N; Shimoyama, Y; Shiroki, R; Tsuzuki, T; Yoshino, Y | 1 |
Chen, KF; Chen, PJ; Chen, YL; Chu, PY; Hsu, CY; Hsu, YC; Huang, JW; Li, YS; Shiau, CW; Tai, WT | 1 |
Brockmöller, J; Tzvetkov, MV | 1 |
Bronowicki, JP; Chen, XP; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Lehr, R; Lencioni, R; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Ye, SL; Yoon, SK | 1 |
Agnello, F; Brancatelli, G; Cabibbo, G; Furlan, A; Genco, C; Giannitrapani, L; Lagalla, R; Marin, D; Midiri, M; Salvaggio, G | 1 |
Bjarnason, GA; Escudier, B; Esteban, E; Hariharan, S; Hutson, TE; Lim, HY; Lu, DR; Motzer, RJ; Niethammer, A; Pittman, KB; Senico, P | 1 |
Cho, T; Emura, M; Igarashi, S; Kobayashi, Y; Nakamura, T; Nomizo, T; Nomura, N; Seto, R | 1 |
Luo, QY; Qiu, ZL; Shen, CT | 2 |
Afsar, B; Benekli, M; Buyukberber, S; Cetin, B; Coskun, U; Deger, SM; Gonul, II; Gumusay, O; Ozet, A | 1 |
Hu, B; Mohty, M; Savani, BN; Vikas, P | 1 |
Dent, P | 1 |
Cha, SW; Cho, YD; Jang, JY; Jeong, SW; Kim, BS; Kim, HS; Kim, JH; Kim, KH; Kim, SG; Kim, YS; Lee, SH; Shim, KY | 1 |
He, XD; Liu, H; Qin, SK; Tao, L; Tong, XH; Wang, ZS; Wu, Q; Yang, Y; Zheng, RS | 1 |
A, M; H J, H; L, M; M, K; N, M; P J, G; S, B | 1 |
Bortlicek, Z; Buchler, T; Dusek, L; Kiss, I; Kubackova, K; Lakomy, R; Melichar, B; Pavlik, T; Poprach, A; Svoboda, M; Vyzula, R | 1 |
Groothuis, GM; Olinga, P; Oosterhuis, D; Westra, IM | 1 |
Chen, MS; Gao, HJ; Xu, L; Zhang, YJ | 1 |
Bhatt, VR; Ganti, AK | 1 |
Akaza, H; Fukuyama, T | 1 |
George, DJ; Liu, NS; Liu, Z; Qi, CZ; Signorovitch, JE; Wang, X; Wong, MK; Yang, H | 1 |
Carriere, C; Eisendle, K; Kluge, R; Mazzoleni, G; Pichler, M | 1 |
Abeni, E; Arici, B; Barlati, S; Conde, I; De Petro, G; Grossi, I; Portolani, N; Salvi, A; Specchia, C | 1 |
Deng, LF; Jia, QA; Li, JH; Ren, ZG; Shen, HJ; Sun, XJ; Wang, YH | 1 |
Ahmad, S; Khattak, J; Murad, S; Naqi, N | 1 |
Garcia-Roig, M; Lokeshwar, V; Ortiz, N | 1 |
Bonington, S; Denton, K; Homer, J; Lee, LW; Mak, SK; Silva, P; Slevin, NJ; Swindell, R; Sykes, AJ; Thomson, DJ; Yap, BK | 1 |
Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Park, HC; Sohn, W; Yoo, BC; Yu, JI | 1 |
Eto, M; Kimura, G; Minami, H; Naito, S; Nonomura, N; Shinohara, N; Tokunaga, S | 1 |
Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM | 1 |
Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M | 1 |
Agarwal, N; Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Knox, JJ; Kollmannsberger, C; Lee, J; Mackenzie, M; North, S; Pal, SK; Rha, SY; Rini, BI; Srinivas, S; Tan, MH; Vaishampayan, UN; Wood, LA; Yuasa, T | 1 |
Fujisawa, M; Harada, K; Kusuda, Y; Miyake, H | 1 |
Appleman, LJ; Bass, MB; Friberg, G; Friedland, D; Gordon, MS; Hong, DS; Kurzrock, R; Mendelson, DS; Rasmussen, E; Samlowski, WE; Tannir, N; Vogelzang, NJ; Wu, BM; Zhong, ZD | 1 |
Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I | 1 |
Chow, W; Chung, C; Frankel, P; Hurria, A; Luu, T; Mortimer, J; Somlo, G | 1 |
bin-Noordin, MI; Davoudi, ET; Javar, HA; Kadivar, A; Sabeti, B | 1 |
Chow, S; Gutierrez, JO; Karovic, S; Karrison, TG; Kistner-Griffin, E; Maitland, ML; Thomeas, V; Wroblewski, K | 1 |
Mei, J; Wang, Z; Zhu, X | 1 |
Chen, K; Janssen, HL; Man, K; Metselaar, HJ; Pan, Q; Peppelenbosch, MP | 1 |
He, J; Li, YS; Wei, LX; Wei, X; Xu, F; Yu, FF; Zhang, TY; Zhang, XJ | 1 |
Burger, S; Gallè, B; Mair, G; Miller, I; Steinborn, R; Walter, I; Wolfesberger, B | 1 |
Barbare, JC; Chauffert, B; Galmiche, A | 1 |
Bruns, CJ; Clevert, DA; Cyran, CC; Dietrich, O; Hinkel, R; Nikolaou, K; Paprottka, PM; Reiser, MF; Schwarz, B; Sourbron, S; von Einem, JC; Wintersperger, BJ | 1 |
Noguchi, S; Takizawa, H; Yamauchi, Y | 1 |
El-Gamal, MI; Oh, CH | 1 |
Chen, CH; Chen, LC; Chen, YJ; Chien, PH; Chien, YF; Hsieh, YL; Hsu, SC; Huang, WC; Hung, CM; Lin, YM; Tu, CY | 1 |
Kanazawa, A; Kawasaki, Y; Kioka, K; Kodai, S; Komatsu, H; Nakai, T; Nakajima, T; Ohira, G; Shimizu, S; Tsukamoto, T; Yamazoe, S | 1 |
Doki, Y; Eguchi, H; Hama, N; Kawamoto, K; Kobayashi, S; Mori, M; Mukai, R; Nagano, H; Tomimaru, Y; Umeshita, K; Wada, H | 1 |
Boerman, OC; Boers-Sonderen, MJ; de Weijert, MC; Desar, IM; Langenhuijsen, JF; Leenders, WP; Mulders, PF; Muselaers, CH; Oosterwijk, E; Oyen, WJ; Stillebroer, AB; van Herpen, CM | 1 |
Petrou, PK; Talias, MA | 1 |
Baker, SD; de Bruijn, P; Hu, S; Mathijssen, RH; Sparreboom, A | 1 |
Bellesoeur, A; Billemont, B; Blanchet, B; Carton, E; Clerc, J; Goldwasser, F; Groussin, L; Mir, O | 1 |
Choi, Y; Hur, DY; Kim, D; Kim, YS; Lee, HK; Park, GB | 2 |
Adenis, A; Assenat, E; Bennouna, J; Bibeau, F; Boissière, F; Bouché, O; Conroy, T; Crapez, E; Desseigne, F; Francois, E; Galais, MP; Laurent-Puig, P; Mazard, T; Poujol, S; Samalin, E; Seitz, JF; Taieb, J; Thézenas, S; Ychou, M | 1 |
Arnaldi, G; Cascinu, S; Conti, A; De Giorgi, U; Iacovelli, R; Massari, F; Procopio, G; Rizzo, M; Santoni, M; Tortora, G; Trementino, L | 1 |
Bae, SH; Choi, JY; Lee, JE; Lee, MA; Yoon, SK; You, YK | 1 |
Aparicio, J; Ayuso, JR; Conill, C; Feliu, J; Fuster, D; García-Mora, C; Martín, M; Maurel, J; Petriz, ML; Sánchez-Santos, ME | 1 |
Dong, S; Gao, J; Gu, F; Ke, S; Kong, F; Kong, J; Pan, B; Shen, Q; Sun, H; Sun, W; Zhang, Q; Zheng, L | 1 |
Dowlati, A; Fu, P; Halmos, B; Ma, P; Mekhail, T; Nickolich, M; Pennell, N; Sharma, N | 1 |
Ali, SM; Araujo, D; Miller, VA; Palmer, GA; Ross, JS; Stephens, PJ; Subbiah, V; Wang, K; Wang, WL; Westin, SN | 1 |
Blanke, CD; El-Khoueiry, AB; Gong, IY; Iqbal, S; Kayaleh, OR; Lenz, HJ; Micetich, KC; Rankin, C; Siegel, AB | 1 |
Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M | 1 |
Hagihara, A; Ikeda, M; Imanaka, K; Inaba, Y; Katayama, K; Kato, M; Kojima, Y; Kondo, S; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Sato, Y; Shimizu, S; Suzuki, E; Tamai, C; Ueno, H | 1 |
Chen, GY; Cheng, Y; Huang, C; Li, AW; Su, J; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhang, L; Zhang, XC; Zhou, CC; Zhou, Q | 1 |
Ackerl, M; Dieckmann, K; Flechl, B; Hainfellner, J; Hassler, MR; Marosi, C; Preusser, M; Sax, C; Widhalm, G; Wöhrer, A | 1 |
Chang, H; Kim, KM; Kim, YJ; Lee, DW; Lee, HJ; Lee, JS | 1 |
Liu, X; Shi, G; Wang, L; Wang, Q; Wu, R | 1 |
Abdel-Rahman, O; Fouad, M | 3 |
Balakan, O; Berk, V; Bilici, A; Buyukberber, S; Cinkir, HY; Demirci, U; Erdogan, B; Gumus, M; Kaplan, MA; Oflazoglu, U; Oksuzoglu, B; Ozdemir, N; Ozkan, M; Ozturk, T; Tastekin, D; Tonyali, O; Turkmen, E; Unal, OU; Uyeturk, U; Yasar, N | 1 |
Cheng, Y; Li, A; Luo, R; Zhu, Y | 1 |
Choi, DJ; Jung, YK; Kim, JH; Kim, YS; Kwon, OS; Shin, SK; Yoon, HH | 1 |
Abd-Alhaseeb, MM; Abou-El-Ela, SH; Moustafa, YM; Zaitone, SA | 1 |
Bangen, JM; Gassler, N; Liedtke, C; Sonntag, R; Trautwein, C | 1 |
Dong, X; He, C; Jiang, H; Jiang, X; Ma, L; Pan, S; Qiao, H; Sun, X; Tan, G; Wei, Z; Zhai, B; Zhao, D | 1 |
Andreeff, M; Arana Yi, C; Borthakur, G; Brandt, M; Cortes, JE; Estrov, Z; Faderl, S; Garcia-Manero, G; Jabbour, E; Kantarjian, H; Konopleva, M; Levis, M; Luthra, R; O'Brien, S; Pierce, S; Pratz, K; Ravandi, F; Thomas, D | 1 |
Li, Y; Meng, Q; Shen, J; Sun, H; Yin, Q; Yu, H; Zhang, Z | 1 |
Bao, J; Dai, Z; Lan, Y; Tu, W; Wei, T; Zhao, B | 1 |
Barroso-Sousa, R; Evangelista, J; Fragoso, MC; Hoff, AO; Kulcsar, MA; Lerario, AM; Lin, CS; Lourenço, DM; Papadia, C | 1 |
Arizumi, T; Hagiwara, S; Inoue, T; Kitai, S; Kudo, M; Minami, Y; Nishida, N; Osaki, Y; Sakurai, T; Takeda, H; Takita, M; Ueshima, K; Yada, N | 1 |
Feng, L; Liu, T; Liu, Y; Wang, L; Yao, Y; Yu, D; Zhang, L; Zhang, N | 1 |
Behnke, M; Bornstein, K; Cotterell, A; Fisher, RA; Fulcher, A; Lee, DD; Posner, MP; Ramanathan, R; Sharma, A; Stravitz, RT; Sydnor, M | 1 |
Eberst, E; Guillot, B; Kluger, N; Pageaux, GP; Rigau, V | 1 |
Bearzi, I; Benedetti, A; Bianconi, M; Bitetto, D; Bolondi, L; Cascinu, S; Colombo, M; D'Errico, A; De Minicis, S; Facchetti, F; Faloppi, L; Fava, G; Gemini, S; Giampieri, R; Granito, A; Iavarone, M; Loretelli, C; Mandolesi, A; Marinelli, S; Piscaglia, F; Scartozzi, M; Svegliati Baroni, G; Toniutto, P; Vavassori, S; Venerandi, L | 1 |
Colecchia, M; De Braud, F; Garanzini, E; Grassi, P; Iacovelli, R; Procopio, G; Testa, I; Torelli, T; Verzoni, E | 1 |
Aktaş, E; Aras, Y; Aydoseli, A; Bilir, A; Civelek, E; Ergüven, M; Gürtekin, M; Imer, M; Sabancι, PA; Yazιhan, N | 1 |
Stadler, WM | 1 |
Chiba, T; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O | 1 |
Chen, CH; Chen, CS; Chen, MC; Liou, JP; Pan, SL; Teng, CM; Tsai, AC; Wang, JC | 1 |
De Lichtenberg, TH; Hermann, GG; Holm, ML; Højer Larsen, MJ; Mansourvar, Z; Rørth, M; Scheike, T | 1 |
Baar, K; Carraway, KL; Gilda, JE; Gomes, AV; Hammock, BD; Hwang, SH; Leon, LJ; Patton, A; Wecksler, AT; Weiss, RH; Wettersten, HI | 1 |
Alba, G; Carlson, T; Chen, A; Coberly, S; Dai, K; Eksterowicz, J; Hollenback, D; Huard, J; Kamb, A; Keegan, K; Li, C; Li, Z; Liang, L; Liu, L; Lo, MC; Ma, J; McGee, LR; Medina, J; Ngo, R; Orf, J; Quéva, C; Ragains, M; Wang, X; Weidner, M; Wickramasinghe, D; Zhao, S | 1 |
Bruix, J; Gores, GJ; Mazzaferro, V | 1 |
Bögemann, M; Herrmann, E; Hertle, L; Hoffmeister, I; Krabbe, LM; Moritz, R; Papavassilis, P; Thielen, B | 1 |
Li, Z; Wang, K; Zhang, H | 1 |
Benedetti, A; Bianconi, M; Bitetto, D; Cascinu, S; D'Anzeo, M; De Minicis, S; Del Prete, M; Faloppi, L; Giampieri, R; Loretelli, C; Scartozzi, M; Svegliati Baroni, G; Toniutto, P | 1 |
Borys, D; Boutin, RD; Canter, RJ; Christensen, SD; Lee, LY; Li, CS; Monjazeb, AM; Olusanya, A; Tamurian, RM | 1 |
Schmidinger, M | 1 |
Bjarnason, GA; Cai, C; Davis, ID; De Giorgi, U; Escudier, B; Esteban, E; Grünwald, V; Kollmannsberger, C; Lee, JL; Marker, M; Melichar, B; Motzer, RJ; Porta, C; Rha, SY; Shi, MM; Squires, M; Sternberg, CN; Szczylik, C; Urbanowitz, G; Vogelzang, NJ; Zolnierek, J | 1 |
Bergmann, L; Burkholder, I; Gauler, T; Grünwald, V; Kahl, C; Kube, U; Maute, L; Weikert, S | 1 |
Anichini, A; Carbone, A; Carlo-Stella, C; Cleris, L; Locatelli, SL; Malorni, W; Pierdominici, M; Saba, E; Stirparo, GG; Tartari, S | 1 |
Cabanillas, ME; Dadu, R; Dong, W; Feng, L; Lai, SY; Regone, RM; Thomas, L | 1 |
Liu, LL; Pan, YH; Yun, JP; Zhang, CZ; Zhang, MF | 1 |
Abdel-Rahman, O; Abdelwahab, M; Abdelwahab, S; Elbassiony, M; Ellithy, M; Shaker, M | 1 |
Atkinson, BJ; Flaherty, AL; Jonasch, E; Matrana, MR; Shetty, AV; Tannir, NM | 1 |
Karagoz, E; Tanoglu, A | 1 |
Amann, J; Araujo, L; Carbone, DP; Greulich, H; Horn, L; Imielinski, M; Kaplan, B; Meyerson, M; Schiller, J; Villalona-Calero, MA | 1 |
Inoue, K; Kamada, M; Karashima, T; Kawada, C; Komatsu, T; Kuroda, N; Niimura, M; Shuin, T; Udaka, K | 1 |
Chen, Y; Li, J; Li, W; Liu, X; Wan, J; Yu, C | 1 |
Berlin, J; Cardin, DB; Chan, E; DeVore, R; Goff, L; Grigorieva, J; Holloway, M; Li, CI; McClanahan, P; Meyer, K; Schlabach, L; Shyr, Y; Winkler, C | 1 |
Antonuzzo, L; Arena, U; Boni, L; Colagrande, S; Di Costanzo, F; Fani, B; Forte, P; Gallori, D; Gianni, E; Inghilesi, AL; Laffi, G; Marra, F; Pradella, S; Tomcikova, D | 1 |
Brose, MS; Frenette, CT; Keefe, SM; Stein, SM | 1 |
Grande, C; Walko, CM | 1 |
Chen, LF; Liang, SN; Liu, J; Shao, HB; Su, HY; Xu, K | 1 |
Chu, JH; Li, WB; Qin, YZ; Qu, XJ; Song, ZY; Wang, RQ; Zhao, CR | 1 |
Jiang, X; Kanda, T; Miyamura, T; Nakamoto, S; Wu, S; Yokosuka, O | 1 |
de Man, RA; Schrier, GH; van der Geest, LG; van Erpecum, KJ; van Meer, S; Verheij, J; Verhoef, C | 1 |
Arruda, LS; Baum, M; Cisar, L; Kim, S; Motzer, RJ; Quinn, DI; Rini, BI; Roberts, WG; Rosbrook, B; Tarazi, J; Wood, LS | 1 |
Bhinder, A; Carson, WE; Clinton, SK; Geyer, S; Kendra, K; Lam, E; Lesinski, GB; Mace, TA; Monk, P; Mortazavi, A; Olencki, T; Tahiri, S | 1 |
Arai, K; Chiba, T; Kanai, F; Kaneko, S; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yamashita, T; Yokosuka, O | 1 |
Bao, X; Chen, J; He, X; Li, Y; Niu, B; Yu, H; Zhang, Z; Zhu, J | 1 |
Bondì, ML; Cavallaro, G; Craparo, EF; Giammona, G; Sardo, C; Serio, R; Zizzo, MG | 1 |
Chow, HC; Gill, H; Kwong, YL; Lam, SS; Leung, AY; Man, CH; Sun, MK | 1 |
Liang, JY; Lü, MD; Pan, FS; Xie, XY; Xu, M; Zheng, SG; Zheng, YL | 1 |
Choueiri, TK; Heng, DY; Lin, X; McKay, RR; Perkins, JJ; Simantov, R | 1 |
Choo, SP; Chow, PK; Gandhi, M; Goh, AS; Han, HS; Khin, MW; Lai, HK; Lim, TG; Lo, RH; Poon, DY; Singh, H; Soo, KC; Tan, SB; Tay, KH | 1 |
Dowlati, A; Eaton, S; Frasure, H; Fu, P; Fusco, N; Schwandt, A; von Gruenigen, VE; Waggoner, S; Wenham, RM; Wright, JJ | 1 |
Andreeff, M; Borthakur, G; Chen, Y; Cortes, JE; Gao, C; Jacamo, RO; Konopleva, M; Ramachandran, A; Ravandi, F; Zhang, W | 1 |
Chen, J; Guo, H; Li, S; Li, Y; Liang, X; Meng, H; Shi, B; Zhang, D; Zhu, Y | 1 |
Busaidy, NL; Cabanillas, ME; Cote, GJ; Dadu, R; Devine, C; Habra, MA; Hernandez, M; Hu, MI; Jimenez, C; Sellin, RV; Sherman, SI; Waguespack, SG; Ying, AK | 1 |
Carbotti, M; Coppola, R; De Florio, L; Galati, G; Graziano, A; Panasiti, V; Rinati, MV; Zanframundo, S | 1 |
Deng, DF; Ding, LM; Kang, XS; Qiu, YQ; Tan, FL; Yu, W; Zhou, J | 1 |
Chen, C; Geng, ZM; Huanchen, S; Jha, RK; Li, B; Li, WZ; Wang, L; Zheng, JB | 1 |
Bakris, GL; Cohen, EE; Fleming, GF; House, LK; Karovic, S; Karrison, TG; Levine, MR; Maitland, ML; Ratain, MJ; Rudek, MA; Thomeas, V; Wen, Y; Wright, JJ; Wu, K | 1 |
Lazarevich, NL; Makarova, AS | 1 |
Banna, G; Bracarda, S; Burattini, L; Calvani, N; Ciuffreda, L; Contu, A; De Giorgi, U; Derosa, L; Felici, A; Ferrari, V; Ferraù, F; Galligioni, E; Gasparro, D; Gernone, A; Iacovelli, R; Lo Re, G; Morelli, F; Pia Brizzi, M; Porta, C; Procopio, G; Rizzo, M; Sabbatini, R; Sava, T; Taibi, E; Zustovich, F | 1 |
Holderfield, M; Nagel, TE; Stuart, DD | 1 |
Chen, CL; Chen, WY; Honda, K; Kawasaki, K; Masuda, M; Miyanaga, A; Nakamura, Y; Ono, M; Sakuma, T; Yamada, T | 1 |
Honda, M; Isobe, T; Komatsu, R; Kuramoto, S; Shindoh, H; Tabo, M | 1 |
Bae, SH; Song, MJ | 1 |
Cai, G; Chen, H; Han, G; Liu, L; Qi, X; Wang, M; Zhao, Y | 1 |
Belghiti, J; Bouattour, M; Bruno, O; Castera, L; Dreyer, C; Faivre, S; Larroque, B; Raymond, E; Ronot, M; Vilgrain, V; Wassermann, J | 1 |
Ferrari, S; Paioli, A; Palmerini, E | 1 |
Bertens, D; Desar, IM; Kessels, RP; Langenhuijsen, JF; Mulder, SF; Mulders, PF; Punt, CJ; van Herpen, CM; van Spronsen, DJ; Vissers, KC | 1 |
Chen, SW; Chiou, JF; Kuo, CC; Kuo, YC; Liang, JA; Lin, LC | 1 |
Bauernhofer, T; Brämswig, K; Brodowicz, T; Girschikofsky, M; Hilbe, W; Hochreiner, G; Kühr, T; Leitgeb, C; Martel, A; Mlineritsch, B; Petzer, A; Ploner, F; Ressler, S; Romeder, F; Seebacher, V; Stöger, H; Wöll, E | 1 |
Croft, SL; Sanderson, L; Yardley, V | 1 |
Aguado, L; Idoate, MA; Iñarrairaegui, M; Lera, JM; Pretel, M | 1 |
Barberis, M; Brunelli, V; Catania, C; Dal Zotto, L; Danesi, R; de Braud, F; De Pas, T; Delmonte, A; Diena, T; Fumagalli, C; Noberasco, C; Rampinelli, C; Santarpia, M; Spitaleri, G; Toffalorio, F; Vecchio, F; Zangarini, M; Zucchetti, M | 1 |
Ambrosetti, D; Amiel, J; Gastaud, L; Grépin, R; Marsaud, A; Pagès, G; Pedeutour, F | 1 |
Duan, H; Gao, M; Guo, J; Liu, J; Meng, L; Peng, Y; Wang, X; Zhang, H; Zhao, Z; Zhu, M | 1 |
Abecassis, M; Al-Saden, P; Baker, T; Cotliar, J; Ganger, D; Habib, A; Karp, J; Koppe, S; Kulik, L; Lacouture, M; Lewandowski, RJ; Mulcahy, MF; Salem, R; Vouche, M | 1 |
Chen, L; Li, M; Liu, M; Ruan, M; Shen, Y | 1 |
de Vos, R; Koldenhof, JJ; Teunissen, SC; Tillier, CN; Verheul, HM; Walraven, M; Witteveen, PO | 1 |
Andreozzi, M; Angel, P; Ben-Neriah, Y; Breuhahn, K; Finkelstein, R; Ganten, T; Grunewald, M; Hess, J; Horwitz, E; Kanarek, N; Koschny, R; Mogler, C; Nemeth, J; Pappo, O; Pikarsky, E; Porat, RM; Quagliata, L; Reuter, H; Schirmacher, P; Schweitzer, N; Shibolet, O; Shoham, A; Stein, I; Terracciano, L; Tornillo, L; Vogel, A; Zreik, F | 1 |
Fukuda, H; Ishii, T; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Moriya, S; Nozaki, A; Numata, K; Sakamaki, K; Shimoyama, Y; Tanaka, K | 1 |
Delabesse, E; Guenounou, S; Récher, C | 1 |
Haybaeck, J; Petru, E; Smolle, E; Taucher, V | 1 |
Chen, C; Daily, MF; Galuppo, R; Gedaly, R; Maynard, E; Shah, M; Spear, BT | 1 |
Alexandre, J; Blanchet, B; Boissier, E; Boudou-Rouquette, P; Cessot, A; Coriat, R; Durand, JP; Giroux, J; Goldwasser, F; Huillard, O; Thomas-Schoemann, A; Vidal, M | 1 |
Belli, LS; Mancuso, A; Mazzarelli, C; Perricone, G; Zavaglia, C | 1 |
Daniele, B; Germano, D | 1 |
Fan, JG; Li, GM; Pan, Q; Sun, C; Wang, J; Wang, YG | 1 |
Geng, CX; Ji, YX; Lan, KT; Liu, SC; Nie, KK; Sun, L; Zhang, L; Zhang, ZC; Zhang, ZF; Zhuang, XJ; Zou, X | 1 |
Chen, W; Chen, Y; Deng, DY; Ren, M; Shang, C; Wang, J; Xiang, Q; Zhang, H; Zhang, L | 1 |
Dong, X; Hu, F; Jiang, H; Jiang, X; Liu, B; Pan, S; Qiao, H; Sun, X; Tan, G; Wei, Z; Xu, J; Zhai, B; Zhao, D | 1 |
Ahn, H; Hong, JH; Jeong, IG; Kim, CS; Kwon, T; Lee, JL; Song, C; You, D | 1 |
Cai, M; Chen, J; Huang, W; Lai, L; Meng, X; Shan, H; Zhou, B; Zhu, K | 1 |
D'Andrea, K; Flaherty, KT; Kirkwood, JM; Kluger, HM; Lee, SJ; Letrero, R; Nathanson, KL; Rimm, DL; Schuchter, LM; Wilson, MA; Zhao, F | 1 |
Choi, HS; Kim, SW; Lee, B; Nam, SW; Park, KC | 1 |
Barbe, M; Berretta, RM; Dunn, J; Duran, JM; Force, T; Gao, E; Gross, P; Houser, SR; Husain, S; Kubo, H; Lal, H; Makarewich, CA; Sharp, TE; Starosta, T; Trappanese, D; Vagnozzi, RJ; Yu, D | 1 |
de Waal, R; de Weijert, M; Desar, I; Hulsbergen-van de Kaa, C; Kats-Ugurlu, G; Leenders, W; Maass, C; Mulders, P; Muselaers, S; Oosterwijk, E; Oosterwijk-Wakka, J; van Herpen, C; van Krieken, H | 1 |
Akisik, FM; Anderson, S; Bu, G; Cardenes, HR; Chiorean, EG; Clark, R; Deluca, J; DeWitt, J; Helft, P; Johnson, CS; Johnston, EL; Loehrer, PJ; Perkins, SM; Sandrasegaran, K; Schneider, BP; Shahda, S; Spittler, AJ | 1 |
Herrick, WG; Moriarty, T; Nguyen, TV; Peyton, SR; Sleiman, M | 1 |
Chen, J; Kim, DH; Larson, AC; Lewandowski, RJ; Li, W; Omary, RA; Shea, LD; Sheu, AY; Zhang, Z | 1 |
Pitoia, F | 1 |
Bassett, RL; Busaidy, NL; Cabanillas, ME; Dadu, R; Habra, MA; Hu, MI; Jimenez, C; Sherman, SI; Waguespack, SG; Ying, AK | 1 |
Chang, FY; Chao, TT; Chen, KF; Chen, PT; Chen, YL; Shiau, CW; Su, WP; Tai, WT; Wang, CY; Weng, CY; Yu, CJ; Yuan, A | 1 |
Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, AO | 1 |
Alvarado, Y; Andreeff, M; Borthakur, G; Cortes, JE; Estrov, Z; Garcia-Manero, G; Kantarjian, HM; Konopleva, M; Luthra, R; Ravandi, F | 1 |
Beveridge, RD; Campos, GB; Daroqui, JC; Esparcia, MF; Estellés, DL; Huerta, ÁS; Imedio, ER; Ortiz, AG; Salcedo, JM; Urtasun, JA | 1 |
Adachi, T; Akutsu, N; Hamamoto, Y; Hirayama, D; Igarashi, M; Kaneto, H; Motoya, M; Sasaki, S; Shinomura, Y; Shitani, M; Takagi, H; Wakasugi, H; Yamamoto, H; Yawata, A; Yonezawa, K | 1 |
Andreeff, M; Cortes, J; Kantarjian, H; Pemmaraju, N; Ravandi, F | 1 |
Bernardi, M; Bolondi, L; Cappelli, A; Cucchetti, A; Erroi, V; Fiumana, S; Golfieri, R; Gramenzi, A; Granito, A; Marinelli, S; Mosconi, C; Pettinato, C; Trevisani, F | 1 |
Dudek, A; Konety, SH; Masri, SC; Misselt, AJ | 1 |
Raza, A; Sood, GK | 1 |
Miyahara, K; Nouso, K; Yamamoto, K | 1 |
Ara, M; Pastushenko, E | 1 |
Haraldsdottir, S; Shah, MH | 1 |
Bastholt, L; Brose, MS; Chung, J; de la Fouchardiere, C; Elisei, R; Jarzab, B; Kappeler, C; Molnár, I; Nutting, CM; Pacini, F; Paschke, R; Peña, C; Schlumberger, MJ; Sherman, SI; Shong, YK; Siena, S; Smit, JW | 1 |
Bai, XL; Chen, YW; Fu, QH; Hu, QD; Liang, TB; Su, RG; Su, W; Zhang, Q | 1 |
Aigner, B; Artl, M; Niederkorn, A; Richtig, E; Schwantzer, G; Wackernagel, W | 1 |
Biondani, P; DE Braud, F; Grassi, P; Porcu, L; Procopio, G; Testa, I; Torri, V; Verzoni, E | 1 |
Ben Aissa, A; Bodmer, A; Dietrich, PY; Dunkel, N; Espeli, V; Hottinger, AF; Hundsberger, T; Mach, N; Schaller, K; Squiban, D; Vargas, MI; Weber, DC | 1 |
Chen, XQ; Li, ZY; Lin, TY; Wang, YL | 1 |
Chen, LJ; Chen, YZ; Cheng, C; Fu, XY; Li, LL; Tang, Y; Wei, YQ; Xiang, R; Yang, J; Yang, LL; Yang, SY; Zhong, L; Zhou, S; Zou, C | 1 |
Mu, H; Song, TQ; Wang, M; Wei, K; Zhang, W | 1 |
Afonso, R; Angeles, C; Campos, JM; García-Alfonso, P; Grande, E; Jorge, M; Martínez, V; Montagut, C; Polo, E; Reina, JJ | 1 |
Bellmunt, J; Bracarda, S; Cerbone, L; Choueiri, TK; Fay, AP; Foreshew, A; Hutson, TE; Lampron, ME; Pons, F; Porta, C; Powles, T; Sternberg, CN | 1 |
Chen, W; Guo, E; Liu, Z; Lu, L; Peng, X; Wang, Y; Yan, T; Yang, X; Ye, L; Zhou, F | 1 |
Bhatt, VR; Ganti, AK; Schwarz, JK; Wang, J | 1 |
Bargellini, I; Bartolozzi, C; Masi, G; Mismas, V; Sacco, R; Scionti, A; Vivaldi, C | 1 |
Allen, JC; Bloom, MC; Cohen, KJ; Dhall, G; Eberhart, CG; Fisher, MJ; Goldberg, JD; Harter, DH; Hochman, T; Jones, DT; Karajannis, MA; Korshunov, A; Legault, G; Merkelson, A; Milla, SS; Pfister, SM; Resnick, AC; Sievert, AJ; Wisoff, JH; Zagzag, D | 1 |
Bodoky, G; Fassan, M; Gyöngyösi, B; Járay, B; Kiss, A; Schaff, Z; Székely, E; Végh, É | 1 |
Chiang, IT; Hsu, FT; Hwang, JJ; Lin, WJ; Liu, RS; Liu, YC; Wang, HE | 1 |
Burra, P; Castelli, G; Cillo, U; Farinati, F; Giacomin, A; Senzolo, M; Vitale, A | 1 |
Imagawa, DK; Reataza, M | 1 |
Srimuninnimit, V; Sriuranpong, V; Suwanvecho, S | 1 |
Graham, RM; Thompson, JW; Webster, KA | 1 |
Fu, SR; He, X; Hu, BS; Huang, JW; Li, JP; Li, Y; Lu, LG; Zhan, MX; Zhang, YQ | 1 |
Altun, A; Altun, GG; Babacan, N; Bahceci, A; Kacan, SB; Kacan, T; Sarac, B; Seker, MM | 1 |
Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Yang, Z | 1 |
Beeram, M; Benjamin, D; Ketchum, N; Mahalingam, D; Malik, L; Michalek, J; Mita, A; Rodon, J; Sankhala, K; Sarantopoulos, J; Tolcher, A; Wright, J | 1 |
Aoyagi, Y; Fujimaki, S; Hirose, Y; Kobayashi, T; Kubota, M; Matsuda, Y; Osawa, M; Sakata, J; Takamura, M; Wakai, T; Yamagiwa, S | 1 |
Bjarnason, GA; Choueiri, TK; Donskov, F; Heng, DY; Khambati, HK; Knox, JJ; Kollmannsberger, CK; MacKenzie, MJ; North, S; Rini, BI; Tan, MH; Vaishampayan, UN; Wood, L | 1 |
Beaune, P; de Waziers, I; Favre, A; Figg, WD; Kiehl, P; McMullen, J; Montemurro, M; Narjoz, C; Rochat, B | 1 |
Llovet, JM | 1 |
Cisar, L; Clark, JI; Escudier, B; Hariharan, S; Hutson, TE; Kannourakis, G; Kim, S; Lim, HY; Michaelson, MD; Motzer, RJ; Porfiri, E; Rini, BI; Rosbrook, B; Staehler, M; Tarazi, J; Zalewski, P | 1 |
Black, EP; Karabakhtsian, RG; Massarweh, S; Moss, J; Napier, D; Romond, E; Slone, S; Wang, C; Weiss, H | 1 |
Cui, LJ; Li, AJ; Ma, SL; Wu, B; Wu, MC; Yin, L; Yuan, H | 1 |
Andersen, KJ; Hamilton-Dutoit, S; Kannerup, AS; Knudsen, AR; Ladekarl, M; Mortensen, FV; Nyengaard, JR | 1 |
Izumi, N; Joko, K; Nishikawa, H; Ogawa, C; Orito, E; Osaki, Y; Takeda, H; Taniguchi, H; Tsuchiya, K; Uchida, Y | 1 |
Elledge, R; Elledge, RO; Raskauskiene, D | 1 |
Bella, A; Guerra, JR; Lolo, D; Suelves, AM | 1 |
Dixon, SJ; Gleason, CE; Hayano, M; Lee, ED; Patel, DN; Skouta, R; Slusher, BS; Stockwell, BR; Tatonetti, NP; Thomas, AG; Welsch, M | 1 |
Shouval, D | 1 |
Ito, K; Sugino, K; Takami, H | 1 |
Chen, D; Chen, M; Kuang, M; Lencioni, R; Peng, B; Peng, H; Peng, S; Shen, S; Wang, Y | 1 |
Antonucci, M; Cabibbo, G; Gadaleta-Caldarola, G; Galati, G; Lombardi, G; Mazza, G; Sacco, R; Tremosini, S | 1 |
Jiang, L; Liu, H; Liu, X; Shi, G; Wang, X | 1 |
Falchi, L; Lu, G; Luthra, R; Lyle, LM; Mehrotra, M; Newberry, KJ; Patel, KP; Popat, U; Verstovsek, S | 1 |
Ai, DL; Fu, JL; Li, J; Liu, CZ; Peng, XM; Wang, HM; Wang, JY; Yang, B; Yu, Q; Zhang, LZ; Zhao, Y; Zhou, L | 1 |
Bambury, RM; Morris, PG | 1 |
DeWille, J; Hicks, M; Hu, Q; Macrae, E | 1 |
Berkers, J; Beuselinck, B; De Wever, L; Dumez, H; Joniau, S; Lerut, E; Oyen, R; Paridaens, R; Schöffski, P; Strijbos, M; Van Poppel, H; Wolter, P | 1 |
Bozcuk, H; Coskun, HS; Gunduz, S; Mutlu, H; Uysal, M | 1 |
Akasaka, K; Hisamichi, K; Kondo, Y; Maejima, T; Maekawa, M; Mano, N; Matsuura, M; Mori, M; Okawa, H; Shimada, M; Shimosegawa, T; Suzuki, H; Tsuchiya, M; Yanagi, T | 1 |
Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Giannuzzi, G; Lippolis, C; Messa, C; Refolo, MG | 1 |
Bogdanova, A; Daryadel, A; Frossard, N; Gassmann, M; Lehalle, C; Mueller, X; Seifert, B; Tavakoli, R; Zünd, G | 1 |
Barbarotta, L; Cooper, D; Foss, F; Gibson, JF; Irizarry, D; Lansigan, F; Seropian, S | 1 |
Feng, GS; Luo, X | 1 |
Fujisawa, M; Furukawa, J; Kusuda, Y; Miyake, H | 1 |
Luo, J; Shao, G; Zheng, J | 1 |
Chapiro, J; Duran, R; Geschwind, JF | 1 |
Fujiya, T; Hasegawa, Y; Kakugawa, Y; Kinouchi, M; Miura, K; Philchenkov, A; Satoh, M; Yamamoto, K | 1 |
Abou-Alfa, GK; Harding, JJ | 1 |
Emadi, A; Karp, JE; Pratz, KW; Sammons, SL; Smith, BD | 1 |
Bruera, G; Cannita, K; Carducci, S; Coletti, G; Ficorella, C; Giordano, AV; Iapadre, N; Manetta, R; Ricevuto, E; Saltarelli, P; Vicentini, R | 1 |
Baron Toaldo, M; Bolondi, L; Croci, L; Diana, A; Marinelli, S; Milazzo, M; Palamà, C; Pecorelli, A; Piscaglia, F; Salvatore, V; Venerandi, L | 1 |
Koyakutty, M; Malarvizhi, GL; Nair, S; Retnakumari, AP | 1 |
Bao, LF; Cao, XQ; Dai, YC; Gan, MF; Li, ZY; Liang, XD; Lu, HS; Ma, SL; Wang, DD; Zhang, LM; Zhang, SR; Zheng, BJ | 1 |
Arnold, B; Augustin, HG; Bergeest, JP; Géraud, C; Goerdt, S; Hu, J; Komljenovic, D; Mogler, C; Neumann, A; Rohr, K; Runge, A; Schirmacher, P; Wieland, M | 1 |
Dent, P; Grant, S; Hamed, HA; Poklepovic, A; Tavallai, S | 1 |
Barlogie, B; Hoering, A; Hussein, MA; Mazzoni, S; Orlowski, RZ; Popplewell, LL; Sexton, R; Srkalovic, G; Trivedi, H; Zonder, JA | 1 |
Atkinson, B; Eatock, M; Graham, U | 1 |
Bulla, K; Kolligs, F; Malfertheiner, P; Peck-Radosavljevic, M; Reimer, P; Ricke, J; Sangro, B; Schott, E; Schütte, K; Verslype, C; Walecki, J | 1 |
Brown, WS; Khalili, JS; Lizee, G; McIntyre, BW; Rodriguez-Cruz, TG | 1 |
Bie, P; Chen, X; Hu, P; Zhang, L | 1 |
Alsaied, OA; Banerjee, S; Chugh, R; Jensen, EH; Krosch, TC; Saluja, A; Sangwan, V; Vickers, SM | 1 |
Czarnecka, AM; Oborska, S; Rzepecki, P; Szczylik, C | 1 |
Chen, YF; Liao, MB; Peng, HS; Wang, HY; Xie, Y; Xu, L; Zhang, MY; Zhang, YJ; Zheng, XF | 1 |
Ady, JW; Belin, LJ; Chen, CT; Chen, NG; Fong, Y; Heffner, J; Johnsen, C; Klein, E; Love, D; Mojica, K; Pugalenthi, A; Szalay, AA; Yu, YA | 1 |
Döring, C; Filmann, N; Hansmann, ML; Hartmann, S; Herrmann, E; Mertens, A; Peveling-Oberhag, J; Piiper, A; Trojan, J; Welker, MW; Zeuzem, S | 1 |
Blanchard, F; Di Fiore, F; Nouhaud, FX; Pfister, C; Rebibo, JD; Sabourin, JC | 1 |
Elsner, A; Fitzner, B; Heuschkel, M; Jaster, R; Krause, BJ; Lange, F | 1 |
Cheung, FY; Chiang, CL; Chong, M; Jolivet, J; Kwok, C; Kwong, P; Lai, M; Lee, C; Lee, FA; Leung, KC; Siu, SW; Tung, S; Zee, BC | 1 |
Bogaerts, E; Colle, I; Descamps, B; Devisscher, L; Geerts, A; Janssens, S; Lambrecht, BN; Laukens, D; Libbrecht, L; Paridaens, A; Van Steenkiste, C; Van Vlierberghe, H; Vandewynckel, YP; Vanhove, C; Verhelst, X | 1 |
Alsina, AE; Arrobas, J; Franco, E; Kemmer, N; Makris, A; Nenos, V; Sucre, E | 1 |
Esumi, S; Kawasaki, Y; Kitamura, Y; Matsunaga, H; Miura, T; Nakamura, H; Sendo, T; Takeda, T; Yagi, K | 1 |
Gandhi, S; Grewal, H; Sengodan, P | 1 |
Altekruse, SF; Dickie, LA; Duffy, AG; Greten, TF; Kish, JK; McGlynn, KA; McNeel, TS; Rahma, OE; Ulahannan, SV | 1 |
Blay, JY; Dumont, AG; Dumont, SN; Reynoso, D; Trent, JC; Yang, D | 1 |
Andoh, A; Bamba, S; Fujiyama, Y; Inatomi, O; Nishida, A; Nishimura, T; Sasaki, M; Shioya, M | 1 |
Liu, C; Liu, L; Long, J; Ni, QX; Sun, HC; Tang, ZY; Wang, WQ; Wu, CT; Xu, HX; Xu, J; Yu, XJ; Zhang, W; Zhu, XD | 1 |
Bito, T; Hirai, M; Hirano, T; Kume, M; Makimoto, H; Mizumoto, A; Mukai, A; Nakagawa, T; Nishigori, C; Nishimura, K; Uda, A; Yamamoto, K; Yamashita, K | 1 |
Courville, E; Liegel, J; Sachs, Z; Ustun, C | 1 |
Anouar, Y; Baudin, E; Denorme, M; Dubessy, C; Gonzalez, BJ; Roux, C; Yon, L | 1 |
Blacher, S; Calligaris, D; Cimino, J; De Pauw, E; De Tullio, P; Debois, D; Mari, B; Mazzucchelli, G; Noel, A; Paye, A; Primac, I; Sounni, NE; Truong, A | 1 |
Kim, SW; Lee, B; Nam, SW; Park, KC; Yang, KJ | 1 |
Bernardo, L; Borger, DR; Chen, YB; Durazzo, T; Fathi, AT; Kroshinsky, D; Lin, WM; McAfee, SL; Piris, A; Sadrzadeh, H | 1 |
Bae, SH; Cho, SB; Chung, WJ; Jang, JY; Kim, YS; Lee, SH; Park, JY; Park, SY; Song, DS; Song, MJ; Yang, JM; Yim, HJ | 1 |
Bhargava, P; Bhosale, P; Choi, JI; Imagawa, DK; Lall, C; Seery, TE; Tirkes, T | 1 |
He, C; Liu, J; Mao, K; Sun, J; Tan, C; Wang, J; Wu, G; Xiao, Z; Xu, K; Zeng, Y; Zhang, J | 1 |
Anel, A; Azaceta, G; Galán-Malo, P; Jarauta, V; López-Royuela, N; Marzo, I; Naval, J; Palomera, L; Pardo, J; Ramírez-Labrada, A | 1 |
Augello, C; Barberis, M; Bosari, S; Carnaghi, C; Di Tommaso, L; Fagiuoli, S; Faversani, A; Labianca, R; Maggioni, M; Pressiani, T; Rimassa, L; Roncalli, M; Rota Caremoli, E; Santoro, A; Spagnuolo, G; Vaira, V | 1 |
Cho, NP; Cho, SD; Hong, IS; Jung, JY; Nam, JS; Shin, JA; Yu, HJ | 1 |
Atzori, F; Basso, U; Bracarda, S; Burattini, L; Buti, S; Cascinu, S; Cerbone, L; Conti, A; De Giorgi, U; De Vivo, R; Derosa, L; Di Lorenzo, G; Falconi, M; Iacovelli, R; Masini, C; Massari, F; Milella, M; Montironi, R; Mosca, A; Muzzonigro, G; Ortega, C; Pagano, M; Paglino, C; Porta, C; Procopio, G; Rizzo, M; Rossi, M; Santini, D; Santoni, M; Sternberg, CN; Verzoni, E | 1 |
Chen, IT; Chen, KF; Hsu, CY; Li, YS; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH; Wu, SH | 1 |
Alvarez-Barrientos, A; Bertran, E; Cepeda, EB; Fabra, À; Fabregat, I; Fernández-Rodríguez, CM; Fernández-Salguero, P; Fernando, J; Giannelli, G; Malfettone, A; Raimondi, G; Sancho, P; Vilarrasa-Blasi, R | 1 |
Cao, Y; Chen, W; Ding, Y; Jiang, C; Shi, H; Wang, Z; Wu, J; Zhang, G | 1 |
Anak, O; Assenat, E; Blanc, JF; Cattan, S; Chen, CL; Chen, LT; Daniele, B; Dorval, E; Furuse, J; Jappe, A; Kang, YK; Kudo, M; Lim, HY; Peck-Radosavljevic, M; Perraud, K; Poon, RT; Santoro, A; Sellami, DB; Vogel, A; Zhu, AX | 1 |
Gottesman, MM; Lavi, O; Skinner, J | 1 |
Chi, H; Meng, Z; Wang, H; Wang, P; Xu, L; Zhu, X | 1 |
Basso, U; Maruzzo, M; Montesco, MC; Rastrelli, M; Roma, A; Zanardi, E | 1 |
Bernards, R; Groenendijk, FH; Hauptmann, M; Horlings, HM; Jonkers, J; Mellema, WW; Schut, E; Smit, EF; van den Heuvel, MM; van der Burg, E; Willems, SM | 1 |
Guo, DH; Pei, F; Si, HY; Tang, ZH; Wang, DX; Wang, WL; Xiao, BK; Xie, TT; Zhang, XY; Zhu, M | 1 |
Baron Toaldo, M; Bolondi, L; Cipone, M; Croci, L; Marinelli, S; Milazzo, M; Palamà, C; Piscaglia, F; Salvatore, V; Venerandi, L | 1 |
Chandran, CB; Flombaum, CD; Glezerman, IG; Salvatore, SP; Seshan, SV; Usui, J | 1 |
Bruix, J; Forner, A; Gilabert, M; Raoul, JL | 1 |
Bai, M; Han, GH; Yang, M; Yuan, JQ | 1 |
Guo, QQ; Wang, QD; Yang, GR; Zhao, YL | 1 |
Coplin, MA; Donahue, RN; Farsaci, B; Grenga, I; Hodge, JW; Lepone, LM; Molinolo, AA | 1 |
Ji, B; Liu, K; Liu, S; Liu, Y; Wang, Y; Zhang, W | 2 |
Harms, GS; Jaiswal, BS; Mooz, J; Oberoi-Khanuja, TK; Rajalingam, K; Seshagiri, S; Tikkanen, R; Wang, W | 1 |
Bavishi, K; Bazargan, A; Black, J; Cummins, KD; D'Rozario, J; Filshie, R; Hertzberg, M; Jane, SM; Lane, S; Nikovic, S; Ninkovic, S; Ritchie, D; Scott, A; Sutrave, G; Wei, A; Yannakou, CK | 1 |
Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Song, G; Valdez, BC | 1 |
Akarsu, S; Çarsanbali, S; Fetil, E; İlknur, T; Lebe, B | 1 |
Batalla, A; Blay, P; Curto, JR; Menéndez, L | 1 |
Bandyopadhyay, S; Burlingame, AL; Gordan, JD; Hann, B; Levin, RS; McCormick, F; Oses-Prieto, JA; Salt, M; Shokat, KM; Sos, ML; Webber, JT | 1 |
En, LM; Hao, L; Ju, H; Juan, LW; Kai, HY | 1 |
Ghimire, KB; Shah, BK | 1 |
Gao, C; Peng, FH; Peng, LK | 1 |
Chen, XG; Feng, ZQ; Li, Y; Wang, K; Yang, HZ; Zhang, LJ | 1 |
Anand, BS; Fitzmorris, P; Shoreibah, M; Singal, AK | 1 |
Chang, CJ; Cheng, AL; Gandhi, AK; Hsu, C; Huang, ZM; Jeng, YM; Liao, SC; Lin, YJ; Lin, ZZ; Ou, DL | 1 |
Bitzer, M; Blondin, D; Dollinger, M; Erhardt, A; Gog, C; Häussinger, D; Kolligs, F; Lammert, F; Ohmann, C; Schott, E; Schuchmann, M; Walter, C; Wege, H | 1 |
Lykkesfeldt, AE; Pedersen, AM; Thrane, S; Yde, CW | 1 |
Tan-Shalaby, JL | 1 |
Daoudaki, M; Fouzas, I | 1 |
Fu, SR; He, X; Hu, BS; Huang, JW; Li, Y; Liu, B; Lu, LG; Zhan, MX; Zhao, W; Zhao, Y; Zheng, YB | 1 |
Bianco, V; Francini, E | 1 |
Chen, S; Dong, L; Fang, Y; Hu, T; Huang, X; Ji, L; Liu, T; Shen, X; Tang, W; Wang, Y; Weng, S; Wu, J; Xue, R; Zhang, S | 1 |
Braeuning, A; Kirschnick, M; Muche, S; Schwarz, M | 1 |
Bisagni, G; Boni, C; Gnoni, R; Pagano, M; Panebianco, M; Rossi, G; Sierra, NM | 1 |
Hsiao, HH; Liu, TP; Lo, HL; Wei, LS; Yang, PM | 1 |
Bulai Livideanu, C; Christol, C; Hautier-Mazeereuw, J; Lamant, L; Paul, C; Pauwels, C; Peron, JM; Severino-Freire, M; Sibaud, V; Tournier, E | 1 |
Craveiro, RB; Dilloo, D; Ehrhardt, M; Holst, MI; Pietsch, T | 1 |
Dauch, D; Eilers, M; Geffers, R; Hohmeyer, A; Kang, TW; Laufer, S; Leibold, J; Longerich, T; Lowe, SW; Malek, NP; McJunkin, K; Pesic, M; Powers, S; Rudalska, R; Schirmacher, P; Sipos, B; von Thun, A; Weiss, KH; Wuestefeld, T; Zender, L; Zuber, J | 1 |
Cheong, J; Jung, HU; Kim, HY; Park, BS; Yoo, KS; Yoo, SH; Yoo, YH; Yun, I | 1 |
Dong, X; Jiang, X; Li, G; Li, J; Ma, L; Ni, S; Qiao, H; Sun, X; Zhao, D; Zhu, H | 1 |
Chen, S; Lin, H; Tao, C | 1 |
Jeong, KY; Lee, EJ; Seong, J; Yang, SH | 1 |
Burki, TK | 1 |
Bonekamp, S; Corona-Villalobos, CP; Cosgrove, D; Geschwind, JF; Halappa, VG; Kamel, IR; Pawlik, TM; Reyes, D | 1 |
Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Yokosuka, O; Yoshikawa, M | 1 |
Endo, M; Izumi, N; Joko, K; Nishikawa, H; Ogawa, C; Orito, E; Osaki, Y; Takeda, H; Taniguchi, H; Tsuchiya, K; Uchida, Y | 1 |
Antin, JH; Ballen, K; Chen, YB; Connolly, C; Curtis, M; Cutler, C; Del Rio, C; Dey, BR; El-Jawahri, A; Fathi, AT; Ho, VT; Joyce, A; Lane, AA; Levis, M; Li, S; McAfee, S; Rajkhowa, T; Rudek, M; Soiffer, R; Spitzer, TR; Valles, B; Verselis, S | 1 |
Anichini, A; Carlo-Stella, C; Corradini, P; Di Nicola, M; Dodero, A; Farina, L; Gianni, AM; Giordano, L; Guidetti, A; Locatelli, SL; Malorni, W; Marchianò, A; Mortarini, R; Russo, D; Sorasio, R; Viviani, S | 1 |
Colao, A; Faggiano, A; Marotta, V; Sciammarella, C; Vitale, M | 1 |
Jung, WG; Kim, EH; Kim, MS | 1 |
Gores, GJ | 1 |
Hsieh, SC; Hsieh, YH; Tang, MJ; Tsai, JP; Yang, SF | 1 |
Hamilton, G; Rath, B | 1 |
Koyanagi, T; Masumoto, A; Morita, Y; Motomura, K; Senju, T; Suzuki, H; Tajiri, H; Yada, M | 1 |
Rupasinghe, HP; Sudan, S | 1 |
Erlacher, M; Hertrampf, A; Herz, C; Kleinhans, C; Lamy, E; Mersch-Sundermann, V; Platz, S; Rohn, S; Schüler, J; Stetter, N; Wagner, M; Zimmermann, S | 1 |
Bruix, J; Di Donato, R; Gazzola, A; Reig, M | 2 |
Aichler, M; Borgmann, DM; Feuchtinger, A; Hauck, SM; Huber, K; Keller, U; Li, Z; Schwaiger, M; Walch, A; Zitzelsberger, H | 1 |
Alencar, RS; Alvares-da-Silva, MR; Alves, VA; Campos, PB; Carrilho, FJ; Chagas, AL; Diniz, MA; Kikuchi, L; Oliveira, CP; Ratziu, V; Santos, GR; Stefano, JT; Tani, CM; Vezozzo, DC | 1 |
Choi, GH; Han, S; Kang, YK; Kim, KM; Lee, HC; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH | 1 |
Badalamenti, G; Baldi, GG; Casali, PG; Cominetti, D; Dagrada, GP; Dei Tos, AP; Festinese, F; Fumagalli, E; Grignani, G; Gronchi, A; Morosi, C; Negri, T; Pennacchioli, E; Pilotti, S; Provenzano, S; Spagnuolo, RD; Stacchiotti, S; Tortoreto, M; Toss, A; Zaffaroni, N | 1 |
Ahn, SH; Han, KH; Kim, BK; Kim, DY; Kim, HJ; Kim, JK; Kim, SU; Kweon, YO; Lee, HW; Lee, JI; Lee, KS; Lee, S; Park, JY; Park, SY; Tak, WY | 1 |
Barroso-Sousa, R; Bento, Ada S; Blanco, BP; da Fonseca, LG; Hoff, PM; Pfiffer, TE; Sabbaga, J; Valente, GL | 1 |
Giusti, M; Minuto, F; Monti, E; Morbelli, S; Mortara, L; Pera, G; Sambuceti, G | 1 |
Fan, W; Huang, Y; Ke, S; Li, J; Ran, H; Wang, W; Wang, Y; Yang, J; Zhang, F; Zhang, Y | 1 |
Adjei, AA; Chai, F; Dy, GK; Goff, L; Lamar, M; Ma, WW; Martell, R; Means-Powell, JA; Puzanov, I; Saif, MW; Santoro, A; Savage, RE; Schwartz, B; Simonelli, M; Sosman, J; Zucali, P | 1 |
Choi, HJ; Heo, J; Hsieh, WS; Hsu, C; Jeffers, M; Kappeler, C; Krissel, H; Lim, HY; Lin, CY; Park, JW; Poon, RT; Rajagopalan, P; Rau, KM; Tak, WY; Tay, MH; Yen, CJ; Yeo, W; Yoon, JH | 1 |
Ames, E; Borys, D; Canter, RJ; Chen, M; Grossenbacher, SK; Li, CS; Mac, S; Monjazeb, AM; Murphy, WJ; Sayers, TJ; Smith, RC; Tellez, J | 1 |
Chen, X; Feng, Z; Li, C; Li, Y; Niu, F; Tang, K; Yang, H; Zhang, L; Zhou, W | 1 |
Bortlicek, Z; Buchler, T; Kubackova, K; Linke, Z; Melichar, B; Pavlik, T; Pokorna, P; Prausova, J; Vyzula, R | 1 |
Li, W; Li, XS; Pan, T; Wang, JP; Wu, PH; Xie, QK; Zhao, M | 1 |
Buonomano, P; Camera, L; Circelli, L; Colao, A; Del Prete, M; Di Somma, C; Faggiano, A; Marciello, F; Marotta, V; Modica, R; Ramundo, V; Rubino, M; Sciammarella, C | 1 |
Gadot, N; Lassau, N; Leguerney, I; Pénault-Llorca, F; Robin, N; Scoazec, JY; Victorin, S | 1 |
Chen, J; Shi, JH; Wang, J; Zhu, YY | 1 |
Alexandre de Azevedo, R; Barbuto, JA; Bydlowski, SP; Ferreira, AK; Jorge, SD; Levy, D; Pizzo, CR; Rodrigues, CP; Salomon, MA; Teixeira, SF | 1 |
Albines, GS; Fernández-Molina, J; Fuentes-Martínez, N; Mesa, A; Pérez, R; Rodríguez, M; Varela, M | 1 |
Chen, KF; Chiang, HC; Chu, PY; Hsu, CY; Huang, JW; Ko, CH; Li, YS; Lin, MW; Liu, CY; Shiau, CW; Su, JC; Tai, WT; Tseng, PH | 1 |
Kim, JI; Kim, SY; Lee, MH; Lee, SJ | 1 |
Ahmed, M; Coleman, CN; Curran, WJ; Dicker, AP; Finkelstein, SE; Houghton, P; Kirsch, DG; Machtay, M; Monjazeb, AM; Teicher, BA; Vikram, B; Wang, D; Wong, P; Xu-Welliver, M | 1 |
D'Argenio, DZ; Hsu, CP; Huard, J; Kuchimanchi, M; Lu, JF; Ma, J; Sun, YN; Weidner, M; Xu, G; Xu, Y; Zhang, Y | 1 |
Ameye, L; Awada, A; Flamen, P; Garcia, C; Lalami, Y; Paesmans, M | 1 |
Chang, CH; Chiang, WF; Feng, LY; Feng, YH; Hsiao, JR; Hsieh, JL; Huang, WT; Lin, CL; Liu, SY; Tsao, CJ; Tung, CL | 1 |
Chang, YF; Chuang, HY; Hwang, JJ; Liu, RS | 1 |
Liu, BL; Liu, X; Qi, MY; Xu, B; Zhou, NC | 1 |
Bie, P; Huan, HB; Lau, WY; Ma, KS; Xia, F | 1 |
Binder, H; Elsäßer, A; Schmidtmann, I; Weinmann, A | 1 |
Abiraj, K; Boerman, OC; Franssen, GM; Gerrits, D; Lok, J; Oyen, WJ; Terry, SY | 1 |
Bolondi, L; Boni, C; Bruzzi, P; Cammà, C; Colombo, M; Craxi, A; Danesi, R; Daniele, B; Di Costanzo, GG; Fagiuoli, S; Santoro, A; Spandonaro, F; Trevisani, F | 1 |
Falchook, GS; Fu, S; Hong, DS; Huang, M; Janku, F; Jiang, Y; Kurzrock, R; Lin, Q; Naing, A; Parkhurst, K; Piha-Paul, SA; Tsimberidou, AM; Wheler, JJ; Zinner, R | 1 |
Chen, G; Li, H; Wang, Z; Xu, X; You, W; Zhang, J; Zhou, D | 1 |
Baert, M; Chauffert, B; Diouf, M; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Saidak, Z | 1 |
Kawabata, M; Kuroyanagi, J; Miyabe, M; Nishimura, Y; Shimada, Y; Tanaka, T; Umemoto, N; Zhang, B | 1 |
Li, H; Liang, Q; Liu, B; Ma, Y; Mei, X; Wang, Y | 1 |
Adjei, AA; Brady, W; DePaolo, D; Ding, Y; Dy, GK; Fetterly, G; Ma, WW; Ngamphaiboon, N; Reungwetwattana, T; Zhao, Y | 1 |
Chen, Y; Hong, S; Luo, S; Tan, M; Wang, S; Zhang, L | 1 |
Bracarda, S; D Buono, S; Hamzaj, A; Marrocolo, F; Paglino, C; Porta, C; Sisani, M; Sternberg, CN | 1 |
Arizumi, T; Chishina, H; Hagiwara, S; Inoue, T; Kitai, S; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N | 3 |
Chen, WT; Jeng, WJ; Lin, CC; Lin, CY; Lin, SM; Sheen, IS | 1 |
Chen, KF; Hung, MH; Shiau, CW; Tai, WT | 1 |
Dai, B; Lin, GW; Ma, CG; Qin, XJ; Shen, YJ; Shi, GH; Wang, HK; Xiao, WJ; Yao, XD; Ye, DW; Zhang, HL; Zhang, SL; Zhu, Y; Zhu, YP | 1 |
Albers, P; Greife, A; Hader, C; Knievel, J; Lübke, T; Niegisch, G; Schmitz, I; Schulz, WA | 1 |
Corssmit, EP; Kapiteijn, E; Links, TP; Oosting, SF; Schneider, TC; van der Horst-Schrivers, AN | 1 |
Du, G; Tian, J; Wang, H; Ye, L; Yu, P; Zhang, J | 1 |
Dou, K; Du, X; Feng, X; Guo, C; Jia, W; Liu, T; Ma, K; Qin, X; Wang, Z; Xu, J; Xu, R; Yang, S; Zhao, H | 1 |
Bianco, V; Fiaschi, AI; Francini, E; Laera, L; Mazzaroppi, S; Pellicelli, AM; Petrioli, R; Pira, T; Roviello, G | 1 |
Arvat, E; Castiglione, A; Ciccone, G; Felicetti, F; Gallo, M; Michelon, F; Nervo, A; Piovesan, A; Viansone, AA; Zichi, C | 1 |
He, C; Jiang, H; Jiang, X; Ma, L; Sun, X; Xu, L; Zhai, B; Zhao, D | 1 |
Dill, MT; Djonov, V; Heim, MH; Hlushchuk, R; Makowska, Z; Quagliata, L; Rothweiler, S; Semela, D; Terracciano, L | 1 |
Fujii, Y; Hatano, T; Horie, S; Kawata, N; Kimura, G; Kondo, T; Kume, H; Morita, M; Murakami, M; Nakajima, K; Nakazawa, H; Ohno, Y; Okegawa, T; Oya, M; Saito, K; Takahashi, S; Wakumoto, Y; Yamaguchi, R | 1 |
Adenis, A; Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Cassier, P; Chaigneau, L; Chevreau, C; Collard, O; Cropet, C; Cupissol, D; Duffaud, F; Eberst, L; Gentet, JC; Le Cesne, A; Marec-Berard, P; Pautier, P; Penel, N; Piperno-Neumann, S; Ray-Coquard, I; Thyss, A | 1 |
Becherer, A; Dierneder, J; Gallowitsch, H; Hoffmann, M; Lind, P; Lindner, C; Lipp, R; Niederle, B; Pall, G; Pirich, C; Raderer, M; Romeder, F; Virgolini, I | 1 |
Mullangi, R; Sharma, K; Srinivas, NR; Suresh, PS | 1 |
Akker, Nv; Benzina, A; Gagliardi, M; Koole, LH; Molin, DG; Wang, Y | 1 |
Galanis, A; Levis, M | 1 |
Hiraoka, A; Ikeda, M; Izumi, N; Kadoya, M; Kudo, M; Matsui, O; Minami, T; Miyayama, S; Ogasawara, S; Okusaka, T; Tsuchiya, K; Ueshima, K; Yamakado, K; Yamashita, T | 1 |
Seong, J; Yoon, HI | 1 |
Kudo, M; Shimada, M; Tanaka, K | 1 |
Bazzica, M; Di Gion, P; Fucile, C; Lantieri, F; Marenco, S; Marini, V; Martelli, A; Mattioli, F; Picciotto, A; Pieri, G; Robbiano, L; Savarino, V; Stura, P; Zuccoli, ML | 1 |
Argilés, JM; Busquets, S; López-Soriano, FJ; Penna, F; Toledo, M | 1 |
Bartsch, G; Blaheta, RA; Haferkamp, A; Juengel, E; Kim, D; Makarević, J; Reiter, M; Tsaur, I | 1 |
Ahn, H; Böckenhoff, A; Escudier, B; Guo, J; Jäger, D; Korbenfeld, E; Leonhartsberger, N; Ma, JH; Mardiak, J; Stauch, K; Ye, DW; Yu, J; Zemanova, M | 1 |
Barbare, JC; Bouhlal, H; Chatelain, D; Chauffert, B; Debuysscher, V; François, C; Galmiche, A; Godin, C; Lachaier, E; Louandre, C; Marcq, I; Saidak, Z | 1 |
Berie, L; Denzer, U; Distelrath, A; Dollinger, MM; Duerr, EM; Ebert, MP; Galle, PR; Geissler, M; Kaiser, AK; Kanzler, S; Kolligs, FT; Lammert, F; Lindig, U; Lohse, A; Lubomierski, N; Maderer, A; Moehler, M; Sauvigny, C; Schadmand-Fischer, S; Schimanski, C; Schütz, M; Trojan, J; Wachtlin, D; Woerns, M; Zimmermann, S | 1 |
Armeanu-Ebinger, S; Dewerth, A; Fuchs, J; Nagel, C; Warmann, SW | 1 |
Cai, H; Kong, WT; Tang, Y; Wang, WP; Yuan, HX; Zhang, XL | 1 |
Seino, S; Tsuchiya, A; Watanabe, M | 1 |
Bresci, G; Caparello, C; Felder, M; Fornaro, L; Granito, A; Masi, G; Mismas, V; Musettini, G; Sacco, R; Vivaldi, C | 1 |
Chao, CC; Lin, YT; Lu, HP | 1 |
Dai, C; Jia, C; Peng, S; Xu, F; Xu, Y; Zhao, Y | 1 |
Jiao, Y; Lu, X; Tang, W; Wu, J; Xin, BT; Zhang, Y; Zheng, Y; Zhou, X | 1 |
Aguggini, S; Allevi, G; Andreis, D; Bazzola, L; Berruti, A; Bertoni, R; Bottini, A; Ferrozzi, F; Foroni, C; Fox, SB; Gatter, K; Generali, D; Giardini, R; Harris, AL; Martinotti, M; Milani, M; Petronini, PG; R Cappelletti, M; Reynolds, AR; Strina, C; Turley, H; Venturini, S; Zanoni, V | 1 |
Ackermann, K; Esposito, I; Galle, PR; Heikenwälder, M; Lang, H; Protzer, U; Puschnik, A; Schad, A; Schlitter, AM; Sprinzl, MF; Weinmann, A | 1 |
Cowen, EW; Massey, PR; Okman, JS; Wilkerson, J | 1 |
Abdel-Rehim, M; Castéra, L; Chatellier, G; Lebtahi, R; Ronot, M; Sibert, A; Vilgrain, V | 1 |
Gong, W; Liu, DJ; Liu, J; Sun, P; Xu, YT; Yu, GS; Zheng, SZ | 1 |
Boucher, E; Brunot, A; Cattenoz, C; Crouzet, L; Edeline, J; Gédouin, D; Guillygomarc'h, A; Larible, C; Latournerie, M; Le Roy, F; Le Sourd, S | 1 |
Chiba, T; Kanogawa, N; Kobayashi, K; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O | 1 |
Narang-Master, J; Rizzolo, D | 1 |
Luo, CL; Wu, XH; Zhao, CX | 1 |
Cainap, C; Carlson, DM; Chen, PJ; Cheng, Y; Chung, IJ; El-Nowiem, S; Eskens, FA; Gorbunova, V; Huang, WT; Kang, YK; Kudo, M; McKee, MD; Pan, H; Qian, J; Qin, S; Ricker, JL; Toh, HC | 1 |
Gillani, TB; Murray, M; Rawling, T | 1 |
Allen, JW; Gandara, DR; Gitlitz, BJ; Kelly, K; Lara, PN; Mack, PC; Moon, J; Redman, MW; Semrad, TJ | 1 |
Bernardini, M; Brossa, A; Bussolati, B; Fiorio Pla, A; Genova, T; Gkika, D; Grolez, G; Leroy, X; Prevarskaya, N; Villers, A | 1 |
Fukuda, H; Hidaka, H; Ishii, T; Kobayashi, S; Kondo, M; Maeda, S; Morimoto, M; Morita, S; Nakazawa, T; Nozaki, A; Numata, K; Ohkawa, S; Okuse, C; Sakamaki, K; Shibuya, A; Suzuki, M; Tanaka, K | 1 |
Gao, ZH; Li, Y; Qu, XJ | 1 |
Aglietta, M; Asaftei, SD; Bertulli, R; Biagini, R; Capozzi, F; Casali, PG; D'Ambrosio, L; Fagioli, F; Ferraresi, V; Ferrari, S; Gambarotti, M; Grignani, G; Marchesi, E; Palmerini, E; Picci, P; Pignochino, Y; Sangiolo, D; Tamburini, A | 1 |
Artaza Varasa, T; de la Cruz Pérez, G; Gómez Rodríguez, R; González de Frutos, C; Muñoz López, D; Romero Gutiérrez, M; Ruano Díaz, L; Sánchez Ruano, JJ | 1 |
Fischer, K; Göke, B; Kolligs, FT; op den Winkel, M; Paprottka, PM; Rauch, B; Schmidt, L; Straub, G | 1 |
Ikeda, M; Kuwahara, A; Mitsunaga, S; Ohno, I; Okusaka, T; Okuyama, H; Senda, S; Shimizu, S; Takahashi, H | 1 |
Götze, L; Hegele, A; Hofmann, R; Keil, C; Nockher, WA; Olbert, P | 1 |
Ball, DW; Byrd, D; Dickson, P; Duh, QY; Ehya, H; Haddad, RI; Haymart, M; Hoffmann, KG; Hoh, C; Hughes, M; Hunt, JP; Iagaru, A; Kandeel, F; Kopp, P; Lamonica, DM; Lydiatt, WM; McCaffrey, J; Moley, JF; Parks, L; Raeburn, CD; Ridge, JA; Ringel, MD; Scheri, RP; Shah, JP; Sherman, SI; Sturgeon, C; Tuttle, RM; Waguespack, SG; Wang, TN; Wirth, LJ | 1 |
Chen, J; Chen, S; Wu, B; Xi, W; Yu, H | 1 |
Ahn, JM; Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Lim, HY; Paik, SW; Paik, YH; Sinn, DH; Sohn, W; Yoo, BC | 1 |
Bardeesy, N; Chen, Y; Duda, DG; Fan, C; Hato, T; Huang, P; Huang, Y; Jain, RK; Kitahara, S; Ng, MR; Ochiai, H; Ramjiawan, RR; Reddy, TP; Reiberger, T; Unan, EC; Zhu, AX | 1 |
Fang, Q; Liu, S; Sun, J; Xu, H; Zhan, C; Zhang, S; Zhang, Y; Zhao, L | 1 |
Bode, B; Cathomas, R; Fuchs, B; Rothermundt, C; Schwitter, M; von Moos, R | 1 |
Donskov, F; Fode, K; Geertsen, PF; Hermann, GG; Ibsen, R; Jensen, NV; Kjellberg, J; Soerensen, AV | 1 |
Bruix, J; Carrilho, FJ; Evans, TR; Jensen, M; Kang, YK; Leberre, MA; Llovet, JM; Meinhardt, G; Qin, S; Rosmorduc, O; Ross, PJ; Santoro, A; Thuluvath, PJ; Zhu, AX | 1 |
Antar, A; Bazarbachi, A; Kharfan-Dabaja, MA; Mahfouz, R | 1 |
Duan, F; Fan, QS; Fu, JX; Liu, FY; Wang, MQ; Zhang, L | 1 |
Du, G; Tian, J; Wang, H; Ye, L; Yu, P; Zhang, J; Zuo, Y | 1 |
Bismayer, JA; Dudley, BS; Finney, LH; Gian, VG; Hainsworth, JD; Merritt, WM; Thompson, DS; Whorf, RC | 1 |
Liu, C; Meng, FD; Pang, Q; Qu, K; Wang, ZX; Wei, JC; Wu, QF; Zhang, LQ | 1 |
Berger, W; Dornetshuber-Fleiss, R; Heffeter, P; Heilos, D; Lemmens-Gruber, R; Mohr, T; Novicky, A; Richter, L; Süssmuth, RD; Zlesak, M | 1 |
Boige, V; Ducreux, M; Ferté, C; Hollebecque, A; Malka, D | 1 |
Ardizzoni, A; Campanini, N; Dal Bello, B; Fanello, S; Maria, SE; Missale, G; Negri, FV; Poggi, G; Porta, C; Rossi, S; Salvagni, S; Tinelli, C | 1 |
Karakurt Eryılmaz, M; Kıvrak Salim, D; Musri, FY; Mutlu, H; Şenol Coşkun, H; Tural, D; Ünal, B | 1 |
Albares, MP; Berbegal, L; Blanes, MM; de León, FJ | 1 |
Chan, SY; Cheng, AL; Hsu, CH; Lu, LC; Shao, YY; Shau, WY | 1 |
Arora, J; Boonkaew, B; Callaghan, C; Chava, S; Dash, S; He, J; John, VT; Lee, BR; Liu, J; Maddox, MM; Mandava, SH | 1 |
Huang, YS; Xue, Z; Zhang, H | 1 |
Andrade, R; Arenas, J; Bustamante, J; Castells, L; Díaz, R; Espinosa, MD; Fernández-Castroagudín, J; Gómez, M; Gonzálvez, ML; Granizo, IM; Hernandez-Guerra, M; Polo, BA; Rendón, P; Sala, M; Salgado, M; Serrano, T; Turnes, J; Vergara, M; Viudez, A | 1 |
Bedi, A; Bishop, J; Chung, CH; Gilbert, J; Haigentz, M; Leon, ME; Murphy, B; Neil Hayes, D; Nieva, J; Ravi, R; Saba, N; Schell, MJ; Sidransky, D; Tanvetyanon, T; Zhao, X | 1 |
Handkiewicz-Junak, D; Jarzab, B; Krajewska, J | 1 |
Choi, HJ; Han, J; Han, KH; Kim, GM; Lim, S | 1 |
Chung, YH; Jung, J; Kang, YK; Kim, GA; Kim, JH; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Ryoo, BY; Ryu, MH; Shim, JH; Yoon, SM | 1 |
Hu, W; Liu, XH; Lv, SQ; Wang, XH; Yuan, Q; Zhu, HC | 1 |
Colevas, AD; Gruber, JJ | 1 |
Barceló-Batllori, S; Bell, O; Corra, M; de Leiva, A; González, C; Lerma, E; Mato, E; Moral, A; Orera, I; Pérez, JI; Selva, L | 1 |
Chan, JK; Chung, AY; Endaya, BB; Gnecchi, M; Ho, IA; Hui, KM; Huynh, H; Iyer, NG; Lam, PY; Leong, HS; Lim, KH; Newman, JP; Sia, KC; Toh, XY; Yulyana, Y | 1 |
Cao, H; Chen, L; Chen, Y; Gu, W; He, X; Huang, Y; Li, Y; Wang, Y; Xu, M; Yin, Q; Yu, H; Zhang, Z | 1 |
Jin, G; Liu, Y; Sun, K; Tian, Y; Wang, Y; Yang, X; Zhang, Q; Zhou, C | 1 |
Colquhoun, S; Hata, K; Hoon, DS; Hoshino, H; Huang, SK; Iida, Y; Ohta, K; Ono, S; Wang, J | 1 |
Hagström, MV; Hirvonen, JT; Kaasalainen, MH; Mäkilä, EM; Salonen, JJ; Santos, HA; Wang, CF | 1 |
Chen, M; Gao, H; Huang, J; Li, S; Wang, H; Xu, L; Zhang, Y; Zhou, Z | 1 |
Kong, D; Li, Q; Ma, W; Song, T; Wei, K; Wu, Q; Zhang, Q; Zhang, T; Zhang, W; Zhao, G | 2 |
Belli, L; Cabibbo, G; Cammà, C; Enea, M; Galvano, A; Mancuso, A; Mazzola, A; Perricone, G; Zavaglia, C | 1 |
Coy, DH; Sun, G; Sun, L; Yu, Y | 1 |
Hsia, CY; Hsu, CY; Huang, YH; Huo, TI; Lee, RC; Lee, YH; Lin, HC; Liu, PH; Su, CW | 1 |
Barbara, M; Basso, M; Biolato, M; Cabibbo, G; Cammà, C; Colombo, M; Craxì, A; Della Corte, C; Grieco, A; Iavarone, M; Maida, M; Vavassori, S | 1 |
Chen, CY; Chen, SC; Feng, CW; Feng, YM; Lee, MY; Lu, CL | 1 |
Deng, J; Ji, Z; Li, H; Li, Y; Yu, H; Zhang, Y | 1 |
Feng, X; Hu, Y; Liu, A; Liu, D; Peng, J | 1 |
Cohen, MS; White, PT | 1 |
Adlard, K; Chang, B; Cooper, T; Estey, E; Garee, A; Gross, T; Gupta, S; Ho, PA; McGoldrick, S; Meshinchi, S; Neudorf, S; Pollard, JA; Sisler, I; Tarlock, K; Templeman, T; Thomson, B; Watt, T; Woolfrey, A | 1 |
Li, CS; Liu, QY; Qi, HL; Zhuang, BJ | 1 |
Brendel, C; Burchert, A; Fouladi, F; Henkenius, K; Hub, F; Jehn, LB; Metzelder, SK; Neubauer, A; Stiewe, T | 1 |
Azijli, K; Broxterman, HJ; de Haas, RR; Dekker, H; Gotink, KJ; Honeywell, RJ; Peters, GJ; Poel, D; Rovithi, M; Verheul, HM | 1 |
Aguilar, G; Chan, YC; Chen, CL; Kabiling, CS; Pillai, VG; Wang, CC | 1 |
Bai, Y; Guo, X; Kang, H; Lu, L; Lu, M; Qu, Z; Ren, Z; Shi, L; Song, T; Wang, H; Wang, X; Yang, W; Yang, Y; Ye, SL; Zhou, W; Zhu, K | 1 |
Liu, J; Zhang, B; Zhang, X; Zhou, T | 1 |
Bi, F; Hao, P; Li, J; Li, Q; Wen, F; Xia, F; Yan, W; Yang, Y; Zhang, P | 1 |
Boucher, E; Boudjema, K; Breton, M; Clement, B; Edeline, J; Garin, E; Icard, N; Laffont, S; Lenoir, L; Mesbah, H; Raoul, JL; Rohou, T; Rolland, Y; Sulpice, L | 1 |
Chen, Z; Duan, Z; Fu, R; Ge, H; Gui, B; Han, J; Jia, L; Ma, X; Ou, Y; Tian, L; Wang, L | 1 |
Rupasinghe, HV; Sudan, S | 1 |
Kirstein, MM; Klöpper, A; Lehmann, U; Manns, MP; Ringe, KI; Schmidt, S; Schweitzer, N; Vogel, A; Wedemeyer, H | 1 |
Ishijima, N; Kanki, K; Shimizu, H; Shiota, G | 1 |
Chen, G; Derwahl, M; Nicula, D; Renko, K | 1 |
Han, M; Jing, Y; Kan, X; Liu, KH; Pan, JC; Wan, QY; Wang, Q; Yang, Y; Zhu, M | 1 |
Fu, Q; Liu, J; Liu, Y; Ouyang, H; Qiao, K; Shen, Z; Tao, S; Wang, W; Wu, J; Wu, Y; Xie, Y; Yang, X; Ye, X; Zhang, J; Zhang, JB | 1 |
Ali, LA; Elmashad, N; Elmashad, W; Farouk, M; Ibrahim, WS; Mayah, WW; Taha, A | 1 |
Dai, JQ; Gao, F; Li, G; Li, GC; Liu, X; Mu, J; Ren, JJ; Song, YP; Wang, H; Wang, L; Wang, QX; Xie, J; Zhang, XB; Zhang, YJ; Zhou, NC | 1 |
Duan, Z; Hertzanu, Y; Hu, H; Liu, S; Long, X; Shi, H; Tong, X; Xu, X; Yang, Z | 1 |
Cen, J; He, X; Hu, C; Hui, L; Li, C; Li, Y; Mu, W; Qiu, Z; Qu, Z; Ren, H; Shi, X; Zhang, H | 1 |
Airaksinen, AJ; Hirvonen, JT; Hyvönen, ML; Laakkonen, PM; Mäkilä, EM; Salonen, JJ; Santos, HA; Sarparanta, MP; Wang, CF | 1 |
Bellentani, S; Biasco, G; Brandi, G; De Lorenzo, S; Di Girolamo, S; Saccoccio, G | 1 |
Booth, L; Chuckalovcak, J; Cruickshanks, N; Dent, P; Hamed, HA; Poklepovic, A; Roberts, JL; Tavallai, M | 1 |
Kumar, S | 1 |
Li, K; Liu, Y; Ma, N; Qiao, L; Wang, F; Wang, J; Xu, S; Yue, H | 1 |
Gu, D; Pan, X; Qian, L; Shan, Y; Xue, B; Yang, D; Zheng, B; Zhou, J; Zhu, H | 1 |
An, L; Chen, Y; Feng, F; Gao, X; Lu, Y; Qu, J; Sun, H; Wang, C; Wang, F; Yang, Y; Zeng, Z; Zhang, C | 1 |
Barbeiro, DF; Bida, PM; Carrilho, FJ; Coelho, AM; Cogliati, B; D'Albuquerque, LA; Kubrusly, MS; Mazo, DF; Oliveira, CP; Pereira, IV; Souza, HP; Stefano, JT; Torres, MM; Xerfan, MP | 1 |
Jin, Y; Lin, L; Lin, Y; Tan, Y; Wang, D; Zhang, Y; Zheng, C | 1 |
Doi, Y; Kikkawa, H; Kitayama, T; Nakaba, H; Oguchi, Y; Sasaki, M; Tamagawa, H; Taniguchi, E; Watanabe, Y | 1 |
Hosoda, Y; Kakita, N; Kim, Y; Nagai, K; Nishino, M; Okano, M; Tsujinaka, T; Yamada, Y; Yamasaki, M; Yasui, M | 1 |
Dong, R; Kang, M; Yang, Q; Zhang, S; Zhao, J | 1 |
Lee, HW; Park, JG; Park, SY | 1 |
Blair, HA; Plosker, GL | 1 |
Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Conte, MA; Diouf, M; Galmiche, A; Ganne, N; Godin, C; Louandre, C; Saidak, Z; Trinchet, JC | 1 |
Colao, A; Faggiano, A; Marotta, V | 1 |
Addario, L; Caporaso, N; Cordone, G; de Stefano, G; Di Costanzo, GG; Farella, N; Imparato, M; Lampasi, F; Lanza, AG; Tortora, R | 1 |
Chen, L; Dong, Q; Liu, M; Ruan, M | 1 |
Lauer, R; Rao, A | 1 |
Bornemann, L; Dicken, V; Moltz, JH; Peitgen, HO; Scheuring, U; Zaim, S | 1 |
Barba, M; Bernardini, C; Castellini, L; Gasbarrini, A; Maulucci, G; Pani, G; Piscaglia, AC; Pontoglio, A; Puglisi, MA; Samengo, D; Scatena, R; Spelbrink, JN; Tesori, V | 1 |
Araki, H; Gotoh, M; Hattori, R; Kimura, T; Sassa, N; Tanaka, K; Tsuzuki, T; Yamada, S; Yoshino, Y | 1 |
Arias, A; Catania, VA; Ceballos, MP; Ciriaci, N; Ghanem, CI; Luquita, MG; Mottino, AD; Rigalli, JP; Ruiz, ML; Villanueva, SS | 1 |
Davidoff, AM; Interiano, RB; McCarville, MB; Navid, F; Sandoval, J; Wu, J | 1 |
Kawai, K; Minemura, M; Nakajima, T; Sugiyama, T; Tajiri, K | 1 |
de Bont, ES; den Dunnen, WF; Hoving, EW; Kampen, KR; Lourens, HJ; Meeuwsen-de Boer, TG; Scherpen, FJ; Sie, M; Zomerman, WW | 1 |
Abdel-Maksoud, MS; El-Gamal, MI; Gamal El-Din, MM; Oh, CH; Yoo, KH | 1 |
Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Cessot, A; Coriat, R; Durand, JP; Giroux, J; Goldwasser, F; Huillard, O; Thomas-Schoemann, A; Tlemsani, C | 1 |
Chen, YL; Cheng, YS; Chuai, ML; Ding, XY; Lee, KK; Li, Y; Wang, G; Wang, XY; Yang, XS | 1 |
Amir, E; Ethier, JL; Krzyzanowska, MK; Ocana, A; Seruga, B; Srikanthan, A | 1 |
English, PA; Escudier, B; Huang, X; Kim, S; Loomis, AK; Motzer, RJ; Rini, BI; Rosbrook, B; Tarazi, J; Williams, JA | 1 |
Bussom, S; Cheng, YC; Guan, F; Hu, R; Huang, X; Jiang, Z; Lam, W; Liu, SH; Wang, J; Yen, Y; Zhao, H | 1 |
Choi, WW; Chow, HC; Gill, H; Ip, AH; Kwong, YL; Leung, AY; Man, CH | 1 |
Brochot, E; Castelain, S; Descamps, V; Duverlie, G; Fournier, C; François, C; Galmiche, A; Helle, F; Hoffmann, TW; Izquierdo, L; Louandre, C; Martin, E | 1 |
Hoshida, Y; Kishikawa, T; Koike, K; Kojima, K; Kondo, Y; Noyama, T; Ohishi, M; Ohno, M; Ota, S; Otsuka, M; Sato, M; Shibata, C; Soga, T; Sun, X; Takata, A; Takehana, K; Tan, PS; Yoshikawa, T | 1 |
Fishman, MN; Foreman, PK; Fulp, WJ; Tomshine, J | 1 |
Delire, B; Stärkel, P | 1 |
Azuma, K; Esaki, M; Kitazono, T; Matsumoto, T; Nakamura, S; Ooho, A; Yanai, S | 1 |
Alloisio, M; Fatuzzo, G; Lorenzi, E; Rubino, L; Santoro, A; Simonelli, M; Suter, MB; Zucali, PA | 1 |
Kim, YH; Lee, EW; Quirk, M; Saab, S | 1 |
Choi, SJ; Gu, HR; Han, CJ; Jeong, JH; Kim, J; Kim, YC; Kim, YJ; Lee, JC; No, SH; Noh, GY; Park, SC; Yang, KY | 1 |
Choi, HS; Hahm, JS; Jun, DW; Kim, JO; Lee, HL; Lee, KN; Lee, OY; Tae, HJ; Yoon, BC | 1 |
Qin, S; Zhang, S | 1 |
Eto, M; Harada, M; Horlad, H; Kawano, Y; Komohara, Y; Maeda, Y; Motoshima, T; Takeuchi, A; Takeya, M; Tanoue, K | 1 |
de Man, RA; Ijzermans, JN; Klümpen, HJ; Schrier, JG; van der Geest, LG; van Erpecum, KJ; van Meer, S | 1 |
Chow, LP; Feng, WC; Ho, WC; Hsu, CH; Shao, YY; Tsai, MH; Yeh, CC | 1 |
Ai, H; Han, L; Liu, S; Mi, R; Song, Y; Wang, P; Wei, X; Yin, Q; Zhang, Y; Zhao, H | 1 |
Booth, L; Cruz-Luna, T; Cycon, KA; Dent, P; Doern, CD; Fidanza, A; Nourbakhsh, A; Plamondon, P; Roberts, JL; Siembida, P; Smith, E; Tavallai, M | 1 |
Chao, Y; Chen, YT; Huang, YH; Huo, TI; Lee, FY; Lee, IC; Li, CP; Lin, HC; Su, CW | 1 |
Bil, J; Bobrowicz, M; Bojarczuk, K; Dwojak, M; Giannopoulos, K; Golab, J; Lech-Maranda, E; Malenda, A; Pyrzynska, B; Siernicka, M; Tomczak, W; Winiarska, M | 1 |
Chiba, T; Kanai, F; Kanogawa, N; Motoyama, T; Ogasawara, S; Ooka, Y; Saito, T; Suzuki, E; Tawada, A; Yokosuka, O | 3 |
Cao, L; Choyke, P; Do, K; Doroshow, JH; Eugeni, M; Figg, WD; Holkova, B; Jacobs, P; Kang, Z; Kummar, S; Larkins, E; Lindenberg, ML; Peer, CJ; Raffeld, M; Steinberg, SM; Turkbey, B; Wright, JJ | 1 |
Benevento, F; Bolondi, L; Granito, A; Marinelli, S; Piscaglia, F; Renzulli, M; Terzi, E; Venerandi, L | 1 |
Fujisawa, M; Miyake, H; Tei, H | 1 |
Aderhold, C; Birk, R; Faber, A; Hörmann, K; Schultz, JD; Sommer, JU; Umbreit, C; Weiss, C | 1 |
Ha, TY; Hong, HN; Hwang, S; Kim, N; Moon, KM; Ryoo, BY; Song, GW; Tak, E; Won, YJ | 1 |
Choi, YI; Ha, TY; Hong, HN; Hwang, S; Kim, N; Ryoo, BY; Song, GW; Tak, E; Won, YJ; Yoon, SY | 1 |
Higai, K; Igarashi, Y; Matsui, D; Matsui, T; Momiyama, K; Mukozu, T; Nagai, H; Ogino, YU; Sumino, Y; Wakui, N | 1 |
Chen, C; Cheng, Z; Cong, WM; Ding, J; Feng, GS; Han, T; Li, HY; Liu, N; Shen, WF; Sun, HL; Sun, W; Wang, HY; Wang, RY; Wang, X; Wen, W; Wu, MC; Xiang, DM | 1 |
Abbattista, MR; Gu, Y; Guise, CP; Jamieson, SM; Nickel, JE; Patterson, AV; Pullen, SM; Wilson, WR | 1 |
Anseth, KS; Jones, CE; Leight, JL; Lin, AJ; Tokuda, EY | 1 |
Gavrancic, T; Park, YH | 1 |
Bruckner, T; Ganten, MK; Ganten, TM; Koschny, R; Schuessler, M | 1 |
Britten, M; Broecker-Preuss, M; Fuhrer, D; Mann, K; Müller, S; Schmid, KW; Worm, K | 1 |
Abei, M; Danjoh, I; Hyodo, I; Nakamura, Y; Shirota, R; Yamada, T; Yamashita, T | 1 |
Chae, HB; Kang, HY; Kang, YW; Kim, AN; Kim, HS; Kim, SB; Kim, SH; Ko, SY; Lee, BS; Lee, ES; Lee, HY; Lee, JD; Lee, SH; Lee, TH; Noh, R; Song, IH | 1 |
Dong, M; Kong, FM; Li, YJ; Zhou, JP | 1 |
Abe, Y; Aiura, K; Ei, S; Hibi, T; Itano, O; Kishida, N; Kitagawa, Y; Kitago, M; Masugi, Y; Sakamaoto, M; Shinoda, M; Tanabe, M; Tanimoto, A; Ueno, A; Yagi, H | 1 |
de Stefano, G; Farella, N; Iodice, V | 1 |
Dou, H; Feng, K; Jiang, X; Li, Z; Wang, T; Zhang, Y; Zhou, F | 1 |
Cho, M; Choi, CW; Heo, J; Hong, YM; Kang, DH; Kim, HW; Lim, W; Park, SB; Woo, HY; Yoon, KT | 2 |
Ang, MK; Chau, NM; Chowbay, B; Haaland, B; Hui, KM; Koh, TS; Li, WY; Lim, WT; Ng, QS; Tan, DS; Tan, EH; Tan, IB; Thng, CH; Toh, CK | 1 |
Ho, TH; Hoang, A; Huang, Y; Johnson, MM; Jonasch, E; Liu, XD; Tamboli, P; Wang, F; Warneke, CL | 1 |
Chen, Y; Ding, J; Ding, R; Dou, K; Gao, Y; Guo, X; Liu, D; Lv, X; Ruan, B; Zhou, T | 1 |
Cheng, BY; Ching, RH; Lau, EY; Lee, TK; Lo, J; Ma, MK; Ng, IO | 1 |
Carella, N; Carr, BI; Cavallini, A; D'Alessandro, R; Lippolis, C; Messa, C; Refolo, MG | 2 |
Chen, E; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S | 1 |
Aydınok, Y; Balkan, C; Karadaş, N; Kavaklı, K; Önder Siviş, Z; Yılmaz Karapınar, D | 1 |
Barone, M; Carr, BI; Di Leo, A; Facciorusso, A; Licinio, R | 1 |
Ai, H; Mi, R; Wang, P; Wei, X; Xu, H; Yin, Q | 1 |
Du, Z; He, X; Li, Q; Tang, R; Wen, F; Yang, Y; Zhang, J; Zhang, P; Zhou, J | 1 |
Kalyan, A; Kulik, L; Nimeiri, H | 1 |
Cho, JY; Choi, MS; Gwak, GY; Koh, KC; Lee, JH; Paik, SW; Paik, YH; Sinn, DH; Yoo, BC | 1 |
Hanai, T; Ideta, T; Imai, K; Kochi, T; Miyazaki, T; Shimizu, M; Shiraki, M; Suetsugu, A; Takai, K | 1 |
Bos, MM; De Santis, M; Eichelberg, C; Fischer von Weikersthal, L; Flörcken, A; Freier, W; Goebell, PJ; Gottstein, D; Hauswald, K; Indorf, M; Lerchenmüller, C; Los, M; Michel, MS; Pahernik, S; Schenck, M; Schirrmacher-Memmel, S; Staehler, M; van Arkel, C; Vervenne, WL; Zimmermann, U | 1 |
Baker, SD; Durmus, S; Gibson, AA; Hu, S; Li, L; Mani, S; Panetta, JC; Schinkel, AH; Sparreboom, A; Vasilyeva, A; Wagenaar, E | 1 |
Aglietta, M; Basiricò, M; Canta, M; Capozzi, F; Cemmi, F; Dell'Aglio, C; Gammaitoni, L; Grignani, G; Inghilleri, S; Luisetti, M; Marchiò, S; Morbini, P; Pignochino, Y; Piloni, D; Pozzi, E; Sangiolo, D; Soster, M; Stella, GM; Zorzetto, M | 1 |
De Velasco, MA; Hatanaka, Y; Kura, Y; Minami, T; Nishio, K; Nozawa, M; Oki, T; Ozeki, T; Shimizu, N; Uemura, H; Yamamoto, Y; Yoshikawa, K; Yoshimura, K | 1 |
Sioulas, AD; Triantafyllou, K | 1 |
Büchler, MW; Ganten, T; Gotthardtp, D; Hoffmann, K; Jäger, D; Karapanagiotou-Schenkel, I; Kollmar, O; Nadalin, S; Radeleff, B; Schemmer, P; Settmacher, U; von Kalle, C | 1 |
Petrou, P | 2 |
Barrois, C; Berger, F; Cassier, P; El-Madani, M; Freyer, G; Guitton, J; Hénin, E; Lachuer, J; Lefort, T; Rodriguez-Lafrasse, C; Slimane, K; Tod, M; Valette, PJ; You, B | 1 |
Akkar, OB; Cetin, A; Kacan, SB; Kacan, T; Karakus, S; Ozer, H; Yildiz, C | 1 |
Bhatt, VR; Giri, S; Hamdeh, S; Schwarz, JK | 1 |
Bhak, J; Hong, SH; Hwang, JA; Kim, BC; Kim, BH; Kim, JS; Lee, JA; Lee, SH; Lee, YS; Nam, S; Park, JW; Shin, A | 1 |
Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; Haas, NB; Jewett, M; Kane, CJ; Ky, B; Manola, J; Uzzo, RG; Wilding, G; Wood, CG; Wood, L | 1 |
Karedan, T; Perez, CA; Wang, E | 1 |
Bornhäuser, M; Brendel, C; Burchert, A; Charles, J; Ellenrieder, V; Gattenlöhner, S; Hessmann, E; Inselmann, S; Metzelder, SK; Michel, C; Neubauer, A; Rehberger, M; Sohlbach, K; Solovey, M; Stiewe, T; Ten Haaf, A; von Bonin, M; Wang, Y | 1 |
Labgaa, I; Villanueva, A | 1 |
Chan, SY; Cheng, AL; Hsu, CH; Huang, CY; Lin, TH; Shao, YY | 1 |
Ku, CY; Lin, HY; Lin, JY; Lu, SC; Wang, YR | 1 |
Chapiro, J; Duran, R; Geschwind, JF; Schernthaner, RE | 1 |
Chen, J; Shi, JH; Wang, J; Wang, Q; Zhu, YY | 1 |
Hu, X; Li, Q; Li, Y; Liang, R; Liao, S; Liao, X; Lin, Y; Liu, Z; Lv, Y; Yuan, C; Zhang, J | 1 |
Aldridge, J; Atkins, MB; Conley, C; Flaherty, KT; Giobbie-Hurder, A; Hodi, FS; Ibrahim, N; Lawrence, DP; McDermott, DF; Mier, JW; Sullivan, RJ | 1 |
Amoroso, D; Angelico, M; Attili, A; Barni, S; Benedetti, A; Buonadonna, A; Burlone, ME; Calvani, N; Cascinu, S; Cengarle, R; Cillo, U; Crocè, LS; Cuttone, F; D'Angelo, S; Di Costanzo, F; Erminero, C; Fava, G; Gasbarrini, A; Germano, D; Giannitrapani, L; Giovanis, P; Lencioni, R; Lorusso, V; Magini, G; Marenco, S; Marignani, M; Massa, E; Montesarchio, V; Noto, A; Palmieri, V; Picardi, A; Poggi, G; Proserpio, I; Saitta, C; Sansonno, D; Tumulo, S; Villa, E; Zolfino, T | 1 |
Altomonte, J; Braren, R; Dworniczak, J; Ebert, O; Esposito, I; Feuchtinger, A; Groß, C; Heid, I; Heß, J; Rummeny, E; Sayyed, S; Schlitter, AM; Schwaiger, M; Settles, M; Steiger, K; Steingötter, A; Unger, K; Walch, A; Zitzelsberger, H | 1 |
Bensalah, K; Ouzaid, I | 1 |
Brzózka, K; Mikula, M; Rzymski, T; Wiklik, K | 1 |
Baba, H; Beppu, T; Chikamoto, A; Hayashi, H; Imai, K; Ishiko, T; Nakamura, K; Nitta, H; Okabe, H; Sasaki, M | 1 |
Charbit, D; Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Sabourin, JC | 1 |
Chen, J; Harris, KR; Kim, DH; Larson, AC; Lewandowski, RJ; Li, W; Shea, LD; White, SB; Yap, JW | 1 |
Huang, A; Shi, Y | 1 |
Di Bella, S; Facchetti, R; Giannattasio, C; Giganti, MO; Maloberti, A; Mancia, G; Meani, P; Moreo, A; Musca, F; Pozzi, M; Ricotta, R; Sartore-Bianchi, A; Siena, S; Stucchi, M; Vallerio, P | 1 |
Bao, J; Che, S; Hao, C; Li, Z; Liu, J; Qian, Z; Shang, H; Wang, H; Zhang, H; Zhang, X; Zhao, H | 1 |
Cho, KJ; Han, KH; Kim, da Y; Kim, DY; Kim, MN; Lim, HY; Park, JH; Ro, SW | 1 |
Calucci, L; Cappello, V; Ciofani, G; de Julian Fernandez, C; Forte, C; Gemmi, M; Grillone, A; Innocenti, C; Mattoli, V; Mondini, A; Moscato, S; Riva, ER; Ronca, F; Sacco, R | 1 |
Chen, DS; Chen, KF; Chen, PJ; Cheng, HR; Huang, HP; Jao, P; Jeng, YM; Kao, JH; Liu, CH; Liu, CJ; Shiau, CW; Su, TH; Tai, WT; Tseng, TC; Yang, HC | 1 |
Fujie, S; Fukubayashi, K; Izumi, K; Kawasaki, T; Kikuchi, K; Naoe, H; Sasaki, Y; Setoyama, H; Tanaka, M; Tateyama, M; Watanabe, T; Yoshimaru, Y | 1 |
Eriksson, LA; Gao, C; Grøtli, M | 1 |
Jia, B; Jin, Z; Liu, K; Liu, S; Liu, Y; Tan, L; Zhang, W | 1 |
Li, S; Liu, R; Liu, Y; Shen, H; Wang, P; Yin, L | 1 |
Izumi, N; Joko, K; Nishijima, N; Nishio, K; Orito, E; Osaki, Y; Sakai, K; Takeda, H; Uchida, Y | 1 |
Albuquerque, M; Benhadji, KA; de Gramont, A; Dos Santos, C; Faivre, S; Neuzillet, C; Paradis, V; Raymond, E; Serova, M; Tijeras-Raballand, A | 1 |
Ghosh, AK; Giroux, V; Jossé, R; Luo, J; Pommier, Y; Zhang, YW | 1 |
Chang, E; Foerster, S; Gondek, L; Huso, DL; Levis, M; Li, L; Lim, Y; Ma, H; Marchionni, L; Matsui, W; McGovern, K; Merchant, AA; Peacock, CD; Small, D; Smith, BD; Wang, Q; Watkins, DN | 1 |
Eickhoff, J; Groteluschen, D; LoConte, NK; Lubner, SJ; Makielski, RJ; Mulkerin, DL; Traynor, AM | 1 |
Brown, JM; Chang, DT; Deng, L; Giaccia, A; Koong, AC; Le, QT; Loo, BW; Pai, RK; Pollom, EL; Shultz, DB | 1 |
Iguchi, T; Kato, M; Nakatani, T; Ninomiya, N; Tamada, S; Yamasaki, T | 1 |
Cosgrove, DP; Feng, AL; Geschwind, JF; Kamel, IR; Pawlik, TM; Reyes, DK | 1 |
Chen, YC; Chin, SY; Chou, CL; Jiang, MC; Lee, WR; Liu, KH; Shen, SC; Shih, YH; Tseng, JT | 1 |
Austin, T; Beckman, RA; Cheng, AL; Greenberg, J; He, AR; Hung, CH; Izumi, N; Kang, YK; Kudo, M; Lim, HY; Ryoo, BY; Sheen, IS; Shiratori, S; Wang, Q | 1 |
Guo, XL; Li, WB; Lu, YY; Wang, JJ; Zhang, XK | 1 |
Atkins, MB; DiPaola, RS; Dutcher, JJ; Flaherty, KT; George, DJ; Manola, JB; Margolin, KA; McDermott, DF; Pins, M | 1 |
Komarov, YI; Latipova, DH; Novik, AV; Protsenko, SA; Semenova, AI; Teletaeva, GM | 1 |
Guo, WH; Lu, J; Wang, XZ; Zhang, JX; Zheng, JF | 1 |
Fan, W; Fu, S; Huang, J; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y; Zhu, K | 1 |
Abada, PB; Baron, AD; Blanc, JF; Chang, SC; Chau, I; Chung, HC; Kubackova, K; Kudo, M; Okusaka, T; Park, JO; Pastorelli, D; Pfiffer, TE; Poon, R; Ryoo, BY; Sastre, J; Schwartz, JD; Trojan, J; Yang, L; Yen, CJ; Zhu, AX | 1 |
Cha, TL; Chang, SY; Chen, MR; Chen, YC; Chuang, MJ; Ho, JY; Hsiao, PW; Huang, SM; Lee, HJ; Lin, CC; Lin, HK; Lin, VC; Sun, GH; Tang, SH; Tsai, YT; Wu, ST; Yu, CP; Yu, DS | 1 |
Agulnik, M; Carneiro, BA; Carneiro, RM; Giles, FJ; Kopp, PA | 1 |
Bessarabova, M; Dorner, A; Gulbekyan, G; Hope, A; Kolpakova-Hart, E; Li, B; Merberg, D; Nikolsky, Y; Pustovalova, O; Schu, M; Shin, H; Trepicchio, WL | 1 |
Trojan, J; Waidmann, O | 1 |
Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Mazzi, V; Miccoli, M; Miccoli, P; Politti, U; Ulisse, S | 1 |
Chen, MS; Li, SP; Pawlik, TM; Spolverato, G; Xu, L; Zhang, YJ; Zhao, J; Zhou, DS | 1 |
Akaza, H; Eto, M; Fujisawa, M; Hashine, K; Naito, S; Ozono, S; Sakai, H; Shinohara, N; Tomita, Y | 1 |
Aikata, H; Chayama, K; Fukuhara, T; Hatooka, M; Hiramatsu, A; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Miyaki, D; Morio, K; Morio, R; Moriya, T; Naeshiro, N; Takahashi, S; Tsuji, K; Waki, K | 1 |
Huang, YH; Siao, FY; Yen, HH | 1 |
Im, GH; Jeon, TY; Kim, CK; Kim, JH; Lee, JH; Park, BK | 1 |
Cheng, SP; Chuang, JH; Lin, LL; Shieh, DB; Wang, PW; Wang, SY; Wei, YH | 1 |
Azmi, AN; Chan, WK; Goh, KL | 1 |
Aedo, V; Cristina, V; Faivre, S; Raymond, E | 1 |
Antonelli, A; Baldini, E; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Politti, U; Spisni, R; Ulisse, S | 1 |
Igarashi, Y; Ikehara, T; Ishii, K; Kikuchi, Y; Kogame, M; Makino, H; Matsui, T; Nagai, H; Okano, N; Shiozawa, K; Sumino, Y; Watanabe, M | 1 |
Bu, W; Chen, H; Cong, N; Li, J; Shi, C; Song, J; Wang, L | 1 |
Bodoky, G; Bronowicki, JP; Croitoru, A; Daniele, B; Mathurin, P; Papandreou, C; Ratziu, V; Serejo, F; Stål, P; Turnes, J | 1 |
He, D; Liu, R; Lu, X; Sun, C; Tang, C; Wei, X; Wu, Z; Zheng, D; Zhou, M | 1 |
Abbate, I; Brandi, M; De Rose, F; Divella, R; Ferraro, E; Filippelli, G; Gadaleta-Caldarola, G; Infusino, S; Mazzocca, A | 1 |
Hashimoto, Y; Iizuka, J; Kennoki, T; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K | 1 |
Batteux, F; Cerles, O; Chapron, C; Chouzenoux, S; Dousset, B; Leconte, M; Marcellin, L; Santulli, P | 1 |
Heikenwalder, M; O'Connor, T; Weber, A | 1 |
Cai, X; Chen, J; Huang, D; Jin, R; Liang, X; Liang, Y; Lin, H; Liu, J; Yan, H; Ying, H; Yu, H; Zhao, J; Zhou, S | 1 |
Cheng, AL; Fan, HH; Feng, ZR; Hsu, C; Lee, BS; Lin, LI; Liou, JY; Ou, DL; Shyue, SK | 1 |
Cheng, X; Cheng, Y; Kuang, Y; Pan, X; Yang, X | 1 |
Chen, L; Liang, S; Liu, J; Shao, H; Su, H; Xu, K | 1 |
Bettinger, D; Brunner, TB; Neeff, HP; Schultheiß, M; Thimme, R | 1 |
Albiges, L; Escudier, B | 1 |
Hayward, S; Iakovou, G; Laycock, SD | 1 |
Chun, HG; Chun, HJ; Hong, SH; Hwang, SW; Jung, ES; Lee, JE; Lee, JM; Lee, MA; Lee, SH | 1 |
Hijikawa, T; Ishizaki, M; Kaibori, M; Kitade, H; Kon, M; Matsui, K; Yamada, M; Yanagida, H; Yokoigawa, N; Yoshioka, K | 1 |
Amela, EY; Bertucci, F; Blay, JY; Bompas, E; Chevreau, C; Clisant, S; Collard, O; Isambert, N; Italiano, A; Laurence, V; Le Cesne, A; Lebellec, L; Penel, N; Saada-Bouzid, E; Salas, S; Tresch-Bruneel, E | 1 |
Llovet, JM; Torrecilla, S | 1 |
Adachi, M; Akaza, H; Gemma, A; Hyodo, I; Iijima, M; Inuyama, L; Itoh, H; Okayama, Y; Oya, M; Sunaya, T | 1 |
Chen, DS; Chen, KF; Chen, PJ; Lin, WH; Shiau, CW; Teng, YC; Tsai, TF; Wang, SH; Yeh, SH | 1 |
Blaney, SM; Fox, E; Jayaprakash, N; Kim, A; Krailo, M; Weigel, B; Widemann, BC | 1 |
Costentin, C; Decaens, T; Diao, G; Duvoux, C; Katsahian, S; Laurent, A; Luciani, A; Mallat, A; Nault, JC; Nelson, AC; Pigneur, F; Tselikas, L | 1 |
Amore, E; Augello, G; Bondì, ML; Botto, C; Cervello, M; Craparo, EF; Emma, MR | 1 |
Angarano, G; Brunetti, O; Faloppi, L; Gnoni, A; Guarini, A; Licchetta, A; Lorusso, V; Lupo, L; Memeo, V; Palasciano, G; Palmieri, V; Pisconti, S; Russo, A; Santini, D; Scartozzi, M; Silvestris, N | 1 |
Chang, CC; Chen, Y; Chiang, WH; Gao, DY; Lin, TsT; Liu, JY; Liu, YC; Sung, YC | 1 |
Berretta, M; Di Francia, R; Tirelli, U | 1 |
Cheng, K; Cheng, Z; Fan, Q; Huang, W; Lu, X; Yang, M; Zhang, L; Zhang, R | 1 |
Hamdeh, S; Khanal, N; Lanspa, S; Upadhyay, S | 1 |
Gerull, S; Halter, JP; Heim, D; Medinger, M; Passweg, JR; Tschan-Plessl, A | 1 |
Álamo-Martínez, JM; Barcena, JA; Barrera-Pulido, L; Bernal-Bellido, C; Blanco-Fernández, G; Gila-Bohórquez, A; Gómez-Bravo, MA; González, R; Marín-Gómez, LM; Muntané, J; Navarro-Villarán, E; Nogales-Muñoz, A; Pacheco, D; Padilla, CA; Padillo, FJ; Pereira, S; Rodríguez-Hernández, A; Sarrias-Giménez, A; Serrablo-Requejo, A; Serrano-Díaz-Canedo, J; Soriano-De Castro, LB; Suárez-Artacho, G; Torres-Nieto, MA | 1 |
Cen, X; Deng, P; Du, C; Fu, D; Gu, H; Hu, C; Kong, J; Li, Y; Long, H; Luo, L; Shao, X; Wang, H; Zhao, Q; Zhao, Y; Zhu, R | 1 |
Casado Sáenz, E; Falagan, S; García Sánchez, S; Gómez-Raposo, C; Hernández Jusdado, R; Moreno Rubio, J; Moreno, V; Sereno, M; Zambrana Tébar, F | 1 |
Byrd, JC; Caligiuri, MA; Campbell, AR; Carson, WE; Fairchild, ET; Grignol, VP; Guenterberg, KD; Jaime-Ramirez, AC; Karpa, VI; Kondadasula, SV; Lesinski, GB; Levine, KM; Mace, TA; Markowitz, J; Martin del Campo, SE; McClory, S; Monk, JP; Mortazavi, A; Mundy-Bosse, BL; Olencki, TE; Pan, X; Paul, BK; Shah, MH; Tridandapani, S; Trikha, P | 1 |
Arencibia, JM; Augusto, EA; Groner, B; Ibrahim, AA; Kakoschky, B; Köberle, V; Korf, HW; Korkusuz, H; Kronenberger, B; Piiper, A; Pleli, T; Schmithals, C; Vafaizadeh, V; Vogl, TJ; Waidmann, O; Zeuzem, S | 1 |
Hur, DY; Kim, D; Kim, JW; Kim, YS; Park, GB; Roh, KH; Sun, H; Yang, JW | 1 |
Fujimoto, Y; Hatano, E; Kaido, T; Kitajima, T; Minamiguchi, S; Mitsunori, Y; Mizumoto, M; Okajima, H; Taura, K; Uemoto, S | 1 |
Dong, X; Li, J; Li, T; Liu, F; Wang, F; Wang, X; Wang, Y; Wei, H; Xiu, P; Xu, Z; Zhong, J | 1 |
Di Cesare Mannelli, L; Farina, C; Ghelardini, C; Maresca, M; Scherz, MW | 1 |
Kim, JK; Seo, MS; Shim, JY | 1 |
Bao, WD; Chen, TW; Cheng, SQ; Deng, YZ; Feng, YY; Guan, DX; Koeffler, HP; Li, JJ; Long, LY; Qiu, L; Shi, J; Xie, D; Zhang, EB; Zhang, XL; Zhang, Y; Zhao, JS | 1 |
Assanelli, A; Bernardi, M; Carrabba, MG; Ciceri, F; Corti, C; De Freitas, T; Lupo Stanghellini, MT; Marktel, S; Messina, C; Peccatori, J; Piemontese, S; Tresoldi, C; Vago, L | 1 |
Abbate, I; Brandi, M; Daniele, A; Divella, R; Ferraro, E; Filippelli, G; Gadaleta-Caldarola, G; Infusino, S; Mazzocca, A; Sabbà, C | 1 |
Antonucci, M; Bargellini, I; Cabibbo, G; Marceglia, S; Mismas, V; Sacco, R | 1 |
Berger, M; Bouvier, N; Capanu, M; Herrera, JM; Ilson, DH; Janjigian, YY; Ku, GY; Socci, ND; Tang, LH; Vakiani, E; Viale, A | 1 |
Chen, Y; Chern, GG; Chiang, T; Gao, DY; Lin, TT; Liu, CH; Liu, JY | 1 |
Nishio, K; Togashi, Y | 1 |
Gemma, A; Miyanaga, A | 1 |
Kato, S | 1 |
Abastado, JP; Chew, V; Ho, V; Kaldis, P; Lee, J; Lim, TS; Steinberg, J; Szmyd, R; Tham, M; Yaligar, J | 1 |
Arora, R; Astorga-Wells, J; Bonnet, P; Brehmer, D; Di Michele, M; Gevaert, K; Jacoby, E; Linders, JT; Martens, L; Stes, E; van Heerde, E; Vandenbussche, J; Vandermarliere, E; Zubarev, R | 1 |
Ford, LA; Freyer, CW; Griffiths, EA; Muppidi, MR; Portwood, S; Thompson, JE; Wang, ES; Wetzler, M | 1 |
Aigner, A; Kiprianova, I; Kögel, D; Milosch, N; Mohrenz, IV; Remy, J; Seifert, V | 1 |
Kiyota, N | 1 |
Chen, W; Lv, Y; Xie, R; Yu, J; Zhang, J | 1 |
Afaq, F; Agarwal, J; Athar, M; Baxter, RD; Elmets, CA; Hunt, KM; Pal, HC | 1 |
Andreeff, M; Badar, T; Borthakur, G; Champlin, R; Cortes, JE; Daver, N; Garcia Manero, G; Kadia, TM; Kantarjian, HM; Konopleva, M; Luthra, R; Nogueras-Gonzalez, GM; Oran, B; Patel, K; Ravandi, F; Wierda, WG | 1 |
Fu, Y; Sima, H; Yang, G; Yang, N; Zhang, H; Zhu, N | 1 |
D'Andrea, K; Flaherty, KT; Khare, S; Kirkwood, JM; Kluger, HM; Lee, SJ; Nathanson, KL; Rimm, DL; Roszik, J; Schuchter, LM; Wilson, MA; Woodman, SE; Wubbenhorst, B; Zhao, F | 1 |
Chung, J; Hong, SH; Joo, KJ; Kim, CS; Kim, S; Kim, SH; Kim, TN; Kwak, C; Kwon, TG; Lee, SE; Nam, BH; Seo, IY; Seo, SI; Song, K | 2 |
Asai, A; Matsuo, T; Mitsunari, K; Miyata, Y; Ohba, K; Sakai, H | 1 |
Dong, D; Dong, X; He, C; Jiang, H; Jiang, X; Li, B; Sun, X; Xu, S; Zhai, B | 1 |
Fang, D; Guo, G; Huang, L; Li, X; Song, Y; Yu, X; Zhang, C; Zhang, X; Zhou, L | 1 |
Ali, SM; Chmielecki, J; Chudnovsky, J; Elvin, JA; Gay, L; Gray, A; Johnson, A; Lipson, D; Miller, VA; Nakamura, BN; Roels, S; Ross, JS; Stephens, PJ; Vergilio, JA; Wang, K; Wong, MK; Yelensky, R | 1 |
Djokovic, D; Duarte, A; Gigante, J; Harris, AL; Pinho, M; Trindade, A | 1 |
Choi, HG; Choi, JY; Gupta, B; Hiep, TT; Kim, JO; Pathak, S; Poudel, BK; Thapa, RK; Yong, CS | 1 |
Aliper, A; Borisov, N; Buzdin, A; Kholodenko, R; Malakhova, G; Roumiantsev, S; Shepelin, D; Suntsova, M; Vasilov, R; Venkova, L; Zhavoronkov, A | 1 |
Igarashi, Y; Ikehara, T; Kikuchi, Y; Kogame, M; Matsukiyo, Y; Okano, N; Shiozawa, K; Sumino, Y; Watanabe, M | 1 |
Bandukwala, H; Belsúe, V; Casares, N; Coffer, PJ; Durántez, M; Gorraiz, M; Hervás-Stubbs, S; Lasarte, JJ; Lourenço, AR; Lozano, T; Oyarzábal, J; Prieto, J; Riezu-Boj, JI; Ruiz, M; Sarobe, P; Villanueva, L | 1 |
Chen, L; Chen, T; Cui, Y; Fang, T; Ge, C; Jiang, G; Li, H; Li, J; Li, M; Liu, J; Tian, H; Xie, H; Yao, M; Zhang, L | 1 |
Guo, W; Li, J; Qiu, X; Yan, B; Zhang, S | 1 |
Abernethy, AP; George, DJ; Harrison, MR; Hirsch, BR; Mitchell, AP; Walker, MS | 1 |
Abelleira, E; Cross, G; Jerkovich, F; Pitoia, F; Urciuoli, C | 1 |
Covell, LL; Ganti, AK | 1 |
Fujisawa, M; Harada, K; Imai, S; Miyake, H; Miyazaki, A | 1 |
Gish, RG | 1 |
Gholam, P | 1 |
Abouzied, Mel-D; Aklabi, S; Duaiji, N; Hammami, MM; Mutairi, G; Qattan, N; Sous, MW | 1 |
Bose, SK; Di Bisceglie, AM; Kwon, YC; Meyer, K; Ray, R; Ray, RB; Steele, R | 1 |
Chua, MS; Lu, WJ; So, SK; Wei, W | 1 |
Berre, MA; Bolondi, L; Bruix, J; Cai, J; Chau, GY; Han, KH; Kudo, M; Lee, HC; Lee, KS; Llovet, JM; Makuuchi, M; Mazzaferro, V; Meinhardt, G; Poon, RT; Roayaie, S; Song, T; Souza, F; Tak, WY; Takayama, T; Yang, J | 1 |
Choi, BI; Choi, WS; Han, JK; Kim, J; Kim, JH; Kim, YJ; Yoon, SH | 1 |
Ando, Y; Bonichon, F; Brose, MS; Chung, J; Fassnacht, M; Fugazzola, L; Gao, M; Hadjieva, T; Hasegawa, Y; Kappeler, C; Meinhardt, G; Park, DJ; Schlumberger, M; Shi, Y; Shong, YK; Smit, JW; Worden, F | 1 |
Fang, T; Hu, F; Jin, X; Pan, S; Sun, X; Xu, L; Yan, H; Zhai, B; Zhao, D | 1 |
Fujisawa, M; Harada, K; Imai, S; Miyake, H | 1 |
Aitini, E; Andrikou, K; Barni, S; Berardi, R; Bianconi, M; Bittoni, A; Boni, C; Caprioni, F; Cascinu, S; Cinquini, M; Faloppi, L; Fanello, S; Ferrari, D; Giampieri, R; Labianca, R; Mosconi, S; Scartozzi, M; Sobrero, A; Torri, V; Zaniboni, A | 1 |
Fukunaga, K; Iwasaki, K; Kohno, K; Kurokawa, T; Murata, S; Ohkohchi, N; Zheng, YW | 1 |
Cabibbo, G; Cammà, C; Maida, M; Petta, S | 1 |
Boers-Sonderen, MJ; De Geus-Oei, LF; Desar, IM; Fütterer, JJ; Mulder, SF; Mulders, PF; Oyen, WJ; Van Der Graaf, WT; Van Herpen, CM | 1 |
Aci-Sèche, S; Bonnet, P; Bosc, N; Meyer, C; Wroblowski, B | 1 |
Devapatla, B; Sharma, A; Woo, S | 1 |
Baltatzis, G; Björklund, AC; Chioureas, D; Egevad, L; Fonseca, P; Gogvadze, V; Grandér, D; Kharaziha, P; Lennartsson, L; Nilsson, S; Panaretakis, T; Rodriguez, P; Zhivotovsky, B | 1 |
Booth, L; Carter, J; Dent, P; McGuire, WP; Poklepovic, A; Roberts, JL; Webb, T | 1 |
Cheng, AL; Hsu, CH; Shao, YY | 1 |
Gao, ZL; Lin, CH; Liu, QZ; Men, CP; Wang, J; Wang, K; Wu, JT; Yu, SQ; Yuan, HJ | 1 |
Ameye, L; Barbuto, AM; Ceyssens, S; Delaunoit, T; Deleporte, A; Demolin, G; El Mansy, H; Filleul, B; Flamen, P; Garcia, C; Guiot, T; Hendlisz, A; Holbrechts, S; Houbiers, G; Lhommel, R; Maréchal, R; Moreau, M; Paesmans, M; Peeters, M; Piccart, M; Van den Eynde, M; Van Laethem, JL | 1 |
Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Katano, Y; Kuzuya, T; Nakano, I | 1 |
Cardones, AR; Chu, EY; Dahut, WL; Kong, HH; Pichard, DC | 1 |
Wirth, LJ | 1 |
Atkins, MB; Barac, A; Freedman, AN; Fu, AZ; Jang, S; Minasian, L; Potosky, AL; Tsai, HT; Zheng, C | 1 |
Almeida, S; Correia, A; Hirvonen, J; Mäkilä, E; Salonen, J; Santos, HA; Shahbazi, MA | 1 |
Burns, K; Knights, KM; Mackenzie, PI; Miners, JO; Nair, PC; Rowland, A | 1 |
Ito, D; Kawanishi, K; Kojima, K; Ohki, T; Sato, K; Seki, M; Tagawa, K; Toda, N; Yamada, T; Yamagami, M | 1 |
Fan, W; Fu, S; Huang, Y; Li, J; Lu, L; Wang, Y; Yang, J; Yao, W; Zhang, Y | 1 |
Dorsch-Vogel, K; Gabrielson, A; He, AR; Jha, R; Marshall, JL; Pishvaian, MJ; Smaglo, B; Tesfaye, AA; Wang, H | 1 |
Arai, Y; Eto, M; Fujioka, T; Hashine, K; Hinotsu, S; Hirao, Y; Kawano, Y; Kimura, G; Matsubara, A; Mita, K; Naito, S; Shinohara, N; Tatsugami, K; Tsukamoto, T | 1 |
Adhoute, X; Blanc, JF; Boucher, E; Boudjema, K; Campillo-Gimenez, B; Clément, B; Crouzet, L; Edeline, J; Garin, E; Guillygomarc'h, A; Lenoir, L; Pracht, M; Rohou, T; Rolland, Y | 1 |
Defortescu, G; Di Fiore, F; Giwerc, A; Gouerant, S; Nouhaud, FX; Pfister, C; Rebibo, JD | 1 |
Kanda, M; Kodera, Y; Sugimoto, H | 1 |
Ekser, B; Fridell, JA; Klingler, KR; Kubal, CA; Maluccio, MA; Mangus, RS; Nagai, S; Tector, AJ | 1 |
Gabrilove, J; Jing, Y; Wang, R; Waxman, S; Xia, L | 1 |
Heaton, N; Karani, J; Peddu, P; Quaglia, A; Satyadas, T; Sharma, R; Suddle, A | 1 |
Kim, HR; Kim, JB; Kim, YJ; Lee, HS; Lee, M; Lee, S; Park, SY; Yoon, JH | 1 |
Chubachi, S; Nakagawa, T | 1 |
Ajiki, T; Fukumoto, T; Fukushima, K; Gon, H; Kido, M; Kinoshita, H; Ku, Y; Kuramitsu, K; Matsumoto, I; Shinzeki, M; So, S; Takebe, A; Tanaka, M; Urade, T | 1 |
Aino, H; Iwamoto, H; Koga, H; Kuromatsu, R; Nagamatsu, H; Nakano, M; Niizeki, T; Okamura, S; Satani, M; Shimose, S; Shirono, T; Tajiri, N; Tanaka, M; Torimura, T | 1 |
Gu, WJ; Ma, CG; Qin, XJ; Shi, GH; Wang, HK; Ye, DW; Zhang, HL; Zhou, LP | 1 |
Chen, L; Sun, J; Yang, X | 1 |
Cao, G; Li, J; Li, X; Qin, C | 1 |
Hisamichi, K; Jin, Y; Kataoka, Y; Kondo, Y; Maejima, T; Maekawa, M; Mano, N; Matsuura, M; Mori, M; Okawa, H; Shimada, M; Shimosegawa, T; Suzuki, H | 1 |
Carr, BI; D'Alessandro, R; Messa, C; Refolo, MG | 1 |
Akiba, J; Bae, KH; Igawa, T; Kurisawa, M; Kusano, H; Nakayama, M; Ogasawara, S; Sanada, S; Suekane, S; Sumi, A; Todoroki, K; Ueda, K; Xu, K; Yano, H | 1 |
Anders, RA; Fan, J; Gao, YB; Hu, B; Maitra, A; Sun, C; Sun, D; Sun, HX; Sun, YF; Tang, WG; Xu, Y; Yang, XR; Zhu, QF | 1 |
Chandra, S; Dahl, NA; McMasters, RL; Michaels, ST; O'Brien, MM | 1 |
Chang, B; Chen, JC; Chiang, IT; Hsu, FT; Hwang, JJ; Kwang, WK; Liu, YC | 1 |
Kitano, M; Kudo, M; Nishida, N; Sakurai, T | 1 |
Arizumi, T; Chishina, H; Hagiwara, S; Ida, H; Inoue, T; Iwanishi, M; Kitai, S; Kitano, M; Kono, M; Kudo, M; Minami, Y; Nishida, N; Sakurai, T; Takita, M; Ueshima, K; Yada, N | 1 |
Liang, Y; Su, Z; Yao, Y; Zhang, N | 1 |
Azoulay, D; Carra, MC; de'Angelis, N; Landi, F | 1 |
Deguchi, T; Horie, K; Kato, T; Kawata, K; Kikuchi, M; Miyazaki, T; Mizutani, K; Nakano, M; Seike, K; Takagi, K; Takai, M; Tsuchiya, T; Ushikoshi, H; Yasuda, M; Yokoi, S | 1 |
Zhong, JH | 1 |
Hidaka, H; Kobayashi, S; Koizumi, W; Kondo, M; Matsunaga, K; Morimoto, M; Nakazawa, T; Numata, K; Ohkawa, S; Okuse, C; Takada, J; Tanaka, K | 1 |
Chen, T; Cheng, X; Jia, Y; Jiang, T; Li, J; Liu, T; Liu, Z; Wang, F; Zeng, J; Zhang, C; Zhang, L; Zhu, H | 1 |
Cai, J; Ye, X; Zhu, Y | 1 |
Chen, L; Luo, R; Tang, Q; Wang, M; Wu, C; Zheng, P; Zhu, W | 1 |
Brunetti, O; Casadei Gardini, A; Cascinu, S; Faloppi, L; Foschi, FG; Frassineti, GL; Marisi, G; Masi, G; Nanni, O; Ricca Rosellini, S; Scarpi, E; Scartozzi, M; Silvestris, N; Tamberi, S; Tamburini, E; Tenti, E; Ulivi, P; Vivaldi, C | 1 |
Chen, Z; Liu, Y; Lou, G; Song, X; Wang, J; Wu, S; Yang, F | 1 |
Alkhatib, A; Allam, N; Gomaa, A; Rewisha, E; Waked, I | 1 |
Chao, CC; Lin, YT | 1 |
Afaq, F; Athar, M; Diamond, AC; Elmets, CA; Kappes, JC; Katiyar, SK; Pal, HC; Strickland, LR | 1 |
Crawford, K; Dusing, M; Frischer, JS; Knod, JL | 1 |
Andoh, A; Hira, D; Morita, SY; Noda, S; Saita, T; Shin, M; Shioya, M; Terada, T; Yamamoto, Y | 1 |
Ahn, JH; Cho, YM; Lee, DH; Lee, JL; Park, I | 1 |
Park, JG | 1 |
Amore, E; Azzolina, A; Balasus, D; Bondì, ML; Botto, C; Cervello, M; Mazzaglia, A; Scala, A; Sortino, G | 1 |
Albiges, L; Choueiri, TK; De Velasco, G; Fay, AP; Heng, DY; Kaymakcalan, MD; Kollmannsberger, CK; Kroeger, N; Lee, JL; McKay, RR; North, SA; Rha, SY; Smoragiewicz, M; Wells, JC; Xie, W | 1 |
Chen, L; Ge, N; Li, J; Liu, H; Qian, H; Shi, L; Sun, B; Wu, M; Yang, X; Yang, Y; Yin, Z; Zhang, X | 1 |
Brandon, VL; Chen, MY; Hsu, LC; Jandial, R; Jove, R; Li, G; Lin, J; Yang, F; Yin, Y; Zou, Z | 1 |
Barbare, JC; Bochereau, F; Chauffert, B; Degonville, J; Drullion, C; Fournier, E; François, C; Galmiche, A; Gicquel, A; Godin, C; Houessinon, A; Louandre, C; Nyga, R; Pluquet, O; Saidak, Z | 1 |
Henderson, M; Heriot, AG; Knowles, J; Lynch, AC; Warrier, SK | 1 |
Chaudary, N; Clarke, B; Fan, S; Fyles, A; Glicksman, R; Haider, M; Hill, RP; Kim, S; MacKay, H; Milosevic, MF; Oza, AM; Pintilie, M; Townsley, CA; Yeung, I | 1 |
Daver, N; Konopleva, M | 1 |
Aulitzky, W; Baldus, CD; Berdel, WE; Bornhäuser, M; Brandts, CH; Burchert, A; Dürk, H; Ehninger, G; Einsele, H; Frickhofen, N; Geer, T; Giagounidis, A; Görner, M; Hänel, M; Hase, J; Heits, F; Herbst, R; Hüttmann, A; Illmer, T; Junghanß, C; Kaiser, U; Kiani, A; Klut, IM; Krämer, A; Kramer, M; Krause, SW; Krug, U; Kullmer, J; Kunzmann, V; Link, H; Mackensen, A; Müller-Tidow, C; Neubauer, A; Noppeney, R; Parmentier, S; Reichle, A; Repp, R; Röllig, C; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Serve, H; Thiede, C; von Bonin, M | 1 |
Chen, TC; Chen, YC; Chien, CC; Lee, YC; Wu, MS; Yu, MC | 1 |
Chen, Y; Chiang, T; Gao, DY; Lin, TsT; Liu, JY; Liu, YC; Sung, YC; Wan, D; Wang, L | 1 |
Chang, HC; Chen, CS; Chen, YW; Chiu, HC; Huang, YT; Shiau, CW; Su, JC; Teng, LJ | 1 |
Grünwald, V; Ivanyi, P | 1 |
Adjibade, P; Coudert, L; Fournier, MJ; Khandjian, EW; Mazroui, R; Quevillon Huberdeau, M; Savard, A; St-Sauveur, VG | 1 |
George, J; Hebbard, L; Qiao, L; Wilson, G; Wu, G; Zhou, G | 1 |
Correia, A; De Stefano, L; Lamberti, A; Rea, I; Santos, HA; Shahbazi, MA; Terracciano, M | 1 |
Cai, J; Wang, KL; Yang, YC; Yin, J; Zhang, J; Zhang, ZT | 1 |
Chen, X; Liu, C; Lu, Y; Miao, H; Tang, B; Wang, L; Xu, Q; Yang, Z | 1 |
Gao, JJ; Inagaki, Y; Shi, ZY; Tang, W; Xia, JF | 1 |
Borad, MJ; Erlichman, C; Grothey, A; Hubbard, JM; Johnson, E; Kim, G; Lensing, J; Puttabasavaiah, S; Qin, R; Wright, J | 1 |
Danhier, P; Gallez, B; Gregoire, V; Jordan, BF; Magat, J; Masquelier, J; Mignion, L; Muccioli, GG; Porporato, PE; Sonveaux, P | 1 |
Clément, B; Coulouarn, C; Crouzet, L; Edeline, J; Garin, E; Lepareur, N; Pracht, M | 1 |
Chen, L; Ge, C; Li, H; Li, J; Li, M; Liu, J; Tian, H; Wang, T; Yao, M; Zhang, L; Zhao, F | 1 |
Cai, Y; Li, H; Li, Y; Wang, K; Zhang, Y | 1 |
Cheng, AL; Cheng, YC; Feng, ZR; Hsu, C; Lin, LI; Ou, DL; Shao, YY | 1 |
Chen, J; Jia, H; Lu, L; Lu, M; Pei, Y; Qin, L; Zhu, W | 1 |
Abdel-Rahman, O | 2 |
Cartenì, G; Vitale, MG | 1 |
Chen, L; Dong, S; Gao, J; Ji, L; Kong, F; Kong, J; Pan, B; Sun, W; Zheng, L | 1 |
Chen, L; Guo, Y; Hao, H; Jiang, H; Jiang, X; Ma, J; Shi, J; Wang, Y; Zhang, D | 1 |
BelHadj, N; Ben Nejma, H; Bougassas, W; Cheikh, M; Elleuch, N; Ennaifer, R; Hefaiedh, R; Romdhane, H | 1 |
Adjei, AA; Becerra, CH; Braiteh, F; Clendeninn, NJ; El-Khoueiry, A; Garbo, L; Gunawan, S; Hezel, AF; Iverson, C; Krissel, H; Leffingwell, DP; Manhard, KJ; Miner, JN; Rajagopalan, P; Richards, DA; Shen, Z; Sherman, M; Stephenson, JJ; Wilson, DM; Yeh, LT | 1 |
Grieco, A; Mazzoccoli, G; Miele, L; Oben, J; Vinciguerra, M | 1 |
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ | 1 |
Huang, J; Liu, L; Luo, Y; Ma, L; Qian, C; Shan, J; Shen, J; Xu, Y; Yang, Z; Yao, C | 1 |
Chen, P; Li, P; Lu, J; Lu, X; Wang, F; Wang, J; Wang, Q; Wang, Y; Wang, Z; Wu, G; Yuan, J; Zhang, L; Zheng, Y | 1 |
Alsinet, C; Cabellos, L; Cornella, H; Desbois-Mouthon, C; Domingo-Domenech, J; Hoshida, Y; Llovet, JM; Lozano, JJ; Martinez-Quetglas, I; Moeini, A; Peix, J; Sia, D; Solé, M; Torrecilla, S; Tovar, V; Vidal, S; Villanueva, A | 1 |
Abou-Alfa, GK; Ang, C; Gamblin, TC; Gatalica, Z; He, R; Millis, SZ; Miura, JT; Reddy, SK; Xiu, J; Yee, NS | 1 |
Cheng, CW; Hsieh, YH; Lin, CL; Lin, MT; Lin, TY; Tsai, JP; Wu, CC; Yang, SF | 1 |
Bai, XL; Chen, ZL; Fu, QH; Li, GG; Liang, TB; Lou, Y; Sun, X; Zhang, JY; Zhang, Q | 1 |
Ali, FR; Griffiths, CE; Yiu, ZZ | 1 |
Baker, SD; Chen, T; Du, G; Gibson, AA; Hu, S; Inaba, H; Maitland, ML; Mascara, GP; Ong, SS; Orwick, SJ; Sparreboom, A; Vasilyeva, A; Vogel, P; Zimmerman, EI | 1 |
Chang, MJ; Chao, TI; Chen, KF; Chen, MH; Hung, MH; Shiau, CW; Tai, WT; Tsai, MH | 1 |
Hongo, F; Hosokawa, T; Itoh, Y; Kanbayashi, Y; Miki, T; Moriguchi, M; Yamaguchi, K; Yasui, K | 1 |
Hammock, BD; Hwang, SH; Li, H; Liao, J; Liu, JY; Wecksler, AT; Yang, GY; Yang, J; Yang, Y | 1 |
Ahn, H; Ahn, JH; Hong, B; Hong, JH; Jeong, IG; Koo, DH; Lee, DH; Lee, JL; Park, I; Song, C; You, D | 1 |
Adhoute, X; Bayle, O; Beaurain, P; Blanc, JF; Bourlière, M; Bronowicki, JP; Castellani, P; Conroy, G; Edeline, J; Monnet, O; Muller, C; Pénaranda, G; Perrier, H; Pol, B; Raoul, JL | 1 |
Axelrod, JH; Divon, MS; Galun, E; Lanton, T; Peretz, T; Salmon, A; Sonnenblick, A; Zahavi, T | 1 |
de Castro, G; de Castroneves, LA; de Freitas, RM; Fukushima, JT; Hoff, AO; Hoff, PM; Jorge, AA; Kulcsar, MA; Lima, JV; Negrão, MV; Papadia, C; Simão, EF; Tavares, MR | 1 |
Arai, T; Atsukawa, M; Itokawa, N; Iwakiri, K; Kondo, C; Nakagawa, A; Okubo, T; Tsubota, A | 1 |
Koo, V; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ | 1 |
Czarnecka, AM; Kornakiewicz, A; Solarek, W; Szczylik, C | 1 |
Chen, Y; Chen, Z; Li, Y; Liu, C; Lu, J; Qian, F; Wang, S; Wu, G | 1 |
Bhoori, S; Bongini, M; Facciorusso, A; Flores, M; Gasbarrini, A; Germini, A; Mazzaferro, V; Ponziani, FR; Sposito, C | 1 |
Chi, Z; Cui, C; Guo, J; Kong, Y; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X | 1 |
Cao, L; Chen, L; Ge, N; Li, J; Qian, H; Sun, B; Yin, Z; Zhai, B; Zhang, X; Zhao, L | 1 |
Jian, C; Pei-hua, L; Xiao-chun, Y; Xu, L; Yuan-run, Z | 1 |
Caracciolo, J; Gill, J; Goldberg, J; Hale, GA; Isakoff, MS; Juan, TH; Lee, JK; Lush, RM; Manning, K; Mascarenhas, L; Neuger, AM; Reed, DR; Sandler, E; Smith, T; Sullivan, DM | 1 |
Aguilar-Suárez, LE; Barroso-Flores, J; Galindo-Murillo, R | 1 |
Balar, AV; Bangalore, S; Kang, SK; Ohmann, EL; Volodarskiy, A | 1 |
Ayav, A; Bronowicki, JP; Claudon, M; Gavanier, M; Laurent, V; Orry, X; Sellal, C | 1 |
Mihaila, RG | 1 |
Daido, Y; Kitamura, Y; Nishimoto, K; Shinchi, Y; Takao, M; Tokonabe, S; Yoshii, H | 1 |
Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lu, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yip, CS; Yuan, Y; Zhang, S; Zhou, J | 1 |
Bao, G; Du, B; Gong, P; Ma, Y; Zhai, X; Zhao, M | 1 |
Arén, O; de Marinis, F; Hirsh, V; Juhász, E; Mok, TS; Novello, S; Ong, TJ; Paz-Ares, L; Peña, C; Schmelter, T; Seto, T; Smit, EF; Sun, Y; Wakelee, HA; Wu, YL; Yang, JC; Zhang, L | 1 |
Jonasch, E; Li, N; Liu, Z; Pal, SK; Perez, JR; Reichmann, WM; Signorovitch, JE; Vogelzang, NJ; Yang, C | 1 |
Bronowicki, JP; Chen, XP; Dagher, L; Furuse, J; Geschwind, JF; Heldner, S; Kudo, M; Ladrón de Guevara, L; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK | 2 |
Mikagi, K; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y | 1 |
Mokdad, AA; Singal, AG; Yopp, AC | 1 |
Bortlicek, Z; Buchler, T; Dusek, L; Fiala, O; Honzirkova, M; Kubackova, K; Melichar, B; Pavlik, T; Poprach, A; Slaby, O; Svoboda, M; Veskrnova, V; Vyzula, R; Zemanova, M | 1 |
Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X | 1 |
Gwon, DI; Han, K; Kim, JH; Ko, GY; Sung, KB | 1 |
Chun, G; Dua, S; Hiensch, R; Meinhof, K; Nandedkar, D | 1 |
Fiskus, W; Mitsiades, N | 1 |
Ni, Y; Tian, J; Wang, H; Wang, W; Yao, Z; Ye, L | 1 |
Fujimoto, S; Kimura, T; Miyamoto, H; Muguruma, N; Okamoto, K; Takayama, T; Takeishi, S; Tanaka, H; Tanaka, T; Taniguchi, T; Tomonari, T | 1 |
Meng, Z; Ning, Z; Wang, H; Xu, L; Zhang, C; Zhu, X | 1 |
Lin, Z; Shu, M; Wang, R; Zai, X; Zhang, B | 1 |
Ha, AS; Imran, TF; Joseph, J; Shah, R; Thomas, R | 1 |
Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JWA; van der Hoeven, JJM; van Wezel, T | 1 |
Brossart, P; Diehl, L; Garbi, N; Gevensleben, H; Grünwald, B; Heine, A; Held, SA; Höchst, B; Knolle, P; Krüger, A; Kurts, C; Schilling, J | 1 |
Adametz, D; Boldanova, T; Colombi, M; Dazert, E; Hall, MN; Heim, MH; Jenoe, P; Moes, S; Quagliata, L; Roth, V; Terracciano, L | 1 |
Atabey, N; Erdal, E; Firtina Karagonlar, Z; Iscan, E; Koc, D | 1 |
Blüthgen, N; Brummer, T; Fritsche-Guenther, R; Kempa, S; Sers, C; Witzel, F | 1 |
Bazin, I; Bondarenko, I; Ciuleanu, T; Deptala, A; Ding, M; Egger, J; Fox, NL; Giantonio, B; Gribbin, M; Humphreys, R; Kalyani, RN; Lungulescu, D; Miron, L; Rodriguez-Torres, M; Sun, W; Wissel, P | 1 |
Cai, Y; Gao, D; Gao, L; Jia, B; Lai, J; Liu, H; Liu, Z; Wang, F; Zhang, C | 1 |
Kakisaka, T; Kamachi, H; Kamiyama, T; Orimo, T; Shimada, S; Taketomi, A; Tsuruga, Y; Wakayama, K; Yokoo, H | 1 |
Matoba, H; Seta, S | 1 |
Asaoka, T; Doki, Y; Eguchi, H; Kawamoto, K; Marubashi, S; Mori, M; Mukai, Y; Nagano, H; Tomimaru, Y; Tomokuni, A; Umeshita, K; Wada, H | 1 |
Deguchi, S; Inoue, T; Kanazawa, A; Murata, A; Nakajima, T; Nishiguchi, Y; Sakae, M; Shimizu, S; Tachimori, A; Tamamori, Y; Tsukamoto, T; Yamamoto, A; Yamamoto, S; Yamashita, Y | 1 |
Deguchi, S; Kanazawa, A; Kawasaki, Y; Kioka, K; Kurihara, S; Murata, A; Nakai, T; Sakae, M; Shimizu, S; Tashima, T; Tsukamoto, T | 1 |
Bruix, J; Chau, GY; Del Arbol, LR; Guglielmi, A; Han, G; Kim, DY; Leberre, MA; Lencioni, R; Llovet, JM; Luca, A; Meinhardt, G; Nicholson, K; Niu, W; Paik, SW; Reig, M; Tak, WY; Yang, J | 1 |
Cai, Z; Chiu, DK; Koh, HY; Lai, RK; Law, CT; Lin, SH; Ng, IO; Tse, AP; Wong, CC; Wong, CM; Xu, IM | 1 |
Barbero-Camps, E; Bárcena, C; Colell, A; de Gregorio, E; Fernandez-Checa, JC; García-Ruiz, C; Marí, M; Martinez-Nieto, GA; Morales, A; Moutinho, C; Stefanovic, M; Tutusaus, A; Villanueva, A | 1 |
Archibald, M; Greish, K; Nehoff, H; Pritchard, T; Rosengren, RJ; Taurin, S | 1 |
Guo, GH; Hu, MD; Jia, LH; Liu, HB; Zhang, KH | 1 |
Bower, M; Erbacher, I; Fortunak, J; Gotham, D; Hill, A; Levi, J; Martin, M; Meldrum, J; Powderly, WG; Shoman, H | 1 |
Aurilio, G; Cossu Rocca, M; Cullurà, D; de Cobelli, O; Iacovelli, R; Nolé, F; Santoni, M; Verri, E | 1 |
Li, X; Song, Y; Xiao, Y; Xing, Y; Xing, Z; Zhang, P; Zhao, J | 1 |
Garg, P; Shaikh, N; Sharma, M | 1 |
Moriyasu, F; Saito, K; Shirota, N; Sugimoto, K; Takara, K; Tokuuye, K | 1 |
Amitay-Laish, I; Didkovsky, E; Hendler, D; Hodak, E; Lotem, M; Merims, S; Ollech, A; Popovtzer, A; Stemmer, SM | 1 |
de la Fouchardière, C | 2 |
Cai, H; Cao, Q; Chen, J; Chu, H; Cui, L; Dong, B; Huang, Y; Ji, J; Jiang, M; Ju, X; Li, P; Li, X; Liu, F; Qin, C; Shao, P; Sun, L; Sun, X; Wang, J; Wang, M; Wang, S; Wang, X; Wu, B; Ye, D; Yin, C; Zhang, H; Zhang, Z; Zhao, H; Zhou, H; Zhou, L; Zhu, J; Zou, Q | 1 |
Bai, W; Cai, H; Chen, H; Fan, D; Guo, W; Han, G; He, C; Jia, J; Liu, L; Niu, J; Xia, J; Yang, M; Yin, Z; Yuan, J; Zhang, L; Zhao, Y | 1 |
Alexandre, J; Arrondeau, J; Blanchet, B; Boudou-Rouquette, P; Bretagne, M; Cabanes, L; Cessot, A; Chahwakilian, A; Coriat, R; Goldwasser, F; Huillard, O; Orvoen, G; Thomas-Schoemann, A; Tlemsani, C | 1 |
Diekstra, MH; Gelderblom, H; Guchelaar, HJ; Swen, JJ | 1 |
Chen, KF; Chen, LJ; Chen, YL; Chu, PY; Huang, JW; Hung, MH; Shiau, CW; Tai, WT; Tsai, MH | 1 |
Jiang, D; Liu, Y; Wang, T; Xiao, Y; Yang, S; Yu, D; Zhang, B; Zhang, J; Zhang, N | 1 |
Brekken, RA; Cheng, X; Huang, X; Li, L; Thorpe, PE; Yopp, AC | 1 |
Jaffry, A; Jean, GW; Khan, SA; Mani, RM | 1 |
Callaghan, C; Dash, S; Lee, BR; Liu, J; Maddox, M; Mandava, SH; Peralta, D; Tarr, MA | 1 |
Ellis, LM; Harris, AL; Jayson, GC; Kerbel, R | 1 |
Liu, Y; Qiu, P; Wang, G; Wen, J; Wen, P; Xiao, X; Xu, L; Zhou, SF | 1 |
Almhanna, K; Campos, T; Chen, DT; Hoffe, SE; Jiang, K; Kim, R; Prithviraj, GK; Shibata, D; Shridhar, R; Strosberg, J; Zhao, X | 1 |
Duda, DG; Hato, T; Zhu, AX | 1 |
Brade, AM; Brierley, J; Cho, C; Dawson, LA; Dinniwell, R; Kim, J; Knox, J; Ng, S; Ringash, J; Wong, RR | 1 |
Darstein, F; Galle, PR; Grimm, D; Hoppe-Lotichius, M; Koch, S; Lautem, A; Lieb, J; Schad, A; Schattenberg, JM; Vollmar, J; Weinmann, A; Weyer, V; Wörns, MA; Zimmermann, T | 1 |
Chen, KF; Chen, YL; Chu, PY; Hung, MH; Shiau, CW; Shih, CT; Tai, WT; Yu, HC | 1 |
Bodoky, G; Buehlmann, M; Demeter, G; Dufour, JF; Feilchenfeldt, J; Horber, D; Koeberle, D; Lakatos, G; Li, Q; Montemurro, M; Peck-Radosavljevic, M; Rauch, D; Ribi, K; Roth, AD; Saletti, P; Samaras, P; Tschanz, B; Wagner, AD | 1 |
Diaz, J; Pandha, H; Sapunar, F; Sehgal, M; Takyar, S | 1 |
Albers, T; Booth, L; Bottaro, D; Chen, CS; Dent, P; Ecroyd, H; Lebedyeva, IO; Proniuk, S; Roberts, JL; Shuch, B; Tavallai, M; Wang, D; Zukiwski, A | 1 |
Chen, C; Hu, H; Li, H | 1 |
Okano, S | 1 |
Goto, K; Iino, M; Kikuchi, N; Tanaka, T | 1 |
Bisulli, M; Casadei Gardini, A; Cascinu, S; Corbelli, J; Donati, G; Faloppi, L; Foschi, FG; Frassineti, GL; Gardini, A; Giampalma, E; La Barba, G; Marisi, G; Scarpi, E; Scartozzi, M; Silvestris, N; Tamberi, S; Veneroni, L | 1 |
Chi, Z; Cui, C; Guo, J; Li, S; Lian, B; Mao, L; Sheng, X; Si, L; Tang, B; Wang, X; Yan, X | 1 |
Cho, BC; Choi, JH; Choi, JR; Heo, DS; Jung, M; Kang, SY; Kim, DW; Kim, HT; Kim, JH; Kim, SW; Lee, DH; Lim, SM; Shim, HS | 1 |
Horai, T; Horiike, A; Ishikawa, Y; Kaburaki, K; Kawano, Y; Kudo, K; Motoi, N; Nishio, M; Ohyanagi, F; Takeuchi, K; Tambo, Y; Tanimoto, A; Uenami, T; Yanagitani, N | 1 |
Bersanelli, M; Buti, S; Castagneto, B; Di Meglio, G; Leonetti, A; Masini, C; Pellegrino, B | 1 |
Alonso López, S; Burgos, Rde L; Fernandez Cebrián, JM; Fernández Rodríguez, C; Gutiérrez Garcia, ML; LIedó Navarro, JL; Loinaz Segurola, C; Martel Villagrán, J; Martín Ríos, D; Ochando Cerdán, F | 1 |
Abdel-Rahman, OM; Elsayed, Z | 1 |
Brüssow, C; Guckenberger, M; Pestalozzi, B; Riesterer, O; Stieb, S; Weiler, S | 1 |
Bayhan, T; Cetin, M; Gumruk, F; Isgandarova, F; Kuskonmaz, B; Tavil, B; Unal, S | 1 |
Blumenstengel, K; Busies, S; Hutzschenreuter, U; Marschner, N; Müller, L; Münch, A | 1 |
Han, KH; Han, SY; Heo, J; Kim, DY; Kim, HJ; Kim, YH; Kweon, YO; Lee, BS; Lee, HC; Lee, WS; Lim, HY; Ryoo, BY; Um, SH; Woo, HY; Yoon, JH; Yoon, SK | 1 |
Arenas, JI; Buades-Mateu, J; Bustamante, FJ; de la Rosa, PA; de la Torre, MA; Gil, C; Iñarrairaegui, M; Lorente, S; Lué, A; Sangro, B; Serrano, MT; Testillano, M | 1 |
Ahn, KS; Baek, SH; Kim, C; Shim, BS; Um, JY | 1 |
Brummer, T; Dengjel, J; Ellermann, J; Gretzmeier, C; Halbach, S; Hu, Z; Wöhrle, FU | 1 |
Gao, M; Hua, H; Jiang, Y; Kong, Q; Luo, T; Wang, J; Yin, Y | 1 |
Bin, L; Heqing, Y; Linfa, L; Xuemei, Y | 1 |
Cao, Y; Chen, EB; Dai, Z; Fan, J; Hu, ZQ; Huang, XW; Wang, Z; Zhou, J; Zhou, SL; Zhou, ZJ | 1 |
El-Sahrawy, HM; Fahmy, HH; Ismail, MM; Khalifa, NM; Nossier, ES | 1 |
Dinçaslan, H; Ensari, A; Kiremitçi, S; Özçakar, ZB; Taktak, A; Yalçınkaya, F; Yılmaz, S | 1 |
Furuse, J; Ikeda, K; Inuyama, L; Ito, Y; Kaneko, S; Matsuzaki, Y; Minami, H; Okayama, Y; Okita, K; Sunaya, T | 1 |
Cai, X; Chang, C; Jin, RA; Li, G; Lin, H; Ma, WL; Shi, L; Sun, Y; Xu, J; Yeh, S | 1 |
Abrantes, AM; Botelho, MF; Brito, AF; Casalta-Lopes, JE; Gonçalves, AC; Laranjo, M; Mamede, AC; Ribeiro, M; Sarmento-Ribeiro, AB; Tralhão, JG | 1 |
Dickson, N; Drosick, D; Earwood, C; Hainsworth, JD; Inhorn, R; Murphy, P; Yardley, DA | 1 |
Ammendola, AS; Bitzer, M; Cillo, U; Dollinger, MM; Ganten, TM; Gerken, G; Giannini, EG; Hauns, B; Henning, SW; Hentsch, B; Herz, T; Holzapfel, J; Horger, M; Lauer, UM; Mais, A; Malek, NP; Montesarchio, V; Pegoraro, S; Santoro, A; Scheulen, ME; Siveke, JT; Trevisani, F; Wege, H; Wörns, MA; Zagonel, V | 1 |
Boakye, J; Chaiteerakij, R; Chen, G; Ding, X; Huang, S; Li, Y; Moser, CD; Ndzengue, A; Roberts, LR; Shaleh, H; Sinicrope, FA; Smith, CD; Thomas, MB; Zhou, Y; Zou, X | 1 |
Cao, M; Cui, Y; Fang, F; Gao, J; Guo, Z; Li, H; Li, Q; Song, T; Sun, H; Yin, H; You, A; Zhang, T; Zhang, W; Zhou, H; Zhu, X; Zuo, B | 1 |
Boo, YP; Chen, KF; Chen, LJ; Chen, MH; Chen, YL; Chu, PY; Hung, MH; Shiau, CW; Tai, WT; Tsai, MH | 1 |
Chan, HF; Chen, M; Hu, J; Liang, G; Skibba, M; Zhang, J | 1 |
Chen, D; Chen, W; Lai, J; Liang, L; Xiao, W; Yin, X; Zhang, K | 1 |
Delhaas, T; Gagliardi, M; Grandfils, C; Knetsch, ML; Koole, LH; Molin, DG; Sevrin, C; van den Akker, NM; Wang, Y | 1 |
Atkins, MB; Carducci, M; Cella, D; Choueiri, TK; Coomes, R; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Jewett, M; Kane, C; Kohli, M; Kuzel, TM; Manola, J; Matin, S; Pili, R; Pins, M; Puzanov, I; Sexton, WJ; Stadler, W; Uzzo, RG; Wagner, L; Wilding, G; Wong, YN; Wood, CG | 1 |
Dai, Y; Liu, X; Sun, K; Wang, H | 1 |
Brierley, JD; Brock, KK; Coolens, C; Dawson, LA; Dinniwell, R; Kassam, Z; Kim, J; Knox, JJ; Swaminath, A; Wong, R | 1 |
Beck, JF; Ernst, J; Ernst, T; Gruhn, B; Rinke, J; Schäfer, V; Wittig, S | 1 |
Bodnar, L; Chrom, P; Semeniuk-Wojtas, A; Spencer, NJ; Stec, R; Szczylik, C | 1 |
Hao, J; Lei, J; Li, B; Liu, Z; Wang, W; Wen, T; Wu, L; Yan, L; Zeng, Y; Zhang, P; Zhong, J; Zhu, J | 1 |
Cheng, KS; Chou, JW; Huang, CW | 1 |
Chen, MS; Cheng, SQ; Cong, WM; Guo, WX; Lau, WY; Mao, YL; Meng, Y; Shi, J; Sun, BC; Wang, K; Wu, MC; Yang, YF; Zhang, YJ | 1 |
Chen, KH; Chou, YH; Hsieh, CH; Lu, YF; Weng, MT | 1 |
Bugiantella, W; Carnelutti, A; Leo, CA; Lorenzin, D; Pravisani, R; Risaliti, A; Soardo, G; Umberto, B | 1 |
Li, H; Liu, D; Yan, D; Yao, X; Zeng, H | 1 |
Brose, MS; Chen, EY; Cohen, AB; Feldman, MD; Johnson, BA; Ma, C; Pappas-Paxinos, M; Stopenski, SJ; Tang, W; Troxel, AB; Yarchoan, M | 1 |
de Gramont, A; Faivre, S; Raymond, E | 1 |
Galsky, MD; Mehrazin, R; Sfakianos, J; Tsao, CK | 1 |
Gentile, M; Martino, M; Morabito, F; Morabito, L; Recchia, AG; Vigna, E | 1 |
Kini, S; Panda, D; Poojari, R; Srivastava, R | 1 |
Borg, Å; Cordero, E; Haraldsson, K; Hemann, MT; Kabir, NN; Kazi, JU; Levander, F; Lindblad, O; Macaulay, L; Pietras, K; Puissant, A; Ramos, A; Rönnstrand, L; Stegmaier, K; Sun, J; Vallon-Christersson, J | 1 |
Chen, D; Chen, R; He, W; Kang, R; Niu, X; Sun, X; Tang, D | 1 |
Becker, B; Busch, CJ; Dikomey, E; Gleißner, L; Grénman, R; Hoffer, K; Knecht, R; Kriegs, M; Laban, S; Möckelmann, N; Omniczynski, M; Petersen, C; Rieckmann, T; Rothkamm, K; Steinmeister, L | 1 |
Boone, DL; Booth, L; Chuckalovcak, J; Dent, P; Koromilas, AE; McGuire, WP; Poklepovic, A; Roberts, JL; Stringer, DK; Tavallai, M | 1 |
Stone, L | 1 |
Chen, GH; Fu, CC; Gu, B; Han, Y; Ma, X; Miao, M; Qiu, HY; Shen, HJ; Sun, AN; Tang, XW; Wu, DP | 1 |
Gao, F; Huang, C; Sun, R; Wang, H; Zhang, S; Zhang, Y | 1 |
Ding, X; Li, H; Zhang, Z; Zhou, G; Zhou, Z | 1 |
Antony, AN; Bisetto, S; Doria, C; Hoek, JB; Levine, M; Monti, DA; Newberg, A; Rouleau, L | 1 |
Bai, W; Duran, R; Fan, D; Gu, S; Guan, S; Guo, W; Han, G; Li, H; Liu, J; Lv, W; Ma, Y; Mu, W; Qin, X; Ren, W; Sahu, S; Wang, W; Wang, Y; Yin, Z; Zhang, Z; Zhao, Y | 1 |
Jimenez, CR; Knol, JC; Lind, JS; Pham, TV; Rovithi, M; Smit, EF; Verheul, HM; Voortman, J | 1 |
Jerkovich, F; Pitoia, F | 1 |
Chauhan, AK; Choi, SM; Choi, WY; Chung, WJ; Hwang, JS; Jang, BK; Kang, KJ; Kim, BS; Kim, YH; Kweon, YO; Lee, CH; Lee, JM; Lee, YJ; Park, SY; Tak, WY | 1 |
Baker, SD; Edginton, AN; Panetta, JC; Vasilyeva, A; Zimmerman, EI | 1 |
Bai, T; Chen, J; Chen, JZ; Li, LQ; Lu, Z; Ma, L; Peng, YC; Qin, HG; Xiang, BD; Xie, ZB; Ye, HH; Ye, JZ | 1 |
Amadori, D; Casadei Gardini, A; Cascinu, S; Corbelli, J; Della Corte, C; Facchetti, F; Faloppi, L; Foschi, FG; Frassineti, GL; Iavarone, M; Lauletta, G; Marisi, G; Nanni, O; Neri, LM; Scarpi, E; Scartozzi, M; Tamberi, S; Tenti, E; Ulivi, P; Valgiusti, M | 1 |
Bar-Zion, A; Butz, H; Daley, F; Foster, FS; Kerbel, RS; Kuczynski, EA; Lee, CR; Man, S; Reynolds, AR; Vermeulen, PB; Yin, M; Yousef, GM | 1 |
Igarashi, Y; Ikehara, T; Kikuchi, Y; Kogame, M; Matsukiyo, Y; Shinohara, M; Shiozawa, K; Sumino, Y; Watanabe, M | 2 |
Ameye, L; Delaunoit, T; Deleporte, A; Demolin, G; Flamen, P; Garcia, C; Gauthier, N; Guiot, T; Hendlisz, A; Holbrechts, S; Lhommel, R; Maréchal, R; Van den Eynde, M; Vierasu, I; Woff, E | 1 |
Bucci, L; Camelli, V; Garuti, F; Spinardi, L; Trevisani, F | 1 |
Balsara, B; Chan, SL; Chao, Y; Cheng, AL; Han, G; Ikeda, M; Kang, YK; Kudo, M; Lim, HY; Numata, K; Pan, H; Poon, RT; Rodriguez, AM; Sukeepaisarnjaroen, W; Thongprasert, S; Wang, Y; Wu, CC; Yang, TS; Zhang, Y | 1 |
Ahmed, AA; Elnakish, MT; Floyd, K; Janssen, PM; Mohler, PJ; Saad, NS | 1 |
Dicken, V; Felsch, M; Lehmacher, W; Scheuring, UJ; Zaim, S | 1 |
Abd El-Fattah, EE; El-Ashmawy, NE; El-Bahrawy, HA; Khedr, EG | 1 |
Fujiwara, T; Kagawa, S; Katsube, R; Kimura, F; Matsukawa, A; Ninomiya, T; Noma, K; Nouso, K; Ohara, T; Shirakawa, Y; Tazawa, H; Tomono, Y; Urano, S; Yamamoto, K | 1 |
Hu, P; Tang, F; Wang, Z; Xie, C | 1 |
Cao, Y; Feng, F; Hou, MX; Jia, H; Jiang, QY; Ma, HD; Sun, HW; Wang, T; Yang, Q; Yang, YP | 1 |
Chen, GG; Ho, RL; Hu, B; Lai, PB; Lee, CG; Leung, BC; Liu, Y; Lu, G; Ren, J; Su, X; Wang, Y; Yang, S | 1 |
Fan, Z; Gao, Y; Huang, F; Jiang, Q; Liu, Q; Sun, J; Xu, N; Xuan, L; Zhang, Y | 1 |
Cai, XB; Hou, Y; Li, J; Liu, B | 1 |
Chan, TH; Chen, L; Chow, RK; Fang, S; Guan, XY; Jiang, L; Li, Y; Liu, M; Ma, NF; Song, Y; Xi, S; Yang, X; Yuan, YF; Zeng, TT | 1 |
Cai, JB; Dong, ZR; Fan, J; Gao, DM; Gao, PT; Hu, ZQ; Huang, XY; Ke, AW; Li, KS; Shen, YH; Shi, GM; Tian, MX; Zhang, C; Zhang, PF | 1 |
Aplan, PD; Bruner, JK; Duffield, AS; Ghiaur, G; Greenblatt, SM; Jones, RJ; Jung, E; Li, L; Ma, HS; Nguyen, B; Shirley, CM; Small, D | 1 |
Kim, HR; Kim, JH; Kim, S; Kwack, K; Lee, MG; Lim, SM; Moon, YW; Park, HS | 1 |
Chen, W; Dan, Y; Li, M; Li, W; Liu, K; Mo, P; Qin, L; Tong, Z; Wang, W; Yu, C | 1 |
Furuse, J; Ikeda, M; Ito, Y; Izumi, N; Kadoya, M; Kokudo, N; Kudo, M; Numata, K; Okusaka, T; Takayama, T; Yamashita, S | 1 |
Chen, SH; Chen, YY; Cheng, KS; Chou, JW; Chuang, PH; Feng, CL; Hsiao, WD; Kao, JT; Lai, HC; Peng, CY; Su, WP; Yu, CJ | 1 |
Fu, P; Li, Q; Wen, F; Wheeler, J; Yang, Y; Zhang, P | 1 |
Amadori, D; Bianchini, E; Casadei Gardini, A; Frassineti, GL; Gallani, ML; Masini, C; Maugeri, A; Menozzi, S; Minguzzi, M; Nanni, O; Palazzini, S; Restuccia, S; Scarpi, E; Tenti, E; Valgiusti, M | 1 |
Keck, B; Lieb, V; Lüdecke, G; Sikic, D | 1 |
Asaoka, T; Doki, Y; Eguchi, H; Gotoh, K; Kawamoto, K; Mori, M; Noda, T; Ogawa, H; Umeshita, K; Wada, H; Yamada, D; Yamashita, M | 1 |
Cai, X; Cang, Y; Chen, J; Huang, D; Ji, T; Jin, R; Li, G; Liang, X; Lin, H; Liu, J; Liu, X; Xie, A; Zhang, J; Zhao, J | 1 |
Garcia-Manero, G; Hu, Y; Huang, A; Huang, P; Ju, HQ; Liu, D; Liu, K; Wen, S; Zhan, G | 1 |
Amadoz, A; Carbonell-Caballero, J; Crespo, D; Çubuk, C; Dopazo, J; Hidago, MR; Medina, I; Salavert, F | 1 |
Bae, SH; Cho, YY; Chung, JW; Gwak, GY; Heo, J; Kim, do Y; Kim, HC; Kim, YH; Kim, YJ; Lee, M | 1 |
DU, QF; Huang, YX; Liu, XS; Long, H; Wu, BY; Xu, JH; Zhu, JY | 1 |
Chen, H; Fisher, DE; Li, Y; Sun, J; Westover, KD; Xia, Y; Zhang, J | 1 |
Chen, Y; Ding, J; Fang, T; Guo, LN; Li, T; Liang, D; Lv, GS; Lv, HW; Tan, YX; Tang, L; Tang, SH; Wang, CZ; Wang, HY; Wu, FQ; Yang, W; Yu, LX | 1 |
Aycart, SN; Berger, Y; Edwards, MP; Heskel, M; Kim, E; Labow, DM; Sarpel, U; Spivack, JH; Sweeney, R | 1 |
Chen, J; Cho, S; Kim, DH; Larson, AC; Na, K; Park, SJ; Park, W | 1 |
Arachchi, N; Bell, S; Dev, A; Doyle, A; Fink, MA; Gill, R; Gow, PJ; Hong, T; Kemp, W; Knight, V; Kronborg, I; Lubel, J; Marsh, P; Mohsen, W; Nicoll, A; Roberts, S; Rodov, M; Ryan, M; Strasser, SI; Varma, P | 1 |
Guo, X; Han, G; Li, H; Qi, X; Zhao, Y | 1 |
Cui, SX; Gao, ZH; Qu, XJ; Shi, WN; Song, ZY; Wang, SQ; Yu, XF | 1 |
Gan, H; Gu, W; Shi, G; Wang, B; Wang, H; Ye, D; Zhang, H; Zhou, L; Zhu, Y | 1 |
Fan, XX; Huang, YC; Li, ZY; Liu, ZW; Pan, WT; Wang, YJ; Wu, ZM; Yang, P; Yao, K; Ye, YL; Zhou, FJ | 1 |
Chen, B; Cooper, JL; Dovey, OM; Friedrich, M; Grove, CS; Huang, Y; Lee, B; Mupo, A; Varela, I; Vassiliou, GS | 1 |
Gerber, JM; Grunwald, MR; Induru, R; McDonnell, MH | 1 |
Kim, do Y; Kim, GM; Kim, MD; Kim, SH; Lee, do Y; Park, SI; Shin, M; Shin, W; Won, JY | 1 |
Barbare, JC; Barget, N; Bodeau, S; Chauffert, B; Coriat, R; François, C; Galmiche, A; Ganne, N; Godin, C; Gutierrez, L; Houessinon, A; Louandre, C; Mongelard, G; Régimbeau, JM; Saidak, Z; Sauzay, C; Takahashi, S | 1 |
Chang, Y; Dusetzina, SB; Lund, JL; O'Neil, BH; Sanoff, HK | 2 |
He, J; Sun, J; Sun, T; Zeng, M; Zeng, Z; Zhang, S | 1 |
Chan, AL; Leung, HW; Liu, CF | 1 |
Campana, D; Chang, YH; Kamiya, T | 1 |
Deng, YR; Hou, X; Li, X; Lian, ZX; Liu, WB | 1 |
Abraham, LJ; Callus, BA; Diepeveen, LA; Dwyer, BJ; Elsegood, CL; Finch-Edmondson, ML; Kampmann, SS; Kong, GS; Olynyk, JK; Passman, AM; Stewart, SG; Tirnitz-Parker, JE; Woo, K; Yeoh, GC; Yeung, SY | 1 |
Adachi, M; Akaza, H; Ito, Y; Kabu, K; Oya, M; Tatsugami, K | 1 |
Ducerf, C; Golse, N; Mabrut, JY; Merle, P; Radenne, S; Rode, A | 1 |
Booth, L; Bose, P; Dent, P; Geyer, CE; Gordon, S; Kmieciak, M; Massey, HD; McGuire, WP; Moran, RG; Poklepovic, A; Quigley, M; Roberts, JD; Shafer, DA; Shrader, E; Strickler, K; Tombes, MB; Wan, W | 1 |
Blanc, JF; Campillo-Gimenez, B; Collins, P; Darby, S; Edeline, J; Evans, J; Hubner, RA; Iwuji, C; Johnson, P; King, J; Ma, YT; Meyer, T; Muazzam, I; Palmer, DH; Patel, K; Ross, P; Sumpter, K; Swinson, D | 1 |
Abbiati, RA; Manca, D | 1 |
Abe, H; Baba, H; Kamimura, H; Kamimura, K; Kawai, H; Kobayashi, Y; Ogawa, K; Shinagawa, Y; Suda, T; Terai, S; Yamagiwa, S; Yokoo, T | 1 |
Evans, TR; Gane, E; Jeffers, M; Kang, YK; Meinhardt, G; Peña, CE; Rosmorduc, O; Ross, P; Santoro, A; Vogel, A; Zhu, AX | 1 |
Grünwald, V; Kalanovic, D; Lin, X; Simantov, R | 1 |
Arai, K; Honda, M; Horii, R; Kaneko, S; Kawaguchi, K; Kitamura, K; Mizukoshi, E; Sakai, Y; Terashima, T; Yamashita, T | 1 |
Kong, P; Liao, J; Liu, Y; Shen, Z; Wang, X; Yi, H; Zeng, D; Zhang, X | 1 |
Delcambre, C; Dutriaux, C; Heutte, N; Joly, F; Lesimple, T; Mouriaux, F; Neidhart-Berard, EM; Parienti, JJ; Penel, N; Peyro Saint Paul, L; Pham, AD; Piperno-Neumann, S; Servois, V; Thyss, A | 1 |
Althouse, SK; Chiorean, EG; Clark, RS; Loehrer, PJ; Shahda, S; Spittler, AJ | 1 |
Fergusson, D; Henderson, VC; Kimmelman, J; MacKinnon, N; Mattina, J | 1 |
Fujisaki, H; Hara, J; Nakano, Y; Nitani, C; Okada, K; Yamasaki, K | 1 |
Andreoli, JM; Baker, T; Gabr, A; Hickey, R; Kallini, JR; Kircher, S; Kulik, L; Lewandowski, RJ; Salem, R | 1 |
Abdelmaksoud, AH; Attar, IE; Aziz, AO; Elbaz, TM; Nabeel, MM; Omran, D; Shousha, HI | 1 |
Chapiro, J; Duran, R; Gebauer, B; Geschwind, JF; Gorodetski, B; Lee, H; Lenis, D; Lin, M; Nonyane, BA; Pawlik, TM; Pekurovsky, V; Schernthaner, R; Schlachter, T; Stuart, EA; Tamrazi, A | 1 |
Bedke, J; Gauler, T; Grünwald, V; Hegele, A; Herrmann, E; Hinz, S; Janssen, J; Miller, K; Schmitz, S; Schostak, M; Tesch, H; Zastrow, S | 1 |
Ahmad Panahi, H; Faramarzi, M; Farjadian, F; Heidarinasab, A | 1 |
Bai, Q; Guo, J; Liu, L; Long, Q; Qu, Y; Wang, J; Xi, W; Xia, Y; Xiong, Y; Xu, J | 1 |
Dolcet, X; Dosil, MA; Eritja, N; Felip, I; Gatius, S; Matias-Guiu, X; Mirantes, C; Santacana, M | 1 |
Cappello, J; Ghandehari, H; Hellgeth, JW; Jensen, MM; Nourbakhsh, I; Poursaid, A; Sampath, S; Weisenberger, M | 1 |
Fu, CX; Gao, DM; Han, ZH; Lin, J; Liu, H; Lu, F; Lv, P; Yang, SH | 1 |
Amantea, MA; Chen, Y; Nickens, DJ; Pithavala, YK; Valota, O; Zierhut, ML | 1 |
Cui, X; Hua, L; Liu, J; Lu, C; Ni, R; Qu, L; Shen, Z; Wu, M | 1 |
Abdulghani, J; Cooper, T; Derr, J; Dicker, D; El-Deiry, WS; Finnberg, NK; Gallant, JN; Gokare, P; Goldenberg, D; Liao, J; Liu, J; Whitcomb, T | 1 |
Gong, X; Liu, Y; Wang, T; Yang, S; Zhang, B; Zhang, N | 1 |
Macaluso, FS; Maida, M; Valenza, F; Virdone, R | 1 |
Chikui, K; Igawa, T; Matsuo, M; Nakiri, M; Nishihara, K; Ogasawara, N; Suekane, S; Suyama, S; Ueda, K | 1 |
Furlan, A; Marsh, JW; Patchett, N | 1 |
Ashman, LK; Don, AS; Dun, MD; Enjeti, A; Flanagan, H; Guthridge, MA; Harrison, C; Kahl, R; Lee, EM; Lock, RB; Mashkani, B; Moore, A; Morris, J; Panicker, N; Powell, JA; Skelding, KA; Smith, AM; Thomas, D; Toop, H; Verrills, NM | 1 |
Augello, G; Bachvarov, D; Cancila, V; Candido, S; Cervello, M; Emma, MR; Gulino, A; Iovanna, JL; Libra, M; Loria, GR; McCubrey, JA; Montalto, G; Puleio, R | 1 |
Lv, L; Mei, ZC; Zeng, J | 1 |
Chen, YL; Ding, X; Gao, Z; Gu, T; Liu, W; Qu, M; Wang, W; Wu, X; Xu, L; Zhang, W | 1 |
Bie, P; Huan, HB; Lau, WY; Li, XW; Ma, KS; Wen, XD; Wu, LL; Xia, F | 1 |
Becker, M; Galle, PR; Martchenko, K; Möhler, M; Schimanski, CC; Schmidtmann, I; Thole, V; Thomaidis, T; Wehler, TC | 1 |
Apolo, AB; De Santis, M; Galsky, MD; Leibovich, BC; Milowsky, MI; Pham, MN; Pisters, LL; Siefker-Radtke, AO; Sonpavde, G; Steinberg, GD; Sternberg, CN; Tagawa, ST; Weizer, AZ; Woods, ME | 1 |
Borentain, P; Gerolami, R; Gregoire, E; Louis, G | 1 |
Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Kohno, H; Mori, N; Morio, K; Moriya, T; Murakami, E; Nonaka, M; Takaki, S; Tsuji, K; Waki, K | 1 |
Bhatia, S; Dinh, VY; Feun, L; Martin, P; Narayanan, G; O'Brien, C; Savaraj, N; Yrizarry, J | 1 |
Chen, LZ; Dai, ZY; Li, CL; Li, WW; Pan, J; Wan, HG; Wang, XJ; Yao, LZ; Zhu, J | 1 |
Choi, HG; Choi, JY; Kim, JO; Poudel, BK; Thapa, RK; Yong, CS | 1 |
Cai, XF; Chen, J; Chen, K; Chen, X; Cheng, ST; Huang, AL; Huang, LX; Li, WY; Liu, B; Ren, JH; Tang, H; Tao, NN; Yang, QX; Zhang, WL; Zhou, HZ; Zhou, L | 1 |
Blaziene, A; Chomiciene, A; Linauskiene, K; Malinauskiene, L; Vitkauskaite, E | 1 |
Arora, JS; Ashe, S; Halliburton, G; He, J; John, VT; Khismatullin, DB; Murad, HY; Yu, H | 1 |
De Velasco, MA; Haji, S; Iida, H; Ishizaki, M; Kaibori, M; Kanazawa, A; Kitade, H; Kubo, S; Kwon, AH; Matsui, K; Matsushima, H; Nagano, H; Nishio, K; Sakai, K; Takeda, Y; Takemura, S; Tsukamoto, T; Wada, H | 1 |
Azumi, J; Sakabe, T; Shiota, G; Tsubota, T | 1 |
Casadei Gardini, A; Chiadini, E; Delmonte, A; Dubini, A; Faloppi, L; Frassineti, GL; Loretelli, C; Lucchesi, A; Marisi, G; Oboldi, D; Scartozzi, M; Ulivi, P | 1 |
Jarzab, B; Krajewska, J; Kukulska, A | 1 |
Tan, S; Tong, J; Yu, J; Zhang, L; Zou, F | 1 |
Itoh, Y; Moriguchi, M; Umemura, A | 1 |
Cho, NC; El-Damasy, AK; Keum, G; Nam, G; Pae, AN | 1 |
Cheng, AL; Feng, WC; Hsu, CH; Lin, HH; Lu, LC; Shao, YY | 1 |
Hong, TH; Kim, DG; Na, GH; You, YK | 1 |
Alyea, EP; Antin, JH; Ballen, KK; Brunner, AM; Chen, YB; Collier, K; Connolly, C; Cutler, CS; Deangelo, DJ; Dey, BR; El-Jawahri, A; Fathi, AT; Ho, VT; Koreth, J; Li, S; McAfee, SL; Nikiforow, S; Soiffer, RJ; Spitzer, TR; Stone, RM; Wadleigh, M | 1 |
Chagin, K; Djousse, L; Fraeman, KH; Gagnon, DR; Hall, SA; Nelson, J; Nordstrom, BL; Shantakumar, S; van Herk-Sukel, M | 1 |
Cao, M; Liu, C; Lu, Z; Nelson, D; Ren, Y; Wang, T; Zhao, X | 1 |
Aziz, SA; Bhat, GM; Changal, KH; Lone, AR; Mir, MH | 1 |
Cai, H; Kong, WT; Tang, Y; Wang, WP; Zhang, XL | 1 |
Durmus, S; Schinkel, AH; van Hoppe, S | 1 |
Li, LQ; Liao, YY; Peng, NF; Tong, TJ; Zhong, JH | 1 |
Jalkanen, S; Joensuu, H; Laukkanen, MO; Laurila, JP; Salmi, M | 1 |
Cao, J; Cao, X; Li, D; Peng, Y; Quan, M; Ren, K; Sheng, X; Song, Z; Xiao, Q; Zeng, W; Zheng, Y; Zou, H | 1 |
Iwamoto, H; Koga, H; Kuromatsu, R; Nagamatsu, H; Nakano, M; Niizeki, T; Noda, Y; Okamura, S; Satani, M; Shimose, S; Shirono, T; Tanaka, M; Torimura, T | 1 |
Chen, X; Cui, T; Diao, X; Huang, S; Sun, J | 1 |
Addeo, R; Del Prete, S; Montella, L; Palmieri, G | 1 |
Bruno, R; Chanu, P; Chen, Y; Claret, L; Mercier, F; Milligan, PA; Rosbrook, B; Yazdi, P; Zheng, J | 1 |
Bronowicki, JP; Chen, XP; Dagher, L; de Guevara, LL; Furuse, J; Geschwind, JH; Heldner, S; Kudo, M; Lehr, R; Lencioni, R; Marrero, JA; Nakajima, K; Papandreou, C; Sanyal, AJ; Takayama, T; Venook, AP; Ye, SL; Yoon, SK | 1 |
Abdel-Naim, AB; Badawy, NN; El-Ahwany, E; Khalifa, AE; Liu, AW; Tolba, MF; Youssef, MM; Zada, S | 1 |
Jia, HL; Qin, LX | 1 |
Chang, LL; Chen, Y; Chen, ZB; He, QJ; Hu, Y; Lin, WK; Lou, JS; Wan, ZQ; Wang, DD; Yang, B; Ye, S; Ying, MD; Zhou, TY; Zhou, YL; Zhu, H; Zhuang, LH | 1 |
Farinati, F; Murer, F; Peserico, G; Pozzan, C | 1 |
Cao, J; He, HG; Huang, JL; Liu, F; Lu, JH; Shen, YN; Shi, CF; Shi, Y; Wang, ZC; Wei, YP; Yang, GS; Yuan, JY; Zhu, N | 1 |
Gui, RR; Han, LJ; Hou, YJ; Song, YP; Zhang, YL; Zhao, HF; Zhou, J; Zu, YL | 1 |
Chung, J; Joo, J; Joung, JY; Kim, S; Kim, SH; Lee, KH; Seo, HK | 1 |
Baulies, A; Fernández, A; Fernández-Checa, JC; Garcia-Ruiz, C; González-Gallego, J; Mauriz, JL; Méndez-Blanco, C; Ordóñez, R; Prieto-Domínguez, N | 1 |
Li, Q; Wen, F; Zhang, P | 1 |
Han, KH; Jung, I; Seong, J; Yoon, HI | 1 |
Chapiro, J; Geschwind, JF | 1 |
Gao, Y; Guo, G; Li, H; Liu, K; Ma, X; Meng, Q; Song, Z; Wang, D; Wang, L; Zhang, X; Zhang, Y; Zhao, C | 1 |
Chung, YH; Ha, Y; Kang, YK; Kim, KM; Lee, D; Lee, HC; Lee, YS; Lim, YS; Park, SR; Ryoo, BY; Ryu, MH; Shim, JH | 1 |
Burgoyne, AM; Durden, DL; Garlich, JR; Ikeda, S; Joshi, S; Kono, Y; Morales, GA; Sicklick, JK; Singh, AR | 1 |
Al-Shukri, S; Andrews, GI; Bair, AH; Hutson, TE; Lipatov, ON; Rosbrook, B; Shparyk, Y; Stus, VP; Vogelzang, NJ | 1 |
Basu, S; Joshi, A | 1 |
Addario, L; Caporaso, N; Cordone, G; Di Costanzo, GG; Falco, L; Guarino, M; Morisco, F; Tortora, R | 1 |
Finkenstedt, A; Zoller, H | 1 |
Lange, N; Loscher, C; Mkounga, P; Nkengfack, AE; Sass, G; Tiegs, G; Tontsa, AT; Wegscheid, C | 1 |
Chen, HA; Kuo, TC; Ma, JT; Su, JL; Sung, SY; Tseng, CF; Yang, CY; Yang, ST; Yen, CJ | 1 |
Bins, S; El Bouazzaoui, S; Eskens, FA; Lenting, A; Mathijssen, RH; Oomen-de Hoop, E; van Doorn, L; van Schaik, RH | 1 |
Chiba, T; Inoue, M; Ogasawara, S; Ooka, Y; Suzuki, E; Tawada, A; Wakamatsu, T; Yokosuka, O | 1 |
Fujita, T; Iwamura, M; Matsumoto, K; Nishi, M; Tabata, K; Yoshida, K | 1 |
Abdel-Rahman, O; Hubner, RA; Lamarca, A; McNamara, MG; Salu, I; Valle, JW | 1 |
Dikomey, E; Köcher, S; Kriegs, M; Müller-Goebel, J; Petersen, C; Riedel, M; Rothkamm, K; Struve, N | 1 |
Abhari, BA; Fulda, S; Hinrichs, TM; Lange, M; Liese, J | 1 |
Brizzi, MP; Di Maio, M; Pignataro, D; Scagliotti, GV; Tampellini, M | 1 |
Abada, PB; Fujii, H; Furuse, J; Hatano, E; Ikeda, M; Ishii, H; Kaneko, S; Kawazoe, S; Kudo, M; Kudo, T; Masumoto, A; Morita, S; Obi, S; Ohkawa, S; Okusaka, T; Osaki, Y; Shimada, M; Sugiyama, G; Tateishi, R; Tsuji, A; Ukai, K; Wada, Y; Yang, L; Yokosuka, O; Zhu, AX | 1 |
Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yagisawa, T | 1 |
Azoulay, D; Calderaro, J; Compagnon, P; Costentin, C; de'Angelis, N; Feray, C; Lahat, E; Landi, F; Lim, C; Luciani, A; Nencioni, M; Palen, A; Salloum, C | 1 |
Castinetti, F; Eroukhmanoff, J; Penel, N; Salas, S | 1 |
Li, J; Shen, F; Wan, X; Wang, K; Wu, D; Xia, Y; Yan, Z; Yang, P; Zhai, X | 1 |
Baroni, GS; Bernardi, M; Biasini, E; Borzio, F; Cabibbo, G; Caturelli, E; Ciccarese, F; Di Marco, M; Farinati, F; Felder, M; Foschi, FG; Garuti, F; Gasbarrini, A; Giannini, EG; Gramenzi, A; Lenzi, B; Masotto, A; Morisco, F; Pecorelli, A; Piscaglia, F; Rapaccini, GL; Sacco, R; Trevisani, F; Virdone, R; Zoli, M | 1 |
Hosoi, H; Imamura, T; Ishida, H; Kanayama, T; Kawashima-Goto, S; Miyachi, M; Nakatani, T; Osone, S; Sugimoto, A; Takai, A; Tamura, S; Tsuma, Y | 1 |
Furuse, J; Hagihara, A; Ikeda, M; Inaba, Y; Ishii, H; Kaneko, S; Kojima, Y; Kudo, M; Morimoto, M; Nakamori, S; Ohmura, T; Okusaka, T; Sato, K; Sato, T; Shimizu, S; Sugimoto, R; Tahara, T; Yasui, K | 2 |
Chen, KF; Fan, LC; Hung, MH; Jiang, JK; Shiau, CW; Tai, WT; Teng, HW; Yang, SH | 1 |
Abel, T; Haralampiev, I; Herrmann, A; Huster, D; Luckner, M; Müller, P; Scheidt, HA | 1 |
Ahmad, L; Akhlaq Mughal, M; Hassan, M; Iqbal, Z; Khan, A; Khan, I; Nasir, F; Raza, A | 1 |
Bruix, J; Reig, M; Ribeiro de Souza, A | 1 |
Abdelmageed, MM; El-Demerdash, E; El-Naga, RN; Elmazar, MM | 1 |
Buchfelder, M; Eyüpoglu, IY; Rauh, M; Savaskan, NE; Sehm, T; Wiendieck, K | 1 |
Imramovský, A; Kryštof, V; Páchniková, G; Slaninová, I; Uldrijan, S | 1 |
Casadei Gardini, A; de Stefano, G; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Marisi, G; Negri, FV; Santini, D; Scarpi, E; Scartozzi, M; Silvestris, N; Valgiusti, M | 1 |
Alsinet, C; Dauch, D; Esteller, M; Llovet, JM; Lujambio, A; Martinez-Quetglas, I; Moeini, A; Pinyol, R; Portela, A; Rodriguez-Carunchio, L; Solé, M; Thung, S; Torrecilla, S; Tovar, V; Villanueva, A; Zender, L | 1 |
Garg, M; Guha, C; Kaubisch, A; Ohri, N | 1 |
Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kuzuya, T; Nakano, I | 2 |
Al-Khadimi, G; Allen, N; Chowdhury, R; Heaton, N; Korantzis, I; O'Grady, J; Papadatos-Pastos, D; Ross, PJ; Sarker, D; Suddle, A; Thillai, K; Ziogas, DC | 1 |
Cho, NP; Cho, SD; Chung, TH; Jang, B; Jeong, JH; Kim, LH; Shin, JA; Won, DH; Yang, IH | 1 |
Chen, L; Liu, H; Liu, J; Liu, Y; Wang, X; Wang, Z; Yang, J | 1 |
Azzariti, A; Caligiuri, A; Dituri, F; Giannelli, G; Lupo, L; Mancarella, S; Porcelli, L; Quatrale, AE | 1 |
Bertucci, F; Blay, JY; Bompas, E; Camoin, L; Clisant, S; Decoupigny, E; Goncalves, A; Laurence, V; Lebellec, L; Mir, O; Penel, N; Toiron, Y; Tresch-Bruneel, E | 1 |
Dai, B; Gu, WJ; Shi, GH; Wan, FN; Wang, HK; Ye, DW; Zhang, HL; Zhu, Y | 1 |
Bolzacchini, E; Chini, C; Pinotti, G | 1 |
Calvo, E; Escudier, B; Grünwald, V; Heng, DY; Schmidinger, M | 1 |
Aburas, S; Colagrande, S; Inghilesi, AL; Marra, F; Nardi, C; Taliani, GG | 1 |
Bai, W; Cai, H; Fan, D; Han, G; Liu, L; Niu, J; Wang, E; Wang, W; Xia, D; Xia, J; Yang, M; Yin, Z; Zhang, L; Zhang, Z; Zhao, Y | 1 |
Choo, SP; Goh, BC; Hartano, S; Huynh, H; Koh, TS; Lim, C; Lim, KT; Low, LS; Ng, QS; Tai, WM; Tham, CK; Thng, CH; Toh, HC; Wang, LZ; Wang, WW; Yong, WP | 1 |
Cai, X; Chang, C; Chen, J; Li, G; Lin, H; Shi, L; Sun, Y; Xu, J | 1 |
Dong, X; Han, P; Jiang, H; Jiang, X; Qiao, H; Sun, X; Tan, G; Tang, S; Zhai, B | 1 |
Au, CH; Chan, TL; Cher, CY; Cheung, AM; Gill, H; He, BL; Ho, DN; Ho, ES; Ip, HW; Kwong, YL; Lam, SS; Leung, AY; Liang, R; Ma, ES; Man, CH; Ng, NK; So, CC; So, CW; Tamburini, J; Wong, WW | 1 |
Ding, Y; Jiang, C; Luo, D; Qu, Z; Wu, J | 1 |
Brzostek, T; Kawalec, P; Kózka, M; Malinowska-Lipień, I | 1 |
He, C; Li, Q; Liu, C; Liu, Q; Ma, W; Tao, L; Wang, X; Xue, D; Zhang, J; Zhang, W | 1 |
Camille, N; Dang, RP; Genden, EM; Le, VH; McFarland, D; Miles, BA; Misiukiewicz, KJ; Teng, MS | 1 |
Han, XY; Hu, J; Huang, H; Huang, Y; Sun, J; Ying, SW; Zheng, YL | 1 |
Chen, B; Chen, Y; Hu, B; Hua, L; Liu, J; Wu, M; Yan, D; Zhang, C; Zhang, X; Zhao, F; Zhou, H | 1 |
Delgado-Fernández, M; Galindo, MJ; García, MA; Garcia-Deltoro, M; Ibarra, S; Merchante, N; Merino, E; Mínguez, C; Montero-Alonso, M; Pineda, JA; Revollo, B; Rivero-Juárez, A; Rodríguez-Arrondo, F; Romero-Palacios, A; Téllez, F | 1 |
Abou-Alfa, GK; Dika, IE; Harding, JJ | 1 |
Bourlon, MT; Breaker, K; Clemons, JE; Flaig, TW; Gao, D; Lam, ET; Trigero, S | 1 |
Cai, Z; Han, Y; Liu, N; Liu, P; Shen, P; Wang, C | 1 |
Alvares, C; Chakraborty, M; Conner, C; Gosrani, D; Mahdi, AJ; Rayment, R; Rees, A; Wilson, K | 1 |
Balkrishnan, R; Lok, AS; Marshall, VD; Nathan, H; Parikh, ND; Shahinian, V; Singal, AG | 1 |
Ando, M; Ando, Y; Gyawali, B; Honda, K; Shimokata, T | 1 |
Fleischmann, M; Hilgendorf, I; Hochhaus, A; Sayer, HG; Schmidt, V; Schnetzke, U; Scholl, S; Schrenk, KG | 1 |
Chen, X; He, L; Huang, Y; Liang, C; Liu, Z; Ma, Z; Shi, C; Zhang, Z | 1 |
Gao, C; Huang, Z; Jia, W; Jiang, X; Lau, WY; Li, J; Li, X; Luo, X; Shen, F; Si, A; Xing, B; Yang, T | 1 |
Amendola, F; Calvanese, A; Coppola, C; DI Sarno, A; Gatti, P; Giorgio, A; Giorgio, V; Matteucci, P; Merola, F; Merola, MG; Montesarchio, L; Santoro, B | 1 |
An, D; Dong, M; Feng, M; Guan, Z; Jiang, S; Kuerban, K; Li, J; Peng, Y; Wang, Q; Ye, L | 1 |
Andres, D; Becker, A; Fernandez-Montalvan, AE; Georgi, V; Mueller-Fahrnow, A; Stegmann, CM | 1 |
Bian, J; Cheng, Y; Duan, J; Gao, X; Wu, H; Yang, Y; You, L; Zhang, L; Zhang, X; Zhu, Q | 1 |
Ding, S; Gao, D; Gao, M; Liu, S; Lv, J; Niu, Z; Wang, X; Wang, Z | 1 |
Boucher, E; Brunot, A; Crouzet, L; Duval, M; Edeline, J; Guillygomarc'h, A; Laguerre, B; Le Roy, F; Le Sourd, S; Lelievre, N; M'Sadek, A; Ventroux, E | 1 |
Cheow, PC; Choo, SP; Chow, PK; Gandhi, M; Goh, AS; Goh, BK; Liew, WM; Lo, RH; Low, AS; Ng, DC; Soo, KC; Tan, SB; Tay, KH; Thng, CH; Wong, JS | 1 |
Alfieri, S; Bergamini, C; Bossi, P; Civelli, E; Cortelazzi, B; Dagrada, GP; Granata, R; Imbimbo, M; Licitra, L; Lo Vullo, S; Locati, LD; Mariani, L; Mirabile, A; Morosi, C; Orlandi, E; Perrone, F; Pilotti, S; Quattrone, P; Resteghini, C; Saibene, G | 1 |
Elsadek, B; Kratz, F; Mansour, A; Saleem, T; Warnecke, A | 1 |
Arachchi, NJ; Bhullar, A; Bhullar, M | 1 |
Arase, Y; Hirose, S; Kagawa, T; Mine, T; Okabe, H; Shiraishi, K; Shomura, M; Takahira, S; Tsuruya, K | 1 |
Igarashi, Y; Ikehara, T; Shimizu, R; Shinohara, M; Shiozawa, K; Sumino, Y; Watanabe, M | 1 |
Anai, S; Fujimoto, K; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y | 1 |
Bao, Y; Chen, C; Li, J; Liu, B; Liu, J; Qu, L; Sun, S; Tan, H; Wang, J; Wang, L; Wei, D; Wu, D; Wu, Z; Xu, Z; Yang, F | 1 |
Heo, J; Woo, HY; Yoo, SY | 1 |
Bian, CB; Bollard, J; Hoshida, Y; Llovet, JM; Lujambio, A; Miguela, V; Molina-Sánchez, P; Nakagawa, S; Nguyen, CB; Roberto, MP; Ruiz de Galarreta, M; Sia, D; Tovar, V; Venkatesh, A | 1 |
Bai, R; Huang, C; Peng, R; Wei, D; Zhang, H | 1 |
Li, W; Wang, M; Wu, C; Xu, S; Zheng, P; Zhu, W; Zhu, Y | 1 |
Han, C; Ungerleider, N; Wu, T; Yao, L; Zhang, J | 1 |
Horne, DA; Kowolik, CM; Lin, M; Overman, LE; Xie, J | 1 |
Chen, JC; Chen, YC; Chien, YC; Chuang, HY; Hsu, FT; Hwang, JJ | 1 |
Bennett, LL; Mondal, A | 1 |
Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH | 1 |
Cai, X; Chen, G; Chen, L; Fu, T; Jin, W; Ma, D; Yu, F; Yu, Z; Zhang, J; Zhang, Y | 1 |
Bi, XY; Cai, JQ; Han, Y; Huang, Z; Li, H; Li, MX; Li, ZY; Yao, XS; Zhang, YF; Zhao, DB; Zhao, H; Zhao, JJ; Zhou, JG | 1 |
Abdel-Rahman, O; Lamarca, A | 1 |
Wu, CH; Wu, X; Zhang, HW | 1 |
Kerbel, RS; Kuczynski, EA | 1 |
Bouattour, M; de Gramont, A; Faivre, S; Soubrane, O | 1 |
Dienst, A; Germing, U; Haas, R; Heyn, C; Kobbe, G; Kondakci, M; Nachtkamp, K; Rautenberg, C; Schmidt, PV; Schroeder, T | 1 |
Cao, D; Fu, GB; Guo, LN; Huang, S; Liu, J; Qin, CJ; Tang, L; Wang, HY; Wang, MD; Wu, H; Yan, HX; Zeng, M; Zhang, HL; Zhao, LH; Zhou, X | 1 |
Amikura, K; Kageyama, Y; Kokudo, T; Miyazaki, Y; Sakamoto, H; Takahashi, A; Takano, M | 1 |
Chen, PT; Chen, SC; Grevel, J; Hu, CT; Jeng, LB; Le Berre, MA; Lin, SM; Liu, X; Lu, SN; Meinhardt, G; Mitchell, DY; Peña, CA; Prins, K; Yang, SS | 1 |
Chen, S; Fu, S; Li, Y; Liang, C; Liu, Z; Lu, L; Zhu, Y | 1 |
Bergheim, D; Branchi, V; Dietrich, D; Dietrich, J; Fischer, HP; Goltz, D; Kalff, JC; Kristiansen, G; Matthaei, H; Semaan, A | 1 |
Forgez, P; Galmiche, A; Liu, J; Paradis, V; Segal-Bendirdjian, E; Stadler, N; Wendum, D; Wu, Z | 1 |
Bauernhofer, T; Gerger, A; Hutterer, GC; Karbiener, M; Kiesslich, T; Mayr, C; Pehserl, AM; Pichler, M; Resel, M; Ress, AL; Scheideler, M; Stadelmeyer, E; Stanzer, S; Stiegelbauer, V | 1 |
Chen, XW; Han, JH; Hong, D; Ma, TC; Niu, M; Sun, J; Xu, K | 1 |
Baumhauer, A; Bodoky, G; Breder, V; Bronowicki, JP; Bruix, J; Cheng, AL; Finn, RS; Gerolami, R; Granito, A; Han, G; Huang, YH; Kudo, M; LeBerre, MA; Llovet, JM; Masi, G; Meinhardt, G; Merle, P; Ollivier-Hourmand, I; Pracht, M; Qin, S; Rosmorduc, O; Ross, PJ; Song, T; Yokosuka, O | 1 |
Chuang, WL; Lin, ZY | 1 |
Ghoshal, K; Jacob, ST; Motiwala, T; Reyes, R; Wani, NA | 1 |
Albiges, L; Bensalah, K; Bex, A; Canfield, SE; Dabestani, S; Fernández-Pello, S; Giles, RH; Hofmann, F; Hora, M; Kuczyk, MA; Lam, TB; Ljungberg, B; Marconi, L; Merseburger, AS; Powles, T; Staehler, M; Tahbaz, R; Volpe, A | 1 |
Alberts, SR; Borad, M; Gatalica, Z; Hubbard, JM; Kumar, S; Loui, WS; Mahoney, MR; Roberts, LR; Smyrk, TC | 1 |
Anderson, DG; Conte, D; Fischer, A; Hough, S; Kennedy, Z; Li, Y; Moore, J; Mou, H; Park, A; Pomyen, Y; Song, CQ; Thorgeirsson, S; Wang, XW; Weng, Z; Xue, W; Yin, H; Zender, L | 1 |
Fan, N; Feng, T; Hou, Z; Huang, Q; Li, Y; Ling, S; Liu, L; Liu, Y; Shi, L; Song, L; Tian, Y; Wang, M; Xu, F; Yang, X; Zhao, F | 1 |
Blesing, C; Braconi, C; Collins, P; Darby, S; Hubner, RA; Iwuji, C; Johnson, P; King, J; Kirkwood, A; Meyer, T; Muazzam, I; Nash, S; Nobes, J; Palmer, DH; Patel, K; Ross, P; Sumpter, K; Swinson, D | 1 |
Alfaro, V; Aspeslagh, S; Bahleda, R; Extremera, S; Fudio, S; Gyan, E; Hollebecque, A; Salles, G; Soria, JC; Soto-Matos, A; Stein, M | 1 |
Arihara, Y; Hayasaka, N; Kamihara, Y; Kato, J; Kikuchi, S; Kobune, M; Miyanishi, K; Murase, K; Nakamura, H; Okagawa, Y; Osuga, T; Takada, K; Usami, M | 1 |
He, D; Liu, F; Meng, Z; Shao, G; Wang, J; Wang, Z; Yang, J; Yip, CS | 1 |
Bearz, A; Demkow, T; Gore, ME; Jones, RJ; Kuczyk, M; Porta, C; Ravaud, A; Shapiro, J; Strauss, UP | 1 |
Caraglia, M; Castiello, F; Ferri, C; Giordano, A; Mosca, N; Panella, M; Potenza, N; Russo, A; Stiuso, P; Vanacore, D; Zappavigna, S | 1 |
Agard, DA; Duan, D; Elnatan, D; Logie, J; McLaughlin, CK; Shoichet, BK; Shoichet, MS; Torosyan, H | 1 |
Dai, XJ; Fan, JH; Liu, C; Liu, Q; Shen, YJ; Sun, WD; Sun, Y; Wang, J; Yang, H; Zhang, YQ; Zhao, JX | 1 |
Carter, JJ; Fretwell, LV; Woolard, J | 1 |
Katare, DP; Mishra, S | 1 |
Charamis, H; Esfahani, K; Ferrario, C; Langleben, A; Miller, WH; Nanni, O; Panasci, LC; Scarpi, E; Strepponi, I | 1 |
Bargellini, I; Fornaro, L; Lorenzoni, G; Masi, G; Vivaldi, C | 1 |
Hu, Y; Lin, A; Ma, C; Niu, Y; Shi, L; Su, Y; Zhang, C; Zhou, L; Zhu, X | 1 |
Brauner, J; Dudeck, O; Jürgens, J; Kalinski, T; Nass, N; Powerski, M; Ricke, J; Schulz, N; Seidensticker, M; Streit, S; Wybranski, C | 1 |
Arslan, A; Duensing, S; Grüllich, C; Hadaschik, B; Hallscheidt, P; Hatiboglu, G; Hohenfellner, M; Huesing, J; Pahernik, S; Radtke, JP; Roth, W; Teber, D; Tolstov, Y | 1 |
Chishima, T; Dry, SM; Eilber, FC; Elliott, I; Endo, I; Federman, N; Hiroshima, Y; Hoffman, RM; Igarashi, K; Kawaguchi, K; Kiyuna, T; Li, Y; Matsuyama, R; Murakami, T; Nelson, SD; Russell, T; Singh, A; Tanaka, K; Yanagawa, J; Zhang, Y; Zhao, M | 1 |
Chen, PC; Guo, L; Huang, Y; Kwok, HF; Li, B; Li, L; Lin, Y; Meng, C; Neves, H; Xiao, Y; Yan, W | 1 |
Campitiello, M; Eid, N; Hennequin, L; Longo, R; Plastino, F; Quétin, P; Wendel, C | 1 |
Berhane, S; Jackson, R; Johnson, P; Khan, H; Psarelli, EE | 1 |
Torjesen, I | 1 |
Byun, KS; Je, JH; Kang, SH; Kim, JH; Ko, E; Lee, HJ; Seo, YS; Suh, SJ; Yeon, JE; Yim, HJ; Yoo, YJ; Yoon, EL | 1 |
Bergadà, L; Boyd, J; Chen, BJ; Dolcet, X; Encinas, M; Eritja, N; Gatius, S; Llobet-Navàs, D; Martí, MD; Matias-Guiu, X; Ponce, J; Reventós, J; Ribera, J; Rodríguez-Barrueco, R; Santacana, M; Vidal, A; Villanueva, A; Yeramian, A | 1 |
Fritz, C; Guckenberger, M; Hoyer, M; Kroeze, SG; Lo, SS; Ricardi, U; Sahgal, A; Stahel, R; Stupp, R | 1 |
Chi, ZH; Guo, J; He, ZS; Li, XS; Sheng, XN; Wang, HK; Ye, DW; Zhang, HL | 1 |
Jang, H; Kim, EH; Roh, JL; Shin, D | 1 |
Calvisi, D; Eferl, R | 1 |
Chen, J; Fang, H; Jiang, B; Kang, M; Tang, Z; Wu, Y; Ye, Q; Zhang, B | 1 |
Burns, K; Chau, N; Kichenadasse, G; Knights, KM; Mackenzie, PI; McKinnon, RA; Miners, JO; Rowland, A; Tucker, GT | 1 |
Cheng, AL; Hocke, J; Loembé, AB; Meyer, T; Palmer, DH; Yen, CJ | 1 |
Gao, L; Hu, CA; Huang, S; Tang, Y; Teng, Y; Wang, X | 1 |
Brachet, PE; Chevreau, C; Dos Santos, M; Joly, F | 1 |
Badary, OA; Barrois, C; Cassier, P; Colomban, O; El-Demerdash, E; El-Madani, M; El-Shenawy, SM; Freyer, G; Gagnieu, MC; Guitton, J; Hommel-Fontaine, J; Ibrahim, BM; Lefort, T; Maillet, D; Peron, J; Rodriguez-Lafrasse, C; Tod, M; Valette, PJ; You, B | 1 |
Joshi, A; Kannan, RA; Kothari, R; Menon, S; Noronha, V; Patil, VM; Popat, P; Prabhash, K; Ramaswamy, A; Sable, N; Sahu, A | 1 |
Brown, P; Levis, M; Li, L; Ma, H; Nguyen, B; Small, D; Williams, AB; Young, DJ | 1 |
Bonsignore, R; Gentile, C; Lauria, A; Martorana, A | 1 |
Angenstein, F; Baldauf, L; Daniel, EA; Kirches, E; Mawrin, C; Pachow, D; Scholz, J; Stork, O; Tuchen, M; Wilisch-Neumann, A | 1 |
Chen, KF; Chu, PY; Huang, CT; Huang, TT; Lau, KY; Lee, CH; Liu, CY; Shiau, CW; Su, JC; Tsai, WC; Tseng, LM; Wang, WL; Yang, HP | 1 |
Bedke, J; Burchardt, M; Kroeger, N; Stenzl, A | 1 |
Booth, L; Dent, P; Poklepovic, A; Roberts, JL | 1 |
Gallacher, D; Gallacher, J; Jones, A; Narov, K; Sampson, JR; Samsel, PA; Shen, MH; Yang, J | 1 |
Baglioni, M; Baldassarre, M; Baron Toaldo, M; Bolondi, L; Callegari, E; Casadei Gardini, A; Cescon, M; Fornari, F; Galassi, M; Giovannini, C; Gramantieri, L; La Bella, T; Marinelli, S; Marisi, G; Negrini, M; Patrizi, C; Pollutri, D; Ravaioli, M; Salvatore, V | 1 |
Li, Y; Liu, L; Lu, L; Tong, X; Wang, F; Wang, X; Wu, G; Xie, J; Xue, Q; Zheng, A; Zhou, H; Zhu, X | 1 |
Huang, L; Luo, C; Wen, T; Xiao, H; Xiong, M | 1 |
Gu, J; Huang, W; Mao, X; Wang, Y; Wang, Z; Xiao, M; Zhu, L | 1 |
Arizumi, T; Bettinger, D; Burlone, ME; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sharma, R; Thimme, R; Ward, C; Yen, C | 1 |
Abou-Alfa, GK; Agajanov, T; Beylergil, V; Boisserie, F; Carrasquilo, JA; Chen, YC; Cheng, AL; Di Laurenzio, L; Frenette, C; Gansukh, B; Hsu, CH; Larson, SM; Lee, R; Lin, ZZ; Lyashchenko, SK; Ma, J; Maki, Y; Morikawa, H; O'Donoghue, J; O'Neil, B; Ohishi, N; Ohtomo, T; Pandit-Taskar, N; Ruan, S; Schwartz, L; Shao, YY; Smith-Jones, PM; Tanaka, T; Wan, P; Yen, CJ | 1 |
He, J; Liu, P; Lv, X; Wang, L; Xu, X; Yan, Y; Zhang, L; Zhang, Y | 1 |
Cai, X; Chen, J; Liang, X; Liang, Y; Lin, S; Ma, R; Zhu, L | 1 |
Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Xi, W; Xiong, Y; Xu, J; Yao, J | 1 |
Kong, W; Liu, G; Liu, X; Qu, J; Suo, S; Wu, G; Xu, J; Zhang, J | 1 |
Hasegawa, J; Hirota, M; Kameda, C; Kawabata, R; Koga, C; Matsumura, T; Murakami, M; Noura, S; Shimizu, J; Shuto, T; Yasuyama, A; Yoshikawa, M | 1 |
Akahori, T; Hokuto, D; Kanehiro, H; Kawaguchi, C; Kinoshita, S; Nagai, M; Nakajima, Y; Nishiwada, S; Nomi, T; Obara, S; Sho, M; Yamada, T; Yamato, I; Yasuda, S; Yoshikawa, T | 1 |
Bhosale, P; Dalton, HJ; Fleming, ND; Gershenson, DM; Schmeler, KM; Sun, CC | 1 |
Agarwal, N; Ghate, SR; Li, N; Pal, SK; Peeples, M; Perez, JR; Swallow, E; Vogelzang, NJ; Zichlin, ML | 1 |
Afriansyah, A; Hamid, AR; Mochtar, CA; Umbas, R | 1 |
Daniel, PT; Essmann, F; Gillissen, B; Preissner, R; Richter, A; Schulze-Osthoff, K | 1 |
Bian, S; Cai, H; Cui, Y; Fan, Y; Liang, J; Sui, J; Sun, Y; Xu, Z; Zhang, X; Zhou, L | 1 |
Chen, B; Chen, W; Dao, H; Huang, Y; Li, N; Liu, N; Yang, J | 1 |
Carlisle, B; Fergusson, D; Hachem, Y; Kimmelman, J; Mattina, J | 1 |
Almeida, PV; Correia, A; Herranz-Blanco, B; Hirvonen, J; Mäkilä, E; Salonen, J; Santos, HA; Shahbazi, MA; Shrestha, N | 1 |
Galmiche, A; Giacobbi, AS; Louandre, C; Mammeri, Y; Saidak, Z; Sauzay, C | 1 |
Ding, W; Wang, B; Xu, L | 1 |
Han, P; Jiang, H; Jiang, X; Li, H; Liu, B; Qiao, H; Sun, X; Tan, G; Zhai, B; Zhao, D | 1 |
Duan, XC; Guo, Y; Huang, D; Ren, W; Yao, X; Yin, YF; Zhang, Q; Zhang, S; Zhang, X; Zhong, T | 1 |
Aubert, RE; Clore, G; Epstein, RS; Herrera, V; Kourlas, H; La-Beck, NM; McLeod, HL; Walko, CM | 1 |
Dutta, R; Mahato, RI | 1 |
Cheng, S; Wang, K; Wang, M; Wu, M; Yang, G; Ye, X; Zhang, X | 1 |
Gao, C; Herr, I; Hoffmann, K; Lin, S; Petrulionis, M; Schemmer, P | 1 |
Al-Abdulla, R; Bantel, H; Bettinger, D; Geier, A; Jahn, D; Macias, RI; Marin, JJ; Weiss, J | 1 |
Acosta, LF; Butterfield, DA; Gedaly, R; Marti, F; Mitov, M; Poyil, P; Turcios, L; Vilchez, V | 1 |
Harada, N; Harimoto, N; Ikegami, T; Itoh, S; Kawasaki, J; Maehara, Y; Motomura, T; Nagatsu, A; Soejima, Y; Uchiyama, H; Yoshizumi, T | 1 |
Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhou, L | 2 |
Abe, K; Iwata, T; Kakoki, K; Miyata, Y; Mochizuki, Y; Nagayasu, T; Obatake, M; Sakai, H | 1 |
Atkin, C; Earwaker, P; Ma, YT; Pallan, A; Punia, P; Shetty, S | 1 |
Garcia-Manero, G; Hu, Y; Huang, A; Huang, P; Ju, HQ; Li, J; Li, Y; Lu, WH; Sun, Y; Wen, S; Xu, RH; Yang, J; Zhan, G | 1 |
Blaise, D; Charbonnier, A; D'Incan, E; Mohty, B; Rey, J; Sid, S; Vey, N | 1 |
Brade, AM; Brierley, J; Cho, C; Craig, T; Dawson, LA; Dinniwell, R; Goody, RB; Kassam, Z; Kim, J; Knox, JJ; Ringash, J; Wang, L; Wong, RKS | 1 |
Gobe, GC; He, Y; Hooper, J; Jeffery, PL; Lourie, R; McGuckin, MA; Morais, C; Ng, CP; Oancea, I; Seim, I; Shah, ET; Sheng, Y; Wong, KY | 1 |
Arizumi, T; Black, J; Burlone, ME; Ferrari, C; Gibbin, A; Guaschino, G; Howell, J; Kudo, M; Pinato, DJ; Pirisi, M; Ramaswami, R; Sellers, L; Sharma, R; Toniutto, P | 1 |
Affolter, A; Brenner, W; Brieger, J; Heimes, AS; Jensen, A; Mann, WJ; Mayer, A; Samosny, G; Schneider, J; Sommer, K; Stenzinger, A; Weichert, W | 1 |
Liang, J; Liu, CQ; Meng, YM; Xu, J; Xu, L; Yan, J; Yu, XJ; Zheng, L; Zhuang, SM | 1 |
Bauer, J; Grimm, D; Magnusson, NE; Randrup Hansen, C; Wehland, M | 1 |
Bito, T; Hirai, M; Hirano, T; Ishida, T; Nakagawa, T; Nishigori, C; Shichiri, H; Tokura, M; Uda, A; Yamamoto, K; Yano, I | 1 |
Aikata, H; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, F; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kobayashi, T; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Teraoka, Y; Tsuge, M | 1 |
Aihara, A; Akiyama, Y; Arii, S; Ban, D; Kudo, A; Matsumura, S; Mitsunori, Y; Mogushi, K; Nakao, K; Ochiai, T; Ohata, Y; Shimada, S; Tanabe, M; Tanaka, S | 1 |
Arizumi, T; Bettinger, D; Black, J; Burlone, ME; Ferrari, C; Gibbin, A; Guaschino, G; Howell, J; Kudo, M; Park, JW; Pinato, DJ; Pirisi, M; Ramaswami, R; Sellers, L; Sharma, R; Thimme, R; Yen, C | 1 |
Chiba, N; Hikita, K; Kawachi, S; Okihara, M; Ozawa, Y; Sano, T; Takano, K; Tomita, K | 1 |
Dragomir, A; Edqvist, PH; Enblad, G; Niinivirta, M; Pontén, F; Ullenhag, GJ | 1 |
Cheong, JY; Cho, HJ; Cho, SW; Hwang, JC; Kang, DR; Kim, B; Kim, JK; Kim, SS; Lee, JH; Lee, KJ; Lee, KM; Lim, SG; Nam, JS; Oh, MJ; Shin, SJ; Yang, MJ; Yoo, BM | 1 |
Ali, EN; El-Mokhtar, MA; Elsabahy, M; Elzeny, H; Fathi, HA; Hamad, MA; Li, R; Wooley, KL; Zhang, F; Zhang, S | 1 |
Chen, L; Ni, CF; Teng, GJ; Zhong, BY; Zhu, HD | 1 |
Brose, MS; DeSanctis, Y; Fellous, M; Lin, CC; Pitoia, F; Schlumberger, M; Smit, J; Sugitani, I; Tori, M | 1 |
Cheong, H; Hong, SM; Kim, N; Lee, CK; Lee, SS; Lee, Y; Son, WC | 1 |
Cao, J; Chen, Y; Li, W; Liu, K; Shang, C; Tan, W; Zhang, L; Zhong, J; Zhu, S | 1 |
Albiges, L; Ficarra, V; Heng, DY; Hsieh, JJ; Larkin, J; Purdue, MP; Schmidinger, M; Signoretti, S; Swanton, C | 1 |
Bardeesy, N; Benes, CH; Chang, CC; Chang, CF; Chen, Y; Dima, S; Duda, DG; Duyverman, AM; Flaherty, KT; Gao, DY; Hsu, FF; Huang, P; Jain, RK; Jeng, KS; Kitahara, S; Lin, TT; Liu, CH; Liu, YC; Popescu, I; Ramjiawan, RR; Sung, YC; Zhu, AX | 1 |
Atkins, MB; Choueiri, TK; DiPaola, RS; Dutcher, JP; Flaherty, KT; Haas, NB; Manola, J; Uzzo, RG | 1 |
Davidson, BR; Gurusamy, KS; Majumdar, A; Roccarina, D; Thorburn, D; Tsochatzis, E | 1 |
Butte, AJ; Chen, B; Chua, MS; Gill, RM; Ma, L; So, S; Wei, W; Yang, B | 1 |
Cho, A; Choi, YD; Hwang, SH; Kang, WJ; Rha, SY; Yun, M | 1 |
Bonhomme-Faivre, L; Cailliez, V; Farinotti, R; Mhiri, A; Noé, G; Paule, B; Saffroy, R; Tandia, M | 1 |
Ciani, O; Rognoni, C; Sommariva, S; Tarricone, R | 1 |
Chen, CH; Hu, TH; Hung, CH; Kee, KM; Kuo, YH; Lu, SN; Rau, KM; Wang, JH; Wu, IP | 1 |
Alivon, M; Boutouyrie, P; De Lepper, AG; Delhaas, T; Giroux, J; Goldwasser, F; Reesink, KD; Spronck, B | 1 |
Keating, GM | 1 |
Fukuda, K; Inami, T; Kataoka, M; Kimura, G; Satoh, T; Yoshino, H | 1 |
Babajanyan, S; Bruenderman, E; Cohn, A; Foreman, P; Geschwind, JF; Gholam, P; Goldenberg, A; Mantry, P; Martin, RC; McGuire, B; Miksad, R; Piperdi, B; Sanyal, A; Zigmont, E | 1 |
Baglioni, M; Baron Toaldo, M; Bolondi, L; Cescon, M; Giovannini, C; Gramantieri, L | 1 |
Haga, Y; Kanda, T; Nakamoto, S; Nakamura, M; Sasaki, R; Takahashi, K; Wu, S; Yokosuka, O | 1 |
Ahn, SH; Han, KH; Kang, JH; Kim, BK; Kim, DY; Kim, SU; Lee, S; Park, JY | 1 |
Amadori, D; Andreis, D; Bravaccini, S; Bronte, G; Cecconetto, L; Donati, C; Farolfi, A; Fedeli, A; Maltoni, R; Rocca, A; Schirone, A; Serra, P | 1 |
Cheng, HJ; Chu, YY; Li, G; Li, WB; Sun, CJ; Tian, ZH; Zhao, JC | 1 |
Choe, SW; Kim, MJ; Kim, YH; Lee, YJ; P Oh, S; Sprecher, D | 1 |
Mu, S; Olerile, LD; Wang, T; Yu, X; Zhang, J; Zhang, N | 1 |
Lee, WJ; Tam, HP | 1 |
Chen, L; Wang, HY; Zheng, B; Zhu, YJ | 1 |
Bie, P; Chen, X; Dou, K; Liu, F; Liu, L; Yang, J; Yang, X; Ye, SL; Yip, CS; Zhang, S; Zhou, J | 1 |
Hu, XG; Huang, DS; Li, T; Xu, QR; Yang, HM; Yang, L; Ye, S; Zhao, XY | 1 |
Cao, XH; Lu, AQ; Lv, B; Qiu, F; Wang, XY | 1 |
Altman, RB; Giacomini, C; Giacomini, MM; Gong, L; Klein, TE; Maitland, ML | 1 |
Chang, Y; Cho, EJ; Cho, H; Cho, YY; Jo, A; Kim, JB; Kim, YJ; Lee, JH; Lee, M; Lee, S; Nam, JY; Yoon, JH; Yu, SJ | 1 |
Baker, SD; Bins, S; de Bruijn, P; Du, G; Eskens, F; Gibson, AA; Hamberg, P; Hu, S; Li, L; Mathijssen, R; Phelps, MA; Sparreboom, A; van Doorn, L; Vasilyeva, A | 1 |
Cho, HJ; Cho, HR; Choi, JW; Chung, JW; Kim, DD; Kim, HC; Park, JH | 1 |
Chen, C; Chu, X; Geng, J; Han, D; Huang, M; Lei, Z; Wang, C; Wang, L; Wang, T; Wang, Y; Xie, T | 1 |
Chao, Y; Chen, SC; Yang, MH | 1 |
Ambert, V; Cambon-Thomsen, A; Castellano, D; Diekstra, MHM; Eisen, T; Fritsch, A; Garcia Donas, J; Guarch Troyas, R; Guchelaar, HJ; Hartmann, A; Hulsbergen-van de Kaa, C; Jaehde, U; Junker, K; Kiemeney, LALM; Martinez-Cardus, A; Masson, G; Maurits, JSF; Oosterwijk, E; Oosterwijk-Wakka, J; Oskarsdottir, A; Radu, MT; Rafnar, T; Rodriguez-Antona, C; Roessler, M; Ruijtenbeek, R; Stefansson, K; van der Zanden, LFM; Vermeulen, SH; Warren, A; Wessels, L | 1 |
Ahmed, SO; Aljurf, M; Antar, A; Battipaglia, G; Bazarbachi, A; Belhocine, R; Brissot, E; Dulery, R; Eder, S; El Cheikh, J; Giannotti, F; Isnard, F; Jestin, M; Lapusan, S; Legrand, O; Massoud, R; Mohty, M; Rasheed, W; Rubio, MT; Ruggeri, A; Shaheen, M; Vekhoff, A | 1 |
Guignabert, C; Humbert, M; Montani, D; Weatherald, J | 1 |
Karasawa, Y; Kawamura, S; Kojima, K; Kondo, M; Maeshima, S; Ohki, T; Seki, M; Shioda, Y; Tagawa, K; Toda, N | 1 |
Chang, HH; Chen, JS; Chia-Hsun Hsieh, J; Chou, WC; Hou, MM; Huang, CY; Lee, CL; Lin, YC; Teng, W; Tseng, YT; Yang, TS | 1 |
Chen, CP; Liao, XH; Liu, H; Lu, KP; Lu, W; Wang, J; Wang, L; Xu, H; Yang, D; Zhang, AL; Zheng, M; Zhou, XZ | 1 |
Chen, L; Huang, J; Liu, J; Mai, H; Mei, GH; Qu, H; Qu, N; Xu, X; Zhang, Y | 1 |
Best, J; Dechêne, A; Gerken, G; Lohmann, G; Schotten, C | 1 |
DeVere White, RW; Duan, Z; Ho, PY; Jian, C; Lam, KS; Lara, PN; Qiu, JX; Tu, MJ; Wun, T; Yu, AM; Yu, AX; Zhang, Q | 1 |
Friedman, T; Kishore, S; Madoff, DC | 1 |
Chen, J; Cheng, Y; Li, A; Liu, D; Liu, Y; Luo, R; Wang, B; Xu, W; Zheng, H; Zhu, Y | 1 |
Huachuan, Z; Jianhua, H; Li, R; Rongjian, S; Wubin, H; Yanjiao, G; Yue, W; Zhidong, L | 1 |
Braiteh, F; Burris, H; Cohn, AL; Foster, P; Kelley, RK; Lee, Y; Spira, A; Su, WC; Van Cutsem, E; Verslype, C; Vogelzang, N; Yang, TS | 1 |
Cho, EJ; Cho, H; Cho, KH; Cho, SH; Choi, WM; Hwang, CY; Jang, JJ; Kim, CY; Kim, K; Kim, YJ; Lee, JH; Lee, KB; Park, SM; Suh, KS; Won, JK; Yoon, JH; Yu, SJ | 1 |
Duan, P; Fan, L; Gao, Q; Qu, W; Ren, M; Shen, Y; Silwal, BM | 1 |
Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, HJ; Kim, HS; Park, CH; Rew, JS; Shin, SS; Yoon, JH | 1 |
Dybowski, N; Godl, K; Junghanss, C; Knuebel, G; Mueller, S; Murua Escobar, H; Roolf, C; Schaab, C; Sekora, A; Tebbe, A | 1 |
Mancuso, A; Maringhini, A | 1 |
Dhungel, B; Jayachandran, A; Mir, N; Shrestha, R; Steel, JC | 1 |
Chen, D; Eyupoglu, IY; Savaskan, N | 1 |
Chen, T; Cui, M; Cui, Y; Ge, C; Huo, Q; Li, H; Li, J; Sun, J; Tian, H; Xie, H; Yao, M; Zhao, F | 1 |
Caraglia, M; Cervi, C; Di Biase, S; Lo Re, O; Panebianco, C; Pazienza, V; Porto, S; Rappa, F; Vinciguerra, M | 1 |
Clare, KE; Dillon, JF; Miller, MH | 1 |
Sharma, R | 1 |
Chen, B; Cui, X; Hu, B; Hua, L; Liu, J; Shen, C; Shen, Y; Yan, D; Zhao, F | 1 |
Chen, HM; Chen, PJ; Cheng, AL; Hsu, CH; Lai, MS; Lu, LC; Shao, YY; Yeh, YC | 1 |
Bay, JO; Bertucci, F; Blay, JY; Bompas, E; Bonneville-Levard, A; Chauffert, B; Chevreau, C; Cupissol, D; Duffaud, F; Fabbro, M; Feuvret, L; Le Cesne, A; Lebellec, L; Mir, O; Noel, G; Penel, N; Saada-Bouzid, E; Vauleon, E; Vinceneux, A | 1 |
Cao, V; Chen, L; Huang, W; Ting, J; Wilson, L | 1 |
Arneson, K; Attia, A; Chakravarthy, AB; Cmelak, AJ; Horn, L; Mondschein, J; Niermann, K; Puzanov, I; Stavas, M; Xia, F | 1 |
Allard, M; Blanchet, B; Costentin, C; Hulin, A; Joly, C; Khoudour, N; Rousseau, B; Tournigand, C | 1 |
Antonuzzo, L; Balestri, V; Brugia, M; Costanzo, FD; Giommoni, E; Laffi, A; Lunghi, A; Mazzoni, F; Mela, MM; Petreni, P | 1 |
Guo, Z; Li, T; Pu, J; Wei, X; Wu, Z; Zhu, D | 1 |
Lee, SJ; Lim, HY | 1 |
Badrinath, N; Heo, J; Woo, HY; Yoo, SY | 1 |
Chen, C; Chen, W; Guo, L; Ju, R; Li, J; Shi, J; Sun, F; Ye, C; Zhang, D; Zhu, L | 1 |
Chang, Y; Cho, EJ; Chung, GE; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Lee, JM; Nam, JY; Yoo, JJ; Yoon, JH; Yu, SJ | 1 |
Cai, W; Chen, Y; Huang, J; Huang, Y; Kong, W; Zhang, J; Zhou, L | 1 |
Lou, L; Quan, H; Wang, H | 1 |
Gülow, K; Kießling, MK; Klemke, CD; Krammer, PH; Nicolay, JP; Schlör, T; Süss, D | 1 |
Lim, SY; Menzies, AM; Rizos, H | 1 |
Ahn, KS; Baek, SH; Kim, C; Ko, JH; Lee, JH; Nam, D | 1 |
Barbieri, F; Carra, E; Daga, A; Favoni, RE; Filiberti, RA; Florio, T; Marubbi, D; Mutti, L; Pattarozzi, A; Würth, R | 1 |
Cho, EJ; Cho, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, KW; Suh, KS; Yi, NJ; Yoon, JH; Yu, SJ | 1 |
Bruix, J; Cleton, A; Drenth, HJ; Fiala-Buskies, S; Keunecke, A; Meinhardt, G; Ploeger, B; Reinecke, I; Solms, A | 1 |
Cho, EJ; Cho, Y; Cho, YY; Jun, J; Kim, H; Kim, Y; Kim, YJ; Lee, DH; Lee, JH; Lee, S; Park, T; Yeo, I; Yoon, JH; Yu, SJ | 1 |
Aoki, Y; Arai, T; Atsukawa, M; Doi, H; Fukai, M; Itokawa, N; Kanto, T; Kimura, K; Mano, Y; Mizokami, M; Osawa, Y; Shoji, H; Sugiyama, M; Taketomi, A; Yoshio, S | 1 |
Abeni, E; Arici, B; De Petro, G; Marchina, E; Salvi, A; Traversa, M | 1 |
Agarwal, N; Gill, DM; Vaishampayan, U | 1 |
Goto, H; Goto, S; Hamanoue, S; Iwasaki, F; Keino, D; Kitagawa, N; Miyagawa, N; Miyagi, Y; Sarashina, T; Sekiguchi, H; Shiomi, M; Sugiyama, M; Tanaka, Y; Yokosuka, T | 1 |
Beukhof, CM; Bins, S; Chaker, L; de Herder, WW; de Rijke, YB; Mathijssen, RH; Peeters, RP; van Doorn, L; van Heerebeek, R; van Kemenade, FJ; Visser, TJ; Visser, WE | 1 |
Personeni, N; Pressiani, T; Rimassa, L; Santoro, A | 1 |
Go, ML; Huynh, H; Sim, MY; Yuen, JSP | 1 |
Franzesi, CT; Ippolito, D; Okolicsanyi, S; Querques, G; Sironi, S; Strazzabosco, M | 1 |
Choi, YK; Ham, HJ; Jang, SY; Jeon, HJ; Kim, BG; Kim, JG; Kim, JH; Kim, MJ; Lee, IK; Lee, JY; Park, KG; Park, SY | 1 |
Bądziul, D; Jakubowicz-Gil, J; Langner, E; Rzeski, W; Wertel, I; Zając, A | 1 |
Abada, PB; Baron, AD; Blanc, JF; Borg, C; Bowman, L; Chau, I; Chung, HC; Cui, ZL; Girvan, AC; Kudo, M; Malfertheiner, P; Okusaka, T; Park, JO; Pastorelli, D; Peck-Radosavljevic, M; Poon, R; Ryoo, BY; Seitz, JF; Yang, L; Yen, CJ; Zhu, AX | 1 |
Abou-Alfa, GK; Bass, M; Blanc, JF; Bradley, M; Cebon, J; Ganten, T; Gupta, C; Hollywood, E; Liem, AK; Lipton, L; Litten, J; Ma, J; Miles, S; Saltz, LB; Trojan, J; Wu, B | 1 |
Murata, K; Nitta, N; Nitta-Seko, A; Ohta, S; Sonoda, A; Tomozawa, Y; Tsuchiya, K; Watanabe, S | 1 |
Ishihara, H; Kondo, T; Tanabe, K | 1 |
Eggert, T; Greten, TF | 1 |
Adam, R; Amaddeo, G; Bricault, I; Calderaro, J; Cherqui, D; Costentin, CE; Decaens, T; Duvoux, C; Ganne-Carrié, N; Laurent, A; Letoublon, C; Luciani, A; Mallat, A; Nault, JC; Paule, B; Roudot-Thoraval, F; Samuel, D; Vibert, E | 1 |
Li, L; Long, B; Yan, F; Yang, Y; Ye, T; Ye, X; Yi, H; Zhang, L | 1 |
Itoh, K; Matsueda, S; Morita, M; Muroya, D; Sasada, T; Shichijo, S; Shirahama, T; Yamada, A; Yamaguchi, R; Yutani, S | 1 |
Altamura, E; Azzariti, A; Cutrignelli, A; Denora, N; Di Fonte, R; Franco, M; Iacobazzi, RM; Laquintana, V; Lopalco, A; Lopedota, AA; Porcelli, L | 1 |
Atrih, A; Auciello, FR; Gowans, GJ; Hardie, DG; Hawley, SA; Lamont, DJ; Ross, FA | 1 |
Kim, D; Ko, HS; Park, GB | 1 |
Ji, B; Liu, J; Liu, K; Liu, Y; Meng, L | 1 |
Fujimoto, N; Kamba, T; Kitada, S; Komohara, Y; Ma, C; Motoshima, T; Nakayama, T; Pan, C; Takeya, M; Yamada, S; Yano, H | 1 |
Ito, KI; Ito, Y; Kabu, K; Onoda, N; Sugitani, I; Takahashi, S; Tsukada, K; Yamaguchi, I | 1 |
Cheng, YY; Ting, CT; Tsai, TH | 1 |
Choueiri, TK; Kaymakcalan, MD; Lalani, AA; Lin, X; McKay, RR; Simantov, R | 1 |
Cheng, Z; Ke, X; Li, C; Li, H; Li, X; Liu, S; Qu, Y; Shen, Y; Wu, G; Xie, N; Xu, X; Yang, N; Yuan, X; Zhang, W; Zhou, J; Zu, X | 1 |
Cheng, LKW; Copland, JA; Ding, J; Ho, NPY; Lau, EYT; Lee, TKW; Leung, DHW; Lin, CH; Lo, J; Lo, RCL; Ma, MKF; Ma, S; Ng, IOL | 1 |
Collins, P; Cunningham, D; Evans, TRJ; Fox, R; Hacking, N; Hubner, RA; James, MW; Johnson, PJ; Ma, YT; Meyer, T; Palmer, DH; Primrose, JN; Ross, PJ; Stocken, DD; Stubbs, C; Sturgess, R; Wall, L; Watkinson, A | 1 |
Ahn, SH; Han, KH; Heo, JY; Jang, SK; Jang, SY; Jeon, MY; Kim, BK; Kim, DY; Kim, HS; Kim, SU; Lee, HW; Lee, SH; Lee, YR; Park, JY; Park, SY; Tak, WY | 1 |
Gao, Q; Lin, H; Song, Y; Yang, Y; Zhao, L | 1 |
Benech, N; Saurin, JC; Walter, T | 1 |
Augustyns, K; Bräsen, JH; Feldmann, F; Fulda, S; Goossens, V; Hofmans, S; Jeong, M; Joossens, J; Lee, EW; Linkermann, A; Martens, S; Song, J; Takahashi, N; Tonnus, W; Van der Veken, P; Vandenabeele, P | 1 |
Baxi, SS; Cullen, G; Dunn, LA; Fagin, JA; Fury, MG; Ghossein, RA; Haque, S; Ho, AL; Pfister, DG; Sherman, EJ; Sima, CS | 1 |
Brade, A; Chung, C; Dawson, L; Longo, J; Milosevic, M; Murray, L; Oza, A; Wan, J; Wang, L | 1 |
Bunker, E; Chapnick, DA; Eckhardt, SG; Lee, S; Liu, X; Liu, Z; Peng, Y; Ramirez, A; Tan, AC; Zhang, C | 1 |
Galle, PR; Huber, Y; Koch, S; Labenz, C; Marquardt, JU; Prenosil, V; Schattenberg, JM; Weinmann, A; Wörns, MA | 1 |
Abdel-Wahab, R; Abdelsalam, ME; Al-Shamsi, HO; Aloia, TA; Amin, HM; Avritscher, R; Chun, YS; Conrad, C; Dahbour, I; Das, P; Hassan, MM; Kaseb, AO; Koay, EJ; Krishnan, S; Lacin, S; Mahvash, A; Murthy, R; Odisio, BC; Rashid, A; Shalaby, AS; Vauthey, JN; Yao, JC | 1 |
Dai, X; Ding, J; Fu, X; Geng, M; Huang, M; Huang, X; Liu, H; Shen, A; Sun, D; Wei, R; Yan, J; Zheng, X | 1 |
Bruix, J; Cheng, AL; De Sanctis, Y; Llovet, J; Meinhardt, G; Nakajima, K | 1 |
Bansal, P; Fekrazad, HM; Lee, FC; Patt, Y; Rojas-Hernandez, C | 1 |
Barbera, MA; Biasco, G; Brandi, G; Frega, G; Garajova, I; Lorenzo, S; Palloni, A; Pantaleo, MA; Tovoli, F | 1 |
Buder, R; Galle, PR; Ganten, TM; Gerken, G; Göhler, T; Koschny, R; Malfertheiner, P; Schott, E; Stauber, RE; Walther, M | 1 |
Chen, RX; Cui, JF; Dong, G; Dong, YY; Gao, DM; Li, JH; Ma, H; Ma, M; Ren, ZG; Yao, RR; Zhang, R; Zheng, QD | 1 |
Bouarioua, N; Bourmaud, A; Clavel, L; Merle, P; Phelip, JM; Roblin, X; Verot, C; Williet, N | 1 |
Chen, C; Chen, SZ; Cheng, Z; Cong, WM; Ding, J; Lee, TKW; Li, XF; Lu, XY; Ning, BF; Qu, L; Shen, WF; Sun, W; Wang, HY; Wen, W; Xia, MY; Xiang, DM; Yang, W; Zhou, TF | 1 |
Bortlicek, Z; Buchler, T; Chloupková, R; Dusek, L; Fiala, O; Finek, J; Hornova, J; Kiss, I; Kopeckova, K; Kopecky, J; Lakomy, R; Melichar, B; Poprach, A; Slaby, O; Studentova, H; Svoboda, M; Vyzula, R; Zemanova, M | 1 |
Karasic, TB; O'Dwyer, PJ; Rosen, MA | 1 |
Huang, X; Li, G; Li, W; Mu, X; Qian, X; Qin, J; Sun, B; Tan, S; Tan, Z; Wang, X; Xu, X; Zhang, W; Zhu, Z | 1 |
Fujii, Y; Ishioka, J; Kawamura, N; Kihara, K; Matsuoka, Y; Okuno, T; Saito, K; Uehara, S; Yamamoto, S; Yasuda, Y; Yokoyama, M; Yonese, J; Yuasa, T | 1 |
Decker, T; Göhler, T; Indorf, M; Nusch, A; Overkamp, F; Rösel, S; Sahlmann, J; Trarbach, T | 1 |
Cao, JY; Han, X; Li, HS; Yin, HS; Yu, XQ | 1 |
Durand-Zaleski, I; Fleury, L; Maroun, R; Maunoury, F; Nachbaur, G; Vanhille, JL | 1 |
Han, JK; Kim, JH; Lee, JH; Lee, S | 1 |
Ba, Q; Duan, X; Li, H; Li, J; Li, X; Wang, F; Wang, H; Yao, W; Yuan, Y; Zhang, S; Zhang, W | 1 |
Kollmann, D; Selzner, M; Selzner, N | 1 |
Fan, L; Jiang, K; Li, T; Shao, J; Zhao, R; Zheng, G | 1 |
Bai, T; Sun, Y; Wang, S; Wang, W; Zhao, Y; Zhu, R | 1 |
Biondi, RM; Brieger, A; Hinrichsen, I; Huhn, M; Passmann, S; Plotz, G; Weßbecher, IM; Zeuzem, S | 1 |
Brunetti, O; Casadei Gardini, A; Cascinu, S; Di Costanzo, GG; Ercolani, G; Faloppi, L; Foschi, FG; Granata, R; Marisi, G; Palmieri, VO; Scartozzi, M; Silvestris, N; Tortora, R | 1 |
Comerford, CM; Langabeer, SE; Murphy, PT; Quinn, J | 1 |
Arizumi, T; Hagiwara, S; Kamata, K; Kudo, M; Minaga, K; Minami, Y; Nishida, N; Sakurai, T; Takenaka, M; Watanabe, T; Yada, N | 1 |
Choi, HJ; Han, Z; Joo, Y; Kang, D; Oh, GH; Song, JJ | 1 |
Bao, B; Delaney, J; Groves, K; Ho, G; Kossodo, S; Morin, J; Narayanan, N; Peterson, JD; Rajopadhye, M; Tseng, JC; Zhang, J | 1 |
Covell, DG | 1 |
Bavari, S; Brahms, A; Kehn-Hall, K; Kota, K; Mudhasani, R; Nasar, F; Pinkham, C; Zamani, R | 1 |
Bardelang, D; Huang, Q; Lee, SMY; Wang, C; Wang, R; Yang, X | 1 |
Bettinger, D; Boettler, T; Brunner, TB; Buettner, N; Gkika, E; Glaser, N; Maruschke, L; Neumann-Haefelin, C; Schultheiss, M; Spode, R; Thimme, R | 1 |
Akhoundova, D; Aparicio, J; Bruixola, G; Caballero, J; Diaz-Beveridge, R; Giménez, A; Lorente, D; Rodrigo, E; Segura, Á | 1 |
Hayashi, Y; Machihara, K; Murakami, I; Namba, T; Tanaka, H | 1 |
Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Lin, ZZ; Ou, DL; Shao, YY; Wang, MJ | 1 |
Appella, D; Avram, MJ; Chen, Z; Green, R; Gupta, P; Huang, M; Huang, S; Kandela, I; Liu, Y; Lou, G; Mazar, A; Norton, JT; Shank, NI; Tang, S; Wang, C | 1 |
Hoshino, T; Ishihara, H; Kakizaki, S; Kudo, T; Naganuma, A; Sato, K; Suzuki, Y; Takagi, H; Uehara, D; Yamada, M | 1 |
Borgia, F; Cannavò, SP; Franzè, MS; Lentini, M; Saitta, C; Vaccaro, M | 1 |
Argirò, R; Levi Sandri, GB; Lucatelli, P; Saba, L | 1 |
Ballarin, R; Berretta, M; Di Benedetto, F; Guerrini, GP; Magistri, P; Pecchi, A; Tarantino, G | 1 |
Baselga, J; Bergh, J; Bermejo, B; Chan, A; Costa, F; Gómez, HL; Gómez, P; Gradishar, WJ; Huang, L; Hudis, CA; Maeda, P; Mángel, L; Meinhardt, G; Melichar, B; Nagai, SE; Rapoport, BL; Roché, H; Schwartzberg, LS; Zamagni, C; Zhang, J | 1 |
García Carretero, R; Rebollo-Aparicio, N; Romero Brugera, M; Vazquez-Gomez, O | 1 |
Beveridge, DJ; Brown, RM; Candy, P; Chaturvedi, V; Epis, M; Ganda, C; George, J; Kabir, TD; Kalinowski, F; Kopp, C; Leedman, PJ; Richardson, KL; Stuart, LM; Wintle, L; Yeoh, GC | 1 |
Kira, Y; Mizukami, Y; Sugawara, K; Tsuruta, D | 1 |
Kutkowska, J; Rapak, A; Strzadala, L | 1 |
Li, W; Sun, X; Tan, G; Wang, P; Zhai, B; Zhu, M | 1 |
Chen, H; Chen, J; Cui, L; Li, M; Liu, X; Ren, Y; Sun, Y; Wang, L; Wang, X; Wu, C; Yang, J; Zhang, J; Zhou, W | 1 |
Chiba, T; Hara, H; Ishii, J; Kamma, H; Sawa, A; Yamamoto, H | 1 |
Chen, K; Dai, W; Fan, X; Feng, J; Guo, C; Li, J; Li, S; Liu, T; Lu, J; Lu, X; Mo, W; Wang, W; Wu, L; Xia, Y; Xu, L; Xu, S; Yu, Q; Zhang, Q; Zhou, Y | 1 |
Bito, T; Hirai, M; Hirano, T; Ishida, T; Kaku, K; Kume, M; Makimoto, H; Nakagawa, T; Nishigori, C; Nishioka, T; Shichiri, H; Yamamoto, K; Yano, I | 1 |
Zhang, H | 1 |
D'Addeo, K; Kaplan, DE; Mamtani, R; Mehta, R; Reiss, KA; Taddei, TH; Wileyto, EP; Yu, S | 1 |
Bao, XB; Chen, SN; Ding, ZX; He, J; Li, Z; Liu, H; Liu, SB; Qiu, QC; Shen, HJ; Wang, C; Xue, SL; Yang, J; Yao, H | 1 |
Amzal, B; Fu, S; Karcher, H; Lister, J; Meng, J | 1 |
Gandhi, S; George, S; Jain, RK | 1 |
Cai, W; Chen, Y; Dong, B; Huang, J; Huang, Y; Kong, W; Xue, W; Zhang, J; Zhong, H; Zhou, L | 1 |
Bai, T; Chen, J; Li, LQ; Li, ZH; Qi, LN; Wu, FX; Yang, TB; Ye, JZ; Zhu, SL; Zou, L | 1 |
Chang, CS; Chao, Y; Chen, CY; Lee, TY; Lin, CC; Lo, GH; Wang, TE | 1 |
Pacini, F | 1 |
Agate, L; Bottici, V; Cappagli, V; Danesi, R; Del Re, M; Elisei, R; Giani, C; Lorusso, L; Matrone, A; Molinaro, E; Pieruzzi, L; Puleo, L; Valerio, L; Viola, D | 1 |
Biasoni, D; Busico, A; Calareso, G; Catanzaro, M; Colecchia, M; Giannatempo, P; Lo Vullo, S; Mariani, L; Necchi, A; Nicolai, N; Pennati, M; Perrone, F; Piva, L; Raggi, D; Salvioni, R; Stagni, S; Togliardi, E; Torelli, T; Zaffaroni, N | 1 |
Azzolina, A; Balasus, D; Cervello, M; Emma, MR; Giammona, G; Loria, GR; Pitarresi, G; Porsio, B; Puleio, R; Puleo, S; Volpe, AB | 1 |
Bruner, JK; Jones, RJ; Levis, MJ; Li, L; Ma, HS; Pratilas, CA; Pratz, KW; Qin, ACR; Rudek, MA; Small, D | 1 |
Abd El Razik, HA; Abu-Serie, MM; El-Miligy, MM | 1 |
Bitzer, M; Horger, M; Kaufmann, S; Lauer, U; Nikolaou, K; Schulze, M; Thaiss, WM | 1 |
Jia, S; Lei, H; Wang, C; Wang, M; Xiao, Z; Xu, S; Zheng, P; Zhi, J; Zhu, W | 1 |
Carillio, G; Costanzo, R; Daniele, G; Manzo, A; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
Cheng, H; Dong, J; Hu, F; Sun, W; Xu, J; Zhai, B | 1 |
Bersanelli, M; Buti, S; DiPaola, RS; Haas, NB; Manola, J; Puligandla, M; Taguchi, S | 1 |
Clavreul, A; Lautram, N; Menei, P; Montero-Menei, CN; Pourbaghi-Masouleh, M; Roger, E | 1 |
Chow, PK; Gandhi, M; Gebski, V | 1 |
Bain, JR; Beak, JY; Huang, W; Ilaiwy, A; Jensen, BC; Johnson, GL; Muehlbauer, MJ; Newgard, CB; Parry, TL; Patterson, C; Willis, MS | 1 |
Chen, HM; Cheng, AL; Hsu, CH; Lee, YH; Li, YS; Lin, H; Shao, YY | 1 |
Gao, L; Lv, F; Shay, C; Teng, Y; Wang, X | 1 |
Sun, S; Wang, H; Xie, B; Yang, W; Yu, M | 1 |
Aprile, G; Brunetti, O; Casadei Gardini, A; Cascinu, S; De Matteis, S; Ercolani, G; Faloppi, L; Foschi, FG; Frassineti, GL; Granato, AM; Marisi, G; Negrini, G; Palmieri, V; Passardi, A; Perrone, G; Santini, D; Scartozzi, M; Silvestris, N; Tamburini, E; Tovoli, F; Valgiusti, M; Vespasiani-Gentilucci, U | 1 |
Blanc, JF; Campillo-Gimenez, B; Edeline, J; Faluyi, O; Ghazi, S; King, J; Ma, YT; Mathurin, J; Meyer, T; Palmer, DH | 1 |
Arvat, E; Berardelli, R; Felicetti, F; Gallo, M; Marchisio, F; Nervo, A; Piovesan, A | 1 |
Antarianto, RD; Arozal, W; Louisa, M; Rahmaniah, R; Soetikno, V; Yuyuntia, Y | 1 |
Chen, KF; Li, B; Li, Q; Liu, F; Wei, YG; Zhao, RC; Zhou, J | 1 |
Chan, KKW; Earle, CC; Jembere, N; Qiao, Y; Sapisochin, G; Thein, HH; Yoshida, EM; Zaheen, A | 1 |
Cai, X; Chen, J; Jin, RA; Liang, X; Lin, H; Sun, Y; Tang, M; Xu, J; Zheng, L | 1 |
Cai, X; Chen, J; Dai, Y; Ji, T; Liang, X; Liang, Y; Lin, H; Xie, Y; Xu, J; Yu, Q; Zhang, B | 1 |
El-Serag, HB; Johnson, MS; Zhu, AX | 1 |
Kudo, M; Nishida, N; Ueshima, K | 1 |
Deguchi, A; Hiasa, Y; Hiraoka, A; Hirooka, M; Imai, M; Ishikawa, T; Joko, K; Koizumi, Y; Kudo, M; Kumada, T; Michitaka, K; Ochi, H; Shimada, N; Tada, T; Tajiri, K; Toyoda, H; Tsuji, K | 1 |
Dolgikh, N; Fulda, S | 1 |
Angus, SP; Beak, JY; Chen, X; Hicks, ST; Huang, W; Jensen, BC; Johnson, GL; Parry, TL; Sciaky, N; Stuhlmiller, TJ; Willis, MS; Zawistowski, JS | 1 |
Chen, GG; Lai, PBS; Liu, L; Niu, L; Ren, J; Yang, S | 1 |
Arai, J; Goto, K; Ito, S; Kaise, Y; Kato, N; Lim, LA; Matsubara, Y; Morimoto, S; Muroyama, R; Nakagawa, R; Stephanou, A; Tanoue, Y; Yoshida, H | 1 |
Basara, N; Burchert, A; Ditschkowski, M; Dreger, P; Fey, MF; Finck, A; Finke, J; Giagounidis, A; Götze, K; Kobbe, G; Lübbert, M; Metzelder, SK; Meyer, RG; Neubauer, A; Pabst, T; Salih, HR; Scholl, S; Schroeder, T; Wollmer, E | 1 |
Andersen, JB; Beguinot, F; Condorelli, G; Heim, MH; Hindupur, SK; Matter, MS; Ng, CKY; Nigro, C; Pallante, P; Piscuoglio, S; Quagliata, L; Quintavalle, C; Roth, W; Tagscherer, KE | 1 |
He, HL; Yao, WX | 1 |
Bruix, J; Lii Cheng, A; Llovet, J | 1 |
Berhane, S; Jackson, R; Johnson, PJ; Psarelli, E | 1 |
Akiyama, M; Chen, KR; Hioki, T; Makita, S; Takama, H; Watanabe, D | 1 |
Cheng, SB; Huang, CC; Jan, YG; Lin, HC; Lin, YL; P'eng, FK; Shen, CH; Teng, CJ; Wu, CC; Yang, YS | 1 |
Fu, C; Gu, H; Han, Z; Lin, J; Lu, F; Yang, S | 1 |
Cai, M; Cao, Z; Chen, X; Lin, L; Shuai, X; Sun, W; Wang, Y; Zhu, K | 1 |
Adam, R; Allaham, W; Assenat, E; Aubé, C; Barraud, H; Bouattour, M; Brenot-Rossi, I; Bronowicki, JP; Castera, L; Chatellier, G; Costentin, C; Couturier, O; Dinut, A; Gerolami, R; Guiu, B; Ilonca, AD; Itti, E; Laurent, V; Lebtahi, R; Lewin, M; Luciani, A; Mathias, E; Mundler, O; Oberti, F; Pageaux, GP; Perdrisot, R; Pereira, H; Raoul, JL; Ronot, M; Samuel, D; Sarran, A; Seitz, JF; Sibert, A; Silvain, C; Tasu, JP; Vidal, V; Vilgrain, V | 1 |
Chen, X; Shao, J; Shen, Z; Xu, A; Zhao, R; Zheng, G | 1 |
Arima, K; Baba, H; Beppu, T; Chikamoto, A; Hashimoto, D; Hayashi, H; Higashi, T; Imai, K; Ishiko, T; Kaida, T; Nakagawa, S; Nitta, H; Okabe, H; Sasaki, Y; Takeyama, H; Taki, K; Tanaka, M | 1 |
Cai, R; Liao, Y; Ma, H; Pang, P; Song, R; Sun, H; Wang, H; Wang, S; Yan, Y; Zhang, H; Zhou, C; Zhou, X | 1 |
Burris, HA; Gian, VG; Greco, FA; Hainsworth, JD; Kosloff, RA; Quinn, R; Rubin, MS; Shih, KC; Shipley, DL; Spigel, DR | 1 |
Bae, WK; Kim, DY; Kwon, SY; Min, JJ | 1 |
Alonso, V; Asensio, E; Camps, J; Castells, A; Codony-Servat, J; Cuatrecasas, M; Escudero, P; Feliu, J; Fernández-Martos, C; Gaba, L; Gallego, J; García-Albéniz, X; Horndler, C; Jares, P; Marín-Aguilera, M; Martín-Richard, M; Martínez-Balibrea, E; Martínez-Cardús, A; Maurel, J; Méndez, JC; Méndez, M; Montironi, C; Prat, A; Reig, O; Rojo, F; Rosell, R; Rubini, M; Salud, A; Victoria, I | 1 |
Bae, SH; Choi, JY; Hwang, S; Jang, JW; Park, HL; Song, MJ; Sung, PS; Yang, K; Yoo, IR; Yoon, SK | 1 |
Elmasry, MS; Hassan, WS; Shalaby, AA; Zidan, DW | 1 |
Abdel-Rahman, O; Eissa, M; El Gewaity, M; Farag, K; Ghonaim, A; Nada, Y; Rashad, N; Saadawi, I; Sheha, A | 1 |
Fukuda, H; Iizuka, J; Ishihara, H; Kobayashi, H; Kondo, T; Omae, K; Takagi, T; Tanabe, K; Yoshida, K | 1 |
Abdel Gaber, SA; Abdel Kader, MH; Hüttenberger, D; Müller, P; Stepp, H; Wittig, R; Zimmermann, W | 1 |
Fei, Z; Lu, M; Zhang, G | 1 |
Barney, LE; Hall, CL; Jansen, LE; Meyer, AS; Nguyen, TV; Peyton, SR; Schwartz, AD | 1 |
Liu, H; Ming, L; Sun, T | 1 |
Bo, LS; Ke, WB; Li, T; Meng, YP; Zhang, Y | 1 |
Chakraborti, A; Chawla, YK; Dhiman, RK; Kalra, N; Kanthaje, S; Makol, A | 1 |
Fujii, H; Hamamichi, S; Hori, Y; Ito, K; Matsui, J; Ozawa, Y; Umeda, IO | 1 |
Dong, LY; Du, C; Gao, JJ; Ni, YH; Qiao, Z; Sun, JY; Wang, K; Wang, LY; Yu, HX; Zhang, JH; Zhang, SS; Zhao, CR | 1 |
Chang, PY; Huang, YK; Lee, SW; Lee, TY; Shiu, SI; Yeh, HZ; Yen, CL | 1 |
Auriola, S; Bunch, L; Gynther, M; Han, L; Hansen, JC; Hansen, KB; Ishchenko, Y; Kayser, S; Larsen, Y; Malm, T; Nielsen, B; Petsalo, A; Pickering, DS; Proietti Silvestri, I | 1 |
Ge, M; Jin, S; Li, L; Long, B; Yang, M; Ye, T; Ye, X; Yi, H; Zhang, L | 1 |
Liu, LX; Liu, QX; Luo, JJ; Ma, JQ; Wang, JH; Yan, ZP; Zhang, W; Zhang, ZH | 1 |
Edwards, RJ; Ghassabian, S; Gillani, TB; Murray, M; Rawling, T | 1 |
Bärtschi, D; Berger, MD; Bodoky, G; Hayoz, S; Izzo, P; Klingbiel, D; Koeberle, D; Meier, UR; Plasswilm, L; Rauch, D; Roth, A; Saletti, P; Samaras, P; Schacher, S; von Moos, R; Winterhalder, RC; Yan, P; Zaugg, K; Zwahlen, D | 1 |
Jain, A; Katare, OP; Khurana, RK; Sharma, T; Singh, B | 1 |
Fan, XG; Fu, Y; Hu, X; Huang, Y; Li, N; Quan, J; Sun, L; Xiao, Y; Zhou, P; Zhou, R | 1 |
Barbera, MA; Bernardi, M; Brandi, G; Casadei Gardini, A; De Lorenzo, S; Di Costanzo, GG; Foschi, FG; Garuti, F; Granito, A; Inghilesi, AL; Marra, F; Sacco, R; Tortora, R; Tovoli, F; Trevisani, F | 1 |
Kitazawa, M; Kobayashi, A; Matsumura, T; Miyagawa, SI; Motoyama, H; Notake, T; Shimizu, A; Takeoka, M; Yokoi, K; Yokoyama, T | 1 |
Arizumi, T; Kudo, M | 1 |
Ando, M; Deguchi, A; Kokudo, Y; Kubo, A; Kudo, M; Masaki, T; Matsunaka, T; Minami, Y; Morishita, A; Morita, M; Moriya, A; Nagano, T; Nishida, N; Noda, T; Ogawa, C; Omura, A; Sakurai, T; Senoh, T; Shibatoge, M; Takaguchi, K; Tamaki, H; Tani, J; Tsutsui, A; Ueshima, K; Yoneyama, H | 1 |
Arai, K; Asahina, Y; Hara, Y; Hayashi, T; Honda, M; Kaneko, S; Mizukoshi, E; Nio, K; Okada, H; Sakai, Y; Suda, T; Sunagozaka, H; Takatori, H; Terashima, T; Yamashita, T | 1 |
Bosserhoff, AK; Dietrich, P; Fritz, V; Hartmann, A; Hellerbrand, C; Koch, A | 1 |
García-Alemán, J; Mancha-Doblas, I; Molina-Vega, M; Sebastián-Ochoa, A; Tinahones-Madueño, F; Trigo-Pérez, JM | 1 |
Arakawa, Y; Bando, Y; Ikemoto, T; Imura, S; Ishikawa, D; Iwahashi, S; Morine, Y; Saito, YU; Shimada, M; Takasu, C; Teraoku, H; Yoshimoto, T | 1 |
Matsumura, T; Matsushima, H; Ryu, T; Saitsu, H; Takami, Y; Tateishi, M; Wada, Y; Yoshitomi, M | 1 |
Cheng, IG; Hespel, L; Kato, K; Kobayashi, M; Lee, E; Matsunaga, YT; Nakajima, H; Pauty, J; Soncin, F; Takahashi, H; Usuba, R; Yger, F | 1 |
He, J; Jia, B; Yan, J; Yang, J | 1 |
Dworacki, G; Jaskula, E; Lange, A; Lange, J; Mordak-Domagala, M; Nowak, D; Sedzimirska, M; Simiczyjew, A | 1 |
Ai, S; Fu, H; Pan, T; Tang, L; Wang, F; Zhang, J | 1 |
Abe, S; Fujisawa, K; Furutani-Seiki, M; Goto, R; Inoue, R; Kamimura, K; Koyama, N; Nagoya, T; Nishina, H; Nozawa, Y; Ogawa, K; Sakai, N; Sakaida, I; Sakamaki, A; Shinagawa-Kobayashi, Y; Sugitani, S; Terai, S; Yanagi, M; Yokoo, T | 1 |
Abegg, VF; Bouitbir, J; Grünig, D; Krähenbühl, S; Mingard, C; Paech, F | 1 |
Broggini, M; Caiola, E; Frapolli, R; Garassino, MC; Iezzi, A; Marabese, M; Tomanelli, M; Valerio, R | 1 |
Benoukraf, T; Chow, EK; Fong, ELS; Hooi, L; Huynh, TH; Lin, QXX; Liu, Z; Mohd Abdul Rashid, MB; Toh, TB; Yu, H | 1 |
D'Addeo, K; Kaplan, DE; Mehta, R; Taddei, TH; Valderrama, A | 1 |
Cao, S; Cao, Y; Chai, Y; Feng, F; Jiang, Q; Li, BA; Li, R; Li, X; Liang, E; Liu, G; Shen, L; Sun, H; Sun, L; Wang, T; Xin, S; Yang, R; Yang, Y; Yang, Z; Zhu, H | 1 |
Chen, X; Guo, J; Lin, Z; Liu, L; Qu, Y; Wang, J; Wang, Z; Xiong, Y; Xu, J; Yang, Y | 1 |
Cheng, Y; Wang, B; Xu, J; Xu, W; Zheng, H; Zhu, Y | 1 |
Antoniewicz, MR; Au, J; DeWaal, D; Guzman, G; Hay, N; Jeon, SM; Long, CP; Nogueira, V; Patra, KC; Terry, AR | 1 |
Chen, M; Chen, S; Jiang, C; Kuang, M; Li, B; Li, J; Lin, M; Mei, J; Peng, Z; Qian, G; Wang, Y; Wei, M; Xie, X | 1 |
Cai, MY; Chen, BH; Guo, YJ; Huang, JJ; Huang, WS; Meng, XC; Zhou, JW; Zhu, KS | 1 |
Hasegawa, K; Kokudo, N; Kokudo, T | 1 |
Finn, RS; Llovet, JM | 1 |
Campillo-Gimenez, B; Edeline, J; Garin, E; Rolland, Y | 1 |
Chatellier, G; Dinut, A; Pereira, H; Vilgrain, V | 1 |
An, G; Bae, S; D'Cunha, R; Shao, J | 1 |
Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kimura, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nagata, Y; Nakahara, T; Nishida, Y; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S | 1 |
Baron, A; Blanc, JF; Cheng, AL; Dutcus, C; Evans, TRJ; Finn, RS; Guo, M; Han, G; Han, KH; Ikeda, K; Jassem, J; Komov, D; Kraljevic, S; Kudo, M; Lopez, C; Park, JW; Piscaglia, F; Qin, S; Ren, M; Saito, K; Tamai, T; Vogel, A | 1 |
Dong, X; Li, L; Li, Z; Lu, H; Shi, X; Sun, P; Yu, X; Zhong, J; Zhou, W | 1 |
Aramaki, T; Asagi, A; Furuse, J; Hosokawa, A; Ikeda, M; Ishii, H; Kaneko, S; Kato, N; Okusaka, T; Sano, K; Sato, T; Sugimoto, R; Suzuki, E; Yamaguchi, K; Yasui, K | 1 |
D'Addeo, K; Gade, TP; Kaplan, DE; Mehta, R; Taddei, TH | 1 |
Golinelli, G; Pia, F; Rosa, MS; Toso, A; Valletti, PA | 1 |
Bie, P; Chen, X; Chen, Y; Deng, X; Dou, K; Fu, Z; Hao, C; Liu, F; Liu, L; Liu, Y; Lv, Z; Nakajima, K; Shao, G; Xia, Q; Yang, J; Ye, SL; Yuan, Y; Zhang, S; Zhou, J | 1 |
Chen, ZH; Cheng, SQ; Guo, WX; Wang, K; Zhang, XP | 1 |
Dore, GJ; Gomaa, A; Waked, I; Waziry, R | 1 |
Jiang, W; Li, L; Lian, ZX; Liu, QZ; Long, J; Wang, YC; Yan, K; Yang, JB; Zhao, YY; Zhao, ZB | 1 |
Jian, W; Li, C; Sun, X; Xie, F; Zhang, K | 1 |
Meyer, T | 1 |
Ali, S; Khan, MA; Ovais, M; Raza, A; Sohail, MF; Venkatraman, SS | 1 |
Cho, EJ; Cho, YY; Kim, HY; Kim, YJ; Lee, DH; Lee, JH; Yoon, JH; Yu, SJ | 1 |
Carlisle, B; Federico, CA; Kimmelman, J | 1 |
Agazzi, R; Colledan, M; Conte, G; De Giorgio, M; Fagiuoli, S; Iegri, C; Lucà, MG; Nani, R; Nicora, C; Pinelli, D; Sala, F; Sarti, D; Schranz, M; Sironi, S; Virotta, G | 1 |
Costentin, C; Durot, C; Hoeffel, C; Luciani, A; Mulé, S; Rahmouni, A; Thiefin, G | 1 |
Chen, CW; Hsu, FT; Kuo, YC; Pan, PJ; Tsai, JJ | 1 |
Almeida-Carvalho, SR; D'Ippolito, G; Loureiro-Matos, CA; Miziara-Gonzalez, A; Pereira-Lanzoni, V; Salzedas-Netto, AA; Souza-Silva, I; Szejnfeld, D; Tannus, RK | 1 |
Chi, H; Meng, Z; Wang, H; Zhang, C | 2 |
Andreone, A; Badea, RI; Benevento, F; Brocchi, S; Ferrarini, A; Golfieri, R; Mastroroberto, M; Morselli-Labate, AM; Negrini, G; Piscaglia, F; Renzulli, M; Tovoli, F | 1 |
Aikata, H; Aisaka, Y; Chayama, K; Hatooka, M; Hiramatsu, A; Honda, Y; Hyogo, H; Imamura, M; Inagaki, Y; Kawakami, Y; Kawaoka, T; Kodama, K; Kohno, H; Masaki, K; Mori, N; Morio, K; Moriya, T; Murakami, E; Nakahara, T; Nonaka, M; Takaki, S; Tsuge, M; Tsuji, K; Uchikawa, S | 1 |
Han, HK; Kim, HY; Lee, SH; Song, JG; Zhao, M | 1 |
Cao, YW; Dong, Z; Guo, L; Kang, EH; Liu, Y; Niu, HT; Wang, YH; Zhang, W | 1 |
Akhtar, S; Arif, JM; Jamal, QMS; Kamal, MA; Khan, MKA; Sayeed, U; Shakeel, E; Sharma, M; Sharma, N; Siddiqui, MH | 1 |
Asabe, S; Asano, T; Mashima, H; Matsuura, K; Tsuboi, R | 1 |
Cai, M; Chen, J; Guo, Y; Huang, J; Huang, W; Lai, L; Zhou, J; Zhu, K | 1 |
Cai, L; Luo, L; Meng, X; Tang, Z | 1 |
Bamodu, OA; Chang, HL; Chen, HA; Lee, KF; Lee, WH; Tsai, JT; Tzeng, YM | 1 |
Kang, MK; Lee, HJ; Park, JG | 1 |
Chuang, PH; Ho, JC; Hsieh, ML; Hsieh, VC | 1 |
Asha, VV; Isaac, R; Jiji, SG; Philip, S; Praseetha, PK; Tom, G | 1 |
Anderton, K; Anis, M; Baron, A; Bendell, J; Bentz, T; Brisendine, A; Duddalwar, V; Edwards, A; El-Khoueiry, A; Garrett-Mayer, E; Siegel, AB; Thomas, MB; Weiss, G | 1 |
Fan, ZP; Huang, F; Liu, QF; Sun, J; Wang, ZX; Xu, N; Xuan, L; Ye, JY; Zhang, Y; Zhou, X | 1 |
Borok, J; Friedlander, SF; Han, AM; Kusari, A; Valderrama, AJ | 1 |
Chen, D; Chen, X; Chen, Y; Cui, T; Kabir, N; Ma, J; Mao, J; Pan, P; Yang, H; Yang, Y | 1 |
Edeline, J; Finn, RS; Galle, PR; Kudo, M; Raoul, JL; Reig, M | 1 |
Bonani, FA; Camargo, RY; Castro, G; Coura-Filho, GB; Danilovic, DLS; Freitas, RMC; Hoff, AO; Kulcsar, MA; Marui, S; Roitberg, FSR; Vanderlei, FAB | 1 |
Bettinger, D; Fichtner-Feigl, S; Schultheiß, M; Thimme, R | 1 |
An, L; Chen, L; Dai, Z; Feng, Y; Gan, H; Gong, C; Haydon, RC; He, F; He, TC; Huang, B; Huang, S; Ji, X; Lei, J; Liu, B; Liu, F; Liu, W; Luu, HH; Shu, Y; Wang, X; Wu, K; Wu, X; Wu, Y; Yan, S; Yang, C; Yu, X; Yuan, C; Zeng, L; Zeng, Z; Zhang, B; Zhang, L; Zhang, R; Zhang, W; Zhao, C | 1 |
Choi, GH; Jang, SJ; Jung, Y; Kim, JS; Kim, KM; Lee, HC; Yu, ES | 1 |
Abdelghany, RH; El-Ahwany, E; Goda, R; Helal, NS; Mahmoud, AAA; Saber, S | 1 |
Cai, W; Chen, YH; Dong, BJ; Huang, JW; Huang, YR; Kong, W; Li, MY; Xue, W; Yuan, YC; Zhang, J; Zhou, LX | 1 |
Huang, K; Liu, CH; Liu, HL; Lü, J; Sun, X; Tao, YY; Zhao, ZM | 1 |
Abaza, MSI; Al-Attiyah, RJ; Bahman, AA; Khoushiash, SI | 1 |
Cai, S; Chen, L; Jiang, Z; Li, A; Liang, Y; Liu, X; Ma, D; Tang, X; Zhang, Y | 1 |
Duo, J; Ma, X; Zhao, Y; Zhu, H | 1 |
Abo, D; Inaba, Y; Kodama, Y; Matsuo, K; Nakatsuka, A; Nishiofuku, H; Okubo, H; Sato, Y; Takaki, H; Yamakado, K; Yasumoto, T | 1 |
Chen, Y; Dong, H; Liu, X; Ma, Z; Wang, L; Xia, D; Xiong, Y | 1 |
Fang, Z; Han, B; Hong, SS; Jung, KH; Kang, YW; Kim, SJ; Lee, JE; Lim, JH; Park, JH; Rumman, M; Yan, HH | 1 |
Abraham, IE; Dudek, AZ; Liu, LI; Schmidt, TM; Uy, AB | 1 |
Chen, LJ; Li, BT; Mai, HX; Mei, GH; Tang, YY; Xu, XJ; Zhang, B; Zhao, FL | 1 |
Chen, XY; Dai, XJ; Lü, BH; Wang, J; Zhang, YF; Zhong, DF | 1 |
Álvares-da-Silva, MR; de Freitas, LBR; Grivicich, I; Longo, L; Santos, D | 1 |
Gu, C; Huang, Y; Liu, S; Mai, W; Nie, Y; Wang, K; Yang, H; Yu, G; Zhao, D; Zhong, Y | 1 |
Hirai, S; Kakinoki, N; Kamoshida, T; Ochi, M; Ohkawara, A; Ohkawara, H; Yanaka, A | 1 |
Cheng, B; Du, J; Fan, Y; Li, J; Li, X; Lin, W; Ling, C; Liu, D | 1 |
Hikasa, Y; Leong, ZP | 1 |
Fujita, M; Kuroda, T; Mukai, M; Nakai, Y; Nishimura, K; Oka, T; Shioyama, W; Takada, M; Yasui, T | 1 |
Hu, J; Li, L; Liu, L; Wang, E; Wang, M; Zhao, W; Zhao, Y | 1 |
Fuss, H; Jung, S; Lademann, J | 1 |
Chen, J; Chen, RX; Cui, JF; Gao, DM; Lin, XH; Liu, HH; Ma, M; Ren, ZG; Zhang, R | 1 |
Ikeda, M; Kaneko, S; Kobayashi, M; Tahara, M | 1 |
Cho, E; Cho, SB; Choi, SK; Jun, CH; Kim, DH; Kim, S; Koh, YI; Sim, DW; Yu, J | 1 |
Egawa, C; Inatome, J; Kagawa, Y; Katsura, Y; Kawai, K; Masuzawa, T; Mori, R; Murakami, K; Murata, K; Naito, A; Nose, Y; Ohmura, Y; Sakamoto, T; Takeda, Y; Takeno, A | 1 |
Beraza, N; Musso, O | 1 |
Altavilla, A; Attademo, L; De Giorgi, U; De Lisi, D; Pignata, S; Procopio, G; Santini, D; Verzoni, E | 1 |
Dehua, WU; Xiaohui, C; Xin, LI | 1 |
Baer, MR; Dezern, A; Duong, VH; Emadi, A; Gocke, C; Gojo, I; Greer, J; Jones, RJ; Karp, J; Levis, M; Pratz, KW; Rosner, G; Rudek, MA; Smith, BD; Wright, JJ; Zahurak, M | 1 |
Achterbergh, R; Klümpen, HJ; Labeur, TA; Mathôt, R; Takkenberg, B; Van Delden, O | 1 |
Ahmed, AR; Alaaeldin, E; Allam, S; Elsadek, BE; Elsayed, MM; Mostafa, ME; Sarhan, HA; Shaykoon, MS | 1 |
Abballe, L; Allegri, L; Bulotta, S; Celano, M; Damante, G; Maggisano, V; Pecce, V; Russo, D | 1 |
Li, JX; Liang, GL; Liu, X; Tang, ST; Xiang, BD | 1 |
Bruix, J; Reig, M; Sanduzzi-Zamparelli, M; Sapena, V | 1 |
Berhane, S; Johnson, PJ; Labeur, TA | 1 |
Chen, J; Duda, DG | 1 |
Aballay Soteras, G; Alvares-da-Silva, MR; Alves, R; Anders, M; Arenas, JI; Bruix, J; Chagas, AL; Coll, S; da Fonseca, LG; Delgado, M; Di Costanzo, GG; Díaz-González, Á; França, A; Gallego, A; García Juárez, I; Giannini, EG; Granito, A; Hernáez, T; Hernández-Guerra, M; Huertas, C; Iavarone, M; Ladekarl, M; Leal, C; Lledó, JL; Lozano, M; Lue, A; Marín, J; Matilla, AM; Mello, V; Menéndez, J; Mínguez, B; Nault, JC; Pascual, S; Pereira, G; Perelló, C; Piñero, F; Pinter, M; Reig, M; Rimassa, L; Rodríguez de Lope, C; Rojas, Á; Sacco, R; Sala, M; Sánchez-Torrijos, Y; Sanduzzi-Zamparelli, M; Sangro, B; Varela, M; Vergara, M; Wörns, MA | 1 |
Chao, Y; Chen, BB; Cheng, AL; Hsu, C; Hsu, CH; Huang, PH; Hung, YP; Lee, RC; Lin, ZZ; Shao, YY; Shen, YC | 1 |
Ananth, S; Arora, SP; Gelfond, J; Ketchum, N; Mahalingam, D; Michalek, J | 1 |
Cao, J; Chen, X; Du, J; He, Q; Luo, P; Ma, S; Xu, Z; Yan, H; Yang, B; Zeng, S; Zhang, X; Zhang, Y; Zhao, Z; Zhu, Y | 1 |
Hopkins, AM; Rowland, A; Ruanglertboon, W; Sorich, MJ | 1 |
Adachi, T; Aibiki, T; Hiraoka, A; Iwasaki, R; Izumoto, H; Michitaka, K; Miyata, H; Mori, K; Nagamatsu, K; Ninomiya, T; Okazaki, H; Okudaira, T; Suga, Y; Tsubouchi, E; Tsuruta, M; Yamago, H; Yoshino, T | 1 |
Fletcher, P; Kunene, V; Ma, YT; Razak, RA | 1 |
Ayuso, C; Belmonte, E; Bruix, J; Darnell, A; Díaz, A; Díaz-González, Á; Feu, F; Forner, A; Gomes da Fonseca, L; Iserte, G; Llarch, N; Reig, M; Rimola, J; Sanduzzi-Zamparelli, M; Sapena, V | 1 |
Abou-Alfa, GK; Boussayoud, C; Capanu, M; Chou, JF; Do, GK; El Dika, I; Ferrer, CS; Harding, JJ; Iyer, R; Kelley, RK; Khalil, DN; Kuhn, P; Muenkel, K; Rodriguez-Lee, M; Ruiz, C; Shia, J; Tan, B; Wilton, J; Yarmohammadi, H | 1 |
Cao, B; Chen, DT; Kim, DW; Kim, R; Machado, C; Mahipal, A; Masawi, F; Tan, E; Wang, E; Yu, J | 1 |
Aby, ES; Bane, A; Debes, JD; Sultan, A; Wondifraw, Z | 1 |
Cheng, Z; Guo, Y; He, L; Song, S; Song, Y; Zhang, L | 1 |
Deng, Y; Dong, L; Li, Y; Liu, J; Liu, TT; Shen, XZ; Sun, Y; Weng, SQ; Yu, XN; Zhang, GC; Zhu, CF; Zhu, JM | 1 |
Ayuso, C; Belmonte, E; Boix, L; Bruix, J; Brunet, M; Corominas, J; da Fonseca, LG; Darnell, A; Díaz-González, Á; Forner, A; Iserte, G; LLarch, N; Millán, O; Reig, M; Samper, E; Sanduzzi-Zamparelli, M; Sapena, V; Torres, F | 1 |
Hendrikse, NH; Hoekstra, OS; Honeywell, RJ; Lammertsma, AA; Mammatas, LH; Meijerink, M; Menke-van der Houven van Oordt, CW; Peters, GJ; Schuit, RC; Schwarte, LA; Verheul, HMW; Yaqub, M | 1 |
Carvalhana, S; Cortez-Pinto, H; Freitas, LC; Gaio, R; Marinho, RT; Moura, M; Nogueira, PJ; Reis, D | 1 |
Bottomly, D; Damnernsawad, A; Eide, CA; Kurtz, SE; McWeeney, SK; Nechiporuk, T; Tyner, JW | 1 |
Abdelghani, MB; Audemar, F; Blanc, JF; Bourgeois, V; Bronowicki, JP; Costentin, C; Deplanque, G; Edeline, J; Faroux, R; Khemissa, F; Locher, C; Mabile-Archambeaud, I; Manfredi, S; Monterymard, C; Obled, S; Perarnau, JM; Seitz, JF; Senellart, H; Villing, AL | 1 |
Colmenero, I; Hernández-Martín, Á; Martos-Cabrera, L; Mateos-Mayo, A; Ramírez-Lluch, M; Torrelo, A | 1 |
Braghiroli, MI; da Fonseca, LG; Hoff, PM; Marta, GN; Moura, F; Sabbaga, J | 1 |
Álvarez-Navascués, C; Álvarez-Velasco, R; Cadahía, V; Carballo-Folgoso, L; Castaño-García, A; Cuevas, J; González-Diéguez, ML; Lorca, R; Martín, M; Morís, C; Rodríguez, M; Varela, M | 1 |
Kim, SH; Lee, HJ; Park, SC; Shin, NR; Son, Y | 1 |
Huang, S; Li, D; Sun, L; Wu, J; Zhuang, L | 1 |
Abrams, TA; Ahmed, M; Alsop, DC; Bockorny, B; Bullock, AJ; Faintuch, S; Goldberg, SN; Miksad, RA | 1 |
Farias, EC; Hoff, AO | 1 |
Araki, M; Ikegami, T; Kamoshida, T; Ochi, M | 1 |
Abbas, MN; Kichenadasse, G; Tan, WS | 1 |
Hu, SH; Lien, RY; Lu, LC; Lu, SF; Tung, HH; Wu, SL | 1 |
Guan, XY; Li, GB; Ma, X; Song, C; Wang, HL; Yang, LL; Yu, YM | 1 |
Chang, ML; Chen, WT; Lee, WC; Lin, CC; Lin, CL; Lin, SM; Shen, CH; Wu, TJ; Yeh, CT | 1 |
Aldrighetti, L; Antonucci, A; Baiocchi, GL; Baroni, GS; Bernasconi, DP; Biasini, E; Campani, C; Celsa, C; Chiarelli, M; Cipriani, F; Crespi, M; Donadon, M; Famularo, S; Ferrero, A; Ferri, S; Foschi, FG; Gasbarrini, A; Giuliante, F; Grazi, GL; Griseri, G; Jovine, E; Maestri, M; Mega, A; Memeo, R; Morisco, F; Pelizzaro, F; Raimondo, G; Rapaccini, GL; Romano, F; Ruzzenente, A; Sacco, R; Torzilli, G; Trevisani, F; Valle, RD | 1 |
Ford, CN; Johns, MS; Lee, WM; Merritt, WT; Petrelli, NJ; Rhodes, L; Sheldon, Y; Thompson, M; Tiesi, GJ | 1 |
Bai, M; Gong, S; Guo, T; Hao, X; Lei, C; Li, X; Si, M; Song, S; Tian, H; Yang, W | 1 |
Habiba, YH; Helmy, MW; Houssen, ME; Omran, GA | 1 |
Ankathi, SK; Banavali, SD; Bhargava, PG; Daddi, A; Goel, M; Gota, V; Jadhav, S; Mandavkar, S; Nashikkar, C; Naughane, D; Ostwal, V; Patkar, S; Ramaswamy, A; Shetty, N; Shriyan, B; Srinivas, S | 1 |
Maeda, S; Momoi, Y; Yokota, S; Yonezawa, T | 1 |
Imai, T; Kaneko, S; Okayama, Y; Oya, M; Sunaya, T; Tsujino, T | 1 |
Claxton, L; Eastwood, A; Hodgson, R; Sharif-Hurst, S; Wade, R; Walton, M | 1 |
Chapin, WJ; Hwang, WT; Kaplan, DE; Karasic, TB; McCarthy, AM | 1 |
Deng, WX; Huang, ST; Li, JX; Li, LQ; Liang, CF; Liang, SX; Lin, XF; Long, MY; Lu, HY; Pang, YD; Su, TS; Xiang, BD; Zhang, J; Zhou, HM | 1 |
Alunni-Fabbroni, M; Benckert, J; Chow, PKH; Gasbarrini, A; Kuhl, C; Malfertheiner, P; Öcal, E; Pech, M; Ricke, J; Sangro, B; Schinner, R; Shuen, TWH; Toh, HC; Wildgruber, M | 1 |
Fang, S; Li, X; Liu, G; Ma, Y; Yang, J; Yang, X; Zhao, B | 1 |
Kuppusamy, P; Nagalingam, A; Saxena, NK; Sharma, D; Siddharth, S; Wu, Q | 1 |
Aydin, S; Brunello, L; Busca, A; Cattel, F; Dellacasa, CM; Dogliotti, I; Giaccone, L; Passera, R; Poggiu, M; Scaldaferri, M; Zallio, F | 1 |
Guo, F; Jin, X; Meng, J; Ren, D; Sun, Y; Wu, H; Zhang, H | 1 |
Li, J; Tan, XP; Wang, SL; Xiong, BH; Zhang, YX; Zuo, Q | 1 |
Chai, MY; Chen, DX; Dou, SS; Fu, Z; Kou, BX; Liu, XN; Wei, FL | 1 |
Chen, CT; Cheng, AL; Hsu, CH; Shao, YY | 1 |
Chang, SY; Chen, YC; Hsu, CS; Peng, TR; Wu, CC; Wu, TW | 1 |
Atkins, MB; Escudier, B; Hutson, TE; Kasturi, V; McDermott, DF; Pal, SK; Porta, C; Rini, B; Verzoni, E; Zengin, ZB | 1 |
Aboulwafa, MM; Helmy, OM; Taha, AM; Zedan, H | 1 |
Cheon, C; Kim, B; Kim, DB; Lee, DK; Ribeiro, RIMA | 1 |
Chen, PH; Dai, HQ; Feng, J; Hooi, SC; Liao, XW; Lu, G; Lu, GD; Lu, PZ; Peng, T; Shen, HM; Su, WJ; Wang, LM; Wu, Y; Ye, XP; Zhou, J; Zhu, GZ | 1 |
Abbadessa, G; Decaens, T; Kurma, K; Lerat, H; Macek Jilkova, Z; Marche, PN; Mercey-Ressejac, M; Roth, GS; Sturm, N; Yu, Y; Zeybek Kuyucu, A | 1 |
Chen, MY; Gong, JX; Hsu, CH; Setiawan, SA; Tzeng, DTW; Tzeng, YM; Weng, PW; Wu, ATH; Yadav, VK; Yang, Z; Yeh, CT | 1 |
Chen, Y; He, K; Liu, X; Song, W; Wang, S; Yang, Y; Yang, Z | 1 |
Chen, LW; Chien, CH; Chien, RN; Hu, CC; Liang, KH; Lin, CL; Lin, YH; Yeh, CT | 1 |
Ai, H; Chen, L; Ji, X; Mi, RH; Song, YP; Wei, XD; Yin, QS | 1 |
Gudkov, SV; Khabatova, VV; Turovsky, EA; Varlamova, EG | 1 |
Augu-Denechere, D; Bonnin, N; Calattini, S; Colomban, O; Fontaine, J; Freyer, G; Guitton, J; Lopez, J; Maillet, D; Payen, L; Peron, J; Puszkiel, A; Schwiertz, V; Tartas, S; Tod, M; Varnier, R; You, B | 1 |
Augu-Denechere, D; Bonnin, N; Colomban, O; Fontaine, J; Freyer, G; Guitton, J; Lopez, J; Maillet, D; Payen, L; Péron, J; Puszkiel, A; Rousset, P; Tartas, S; Tod, M; Trillet-Lenoir, V; You, B | 1 |
Aisner, J; Cerchio, R; Chan, N; Chen, S; Ganesan, S; Goodin, S; Gounder, M; Li, J; Lin, H; Malhotra, J; Marinaro, C; Mehnert, JM; Portal, DE; Shih, W; Silk, AW; Spencer, KR; Stein, MN | 1 |
Barwad, A; Dhamija, E; Gamangatti, S; Gangadharaiah, BB; Garg, V; Rastogi, S; Upadhyay, A | 1 |
Bi, QC; Deng, ZQ; He, YQ; Liu, Y; Lv, YF; Tang, Q; Xie, CS | 1 |
Liang, B; Lu, H; Xia, X; Zheng, C | 1 |
Reviews
686 review(s) available for niacinamide and sorafenib
Article | Year |
---|---|
BAY 43-9006: early clinical data in patients with advanced solid malignancies.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2002 |
BAY 43-9006: preclinical data.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Disease Progression; Humans; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2002 |
Targeting intracellular signal transduction. A new paradigm for a brave new world of molecularly targeted therapeutics.
Topics: Adult; Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Child; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Molecular Structure; Neoplasm Proteins; Neoplasms; Niacinamide; Oligodeoxyribonucleotides, Antisense; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Thionucleotides; Xenograft Model Antitumor Assays | 2002 |
Activity of the Raf kinase inhibitor BAY 43-9006 in patients with advanced solid tumors.
Topics: Benzenesulfonates; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2003 |
BAY-43-9006 Bayer/Onyx.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Drugs, Investigational; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Technology, Pharmaceutical | 2003 |
Raf pathway inhibitors in oncology.
Topics: Animals; Benzenesulfonates; Enzyme Inhibitors; Humans; MAP Kinase Signaling System; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib | 2003 |
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Mutation; Niacinamide; Oncogenes; Phenylurea Compounds; Phosphotransferases; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Neoplasms | 2004 |
Raf kinase inhibitors in oncology.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Drug Delivery Systems; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Sorafenib | 2005 |
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2005 |
Raf kinase as a target for anticancer therapeutics.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Humans; Membrane Proteins; Models, Biological; Neovascularization, Pathologic; Niacinamide; Oligonucleotides, Antisense; Phenylurea Compounds; Phosphorylation; Protein Structure, Tertiary; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2005 |
Angiogenesis and lung cancer: prognostic and therapeutic implications.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Lung; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2005 |
Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery.
Topics: Animals; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Diphenylamine; Extracellular Signal-Regulated MAP Kinases; Humans; Molecular Structure; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib | 2005 |
Cutaneous side-effects of kinase inhibitors and blocking antibodies.
Topics: Antibodies, Blocking; Antineoplastic Agents; Benzamides; Benzenesulfonates; ErbB Receptors; Hair Diseases; Humans; Imatinib Mesylate; Nail Diseases; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Skin Diseases; Sorafenib | 2005 |
Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2005 |
Promising systemic therapy for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Administration Schedule; Epothilones; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2005 |
Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: novel agents with potential in lung cancer.
Topics: Benzenesulfonates; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2005 |
Novel agents for the treatment of advanced kidney cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Epothilones; Gefitinib; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2004 |
Raf: a strategic target for therapeutic development against cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Down-Regulation; Drug Delivery Systems; Humans; MAP Kinase Kinase 1; MAP Kinase Signaling System; Molecular Biology; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins A-raf; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; raf Kinases; Sensitivity and Specificity; Signal Transduction; Sorafenib | 2005 |
Update on angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2005 |
Regulation of c-Raf-1: therapeutic implications.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Screening Assays, Antitumor; Humans; Neoplasms; Niacinamide; Oligodeoxyribonucleotides, Antisense; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Thionucleotides | 2003 |
Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; ErbB Receptors; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyridines; Signal Transduction; Sorafenib; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2005 |
Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Eruptions; Exanthema; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2006 |
Targeted therapy for metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sorafenib | 2005 |
[Progress in therapeutic strategy for renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Female; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Minimally Invasive Surgical Procedures; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2006 |
Sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2006 |
VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; ErbB Receptors; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
What's new in pancreatic cancer treatment pipeline?
Topics: Adenoviridae; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cancer Vaccines; Cetuximab; Cyclic N-Oxides; Deoxycytidine; Drug Combinations; Gastrins; Gemcitabine; Humans; Niacinamide; Oxonic Acid; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Tegafur; Tumor Necrosis Factor-alpha | 2006 |
Multi-target inhibitors in non-small cell lung cancer (NSCLC).
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2006 |
Molecule of the month. Sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2006 |
Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Survival Rate; Treatment Outcome | 2006 |
Targeting Raf-kinase: molecular rationales and translational issues.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib | 2006 |
Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.
Topics: Antimetabolites, Antineoplastic; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Drug Delivery Systems; Endpoint Determination; Floxuridine; Fluorouracil; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk; Sorafenib; Survival Analysis; Treatment Outcome | 2006 |
Molecular targeting therapy for renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2006 |
Cancer targets in the Ras pathway.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Design; Female; Genes, ras; Humans; Male; Models, Biological; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; ras Proteins; Signal Transduction; Sorafenib | 2005 |
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Extracellular Signal-Regulated MAP Kinases; Melanoma; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Isoforms; Protein Kinase Inhibitors; Pyridines; raf Kinases; Signal Transduction; Sorafenib | 2006 |
Raf kinases: oncogenesis and drug discovery.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Disease Models, Animal; Enzyme Inhibitors; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Signal Transduction; Sorafenib | 2006 |
New treatment approaches in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2006 |
Multitargeted agents for therapeutically challenging tumor: an introduction for oncology nurses.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Drug Monitoring; Gastrointestinal Stromal Tumors; Humans; Indoles; Kidney Neoplasms; Niacinamide; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Education as Topic; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib | 2006 |
Sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2006 |
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Combinatorial Chemistry Techniques; Drug Design; Humans; Kidney Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2006 |
[Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].
Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Female; Gastrointestinal Diseases; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Molecular biology of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Exons; Humans; Indoles; Kidney Neoplasms; Molecular Biology; Mutation; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2006 |
Protein kinases as drug targets in cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Benzenesulfonates; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Trastuzumab | 2006 |
New weapons to snuff out kidney cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Targeted therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
Molecularly targeted therapy in renal cell carcinoma: where do we go from here?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Case Management; Clinical Trials as Topic; Combined Modality Therapy; Cytokines; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2006 |
Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Delivery Systems; Drug Therapy, Combination; Forecasting; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2006 |
Targeting von Hippel-Lindau pathway in renal cell carcinoma.
Topics: Benzenesulfonates; Biomedical Research; Carcinoma, Renal Cell; Enzyme Inhibitors; Everolimus; Humans; Indoles; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2006 |
Sorafenib for the treatment of advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Drug Evaluation; Humans; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; United States; United States Food and Drug Administration | 2006 |
Tyrosine kinase inhibitors compared with cytokine therapy for metastatic renal cell carcinoma: overview of recent clinical trials differentiating clinical response and adverse effects.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Improving outcomes with novel therapies for patients with newly diagnosed renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2006 |
Sorafenib in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Disease-Free Survival; Humans; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Research Design; Sorafenib; Time Factors | 2007 |
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Drug insight: VEGF as a therapeutic target for breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forecasting; Humans; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A | 2007 |
Sorafenib: in advanced renal cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Humans; Kidney Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sorafenib | 2007 |
[Clinical studies with sorafenib (Nexavar) in metastatic melanoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib; Treatment Outcome | 2007 |
[Efficacy of multikinase inhibitors in the treatment of advanced renal cell cancer. A snapshot].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Drug Approval; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Genetic basis of kidney cancer: a model for developing molecular-targeted therapies.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Leiomyomatosis; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; von Hippel-Lindau Disease | 2007 |
Combination of target agents: challenges and opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Drug Resistance, Neoplasm; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2007 |
Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition.
Topics: Adaptor Proteins, Signal Transducing; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Delivery Systems; Enzyme Inhibitors; Heart; Heart Diseases; Humans; Indoles; Lapatinib; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Trastuzumab | 2007 |
Angiogenesis in cancer: molecular mechanisms, clinical impact.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Indoles; Microcirculation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Humans; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib | 2007 |
Design of clinical trials of radiation combined with antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Combined Modality Therapy; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiation Dosage; raf Kinases; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sorafenib: delivering a targeted drug to the right targets.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Humans; Kidney Neoplasms; Liver Neoplasms; Melanoma; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib | 2007 |
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Thrombosis; Vascular Endothelial Growth Factor A; Wound Healing | 2007 |
[Clinical results of Nexavar for the treatment of kidney cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2007 |
Protein kinase inhibitors in the treatment of renal cell carcinoma: sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Drug Evaluation; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2007 |
CCR drug updates: sorafenib and sunitinib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
The effect of recent drug approvals on translational research and drug development.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomedical Research; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Approval; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; United States; United States Food and Drug Administration | 2007 |
The role of targeted therapy in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
B-Raf kinase inhibitors for cancer treatment.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Enzyme Inhibitors; Humans; Imidazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib | 2007 |
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1 | 2007 |
Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Growth Factor; Sorafenib; Sunitinib | 2007 |
[Effect of angiogenesis inhibitors on renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
[The hepatocellular carcinoma: alternative therapeutical strategies].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Genetic Therapy; Humans; Immunotherapy; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Time Factors | 2007 |
Treatment options in renal cell carcinoma: past, present and future.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cytokines; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2007 |
[Oral drugs inhibiting the VEGF pathway].
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Asthenia; Axitinib; Benzenesulfonates; Humans; Hypertension; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperidines; Proteinuria; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
[Angiogenesis and renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Hypertension; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Vascular Endothelial Growth Factors | 2007 |
[Cutaneous side effects of antiangiogenic agents].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Pyridines; Pyrroles; Skin Diseases; Sorafenib; Sunitinib | 2007 |
Managing side effects of angiogenesis inhibitors in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Safety and tolerability of sorafenib in clear-cell renal cell carcinoma: a Phase III overview.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
[Promising new treatment options for metastatic androgen-independent prostate cancer].
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Benzamides; Benzenesulfonates; Bevacizumab; Calcitriol; Cancer Vaccines; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Forecasting; Humans; Imatinib Mesylate; Male; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Pyrrolidines; Randomized Controlled Trials as Topic; Salvage Therapy; Sorafenib; Taxoids; Thionucleotides | 2007 |
Neoadjuvant therapy for hepatocellular carcinoma: is there an optimal approach?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Doxorubicin; Ethanol; Humans; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Indoles; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2007 |
Sorafenib: a promising new targeted therapy for renal cell carcinoma.
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Drug Delivery Systems; Drug Eruptions; Drug Interactions; Drug Monitoring; Fatigue; Humans; Hypertension; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Compliance; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Risk Factors; Social Support; Sorafenib; Survival Rate; Treatment Outcome | 2007 |
[Acute lymphoblastic leukemia with Philadelphia chromosome: treatment with kinase inhibitors].
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents; Benzamides; Benzenesulfonates; Dasatinib; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2007 |
[Angiogenesis targeting in renal carcinomas].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2007 |
New developments in multitargeted therapy for patients with solid tumours.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Dasatinib; Drug Delivery Systems; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2008 |
Safety and anti-tumor activity of sorafenib (Nexavar) in combination with other anti-cancer agents: a review of clinical trials.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Drug Interactions; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
[Renal cell carcinoma and antiangiogenic therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib | 2008 |
Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib | 2007 |
Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib.
Topics: Acneiform Eruptions; Antineoplastic Agents; Benzenesulfonates; Erythema; Esophagitis; Exanthema; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Sorafenib: in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Doxorubicin; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2008 |
Systematic review to establish the safety profiles for direct and indirect inhibitors of p38 Mitogen-activated protein kinases for treatment of cancer. A systematic review of the literature.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thalidomide | 2008 |
Risk of hand-foot skin reaction with sorafenib: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Eruptions; Foot; Hand; Humans; Incidence; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk Assessment; Risk Factors; Skin; Skin Diseases; Sorafenib | 2008 |
Incidence and risk of hypertension with sorafenib in patients with cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Incidence; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Risk; Sorafenib | 2008 |
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Disease Progression; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Mutation; Neoplasm Proteins; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Staurosporine; Sunitinib; Thiazoles | 2008 |
[Molecular targeted therapy for renal cell carcinoma].
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indoles; Interferon-beta; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Liposomes; Mitochondrial Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
FLT3 kinase inhibitors in the management of acute myeloid leukemia.
Topics: Benzenesulfonates; Carbazoles; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Furans; Humans; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib | 2007 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
Novel advancements in the management of hepatocellular carcinoma in 2008.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Ethanol; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Pharmacodynamic monitoring of molecular-targeted agents in the peripheral blood of leukemia patients using flow cytometry.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Drug Monitoring; Flow Cytometry; Gene Targeting; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
[Cutaneous side effects of sorafenib and sunitinib].
Topics: Acrodermatitis; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Hair Diseases; Humans; Indoles; Nail Diseases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib; Sunitinib | 2008 |
[Cutaneous side effects associated with epidermal growth factor receptor and tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2008 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
New therapeutic directions for advanced pancreatic cancer: targeting the epidermal growth factor and vascular endothelial growth factor pathways.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Benzenesulfonates; Bevacizumab; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2008 |
[Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Mcl-1: a gateway to TRAIL sensitization.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Down-Regulation; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand | 2008 |
Renal cell carcinoma.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Mutation; Niacinamide; Nomograms; Phenylurea Compounds; Prognosis; Pyridines; Sirolimus; Sorafenib; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2008 |
Treatment options for metastatic renal cell carcinoma: a review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Graft vs Host Disease; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
[Lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Combined Modality Therapy; Drugs, Investigational; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Pneumonectomy; Pyridines; Pyrroles; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2008 |
Early clinical studies of novel therapies for thyroid cancers.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2008 |
Targeted therapy in advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Sorafenib in lung cancer: clinical developments and future directions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Female; Follow-Up Studies; Forecasting; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factors | 2008 |
K-ras as a target for lung cancer therapy.
Topics: Benzamides; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drugs, Investigational; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sensitivity and Specificity; Sorafenib; Survival Analysis; Treatment Outcome | 2008 |
[Oncology 2008].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Combined Modality Therapy; Disease Progression; Epothilones; Humans; Lapatinib; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2008 |
Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials as Topic; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
[Value of targeted therapies for renal cell cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2008 |
Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Catheter Ablation; Diffusion of Innovation; Humans; Incidence; Indoles; Interferon-alpha; Interleukin-2; Molecular Biology; Neoplasm Staging; Nephrectomy; Niacinamide; Oncology Nursing; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Rare Diseases; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Science; Skin Neoplasms; Sorafenib; Treatment Outcome | 2008 |
An update on the medical therapy of advanced metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; raf Kinases; Severity of Illness Index; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Sorafenib (BAY 43-9006): review of clinical development.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Design; Drug Therapy, Combination; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib | 2006 |
Targeted therapy in renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
New therapies in renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Contemporary management of hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Hepatectomy; Humans; Iodine Radioisotopes; Iodized Oil; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Yttrium Radioisotopes | 2008 |
[Molecular basis of targeted therapy in metastatic renal cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2008 |
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Benzenesulfonates; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quality of Life; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2008 |
[Molecular targeted therapy for renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Gene Targeting; Humans; Indoles; Kidney Neoplasms; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Protein Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2008 |
Exploring the role of novel agents in the treatment of renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
Novel drugs for renal cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2008 |
Review article: pharmacological therapy for hepatocellular carcinoma with sorafenib and other oral agents.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Signal Transduction; Sorafenib; Survival Rate | 2008 |
Molecular targeted therapies in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Design; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib | 2008 |
Recent advances in the treatment of renal cell carcinoma and the role of targeted therapies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
Medical therapies to extend survival in hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Rate | 2008 |
Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recombinant Proteins; Sirolimus; Sorafenib; Sunitinib | 2008 |
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Humans; Imidazoles; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Xanthones | 2008 |
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.
Topics: Animals; Benzenesulfonates; Drug Screening Assays, Antitumor; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2008 |
Vascular complications of selected cancer therapies.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cisplatin; Fluorouracil; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Thrombosis; Vascular Diseases | 2008 |
Systemic therapy of hepatocellular carcinoma: are we making progress?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Estrogens; Humans; Injections, Intravenous; Interferons; Liver Neoplasms; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib; Tretinoin | 2008 |
Systemic therapy for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cytotoxins; Disease-Free Survival; Drug Therapy, Combination; Everolimus; Humans; Immunosuppressive Agents; Immunotherapy; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Stem Cell Transplantation; Sunitinib; TOR Serine-Threonine Kinases; Transplantation, Homologous | 2008 |
Molecular therapy for the treatment of hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Dermatologic symptoms associated with the multikinase inhibitor sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Diseases; Sorafenib | 2009 |
Evolution of systemic therapy of advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Immunologic Factors; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Somatostatin; Sorafenib; Thalidomide; Treatment Outcome | 2008 |
Potential role of sorafenib in the treatment of acute myeloid leukemia.
Topics: Benzenesulfonates; Drug Delivery Systems; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib | 2008 |
Management of advanced hepatocellular carcinoma in the era of targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Drug Delivery Systems; Epidermal Growth Factor; Humans; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pyridines; Signal Transduction; Sorafenib | 2009 |
Sorafenib for the treatment of unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Approval; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; United States; United States Food and Drug Administration | 2009 |
[Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Controlled Clinical Trials as Topic; Drug Delivery Systems; Humans; Liver Neoplasms; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Metastatic renal cell cancer treatments: an indirect comparison meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib | 2009 |
Multimodal approaches to the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Embolization, Therapeutic; Ethanol; Humans; Injections; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Preoperative Care; Pyridines; Radiotherapy, Adjuvant; Salvage Therapy; Sorafenib; Waiting Lists | 2009 |
New drugs for the treatment of hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; ErbB Receptors; Humans; Mitogen-Activated Protein Kinase 1; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Growth Factor; Signal Transduction; Sorafenib | 2009 |
Sorafenib: a review of its use in advanced hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Interactions; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Recent advances in the systemic treatment of metastatic papillary renal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Papillary; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2009 |
Recent advances in molecular targeted therapy for metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Epidemiology, screening, diagnosis and treatment of hepatocellular carcinoma.
Topics: Algorithms; alpha-Fetoproteins; Anti-Infective Agents, Local; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Drug Therapy, Combination; Embolization, Therapeutic; Ethanol; Evidence-Based Medicine; Global Health; Hepatectomy; Humans; Incidence; Liver Neoplasms; Liver Transplantation; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Population Surveillance; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib; Survival Rate; Texas; Treatment Outcome | 2009 |
Systemic treatment in hepatocellular carcinoma; 'A small step for man...'.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Response to sorafenib after sunitinib-induced acute heart failure in a patient with metastatic renal cell carcinoma: case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Case-Control Studies; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Therapy, Combination; Humans; Hypothyroidism; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Thyroid Function Tests; Treatment Outcome | 2009 |
PDGFRalpha: a new therapeutic target in the treatment of hepatocellular carcinoma?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Embryonic Development; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Transgenic; Neoplasm Proteins; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; Sorafenib | 2009 |
Targeting angiogenesis in bladder cancer.
Topics: Angiogenesis Inhibitors; Antibodies; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2009 |
Targeted therapies in metastatic renal cancer in 2009.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factors | 2009 |
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).
Topics: Benzenesulfonates; Biopsy, Needle; Humans; Isoquinolines; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Neoplasms | 2009 |
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2009 |
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Routes; Female; Hemorrhage; Humans; Hypertension; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Cardiac dysfunction induced by novel targeted anticancer therapy: an emerging issue.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Delivery Systems; Female; Heart; Heart Diseases; Heart Failure; Humans; Indoles; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Trastuzumab | 2009 |
Pathogenesis of hepatocellular carcinoma and molecular therapies.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Signal Transduction; Sorafenib | 2009 |
Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Selection of patients with hepatocellular carcinoma for sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2009 |
Prognostic markers and new, innovative treatments in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cancer Vaccines; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Renal toxicity of targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hypertension; Indoles; Kidney; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
[The treatment of hepatocellular carcinoma. New developments].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome | 2009 |
Sorafenib tosylate in advanced kidney cancer: past, present and future.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
BRAF signaling and targeted therapies in melanoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Drug Delivery Systems; Drugs, Investigational; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Humans; Melanoma; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2009 |
Angiogenesis regulated by VEGF and its receptors and its clinical application.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Design; Humans; Indoles; Neoplasms; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Management of sorafenib, sunitinib, and temsirolimus toxicity in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib | 2009 |
The role of antiangiogenesis therapy: bevacizumab and beyond.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Forecasting; Humans; Indoles; Neoadjuvant Therapy; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
[Sorafenib(Nexavar)].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
[Current advances in molecular targeted therapy of primary hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Adhesion; Cell Proliferation; Humans; Liver Neoplasms; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib | 2009 |
Current management of hepatocellular carcinoma.
Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease Progression; Hepatectomy; Hepatitis B; Hepatitis C; Humans; Liver; Liver Neoplasms; Liver Transplantation; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2009 |
Adverse effects of anticancer agents that target the VEGF pathway.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Brain Diseases; Capillary Leak Syndrome; Cardiovascular Diseases; Clinical Trials as Topic; Drug Delivery Systems; Drug Interactions; Forecasting; Gastrointestinal Diseases; Hemorrhage; Humans; Indoles; Kidney Diseases; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing | 2009 |
[Interferon alpha and half-dose sorafenib is an effective treatment modality for interferon alpha-resistant metastatic renal cell carcinoma: a case report].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
VEGF inhibitors and prostate cancer therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Humans; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Quinazolines; Signal Transduction; Sorafenib; Thalidomide; Vascular Endothelial Growth Factors | 2009 |
Sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Interactions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Quality of life in patients with metastatic renal cell carcinoma: the importance of patient-reported outcomes.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Health Status; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Patient Satisfaction; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
An overview of small-molecule inhibitors of VEGFR signaling.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cadherins; Clinical Trials, Phase III as Topic; Extracellular Matrix Proteins; Humans; Indoles; Integrins; Intercellular Signaling Peptides and Proteins; National Cancer Institute (U.S.); Neoplasms; Niacinamide; Peptide Hydrolases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Structure-Activity Relationship; Sunitinib; Transcription Factors; United States | 2009 |
Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Hemorrhage; Humans; Incidence; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Sorafenib; Sunitinib | 2009 |
Molecular targeting for treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2009 |
Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
It takes two to tango: combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor-vascular endothelial growth factor receptor pathway in patients with solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A | 2010 |
Medical treatments: in association or alone, their roles and their future perspectives: the Western experience.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; United States | 2010 |
[Molecular targeted drugs in the developmental stage: 2) Various molecular targets and therapeutic agents under investigation].
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Drug Resistance; ErbB Receptors; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Vascular Endothelial Growth Factors | 2009 |
Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Niacinamide; Paresthesia; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Syndrome | 2009 |
Review article: the management of hepatocellular carcinoma.
Topics: Ablation Techniques; Adult; Antineoplastic Agents; Asian People; Benzenesulfonates; Biopsy; Black People; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Drug Eruptions; Female; Health Care Costs; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Population Surveillance; Practice Guidelines as Topic; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Recurrence; Risk Factors; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome; United States; Young Adult | 2010 |
Tyrosine kinase inhibitors and the thyroid.
Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms | 2009 |
Metastatic renal cell carcinoma: current standards of care.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Management of vascular endothelial growth factor and multikinase inhibitor side effects.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Drug Eruptions; Drug Monitoring; Fatigue; Humans; Indoles; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Male; Niacinamide; Oncology Nursing; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2009 |
Sorafenib therapy for metastatic renal carcinoma in patients with low cardiac ejection fraction: report of two cases and literature review.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Heart Diseases; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stroke Volume | 2010 |
Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Diarrhea; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Syndrome; Treatment Outcome | 2010 |
[Bemusement and strategy on the efficacy of clinical application of targeted anticancer drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Deoxycytidine; Drug Delivery Systems; Gastrointestinal Stromal Tumors; Gemcitabine; Humans; Imatinib Mesylate; Indoles; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2009 |
Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Compounds in clinical Phase III and beyond.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Clinical Trials, Phase III as Topic; Endostatins; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2010 |
Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Diagnostic Techniques; Niacinamide; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Sorafenib | 2010 |
Maintenance therapy in acute myeloid leukemia revisited: will new agents rekindle an old interest?
Topics: Azacitidine; Benzenesulfonates; Decitabine; Enzyme Inhibitors; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Prenylation; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Staurosporine | 2010 |
Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now?
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Design; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2010 |
Toxicity of sorafenib: clinical and molecular aspects.
Topics: Animals; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Exanthema; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2010 |
Progress in the management of advanced renal cell carcinoma (RCC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Everolimus; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2010 |
Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Humans; MAP Kinase Signaling System; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Thyroid Neoplasms; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Targeted molecular therapies in thyroid carcinoma.
Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2009 |
Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Cardiovascular Diseases; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
[Current aspects of second-line and sequence therapy of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cytokines; Disease Progression; Drug Administration Schedule; Drug Delivery Systems; Drugs, Investigational; Everolimus; Evidence-Based Medicine; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2010 |
Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Chemotherapy, Adjuvant; Humans; Indoles; Neoadjuvant Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A; Wound Healing | 2010 |
Current strategy for staging and treatment: the BCLC update and future prospects.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Female; Forecasting; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Spain; Survival Analysis; Treatment Outcome | 2010 |
Update on systemic therapies of metastatic renal cell carcinoma.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biopsy, Needle; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Delivery Systems; Everolimus; Female; Follow-Up Studies; Humans; Immunohistochemistry; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sirolimus; Sorafenib; Sunitinib; Survival Analysis | 2010 |
[Use of sorafenib in patients with hepatocellular or renal carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Fatigue; Foot Dermatoses; Hand Dermatoses; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Raf inhibitors as therapeutic agents against neurodegenerative diseases.
Topics: Animals; Benzenesulfonates; Brain; Disease Models, Animal; Drug Design; Encephalitis; Humans; Inflammation Mediators; Neurodegenerative Diseases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib | 2010 |
Receptor tyrosine kinase inhibitors in rodent pulmonary hypertension.
Topics: Animals; Benzenesulfonates; Calmodulin-Binding Proteins; Gene Expression; Gene Expression Profiling; Hemodynamics; Humans; Hypertension, Pulmonary; Lung; Microarray Analysis; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib | 2010 |
[Chemotherapy].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2010 |
BRAF as therapeutic target in melanoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib | 2010 |
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
Topics: Administration, Oral; Aged; Angiogenesis Inhibitors; Arterial Occlusive Diseases; Benzenesulfonates; Humans; Incidence; Indoles; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thromboembolism | 2010 |
Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Drug Design; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Novel inhibitors in development for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Delivery Systems; Drug Design; Drugs, Investigational; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib | 2010 |
Antiangiogenesis agents in colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Molecular therapy of pancreatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Capecitabine; Carcinoma, Pancreatic Ductal; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Imidazoles; Indazoles; Neoplasm Invasiveness; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phthalazines; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Experience with sorafenib and adverse event management.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypertension; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib | 2011 |
[Treatment of locally advanced renal tumors].
Topics: Adrenalectomy; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Lymph Node Excision; Neoadjuvant Therapy; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2010 |
Systemic treatment of hepatocellular carcinoma: dawn of a new era?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2010 |
[Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Humans; Indoles; Kidney Neoplasms; Markov Chains; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sirolimus; Sorafenib; Sunitinib | 2010 |
Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Treatment of metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Interferons; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib | 2010 |
Clinical overview of sorafenib in breast cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Clinical Trials as Topic; Female; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib | 2010 |
The hand-foot-syndrome associated with medical tumor therapy - classification and management.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dermatologic Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Keratoderma, Palmoplantar; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
[Antiangionic drugs in soft tissue sarcoma].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Doxorubicin; Humans; Indazoles; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
[Focus on GIST management].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2010 |
In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Docetaxel; Drug Interactions; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Taxoids | 2010 |
[Hepatocellular carcinoma: occurrence, risk factors, biomarkers].
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Copper; Developed Countries; Developing Countries; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Incidence; Iron; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Biliary; Liver Neoplasms; Metabolic Diseases; Niacinamide; Phenylurea Compounds; Pyridines; Risk Factors; Smoking; Sorafenib | 2010 |
Hepatoid adenocarcinoma - review of the literature illustrated by a rare case originating in the peritoneal cavity.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Diagnosis, Differential; Humans; Magnetic Resonance Imaging; Male; Niacinamide; Peritoneal Neoplasms; Peritoneum; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Young Adult | 2010 |
Sorafenib for the treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Disease Progression; Humans; Liver Neoplasms; Models, Economic; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Sorafenib; Survival Analysis; Treatment Outcome; United Kingdom | 2010 |
[Anti-angiogenic drugs].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Hypoxia-Inducible Factor 1; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
[Current therapy for hepatocellular carcinoma].
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Embolization, Therapeutic; Hepatic Artery; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
The present and the future landscape of treatment of advanced hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Drug Design; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Analysis | 2010 |
Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cardiovascular Diseases; Female; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2010 |
Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Patient Selection; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2010 |
Sorafenib: where do we go from here?
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; TOR Serine-Threonine Kinases | 2010 |
Sorafenib: a clinical and pharmacologic review.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Child; Clinical Trials as Topic; Drug Approval; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; United States; United States Food and Drug Administration | 2010 |
Hepatocellular carcinoma--what's new?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Metabolic Syndrome; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sorafenib; Treatment Outcome | 2010 |
Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Topics: Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
Positioning and indication of sorafenib in the treatment algorithm and real practice setting: Western and eastern approach--Asian perspective.
Topics: Algorithms; Asia; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2010 |
[Cutaneous side effects of the multikinase inhibitors sorafenib and sunitinib].
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Drug Eruptions; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Structure-Activity Relationship; Sunitinib | 2010 |
Present state of target therapy for disseminated renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Tumor-stromal cell interactions and opportunities for therapeutic intervention.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Cell Communication; Endothelial Cells; Fibroblasts; Humans; Mesenchymal Stem Cells; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Stromal Cells | 2010 |
Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Does basal cell carcinoma belong to the spectrum of sorafenib-induced epithelial skin cancers?
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Female; Humans; Male; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib | 2010 |
Angiogenesis as a therapeutic target in urothelial carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Humans; Indoles; Matrix Metalloproteinases; Neoadjuvant Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Xenograft Model Antitumor Assays | 2010 |
[Nonsurgical management of hepatocellular carcinoma].
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Drug Delivery Systems; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Radiotherapy, Conformal; Sorafenib; Yttrium Radioisotopes | 2010 |
[Treatment of primary hepatocellular carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Internationality; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Population Surveillance; Pyridines; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib | 2010 |
Novel therapies for hypereosinophilic syndromes.
Topics: Adrenal Cortex Hormones; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bone Marrow Transplantation; CD52 Antigen; Glycoproteins; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Immunologic Factors; Interferon-alpha; Interleukin-5; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sorafenib | 2010 |
Evolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Delivery Systems; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
Sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Developing better treatments in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Research Design; Sorafenib; Treatment Outcome | 2010 |
[Multimodality treatment for hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Cooperative Behavior; Ethanol; Hepatectomy; Humans; Injections, Intralesional; Interdisciplinary Communication; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sorafenib; Survival Rate | 2010 |
[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Cell Cycle; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Epigenesis, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hepatectomy; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Wnt Proteins | 2010 |
[Hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
[Molecular targeted therapy for renal cell carcinoma and other urological cancers].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Urologic Neoplasms | 2010 |
Sorafenib: rays of hope in thyroid cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Disease-Free Survival; Drug Interactions; Humans; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroid Neoplasms | 2010 |
Inherited hepatocellular carcinoma.
Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Genetic Predisposition to Disease; Hemochromatosis; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Population Surveillance; Prognosis; Pyridines; Risk Factors; Severity of Illness Index; Sorafenib; Treatment Outcome; United States | 2010 |
Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis | 2010 |
[Hand-foot syndrome after administration of tyrosinkinase inhibitors].
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Syndrome | 2010 |
Antiangiogenic therapy for breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Female; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Designer Drugs; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient-Centered Care; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome | 2011 |
Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Standard of Care; Treatment Outcome | 2010 |
The therapy of kidney cancer with biomolecular drugs.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Immunotherapy; Indazoles; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides; TOR Serine-Threonine Kinases | 2010 |
Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers; Breast Neoplasms; Cardiotoxins; Cardiovascular Diseases; Female; Heart Failure; Humans; Indoles; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Risk Assessment; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Endoscopy; Female; Humans; Indoles; Intestinal Perforation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib | 2011 |
In pursuit of new anti-angiogenic therapies for cancer treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2011 |
Targeting EGFR in bilio-pancreatic and liver carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2011 |
Therapeutic advances in women's cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cetuximab; ErbB Receptors; Female; Genital Neoplasms, Female; Humans; Indoles; Intestinal Perforation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Novel molecular therapies in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptor, IGF Type 1; Receptors, Platelet-Derived Growth Factor; Sorafenib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors | 2011 |
Sorafenib: activity and clinical application in patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Interactions; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Emerging strategies in the treatment of advanced hepatocellular carcinoma: the role of targeted therapies.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Epidermal Growth Factor; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
[Sorafenib and radiotherapy association for hepatocellular carcinoma].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Radiotherapy, Adjuvant; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
Assessment of the treatment response of HCC.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Contrast Media; Ethanol; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Yttrium Radioisotopes | 2011 |
Recent advances in cytogenetics and molecular biology of adult hepatocellular tumors: implications for imaging and management.
Topics: Adenoma, Liver Cell; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cytogenetic Analysis; Focal Nodular Hyperplasia; Genetic Association Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2011 |
Sorafenib-associated hand-foot syndrome in Japanese patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Foot Dermatoses; Hand Dermatoses; Humans; Japan; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Syndrome | 2011 |
Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease-Free Survival; Everolimus; Humans; Immunotherapy; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality of Life; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Everolimus; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Sorafenib for advanced hepatocellular carcinoma: a systematic review.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.
Topics: Anilides; Benzenesulfonates; Disease Progression; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2011 |
Sorafenib-induced premalignant and malignant skin lesions.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Niacinamide; Phenylurea Compounds; Precancerous Conditions; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib | 2011 |
Sorafenib in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2011 |
[Sorafenib in combination with chemotherapy in the induction therapy for FLT3-ITD positive acute monocytic leukemia: a case report and literature review].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Monocytic, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
[Novelties in the treatment for advanced renal-cell cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Treatment of metastatic renal cell carcinoma and renal pelvic cancer.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cisplatin; Deoxycytidine; Everolimus; Gemcitabine; Humans; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2011 |
[Treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2011 |
[Hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Meta-analysis of dermatological toxicities associated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Skin Diseases; Sorafenib | 2011 |
Classic biphasic pulmonary blastoma: a case report and review of the literature.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Fatal Outcome; Humans; Intestinal Perforation; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pulmonary Blastoma; Pyridines; Sorafenib | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Candidacy for sorafenib in HCC patients: is there a slippery slope beyond a SHARP edge?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Sorafenib for HCC: a pragmatic perspective.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Targeting receptor tyrosine kinase pathways in hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Signal Transduction; Sorafenib | 2011 |
Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Gland; Vascular Endothelial Growth Factors | 2011 |
[Indications and current development of new targeted therapies in pediatric oncology].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Benzenesulfonates; Bevacizumab; Child; Dasatinib; Erlotinib Hydrochloride; Hedgehog Proteins; Humans; Imatinib Mesylate; Indoles; Integrins; Molecular Targeted Therapy; Neoplasms; Niacinamide; Nifurtimox; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; TOR Serine-Threonine Kinases | 2011 |
Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Atrasentan; Benzenesulfonates; Castration; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Humans; Indoles; Lenalidomide; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Pyrrolidines; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A | 2011 |
t(8;22)/BCR-FGFR1 myeloproliferative disorder presenting as B-acute lymphoblastic leukemia: report of a case treated with sorafenib and review of the literature.
Topics: Antineoplastic Agents; Benzenesulfonates; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 8; Diagnosis, Differential; Humans; Myeloproliferative Disorders; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcr; Pyridines; Receptor, Fibroblast Growth Factor, Type 1; Sorafenib; Translocation, Genetic | 2011 |
Targeting angiogenesis in esophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Clinical Trials, Phase III as Topic; Disease Models, Animal; Disease-Free Survival; Esophageal Neoplasms; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Protein Kinase Inhibitors; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Strategies for assessing and managing the adverse events of sorafenib and other targeted therapies in the treatment of renal cell and hepatocellular carcinoma: recommendations from a European nursing task group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Diarrhea; Drug Eruptions; Europe; Fatigue; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Liver Neoplasms; Molecular Targeted Therapy; Mucositis; Niacinamide; Nursing Assessment; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Societies, Nursing; Sorafenib | 2012 |
Targeted-therapy and imaging response: a new paradigm for clinical evaluation?
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Clinical Trials as Topic; Diagnostic Imaging; Fluorodeoxyglucose F18; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2011 |
[Sorafenib in the treatment of hepatocellular carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Sorafenib for the management of advanced renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
[Targeting the RAS signalling pathway in cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Colorectal Neoplasms; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; ras Proteins; Signal Transduction; Sorafenib | 2011 |
[Progression of sorafenib in the treatment of acute myeloid leukemia].
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2011 |
Targeted drug therapies and cancer.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Drug Delivery Systems; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gefitinib; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Signaling pathway and molecular-targeted therapy for hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib | 2011 |
Molecularly targeted therapies for hepatocellular carcinoma: sorafenib as a stepping stone.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Role of BRAF in thyroid oncogenesis.
Topics: Benzenesulfonates; Cell Transformation, Neoplastic; Genetic Predisposition to Disease; Humans; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Thyroid Gland; Thyroid Neoplasms; Treatment Outcome | 2011 |
[Renal carcinoma and fatigue: which challenge in the era of antiangiogenic drugs?].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Fatigue; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Hepatocellular carcinoma and liver transplantation: clinical perspective on molecular targeted strategies.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2011 |
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Hematologic Neoplasms; Humans; Indoles; Multiple Myeloma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib; Thalidomide; Vascular Endothelial Growth Factor A; Wnt Signaling Pathway | 2011 |
A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Epidemiologic Methods; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Young Adult | 2011 |
Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Disease Management; Exanthema; Humans; Keratoacanthoma; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pruritus; Pyridines; Severity of Illness Index; Skin; Sorafenib | 2012 |
[Systemic treatment of renal cell carcinoma - recent update].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Evidence-Based Medicine; Humans; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Palliative Care; Phenylurea Compounds; Practice Guidelines as Topic; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
[Role of mitogen-activated protein kinase (MAPK) in the sporadic renal cell carcinoma].
Topics: Antigens, Neoplasm; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Enzyme Activation; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kidney Neoplasms; MAP Kinase Signaling System; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Pyridines; Radiation Tolerance; Sorafenib; Von Hippel-Lindau Tumor Suppressor Protein | 2012 |
Are there opportunities for chemotherapy in the treatment of hepatocellular cancer?
Topics: Antibiotics, Antineoplastic; Benzenesulfonates; Carcinoma, Hepatocellular; Doxorubicin; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Clinical experience with antiangiogenic therapy in leukemia.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Humans; Indoles; Lenalidomide; Leukemia; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Staurosporine; Sunitinib; Thalidomide; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
[Dermatologic side effects induced by new angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Drug Eruptions; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Skin; Sorafenib; Sulfonamides; Sunitinib | 2011 |
The two faces of FBW7 in cancer drug resistance.
Topics: Amyloid Precursor Protein Secretases; Apoptosis; Benzenesulfonates; Biphenyl Compounds; Cell Cycle Proteins; Drug Resistance, Neoplasm; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; MAP Kinase Signaling System; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms; Niacinamide; Nitrophenols; Paclitaxel; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Sulfonamides; Tumor Suppressor Protein p53; Ubiquitin-Protein Ligases; Ubiquitination; Vincristine | 2011 |
Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Female; Hand-Foot Syndrome; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Diagnostic and prognostic molecular markers in hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Benzenesulfonates; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; DNA Methylation; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Risk Factors; Severity of Illness Index; Sorafenib; Survival Rate; Tumor Microenvironment | 2011 |
Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Management; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Tyrosine kinase inhibitors for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Humans; Indazoles; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Anti-angiogenic therapy: concept to clinic.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Humans; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
[Myocardial metastasis from renal cell carcinoma treated with sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Heart Neoplasms; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Management of hepatocellular carcinoma with transarterial chemoembolization in the era of systemic targeted therapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Delivery Systems; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
VEGF pathway-targeted therapy for advanced renal cell carcinoma: a meta-analysis of randomized controlled trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Liver Neoplasms; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Sorafenib | 2011 |
Signaling pathways in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB Receptors; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factors | 2011 |
Adjuvant therapy after curative treatment for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Trials as Topic; Hepatitis C; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Meta-Analysis as Topic; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Pyridines; Recombinant Proteins; Ribavirin; Sorafenib | 2011 |
Radiotherapeutic strategies in the management of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Sorafenib (BAY 43-9006) in hepatocellular carcinoma patients: from discovery to clinical development.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Discovery; Humans; Inhibitory Concentration 50; Liver Neoplasms; Molecular Structure; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Targeted therapies for renal cell carcinoma: review of adverse event management strategies.
Topics: Anorexia; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular System; Drug Eruptions; Europe; Everolimus; Evidence-Based Medicine; Gastrointestinal Tract; Humans; Hypothyroidism; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pneumonia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Weight Loss; Wound Healing | 2012 |
Immunology in the clinic review series; focus on cancer: tumour-associated macrophages: undisputed stars of the inflammatory tumour microenvironment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Chemotaxis; Clodronic Acid; Cytokines; Dioxoles; Disease Progression; Humans; Immunity, Innate; Inflammation; Liposomes; Macrophages; Mice; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Tetrahydroisoquinolines; Trabectedin; Tumor Escape; Tumor Microenvironment | 2012 |
[Hepatocellular carcinoma: what's new?].
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diagnostic Imaging; Gene Expression Profiling; Humans; Immunosuppressive Agents; Liver Function Tests; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sirolimus; Sorafenib; Survival Rate; Treatment Outcome | 2012 |
Sorafenib for the treatment of renal cancer.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Evidence-Based Medicine; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Time Factors; Treatment Outcome | 2012 |
Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Targeted therapy for biliary tract cancers.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cetuximab; Cholangiocarcinoma; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Gallbladder Neoplasms; Humans; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Panitumumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Quinazolines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Humans; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Targeted therapeutic strategies for the management of renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Indazoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides; Tuberous Sclerosis; United States | 2012 |
Hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Ultrasonography | 2012 |
Using NF-κB as a molecular target for theranostics in radiation oncology research.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasms; NF-kappa B; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Radiation Oncology; Radiation Tolerance; Signal Transduction; Sorafenib | 2012 |
Developments in metastatic pancreatic cancer: is gemcitabine still the standard?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Erlotinib Hydrochloride; Gemcitabine; Humans; Meta-Analysis as Topic; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib | 2012 |
Sorafenib in melanoma.
Topics: Animals; Benzenesulfonates; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2012 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib | 2012 |
Advanced HCC: emerging molecular therapies.
Topics: Antibodies, Monoclonal; Benzenesulfonates; California; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Clinical Trials as Topic; Evidence-Based Medicine; Global Health; Hepatectomy; Humans; Incidence; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prevalence; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Treatment Outcome | 2012 |
Management of hepatocellular carcinoma: beyond sorafenib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Sorafenib for treatment of hepatocellular carcinoma: a systematic review.
Topics: Antineoplastic Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Chemoembolization, Therapeutic; Hand-Foot Syndrome; Hepatitis, Viral, Human; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sorafenib; Treatment Outcome | 2012 |
Molecular targeted therapy in acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; fms-Like Tyrosine Kinase 3; Humans; Janus Kinase 2; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; ras Proteins; Sorafenib; Staurosporine | 2012 |
Sorafenib in liver cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Combining antiangiogenics to overcome resistance: rationale and clinical experience.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Drug Resistance, Neoplasm; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2012 |
Targeting the FMS-like tyrosine kinase 3 in acute myeloid leukemia.
Topics: Benzenesulfonates; Benzothiazoles; Carbazoles; CCAAT-Enhancer-Binding Protein-alpha; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Staurosporine | 2012 |
Sorafenib in locally advanced or metastatic breast cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Disease-Free Survival; Docetaxel; Double-Blind Method; Female; Fluorouracil; Gemcitabine; Humans; Letrozole; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sorafenib; Taxoids; Triazoles | 2012 |
Neoadjuvant therapy of renal cell carcinoma: a novel treatment option in the era of targeted therapy?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vena Cava, Inferior | 2012 |
Sorafenib in non-small cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Cardiac side effects of anticancer treatments: new mechanistic insights.
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Daunorubicin; Doxorubicin; Heart Failure; Humans; Indoles; Myocardial Contraction; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Trastuzumab | 2012 |
Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Differentiation; ErbB Receptors; Everolimus; Histone Deacetylases; Humans; Immunologic Factors; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptors, Somatostatin; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
[Treatment of advanced hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
[Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
[Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Current status of hepatocellular carcinoma treatment in Japan: transarterial chemoembolization.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiodized Oil; Humans; Japan; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors | 2012 |
Current status of hepatocellular carcinoma treatment in Japan: hepatic arterial infusion chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Japan; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Current status of hepatocellular carcinoma treatment in Japan: practical use of sorafenib (Nexavar®).
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Japan; Liver Neoplasms; Medication Adherence; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors | 2012 |
Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Area Under Curve; Benzamides; Benzenesulfonates; Cetuximab; Dasatinib; Drug Monitoring; Everolimus; Evidence-Based Medicine; Half-Life; Humans; Imatinib Mesylate; Indoles; Injections, Intravenous; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Rituximab; Sirolimus; Sorafenib; Sunitinib; Thiazoles | 2012 |
Hypothyroidism during treatment with tyrosine kinase inhibitors.
Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Function Tests; Thyroid Gland; Thyroid Neoplasms | 2012 |
State of the art of the therapeutic perspective of sorafenib against hematological malignancies.
Topics: Apoptosis; Clinical Trials as Topic; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Receptors, Vascular Endothelial Growth Factor; Sorafenib; TNF-Related Apoptosis-Inducing Ligand | 2012 |
Targeted agents and systemic therapy in hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Benzenesulfonates; Carcinoma, Hepatocellular; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
Treatment of hepatocellular carcinoma with sorafenib - focus on special populations and adverse event management.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2012 |
Impact of restricting access to high-cost medications for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Making; Drug Costs; Health Services Accessibility; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; United Kingdom | 2012 |
Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.
Topics: Animals; Antineoplastic Agents; Drug Design; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; Signal Transduction; Sorafenib; Sunitinib | 2013 |
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
[Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2012 |
Recurrent hepatocellular carcinoma after liver transplantation - an emerging clinical challenge.
Topics: Animals; Carcinoma, Hepatocellular; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Evaluation; Everolimus; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Retrospective Studies; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome | 2013 |
Sorafenib in treatment of patients with advanced hepatocellular carcinoma: a systematic review.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2012 |
Hypertension as a biomarker in patients with recurrent glioblastoma treated with antiangiogenic drugs: a single-center experience and a critical review of the literature.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Blood Pressure; Disease-Free Survival; Female; Follow-Up Studies; Glioblastoma; Humans; Hypertension; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2013 |
Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Hemorrhage; Humans; Incidence; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib | 2013 |
Extrahepatic spread of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib | 2012 |
Medical therapies for hepatocellular carcinoma: a critical view of the evidence.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Evidence-Based Medicine; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Precision Medicine; Sorafenib | 2013 |
Probability of downsizing primary tumors of renal cell carcinoma by targeted therapies is related to size at presentation.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Probability; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Tumor Burden | 2013 |
Pathways and targets in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Signal Transduction; Sorafenib | 2012 |
[Advances in the study of structural modifications of multi-target anticancer drug sorafenib].
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Structure-Activity Relationship | 2012 |
Second-line treatments for the management of advanced renal cell carcinoma: systematic review and meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).
Topics: Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Comprehensive overview of the efficacy and safety of sorafenib in advanced or metastatic renal cell carcinoma after a first tyrosine kinase inhibitor.
Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Salvage Therapy; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Yttrium-90 radioembolization for hepatocellular carcinoma: what we know and what we need to know.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Chemoembolization, Therapeutic; Drug Carriers; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Yttrium Radioisotopes | 2013 |
Skin cancer associated with the use of sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Skin Neoplasms; Sorafenib; Sunitinib | 2013 |
Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2013 |
Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Drug Discovery; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Treatment Failure | 2013 |
Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Novel therapies for children with acute myeloid leukaemia.
Topics: Adenine Nucleotides; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Child; Clofarabine; Gemtuzumab; Humans; Immunotoxins; Leukemia, Monocytic, Acute; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2013 |
[Pigmentary disorders induced by anticancer agents. Part II: targeted therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Dasatinib; ErbB Receptors; Humans; Imatinib Mesylate; Indazoles; Indoles; Ipilimumab; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Piperazines; Piperidines; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thiazoles | 2013 |
[Current status of molecular targeted therapies in hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Receptor, IGF Type 1; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Wnt Proteins | 2013 |
Antiangiogenic therapies for advanced hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Fibroblast Growth Factors; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
Meta-analysis of the efficacy of sorafenib for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Humans; Hypertension; Hypokinesia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Skin Diseases; Sorafenib; Survival | 2013 |
Risk of hypertension in cancer patients treated with sorafenib: an updated systematic review and meta-analysis.
Topics: Antineoplastic Agents; Blood Pressure; Chi-Square Distribution; Drug Administration Schedule; Humans; Hypertension; Incidence; Molecular Targeted Therapy; Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Severity of Illness Index; Sorafenib; Time Factors | 2013 |
Sorafenib for ovarian cancer.
Topics: Animals; Antineoplastic Agents; Female; Humans; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2013 |
Advanced unresectable hepatocellular carcinoma: new biologics as fresh ammunition or clues to disease understanding?
Topics: Biological Products; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Active targeted therapy for metastatic collecting duct carcinoma of the kidney: a case report and review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Carcinoma, Renal Cell; Disease Progression; Drug Delivery Systems; Fatal Outcome; Humans; Immunohistochemistry; Kidney Neoplasms; Kidney Tubules, Collecting; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Rare Diseases; Risk Assessment; Sorafenib; Tomography, X-Ray Computed | 2013 |
Intermediate hepatocellular carcinoma: current treatments and future perspectives.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Sorafenib: from literature to clinical practice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Evidence-Based Medicine; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Factors; Sorafenib; Time Factors; Translational Research, Biomedical; Treatment Outcome | 2013 |
Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature.
Topics: Aged; Antibody Specificity; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib | 2013 |
Body composition in chemotherapy: the promising role of CT scans.
Topics: Anthracyclines; Body Composition; Body Weight; Chemotherapy, Adjuvant; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Muscle, Skeletal; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2013 |
Sorafenib and thyroid cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Humans; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Xenograft Model Antitumor Assays | 2013 |
A complete response induced by 21-day sorafenib therapy in a patient with advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib; Treatment Outcome | 2013 |
Assessment of nutritional status in cancer--the relationship between body composition and pharmacokinetics.
Topics: Antineoplastic Agents; Body Composition; Body Mass Index; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Neoplasms; Niacinamide; Nutritional Status; Nutritional Support; Phenylurea Compounds; Sorafenib | 2013 |
[Resection or interventional treatment of hepatocellular carcinoma: which method for which patient?].
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Therapy, Computer-Assisted | 2013 |
Molecular markers to predict response to therapy.
Topics: Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Bevacizumab; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Gene Dosage; Humans; Immunotherapy; Indazoles; Indoles; Kidney Neoplasms; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Genetic; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein | 2013 |
Targeted therapies in hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; ErbB Receptors; Humans; Liver; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
Topics: Antineoplastic Agents; Axitinib; Bayes Theorem; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides | 2013 |
Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword?
Topics: Apoptosis; Benzamides; Cell Proliferation; Dasatinib; Endothelial Cells; ErbB Receptors; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Fibroblasts; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Niacinamide; Phenylurea Compounds; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pulmonary Circulation; Pyrimidines; Receptor Protein-Tyrosine Kinases; Sorafenib; src-Family Kinases; Thiazoles; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Endometrial adult/progenitor stem cells: pathogenetic theory and new antiangiogenic approach for endometriosis therapy.
Topics: Adult; Adult Stem Cells; Angiogenesis Inhibitors; Animals; Endometriosis; Endometrium; Female; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Met as a therapeutic target in HCC: facts and hopes.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Models, Biological; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib | 2014 |
Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2013 |
Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Induction Chemotherapy; Interferons; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Hepatocellular carcinoma: options for diagnosing and managing a deadly disease.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Population Surveillance; Risk Factors; Sorafenib | 2013 |
Targeted therapy for advanced hepatocellular cancer in the elderly: focus on sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Risk of gastrointestinal events with sorafenib, sunitinib and pazopanib in patients with solid tumors: a systematic review and meta-analysis of clinical trials.
Topics: Adverse Drug Reaction Reporting Systems; Carcinoma, Renal Cell; Clinical Trials as Topic; Diarrhea; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Incidence; Indazoles; Indoles; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Vomiting | 2014 |
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2013 |
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment | 2014 |
[Medical treatment of renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Immunotherapy; Indoles; Interferon alpha-2; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; Sirolimus; Societies, Medical; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2013 |
Advanced kidney cancer: treating the elderly.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2013 |
Is the efficacy of sorafenib treatment in patients with hepatocellular carcinoma affected by age?
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2014 |
Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update.
Topics: Carbazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous | 2014 |
Axitinib for the treatment of advanced renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Rate | 2014 |
Molecular marker for predicting treatment response in advanced renal cell carcinoma: does the promise fulfill clinical need?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
[Targeted therapies, prognostic and predictive factors in endocrine oncology].
Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free Survival; Endocrine Gland Neoplasms; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Piperidines; Prognosis; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome | 2013 |
Sorafenib in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2014 |
Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation.
Topics: Antineoplastic Agents; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Glucocorticoids; Graft Rejection; Humans; Immunosuppression Therapy; Immunosuppressive Agents; IMP Dehydrogenase; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Risk of treatment-related mortality with sorafenib in patients with cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Survival Rate | 2014 |
New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Precision Medicine; Protein Kinase Inhibitors; Sorafenib | 2014 |
Novel therapeutic strategies for fibrotic lung disease: a review with a focus on epithelial-mesenchymal transition.
Topics: Airway Remodeling; Animals; Epithelial-Mesenchymal Transition; Fibrosis; Humans; Inflammation Mediators; Lung; Lung Diseases; Myofibroblasts; Niacinamide; Patents as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Respiratory Mucosa; Sorafenib; Stromal Cells; Transforming Growth Factor beta | 2014 |
Treatment-related fatigue with sorafenib, sunitinib and pazopanib in patients with advanced solid tumors: an up-to-date review and meta-analysis of clinical trials.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Fatigue; Humans; Incidence; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Risk; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Sorafenib-based combination as a first line treatment for advanced hepatocellular carcinoma: a systematic review of the literature.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
[Therapeutic effect of sorafenib on portal hypertension: research progress and mechanisms].
Topics: Animals; Humans; Hypertension, Portal; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Hepatocellular carcinoma: clinical frontiers and perspectives.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Decision Support Techniques; Embolization, Therapeutic; Genome-Wide Association Study; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sorafenib | 2014 |
Sorafenib in metastatic thyroid cancer: a systematic review.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms | 2014 |
Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Therapy; Humans; Hypertension; Incidence; Kidney Neoplasms; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Treatment Outcome | 2014 |
Deregulation of signaling pathways involved in sorafenib resistance of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib | 2013 |
Mechanism and consequences of RAF kinase activation by small-molecule inhibitors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Enzyme Activation; Humans; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Multimerization; Protein Processing, Post-Translational; raf Kinases; Sorafenib; Sulfonamides; Vemurafenib | 2014 |
Newer treatments for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Radiopharmaceuticals; Signal Transduction; Sorafenib; Treatment Outcome | 2014 |
Combination therapy of sorafenib and TACE for unresectable HCC: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors | 2014 |
Emerging therapeutic targets for synovial sarcoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bevacizumab; Everolimus; Humans; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sarcoma; Sarcoma, Synovial; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
Risk of mucocutaneous toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Topics: Alopecia; Antineoplastic Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Eruptions; Hand-Foot Syndrome; Humans; Incidence; Mucositis; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pruritus; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Risk; Sorafenib | 2014 |
Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; Disease Progression; Epithelial-Mesenchymal Transition; Female; Histone Deacetylase Inhibitors; Humans; Molecular Targeted Therapy; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Signal Transduction; Sorafenib; Transforming Growth Factor beta1; Treatment Outcome | 2014 |
Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Topics: Antineoplastic Agents; Case Management; Drug Interactions; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Assessment; Sorafenib | 2014 |
Systemic therapy of hepatocellular carcinoma: current status and future perspectives.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; ErbB Receptors; Evidence-Based Medicine; Glypicans; Hormones; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Medical Oncology; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Benzothiazoles; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridazines; Sorafenib; Staurosporine | 2014 |
Sorafenib: targeting multiple tyrosine kinases in cancer.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2014 |
Hepatocellular carcinoma review: current treatment, and evidence-based medicine.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Clinical Trials as Topic; Combined Modality Therapy; Evidence-Based Medicine; Humans; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Treatment Outcome | 2014 |
Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.
Topics: Algorithms; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Hepatic Artery; Humans; Liver Neoplasms; Medical Oncology; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Antiangiogenic agents and the skin: cutaneous adverse effects of sorafenib, sunitinib, and bevacizumab.
Topics: Administration, Cutaneous; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2014 |
Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome | 2014 |
The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Camptothecin; Capecitabine; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Genes, ras; Humans; Imidazoles; Indazoles; Indoles; Irinotecan; Niacinamide; Oligonucleotides; Organoplatinum Compounds; Oxaliplatin; Pharmacogenetics; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2014 |
Sorafenib use in the transplant setting.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Treatment Outcome | 2014 |
Advances in managing hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Focal gains of VEGFA: candidate predictors of sorafenib response in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Disease Progression; Drug Resistance, Neoplasm; Gene Amplification; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Macrophages; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Development of molecular targeted drugs for advanced thyroid cancer in Japan.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Japan; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms | 2014 |
Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Sorafenib (Nexavar) for thyroid cancer.
Topics: Animals; Antineoplastic Agents; Dermatitis, Exfoliative; Humans; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms | 2014 |
Combination of intra-arterial therapies and sorafenib: is there a clinical benefit?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Embolization, Therapeutic; Hepatectomy; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Microspheres; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiography, Interventional; Sorafenib; Survival Rate | 2014 |
The preclinical development of regorafenib for the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Colorectal Neoplasms; Drug Design; Drug Discovery; Drug Evaluation, Preclinical; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2014 |
Treating advanced hepatocellular carcinoma: How to get out of first gear.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2014 |
Transarterial chemoembolization (TACE) plus sorafenib versus TACE for intermediate or advanced stage hepatocellular carcinoma: a meta-analysis.
Topics: Aged; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors | 2014 |
Magnetic resonance imaging following treatment of advanced hepatocellular carcinoma with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2014 |
Efficacy and safety of sorafenib for advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2014 |
Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature.
Topics: Acute Kidney Injury; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Female; Humans; Kidney; Kidney Diseases; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Proteinuria; Retrospective Studies; Sorafenib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A | 2014 |
Treatment of intermediate-stage hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2014 |
Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Publication Bias; Sorafenib; Treatment Outcome | 2014 |
Management of hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Management; Hepatitis B; Hepatitis C; Hepatitis, Viral, Human; Humans; Incidence; Liver Neoplasms; Mass Screening; Niacinamide; Palliative Care; Phenylurea Compounds; Population Surveillance; Quality of Life; Sorafenib; Viral Hepatitis Vaccines | 2015 |
Hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib | 2014 |
The evolving field of kinase inhibitors in thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Quinolines; Sorafenib; Thyroid Neoplasms | 2015 |
Decade in review-hepatocellular carcinoma: HCC-subtypes, stratification and sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
A short update on cancer chemoresistance.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Resistance, Neoplasm; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; MicroRNAs; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2014 |
Systemic treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Combining targeted agents with modern radiotherapy in soft tissue sarcomas.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Cycle; Cell Survival; Chemotherapy, Adjuvant; Cyclin-Dependent Kinase 4; Humans; Indazoles; Indoles; Ipilimumab; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Proto-Oncogene Proteins c-mdm2; Pyrimidines; Pyrroles; Radiotherapy, Adjuvant; Sarcoma; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Tumor Microenvironment | 2014 |
Refining sorafenib therapy: lessons from clinical practice.
Topics: Age Factors; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retreatment; Sorafenib; Treatment Outcome | 2015 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Hemorrhage; Humans; Indazoles; Indoles; Lung Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Piperidines; Pyrimidines; Pyrroles; Quinazolines; Ramucirumab; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Thrombocytopenia; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Comparing comparators: a look at control arms in kidney cancer studies over the years.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Sorafenib | 2015 |
Adjuvant therapy for hepatocellular carcinoma after curative treatment.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Immunotherapy; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2014 |
Downregulation of signal transducer and activator of transcription 3 by sorafenib: a novel mechanism for hepatocellular carcinoma therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Down-Regulation; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Treatment Outcome | 2014 |
Risk of cardiovascular toxicities in patients with solid tumors treated with sorafenib: an updated systematic review and meta-analysis.
Topics: Antineoplastic Agents; Cardiotoxicity; Cardiovascular Diseases; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib | 2014 |
Quantitation of VEGFR2 (vascular endothelial growth factor receptor) inhibitors--review of assay methodologies and perspectives.
Topics: Animals; Chromatography, Liquid; Humans; Indoles; Mass Spectrometry; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Transarterial chemoembolization failure/refractoriness: JSH-LCSGJ criteria 2014 update.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiodized Oil; Health Care Surveys; Hepatic Artery; Humans; Japan; Liver Function Tests; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Predictive Value of Tests; Sorafenib; Treatment Failure | 2014 |
Multimodality treatment involving radiotherapy for advanced liver-confined hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Chemotherapy, Adjuvant; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Precursors; Prothrombin; Radiotherapy, Adjuvant; Republic of Korea; Sorafenib; Treatment Outcome | 2014 |
An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Patient Safety; Phenylurea Compounds; Prognosis; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2014 |
Tyrosine kinase inhibitors directed against the vascular endothelial growth factor receptor (VEGFR) have distinct cutaneous toxicity profiles: a meta-analysis and review of the literature.
Topics: Antineoplastic Agents; Humans; Incidence; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Managing localized unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Early Detection of Cancer; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib | 2015 |
The adverse effects of sorafenib in patients with advanced cancers.
Topics: Antineoplastic Agents; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
New therapeutic strategy for hepatocellular carcinoma by molecular targeting agents via inhibition of cellular stress defense mechanisms.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Cytoprotection; Drug Therapy, Combination; Endoplasmic Reticulum Stress; Humans; Keratins; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphorylation; Prognosis; Proteasome Inhibitors; Sorafenib; Unfolded Protein Response | 2014 |
Treatment of hepatocellular carcinoma: beyond international guidelines.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Guidelines as Topic; Humans; Internationality; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib | 2015 |
Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Drugs, Investigational; Humans; Liver Neoplasms; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Failure | 2015 |
Treatment efficacy differences of sorafenib for advanced hepatocellular carcinoma: a meta-analysis of randomized clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Sorafenib for the treatment of thyroid cancer: an updated review.
Topics: Antineoplastic Agents; Disease-Free Survival; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2015 |
Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients.
Topics: Disease-Free Survival; Humans; Indoles; Iodine Radioisotopes; MAP Kinase Kinase Kinase 1; Niacinamide; Oligonucleotides; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Thyroid Neoplasms | 2015 |
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate | 2015 |
Is Notch Signaling a Specific Target in Hepatocellular Carcinoma?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Doxorubicin; Gene Knockdown Techniques; Genetic Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Receptors, Notch; Signal Transduction; Sorafenib; Valproic Acid | 2015 |
Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
The discovery and development of sorafenib for the treatment of thyroid cancer.
Topics: Animals; Antineoplastic Agents; Disease-Free Survival; Drug Approval; Drug Design; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2015 |
Peri-operative use of sorafenib in liver transplantation: a time-to-event meta-analysis.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Chi-Square Distribution; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2015 |
Clinical observation of liver cancer patients treated with axitinib and cabozantinib after failed sorafenib treatment: a case report and literature review.
Topics: Anilides; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Imidazoles; Indazoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retreatment; Sorafenib; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2015 |
[Successful treatment of metastatic hepatocellular carcinoma with sorafenib combined with transcatheter arterial chemoembolization/hepatic arterial infusion chemotherapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Hepatectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Treatment Outcome | 2014 |
Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.
Topics: Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2015 |
Effect of glucuronidation on transport and tissue accumulation of tyrosine kinase inhibitors: consequences for the clinical management of sorafenib and regorafenib.
Topics: Animals; Antineoplastic Agents; Biological Transport; Glucuronides; Glucuronosyltransferase; Humans; Liver; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Tissue Distribution | 2015 |
A systematic review of the efficacy and safety experience reported for sorafenib in advanced renal cell carcinoma (RCC) in the post-approval setting.
Topics: Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Approval; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Safety; Sorafenib | 2015 |
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Carcinogenesis; Carcinoma, Hepatocellular; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Mice; Mitogen-Activated Protein Kinases; Monomeric GTP-Binding Proteins; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; ras GTPase-Activating Proteins; ras Proteins; Rats; Sorafenib; Tumor Suppressor Proteins | 2015 |
Targeted therapy for thymic epithelial tumors: a new horizon? Review of the literature and two cases reports.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Female; Histone Deacetylase Inhibitors; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Sorafenib; Thymus Neoplasms; TOR Serine-Threonine Kinases; Young Adult | 2015 |
Management of hepatocellular carcinoma with portal vein thrombosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contraindications; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Portal Vein; Practice Guidelines as Topic; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Treatment Outcome; Venous Thrombosis | 2015 |
[Sorafenib in combination with chemotherapy as induction therapy for FLT3-ITD positive acute myeloid leukemia:nine cases report and literatures review].
Topics: Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Embolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib | 2015 |
Hypertension and Life-Threatening Bleeding in Children with Relapsed Acute Myeloblastic Leukemia Treated with FLT3 Inhibitors.
Topics: Acidosis; Acute Kidney Injury; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Hemorrhage; Humans; Hypertension; Indoles; Leukemia, Myeloid, Acute; Male; Neoplasm Proteins; Niacinamide; Pain; Pancytopenia; Phenylurea Compounds; Protease Inhibitors; Pyrroles; Salvage Therapy; Sepsis; Sorafenib; Sunitinib | 2015 |
MEK 1/2 inhibitors in the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Hepatocellular; Diphenylamine; Humans; Liver Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2015 |
Systemic therapy of hepatocellular carcinoma: current and promising.
Topics: Alanine; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatectomy; Humans; Indoles; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Preoperative Care; Proto-Oncogene Proteins c-met; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Triazines | 2015 |
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Iodine Radioisotopes; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction; Sorafenib; Thyroid Neoplasms; Treatment Failure | 2015 |
Liquid biopsy in liver cancer.
Topics: Alleles; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; DNA, Neoplasm; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2015 |
Systematic review of catheter-based intra-arterial therapies in hepatocellular carcinoma: state of the art and future directions.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Diffusion of Innovation; Embolization, Therapeutic; Female; Forecasting; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Microspheres; Niacinamide; Patient Selection; Phenylurea Compounds; Radiopharmaceuticals; Sorafenib; Yttrium Radioisotopes | 2015 |
CDK8 kinase--An emerging target in targeted cancer therapy.
Topics: Cyclin-Dependent Kinase 8; Gene Expression Regulation, Neoplastic; Humans; Molecular Structure; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Conformation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Transcription, Genetic | 2015 |
Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Gastrointestinal Tract; Humans; Intestine, Small; Neoplasms; Neovascularization, Pathologic; Niacinamide; Organs at Risk; Phenylurea Compounds; Radiosurgery; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A | 2015 |
Targeted therapies in advanced differentiated thyroid cancer.
Topics: Antineoplastic Agents; Humans; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Quinolines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Neoplasms | 2015 |
Novel drugs in clinical development for hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Design; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Aggressive thyroid cancer: targeted therapy with sorafenib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Mas; Sorafenib; Thyroid Neoplasms | 2017 |
[Advanced hepatocellular carcinoma: importance of clinical trials].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib | 2015 |
New perspectives on the management of hepatocellular carcinoma with portal vein thrombosis.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Sorafenib; Venous Thrombosis | 2015 |
Sorafenib: 10 years after the first pivotal trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2015 |
Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Molecular Targeted Therapy; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tumor Microenvironment | 2015 |
Risk of treatment-related mortality with sorafenib in cancer patients: a meta-analysis of 20 randomly controlled trials : Risk of sorafenib-associated death.
Topics: Antineoplastic Agents; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib | 2015 |
New molecular therapies for hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Fibroblast Growth Factors; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Signal Transduction; Sorafenib; Transforming Growth Factor beta | 2015 |
Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; DNA Methylation; Drug Design; Epigenesis, Genetic; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Microenvironment | 2015 |
[Kinase inhibitors and their resistance].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib | 2015 |
[Anti-angiogenesis and molecular targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Humans; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
[Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Denosumab; Drug Discovery; Everolimus; Gastrointestinal Neoplasms; Humans; Imatinib Mesylate; Indazoles; Indoles; Molecular Targeted Therapy; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sarcoma; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Efficacy and Safety of Sorafenib Therapy on Metastatic Renal Cell Carcinoma in Korean Patients: Results from a Retrospective Multicenter Study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Korea; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Safety; Sorafenib; Treatment Outcome | 2015 |
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug Approval; Humans; Imidazoles; Indazoles; Indoles; MAP Kinase Signaling System; Molecular Targeted Therapy; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Piperidines; Proto-Oncogene Proteins c-ret; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2015 |
Sorafenib for Hepatocellular Carcinoma: From Randomized Controlled Trials to Clinical Practice.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Randomized Controlled Trials as Topic; Sorafenib | 2015 |
Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diagnostic Imaging; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Disease Progression; DNA Methylation; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Interleukin-6; Liver Neoplasms; Membrane Glycoproteins; Microtubule-Associated Proteins; Neoplasm Recurrence, Local; Niacinamide; Nuclear Proteins; Oncogenes; Phenylurea Compounds; Prognosis; Receptors, Immunologic; Sirtuin 1; Sorafenib; Trans-Activators; Transcription Factors; Treatment Outcome; Triggering Receptor Expressed on Myeloid Cells-1 | 2015 |
Congenital extrahepatic portosystemic shunt complicated by the development of hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Vascular Malformations | 2015 |
Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.
Topics: Bevacizumab; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Immunotherapy; Liver Neoplasms; Molecular Targeted Therapy; Nanoparticles; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Prognostic Value of VEGF in Hepatocellular Carcinoma Patients Treated with Sorafenib: A Meta-Analysis.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Observational Studies as Topic; Phenylurea Compounds; Polymorphism, Genetic; Prognosis; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2015 |
Modulation of sensitivity and resistance to multikinase inhibitors by microenvironmental platelet factors in HCC.
Topics: Antineoplastic Agents; Blood Platelets; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Microenvironment | 2015 |
Molecular Mechanism and Prediction of Sorafenib Chemoresistance in Human Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reoperation; Risk Factors; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
Topics: Antineoplastic Agents; Female; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Publication Bias; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2015 |
[Systemic Treatment of Metastatic Renal Cell Cancer--Back to the Future?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Immunotherapy; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2015 |
Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Histone Deacetylase Inhibitors; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Treatment Outcome | 2015 |
Targeting BRAF aberrations in advanced colorectal carcinoma: from bench to bedside.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Sorafenib | 2016 |
Clinical management of metastatic kidney cancer: the role of new molecular drugs.
Topics: Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2016 |
Biology, Epidemiology, Clinical Aspects of Hepatocellular Carcinoma and the Role of Sorafenib.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Female; Genetic Predisposition to Disease; Humans; Liver Neoplasms; Male; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Paradoxical exacerbation of chronic plaque psoriasis by sorafenib.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Psoriasis; Sorafenib | 2016 |
Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Efficacy and Safety of Selective Vascular Endothelial Growth Factor Receptor Inhibitors Compared with Sorafenib for Metastatic Renal Cell Carcinoma: a Meta-analysis of Randomised Controlled Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzimidazoles; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Quinolines; Quinolones; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate; Vascular Endothelial Growth Factor A | 2016 |
A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.
Topics: Amiloride; Antineoplastic Agents; Apoptosis; Cation Transport Proteins; Cell Line, Tumor; DNA Damage; Drug Interactions; fms-Like Tyrosine Kinase 3; Genes, abl; Guanidines; Heme Oxygenase-1; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Osmolar Concentration; Patents as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfones; Tumor Hypoxia; Up-Regulation | 2015 |
Treatment of hepatocellular carcinoma: beyond international guidelines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Societies, Medical; Sorafenib; Survival Rate; Treatment Outcome | 2016 |
Treatment of hepatocellular carcinoma with portal venous tumor thrombosis: A comprehensive review.
Topics: ADAM17 Protein; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Embolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Radiotherapy, Conformal; Sorafenib; Venous Thrombosis | 2016 |
Sorafenib in combination with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
Is there still a role for sorafenib in metastatic renal cell carcinoma? A systematic review and meta-analysis of the effectiveness of sorafenib over other targeted agents.
Topics: Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib | 2016 |
Targeted treatments of radio-iodine refractory differentiated thyroid cancer.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms; Treatment Failure | 2015 |
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Axitinib; Fatigue; Humans; Imidazoles; Indazoles; Indoles; Kidney; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2016 |
A decade of pharmacogenomics research on tyrosine kinase inhibitors in metastatic renal cell cancer: a systematic review.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Renal Cell; Gene Expression; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers.
Topics: Antineoplastic Agents; Carcinoma; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2016 |
Antiangiogenic therapy in oncology: current status and future directions.
Topics: Angiogenesis Inhibitors; Angiopoietin-1; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Quinolines; Receptor, TIE-2; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2016 |
Sorafenib combined with transarterial chemoembolization in patients with hepatocellular carcinoma: a meta-analysis and systematic review.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Rationally combining anti-VEGF therapy with checkpoint inhibitors in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Cell Differentiation; Dendritic Cells; Humans; Immunosuppression Therapy; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tumor Microenvironment | 2016 |
First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Quinazolines; Quinolines; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
[New molecular target therapy for thyroid neoplasms and malignant melanomas].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Ipilimumab; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Quinolines; Skin Neoplasms; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib | 2015 |
Outcome and Safety of Sorafenib in Metastatic Renal Cell Carcinoma Dialysis Patients: A Systematic Review.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Renal Dialysis; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Embolization, Therapeutic; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Yttrium Radioisotopes | 2016 |
Radiation recall dermatitis induced by sorafenib : A case study and review of the literature.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Radiodermatitis; Radiotherapy, Conformal; Sorafenib; Treatment Outcome | 2016 |
The role and mechanism of autophagy in sorafenib targeted cancer therapy.
Topics: Animals; Autophagy; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2016 |
Sorafenib-induced Acute Pancreatitis: A Case Report and Review of the Literature.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreatitis; Phenylurea Compounds; Sorafenib | 2016 |
Systemic adjuvant therapy for renal cell carcinoma: Any hope for future clinical trials?
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Forecasting; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2016 |
Sorafenib for the treatment of multiple myeloma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cell Proliferation; Humans; Lenalidomide; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thalidomide | 2016 |
Selective use of sorafenib in the treatment of thyroid cancer.
Topics: Antineoplastic Agents; Cell Proliferation; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2016 |
The use of genetic alterations in the development of liver cancer drugs.
Topics: Animals; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Liver Neoplasms; Mutation; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2015 |
[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease Progression; Enzyme Inhibitors; Fatigue; Humans; Hypothyroidism; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quality of Life; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Management of hepatocellular carcinoma: an overview of major findings from meta-analyses.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
Cutaneous manifestations in leukemia patients.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Cytarabine; Dermatomycoses; Etoposide; Humans; Leukemia; Mastocytosis; Niacinamide; Paraneoplastic Syndromes; Phenylurea Compounds; Skin Diseases, Bacterial; Skin Neoplasms; Sorafenib | 2016 |
Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Feasibility Studies; Female; France; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Preliminary Data; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Design and Reporting of Targeted Anticancer Preclinical Studies: A Meta-Analysis of Animal Studies Investigating Sorafenib Antitumor Efficacy.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Neoplasms; Niacinamide; Phenylurea Compounds; Research Design; Sorafenib | 2016 |
Systemic therapy in metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Decision Trees; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Nivolumab; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib | 2016 |
Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Docetaxel; Gemcitabine; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Kidney Pelvis; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Taxoids; Ureteral Neoplasms | 2017 |
Current status and future prospects of chemotherapy for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Immunotherapy; Infusions, Intra-Arterial; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice.
Topics: Animals; Antineoplastic Agents; Camptothecin; Doxorubicin; Drug Interactions; Gene Expression; Hepatocytes; Humans; Inactivation, Metabolic; Irinotecan; Liver; Liver-Specific Organic Anion Transporter 1; Methotrexate; Mice; Mice, Transgenic; Neoplasms; Niacinamide; Organic Cation Transport Proteins; Phenylurea Compounds; Platinum Compounds; Sorafenib; Taxoids | 2016 |
Hepatocellular carcinoma: Will novel targeted drugs really impact the next future?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Discovery; ErbB Receptors; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Vascular Endothelial Growth Factors | 2016 |
Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Design; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Selection; Phenylurea Compounds; Randomized Controlled Trials as Topic; Research Design; Sorafenib | 2016 |
Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2016 |
Targeted Therapy for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Bevacizumab; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA-Binding Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; MicroRNAs; Molecular Targeted Therapy; Mutation; Niacinamide; Nivolumab; Nuclear Proteins; Phenylurea Compounds; Precision Medicine; Prognosis; Pyridines; Pyrimidines; Pyrroles; Quinolines; Receptors, CCR4; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcription Factors; Tumor Suppressor Proteins; Ubiquitin Thiolesterase; Vascular Endothelial Growth Factor A; Von Hippel-Lindau Tumor Suppressor Protein | 2016 |
Challenges of advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver; Liver Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Thrombosis | 2016 |
Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
Topics: Antineoplastic Agents; Humans; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate; Thyroid Neoplasms; Treatment Outcome | 2016 |
Neoadjuvant Therapy in Differentiated Thyroid Cancer.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Doxorubicin; Humans; Indazoles; Japan; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quinolines; Slovenia; Sorafenib; Sulfonamides; Thyroid Neoplasms; Treatment Outcome | 2016 |
Hepatocellular carcinoma in patients with HIV.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Coinfection; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Liver Transplantation; Mass Screening; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Risk of serious adverse events and fatal adverse events with sorafenib in patients with solid cancer: a meta-analysis of phase 3 randomized controlled trials†.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Risk; Sorafenib | 2017 |
Binding kinetics in drug discovery - A current perspective.
Topics: Animals; Drug Discovery; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; Ligands; Molecular Conformation; Niacinamide; Oligopeptides; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Sorafenib; Structure-Activity Relationship | 2017 |
New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib | 2017 |
Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Humans; Liver Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2017 |
Short-term and long-term efficacy of 7 targeted therapies for the treatment of advanced hepatocellular carcinoma: a network meta-analysis: Efficacy of 7 targeted therapies for AHCC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Ramucirumab; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Topics: Anilides; Antineoplastic Agents; Axitinib; Benzimidazoles; Bevacizumab; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Erlotinib Hydrochloride; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Pyrrolidinones; Quinolines; Quinolones; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Impact of Viral Status on Survival in Patients Receiving Sorafenib for Advanced Hepatocellular Cancer: A Meta-Analysis of Randomized Phase III Trials.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib | 2017 |
Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; CTLA-4 Antigen; Humans; Immunotherapy; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Radiosurgery; Sorafenib | 2017 |
Impact of targeted therapies in metastatic renal cell carcinoma on patient-reported outcomes: Methodology of clinical trials and clinical benefit.
Topics: Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Quality of Life; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Treatment Outcome | 2017 |
Kinase Inhibitors in Multitargeted Cancer Therapy.
Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib | 2017 |
Efficacy of sequential therapies with sorafenib-sunitinib versus sunitinib-sorafenib in metastatic renal cell carcinoma: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes.
Topics: Animals; Cellular Microenvironment; Humans; Liver; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2017 |
Targeted Therapy for Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Immunologic Factors; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2016 |
Immune Checkpoint Inhibition in Hepatocellular Carcinoma: Basics and Ongoing Clinical Trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; B7-H1 Antigen; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Membrane Transport Proteins; Niacinamide; Nivolumab; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Sorafenib | 2017 |
Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Confidence Intervals; Humans; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Survival Analysis | 2017 |
Recent advances in hepatocellular carcinoma therapy.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease Progression; Drug Delivery Systems; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2017 |
Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Long-term Treatment With Sequential Molecular Targeted Therapy for Xp11.2 Translocation Renal Cell Carcinoma: A Case Report and Review of the Literature.
Topics: Adult; Age of Onset; Antineoplastic Agents; Axitinib; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Catheter Ablation; Child; Combined Modality Therapy; Everolimus; Fatal Outcome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Oncogene Fusion; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Translocation, Genetic; Young Adult | 2017 |
Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2017 |
Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Management; Drug Resistance, Neoplasm; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Renal cell carcinoma.
Topics: Axitinib; Bevacizumab; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Diseases; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Quality of Life; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2017 |
Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Network Meta-Analysis; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Severity of Illness Index; Sorafenib | 2017 |
Sorafenib: A Review in Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Sorafenib for the treatment of breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2017 |
New knowledge of the mechanisms of sorafenib resistance in liver cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2017 |
PharmGKB summary: sorafenib pathways.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Gene Regulatory Networks; Humans; Neoplasms; Niacinamide; Pharmacogenomic Testing; Pharmacogenomic Variants; Phenylurea Compounds; Sorafenib | 2017 |
Tivantinib for the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Sorafenib | 2017 |
Update on Embolization Therapies for Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Liver; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2017 |
Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors.
Topics: Angiogenesis Inhibitors; Bevacizumab; Clinical Trials as Topic; Female; Humans; Indazoles; Molecular Targeted Therapy; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Survival Analysis; Treatment Outcome | 2017 |
Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect.
Topics: Angiogenesis Inhibitors; Bevacizumab; Humans; Indoles; Jaw Diseases; Niacinamide; Osteonecrosis; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Sunitinib | 2017 |
Hepatocellular carcinoma treatment: a comparative review of emerging growth factor receptor antagonists.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Design; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Receptors, Growth Factor; Sorafenib; Survival Rate | 2017 |
Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Niacinamide; Oncolytic Virotherapy; Oncolytic Viruses; Phenylurea Compounds; Sorafenib | 2017 |
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; CTLA-4 Antigen; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunotherapy; Indoles; Ipilimumab; MAP Kinase Kinase 1; Melanoma; Molecular Targeted Therapy; Niacinamide; Nivolumab; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2017 |
Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma.
Topics: Carcinoma, Renal Cell; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Indoles; Neoplasm Metastasis; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolines; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2017 |
Regorafenib for the treatment of unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2017 |
Current Standard and Future Perspectives in Non-Surgical Therapy for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Clinical Trials as Topic; Combined Modality Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Proton Therapy; Radiosurgery; Radiotherapy; Sorafenib; Survival Rate; Treatment Outcome; Tumor Burden; Yttrium Radioisotopes | 2017 |
Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Retreatment; Sorafenib; Treatment Failure; Treatment Outcome | 2017 |
Antiangiogenic tyrosine kinase inhibitors in colorectal cancer: is there a path to making them more effective?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Colorectal Neoplasms; Humans; Models, Biological; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Rate | 2017 |
Bridging to liver transplantation in HCC patients.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Preoperative Care; Risk Assessment; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Waiting Lists | 2017 |
Multimodal oncological approach in patients affected by recurrent hepatocellular carcinoma after liver transplantation.
Topics: Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Patient Selection; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib | 2017 |
Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma: a systemic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Hand-Foot Syndrome; Humans; Liver Neoplasms; Niacinamide; Odds Ratio; Phenylurea Compounds; Quality of Life; Risk Factors; Sorafenib; Treatment Outcome | 2018 |
Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Nivolumab; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Retreatment; Sorafenib; Treatment Outcome | 2017 |
Second-line systemic therapy in metastatic renal-cell carcinoma: A review.
Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib | 2017 |
Which patient with thyroid cancer deserves systemic therapy and when?
Topics: Antineoplastic Agents; Humans; Iodine Radioisotopes; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Failure | 2017 |
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life.
Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms; Treatment Failure | 2017 |
Angiogenesis Inhibitors in NSCLC.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Docetaxel; Humans; Indoles; Lung Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Pyrroles; Quinazolines; Ramucirumab; Sorafenib; Sunitinib; Taxoids | 2017 |
Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.
Topics: Adult; Antineoplastic Agents; Disease Progression; Female; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms; Tomography, X-Ray Computed | 2017 |
New insights into sorafenib resistance in hepatocellular carcinoma: Responsible mechanisms and promising strategies.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Humans; Liver Neoplasms; MicroRNAs; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Sorafenib | 2017 |
A network meta-analysis of short-term efficacy of different single-drug targeted therapies in the treatment of renal cell carcinoma.
Topics: Anilides; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Molecular Targeted Therapy; Network Meta-Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Transcatheter arterial chemoembolization plus sorafenib versus transcatheter arterial chemoembolization alone to treat advanced hepatocellular carcinoma: a meta-analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
Multiple Roles of Autophagy in the Sorafenib Resistance of Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Autophagy; Autophagy-Related Proteins; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Transarterial Chemoembolization in Combination with a Molecular Targeted Agent: Lessons Learned from Negative Trials (Post-TACE, BRISK-TA, SPACE, ORIENTAL, and TACE-2).
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib | 2017 |
Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib | 2018 |
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors | 2018 |
Optimal management of patients with hepatocellular carcinoma treated with lenvatinib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate | 2018 |
Complete response of hepatocellular carcinoma with right atrium and pulmonary metastases treated by combined treatments (a possible treatment effect of natural killer cell): A case report and literature review.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Heart Atria; Heart Neoplasms; Humans; Killer Cells, Natural; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiotherapy, Adjuvant; Remission Induction; Response Evaluation Criteria in Solid Tumors; Sorafenib; Tumor Burden | 2018 |
Role and relevance of quality indicators in the selection of first-line treatment of patients with metastatic renal cell carcinoma: a position paper of the MeetURO Group.
Topics: Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Quality of Life; Quinolines; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2019 |
The combination therapy of transarterial chemoembolisation and sorafenib is the preferred palliative treatment for advanced hepatocellular carcinoma patients: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Palliative Care; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2020 |
A meta-analysis of the efficacy and safety of adjuvant sorafenib for hepatocellular carcinoma after resection.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2021 |
Early predictive value of circulating biomarkers for sorafenib in advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2022 |
Natural Products for Liver Cancer Treatment: From Traditional Medicine to Modern Drug Discovery.
Topics: Antineoplastic Agents; Biological Products; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Discovery; Humans; Liver Neoplasms; Medicine, Traditional; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2022 |
Trials
573 trial(s) available for niacinamide and sorafenib
Article | Year |
---|---|
ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006.
Topics: Administration, Oral; Adolescent; Adult; Aged; Benzenesulfonates; Biomarkers; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Humans; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2002 |
Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors.
Topics: Benzenesulfonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Humans; Maximum Tolerated Dose; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2002 |
Circadian rhythm in the regulation of the MAP kinase pathway--pitfall in the determination of surrogate parameters?
Topics: Benzenesulfonates; Biomarkers; Blotting, Western; Circadian Rhythm; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphorylation; Pyridines; Signal Transduction; Sorafenib | 2003 |
Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors.
Topics: Administration, Oral; Antineoplastic Agents, Phytogenic; Benzenesulfonates; Camptothecin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Irinotecan; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2003 |
A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Aspartate Aminotransferases; Benzenesulfonates; Doxorubicin; Humans; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2003 |
Kinase inhibition with BAY 43-9006 in renal cell carcinoma.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Enzyme Inhibitors; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2004 |
Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006.
Topics: Adult; Area Under Curve; Benzenesulfonates; Diarrhea; Drug Administration Schedule; Exanthema; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2004 |
Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Area Under Curve; Benzenesulfonates; Cholangiocarcinoma; Doxorubicin; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2004 |
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Colonic Neoplasms; Diarrhea; Extracellular Signal-Regulated MAP Kinases; Fatigue; Female; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Rectal Neoplasms; Safety; Sorafenib | 2005 |
Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2005 |
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
Topics: Administration, Oral; Adult; Aged; Benzenesulfonates; Drug Administration Schedule; Enzyme Inhibitors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2005 |
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Time Factors | 2005 |
Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Colorectal Neoplasms; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Sorafenib | 2005 |
Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Dose-Response Relationship, Drug; Drug Interactions; Female; Gemcitabine; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2006 |
Mechanisms of hypertension associated with BAY 43-9006.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Drug Administration Schedule; Female; Humans; Hypertension; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2006 |
Pharmacodynamic monitoring of BAY 43-9006 (Sorafenib) in phase I clinical trials involving solid tumor and AML/MDS patients, using flow cytometry to monitor activation of the ERK pathway in peripheral blood cells.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antigens, CD34; Antigens, Differentiation, Myelomonocytic; Benzenesulfonates; CD13 Antigens; CD3 Complex; Drug Monitoring; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Hemolysis; Humans; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; MAP Kinase Signaling System; Middle Aged; Models, Biological; Myelodysplastic Syndromes; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Sialic Acid Binding Ig-like Lectin 3; Sorafenib; Stem Cell Factor; Stem Cells; Tetradecanoylphorbol Acetate | 2006 |
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Doxorubicin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib | 2006 |
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2006 |
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; DNA Primers; Female; Genes, ras; Humans; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Proto-Oncogene Proteins B-raf; Pyridines; Safety; Sorafenib | 2006 |
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Pyridines; RNA, Neoplasm; Sorafenib; Survival Analysis; Treatment Outcome | 2006 |
Randomized discontinuation trial of sorafenib (BAY 43-9006).
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Double-Blind Method; Drug Administration Schedule; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Reproducibility of Results; Research Design; Sorafenib; Treatment Outcome | 2006 |
Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Microsomes, Liver; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2007 |
Sorafenib in advanced clear-cell renal-cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2007 |
Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Immune System; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Treatment Outcome | 2007 |
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Niacinamide; Pemetrexed; Phenylurea Compounds; Piperidines; Probability; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib | 2007 |
Effects of sorafenib on symptoms and quality of life: results from a large randomized placebo-controlled study in renal cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Sorafenib; Survival Analysis | 2007 |
A randomized phase II study of sorafenib/gemcitabine or sorafenib/erlotinib for advanced non-small-cell lung cancer in elderly patients or patients with a performance status of 2: treatment rationale and protocol dynamics.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate | 2007 |
Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; North Carolina; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2007 |
Sorafenib with interferon alfa-2b as first-line treatment of advanced renal carcinoma: a phase II study of the Southwest Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA Mutational Analysis; Female; Humans; Immunohistochemistry; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Survival Analysis; Treatment Outcome | 2007 |
Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2007 |
Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Disease Progression; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Survival Rate | 2007 |
Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Drug Eruptions; Female; Humans; Kidney Neoplasms; Lipase; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2007 |
Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Sorafenib TARGET trial results in Spanish patients.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spain; Treatment Outcome | 2007 |
A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Fatigue; Humans; Male; Middle Aged; Nausea; Niacinamide; Pain; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2007 |
A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzenesulfonates; Biomarkers, Tumor; Canada; Cell Proliferation; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Hormone-Dependent; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2008 |
A phase II clinical trial of sorafenib in androgen-independent prostate cancer.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Extracellular Signal-Regulated MAP Kinases; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2008 |
Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pilot Projects; Proto-Oncogene Proteins c-raf; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Analysis | 2008 |
Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Cell Survival; Fluorescent Antibody Technique; fms-Like Tyrosine Kinase 3; Humans; Immunoblotting; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Mutation; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyridines; Sorafenib; Transplantation, Heterologous | 2008 |
Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; CA-125 Antigen; Cohort Studies; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pilot Projects; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Reproducibility of Results; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
Sorafenib for metastatic renal cancer: the Princess Margaret experience.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Analysis | 2008 |
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
Topics: Administration, Oral; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Double-Blind Method; Female; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome; United States | 2008 |
Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
Phase II trial of sorafenib in advanced thyroid cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms | 2008 |
Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Drug Eruptions; Female; Foot Dermatoses; France; Hand Dermatoses; Humans; Incidence; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Sorafenib | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Survival Analysis | 2008 |
Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2008 |
A phase I trial of the oral, multikinase inhibitor sorafenib in combination with carboplatin and paclitaxel.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biopsy; Carboplatin; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors; Treatment Outcome | 2008 |
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Contrast Media; Double-Blind Method; Female; Gadolinium DTPA; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Proportional Hazards Models; Prospective Studies; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2008 |
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Retrospective Studies; Sorafenib | 2008 |
Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada.
Topics: Antineoplastic Agents; Benzenesulfonates; Canada; Carcinoma, Hepatocellular; Disease-Free Survival; Europe; Humans; Liver Neoplasms; Markov Chains; Models, Theoretical; Niacinamide; Phenylurea Compounds; Pyridines; Sensitivity and Specificity; Sorafenib; Survival Rate | 2008 |
Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Double-Blind Method; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sorafenib | 2008 |
Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Female; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Taxoids | 2009 |
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2009 |
Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Cirrhosis; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Disease-Free Survival; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Orchiectomy; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; raf Kinases; Soft Tissue Neoplasms; Sorafenib; Treatment Outcome | 2009 |
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib | 2009 |
Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Cell Line, Tumor; Disease-Free Survival; Drug Delivery Systems; Humans; Melanoma; Mitogen-Activated Protein Kinase 3; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib; Treatment Outcome | 2009 |
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Hepatic Insufficiency; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Renal Insufficiency; Sorafenib; Treatment Outcome; Young Adult | 2009 |
Phase II trial of sorafenib in metastatic thyroid cancer.
Topics: Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroglobulin; Thyroid Neoplasms | 2009 |
[Palliative management of hepatocarcinoma with sorafenib (Nexavar). Results of the SHARP study (sorafenib hepatocarcinoma assessment randomized protocol trial)].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sarcoma; Sorafenib; Young Adult | 2009 |
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cross-Over Studies; Diarrhea; Disease-Free Survival; Double-Blind Method; Fatigue; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Nausea; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Transitional Cell; Disease-Free Survival; Drug Evaluation; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retreatment; Sorafenib; Urinary Bladder Neoplasms | 2009 |
[Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib; Survival Rate; Syndrome; Young Adult | 2009 |
Phase II study of sorafenib in patients with sunitinib-refractory metastatic renal cell cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Resistance, Neoplasm; Fatigue; Female; Humans; Lung Neoplasms; Male; Middle Aged; Nausea; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2009 |
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Breast Neoplasms; ErbB Receptors; Female; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2009 |
Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with and without prior cytokine therapy, a subanalysis of TARGET.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Diarrhea; Disease-Free Survival; Double-Blind Method; Female; Hematologic Diseases; Humans; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Progestins; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Vinca Alkaloids | 2010 |
Phase I clinical and pharmacokinetic study of sorafenib in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Demography; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Radiography; Sorafenib; Treatment Outcome | 2010 |
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.
Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Benzenesulfonates; Bone Neoplasms; Disease-Free Survival; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroglobulin; Thyroid Neoplasms | 2009 |
Incidence of brain metastases in renal cell carcinoma treated with sorafenib.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Incidence; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Rate | 2010 |
Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Farnesyltranstransferase; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Treatment Outcome | 2009 |
Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Biliary Tract Neoplasms; Carcinoma; Cholangiocarcinoma; Disease-Free Survival; Drug Eruptions; Fatigue; Female; Gallbladder Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sorafenib | 2010 |
New pharmacological developments in the treatment of hepatocellular cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Liver Neoplasms; Meta-Analysis as Topic; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Assessment; Severity of Illness Index; Signal Transduction; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension.
Topics: Adult; Aged; Benzenesulfonates; Diarrhea; Drug Discovery; Drug Dosage Calculations; Exanthema; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Demography; Female; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sarcoma; Soft Tissue Neoplasms; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
Sorafenib plus octreotide is an effective and safe treatment in advanced hepatocellular carcinoma: multicenter phase II So.LAR. study.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Octreotide; Phenylurea Compounds; Pyridines; Sorafenib; Survival; Treatment Outcome | 2010 |
Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Double-Blind Method; Fatigue; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Muscle, Skeletal; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Placebos; Prognosis; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Wasting Syndrome | 2010 |
Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Body Mass Index; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sarcopenia; Sorafenib | 2010 |
A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study.
Topics: Abdominal Pain; Acute Disease; Adult; Aged; Aged, 80 and over; Area Under Curve; Benzenesulfonates; Diarrhea; Dose-Response Relationship, Drug; Drug Administration Schedule; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Leukemia, Myeloid; Male; Metabolic Clearance Rate; Middle Aged; Myelodysplastic Syndromes; Nausea; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2010 |
A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinosarcoma; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Uterine Neoplasms | 2010 |
Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/I
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy; Radiotherapy, Conformal; Radiotherapy, Intensity-Modulated; Research Design; Sorafenib | 2010 |
Neoadjuvant clinical trial with sorafenib for patients with stage II or higher renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Pyridines; Sorafenib; Treatment Outcome; Young Adult | 2010 |
Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Drug Synergism; Female; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis | 2010 |
A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Urologic Neoplasms; Urothelium | 2011 |
Phase I combination of sorafenib and erlotinib therapy in solid tumors: safety, pharmacokinetic, and pharmacodynamic evaluation from an expansion cohort.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Biomarkers, Pharmacological; Cohort Studies; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2010 |
Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Early Termination of Clinical Trials; Female; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Placebos; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Topics: Administration, Oral; Adult; Aged; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; United States; Young Adult | 2010 |
A multicenter phase II study of erlotinib and sorafenib in chemotherapy-naive patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Quinazolines; ras Proteins; Sorafenib; Vascular Endothelial Growth Factors | 2010 |
Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Drug Eruptions; Fatigue; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tegafur; Uracil | 2010 |
A single-institute experience with sorafenib in untreated and previously treated patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Medical Oncology; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2010 |
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma.
Topics: Adult; Aged; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Brain Neoplasms; Cytochrome P-450 CYP3A; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib; Temozolomide | 2011 |
Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Docetaxel; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms; Survival Rate; Taxoids; Treatment Outcome | 2010 |
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma; Female; Humans; Hypothyroidism; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine | 2010 |
Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Evaluation; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Contrast Media; Female; Gadolinium DTPA; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2010 |
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Blood Pressure; Electrocardiography, Ambulatory; Female; Heart Rate; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Ventricular Function, Left | 2011 |
Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzoquinones; Clinical Trials, Phase II as Topic; Cohort Studies; Colorectal Neoplasms; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lactams, Macrocyclic; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis | 2010 |
Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Brain Neoplasms; Combined Modality Therapy; Dacarbazine; Female; Glioblastoma; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide | 2010 |
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Immunotherapy; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib | 2010 |
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Female; Humans; Iohexol; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Design and rationale for the non-interventional Global Investigation of Therapeutic DEcisions in Hepatocellular Carcinoma and Of its Treatment with Sorafenib (GIDEON) study.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Clinical Trials, Phase IV as Topic; Humans; Liver Neoplasms; Niacinamide; Patient Selection; Phenylurea Compounds; Prospective Studies; Pyridines; Research Design; Sorafenib; Treatment Outcome | 2010 |
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III Treatment Approaches in Renal Cancer Global Evaluation Trial.
Topics: Aged; Antigens, Neoplasm; Benzenesulfonates; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins p21(ras); Pyridines; Sorafenib; Survival Analysis; Tissue Inhibitor of Metalloproteinase-1; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Long-term safety of sorafenib in advanced renal cell carcinoma: follow-up of patients from phase III TARGET.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Young Adult | 2010 |
Sorafenib after combination therapy with gemcitabine plus doxorubicine in patients with sarcomatoid renal cell carcinoma: a prospective evaluation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Deoxycytidine; Doxorubicin; Female; Gemcitabine; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Sorafenib | 2010 |
A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Niacinamide; Peritoneal Neoplasms; Phenylurea Compounds; Phosphorylation; Pleural Neoplasms; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Chicago; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors; Treatment Outcome; Universities | 2012 |
Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2010 |
Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors.
Topics: Aminoimidazole Carboxamide; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease Progression; Female; Humans; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Phase I dose-finding study of sorafenib in combination with capecitabine and cisplatin as a first-line treatment in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Cisplatin; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Republic of Korea; Sorafenib; Stomach Neoplasms; Time Factors; Treatment Outcome | 2012 |
A phase I/II trial of sorafenib and infliximab in advanced renal cell carcinoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Infliximab; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2010 |
Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Deoxycytidine; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2010 |
A phase I trial of sorafenib plus gemcitabine and capecitabine for patients with advanced renal cell carcinoma: New York Cancer Consortium Trial NCI 6981.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Female; Fluorouracil; Follow-Up Studies; Gemcitabine; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Sorafenib in platinum-treated patients with extensive stage small cell lung cancer: a Southwest Oncology Group (SWOG 0435) phase II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyridines; Remission Induction; Salvage Therapy; Small Cell Lung Carcinoma; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate; Young Adult | 2011 |
Sorafenib: rays of hope in thyroid cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Disease-Free Survival; Drug Interactions; Humans; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroid Neoplasms | 2010 |
Phase I/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer.
Topics: Adult; Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Benzenesulfonates; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; Endothelial Cells; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Estrogen; Receptors, Progesterone; Sorafenib; Stem Cells; Time Factors; Treatment Outcome; Triazoles; United States | 2011 |
[Clinical analysis of the treatment:transcatheter arterial chemoembolization combined with sorafenib in advanced hepatocellular carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Young Adult | 2010 |
Continuous administration of sorafenib in combination with transarterial chemoembolization in patients with hepatocellular carcinoma: results of a phase I study.
Topics: Antineoplastic Agents; Antineoplastic Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Catheters, Indwelling; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Humans; Liver Neoplasms; Mitomycin; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
A phase I dose-escalation study to evaluate safety and tolerability of sorafenib combined with sirolimus in patients with advanced solid cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Doxorubicin; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
[Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Survival Rate; Thrombocytopenia; Young Adult | 2010 |
Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; China; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2011 |
A phase II trial of sorafenib in metastatic melanoma with tissue correlates.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Cyclin D1; DNA Mutational Analysis; Female; Humans; Ki-67 Antigen; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sequence Analysis, DNA; Signal Transduction; Sorafenib | 2010 |
Safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors: results of a phase 1 trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Colonic Neoplasms; Deoxycytidine; Diarrhea; Fatigue; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib | 2010 |
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Benzenesulfonates; Female; Follow-Up Studies; Head and Neck Neoplasms; Humans; Interferon alpha-2; Interferon-alpha; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Prospective Studies; Pyridines; Recombinant Proteins; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cytokines; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Genes, ras; Humans; Lung Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Mutation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib | 2011 |
Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Immunologic Factors; Interferon-alpha; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Burden | 2012 |
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Neuroendocrine; Cell Differentiation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Farnesyltranstransferase; Female; Humans; Male; MAP Kinase Kinase Kinases; Middle Aged; Niacinamide; Oncogene Protein p21(ras); Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; raf Kinases; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2011 |
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Compassionate Use Trials; Disease-Free Survival; Europe; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Feasibility Studies; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Sorafenib; Tegafur; Uracil; Young Adult | 2011 |
Reversible decrease of portal venous flow in cirrhotic patients: a positive side effect of sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Regional Blood Flow; Sorafenib; Survival Analysis | 2011 |
Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study.
Topics: Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Cytochrome P-450 Enzyme System; Dextromethorphan; Drug Interactions; Humans; Isoenzymes; Melanoma; Midazolam; Niacinamide; Omeprazole; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Female; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2011 |
A randomized phase II of gemcitabine and sorafenib versus sorafenib alone in patients with metastatic pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cyclooxygenase 2; Cytidine Deaminase; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Nucleoside Deaminases; Pancreatic Neoplasms; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; Ribonucleoside Diphosphate Reductase; Sorafenib; Tumor Suppressor Proteins | 2012 |
[Randomize trial of cisplatin plus gemcitabine with either sorafenib or placebo as first-line therapy for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Female; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Sorafenib | 2011 |
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Drug Interactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2011 |
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial.
Topics: Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Cluster Analysis; Cytokines; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Humans; Interferon-alpha; Kaplan-Meier Estimate; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Baseline patient-reported kidney cancer-specific symptoms as an indicator for median survival in sorafenib-refractory metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quality of Life; Research Design; Self Report; Sorafenib; Surveys and Questionnaires; Survival Analysis; Treatment Outcome | 2011 |
Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Osteosarcoma; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Failure; Treatment Outcome; Young Adult | 2012 |
In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp.
Topics: Adult; Aged; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates; Blotting, Western; Carcinoma, Medullary; Case-Control Studies; Cell Transformation, Neoplastic; Cells, Cultured; Female; Germ-Line Mutation; Humans; Kidney; Luciferases; Male; Mice; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutagenesis, Site-Directed; Niacinamide; NIH 3T3 Cells; Pedigree; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Thyroid Neoplasms; Transcription Factor 4; Transcription Factors; Young Adult | 2011 |
A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Female; Humans; Middle Aged; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Pilot Projects; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Population; Pyridines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Outcome; United Kingdom; Young Adult | 2011 |
Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gastrointestinal Diseases; Genes, erbB-1; Genes, ras; Hematologic Diseases; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Quinazolines; Salvage Therapy; Sorafenib; Treatment Outcome | 2011 |
PR-104 plus sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Female; Half-Life; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Nitrogen Mustard Compounds; Phenylurea Compounds; Prodrugs; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival; Treatment Outcome | 2011 |
Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Follow-Up Studies; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Retrospective Studies; Sorafenib; Sulfonamides; Survival Rate; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2011 |
A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Capecitabine; Cohort Studies; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Hand-Foot Syndrome; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease Progression; Double-Blind Method; Female; Humans; Intention to Treat Analysis; Japan; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Republic of Korea; Sorafenib; Survival Analysis; Treatment Outcome | 2011 |
Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Combinations; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Treatment Outcome | 2012 |
Multikinase inhibitors in metastatic renal cell carcinoma: indirect comparison meta-analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib | 2011 |
Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Immunity, Cellular; Immunity, Humoral; Indoles; Influenza Vaccines; Influenza, Human; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Vaccination | 2011 |
Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib | 2011 |
Thyroid size change by CT monitoring after sorafenib or sunitinib treatment in patients with renal cell carcinoma: comparison with thyroid function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Organ Size; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Gland; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Phase IB study of sorafenib in combination with gemcitabine and cisplatin in patients with refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Cisplatin; Deoxycytidine; Drug Administration Schedule; Drug Resistance, Neoplasm; Gastrointestinal Diseases; Gemcitabine; Hematologic Diseases; Humans; Metabolic Clearance Rate; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Treatment Outcome | 2012 |
Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Azacitidine; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cytarabine; Cytokines; Farnesyltranstransferase; Hematopoietic Stem Cells; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Niacinamide; Oxides; Phenylurea Compounds; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2011 |
SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Cholangiocarcinoma; Disease-Free Survival; Female; Gallbladder Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2012 |
Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dacarbazine; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib | 2011 |
Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Leiomyosarcoma; Liposarcoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sarcoma; Sorafenib; Survival Rate; Vascular Neoplasms | 2012 |
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Benzenesulfonates; Child; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib | 2011 |
A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Nitriles; Orchiectomy; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib; Time Factors; Tosyl Compounds; Treatment Failure | 2012 |
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid ca
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Protocols; Double-Blind Method; Drug Administration Schedule; Humans; Iodine Radioisotopes; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Outcome | 2011 |
The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis | 2011 |
Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib | 2011 |
Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Child; Cisplatin; Disease-Free Survival; Doxorubicin; Female; Follow-Up Studies; Humans; Liver Neoplasms; Liver Transplantation; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Transplantation, Homologous | 2012 |
Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Diarrhea; Disease Progression; Drug Therapy, Combination; Everolimus; Female; Humans; Immunosuppressive Agents; Incidence; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sirolimus; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Epidemiologic Methods; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Young Adult | 2011 |
[Safety and efficacy of Sorafenib in treatment of tumor recurrence in liver transplantation recipients].
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Phase I trial of sorafenib in patients with recurrent or progressive malignant glioma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Distribution; Treatment Outcome; Young Adult | 2011 |
Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Topotecan | 2011 |
[Third-line therapy for metastasized renal cell carcinoma: a randomized, multicenter non-blinded phase III study to compare safety and effectiveness of TF1258 versus sorafenib in patients with metastasized renal cell carcinoma following failure of antiang
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Carcinoma, Renal Cell; Disease Progression; Female; Germany; Humans; Kidney Neoplasms; Male; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Vascular Endothelial Growth Factor A | 2011 |
Sorafenib in hepatocellular carcinoma - a post marketing evaluation.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Product Surveillance, Postmarketing; Protein Kinase Inhibitors; Pyridines; Registries; Sorafenib; Survival Rate | 2012 |
High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Endothelial Cells; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stem Cells | 2011 |
Saturable absorption of sorafenib in patients with solid tumors: a population model.
Topics: Absorption; Administration, Oral; Adult; Aged; Aged, 80 and over; Biological Availability; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2012 |
Feasibility study of intra-patient sorafenib dose-escalation or re-escalation in patients with previously treated advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Dose-Response Relationship, Drug; Drug Tolerance; Feasibility Studies; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Sorafenib | 2012 |
Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Interferons; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sirolimus; Sorafenib; Treatment Failure; Treatment Outcome; Vascular Endothelial Growth Factor A | 2011 |
Phase II trial of sorafenib in combination with 5-fluorouracil infusion in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Young Adult | 2011 |
Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Proteins; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Sorafenib | 2012 |
Sorafenib, but not sunitinib, induces regulatory T cells in the peripheral blood of patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; CD3 Complex; CD4 Antigens; Female; Forkhead Transcription Factors; Humans; Indoles; Interleukin-2 Receptor alpha Subunit; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Treatment Outcome | 2012 |
Preliminary experience with personalized and targeted therapy for pediatric brain tumors.
Topics: Adolescent; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Boronic Acids; Bortezomib; Brain Neoplasms; Child; Child, Preschool; Curcumin; Disease-Free Survival; Estradiol; Female; Follow-Up Studies; Fulvestrant; Humans; Infant; Male; Niacinamide; Phenylurea Compounds; Pyrazines; Pyridines; Sirolimus; Sorafenib; Survival Rate | 2012 |
Phase I trial of everolimus plus sorafenib for patients with advanced renal cell cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome | 2012 |
Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma.
Topics: Adrenal Cortex Neoplasms; Adrenocortical Carcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib | 2012 |
Paclitaxel in combination with sorafenib and bevacizumab in patients with locally advanced or metastatic solid tumors.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Humans; Maximum Tolerated Dose; Neoplasm Metastasis; Neoplasms; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Child; Child, Preschool; Drug Synergism; Erlotinib Hydrochloride; Female; Humans; Indoles; Male; Molecular Targeted Therapy; Neurofibromatosis 2; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome; Valproic Acid; Vascular Endothelial Growth Factor A; Young Adult | 2012 |
Phase II escalation study of sorafenib in patients with metastatic renal cell carcinoma who have been previously treated with anti-angiogenic treatment.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Male; Middle Aged; Mucositis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Sorafenib; Treatment Outcome | 2012 |
Conventional transarterial chemoembolisation in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Radiography; Sorafenib; Treatment Outcome | 2012 |
Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib.
Topics: Adenocarcinoma, Clear Cell; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Reproducibility of Results; Risk Factors; Sorafenib; Young Adult | 2012 |
Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome | 2012 |
Phase I trial of sorafenib in combination with 5-fluorouracil/leucovorin in advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Benzenesulfonates; Drug Administration Schedule; Drug Interactions; Female; Fluorouracil; Humans; Infusions, Intravenous; Injections, Intravenous; Israel; Leucovorin; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Vitamin B Complex | 2012 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III Sorafenib Asia-Pacific trial.
Topics: Adult; Benzenesulfonates; Carcinoma, Hepatocellular; China; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Placebos; Prognosis; Pyridines; Republic of Korea; Sorafenib; Taiwan; Time Factors; Treatment Outcome | 2012 |
Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; alpha-Fetoproteins; Antineoplastic Agents; Aspartate Aminotransferases; Benzenesulfonates; Bilirubin; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Survival Rate; Treatment Outcome | 2012 |
Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Genotype; Humans; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Treatment Outcome | 2012 |
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cohort Studies; Disease Progression; Docetaxel; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Taxoids; Treatment Outcome | 2012 |
Sorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Endpoint Determination; Female; Hemangiosarcoma; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib | 2012 |
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Double-Blind Method; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib | 2012 |
Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Capillary Permeability; Extracellular Fluid; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pressure; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sarcoma; Sorafenib; Vascular Endothelial Growth Factors | 2012 |
Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.
Topics: Adult; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; Benzenesulfonates; Bone Marrow; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Humans; Janus Kinase 3; Leukemia, Myeloid, Acute; Male; Matrix Metalloproteinase 15; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Structure, Tertiary; Pyridines; Retinal Dehydrogenase; Sorafenib; Time Factors; Transplantation, Heterologous | 2012 |
Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.
Topics: Alkaline Phosphatase; alpha-Fetoproteins; Angiopoietin-2; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2012 |
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory disease.
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib | 2012 |
Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Brazil; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Europe; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Sorafenib; Time Factors; Treatment Outcome | 2012 |
A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vorinostat | 2013 |
Cryotherapy is associated with improved clinical outcomes of Sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Cryotherapy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Microvessels; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2012 |
Safety and pharmacokinetics of ganitumab (AMG 479) combined with sorafenib, panitumumab, erlotinib, or gemcitabine in patients with advanced solid tumors.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Deoxycytidine; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Panitumumab; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, IGF Type 1; Sorafenib | 2012 |
The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Treatment Outcome | 2012 |
A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity.
Topics: Antineoplastic Combined Chemotherapy Protocols; Extremities; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Melanoma; Melphalan; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Array Analysis; Skin Neoplasms; Sorafenib; Tissue Distribution | 2012 |
A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2012 |
Phase II study of sorafenib in patients with relapsed or refractory lymphoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lymphoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Young Adult | 2012 |
[First-line therapy of advanced or metastasized renal cell cancer: open randomized phase III sequence study to examine the effectiveness and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2012 |
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cetuximab; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Irinotecan; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tissue Distribution | 2013 |
Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Diarrhea; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome; Ultrasonography | 2012 |
A phase I study of the combination of sorafenib with temozolomide and radiation therapy for the treatment of primary and recurrent high-grade gliomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Dacarbazine; Female; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Sorafenib; Temozolomide; Vascular Endothelial Growth Factor A | 2013 |
The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status.
Topics: Antineoplastic Agents; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; HL-60 Cells; Humans; Imidazoles; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Piperazines; Sorafenib; Tumor Suppressor Protein p53 | 2012 |
AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Double-Blind Method; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Recombinant Fusion Proteins; Sorafenib; Survival Rate | 2012 |
Primary renal cell carcinoma: relationship between 18F-FDG uptake and response to neoadjuvant sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Biological Transport; Carcinoma, Renal Cell; Feasibility Studies; Female; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Safety; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2012 |
Selective internal radiation therapy of hepatocellular carcinoma: potential hepatopulmonary shunt reduction after sorafenib administration.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Hepatopulmonary Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Radiotherapy, Adjuvant; Sorafenib; Treatment Outcome | 2012 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Topics: Aged; Alcoholism; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Fatigue; Female; Hand-Foot Syndrome; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Severity of Illness Index; Sorafenib; Time Factors; Tumor Burden | 2012 |
Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Niacinamide; Orchiectomy; Phenylurea Compounds; Pilot Projects; Prednisone; Prospective Studies; Prostatic Neoplasms; Pyridines; Sorafenib; Taxoids; Testosterone | 2012 |
Sorafenib in advanced melanoma: a critical role for pharmacokinetics?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease-Free Survival; Female; Humans; Male; Melanoma; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib | 2012 |
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Ribonucleotide Reductases; Sorafenib | 2012 |
Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Castration; Drug Administration Schedule; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Prostatic Neoplasms; Pyridines; Pyrimidines; Retreatment; Sorafenib; Treatment Failure | 2012 |
Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome | 2012 |
Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo.
Topics: Advanced Oxidation Protein Products; Aged; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Female; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Kinetics; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Middle Aged; Niacinamide; Nitrates; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib | 2012 |
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Carcinoma, Papillary, Follicular; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Iodine Radioisotopes; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Ontogeny and sorafenib metabolism.
Topics: Adolescent; Age Factors; Azoles; Child; Child, Preschool; Cytochrome P-450 CYP3A; Female; Humans; Infant; Infant, Newborn; Liver; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sex Factors; Sorafenib; Triazoles; Voriconazole; Young Adult | 2012 |
A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Paclitaxel; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib | 2013 |
Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Male; Maximum Tolerated Dose; Neurofibroma, Plexiform; Neurofibromatosis 1; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Leukemia; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Young Adult | 2012 |
Could interferon still play a role in metastatic renal cell carcinoma? A randomized study of two schedules of sorafenib plus interferon-alpha 2a (RAPSODY).
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Interferon alpha-2; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Recombinant Proteins; Sorafenib; Treatment Outcome | 2013 |
A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Salvage Therapy; Sorafenib; Survival Rate | 2012 |
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Piperidines; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate; Tetrahydronaphthalenes | 2012 |
A phase I/II study of sorafenib in combination with low dose cytarabine in elderly patients with acute myeloid leukemia or high-risk myelodysplastic syndrome from the National Cancer Institute of Canada Clinical Trials Group: trial IND.186.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Myelodysplastic Syndromes; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2012 |
Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; Young Adult | 2012 |
Tumour burden is an independent prognostic factor in metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden | 2012 |
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Drug Eruptions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Sorafenib; Survival Analysis; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms | 2013 |
Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.
Topics: Adult; Aged; Antineoplastic Agents; Asia; Asian People; Carcinoma, Hepatocellular; Catheterization; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Research Design; Sorafenib; Treatment Outcome | 2013 |
The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Severity of Illness Index; Sorafenib; Sunitinib | 2012 |
Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors.
Topics: Adolescent; Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Child; Child, Preschool; Cyclophosphamide; Female; Humans; Infant; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Dose-Response Relationship, Drug; Drug Hypersensitivity; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib | 2013 |
[Serum pancreatic enzyme elevation under treatment with sorafenib].
Topics: Adult; Aged, 80 and over; Amylases; Benzenesulfonates; Humans; Lipase; Male; Middle Aged; Niacinamide; Pancreas; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Sorafenib and dacarbazine in soft tissue sarcoma: a single institution experience.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sarcoma; Sorafenib; Treatment Outcome | 2013 |
Phase II study of sorafenib in combination with cisplatin and 5-fluorouracil to treat recurrent or metastatic nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography | 2013 |
A phase II study of sorafenib in patients with platinum-pretreated, advanced (Stage IIIb or IV) non-small cell lung cancer with a KRAS mutation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Platinum; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib; Treatment Outcome | 2013 |
Phase II trial of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic uveal melanoma: SWOG S0512.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Carboplatin; Disease-Free Survival; Drug Administration Schedule; Eye Neoplasms; Female; Humans; Injections, Intravenous; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib; Treatment Outcome; Uvea; Uveal Neoplasms | 2012 |
Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Disease-Free Survival; Female; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Sarcoma; Sorafenib | 2013 |
Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Exanthema; Female; Glucuronosyltransferase; HLA-A24 Antigen; Humans; Kidney Neoplasms; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2013 |
Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Imaging, Three-Dimensional; Iopamidol; Liver Neoplasms; Male; Middle Aged; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Pilot Projects; Radiography, Dual-Energy Scanned Projection; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib | 2013 |
MRI assessment of early tumor response in metastatic renal cell carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Female; Gadolinium; Humans; Kidney Neoplasms; Liver Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2013 |
Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?
Topics: Adult; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Dose-Response Relationship, Drug; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Regional Blood Flow; Sorafenib; Treatment Outcome; Ultrasonography | 2013 |
Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Axitinib; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Hand-Foot Syndrome; Heparin; Humans; Imidazoles; Indazoles; Indoles; Male; Middle Aged; Niacinamide; Ointments; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrroles; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Surveys and Questionnaires | 2013 |
A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biliary Tract Neoplasms; Capecitabine; Demography; Deoxycytidine; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome; Wisconsin | 2013 |
Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Early Detection of Cancer; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Pilot Projects; Prognosis; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2013 |
Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Niacinamide; Paclitaxel; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Sorafenib; Tomography, X-Ray Computed | 2013 |
CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study.
Topics: Adenosine; Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Child; Female; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Purinergic P1 Receptor Agonists; Receptor, Adenosine A3; Sorafenib; Wnt Signaling Pathway | 2013 |
Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: a propensity score matching study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Prospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2013 |
[Phase II clinical trial of sorafenib plus local chemotherapy in the treatment of metastatic renal cell carcinoma with pleural effusion].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pleural Effusion; Sorafenib; Treatment Outcome | 2012 |
NABTT 0502: a phase II and pharmacokinetic study of erlotinib and sorafenib for patients with progressive or recurrent glioblastoma multiforme.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Survival Rate; Tissue Distribution | 2013 |
Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
Topics: Adult; Aged; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinolones; Salvage Therapy; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Renal Cell; Drug Evaluation, Preclinical; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinolones; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Survival Rate; Tissue Distribution; Vascular Endothelial Growth Factor Receptor-1 | 2013 |
Phase II trial of sequential subcutaneous interleukin-2 plus interferon alpha followed by sorafenib in renal cell carcinoma (RCC).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Immunotherapy; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Probability; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome | 2013 |
In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cyclophosphamide; Female; Flow Cytometry; Follow-Up Studies; Humans; Male; Middle Aged; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; raf Kinases; Sorafenib; Survival Rate; Tissue Distribution | 2013 |
Sorafenib in advanced hepatocellular carcinoma: a nationwide retrospective study of efficacy and tolerability.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Hypertension; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2-negative advanced breast cancer that progressed during or after bevacizumab.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Deoxycytidine; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Fatigue; Female; Fluorouracil; Gemcitabine; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Skin Diseases; Sorafenib; Stomatitis; Treatment Outcome | 2013 |
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Pharmacological; Cohort Studies; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Genital Neoplasms, Female; Humans; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Predictive Value of Tests; Proto-Oncogene Proteins c-akt; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Sorafenib in combination with transarterial chemoembolization in Chinese patients with hepatocellular carcinoma: a subgroup interim analysis of the START trial.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Everolimus; Feasibility Studies; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2013 |
Sorafenib in patients with refractory or recurrent multiple myeloma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Eruptions; Drug Resistance, Neoplasm; Fatigue; Female; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Humans; Interferon-alpha; Lenalidomide; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Pain; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Recurrence; Remission Induction; Salvage Therapy; Sorafenib; Thalidomide; Treatment Outcome | 2013 |
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Sirolimus; Sorafenib; Treatment Outcome | 2013 |
A phase I study of sorafenib in combination with S-1 plus cisplatin in patients with advanced gastric cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Combinations; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Oxonic Acid; Patient Compliance; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Tegafur; Treatment Outcome | 2014 |
Sorafenib in combination with oxaliplatin, leucovorin, and fluorouracil (modified FOLFOX6) as first-line treatment of metastatic colorectal cancer: the RESPECT trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Fluorouracil; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neutropenia; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Niacinamide; Pemetrexed; Phenylurea Compounds; Platinum; Pleural Neoplasms; Prognosis; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Survival Rate | 2013 |
Patient-reported outcomes for axitinib vs sorafenib in metastatic renal cell carcinoma: phase III (AXIS) trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Self Report; Sorafenib; Treatment Outcome; Young Adult | 2013 |
A phase II randomized dose escalation trial of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Disease-Free Survival; Drug Administration Schedule; Female; France; Head and Neck Neoplasms; Hemangioendothelioma, Epithelioid; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rare Diseases; Sorafenib; Time Factors; Treatment Outcome | 2013 |
A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Sorafenib | 2013 |
Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Intention to Treat Analysis; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Quality of Life; Sorafenib; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2013 |
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib; Survival Rate; Tandem Repeat Sequences; Young Adult | 2013 |
Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; Treatment Outcome | 2013 |
Efficacy and safety of axitinib versus sorafenib in metastatic renal cell carcinoma: subgroup analysis of Japanese patients from the global randomized Phase 3 AXIS trial.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Axitinib; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Hypertension; Hypothyroidism; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proteinuria; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Lenalidomide for second-line treatment of advanced hepatocellular cancer: a Brown University oncology group phase II study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neutropenia; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Disease Progression; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Quinolines; Quinolones; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Outcome; Valproic Acid | 2013 |
Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
Topics: Aged; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Technetium Tc 99m Aggregated Albumin; World Health Organization; Yttrium Radioisotopes | 2013 |
Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
Topics: Adolescent; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Phase I clinical trial of lenalidomide in combination with sorafenib in patients with advanced cancer.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Humans; Immunologic Factors; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Sorafenib; Thalidomide; Young Adult | 2014 |
Alternative formulations of sorafenib for use in children.
Topics: Administration, Oral; Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Phase I trial of sorafenib in combination with ifosfamide in patients with advanced sarcoma: a Spanish group for research on sarcomas (GEIS) study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Cell Proliferation; Female; Humans; Ifosfamide; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Sarcoma; Sorafenib; Young Adult | 2014 |
A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Female; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
Sorafenib versus capecitabine in the management of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Fluorouracil; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2013 |
Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Brain Neoplasms; Disease-Free Survival; Female; Glioblastoma; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Proportional Hazards Models; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
"Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.
Topics: Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
A phase 3 tRial comparing capecitabinE in combination with SorafenIb or pLacebo for treatment of locally advanced or metastatIc HER2-Negative breast CancEr (the RESILIENCE study): study protocol for a randomized controlled trial.
Topics: Administration, Oral; Algorithms; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Clinical Protocols; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Dosage Calculations; Female; Fluorouracil; Humans; Neoplasm Invasiveness; Niacinamide; Patient Selection; Phenylurea Compounds; Receptor, ErbB-2; Research Design; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Causality; Comorbidity; Drug Eruptions; Female; Germany; Humans; Interferon-alpha; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Prevalence; Recombinant Proteins; Risk Factors; Skin Neoplasms; Sorafenib; Treatment Outcome | 2013 |
Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2013 |
Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Dacarbazine; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Survival Analysis; Temozolomide; Time Factors | 2013 |
A phase II study of gemcitabine and cisplatin plus sorafenib in patients with advanced biliary adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Extrahepatic; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Cholangiocarcinoma; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gallbladder Neoplasms; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Everolimus; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib | 2013 |
Expression of drug targets in patients treated with sorafenib, carboplatin and paclitaxel.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib | 2013 |
Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Dacarbazine; Female; Gene Expression Regulation, Neoplastic; Genomics; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography | 2014 |
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Survival Rate; Triazines; Young Adult | 2013 |
Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Carcinoma, Hepatocellular; Double-Blind Method; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Survival Rate; Triazines; Young Adult | 2013 |
Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Sirolimus; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden | 2014 |
Sorafenib in patients with progressive malignant solitary fibrous tumors: a subgroup analysis from a phase II study of the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Solitary Fibrous Tumors; Sorafenib; Treatment Outcome | 2013 |
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801).
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Asthenia; Bevacizumab; Diarrhea; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mucositis; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Sorafenib; Spain; Treatment Outcome | 2013 |
Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Health Status; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Odds Ratio; Phenylurea Compounds; Quality of Life; Quinolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome | 2013 |
Reasons for non-completion of health related quality of life evaluations in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.
Topics: Adolescent; Boronic Acids; Bortezomib; Child; Child, Preschool; Female; Group Processes; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Parents; Phenylurea Compounds; Pyrazines; Quality of Life; Self Report; Sorafenib; Surveys and Questionnaires; Survival Analysis; Young Adult | 2013 |
Prospective randomized double-blind multicentre phase II study comparing gemcitabine and cisplatin plus sorafenib chemotherapy with gemcitabine and cisplatin plus placebo in locally advanced and/or metastasized urothelial cancer: SUSE (AUO-AB 31/05).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Double-Blind Method; Female; Gemcitabine; Humans; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Treatment Outcome; Urologic Neoplasms | 2014 |
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Sorafenib; Treatment Outcome | 2013 |
Multicenter phase II study of oxaliplatin and sorafenib in advanced gastric adenocarcinoma after failure of cisplatin and fluoropyrimidine treatment. A GEMCAD study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Treatment Outcome | 2013 |
Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib; Young Adult | 2013 |
Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment.
Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Surveys and Questionnaires; Treatment Outcome | 2014 |
Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
[Efficacies of sorafenib plus interferon in advanced renal cell carcinoma: a report of 57 cases].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Interferons; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates.
Topics: Adult; Chemoradiotherapy; Combined Modality Therapy; Female; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Preoperative Period; Radiography; Sarcoma; Sorafenib; Young Adult | 2013 |
Efficacy of sorafenib in advanced renal cell carcinoma independent of prior treatment, histology or prognostic group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2014 |
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Disease-Free Survival; Everolimus; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Piperidines; Quinazolines; Retrospective Studies; Sirolimus; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2013 |
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Drug Resistance, Neoplasm; Humans; Male; Middle Aged; Mitoxantrone; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Sorafenib; Survival Analysis; Taxoids; Treatment Failure | 2014 |
Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering.
Topics: Adult; Aged; CD4 Antigens; Cell Growth Processes; Female; Humans; Interleukin-15; Interleukin-15 Receptor alpha Subunit; Male; Melanoma; Middle Aged; Niacinamide; NK Cell Lectin-Like Receptor Subfamily K; Phenylurea Compounds; Sorafenib; Th1 Cells; Young Adult | 2014 |
Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Confounding Factors, Epidemiologic; Disease-Free Survival; Europe; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; North America; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Research Design; Severity of Illness Index; Sorafenib; Treatment Outcome | 2013 |
Low level of baseline circulating VEGF-A is associated with better outcome in patients with vascular sarcomas receiving sorafenib: an ancillary study from a phase II trial.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Enzyme-Linked Immunosorbent Assay; Hemangioendothelioma, Epithelioid; Hemangiosarcoma; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Young Adult | 2014 |
Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Time Factors; TOR Serine-Threonine Kinases; Treatment Failure; Young Adult | 2014 |
Practical effect of sorafenib monotherapy on advanced hepatocellular carcinoma and portal vein tumor thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease-Free Survival; Fatigue; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nausea; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Sorafenib; Tomography, Spiral Computed; Venous Thrombosis | 2013 |
A cross-sectional investigation of fatigue in advanced renal cell carcinoma treatment: results from the FAMOUS study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cross-Sectional Studies; Everolimus; Fatigue; Female; Humans; Incidence; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Physicians; Pyrroles; Quality of Life; Self Report; Sirolimus; Sorafenib; Sunitinib; Surveys and Questionnaires | 2014 |
Efficacy and safety of sorafenib-gemcitabine combination therapy in advanced hepatocellular carcinoma: an open-label Phase II feasibility study.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Demography; Deoxycytidine; Feasibility Studies; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Phase II trial of sorafenib in advanced salivary adenoid cystic carcinoma of the head and neck.
Topics: Adult; Aged; Carcinoma, Adenoid Cystic; Disease Progression; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Salivary Gland Neoplasms; Sorafenib | 2015 |
The feasibility of combined transcatheter arterial chemoembolization and radiotherapy for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Doxorubicin; Ethiodized Oil; Feasibility Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Republic of Korea; Sorafenib | 2014 |
A randomized multicenter phase II trial on the efficacy of a hydrocolloid dressing containing ceramide with a low-friction external surface for hand-foot skin reaction caused by sorafenib in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Bandages, Hydrocolloid; Carcinoma, Renal Cell; Ceramides; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Surface Properties; Treatment Outcome | 2014 |
Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib.
Topics: Ascites; Astrocytoma; Brain Neoplasms; Child; Humans; Magnetic Resonance Imaging; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Sorafenib; Ventriculoperitoneal Shunt | 2014 |
A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Angiogenic Proteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Recombinant Fusion Proteins; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Phase I/II trial of vinorelbine and sorafenib in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Follow-Up Studies; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate; Vinblastine; Vinorelbine | 2014 |
Technical considerations in the development of circulating peptides as pharmacodynamic biomarkers for angiogenesis inhibitors.
Topics: Adult; Aged; Angiogenesis Inhibitors; Angiopoietin-2; Biomarkers; Exercise; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2014 |
Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma.
Topics: Aged; Antibodies, Monoclonal; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochemistry; Indium Radioisotopes; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Protein-Tyrosine Kinases; Radionuclide Imaging; Sorafenib | 2014 |
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease Progression; Disease-Free Survival; Female; Humans; Irinotecan; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib | 2014 |
A phase I, dose-finding study of sorafenib in combination with gemcitabine and radiation therapy in patients with unresectable pancreatic adenocarcinoma: a Grupo Español Multidisciplinario en Cáncer Digestivo (GEMCAD) study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Tomography, X-Ray Computed | 2014 |
Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Etoposide; Female; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Small Cell Lung Carcinoma; Sorafenib; Treatment Outcome | 2014 |
Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein.
Topics: Antibodies, Monoclonal, Humanized; Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Female; Humans; Immunohistochemistry; Middle Aged; Molecular Targeted Therapy; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; S100 Proteins; Sarcoma; Sequence Analysis, DNA; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gallbladder Neoplasms; Humans; Male; MAP Kinase Signaling System; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A | 2014 |
Phase I study of combination chemotherapy using sorafenib and transcatheter arterial infusion with cisplatin for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease-Free Survival; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
A multicenter phase II study of sorafenib monotherapy in clinically selected patients with advanced lung adenocarcinoma after failure of EGFR-TKI therapy (Chinese Thoracic Oncology Group, CTONG 0805).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinogenesis; China; ErbB Receptors; Female; Genotype; Hand-Foot Syndrome; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Sequence Deletion; Sorafenib; Survival Analysis; Treatment Failure | 2014 |
Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Phase I trial of neoadjuvant conformal radiotherapy plus sorafenib for patients with locally advanced soft tissue sarcoma of the extremity.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Extremities; Female; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Prognosis; Radiotherapy, Conformal; Sarcoma; Sorafenib | 2014 |
Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolones; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Quinazolines; Sorafenib | 2014 |
Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Hypertension; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
A phase I study of high-dose interleukin-2 with sorafenib in patients with metastatic renal cell carcinoma and melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Interleukin-2; Kidney Neoplasms; Male; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; STAT5 Transcription Factor; T-Lymphocytes, Regulatory | 2014 |
A phase I/II study of S-1 with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oxonic Acid; Phenylurea Compounds; Prospective Studies; Sorafenib; Tegafur | 2014 |
Multicenter phase II study of sequential radioembolization-sorafenib therapy for inoperable hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Time Factors; Yttrium Radioisotopes | 2014 |
Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
Topics: Adult; Aged; Blood Pressure; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Young Adult | 2014 |
Impairment of cognitive functioning during Sunitinib or Sorafenib treatment in cancer patients: a cross sectional study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Cognition; Cognition Disorders; Cross-Sectional Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Memory; Middle Aged; Neoplasm Metastasis; Neuropsychological Tests; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib | 2014 |
Phase 2 study of combined sorafenib and radiation therapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoradiotherapy; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Female; Fibrosis; Hand-Foot Syndrome; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiation Dosage; Sorafenib; Time Factors; Treatment Outcome; Venous Thrombosis | 2014 |
Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Extracellular Signal-Regulated MAP Kinases; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; ras Proteins; Sirolimus; Sorafenib | 2014 |
Prospective randomized pilot study of Y90+/-sorafenib as bridge to transplantation in hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Graft Rejection; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Radiation Dosage; Sorafenib; Yttrium Radioisotopes | 2014 |
Sorafenib in liver function impaired advanced hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cross-Over Studies; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Young Adult | 2014 |
Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Female; Humans; Liver Function Tests; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Rate; Tomography, Spiral Computed; Treatment Outcome; Venous Thrombosis | 2014 |
Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Double-Blind Method; Female; Follow-Up Studies; Genotype; GTP Phosphohydrolases; Humans; Male; Melanoma; Membrane Proteins; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Survival Rate | 2014 |
Neoadjuvant sorafenib treatment of clear cell renal cell carcinoma and release of circulating tumor fragments.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Phase 1 pharmacogenetic and pharmacodynamic study of sorafenib with concurrent radiation therapy and gemcitabine in locally advanced unresectable pancreatic cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Deoxycytidine; Disease-Free Survival; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Gemcitabine; Genotype; Humans; Induction Chemotherapy; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Polymorphism, Single Nucleotide; Prospective Studies; Radiotherapy, Intensity-Modulated; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
[First-line therapy of advanced or metastasized renal cell carcinoma: phase III, open, randomized sequence study to examine efficacy and tolerance of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the first-line treatment of pat
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Germany; Humans; Indazoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Survival Rate; Young Adult | 2014 |
A phase I/II trial of capecitabine combined with peginterferon α-2a in Patients with sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Deoxycytidine; Female; Fluorouracil; Humans; Interferon-alpha; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Sorafenib | 2014 |
Safety and efficacy of sorafenib in the treatment of advanced hepatocellular carcinoma: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Safety; Sorafenib; Survival Rate | 2014 |
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Thyroid Neoplasms; Treatment Outcome; Young Adult | 2014 |
Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemoradiotherapy; Dacarbazine; Disease-Free Survival; Female; Glioblastoma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Temozolomide; Treatment Outcome | 2014 |
Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Neutrophils; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Sorafenib; Treatment Outcome | 2014 |
Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.
Topics: Adolescent; Animals; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Child, Preschool; Female; Humans; Kaplan-Meier Estimate; Magnetic Resonance Imaging; Male; MAP Kinase Signaling System; Mice; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2014 |
Efficacy and safety of sorafenib in combination with gemcitabine in patients with advanced hepatocellular carcinoma: a multicenter, open-label, single-arm phase II study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab in combination with sorafenib in patients with advanced malignant melanoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers; Disease Progression; Drug Monitoring; Early Termination of Clinical Trials; Feasibility Studies; Female; Hand-Foot Syndrome; Humans; Hypertension; Kinetics; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Severity of Illness Index; Sorafenib; Vascular Endothelial Growth Factors | 2014 |
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cytokines; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden | 2014 |
Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Bone Neoplasms; Brain Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Receptors, Estrogen; Sorafenib; Tamoxifen; Treatment Outcome | 2014 |
Analysis of survival factors in patients with intermediate-advanced hepatocellular carcinoma treated with transcatheter arterial chemoembolization combined with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Sorafenib | 2014 |
A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Aberrations; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Multiple Myeloma; Neoplasm Grading; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2014 |
Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Europe; Follow-Up Studies; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Treatment Outcome; Yttrium | 2015 |
Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).
Topics: Administration, Oral; Adult; Aged; Carcinoma, Hepatocellular; Cohort Studies; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Oligonucleotides; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Double-Blind Method; Everolimus; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib; Survival Analysis; Young Adult | 2014 |
Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Calcium-Calmodulin-Dependent Protein Kinase Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Female; Humans; Lung Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Reactive Oxygen Species; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
The combination of transcatheter arterial chemoembolization and sorafenib is well tolerated and effective in Asian patients with hepatocellular carcinoma: final results of the START trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib | 2015 |
TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Ethiodized Oil; Fatigue; Hepatic Encephalopathy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Poor results for everolimus in patients with liver cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Everolimus; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sirolimus; Sorafenib; Survival Analysis; Treatment Failure | 2014 |
Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Delayed-Action Preparations; Dose-Response Relationship, Drug; Doxorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Maryland; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate; Time Factors; Tumor Burden | 2015 |
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
Topics: Adult; Aged; Allografts; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mutagenesis, Insertional; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Rate | 2014 |
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lymphoproliferative Disorders; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Proto-Oncogene Proteins c-akt; Recurrence; Sorafenib; Treatment Outcome; Young Adult | 2014 |
Preclinical and clinical evidence of activity of pazopanib in solitary fibrous tumour.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Humans; Imidazoles; Indazoles; Indoles; Male; MAP Kinase Signaling System; Mice, SCID; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Solitary Fibrous Tumors; Sorafenib; Sulfonamides; Sunitinib; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytochrome P-450 CYP2C19; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Proto-Oncogene Proteins c-met; Pyrrolidinones; Quinolines; Sorafenib; Treatment Outcome; Young Adult | 2015 |
A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers; Carcinoma, Hepatocellular; Diphenylamine; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Sulfonamides; Treatment Outcome | 2014 |
Phase II trial evaluating the efficacy of sorafenib (BAY 43-9006) and correlating early fluorodeoxyglucose positron emission tomography-CT response to outcome in patients with recurrent and/or metastatic head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Dual antiangiogenic inhibition: a phase I dose escalation and expansion trial targeting VEGF-A and VEGFR in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Class I Phosphatidylinositol 3-Kinases; Female; Humans; Male; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins; PTEN Phosphohydrolase; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A | 2015 |
A phase I study of the histone deacetylase (HDAC) inhibitor entinostat, in combination with sorafenib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Female; Histone Deacetylase Inhibitors; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2015 |
A Phase II trial of dosage escalation of sorafenib in Asian patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Young Adult | 2014 |
Clinical efficacy and prognostic factors of tumor progression in Japanese patients with advanced renal cell carcinoma treated with sorafenib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
The off-label use of targeted therapies in sarcomas: the OUTC'S program.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cyclophosphamide; Disease-Free Survival; Drug Delivery Systems; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Off-Label Use; Phenylurea Compounds; Pyrroles; Registries; Sarcoma; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2014 |
Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biliary Tract Neoplasms; Biomarkers, Tumor; Chemokine CXCL12; Deoxycytidine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Gallbladder Neoplasms; Gemcitabine; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality of Life; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factors | 2014 |
Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Protocols; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Embolization, Therapeutic; France; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Quality of Life; Research Design; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Hypertension; Indazoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Odds Ratio; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyrazines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Recurrence; Small Cell Lung Carcinoma; Sorafenib; Topotecan; Young Adult | 2015 |
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Disease Progression; Disease-Free Survival; Everolimus; Female; Humans; Intention to Treat Analysis; Italy; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Grading; Niacinamide; Osteosarcoma; Phenylurea Compounds; Sirolimus; Sorafenib; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome; Young Adult | 2015 |
[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sulfonamides; Sunitinib | 2015 |
SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Double-Blind Method; Erlotinib Hydrochloride; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Quinazolines; Sorafenib | 2015 |
Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of the Sarah Cannon Research Institute.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Female; Humans; Middle Aged; Neoplasm Grading; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
[Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Diarrhea; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Fatigue; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Salvage Therapy; Severity of Illness Index; Sorafenib; Spain; Treatment Outcome | 2015 |
A randomized phase II efficacy and correlative studies of cetuximab with or without sorafenib in recurrent and/or metastatic head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Female; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib | 2015 |
Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Emulsions; Female; Hand-Foot Syndrome; Humans; Incidence; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Niacinamide; Odds Ratio; Phenylurea Compounds; Quality of Life; Skin; Sorafenib; Surveys and Questionnaires; Treatment Outcome; Urea; Young Adult | 2015 |
Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Female; Follow-Up Studies; gamma-Glutamyltransferase; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2015 |
Phase II study of sorafenib and bortezomib for first-line treatment of metastatic or unresectable renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
Comparison of volumetric and linear serial CT assessments of lung metastases in renal cell carcinoma patients in a clinical phase IIB study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Tomography, X-Ray Computed; Tumor Burden | 2015 |
Genotype Correlations With Blood Pressure and Efficacy From a Randomized Phase III Trial of Second-Line Axitinib Versus Sorafenib in Metastatic Renal Cell Carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Axitinib; Blood Pressure; Carcinoma, Renal Cell; Disease-Free Survival; Female; Genetic Association Studies; Humans; Imidazoles; Indazoles; Kaplan-Meier Estimate; Kidney Neoplasms; Linkage Disequilibrium; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Proportional Hazards Models; Sorafenib; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (iTRAQ) Quantitative Proteomic Analysis Identifies Galectin-1 as a Potential Biomarker for Predicting Sorafenib Resistance i
Topics: Amino Acids; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Galectin 1; Gene Knockdown Techniques; Humans; Isotope Labeling; Liver Neoplasms; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Interaction Maps; Proteomics; Sorafenib; Treatment Outcome | 2015 |
A Phase II Study of Sorafenib Combined With Cetuximab in EGFR-Expressing, KRAS-Mutated Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Humans; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Sorafenib; Vascular Endothelial Growth Factor A; Young Adult | 2015 |
The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Membrane Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Receptor, Fibroblast Growth Factor, Type 1; Sorafenib; Treatment Outcome | 2015 |
SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib | 2015 |
Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Germany; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2015 |
Multiparameter Phase I trials: a tool for model-based development of targeted agent combinations--example of EVESOR trial.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Everolimus; Humans; Models, Theoretical; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genome, Human; Genotype; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Sequence Analysis, DNA; Sorafenib; Symporters; Treatment Outcome | 2015 |
Effects of Adjuvant Sorafenib and Sunitinib on Cardiac Function in Renal Cell Carcinoma Patients without Overt Metastases: Results from ASSURE, ECOG 2805.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Chemotherapy, Adjuvant; Double-Blind Method; Female; Heart Failure; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Ventricular Function, Left | 2015 |
A Phase I Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Disease-Free Survival; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
A phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Female; Fluorouracil; Humans; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2015 |
Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast Media; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2015 |
Safety and efficacy of tigatuzumab plus sorafenib as first-line therapy in subjects with advanced hepatocellular carcinoma: A phase 2 randomized study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2015 |
BEST: A Randomized Phase II Study of Vascular Endothelial Growth Factor, RAF Kinase, and Mammalian Target of Rapamycin Combination Targeted Therapy With Bevacizumab, Sorafenib, and Temsirolimus in Advanced Renal Cell Carcinoma--A Trial of the ECOG-ACRIN C
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; raf Kinases; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome; Vascular Endothelial Growth Factor A | 2015 |
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Hepatocellular; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Proportional Hazards Models; Ramucirumab; Remission Induction; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2015 |
Phase I/II study of S-1 in combination with sorafenib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Drug Combinations; Female; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Oxonic Acid; Phenylurea Compounds; Sorafenib; Tegafur; Treatment Outcome | 2015 |
Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Young Adult | 2015 |
Sorafenib in patients with locally advanced and metastatic chordomas: a phase II trial of the French Sarcoma Group (GSF/GETO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chordoma; Female; Follow-Up Studies; France; Humans; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sarcoma; Sorafenib; Survival Rate | 2015 |
Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Kidney Neoplasms; Male; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rhabdomyosarcoma; Salvage Therapy; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Wilms Tumor; Young Adult | 2015 |
Phase II Trial of Sorafenib in Patients with Chemotherapy Refractory Metastatic Esophageal and Gastroesophageal (GE) Junction Cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Esophageal Neoplasms; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Survival Analysis | 2015 |
Copy Number Changes Are Associated with Response to Treatment with Carboplatin, Paclitaxel, and Sorafenib in Melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; DNA Copy Number Variations; DNA Mutational Analysis; Double-Blind Method; Genes, ras; Humans; Melanoma; Mutation; Neoplasm Staging; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Sorafenib; Treatment Outcome | 2016 |
Safety and efficacy of combination therapy with low-dose gemcitabine, paclitaxel, and sorafenib in patients with cisplatin-resistant urothelial cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Paclitaxel; Pain Measurement; Phenylurea Compounds; Quality of Life; Sorafenib; Urinary Bladder Neoplasms | 2015 |
Prospective analysis of tiopronin in prevention of sorafenib and antiviral therapy inducing liver toxicity in advanced hepatitis B virus-related hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Hepatitis B, Chronic; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Tiopronin | 2015 |
Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asia; Australia; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Double-Blind Method; Europe; Female; Hepatectomy; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; New Zealand; Niacinamide; North America; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; South America; Time Factors; Treatment Outcome; Young Adult | 2015 |
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Papillary; Diarrhea; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Dyspnea; Fatigue; Female; Humans; Hypertension; Hypocalcemia; Incidence; Iodine Radioisotopes; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prevalence; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Thyroid Neoplasms; Weight Loss | 2015 |
The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Sorafenib | 2015 |
Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Withholding Treatment | 2015 |
The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Disease-Free Survival; Female; Glucose-6-Phosphate; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prospective Studies; Radiography; Sorafenib; Survival Rate | 2015 |
Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Survival Rate; Time Factors | 2015 |
Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Thrombosis; Treatment Outcome | 2015 |
Phase II study of temozolomide and veliparib combination therapy for sorafenib-refractory advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Dacarbazine; Disease-Free Survival; DNA Methylation; DNA Repair; DNA, Neoplasm; Drug Resistance, Neoplasm; Fatigue; Female; Genes, BRCA1; Genes, BRCA2; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerase Inhibitors; Salvage Therapy; Sorafenib; Temozolomide; Treatment Failure | 2015 |
Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Japan; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
Liver function assessment according to the Albumin-Bilirubin (ALBI) grade in sorafenib-treated patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease Progression; Exanthema; Fatigue; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Serum Albumin; Serum Albumin, Human; Sorafenib; Treatment Outcome | 2015 |
Sorafenib Increases Tumor Hypoxia in Cervical Cancer Patients Treated With Radiation Therapy: Results of a Phase 1 Clinical Study.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Brachytherapy; Carcinoma, Squamous Cell; Cell Hypoxia; Chemoradiotherapy; Cisplatin; Drug Administration Schedule; Early Termination of Clinical Trials; Female; Follow-Up Studies; Humans; Niacinamide; Oxygen; Partial Pressure; Phenylurea Compounds; Radiation Tolerance; Sorafenib; Time Factors; Tumor Burden; Uterine Cervical Neoplasms | 2016 |
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial.
Topics: Adult; Age Factors; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cytarabine; Daunorubicin; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Germany; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Recurrence; Risk Factors; Sorafenib; Time Factors; Transplantation, Homologous; Treatment Outcome | 2015 |
Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Diphenylamine; Female; Half-Life; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2016 |
Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Child; Drug Administration Schedule; Drug Monitoring; Female; Humans; Male; Maximum Tolerated Dose; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2016 |
Safety and efficacy of sorafenib therapy in patients with hepatocellular carcinoma: final outcome from the Chinese patient subset of the GIDEON study.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Canc
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Sorafenib; Treatment Outcome | 2015 |
Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors | 2016 |
A randomized, double-blind, placebo-controlled phase II study to assess the efficacy and safety of mapatumumab with sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2016 |
Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Double-Blind Method; Doxorubicin; Drug Carriers; Female; Follow-Up Studies; Humans; Injections, Intra-Arterial; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors; Treatment Outcome | 2016 |
The influence of genetic variants of sorafenib on clinical outcomes and toxic effects in patients with advanced renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Sorafenib; Survival Rate | 2016 |
The Prognostic Value of Alpha-Fetoprotein Response for Advanced-Stage Hepatocellular Carcinoma Treated with Sorafenib Combined with Transarterial Chemoembolization.
Topics: Adult; Aged; alpha-Fetoproteins; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate | 2016 |
Antibody-Mediated Blockade of Phosphatidylserine Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinomas Xenografts.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Endothelium; Female; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Mice; Middle Aged; Neoplasm Transplantation; Niacinamide; Phenotype; Phenylurea Compounds; Phosphatidylserines; Rituximab; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
Phase I study of pre-operative continuous 5-FU and sorafenib with external radiation therapy in locally advanced rectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Dose-Response Relationship, Drug; Female; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Rectal Neoplasms; Sorafenib; Treatment Outcome | 2016 |
Phase 1 Trial of Sorafenib and Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose Fractionation, Radiation; Female; Humans; Intestines; Liver; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Radiosurgery; Radiotherapy Dosage; Sorafenib | 2016 |
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Risk Factors; Sorafenib; Treatment Outcome | 2016 |
Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epothilones; Female; Humans; Kaplan-Meier Estimate; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib; Treatment Outcome | 2016 |
Resminostat plus sorafenib as second-line therapy of advanced hepatocellular carcinoma - The SHELTER study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Hydroxamic Acids; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Sulfonamides | 2016 |
Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Changes in Liver Volume Observed Following Sorafenib and Liver Radiation Therapy.
Topics: Adult; Aged; Antineoplastic Agents; Breath Holding; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organ Size; Phenylurea Compounds; Radiotherapy Planning, Computer-Assisted; Radiotherapy, Image-Guided; Sorafenib; Time Factors; Tomography, Spiral Computed; Tumor Burden; Young Adult | 2016 |
Concurrent sorafenib therapy extends the interval to subsequent TACE for patients with unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2016 |
Response and toxicity prediction by MALDI-TOF-MS serum peptide profiling in patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mutation; Niacinamide; Peptides; Phenylurea Compounds; Proteomics; Proto-Oncogene Proteins p21(ras); Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2016 |
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2016 |
Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Asia, Eastern; Benzimidazoles; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Quinolones; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Comparison of central and local serial CT assessments of metastatic renal cell carcinoma patients in a clinical phase IIB study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Data Interpretation, Statistical; Humans; Interferon alpha-2; Interferon-alpha; Kidney; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Recombinant Proteins; Reproducibility of Results; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2017 |
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Female; Humans; Inflammation; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pemetrexed; Phenylurea Compounds; PTEN Phosphohydrolase; Sorafenib; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Intercellular Signaling Peptides and Proteins; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Sorafenib | 2016 |
Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.
Topics: Aged; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Male; Melanoma; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Uveal Neoplasms | 2016 |
Phase I Study of Lenalidomide and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Lenalidomide; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide | 2016 |
Angiogenic Response following Radioembolization: Results from a Randomized Pilot Study of Yttrium-90 with or without Sorafenib.
Topics: Aged; Angiogenesis Inhibitors; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chicago; Down-Regulation; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pilot Projects; Platelet-Derived Growth Factor; Prospective Studies; Radiopharmaceuticals; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2016 |
Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Risk Factors; Sorafenib; Spain; Survival Rate; Treatment Outcome; Young Adult | 2016 |
Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Hepatocellular; Cisplatin; Female; Hepatic Artery; Hepatitis C; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Sorafenib | 2016 |
Axitinib Versus Sorafenib in First-Line Metastatic Renal Cell Carcinoma: Overall Survival From a Randomized Phase III Trial.
Topics: Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Ramucirumab; Sorafenib; Treatment Outcome | 2017 |
Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2016 |
Homoharringtonine (omacetaxine mepesuccinate) as an adjunct for FLT3-ITD acute myeloid leukemia.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Culture Techniques; Cell Line, Tumor; Cluster Analysis; Drug Evaluation, Preclinical; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Harringtonines; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Male; Mice; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Remission Induction; Sorafenib; Treatment Outcome; Young Adult | 2016 |
Real-life experience with sorafenib for the treatment of hepatocellular carcinoma in HIV-infected patients.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Spain; Survival Analysis; Treatment Outcome | 2017 |
Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
Topics: Aged; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Diarrhea; Drug Administration Schedule; Exanthema; Fatigue; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2017 |
Sorafenib Combined with Radio-frequency Ablation Compared with Sorafenib Alone in Treatment of Hepatocellular Carcinoma Invading Portal Vein: A Western Randomized Controlled Trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib | 2016 |
Single administration of Selective Internal Radiation Therapy versus continuous treatment with sorafeNIB in locally advanced hepatocellular carcinoma (SIRveNIB): study protocol for a phase iii randomized controlled trial.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Clinical Protocols; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Research Design; Sorafenib | 2016 |
A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Diarrhea; Disease-Free Survival; Drug Eruptions; Fatigue; Hand-Foot Syndrome; Humans; Hypertension; Immunohistochemistry; Male; Middle Aged; Myoepithelioma; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-ret; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Salivary Gland Neoplasms; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2016 |
Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.
Topics: Adult; Allografts; Azacitidine; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Salvage Therapy; Sorafenib; Survival Rate | 2017 |
HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Topics: Administration, Topical; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Ointments; Phenylurea Compounds; Sorafenib; Taiwan | 2017 |
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2017 |
Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Young Adult | 2017 |
Phase I dose-escalation study of plitidepsin in combination with sorafenib or gemcitabine in patients with refractory solid tumors or lymphomas.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Depsipeptides; Dose-Response Relationship, Drug; Female; Gemcitabine; Humans; Lymphoma; Male; Middle Aged; Neoplasms; Niacinamide; Peptides, Cyclic; Phenylurea Compounds; Prospective Studies; Sorafenib; Young Adult | 2017 |
Sorafenib dose escalation in treatment-naïve patients with metastatic renal cell carcinoma: a non-randomised, open-label, Phase 2b study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Research Design; Sorafenib; Treatment Outcome | 2017 |
Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vinblastine; Vinorelbine | 2016 |
Effective downsizing but enhanced intratumoral heterogeneity following neoadjuvant sorafenib in patients with non-metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Double-Blind Method; Female; Hepatectomy; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Sorafenib; Treatment Outcome | 2017 |
mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Risk Factors; Sorafenib; Time Factors; Tomography, X-Ray Computed | 2017 |
EVESOR, a model-based, multiparameter, Phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Everolimus; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Patterns of Care and Clinical Outcomes in Patients With Metastatic Renal Cell Carcinoma-Results From a Tertiary Cancer Center in India.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indazoles; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prospective Studies; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Tertiary Care Centers; Treatment Outcome; Young Adult | 2017 |
Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Glypicans; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib | 2017 |
Phase I trial of radiation therapy and sorafenib in unresectable liver metastases.
Topics: Adult; Aged; Antineoplastic Agents; Chemoradiotherapy; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Radiosurgery; Sorafenib | 2017 |
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate | 2017 |
Evaluation of sorafenib in Chinese unresectable hepatocellular carcinoma patients with prior surgery and portal vein tumor thrombosis: A subset analysis of GIDEON study data.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Hepatocellular; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Treatment Outcome; Venous Thrombosis | 2017 |
Influence of OATP1B1 Function on the Disposition of Sorafenib-β-D-Glucuronide.
Topics: Aged; Animals; Biological Transport; Dogs; Female; Glucuronides; HEK293 Cells; Hepatocytes; Humans; Liver-Specific Organic Anion Transporter 1; Madin Darby Canine Kidney Cells; Male; Mice, Knockout; Middle Aged; Multidrug Resistance-Associated Protein 2; Niacinamide; Organic Anion Transporters, Sodium-Independent; Phenylurea Compounds; Rifampin; Sorafenib | 2017 |
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study.
Topics: Adult; Aged; Anilides; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2017 |
A phase I trial of concurrent sorafenib and stereotactic radiosurgery for patients with brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Cohort Studies; Disease-Free Survival; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiosurgery; Sorafenib | 2017 |
Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypoalbuminemia; Indoles; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Exposure-response relationship of regorafenib efficacy in patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2017 |
Pro-angiogenic TIE-2-expressing monocytes/TEMs as a biomarker of the effect of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Flow Cytometry; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Monocytes; Niacinamide; Phenylurea Compounds; Pilot Projects; Proportional Hazards Models; Prospective Studies; Receptor, TIE-2; Response Evaluation Criteria in Solid Tumors; ROC Curve; Sorafenib | 2017 |
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Double-Blind Method; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quality of Life; Ramucirumab; Sorafenib | 2017 |
Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Angiopoietin-2; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recombinant Fusion Proteins; Sorafenib; Treatment Outcome | 2017 |
Feasibility study of personalized peptide vaccination for hepatocellular carcinoma patients refractory to locoregional therapies.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cancer Vaccines; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Resistance, Neoplasm; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Precision Medicine; Sorafenib; T-Lymphocytes, Cytotoxic; Treatment Outcome; Vaccination; Vaccines, Subunit | 2017 |
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Neuroendocrine; Diarrhea; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Hypertension; Japan; Male; Neoplasm Grading; Niacinamide; Patient Dropouts; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms; Tumor Burden | 2017 |
Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Embolization, Therapeutic; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2017 |
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Radiation Tolerance; Sirolimus; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2017 |
Phase I dose escalation study of concurrent palliative radiation therapy with sorafenib in three anatomical cohorts (Thorax, Abdomen, Pelvis): The TAP study.
Topics: Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2017 |
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Leukocyte Count; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Invasiveness; Neutrophils; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Sorafenib | 2017 |
Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Paclitaxel; Phenylurea Compounds; Receptor, ErbB-2; Sorafenib; Treatment Outcome | 2017 |
Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.
Topics: Adult; Aged; alpha-Fetoproteins; Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Lenalidomide; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thalidomide; Treatment Outcome | 2017 |
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer.
Topics: Administration, Oral; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Diarrhea; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Hand-Foot Syndrome; Humans; Hypertension; Kaplan-Meier Estimate; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Receptor, ErbB-2; Sorafenib; Taxoids; Treatment Outcome | 2017 |
Combination of transcatheter arterial chemoembolization and interrupted dosing sorafenib improves patient survival in early-intermediate stage hepatocellular carcinoma: A post hoc analysis of the START trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Regression Analysis; Sorafenib; Survival Analysis; Taiwan; Treatment Outcome | 2017 |
Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Urinary Bladder Neoplasms | 2018 |
Validation of a new prognostic model to easily predict outcome in renal cell carcinoma: the GRANT score applied to the ASSURE trial population.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Follow-Up Studies; Health Status Indicators; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Prospective Studies; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Survival Rate | 2017 |
Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Serum Albumin; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
Topics: Adult; Aged; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Serum Albumin; Sorafenib | 2017 |
Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Microspheres; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiotherapy Dosage; Sorafenib; Survival Analysis; Treatment Outcome; Yttrium Radioisotopes | 2017 |
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Erlotinib Hydrochloride; Fatigue; Female; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Combined endovascular brachytherapy, sorafenib, and transarterial chemobolization therapy for hepatocellular carcinoma patients with portal vein tumor thrombus.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Portal Vein; Propensity Score; Retrospective Studies; Sorafenib; Stents; Survival Rate; Treatment Outcome; Venous Thrombosis | 2017 |
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS-mutated rectal cancer: A phase I/II trial (SAKK 41/08).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemoradiotherapy; Female; Humans; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Radiotherapy, Adjuvant; Rectal Neoplasms; Sorafenib | 2018 |
Hand-Foot Syndrome and Post-Progression Treatment Are the Good Predictors of Better Survival in Advanced Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Survival Rate; Treatment Outcome | 2017 |
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quinolines; Sorafenib; Survival Rate; Treatment Outcome | 2018 |
Impact of baseline characteristics on outcomes of advanced HCC patients treated with sorafenib: a secondary analysis of a phase III study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Indoles; Kaplan-Meier Estimate; Liver Neoplasms; Male; Multivariate Analysis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Sorafenib; Sunitinib | 2018 |
A multicenter Phase II study of sorafenib in Japanese patients with advanced hepatocellular carcinoma and Child Pugh A and B class.
Topics: Aged; Asian People; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2018 |
A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Hepatocellular; Disease-Free Survival; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2018 |
Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2018 |
A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2020 |
Effect of early adverse events resulting in sorafenib dose adjustments on survival outcomes of advanced hepatocellular carcinoma patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Progression-Free Survival; Sorafenib; Young Adult | 2020 |
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Nitriles; Phenylthiohydantoin; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2020 |
A Phase I Trial of Trametinib in Combination with Sorafenib in Patients with Advanced Hepatocellular Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridones; Pyrimidinones; Sorafenib | 2020 |
Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Combinations; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pravastatin; Prospective Studies; Sorafenib; Treatment Outcome | 2021 |
Priming of Sorafenib Prior to Radiofrequency Ablation Does Not Increase Treatment Effect in Hepatocellular Carcinoma.
Topics: Carcinoma, Hepatocellular; Catheter Ablation; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Radiofrequency Ablation; Retrospective Studies; Sorafenib; Treatment Outcome | 2022 |
Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hand-Foot Syndrome; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Quality of Life; Sorafenib; Urea | 2022 |
GALNT14 genotype-guided chemoembolization plus sorafenib therapy in hepatocellular carcinoma: a randomized trial.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Genotype; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2022 |
A cost analysis of sorafenib for desmoid tumors.
Topics: Aged; Costs and Cost Analysis; Fibromatosis, Aggressive; Humans; Medicare; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; United States | 2023 |
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).
Topics: Antineoplastic Agents; Atorvastatin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Metformin; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2022 |
Extracellular Vesicles May Predict Response to Radioembolization and Sorafenib Treatment in Advanced Hepatocellular Carcinoma: An Exploratory Analysis from the SORAMIC Trial.
Topics: Carcinoma, Hepatocellular; Extracellular Vesicles; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteomics; Sorafenib | 2022 |
Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2022 |
Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cholangiocarcinoma; Everolimus; Female; Humans; Niacinamide; Phenylurea Compounds; Sorafenib | 2023 |
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial.
Topics: Biomarkers; Everolimus; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Progression-Free Survival; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2023 |
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Maximum Tolerated Dose; Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Riluzole; Sorafenib | 2023 |
Other Studies
2816 other study(ies) available for niacinamide and sorafenib
Article | Year |
---|---|
Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Cell Cycle; Colonic Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib; Tumor Cells, Cultured | 2003 |
Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure.
Topics: Adenoma; Animals; Apoptosis; Benzamides; Benzenesulfonates; Cell Differentiation; Cell Division; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mice, Transgenic; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2004 |
B-RAF is a therapeutic target in melanoma.
Topics: Benzenesulfonates; Cell Line, Tumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2004 |
Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum.
Topics: Animals; Benzenesulfonates; Calibration; Enzyme Inhibitors; Mice; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib | 2004 |
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
Topics: Administration, Oral; Animals; Benzenesulfonates; Cell Line, Tumor; Disease Progression; Female; Humans; MAP Kinase Kinase Kinase 1; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Xenograft Model Antitumor Assays | 2004 |
The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; DNA Adducts; Drug Antagonism; Humans; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Pyridines; raf Kinases; Sorafenib | 2005 |
Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
Topics: Animals; Apoptosis; Benzenesulfonates; Cell Growth Processes; Cell Line, Tumor; Humans; MAP Kinase Signaling System; Melanoma; Mice; Mutation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; RNA, Small Interfering; Sorafenib; Vascular Endothelial Growth Factor A | 2005 |
Cancer. Encouraging results for second-generation antiangiogenesis drugs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Gastrointestinal Stromal Tumors; Humans; Kidney Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; United States; United States Food and Drug Administration; Vascular Endothelial Growth Factor A | 2005 |
Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Clinical Trials as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2005 |
Multi-kinase inhibitors create buzz at ASCO.
Topics: Antineoplastic Agents; Benzenesulfonates; Biotechnology; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Phosphotransferases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2005 |
Clinical trials referral resource.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Referral and Consultation; Sorafenib; United States | 2005 |
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006.
Topics: Adamantane; Apoptosis; Base Sequence; Benzenesulfonates; Caspases; Cell Line, Tumor; DNA Primers; Down-Regulation; Enzyme Activation; Humans; Hydroquinones; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib | 2005 |
Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?
Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Nail Diseases; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2005 |
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Caspase 7; Caspase 9; Caspases; Cell Line, Tumor; Chromatography; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; Genes, Reporter; Humans; Immunoblotting; Immunoprecipitation; Jurkat Cells; K562 Cells; Leukemia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Promoter Regions, Genetic; Protein Biosynthesis; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Subcellular Fractions; Time Factors; Transcription, Genetic; Transfection; U937 Cells; Ubiquitin | 2005 |
Lack of effect of ketoconazole-mediated CYP3A inhibition on sorafenib clinical pharmacokinetics.
Topics: Adult; Antifungal Agents; Benzenesulfonates; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2006 |
Spinal cord metastasis of a non-neurofibromatosis type-1 malignant peripheral nerve sheath tumor: an unusual manifestation of a rare tumor.
Topics: Adult; Benzenesulfonates; Chemotherapy, Adjuvant; Fatal Outcome; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Nerve Sheath Neoplasms; Neurofibroma; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spinal Cord Neoplasms | 2005 |
Raf-1 kinase associates with Hepatitis C virus NS5A and regulates viral replication.
Topics: Animals; Benzenesulfonates; Hepacivirus; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Binding; Proto-Oncogene Proteins c-raf; Pyridines; Replicon; RNA-Dependent RNA Polymerase; RNA, Small Interfering; Sorafenib; Viral Nonstructural Proteins; Virus Replication | 2006 |
The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-Associated Death Protein; Benzenesulfonates; Caspases; Cell Line, Tumor; Cell Nucleus; Cytochromes c; Humans; Intracellular Signaling Peptides and Proteins; Melanoma; Mitochondria; Mitochondrial Proteins; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Sorafenib | 2006 |
BAY 43-9006 inhibition of oncogenic RET mutants.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Cycle; Drug Administration Schedule; Enzyme Inhibitors; Fibroblasts; Immunoblotting; Inhibitory Concentration 50; Mice; Mice, Nude; Mutation; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Phosphotransferases; Proto-Oncogene Proteins c-ret; Pyridines; Sorafenib; Thyroid Neoplasms; Transfection; Transplantation, Heterologous | 2006 |
Drug approval triggers debate on future direction for cancer treatments.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Approval; Drug Design; Enzyme Inhibitors; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphotransferases; Pyridines; Sorafenib; United States; United States Food and Drug Administration | 2006 |
BRAF is a therapeutic target in aggressive thyroid carcinoma.
Topics: Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Thyroid Gland; Thyroid Neoplasms; Transplantation, Heterologous | 2006 |
Sorafenib is a potent inhibitor of FIP1L1-PDGFRalpha and the imatinib-resistant FIP1L1-PDGFRalpha T674I mutant.
Topics: Benzamides; Benzenesulfonates; Carcinoma; Cell Proliferation; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; K562 Cells; Kidney Neoplasms; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperazines; Point Mutation; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib | 2006 |
Isolation and characterization of dominant and recessive IL-3-independent hematopoietic transformants.
Topics: Aminacrine; Benzenesulfonates; Butadienes; Cell Transformation, Neoplastic; Clone Cells; Frameshift Mutation; Genes, Dominant; Genes, Recessive; Hematopoiesis; Humans; Interleukin-3; MAP Kinase Kinase Kinases; Mutagenesis, Insertional; Neoplastic Stem Cells; Niacinamide; Nitriles; Nitrogen Mustard Compounds; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Retroviridae; Sorafenib; STAT5 Transcription Factor; Transfection | 2006 |
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytotoxins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Vinblastine; Vinorelbine; Weight Loss; Xenograft Model Antitumor Assays | 2007 |
Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Topics: Benzenesulfonates; Cell Line; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Humans; Immunohistochemistry; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib | 2006 |
Targeted therapy for cytokine-refractory metastatic renal cell carcinoma, and treatment in the community.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Community Health Services; Cytokines; Disease Progression; Drug Delivery Systems; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Failure | 2006 |
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay.
Topics: Area Under Curve; Benzenesulfonates; Calibration; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2007 |
Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Humans; Keratosis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Photosensitivity Disorders; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2006 |
Trials probe new agents for kidney cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Lapatinib; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2006 |
Clinical activity of sorafenib and sunitinib in renal cell carcinoma refractory to previous vascular endothelial growth factor-targeted therapy: two case reports.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2006 |
Renal cell carcinoma: today's targeted therapies improving tomorrow's outcomes.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Delivery Systems; Humans; Indoles; Interleukin-2; Karnofsky Performance Status; Kidney Neoplasms; Neoplasm Staging; Nephrectomy; Niacinamide; Nurse's Role; Oncology Nursing; Patient Education as Topic; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Risk Assessment; Safety Management; Sorafenib; Sunitinib; Survival Analysis | 2006 |
Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells.
Topics: Acetophenones; Annexin A5; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzopyrans; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Proliferation; Cell Survival; Clone Cells; Drug Synergism; Enzyme Inhibitors; Glioma; Humans; Immunohistochemistry; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Folding; Protein Kinase C; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2006 |
To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced Doppler ultrasound.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Disease-Free Survival; Double-Blind Method; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phospholipids; Pilot Projects; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Sulfur Hexafluoride; Survival Analysis; Treatment Outcome; Ultrasonography, Doppler | 2006 |
New therapeutic options for renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Humans; Indoles; Interferons; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Line, Tumor; Drug Synergism; Humans; JNK Mitogen-Activated Protein Kinases; Jurkat Cells; K562 Cells; MAP Kinase Signaling System; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Pyrazines; Pyridines; Sorafenib | 2006 |
Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Cholangiocarcinoma; Clinical Trials as Topic; Enzyme Inhibitors; Female; Humans; Hypertensive Encephalopathy; Magnetic Resonance Imaging; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Sorafenib; Syndrome | 2006 |
Problems with the randomized discontinuation design.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Data Interpretation, Statistical; Drug Administration Schedule; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sorafenib; Survival Analysis; Treatment Outcome | 2006 |
Speeding up cancer-drug development.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Humans; Kidney Neoplasms; Liver Neoplasms; Multiple Myeloma; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2006 |
Inhibition of tumor endothelial ERK activation, angiogenesis, and tumor growth by sorafenib (BAY43-9006).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Collagen; Drug Combinations; Endothelial Cells; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Humans; Kidney Neoplasms; Laminin; Melanoma; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteoglycans; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib | 2006 |
A tale of two drugs.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Benzenesulfonates; Clofarabine; Drug Approval; Drug Design; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2006 |
Current and future management of GIST.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Benzoquinones; Disease Progression; Dose-Response Relationship, Drug; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2006 |
Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Foot; Hand; Humans; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Syndrome; Vasculitis, Leukocytoclastic, Cutaneous | 2006 |
Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Topics: Actins; Adenocarcinoma, Clear Cell; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Capillaries; Cell Line, Tumor; Female; Humans; Hypoxia; Immunohistochemistry; In Situ Nick-End Labeling; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Pyridines; Regional Blood Flow; Sorafenib; Vascular Endothelial Growth Factor A | 2007 |
'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Base Sequence; bcl-X Protein; Benzenesulfonates; Biphenyl Compounds; Blotting, Western; Carcinoma, Small Cell; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Purines; Pyridines; Receptor, Fibroblast Growth Factor, Type 2; RNA Interference; RNA, Small Interfering; Roscovitine; Sorafenib; Sulfonamides; Transmembrane Activator and CAML Interactor Protein; Zinc Fingers | 2007 |
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Transplantation, Heterologous | 2006 |
Keratoacanthomas associated with sorafenib therapy.
Topics: Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Facial Dermatoses; Female; Humans; Keratoacanthoma; Leiomyosarcoma; Lung Neoplasms; Male; Middle Aged; Neck; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Skin Diseases; Sorafenib | 2007 |
Antitumor activity of sorafenib in FLT3-driven leukemic cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line; Drug Screening Assays, Antitumor; Female; fms-Like Tyrosine Kinase 3; Humans; Kidney; Leukemia, Myeloid; Mice; Mice, Nude; Mutant Proteins; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recombinant Fusion Proteins; Sorafenib; Tandem Repeat Sequences; Transfection; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2007 |
Renal-cell carcinoma--molecular pathways and therapies.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Gene Silencing; Humans; Hypoxia-Inducible Factor 1; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Von Hippel-Lindau Tumor Suppressor Protein | 2007 |
The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line; Cell Line, Transformed; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cells; Humans; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Receptor, Platelet-Derived Growth Factor beta; Sorafenib | 2007 |
Hand-foot and stump syndrome to sorafenib.
Topics: Amputation Stumps; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Foot; Hand; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Syndrome | 2007 |
Sorafenib-induced erythema multiforme.
Topics: Administration, Oral; Benzenesulfonates; Erythema Multiforme; Female; Humans; Lung Neoplasms; Melanoma, Amelanotic; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2007 |
Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Cycle Proteins; Cell Proliferation; Cholangiocarcinoma; Enzyme Activation; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Pyridines; Receptor, IGF Type 1; Sorafenib; Tumor Cells, Cultured; Tyrphostins | 2007 |
New drugs 07, part I.
Topics: Abatacept; Acetanilides; Alprostadil; Anidulafungin; Antidiuretic Hormone Receptor Antagonists; Antifungal Agents; Antineoplastic Agents; Arabinonucleosides; Benzazepines; Benzenesulfonates; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Echinocandins; Fatty Acids; Humans; Hypoglycemic Agents; Immunoconjugates; Immunosuppressive Agents; Indoles; Insulin; Insulin Detemir; Insulin, Long-Acting; Intercellular Signaling Peptides and Proteins; Lenalidomide; Lubiprostone; Niacinamide; Patient Education as Topic; Peptides, Cyclic; Phenylurea Compounds; Piperazines; Pyridines; Pyrroles; Ranolazine; Sorafenib; Sunitinib; Thalidomide; United States | 2007 |
American Society of Hematology--48th Annual Meeting and Exposition. Updates on therapies. 9-12 December 2006 Orlando, FL, USA.
Topics: Anemia, Sickle Cell; Antibiotics, Antineoplastic; Antigens, CD20; Benzamides; Benzenesulfonates; CD40 Antigens; Diphenylamine; Hematologic Neoplasms; Hematology; Humans; Ki-1 Antigen; Leukemia, Myeloid; Lymphoma; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib | 2007 |
[Therapy sequence for renal cell carcinoma--new aspects!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Drug Approval; Humans; Interleukin-2; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Thalidomide | 2007 |
Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2007 |
Two new drugs for renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Costs; Drug Interactions; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Newly approved therapies for RCC and their effect on the standard of care.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Interferons; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Von Hippel-Lindau Tumor Suppressor Protein | 2007 |
Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target.
Topics: Benzenesulfonates; Digestive System Neoplasms; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Neuroendocrine Tumors; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; raf Kinases; rap1 GTP-Binding Proteins; Signal Transduction; Sorafenib; Tetrazolium Salts; Thiazoles | 2007 |
ASCO 2006 highlights: targeted therapy for renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2007 |
Sunitinib malate and sorafenib may be beneficial at the treatment of advanced bladder cancer due to their anti-angiogenic effects.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urinary Bladder Neoplasms | 2007 |
Combined targeting of MAPK and AKT signalling pathways is a promising strategy for melanoma treatment.
Topics: Androstadienes; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dimethyl Sulfoxide; Humans; MAP Kinase Signaling System; Melanoma; Neoplasm Invasiveness; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib; Wortmannin | 2007 |
Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.
Topics: Acrodermatitis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Spinal Neoplasms | 2007 |
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Topics: Benzenesulfonates; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; RNA Interference; RNA, Small Interfering; Sorafenib; Transfection; Up-Regulation | 2007 |
Pulmonary blastoma with renal metastasis responds to sorafenib.
Topics: Administration, Oral; Adult; Benzenesulfonates; Biopsy, Needle; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Immunohistochemistry; Kidney Neoplasms; Lung Neoplasms; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonectomy; Pulmonary Blastoma; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome | 2007 |
Sorafenib-induced pancreatitis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Middle Aged; Neoplasm Metastasis; Niacinamide; Pancreatitis; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2007 |
Adjuvant therapy with sorafenib in bone metastases bilateral renal carcinoma: a case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
Do the results of the new trials change the standard treatment of metastatic renal cell cancer?
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cytokines; Drug Costs; Humans; Indoles; Kidney Neoplasms; Long-Term Care; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2007 |
Interstitial nephritis in a patient taking sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Inflammation; Kidney; Kidney Neoplasms; Leukocytes; Male; Nephritis, Interstitial; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed | 2007 |
Sorafenib inhibits imatinib-resistant KIT and platelet-derived growth factor receptor beta gatekeeper mutants.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Proliferation; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Interleukin-3; Mice; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-sis; Pyridines; Pyrimidines; Sorafenib | 2007 |
The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress.
Topics: Animals; Benzenesulfonates; Calcium Signaling; Caspase 2; Caspases, Initiator; Cell Death; Cell Line, Tumor; DNA-Binding Proteins; Dose-Response Relationship, Drug; eIF-2 Kinase; Endoplasmic Reticulum; Endoplasmic Reticulum Chaperone BiP; Enzyme Activation; Enzyme Induction; Eukaryotic Initiation Factor-2; Extracellular Signal-Regulated MAP Kinases; Humans; Mice; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Phosphorylation; Protein Biosynthesis; Protein Folding; Protein Kinase Inhibitors; Pyridines; Reactive Oxygen Species; Regulatory Factor X Transcription Factors; RNA Splicing; Sorafenib; Transcription Factors; X-Box Binding Protein 1 | 2007 |
Radiation therapy and sorafenib: clinical data and rationale for the combination in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2007 |
Re: Börje Ljungberg, Damian C. Hanbury, Marcus A. Kuczyk, Axel S. Merseburger, Peter F.A. Mulders, Jean-Jaques Patard and Ioanel C. Sinescu. Renal cell cacinoma guideline. Eur Urol 2007;51:1502-10.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunologic Factors; Indoles; Interferon-alpha; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Survival Rate | 2007 |
Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Benzenesulfonates; Cell Division; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Transplantation, Heterologous | 2007 |
Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2007 |
Can sorafenib cause hypothyroidism?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Islet Cell; Female; Humans; Hypothyroidism; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; STAT5 Transcription Factor | 2007 |
Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.
Topics: Animals; Antineoplastic Agents; Apoptosis; Baculoviral IAP Repeat-Containing 3 Protein; Benzenesulfonates; Cell Line, Tumor; Female; Humans; Inhibitor of Apoptosis Proteins; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Transcription, Genetic; Ubiquitin-Protein Ligases | 2007 |
Sorafenib [corrected] in kidney cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2007 |
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulation.
Topics: Benzenesulfonates; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Tumor Cells, Cultured; Vorinostat | 2007 |
Cancer drug trials show modest benefit: drugs target liver, gastric, head and neck cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials, Phase III as Topic; Drug Combinations; Head and Neck Neoplasms; Humans; Liver Neoplasms; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms; Tegafur | 2007 |
Combination therapy targeting the tumor microenvironment is effective in a model of human ocular melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Movement; Cell Proliferation; Disease Models, Animal; Endothelial Cells; Eye Neoplasms; Humans; In Vitro Techniques; Lenalidomide; Melanoma; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Thalidomide; Xenograft Model Antitumor Assays | 2007 |
Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice.
Topics: Analysis of Variance; Animals; Benzenesulfonates; Carcinoma, Renal Cell; Catheter Ablation; Combined Modality Therapy; Kidney Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Sorafenib; Statistics, Nonparametric | 2007 |
[Interdisciplinary recommendations on targeted therapy in the treatment of renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Controlled Clinical Trials as Topic; Humans; Immunologic Factors; Immunotherapy; Indoles; Interferon-alpha; Kidney; Kidney Neoplasms; Meta-Analysis as Topic; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors | 2007 |
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting.
Topics: Benzenesulfonates; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50; Lysosomes; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Endocrine Neoplasia Type 2a; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Pyridines; Sorafenib | 2007 |
American Society of Clinical Oncology--43rd annual meeting. Translating research into practice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Technology Transfer; Treatment Outcome | 2007 |
[Application monitoring of the use of sorafenib in papillary renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; T-Lymphocytes, Regulatory; Tumor Escape | 2007 |
Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2 Homologous Antagonist-Killer Protein; Bcl-2-Like Protein 11; bcl-X Protein; Benzenesulfonates; BH3 Interacting Domain Death Agonist Protein; Cell Line, Tumor; HL-60 Cells; Humans; Jurkat Cells; K562 Cells; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand | 2007 |
Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Dasatinib; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Mice; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Sorafenib; Thiazoles | 2007 |
Characterization of tumor specimens for a targeted therapy in metastatic renal cell carcinoma patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2007 |
ASCO 2007: plenary top 5.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Carcinoma, Small Cell; Colorectal Neoplasms; Humans; Kidney Neoplasms; Leukemia, Promyelocytic, Acute; Liver Neoplasms; Lung Neoplasms; Medical Oncology; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Societies, Medical; Sorafenib; United States | 2007 |
Histone deacetylase inhibitor MS-275 alone or combined with bortezomib or sorafenib exhibits strong antiproliferative action in human cholangiocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Benzamides; Benzenesulfonates; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Deoxycytidine; Doxorubicin; Drug Therapy, Combination; Gemcitabine; Histone Deacetylase Inhibitors; Humans; L-Lactate Dehydrogenase; Niacinamide; Phenylurea Compounds; Protease Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrazines; Pyridines; Sorafenib | 2007 |
High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor.
Topics: Adult; Aged; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2008 |
Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2007 |
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome | 2007 |
Acute pancreatitis associated with sorafenib.
Topics: Acute Disease; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Enzyme Inhibitors; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Niacinamide; Pancreatitis; Phenylurea Compounds; Pyridines; raf Kinases; Sorafenib; Tomography, X-Ray Computed | 2007 |
Resolution of macular oedema in occult choroidal neovascularization under oral Sorafenib treatment.
Topics: Administration, Oral; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Choroidal Neovascularization; Humans; Macular Edema; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Cell Growth Processes; Colorectal Neoplasms; Combined Modality Therapy; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Radiation; Drug Administration Schedule; Endothelial Cells; Female; G2 Phase; HCT116 Cells; Humans; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Retinoblastoma Protein; Sorafenib; Xenograft Model Antitumor Assays | 2007 |
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 8; Death Domain Receptor Signaling Adaptor Proteins; Down-Regulation; Drug Synergism; Humans; Leukemia; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; U937 Cells | 2007 |
Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hypothyroidism; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Risk Assessment; Sorafenib; Thyroid Function Tests | 2008 |
Localized palmar-plantar epidermal hyperplasia: a previously undefined dermatologic toxicity to sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Diseases; Sorafenib | 2007 |
Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Colonic Diseases; Colonoscopy; Diagnosis, Differential; Follow-Up Studies; Humans; Intestinal Perforation; Kidney Neoplasms; Male; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Receptors, Vascular Endothelial Growth Factor; Rupture, Spontaneous; Sorafenib; Tomography, X-Ray Computed | 2009 |
GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines.
Topics: Apoptosis; Benzenesulfonates; Cell Adhesion; Cell Death; Cell Line, Tumor; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Melanoma; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
Increased cardiotoxicity of sorafenib in sunitinib-pretreated patients with metastatic renal cell carcinoma.
Topics: Aged; Atrial Fibrillation; Benzenesulfonates; Carcinoma, Renal Cell; Cardiovascular Diseases; Chest Pain; Drug Interactions; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Middle Aged; Myocardial Ischemia; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Assessment; Sampling Studies; Severity of Illness Index; Sorafenib; Sunitinib | 2007 |
Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2008 |
Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Clinical Trials as Topic; ErbB Receptors; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Hand-foot skin reaction in patients treated with sorafenib: a clinicopathological study of cutaneous manifestations due to multitargeted kinase inhibitor therapy.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Blister; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2008 |
Re: damien pouessel, stéphane culine. High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor. Eur urol 2008;
Topics: Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Hemorrhage; France; Humans; Incidence; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Risk Factors; Sorafenib; Treatment Outcome | 2008 |
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Papillary; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2008 |
Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzenesulfonates; Cell Line; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mitochondria; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Pyridines; Signal Transduction; Sorafenib | 2008 |
[News in digestive oncology].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardia; Colonic Neoplasms; Combined Modality Therapy; Digestive System Neoplasms; Esophageal Neoplasms; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms | 2008 |
Examining heterogeneity in phase II trial designs may improve success in phase III.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Confounding Factors, Epidemiologic; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sorafenib; Treatment Outcome | 2008 |
Quantifying hypertension in patients with cancer treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2008 |
Ranibizumab combined with low-dose sorafenib for exudative age-related macular degeneration.
Topics: Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Drug Therapy, Combination; Fluorescein Angiography; Humans; Macular Degeneration; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiography; Ranibizumab; Recurrence; Sorafenib | 2008 |
FDA approves sorafenib for patients with inoperable liver cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Approval; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; United States; United States Food and Drug Administration | 2008 |
[New drugs; sunitinib and sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome | 2007 |
A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proteinuria; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sunitinib | 2008 |
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Complement C1q; Disease Models, Animal; Enzyme Activation; Gene Expression Profiling; Genomics; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Lung; Male; Mitogen-Activated Protein Kinases; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Inbred Dahl; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Transforming Growth Factor beta3; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma.
Topics: Benzenesulfonates; Calibration; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sorafenib | 2008 |
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; CD8-Positive T-Lymphocytes; Cell Division; Cell Movement; Cells, Cultured; Cytokines; Dendritic Cells; Dextrans; Endocytosis; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Indoles; Interleukin-4; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Toll-Like Receptor 4 | 2008 |
Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transforming Growth Factor beta | 2008 |
Complete response in a cutaneous facial metastatic nodule from renal cell carcinoma after hypofractionated radiotherapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Facial Neoplasms; Humans; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Pyridines; Remission Induction; Skin Neoplasms; Sorafenib | 2007 |
Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells.
Topics: Androstadienes; Apoptosis; Benzenesulfonates; Butadienes; Cell Line, Tumor; Cell Proliferation; Chromones; Down-Regulation; Flavonoids; Humans; Mechanistic Target of Rapamycin Complex 1; Melanoma; Mitogen-Activated Protein Kinase Kinases; Morpholines; Multiprotein Complexes; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sirolimus; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Wortmannin | 2008 |
Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Research Design; Sorafenib; Treatment Outcome | 2008 |
Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Lower Extremity; Lymphatic Metastasis; Lymphedema; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation.
Topics: Amino Acid Sequence; Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blood Cells; Blotting, Western; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; G1 Phase; Humans; Hypersensitivity, Delayed; Immunization; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Lectins, C-Type; Lymphocyte Activation; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Pyridines; Receptors, Vascular Endothelial Growth Factor; Resting Phase, Cell Cycle; Sequence Homology, Amino Acid; Sorafenib; T-Lymphocytes | 2008 |
[Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Protocols; Contraindications; Disease-Free Survival; Humans; Liver Neoplasms; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sorafenib; Survival Rate | 2008 |
[New drugs; sunitinib and sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Heart; Humans; Indoles; Myocardium; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Metastatic chest wall malignant schwannoma responding to sorafenib: case report and literature review.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Female; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Nerve Sheath Neoplasms; Neurilemmoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiography, Thoracic; Sorafenib; Thoracic Wall; Treatment Outcome | 2008 |
Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigm.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Differentiation; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 4; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; G1 Phase; Gene Silencing; Humans; Liposarcoma; Mitogen-Activated Protein Kinase Kinases; Mitogen-Activated Protein Kinases; Nerve Sheath Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; ras Proteins; Retinoblastoma Protein; Signal Transduction; Sorafenib | 2008 |
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Papillary; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate | 2007 |
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib.
Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Cell Line, Tumor; Exons; Humans; Male; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyridines; Quinolones; Sorafenib; Thyroid Neoplasms | 2008 |
Bowel perforation after radiotherapy in a patient receiving sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Intestinal Perforation; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiation Injuries; Skin Neoplasms; Sorafenib | 2008 |
Comparison of antitumor effects of multitargeted tyrosine kinase inhibitors in acute myelogenous leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Indoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
[Inhibitory effect of sorafenib combined with arsenic trioxide on hepatocellular carcinoma cells].
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Oxides; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Sorafenib triggers antiproliferative and pro-apoptotic signals in human esophageal adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin E; Esophageal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridines; Sorafenib; STAT3 Transcription Factor | 2008 |
Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Ceramides; Drug Synergism; Humans; Liposomes; Melanoma; Mitogen-Activated Protein Kinases; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib | 2008 |
Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib.
Topics: Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Fluorouracil; Foot Dermatoses; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nicotinic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Urea | 2008 |
Oesophageal variceal bleeding in hepatocellular carcinoma with portal vein thrombosis: improved outcome in response to molecular target therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Sorafenib; Venous Thrombosis | 2008 |
Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Diagnosis, Differential; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quinolones; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib | 2008 |
Sorafenib-induced eruptive melanocytic lesions.
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Diagnosis, Differential; Drug Eruptions; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Nevus, Pigmented; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin; Skin Neoplasms; Sorafenib | 2008 |
Sorafenib-induced palmoplantar hyperkeratosis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Keratoderma, Palmoplantar; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Female; Mammary Neoplasms, Experimental; Niacinamide; Outcome Assessment, Health Care; Perfusion; Phenylurea Compounds; Prognosis; Pyridines; Rats; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Reader seeks clarification on hand-foot skin reaction.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Information Services; Drug Labeling; Foot Dermatoses; Hand Dermatoses; Humans; Internet; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Semantics; Sorafenib | 2008 |
Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia.
Topics: Benzenesulfonates; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Tandem Repeat Sequences | 2009 |
18F-Fluorodeoxyglucose positron emission tomography for monitoring response to sorafenib treatment in patients with hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2008 |
Neoadjuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome; Vena Cava, Inferior | 2008 |
Comment on Di Silverio et al.: Neodajuvant therapy with sorafenib in advanced renal cell carcinoma with vena cava extension submitted to radical nephrectomy. Urol Int 2008;80:451-453.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Treatment Outcome; Vena Cava, Inferior | 2008 |
[Targeted therapy for metastatic bladder cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Transitional Cell; Disease Progression; Drug Delivery Systems; Gefitinib; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Sorafenib; Survival Rate; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Health Surveys; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Quality of Life; Salvage Therapy; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2009 |
[Regression of vena cava tumour thrombus in response to sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Follow-Up Studies; Humans; Kidney; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Renal Veins; Sorafenib; Time Factors; Treatment Outcome; Venae Cavae; Venous Thrombosis | 2008 |
Efficacy of sunitinib and sorafenib in non-clear cell renal cell carcinoma: results from expanded access studies.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Multicenter Studies as Topic; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2008 |
A distinct cutaneous reaction to sorafenib and a multikinase inhibitor.
Topics: Administration, Oral; Benzenesulfonates; Biopsy, Needle; Drug Therapy, Combination; Follow-Up Studies; Head; Humans; Immunohistochemistry; Kidney Neoplasms; Male; Middle Aged; Neck; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Assessment; Severity of Illness Index; Skin Diseases, Papulosquamous; Sorafenib; Treatment Outcome | 2008 |
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyrazines; Pyridines; Sorafenib; Thyroid Neoplasms | 2008 |
[The 43rd Annual Meeting of the European Association for the Study of the Liver (EASL), Milan, Italy, April 23-27, 2008].
Topics: Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Delayed-Action Preparations; Europe; Hepatitis B; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Diseases; Liver Neoplasms; Niacinamide; Oligopeptides; Patient Compliance; Phenylurea Compounds; Polyethylene Glycols; Proline; Pyridines; Recombinant Proteins; Ribavirin; Societies, Medical; Sorafenib | 2008 |
Sunitinib-induced macrocytosis in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia, Macrocytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythrocyte Indices; Female; Hematologic Tests; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib | 2008 |
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chi-Square Distribution; DNA Primers; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A; von Hippel-Lindau Disease | 2008 |
A Kaposi's sarcoma complete clinical response after sorafenib administration.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sarcoma, Kaposi; Skin Neoplasms; Sorafenib; Treatment Outcome | 2008 |
Sorafenib in liver cancer--just the beginning.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Drug Costs; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; raf Kinases; Sorafenib | 2008 |
Effect of the multitargeted tyrosine kinase inhibitors imatinib, dasatinib, sunitinib, and sorafenib on mitochondrial function in isolated rat heart mitochondria and H9c2 cells.
Topics: Adenosine Triphosphate; Animals; Benzamides; Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Electron Transport; Galactose; Glucose; Imatinib Mesylate; Indoles; Male; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Myocytes, Cardiac; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Thiazoles | 2008 |
Challenges and pitfalls of combining targeted agents in phase I studies.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials, Phase I as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Humans; Maximum Tolerated Dose; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2008 |
Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-ret; Pyridines; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2008 |
Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Humans; MAP Kinase Signaling System; Mutagenesis, Site-Directed; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib | 2008 |
Promising newer molecular-targeted therapies in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Models, Biological; Niacinamide; Panitumumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2008 |
[Targeted therapy - point blank or single shot].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Delivery Systems; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Preoperative Care; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
About sorafenib in castration-resistant prostate cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Male; Niacinamide; Orchiectomy; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Pyridines; Sorafenib | 2008 |
Sequential use of the tyrosine kinase inhibitors sorafenib and sunitinib in metastatic renal cell carcinoma: a retrospective outcome analysis.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Time Factors; Treatment Outcome; Young Adult | 2008 |
Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Liver Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Pyridines; Sirolimus; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2008 |
Watchdog set to reject four drugs for kidney cancer on the NHS.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Drug Approval; Drug Costs; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; State Medicine; Sunitinib; United Kingdom | 2008 |
[New therapeutic regimes in metastasic renal-cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2008 |
[Antiangiogenics: new therapeutic standards in metastatic kidney cancer].
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Humans; Indoles; Kidney Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Effectively targeting BRAF in melanoma: a formidable challenge.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides; Treatment Outcome | 2008 |
Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Melanoma; Middle Aged; Niacinamide; Phenylurea Compounds; Polycythemia; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Long-lasting successful cerebral response with sorafenib in advanced renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Cerebral Cortex; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Searching for the Achilles' heel of melanoma cells: new treatment modalities.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Clinical Trials as Topic; Enzyme Inhibitors; Folic Acid Antagonists; Humans; Melanoma; Niacinamide; Organoselenium Compounds; Phenylurea Compounds; Pyridines; Pyrimethamine; Skin Neoplasms; Sorafenib; Treatment Outcome; Urea; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Prospective comparison of sorafenib and sunitinib for second-line treatment of cytokine-refractory kidney cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Sample Size; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2008 |
Sorafenib: tolerance in patients on chronic hemodialysis: a single-center experience.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Renal Dialysis; Sorafenib | 2008 |
Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proctocolitis; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2008 |
Major treatment improvements encourage kidney cancer researchers to seek further gains.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Death; Cell Line, Tumor; Drug Synergism; fas Receptor; Humans; Hydroxamic Acids; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vorinostat | 2008 |
Follicular hyperplasia on the face subsequent to therapy with sorafenib. A new skin side effect.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Humans; Hyperplasia; Lung Neoplasms; Male; Melanoma; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Pyridines; Skin; Skin Diseases; Skin Neoplasms; Sorafenib | 2009 |
Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation.
Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Caspase 8; Cell Survival; Ceramides; eIF-2 Kinase; Endoplasmic Reticulum; Eukaryotic Initiation Factor-2; fas Receptor; Humans; Hydroxamic Acids; Models, Biological; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Vorinostat | 2008 |
CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations.
Topics: Apoptosis; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Glutamic Acid; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Valine | 2009 |
Sorafenib-induced liver failure.
Topics: Adenocarcinoma, Follicular; Aged; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Liver Failure; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms | 2008 |
[Renal cell carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Immunotherapy; Indoles; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2008 |
[Coadministration of sorafenib and cisplatin inhibits proliferation of hepatocellular carcinoma HepG2 cells in vitro].
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Preclinical evaluation of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dacarbazine; Dasatinib; Drug Screening Assays, Antitumor; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Melanoma; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyridines; Pyrimidines; Receptor, EphA2; Sorafenib; Temozolomide; Thiazoles | 2008 |
[Systemic therapy of metastasizing renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Tomography, X-Ray Computed | 2008 |
[Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2008 |
Tyrosine kinase inhibitors: can promising new therapy associated with cardiac toxicity strengthen the concept of teamwork?
Topics: Antineoplastic Agents; Benzenesulfonates; Cardiovascular Diseases; Humans; Indoles; Neoplasms; Niacinamide; Patient Care Team; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2008 |
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Biomarkers; Carcinoma, Renal Cell; Cardiovascular Diseases; Echocardiography; Electrocardiography; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2008 |
Sorafenib inhibits MAPK-mediated proliferation in a Barrett's esophageal adenocarcinoma cell line.
Topics: Adenocarcinoma; Analysis of Variance; Barrett Esophagus; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Esophageal Neoplasms; Humans; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Probability; Protein Kinase Inhibitors; Pyridines; Reference Values; Sorafenib | 2008 |
Apoptosis of CD4(+)CD25(high) T cells in response to Sirolimus requires activation of T cell receptor and is modulated by IL-2.
Topics: Apoptosis; Benzenesulfonates; CD28 Antigens; CD3 Complex; CD4-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Flow Cytometry; Humans; Immunosuppressive Agents; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, Antigen, T-Cell; Sirolimus; Sorafenib | 2009 |
Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B; Hepatitis C; Humans; Korea; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2009 |
Response to sorafenib in cisplatin-resistant thymic carcinoma: a case report.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Cisplatin; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thymus Neoplasms; Tomography, X-Ray Computed | 2009 |
Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Male; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Sorafenib | 2008 |
[Eruptive nevi associated with sorafenib treatment].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Humans; Male; Middle Aged; Nevus; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib; Young Adult | 2008 |
Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib.
Topics: Aged; Antineoplastic Agents; Anus Neoplasms; Benzenesulfonates; Dacarbazine; Humans; Male; Melanoma; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Temozolomide; Treatment Outcome | 2008 |
Editorial comment on: Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Withholding Treatment | 2009 |
Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Withholding Treatment | 2009 |
Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling.
Topics: Animals; Benzamides; Benzenesulfonates; Blood Pressure; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Heart; Heart Ventricles; Hypertension, Pulmonary; Imatinib Mesylate; Lung; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Pulmonary Artery; Pyridines; Pyrimidines; raf Kinases; Rats; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; Ventricular Remodeling | 2008 |
Localized palmar-plantar epidermal hyperplasia associated with use of sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2008 |
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Survival; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; HT29 Cells; Humans; Italy; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Panitumumab; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Retrospective Studies; Sorafenib; Switzerland; Time Factors; Treatment Outcome | 2008 |
Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cerebellar Neoplasms; Cyclin D; Cyclins; Down-Regulation; Humans; Medulloblastoma; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Transfection | 2008 |
Severe cutaneous reaction to sorafenib: induction of tolerance.
Topics: Aged; Benzenesulfonates; Dose-Response Relationship, Drug; Eczema; Female; Humans; Maximum Tolerated Dose; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Failure, Chronic; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
[Vascular and renal effects of anti-angiogenic therapy].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Colorectal Neoplasms; Glomerular Filtration Rate; Glomerulonephritis; Humans; Indoles; Kidney; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Proteinuria; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2008 |
Inhibition of choroidal neovascularisation in mice by systemic administration of the multikinase inhibitor, sorafenib.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blotting, Western; Choroidal Neovascularization; Dextrans; Dose-Response Relationship, Drug; Female; Fluoresceins; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Sorafenib in hepatocellular carcinoma: separating the hype from the hope.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2008 |
Comparison of the effects of the kinase inhibitors imatinib, sorafenib, and transforming growth factor-beta receptor inhibitor on extravasation of nanoparticles from neovasculature.
Topics: Animals; Benzamides; Benzenesulfonates; Cell Line, Tumor; Extravasation of Diagnostic and Therapeutic Materials; Humans; Imatinib Mesylate; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Receptors, Transforming Growth Factor beta; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2009 |
Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer.
Topics: Animals; Antibodies, Monoclonal; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Doxorubicin; Glypicans; Humans; Killer Cells, Natural; Liver Neoplasms; Male; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2008 |
Quo vadis with targeted drugs in the 21st century?
Topics: Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; ErbB Receptors; Female; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptor, ErbB-2; Sorafenib | 2009 |
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Analysis | 2009 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Hypertension; Incidence; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quality of Life; Sorafenib | 2008 |
Targeting metastatic melanoma.
Topics: Antibodies, Monoclonal; Antigens, CD; Antineoplastic Agents; Benzenesulfonates; Cancer Vaccines; Clinical Trials as Topic; CTLA-4 Antigen; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Skin Neoplasms; Sorafenib; Thionucleotides | 2008 |
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Drug Delivery Systems; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Rate | 2008 |
Sorafenib in advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Intensity-Modulated; Salvage Therapy; Sorafenib; Treatment Outcome | 2009 |
Generalised erythematous skin eruptions induced by sorafenib: cutaneous toxicity and treatment outcome.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dermatitis, Exfoliative; Drug Eruptions; Female; Humans; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin; Sorafenib; Treatment Outcome | 2008 |
Multiple keratoacanthomas arising in the setting of sorafenib therapy: novel chemoprophylaxis with bexarotene.
Topics: Adenocarcinoma, Papillary; Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bexarotene; Carboplatin; Clinical Trials as Topic; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Female; Humans; Hypertriglyceridemia; Hypothyroidism; Keratoacanthoma; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Paclitaxel; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Tetrahydronaphthalenes | 2009 |
Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report.
Topics: Adult; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cholangiocarcinoma; Female; Humans; Middle Aged; Niacinamide; Palliative Care; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Treatment Outcome | 2007 |
Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Hepatitis C; Humans; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Sorafenib for liver cancer: the horizon broadens.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Research Design; Sorafenib | 2009 |
Cutaneous drug eruptions induced by sorafenib: a case series.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Erythema; Female; Humans; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2008 |
Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Chromatography, Liquid; Female; Glucuronides; Liver; Male; Mice; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tandem Mass Spectrometry | 2009 |
Antitumor effects of a combination of interferon-alpha and sorafenib on human renal carcinoma cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Interferon-alpha; Kidney Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2008 |
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats.
Topics: Animals; Benzenesulfonates; Collateral Circulation; Enteritis; Heme Oxygenase-1; Hepatitis; Hypertension, Portal; Liver; Liver Cirrhosis; Male; Neovascularization, Physiologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Splanchnic Circulation | 2009 |
Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.
Topics: Animals; Antineoplastic Agents; Base Sequence; Benzenesulfonates; Body Weight; Disease Models, Animal; Disease Progression; Exons; Gastrointestinal Stromal Tumors; Humans; MAP Kinase Signaling System; Mice; Mice, SCID; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Testing molecular therapies in hepatocellular carcinoma: the need for randomized phase II trials.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2009 |
Commentary: Sorafenib -- the end of a long journey in search of systemic therapy for hepatocellular carcinoma, or the beginning?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Approval; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; United States; United States Food and Drug Administration | 2009 |
Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Commentary: Sorafenib use in patients with advanced hepatocellular carcinoma and underlying Child-Pugh B cirrhosis: evidence and controversy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Treating hepatocellular carcinoma without liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Synergistic effect of Sorafenib and Sunitinib with Enzastaurin, a selective protein kinase C inhibitor in renal cell carcinoma cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase C; Protein Kinase C beta; Pyridines; Pyrroles; Ribosomal Protein S6 Kinases; Signal Transduction; Sorafenib; Sunitinib | 2009 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Indoles; Kidney; Kidney Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Time Factors | 2009 |
[Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Cohort Studies; Data Interpretation, Statistical; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Surveys and Questionnaires; Time Factors; Urology | 2009 |
Perforating folliculitis, angioedema, hand-foot syndrome--multiple cutaneous side effects in a patient treated with sorafenib.
Topics: Aged; Angioedema; Antineoplastic Agents; Benzenesulfonates; Diagnosis, Differential; Drug Eruptions; Folliculitis; Foot Dermatoses; Hand Dermatoses; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Syndrome | 2009 |
MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib.
Topics: Antibodies; Antigens, Neoplasm; Benzenesulfonates; Butadienes; CD28 Antigens; CD3 Complex; Epitopes; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-2 Receptor alpha Subunit; Lymphocyte Activation; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Phytohemagglutinins; Protein Kinase Inhibitors; Pyridines; Receptors, Antigen, T-Cell; Signal Transduction; Sorafenib; T-Lymphocytes; Tetradecanoylphorbol Acetate | 2009 |
Brain magnetic resonance imaging changes after sorafenib and sunitinib chemotherapy in patients with advanced renal cell and breast carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Brain; Brain Edema; Brain Neoplasms; Breast Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Seizures; Sorafenib; Sunitinib | 2009 |
Pharmacokinetics of sorafenib in patients with renal impairment undergoing hemodialysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Blood Specimen Collection; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Kidney Diseases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Sorafenib; Time Factors | 2009 |
Sorafenib induces therapeutic response in a patient with metastatic collecting duct carcinoma of kidney.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lymphatic Metastasis; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2009 |
Remission of paraneoplastic dermatomyositis associated with hepatocellular carcinoma under prednisolone and azathiopin, and concommittant sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azathioprine; Benzenesulfonates; Carcinoma, Hepatocellular; Dermatomyositis; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Paraneoplastic Syndromes; Phenylurea Compounds; Prednisolone; Pyridines; Remission Induction; Sorafenib; Treatment Outcome | 2009 |
Unexpected autocrine role of vascular endothelial growth factor in squamous cell carcinoma.
Topics: Aneuploidy; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Squamous Cell; Gene Expression Regulation, Neoplastic; Mice; Mice, Transgenic; Models, Biological; Mutation; Niacinamide; Phenotype; Phenylurea Compounds; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A | 2009 |
A novel FIP1L1-PDGFRA mutant destabilizing the inactive conformation of the kinase domain in chronic eosinophilic leukemia/hypereosinophilic syndrome.
Topics: Amino Acid Sequence; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Molecular Sequence Data; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib | 2009 |
Sorafenib is active on lung metastases from synovial sarcoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Sarcoma, Synovial; Sorafenib; Time Factors; Treatment Outcome | 2009 |
FIP1L1-PDGFRalpha D842V, a novel panresistant mutant, emerging after treatment of FIP1L1-PDGFRalpha T674I eosinophilic leukemia with single agent sorafenib.
Topics: Aged; Animals; Benzenesulfonates; Blast Crisis; Blotting, Western; Cells, Cultured; Chronic Disease; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Male; Mice; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Phosphorylation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Sorafenib | 2009 |
Tyrosine kinase inhibitors in advanced renal cell carcinoma: the evolving treatment paradigm.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Foot Diseases; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Niacinamide; Paresthesia; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Drug Eruptions; Female; Humans; Inflammation; Keratoacanthoma; Keratosis, Actinic; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib | 2009 |
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Cell Line, Tumor; Liver Neoplasms, Experimental; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Sirolimus; Sorafenib | 2009 |
Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Bevacizumab; Dose-Response Relationship, Drug; Female; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib; Vascular Endothelial Growth Factor A | 2009 |
Major achievements in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Survival Rate; Ultrasonography | 2009 |
[Diagnosis and treatment of hepatocellular carcinoma].
Topics: Algorithms; Benzenesulfonates; Carcinoma, Hepatocellular; Early Detection of Cancer; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib | 2009 |
[Hand-foot syndrome and sorafenib].
Topics: Benzenesulfonates; Dermatology; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Liver Neoplasms; Medical Oncology; Niacinamide; Pharmacy; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Sorafenib; Syndrome | 2009 |
Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Linear Models; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factors | 2009 |
Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Dacarbazine; Drug Delivery Systems; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Quinoxalines; Skin Neoplasms; Sorafenib; Substrate Specificity; Temozolomide; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2009 |
Tie2 in tumor endothelial signaling and survival: implications for antiangiogenic therapy.
Topics: Angiopoietin-1; Animals; Apoptosis; Benzenesulfonates; Doxycycline; Endothelial Cells; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; In Vitro Techniques; Melanoma, Experimental; Mice; Mice, Inbred C3H; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Receptor, TIE-2; Recombinant Proteins; Signal Transduction; Sorafenib; Transfection | 2009 |
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Cell Line, Tumor; Dendritic Cells; Humans; Indoles; Interleukin-12; Kidney Neoplasms; Lymphocyte Activation; Lymphocyte Culture Test, Mixed; Monocytes; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes; Vascular Endothelial Growth Factor A | 2009 |
Validation of an HPLC-UV method for sorafenib determination in human plasma and application to cancer patients in routine clinical practice.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality Control; Reference Standards; Reproducibility of Results; Sorafenib; Specimen Handling; Spectrophotometry, Ultraviolet | 2009 |
Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; RNA Interference; RNA, Messenger; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; Time Factors | 2009 |
Hyperkeratosis of nipple skin during sorafenib treatment.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Breast Diseases; Carcinoma, Hepatocellular; Humans; Keratosis; Liver Neoplasms; Male; Niacinamide; Nipples; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Humans; I-kappa B Proteins; Liver Neoplasms; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Invasiveness; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; Transcription Factor RelA | 2009 |
Efficient exploration of large combinatorial chemistry spaces by monomer-based similarity searching.
Topics: Algorithms; Benzenesulfonates; Chemistry, Organic; Combinatorial Chemistry Techniques; Computer Simulation; Databases, Factual; Metoprolol; Molecular Conformation; Niacinamide; Phenylurea Compounds; Pyridines; Reproducibility of Results; Software; Sorafenib | 2009 |
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
Topics: Animals; Benzenesulfonates; Cell Line; Drug Resistance; fms-Like Tyrosine Kinase 3; Indoles; Mice; Models, Molecular; Mutagenesis, Site-Directed; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Receptors, Platelet-Derived Growth Factor; Sorafenib; Staurosporine; Tandem Repeat Sequences | 2009 |
[Hepatocellular carcinoma management in the era of sorafenib].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Pyrroles; Salvage Therapy; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2009 |
Antiangiogenic therapy: not just for cancer anymore?
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Humans; Hypertension, Portal; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Female; Flow Cytometry; Immunohistochemistry; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib | 2009 |
Sorafenib targets dysregulated Rho kinase expression and portal hypertension in rats with secondary biliary cirrhosis.
Topics: Animals; Aorta; Benzenesulfonates; Blotting, Western; Hypertension, Portal; Liver; Liver Cirrhosis, Biliary; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; rho-Associated Kinases; Signal Transduction; Sorafenib | 2009 |
[Toxicity of radiation therapy and antiangiogenics combination: a case report].
Topics: Adenocarcinoma; Benzenesulfonates; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Muscle Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiodermatitis; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2009 |
[Reversion of drug-resistant hepatocellular carcinoma cell line BEL-7402/FU by sorafenib].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Exocytosis; Flow Cytometry; Humans; Immunohistochemistry; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Rhodamine 123; Sorafenib | 2009 |
Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation, Neoplastic; Green Fluorescent Proteins; Humans; Immunohistochemistry; Lentivirus Infections; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Neoplasm; Signal Transduction; Smad2 Protein; Sorafenib; Stomach Neoplasms; Thrombospondin 1; Transforming Growth Factor beta; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2009 |
Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour.
Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Fatal Outcome; Female; Hemangiopericytoma; Humans; Indoles; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Recurrence; Solitary Fibrous Tumors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Ultrasonography | 2010 |
The successful use of sorafenib to treat pediatric papillary thyroid carcinoma.
Topics: Adolescent; Benzenesulfonates; Carcinoma, Papillary; Child; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2009 |
Targeting ELF in therapy of liver cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Carrier Proteins; Humans; Liver Neoplasms; Microfilament Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2007 |
Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
Topics: Acetophenones; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Benzopyrans; Biphenyl Compounds; Boronic Acids; Bortezomib; Caspases; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Interleukin-3; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mitochondria; Mutation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazines; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2009 |
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Topics: Animals; Atorvastatin; Benzenesulfonates; Cystadenoma; Disease Models, Animal; Doxycycline; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Heptanoic Acids; Immunosuppressive Agents; Interferon-gamma; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Burden; Tumor Suppressor Proteins | 2009 |
The crystal structure of BRAF in complex with an organoruthenium inhibitor reveals a mechanism for inhibition of an active form of BRAF kinase.
Topics: Animals; Benzenesulfonates; Cell Cycle Proteins; Crystallography, X-Ray; Humans; Ligands; Mice; Models, Molecular; Molecular Chaperones; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Ruthenium; Sorafenib | 2009 |
A cross-over response to sequential use of sunitinib after sorafenib in a patient with metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Nephrotic-range proteinuria in a patient with a renal allograft treated with sorafenib for metastatic renal-cell carcinoma.
Topics: Angiogenesis Inhibitors; Antihypertensive Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Disease Progression; Glomerulonephritis, IGA; Humans; Hypertension; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Sorafenib; Transplantation, Homologous | 2009 |
Selecting promising treatments in randomized Phase II cancer trials with an active control.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Clinical Trials, Phase II as Topic; Control Groups; Endpoint Determination; Erlotinib Hydrochloride; Humans; Models, Theoretical; Neoplasms; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Sample Size; Sorafenib; Treatment Outcome | 2009 |
Compassionate use of sorafenib in FLT3-ITD-positive acute myeloid leukemia: sustained regression before and after allogeneic stem cell transplantation.
Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Drug Evaluation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome | 2009 |
[Prospect of hepatocellular carcinoma in 2008].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diagnosis, Differential; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Polymerase Chain Reaction; Pyridines; Retrospective Studies; Sorafenib; Survival Rate | 2009 |
A systems biology perspective on cholangiocellular carcinoma development: focus on MAPK-signaling and the extracellular environment.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biological Evolution; Cholangiocarcinoma; Computational Biology; Databases, Genetic; Extracellular Space; Humans; MAP Kinase Signaling System; Mice; Multigene Family; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyridines; Sorafenib; Systems Biology | 2009 |
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Pressure; Carcinoma, Renal Cell; Humans; Hypertension; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Hypothyroidism; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Risk Assessment; Sorafenib; Sunitinib | 2009 |
Evidence and values: requirements for public reimbursement of drugs for rare diseases--a case study in oncology.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Costs; Evidence-Based Medicine; Government Regulation; Health Policy; Health Priorities; Health Services Accessibility; Health Services Needs and Demand; Humans; Insurance, Health, Reimbursement; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Research Support as Topic; Social Values; Sorafenib; Survival Analysis; Treatment Outcome | 2009 |
Sequential sorafenib and sunitinib for renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2009 |
Targeting renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
The reverse side of the victory: flare up of symptoms after discontinuation of sunitinib or sorafenib in renal cell cancer patients. A report of three cases.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
[Sorafenib reverses multidrug resistance of hepatoma cells in vitro].
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzenesulfonates; Cell Line, Tumor; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Long lasting response to the multikinase inhibitor bay 43-9006 (Sorafenib) in a heavily pretreated metastatic thymic carcinoma.
Topics: Base Sequence; Benzenesulfonates; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thymoma; Thymus Neoplasms | 2009 |
Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model?
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Image Processing, Computer-Assisted; Kidney Neoplasms; Linear Models; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spin Labels | 2009 |
Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enzyme Activation; HCT116 Cells; Humans; Hydroxamic Acids; JNK Mitogen-Activated Protein Kinases; Membrane Proteins; Niacinamide; Oxidoreductases; Phenylurea Compounds; Pyridines; Sorafenib; Vorinostat | 2009 |
BCL-2 family inhibitors enhance histone deacetylase inhibitor and sorafenib lethality via autophagy and overcome blockade of the extrinsic pathway to facilitate killing.
Topics: Adenoviridae; Antineoplastic Agents; Autophagy; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Enzyme Inhibitors; fas Receptor; Histone Deacetylase Inhibitors; Humans; Immunohistochemistry; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; RNA, Small Interfering; Sorafenib; Transfection | 2009 |
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Disease Models, Animal; Humans; Indoles; Neoplasm Metastasis; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Erythema multiforme induced by sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Eruptions; Erythema Multiforme; Female; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease Progression; Double-Blind Method; Humans; Liver Function Tests; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Severity of Illness Index; Sorafenib; Survival Rate | 2009 |
Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Chromatography, Liquid; Dasatinib; Drug Monitoring; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2009 |
How well do angiogenesis inhibitors work? Biomarkers of response prove elusive.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Biomarkers, Tumor; Cytokines; Disease-Free Survival; Endothelial Cells; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Vascular Endothelial Growth Factor A | 2009 |
A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
Topics: Aged; Anemia, Hemolytic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hemoglobins; Hemolysis; Humans; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Sorafenib-induced erythema multiforme in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Erythema Multiforme; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2009 |
Localized dyskeratotic plaque with milia associated with sorafenib.
Topics: Acantholysis; Benzenesulfonates; Carcinoma, Hepatocellular; Diabetes Mellitus; Drug Eruptions; Hepatitis B; Humans; Keratosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Multiple Histology Phase II Trials.
Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase II as Topic; Computer Simulation; Humans; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sarcoma; Sorafenib; Treatment Outcome | 2009 |
Nelfinavir induces mitochondria protection by ERK1/2-mediated mcl-1 stabilization that can be overcome by sorafenib.
Topics: Annexin A5; Antineoplastic Agents; Benzenesulfonates; Cell Death; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; HIV Protease Inhibitors; Humans; Membrane Potential, Mitochondrial; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Nelfinavir; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Phosphorylation; Propidium; Protein Stability; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib | 2010 |
Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Drug Eruptions; Female; Foot Dermatoses; Gastrointestinal Stromal Tumors; Hand Dermatoses; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Skin Diseases; Sorafenib; Stomatitis; Sunitinib; Young Adult | 2009 |
Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2009 |
Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Butadienes; Colonic Neoplasms; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3B; Down-Regulation; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; HCT116 Cells; HLA-A2 Antigen; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib | 2009 |
Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib.
Topics: Abdomen, Acute; Aged; Antineoplastic Agents; Benzenesulfonates; Colectomy; Colonic Diseases; Diarrhea; Fatal Outcome; Humans; Ileostomy; Intestinal Perforation; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib; Ulcer | 2009 |
Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors.
Topics: Adenosine Triphosphate; Allosteric Regulation; Amino Acid Sequence; Benzenesulfonates; Binding, Competitive; Catalytic Domain; Crystallography, X-Ray; Drug Evaluation, Preclinical; Enzyme Activation; Enzyme Stability; Fluorescent Dyes; Humans; Kinetics; Models, Molecular; Molecular Sequence Data; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Reproducibility of Results; Small Molecule Libraries; Sorafenib; Structure-Activity Relationship | 2009 |
Portal vein tumor thrombosis revascularization during sorafenib treatment for hepatocellular carcinoma.
Topics: Angiography; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Invasiveness; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Risk Assessment; Sorafenib; Treatment Outcome | 2009 |
Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Female; Follow-Up Studies; Humans; Keratinocytes; Keratoacanthoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Skin Neoplasms; Sorafenib; Time Factors | 2009 |
Array of cutaneous adverse effects associated with sorafenib.
Topics: Benzenesulfonates; Biopsy, Needle; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Eruptions; Female; Humans; Immunohistochemistry; Incidence; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Risk Assessment; Skin Diseases; Sorafenib | 2009 |
Surgical resection of renal cell carcinoma after targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2009 |
Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; China; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2009 |
Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blotting, Western; Cell Line, Tumor; Cell Survival; Cells, Cultured; DNA, Antisense; Doxorubicin; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; GTPase-Activating Proteins; Humans; Indoles; Kidney Neoplasms; Kinetics; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pyridines; Pyrroles; RNA, Small Interfering; Sorafenib; Sunitinib; Transfection; Tumor Burden | 2010 |
Statins potentiate cytostatic/cytotoxic activity of sorafenib but not sunitinib against tumor cell lines in vitro.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Mice; Myocytes, Cardiac; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Prenylation; Pyridines; Pyrroles; Rats; Sorafenib; Sunitinib | 2010 |
Sorafenib induces growth inhibition and apoptosis in human synovial sarcoma cells via inhibiting the RAF/MEK/ERK signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; G1 Phase; Humans; In Situ Nick-End Labeling; Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Retinoblastoma Protein; S Phase; Sarcoma, Synovial; Signal Transduction; Sorafenib | 2009 |
Tumor endothelial cells join the resistance.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Cells, Cultured; Drug Resistance, Neoplasm; Endothelium, Vascular; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Ranibizumab; Sorafenib | 2009 |
Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Doxorubicin; Drug Resistance, Neoplasm; Endoglin; Endothelium, Vascular; Fluorouracil; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Proto-Oncogene Proteins c-akt; Pyridines; Receptors, Cell Surface; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; von Willebrand Factor | 2009 |
Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cyclin E; Drug Delivery Systems; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Genes, ras; Genotype; Humans; Lung Neoplasms; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2009 |
[Expert consensus on standardization of the management of primary liver cancer].
Topics: alpha-Fetoproteins; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Congresses as Topic; Hepatectomy; Hepatic Artery; Humans; Liver Transplantation; Lung Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Radiotherapy, Conformal; Sorafenib; Ultrasonography | 2009 |
Diagnosis and management of leptomeningeal disease.
Topics: Adult; Antineoplastic Agents, Alkylating; Benzenesulfonates; Dacarbazine; Female; Humans; Meningeal Carcinomatosis; Meningeal Neoplasms; Niacinamide; Phenylurea Compounds; Prevalence; Prognosis; Protein Kinase Inhibitors; Pyridines; Sorafenib; Temozolomide | 2009 |
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Computational Biology; Humans; Image Interpretation, Computer-Assisted; Mice; Mice, SCID; Microvessels; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2009 |
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML).
Topics: Animals; Benzenesulfonates; Benzothiazoles; Bone Marrow; Carbazoles; Cell Line, Tumor; Cell Proliferation; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Prognosis; Protein Interaction Mapping; Protein Kinase C; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Staurosporine; Xenograft Model Antitumor Assays | 2009 |
Eruptive keratoacanthoma-type squamous cell carcinomas in patients taking sorafenib for the treatment of solid tumors.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Humans; Keratoacanthoma; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Neoplasms; Sorafenib | 2009 |
Development of a novel chemical class of BRAF inhibitors offers new hope for melanoma treatment.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Humans; Imatinib Mesylate; Imidazoles; Inhibitory Concentration 50; Melanoma; Mice; Microsomes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Sorafenib | 2009 |
[Schedule-dependent effects of sorafenib in combination with paclitaxel on human hepatocellular carcinoma cell line BEL-7402].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Drug Administration Schedule; Drug Interactions; Humans; Liver Neoplasms; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib | 2009 |
The tyrosine kinase inhibitor sorafenib decreases cell number and induces apoptosis in a canine osteosarcoma cell line.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Bone Neoplasms; Caspase 3; Cell Count; Cell Line, Tumor; Dog Diseases; Dogs; Flow Cytometry; Ki-67 Antigen; Microscopy, Electron, Transmission; Niacinamide; Osteosarcoma; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2010 |
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA Methylation; Drug Synergism; Female; Gene Dosage; Genes, ras; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinases; Pyridines; ras Proteins; RNA, Messenger; RNA, Neoplasm; Signal Transduction; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2009 |
Long-term response in primary renal cancer to sequential antiangiogenic therapy.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors | 2009 |
Sorafenib has soluble epoxide hydrolase inhibitory activity, which contributes to its effect profile in vivo.
Topics: Animals; Benzenesulfonates; Cell Line, Tumor; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Male; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Solubility; Sorafenib | 2009 |
UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase I as Topic; Cyclophosphamide; Doxorubicin; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Pyridines; Sorafenib | 2009 |
Rectal fistulae resulting from treatment with sorafenib and bevacizumab.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Female; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Rectal Fistula; Sorafenib | 2009 |
Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Kidney; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
Effect of the UK postcode lottery on survival of patients with metastatic renal cancer: an audit of outcomes in patients with metastatic renal cancer suitable for treatment with tyrosine kinase inhibitors.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney; Kidney Neoplasms; Male; Medical Audit; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; United Kingdom | 2009 |
Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study.
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance; Extracellular Signal-Regulated MAP Kinases; Hepatocytes; Humans; Immunochemistry; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Sorafenib | 2009 |
Hepatocellular carcinoma: The beginning of a long journey.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Matrix Metalloproteinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2009 |
The histologic spectrum of epithelial neoplasms induced by sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Epithelium; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib | 2009 |
Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Extracellular Signal-Regulated MAP Kinases; Hepatocytes; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2009 |
Targeted therapies: Role of sorafenib in HCC patients with compromised liver function.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Fibrosis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Time Factors | 2009 |
New aspects of an anti-tumour drug: sorafenib efficiently inhibits HCV replication.
Topics: Antiviral Agents; Benzenesulfonates; Cells, Cultured; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Hepacivirus; Hepatocytes; Humans; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Replicon; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Viral Nonstructural Proteins; Virus Replication | 2009 |
Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Compassionate Use Trials; Disease Progression; Drug Delivery Systems; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Placebos; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Sorafenib induces partial response in metastatic medullary thyroid carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Neuroendocrine; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Schistosomiasis; Skin Neoplasms; Soft Tissue Neoplasms; Sorafenib; Thyroid Neoplasms | 2010 |
Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Camptothecin; Child; Combined Modality Therapy; Cyclophosphamide; Dacarbazine; Dactinomycin; Etoposide; Fatal Outcome; Female; Foot; Groin; Humans; Ifosfamide; Irinotecan; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Male; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Radiotherapy, High-Energy; Rhabdomyosarcoma, Alveolar; Salvage Therapy; Soft Tissue Neoplasms; Sorafenib; Temozolomide; Thigh; Vincristine | 2009 |
Complete resolution of leukemia cutis with sorafenib in an acute myeloid leukemia patient with FLT3-ITD mutation.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Leukemic Infiltration; Male; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Skin; Sorafenib; Tandem Repeat Sequences; Treatment Outcome | 2009 |
Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Child, Preschool; Cyclophosphamide; Dacarbazine; Female; Humans; Melanoma; Melanosis; Meningeal Neoplasms; Neurocutaneous Syndromes; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide; Treatment Outcome | 2010 |
AZD6244 (ARRY-142886) enhances the therapeutic efficacy of sorafenib in mouse models of gastric cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Blotting, Western; Disease Models, Animal; Drug Synergism; Humans; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Neoplasms | 2009 |
Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Aurora Kinase A; Aurora Kinase B; Aurora Kinases; Benzamides; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; G2 Phase; Humans; Immunoenzyme Techniques; In Vitro Techniques; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2009 |
Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Cell Proliferation; Cytokines; Down-Regulation; Hemodynamics; Hypertension, Portal; Ligation; Male; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Sorafenib; Splanchnic Circulation | 2009 |
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Humans; In Situ Hybridization; Liver Neoplasms; Luciferases; Mice; Mice, Nude; MicroRNAs; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Transfection | 2009 |
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cohort Studies; Disease Progression; Female; Gene Silencing; Humans; Indoles; Male; Melanoma; Middle Aged; Nevus; Niacinamide; Phenols; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Sensitivity and Specificity; Skin Neoplasms; Sorafenib; Young Adult | 2009 |
Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzamides; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Survival; Drug Screening Assays, Antitumor; Drug Synergism; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Membrane Proteins; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins; Pyridines; raf Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Sorafenib; Tumor Cells, Cultured | 2009 |
Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Eruptions; Female; Humans; Hypertension; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2010 |
Sorafenib induced tumor lysis syndrome in an advanced hepatocellular carcinoma patient.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Lysis Syndrome | 2009 |
Spontaneous pyopneumothorax in patients treated with mTOR inhibitors for subpleural pulmonary metastases.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcitonin; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Susceptibility; Everolimus; Fatal Outcome; Female; Humans; Indoles; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Proteins; Nephrectomy; Niacinamide; Phenylurea Compounds; Pneumonia, Bacterial; Pneumothorax; Protein Precursors; Pyridines; Pyrroles; Rupture, Spontaneous; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2010 |
Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Prognosis; Pyridines; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2009 |
Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Calcium; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Cytochromes c; Dose-Response Relationship, Drug; Enzyme Activation; Glutathione; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Intracellular Space; Liver Neoplasms; Microscopy, Confocal; Mitochondria; Niacinamide; Oxidative Stress; Phenylurea Compounds; Pyridines; Reactive Oxygen Species; Sorafenib | 2009 |
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Cohort Studies; Female; Humans; Hypertension; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A | 2009 |
Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters.
Topics: Adenosine Triphosphatases; Animals; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blood-Brain Barrier; Carrier Proteins; Cells, Cultured; Drug Evaluation, Preclinical; Humans; Hydrolysis; Indoles; Mice; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Swine; Xenopus laevis | 2009 |
[Palmoplantar cutaneous reaction to sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases, Vesiculobullous; Sorafenib | 2009 |
Synergistic efficacy of sorafenib and genistein in growth inhibition by down regulating angiogenic and survival factors and increasing apoptosis through upregulation of p53 and p21 in malignant neuroblastoma cells having N-Myc amplification or non-amplifi
Topics: Angiogenesis Inducing Agents; Apoptosis; bcl-2-Associated X Protein; Benzenesulfonates; Caspase 3; Cell Cycle; Cell Proliferation; Cell Shape; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Drug Synergism; Flow Cytometry; Gene Amplification; Genistein; Humans; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neuroblastoma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Pyridines; Signal Transduction; Sorafenib; Telomerase; Treatment Outcome; Tumor Suppressor Protein p53; Up-Regulation | 2010 |
Activation of cytosolic phospholipase A2alpha by epidermal growth factor (EGF) and phorbol ester in HeLa cells: different effects of inhibitors for EGF receptor, protein kinase C, Src, and C-Raf.
Topics: Benzenesulfonates; Cytosol; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Group IV Phospholipases A2; HeLa Cells; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Models, Biological; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase C; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; src-Family Kinases; Temperature; Tetradecanoylphorbol Acetate; Time Factors | 2009 |
Rapid development of hypertension by sorafenib: toxicity or target?
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blood Pressure; Drug Delivery Systems; Drug Dosage Calculations; Drug-Related Side Effects and Adverse Reactions; Humans; Hypertension; Mice; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
Everolimus: in advanced renal cell carcinoma.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Clinical Trials, Phase III as Topic; Disease-Free Survival; Double-Blind Method; Everolimus; Humans; Immunosuppressive Agents; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placebos; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Sorafenib as a feasible therapeutic option in haemophiliacs with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Factor VIII; Hemophilia A; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM).
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Clinical Protocols; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2009 |
The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Colony-Forming Units Assay; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique; Furans; Humans; Immunoenzyme Techniques; Immunosuppression Therapy; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Male; Melanoma; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrimidines; ras Proteins; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Survival Rate; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2010 |
Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2.
Topics: Animals; Apoptosis; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Enzyme Activation; Humans; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Pyridines; Rats; Rats, Inbred F344; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Tyrosine | 2009 |
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2009 |
Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Caspases; Cell Cycle; Cell Proliferation; Cytochromes c; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; Flow Cytometry; Heat-Shock Proteins; Humans; Liver Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Phenylurea Compounds; Pyridines; RNA, Small Interfering; Sorafenib; Tumor Cells, Cultured | 2010 |
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Cell Line, Tumor; fms-Like Tyrosine Kinase 3; Hematologic Diseases; Hematopoietic Stem Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Myelopoiesis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Substrate Specificity; Sulfonamides; Sunitinib | 2009 |
Multidisciplinary treatment including sorafenib stabilized the bone metastases of renal cell carcinoma in an immunosuppressed renal transplant recipient.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imidazoles; Immunosuppressive Agents; Incidental Findings; Interferon-alpha; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiotherapy, Adjuvant; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2009 |
Drug essentials. Small molecule multitargeted TKI therapy.
Topics: Benzenesulfonates; Drug Interactions; Humans; Indoles; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2008 |
Acute aortic dissection during sorafenib-containing therapy.
Topics: Aged; Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Aortic Aneurysm; Aortic Dissection; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Deoxycytidine; Female; Fluorouracil; Gemcitabine; Humans; Hypertension; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Sorafenib-induced hepatic encephalopathy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Hepatic Encephalopathy; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors | 2009 |
Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Transplantation; Markov Chains; Models, Theoretical; Monte Carlo Method; Niacinamide; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years; Sorafenib; Treatment Outcome; Waiting Lists | 2010 |
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins B-raf; Pyridines; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2009 |
Sorafenib-induced bilateral osteonecrosis of femoral heads.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Femur Head Necrosis; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Therapy for metastatic RCC--questions remain.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2009 |
Where does the combination of sorafenib and interferon in renal cell carcinoma stand?
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Drug Delivery Systems; Humans; Interferons; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2010 |
Sorafenib-induced hand-foot skin reaction: a Koebner phenomenon?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Foot Dermatoses; Hand Dermatoses; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Skin Diseases; Skin Tests; Sorafenib | 2009 |
Interstitial pneumonia probably associated with sorafenib treatment: An alert of an adverse event.
Topics: Antineoplastic Agents; Asian People; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Synthesis and antiproliferative activity of pyrrolo[3,2-b]pyridine derivatives against melanoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Structure-Activity Relationship | 2010 |
About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Humans; Indoles; Male; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
AZD6244 enhances the anti-tumor activity of sorafenib in ectopic and orthotopic models of human hepatocellular carcinoma (HCC).
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Successful treatment of a brain-metastasized renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Parietal Lobe; Phenylurea Compounds; Pyridines; Radiotherapy, Adjuvant; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2009 |
Evidence-based urology in practice: when to believe a subgroup analysis?
Topics: Age Factors; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Evidence-Based Medicine; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib | 2010 |
Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Okadaic Acid; Phenylurea Compounds; Protein Phosphatase 2; Proto-Oncogene Proteins c-akt; Pyrazines; Pyridines; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2010 |
Mechanisms of myocyte cytotoxicity induced by the multikinase inhibitor sorafenib.
Topics: Adenosine Triphosphate; Animals; Animals, Newborn; Apoptosis; Benzenesulfonates; Blotting, Western; Cardiotonic Agents; Caspase 3; Caspase 7; Cell Separation; Extracellular Signal-Regulated MAP Kinases; In Vitro Techniques; Iron Chelating Agents; L-Lactate Dehydrogenase; Microscopy, Fluorescence; Myocytes, Cardiac; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Razoxane; Sorafenib | 2010 |
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
Topics: Animals; Benzenesulfonates; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Enzyme Activation; Humans; Immunoprecipitation; MAP Kinase Signaling System; Melanoma; Mice; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; ras Proteins; Sorafenib; Transfection | 2009 |
Elevated International Normalized Ratio associated with concurrent use of sorafenib and warfarin.
Topics: Aged; Anticoagulants; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Interactions; Hemorrhage; Humans; International Normalized Ratio; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Warfarin | 2009 |
Salvage therapy with sorafenib plus vinblastine and fluorouracil for metastatic renal cell carcinoma.
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Fluorouracil; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Salvage Therapy; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vinblastine | 2009 |
The loss of radiographic enhancement in primary renal cell carcinoma tumors following multitargeted receptor tyrosine kinase therapy is an additional indicator of response.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiographic Image Enhancement; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
NICE rules that drug used in advanced liver cancer is not cost effective for the NHS.
Topics: Antineoplastic Agents; Benzenesulfonates; Cost-Benefit Analysis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years; Sorafenib; United Kingdom | 2009 |
Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Drug Synergism; Humans; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; STAT3 Transcription Factor; Vascular Endothelial Growth Factor A | 2010 |
[Impact of immunotherapy in metastatic kidney cancer in Germany after introduction of new target therapy--results of a telephone survey of the German Society of Immuno- and Targeted Therapy (DGFIT)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Attitude of Health Personnel; Benzenesulfonates; Carcinoma, Renal Cell; Cooperative Behavior; Data Collection; Drug Delivery Systems; Drug Utilization; Germany; Humans; Immunotherapy; Indoles; Interdisciplinary Communication; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Medical Oncology; Niacinamide; Patient Care Team; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Urology | 2010 |
Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease Progression; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Secondary Prevention; Sorafenib | 2010 |
Sorafenib-induced acute myocardial infarction due to coronary artery spasm.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Coronary Vasospasm; Humans; Kidney Neoplasms; Male; Myocardial Infarction; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; rho-Associated Kinases; rhoA GTP-Binding Protein; Signal Transduction; Sorafenib | 2009 |
Hepatitis C virus infection reduces hepatocellular polarity in a vascular endothelial growth factor-dependent manner.
Topics: Autocrine Communication; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Polarity; Hep G2 Cells; Hepacivirus; Humans; Liver Neoplasms; Membrane Proteins; Niacinamide; Occludin; Permeability; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tight Junctions; Up-Regulation; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Virus Internalization | 2010 |
Baying for a flexible drug price.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Industry; Fees, Pharmaceutical; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Time Factors | 2010 |
Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiodermatitis; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Health policy: The UK 'postcode lottery' in renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Health Care Rationing; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Regional Health Planning; Sorafenib; Sunitinib; Survival Rate; United Kingdom | 2009 |
Platelet count less than SHARP: what does a case series reveal?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Platelet Count; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Thrombocytopenia | 2010 |
Sorafenib - a small molecule with big promise?
Topics: Abdominal Pain; Acute Disease; Area Under Curve; Benzenesulfonates; Diarrhea; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Fatigue; Humans; Leukemia, Myeloid; Metabolic Clearance Rate; Myelodysplastic Syndromes; Nausea; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Division; Cell Line, Tumor; Cytoskeletal Proteins; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2009 |
[Sorafenib-induced multiple eruptive keratoacanthomas].
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunosuppressive Agents; Keratoacanthoma; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Sunlight | 2009 |
The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Indoles; K562 Cells; Killer Cells, Natural; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib | 2009 |
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.
Topics: Alleles; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Carbazoles; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Indoles; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Pyridines; Pyrroles; Sorafenib; Staurosporine; Sunitinib | 2010 |
CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients.
Topics: AC133 Antigen; Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Glycoproteins; Hematopoietic Stem Cells; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Peptides; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib | 2010 |
Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Posterior Leukoencephalopathy Syndrome; Prognosis; Pyridines; Sorafenib | 2010 |
Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Mitosis; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rhodamines; Sorafenib; Stomach Neoplasms; Taxoids; Xenograft Model Antitumor Assays | 2011 |
Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Hepatitis B, Chronic; Humans; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
[Clinical observation of 21 cases of metastatic renal cell carcinoma treated with sorafenib].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib | 2009 |
[Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Fatigue; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2009 |
Re: Sequential sorafenib and sunitinib for renal cell carcinoma M. P. Sablin, S. Negrier, A. Ravaud, S. Oudard, C. Balleyguier, J. Gautier, C. Celier, J. Medioni and B. Escudier J Urol 2009; 182: 29-34.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment.
Topics: Adrenal Gland Neoplasms; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Contrast Media; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pheochromocytoma; Protein Kinase Inhibitors; Pyridines; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2010 |
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT.
Topics: Adult; Aged; Analysis of Variance; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Lack of association between excretion of sorafenib in sweat and hand-foot skin reaction.
Topics: Antineoplastic Agents; Benzenesulfonates; Chromatography, High Pressure Liquid; Drug Eruptions; Female; Foot Dermatoses; Hand Dermatoses; Humans; Iontophoresis; Limit of Detection; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilocarpine; Pilot Projects; Protein Kinase Inhibitors; Pyridines; Severity of Illness Index; Sorafenib; Sweat; Tandem Mass Spectrometry | 2010 |
Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Remission Induction; Skin Neoplasms; Sorafenib; Treatment Outcome | 2010 |
Multifaceted perspective of the waiting list for liver transplantation: the value of pharmacokinetic models.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Donors; Waiting Lists | 2010 |
[Targeting KRAS pathway in NSCLC therapy].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Farnesyltranstransferase; Genes, ras; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Quinolones; raf Kinases; ras Proteins; Sorafenib | 2009 |
[Treatment approach of hepatocellular carcinoma in Spain. Analysis of 705 patients from 62 centers].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Early Diagnosis; Embolization, Therapeutic; Female; Hemochromatosis; Hepatectomy; Hepatitis, Viral, Human; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mass Screening; Niacinamide; Obesity; Phenylurea Compounds; Prospective Studies; Pyridines; Registries; Retrospective Studies; Sorafenib; Spain; Treatment Outcome; Young Adult; Yttrium Radioisotopes | 2010 |
Sorafenib inhibits ERK1/2 and MCL-1(L) phosphorylation levels resulting in caspase-independent cell death in malignant pleural mesothelioma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Lung Neoplasms; Mesothelioma; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphorylation; Pleural Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand | 2009 |
Hepatocellular carcinoma: sorafenib before liver transplantation?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Experience with sorafenib and the elderly patient.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quality of Life; Randomized Controlled Trials as Topic; Sorafenib; Survival Rate | 2010 |
Tyrosine kinase inhibitor-induced macrocytosis.
Topics: Anemia, Macrocytic; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Neoplasm Staging; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2009 |
Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Eruptions; Exanthema; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis | 2010 |
Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasms, Glandular and Epithelial; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma.
Topics: Animals; Antigens, Bacterial; Bacterial Toxins; Benzenesulfonates; Carcinoma; Cell Line, Tumor; Cell Proliferation; Endocytosis; Humans; Matrix Metalloproteinases; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Time Factors; Xenograft Model Antitumor Assays | 2010 |
Synergistic activity of letrozole and sorafenib on breast cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Inducing Factor; Aromatase; Aromatase Inhibitors; Benzenesulfonates; Breast Neoplasms; Caspase 7; Caspase 9; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cytochromes c; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Female; Humans; Letrozole; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Niacinamide; Nitriles; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-myc; Pyridines; Retinoblastoma Protein; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Testosterone; Time Factors; TOR Serine-Threonine Kinases; Transfection; Triazoles | 2010 |
The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; CASP8 and FADD-Like Apoptosis Regulating Protein; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endometrial Neoplasms; fas Receptor; Female; Humans; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2010 |
Identification of bona fide esophageal adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Clinical Trials as Topic; DNA Fingerprinting; Esophageal Neoplasms; Humans; National Institutes of Health (U.S.); Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tandem Repeat Sequences; United States | 2010 |
Verification and unmasking of widely used human esophageal adenocarcinoma cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzenesulfonates; Biomedical Research; Carcinoma; Carcinoma, Large Cell; Cell Line, Tumor; Clinical Trials as Topic; Colorectal Neoplasms; DNA Fingerprinting; Esophageal Neoplasms; Humans; Lung Neoplasms; National Institutes of Health (U.S.); Niacinamide; Oligonucleotides; Oligopeptides; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Stomach Neoplasms; Tandem Repeat Sequences; Telomerase; United States | 2010 |
Complete response of hepatocellular carcinoma with systemic combination chemotherapy: not to get out the chemotherapy?
Topics: Adult; alpha-Fetoproteins; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Peritoneal Neoplasms; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib | 2010 |
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Compassionate Use Trials; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; North America; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Renal Insufficiency; Sorafenib; Sunitinib | 2010 |
Sorafenib inhibits the shedding of major histocompatibility complex class I-related chain A on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9.
Topics: ADAM Proteins; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Dipeptides; Down-Regulation; Histocompatibility Antigens Class I; Humans; Hydroxamic Acids; Killer Cells, Natural; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzenesulfonates; Biological Transport; Brain; Cell Line; Cell Line, Tumor; Dogs; Gene Expression Regulation, Neoplastic; Humans; Membrane Proteins; Mice; Mice, Transgenic; Models, Chemical; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Hepatitis C virus proteins modulate microRNA expression and chemosensitivity in malignant hepatocytes.
Topics: Apoptosis; Benzenesulfonates; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepacivirus; Hepatocytes; Humans; Liver Neoplasms; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Transfection; Viral Proteins | 2010 |
A retroperitoneal mass with elevated alpha-1-fetoprotein: not always a testicular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Hepatocellular; Choristoma; Diagnosis, Differential; Humans; Liver Diseases; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retroperitoneal Neoplasms; Retroperitoneal Space; Sorafenib; Testicular Neoplasms; Ultrasonography | 2010 |
The mitochondria-independent cytotoxic effect of nelfinavir on leukemia cells can be enhanced by sorafenib-mediated mcl-1 downregulation and mitochondrial membrane destabilization.
Topics: Apoptosis; Benzenesulfonates; Bone Marrow Cells; Caspase 8; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cyclin B; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Activation; Gene Expression Regulation, Leukemic; Humans; Leukemia; Membrane Potential, Mitochondrial; Mitochondria; Mitochondrial Membranes; Myeloid Cell Leukemia Sequence 1 Protein; Nelfinavir; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Up-Regulation | 2010 |
Combination therapy of interleukin-2 and sorafenib improves survival benefits and prevents spontaneous pulmonary metastasis in murine renal cell carcinoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Mice; Mice, Inbred BALB C; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib; Survival Rate | 2010 |
Safety of transarterial chemoembolization plus sorafenib combination treatment in unresectable hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2010 |
Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Humans; Lymphoma, Large B-Cell, Diffuse; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; Transfection | 2010 |
Hepatocellular carcinoma: the search for innovative adjuvant therapies.
Topics: Antineoplastic Agents; Benzenesulfonates; Cancer Vaccines; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Neoplasm Seeding; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib | 2009 |
[Renal cell carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib | 2010 |
Discovery and initial SAR of pyrimidin-4-yl-1H-imidazole derivatives with antiproliferative activity against melanoma cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Binding Sites; Cell Line, Tumor; Crystallography, X-Ray; Drug Discovery; Humans; Imidazoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-raf; Pyridines; Pyrimidines; Sorafenib; Structure-Activity Relationship | 2010 |
Choroidal metastasis of renal cell carcinoma: a case report.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Choroid Neoplasms; Eye Enucleation; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Risk of bleeding not increased by sorafenib or sunitinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Hemorrhage; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2010 |
Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.
Topics: Adolescent; Adult; Antineoplastic Agents; Antiviral Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates; Carcinoma, Renal Cell; Child; Child, Preschool; Chromosomes, Human, Pair 11; Chromosomes, Human, X; Everolimus; Female; Gene Fusion; Humans; Immunosuppressive Agents; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Research Report; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Translocation, Genetic; Treatment Outcome; Vascular Endothelial Growth Factor A; Young Adult | 2010 |
Sorafenib protects human optic nerve head astrocytes from light-induced overexpression of vascular endothelial growth factor, platelet-derived growth factor, and placenta growth factor.
Topics: Adult; Aged; Astrocytes; Benzenesulfonates; Cell Survival; Humans; Light; Middle Aged; Niacinamide; Optic Disk; Phenylurea Compounds; Placenta Growth Factor; Platelet-Derived Growth Factor; Pregnancy Proteins; Protein Kinase Inhibitors; Pyridines; Retina; Retinal Neovascularization; Sorafenib; Vascular Endothelial Growth Factor A | 2010 |
Sorafenib-associated remission of psoriasis in hypernephroma: case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psoriasis; Pyridines; Pyrroles; Retreatment; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Comparative profiling of the novel epothilone, sagopilone, in xenografts derived from primary non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Benzothiazoles; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epothilones; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Sorafenib inhibits STAT3 activation to enhance TRAIL-mediated apoptosis in human pancreatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Carcinoma; Drug Evaluation, Preclinical; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2010 |
Optimal de novo design of MRM experiments for rapid assay development in targeted proteomics.
Topics: Algorithms; Animals; Artificial Intelligence; Benzenesulfonates; Cell Line, Tumor; Chromatography, High Pressure Liquid; Female; Humans; Linear Models; Markov Chains; Mass Spectrometry; Melanoma; Mice; Niacinamide; Peptide Fragments; Phenylurea Compounds; Proteome; Proteomics; Pyridines; Reproducibility of Results; Sorafenib | 2010 |
Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Humans; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psoriasis; Pyridines; Sorafenib; Thyroid Neoplasms | 2010 |
Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Epidemiologic Methods; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2010 |
Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Chorionic Gonadotropin, beta Subunit, Human; Cyclophosphamide; Doxorubicin; Female; Humans; Injections, Subcutaneous; Liver Neoplasms, Experimental; Mice; Mice, Nude; Mice, SCID; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Tegafur; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays | 2010 |
Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Analysis; Tomography, X-Ray Computed | 2010 |
Painless acute pancreatitis associated with sorafenib treatment: a case report.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Immunologic Factors; Interferon-alpha; Kidney Neoplasms; Male; Niacinamide; Pancreatitis; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Sorafenib combined vitamin K induces apoptosis in human pancreatic cancer cell lines through RAF/MEK/ERK and c-Jun NH2-terminal kinase pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; BH3 Interacting Domain Death Agonist Protein; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Fas Ligand Protein; Fas-Associated Death Domain Protein; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphorylation; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-jun; Pyridines; raf Kinases; Sorafenib; Vitamin K 1 | 2010 |
Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Fluorouracil; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Treatment Failure | 2011 |
Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Dosage Calculations; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib | 2010 |
Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
Topics: Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Biliary Tract Surgical Procedures; Carcinoma, Hepatocellular; Disease Progression; Fatal Outcome; Hemobilia; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stents | 2010 |
Highlights from the Eigth International Kidney Cancer Symposium.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Line, Tumor; Disease Models, Animal; Humans; Kidney Neoplasms; Multigene Family; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2009 |
Analysis of imatinib and sorafenib binding to p38alpha compared with c-Abl and b-Raf provides structural insights for understanding the selectivity of inhibitors targeting the DFG-out form of protein kinases.
Topics: Benzamides; Benzenesulfonates; Crystallography, X-Ray; Humans; Imatinib Mesylate; Mitogen-Activated Protein Kinase 14; Models, Molecular; Molecular Structure; Naphthalenes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-abl; Pyrazoles; Pyridines; Pyrimidines; Sorafenib; Structure-Activity Relationship | 2010 |
Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study.
Topics: Antineoplastic Agents; Benzenesulfonates; Biotransformation; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Sorafenib; Treatment Outcome | 2010 |
Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2010 |
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Carbonic Anhydrases; Carcinoma, Renal Cell; Drug Synergism; Female; Humans; Immunohistochemistry; Indoles; Kidney Neoplasms; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2011 |
The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; bcl-X Protein; Benzenesulfonates; Carcinoma, Hepatocellular; Cyclin G1; Down-Regulation; Drug Synergism; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sorafenib; Staurosporine; Up-Regulation | 2010 |
Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; beta Catenin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; DNA Mutational Analysis; Everolimus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Point Mutation; Precision Medicine; Pyridines; Ribavirin; Sirolimus; Sorafenib | 2010 |
Metronomic chemotherapy for renal cancer in the landscape of targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Carcinoma, Renal Cell; Deoxycytidine; Drug Administration Schedule; Fluorouracil; Gemcitabine; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
Topics: Algorithms; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Contrast Media; Early Detection of Cancer; Gadolinium DTPA; Humans; Infusion Pumps; Japan; Liver Neoplasms; Magnetic Resonance Imaging; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Population Surveillance; Protein Precursors; Prothrombin; Pyridines; Sensitivity and Specificity; Sorafenib; Survival Rate | 2010 |
Sorafenib induces growth arrest and apoptosis of human glioblastoma cells through the dephosphorylation of signal transducers and activators of transcription 3.
Topics: Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Cyclin E; DNA, Neoplasm; Glioblastoma; Humans; Interleukin-6; Janus Kinase 1; Janus Kinase 2; Mutant Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Oncogene Proteins; Phenylurea Compounds; Phosphorylation; Phosphotyrosine; Protein Binding; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; src-Family Kinases; STAT3 Transcription Factor; Tumor Cells, Cultured; Vanadates | 2010 |
Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Female; Humans; Imatinib Mesylate; Melanoma; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Skin Neoplasms; Sorafenib | 2010 |
Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzenesulfonates; Breast Neoplasms; Calcium; Cell Division; Cell Line, Tumor; Cytosol; DNA Primers; Endoplasmic Reticulum; Flow Cytometry; Gefitinib; Humans; Lapatinib; Membrane Potentials; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib | 2010 |
Prognostic factors in patients treated with VEGF-targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factors | 2010 |
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Off-Label Use; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Thyroglobulin; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Sequential therapy of transarterial chemoembolisation and sorafenib in intermediate stage hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Preoperative induction with sorafenib pathologically downstaged advanced renal cell carcinoma: a case report.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Preoperative Care; Pyridines; Severity of Illness Index; Sorafenib; Tomography, X-Ray Computed | 2010 |
In vitro to in vivo comparison of the substrate characteristics of sorafenib tosylate toward P-glycoprotein.
Topics: Animals; Anti-Arrhythmia Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzenesulfonates; Brain; Caco-2 Cells; Digoxin; Humans; LLC-PK1 Cells; Male; Mice; Mice, Knockout; Niacinamide; Permeability; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Swine | 2010 |
A case of blast clearance on sorafenib in relapsed FLT3-ITD acute myeloid leukemia: evidence of efficacy continues to mount.
Topics: Antineoplastic Agents; Benzenesulfonates; Blast Crisis; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib | 2010 |
[Renal cell carcinoma management and therapies in 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Everolimus; Humans; Indoles; Interferons; Interleukin-2; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Metabolic Networks and Pathways; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
[Targeted therapies: sequential and combined treatments].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Combined Modality Therapy; Cytokines; ErbB Receptors; Humans; Indoles; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
[Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Digestive System; Heart; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Lung Injury; Mucous Membrane; Muscle Fatigue; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
[Advanced renal carcinomas with special situations. How to treat them?].
Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Everolimus; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2010 |
Sorafenib in patients with advanced non-small cell lung cancer that harbor K-ras mutations: a brief report.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Nucleus; Cell Separation; Doxorubicin; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Flow Cytometry; Gene Knockdown Techniques; Humans; Hydrogen Peroxide; Kidney Neoplasms; NF-E2-Related Factor 2; Niacinamide; Oxidants; Oxidative Stress; Phenylurea Compounds; Phosphorylation; Pyridines; RNA, Small Interfering; Sorafenib | 2010 |
Drug therapy: sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Risk Factors; Sorafenib | 2010 |
Involvement of receptor tyrosine phosphatase DEP-1 mediated PI3K-cofilin signaling pathway in sorafenib-induced cytoskeletal rearrangement in hepatoma cells.
Topics: Actins; Benzenesulfonates; Carcinoma, Hepatocellular; Cofilin 1; Cytoskeleton; Enzyme Activation; Humans; Liver Neoplasms; Models, Biological; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoprotein Phosphatases; Phosphorylation; Phosphotyrosine; Proto-Oncogene Proteins c-met; Pyridines; Receptor-Like Protein Tyrosine Phosphatases, Class 3; Signal Transduction; Sorafenib | 2010 |
Sorafenib-induced acute pancreatitis.
Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreatitis; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis.
Topics: Animals; Apoptosis; Base Sequence; Benzenesulfonates; Caspase 3; Cell Cycle; Cell Proliferation; Cells, Cultured; Collagen Type I; DNA Primers; Down-Regulation; Hepatic Stellate Cells; Humans; In Vitro Techniques; Liver Cirrhosis; Male; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sorafenib | 2010 |
Editorial comment.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Editorial comment.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Sorafenib plus valproic acid for infant spinal glioblastoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Extracellular Signal-Regulated MAP Kinases; Female; Glioblastoma; Humans; Immunohistochemistry; Infant; MAP Kinase Kinase Kinases; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Radiotherapy; raf Kinases; Sorafenib; Spinal Cord Neoplasms; Valproic Acid | 2010 |
Sorafenib exerts anti-glioma activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Glioblastoma; Glioma; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Random Allocation; Sorafenib; Treatment Outcome | 2010 |
The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells.
Topics: Apoptosis; Benzenesulfonates; Caspase 3; Caspases; Cell Line, Tumor; Cytochromes c; Extracellular Signal-Regulated MAP Kinases; Humans; Inhibitor of Apoptosis Proteins; Male; Microtubule-Associated Proteins; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Survivin | 2010 |
Combined anticancer effects of sphingosine kinase inhibitors and sorafenib.
Topics: Adamantane; Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Caspase 3; Caspase 7; Catechols; Cell Line, Tumor; DNA Fragmentation; Drug Synergism; Female; Humans; Kidney Neoplasms; Mice; Mice, SCID; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
A case of variant angina in a patient under chronic treatment with sorafenib.
Topics: Angina Pectoris, Variant; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiac Catheterization; Chronic Disease; Coronary Angiography; Electrocardiography; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors | 2010 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease Progression; Drug Delivery Systems; Everolimus; Humans; Indoles; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy.
Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Sorafenib downregulates ERK/Akt and STAT3 survival pathways and induces apoptosis in a human neuroblastoma cell line.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Survival; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Humans; In Situ Nick-End Labeling; Neuroblastoma; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphorylation; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2010 |
Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Eruptions; Female; Hematologic Diseases; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Rate | 2010 |
A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.
Topics: Activating Transcription Factors; Animals; Apoptosis; Benzenesulfonates; Brain Neoplasms; Cyclic AMP Response Element-Binding Protein; Gene Expression Profiling; Glioma; Humans; Mice; Mice, Inbred C57BL; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2010 |
Effect of sorafenib on experimental choroidal neovascularization in the rat.
Topics: Animals; Benzenesulfonates; Choroidal Neovascularization; Computer Systems; Disease Progression; Dose-Response Relationship, Drug; Down-Regulation; Fluorescein Angiography; Gene Expression; Intercellular Adhesion Molecule-1; Lasers; Male; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pyridines; Radiation Injuries; Rats; Rats, Inbred BN; Sorafenib; Vascular Endothelial Growth Factor A | 2010 |
[Diagnosis and treatment of bone metastasis of renal cancer: an expert consensus statement (2008 version)].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Humans; Interleukin-2; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Pain; Phenylurea Compounds; Pyridines; Recombinant Proteins; Sorafenib | 2010 |
Sorafenib induces apoptosis and autophagy in prostate cancer cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Carcinoma; Drug Evaluation, Preclinical; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Male; Niacinamide; Phagosomes; Phenylurea Compounds; Phosphorylation; Prostatic Neoplasms; Pyridines; Sorafenib; Transfection; Tumor Cells, Cultured | 2010 |
A patient with advanced hepatocellular carcinoma treated with sorafenib tosylate showed massive tumor lysis with avoidance of tumor lysis syndrome.
Topics: Adult; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tumor Lysis Syndrome | 2010 |
Identification of a secondary FLT3/A848P mutation in a patient with FLT3-ITD-positive blast phase CMML and response to sunitinib and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myelomonocytic, Chronic; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib.
Topics: Adult; Benzenesulfonates; Disease Progression; Fatal Outcome; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Carcinoma, Papillary; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms | 2010 |
Non-pigmenting fixed drug eruption induced by sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Drug Eruptions; Erythema; Humans; Kidney Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Skin; Sorafenib | 2010 |
Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Proliferation; Cells, Cultured; Colony-Forming Units Assay; Drug Synergism; Electrophoretic Mobility Shift Assay; Female; Fibroblasts; Humans; Immunoblotting; Immunoenzyme Techniques; Isoenzymes; Isothiocyanates; Luciferases; Mice; Mice, Nude; Neoplastic Stem Cells; Neovascularization, Pathologic; NF-kappa B; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Retinal Dehydrogenase; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Skin; Sorafenib; Spheroids, Cellular; Sulfoxides; Thiocyanates; Xenograft Model Antitumor Assays | 2010 |
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Extracellular Signal-Regulated MAP Kinases; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib | 2010 |
Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Renal Dialysis; Sorafenib | 2011 |
Impact of sorafenib on health-related quality of life in Japanese patients with metastatic renal cell carcinoma: a prospective evaluation.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Epidemiologic Methods; Female; Health Status; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Sorafenib; Treatment Outcome | 2010 |
ZAK is required for doxorubicin, a novel ribotoxic stressor, to induce SAPK activation and apoptosis in HaCaT cells.
Topics: Antibiotics, Antineoplastic; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Doxorubicin; HeLa Cells; Humans; Keratinocytes; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrimidines; RNA, Small Interfering; Signal Transduction; Sorafenib | 2010 |
[Effect of sorafenib combined with daunorubicin on K562 cell line].
Topics: Apoptosis; Benzenesulfonates; Daunorubicin; Drug Synergism; Humans; K562 Cells; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Efficacy and safety of sorafenib in advanced hepatocellular carcinoma under daily practice conditions.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2010 |
Ultraviolet recall dermatitis reaction with sorafenib.
Topics: Benzenesulfonates; Fatal Outcome; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiodermatitis; Sorafenib; Ultraviolet Rays | 2011 |
Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Humans; Imidazoles; Liposomes; Liver Neoplasms, Experimental; Lung Neoplasms; Macrophages; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays; Zoledronic Acid | 2010 |
Sorafenib, a multikinase inhibitor, enhances the response of melanoma to regional chemotherapy.
Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Butadienes; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Melanoma; Melphalan; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitriles; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; Rats; Rats, Nude; Sorafenib; Temozolomide; Tumor Burden; Xenograft Model Antitumor Assays | 2010 |
Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Erythema Multiforme; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Radiotherapy; Sorafenib; Treatment Outcome; Yttrium | 2010 |
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Consensus Development Conferences as Topic; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Radiotherapy; Sorafenib; Treatment Outcome; Yttrium | 2010 |
Long-term stable disease in metastatic renal cell carcinoma: sorafenib sequenced to sunitinib and everolimus: a case study.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Everolimus; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sunitinib | 2011 |
Sensitivity of doxorubicin-resistant cells to sorafenib: possible role for inhibition of eukaryotic initiation factor-2alpha phosphorylation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Proliferation; Cell Survival; Down-Regulation; Doxorubicin; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; eIF-2 Kinase; Eukaryotic Initiation Factor-2; Humans; Hydrogen Peroxide; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Sorafenib; Tumor Cells, Cultured | 2010 |
Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Biological Availability; Crystallography, X-Ray; Female; Humans; Hydrogen Bonding; Imidazoles; Mice; Mice, Inbred BALB C; Models, Molecular; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Binding; Proto-Oncogene Proteins B-raf; Pyrazines; Pyridines; Sorafenib; Structure-Activity Relationship; Transplantation, Heterologous | 2010 |
Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
Topics: Acute Disease; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Hepatitis C; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Differences in effects on myocardium and mitochondria by angiogenic inhibitors suggest separate mechanisms of cardiotoxicity.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Echocardiography; Heart; Immunohistochemistry; In Situ Nick-End Labeling; Indazoles; Indoles; Male; Microscopy, Electron, Transmission; Mitochondria; Myocardium; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Rats; Sorafenib; Sulfonamides; Sunitinib; Troponin I | 2010 |
Management of hepatocellular carcinoma: from prevention to molecular targeted therapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepacivirus; Hepatitis B virus; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: a structural analysis of the binding interactions of Gleevec, Nexavar, and BIRB-796.
Topics: Adenosine Triphosphate; Allosteric Regulation; Amino Acid Sequence; Antineoplastic Agents; Benzamides; Benzenesulfonates; Catalytic Domain; Computer Simulation; Crystallography, X-Ray; Drug Design; Hydrogen Bonding; Imatinib Mesylate; Mitogen-Activated Protein Kinase 14; Naphthalenes; Niacinamide; Oligopeptides; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-abl; Pyrazoles; Pyridines; Pyrimidines; Sorafenib | 2010 |
Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib; Transplantation, Homologous | 2010 |
Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; DNA, Neoplasm; Female; Foot Dermatoses; Genotype; Hand Dermatoses; Humans; Hypertension; Male; Neoplasms; Niacinamide; Phenylurea Compounds; Polymerase Chain Reaction; Polymorphism, Single Nucleotide; Pyridines; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
Vorinostat and sorafenib increase CD95 activation in gastrointestinal tumor cells through a Ca(2+)-de novo ceramide-PP2A-reactive oxygen species-dependent signaling pathway.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Calcium; Carboxylic Ester Hydrolases; Cell Line, Tumor; Ceramides; fas Receptor; Gastrointestinal Neoplasms; Humans; Hydroxamic Acids; Niacinamide; Phenylurea Compounds; Pyridines; Reactive Oxygen Species; Signal Transduction; Sorafenib; Vorinostat | 2010 |
Sorafenib and thyrotoxicosis.
Topics: Benzenesulfonates; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Pyridines; Sorafenib; Thyrotoxicosis | 2010 |
Safe use of sorafenib in a patient undergoing salvage liver transplantation for recurrent hepatocellular carcinoma after hepatic resection.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib | 2011 |
Response to sorafenib in a patient with metastatic xp11 translocation renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chromosomes, Human, X; Disease-Free Survival; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Translocation, Genetic; Treatment Outcome; Young Adult | 2010 |
Whole-cell biotransformation assay for investigation of the human drug metabolizing enzyme CYP3A7.
Topics: Aryl Hydrocarbon Hydroxylases; Benzenesulfonates; Biocatalysis; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dehydroepiandrosterone; Dose-Response Relationship, Drug; Econazole; Firefly Luciferin; Gas Chromatography-Mass Spectrometry; Humans; Isoenzymes; Liver; Mass Spectrometry; Miconazole; Niacinamide; Pharmaceutical Preparations; Phenylurea Compounds; Polymorphism, Genetic; Pyridines; Schizosaccharomyces; Sorafenib; Testosterone | 2011 |
The multikinase inhibitor sorafenib reverses the suppression of IL-12 and enhancement of IL-10 by PGE₂ in murine macrophages.
Topics: Animals; Benzenesulfonates; Cell Line; Dinoprostone; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Interleukin-10; Interleukin-12; Macrophages; Mice; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; STAT3 Transcription Factor; Suppressor of Cytokine Signaling 3 Protein; Suppressor of Cytokine Signaling Proteins; Toll-Like Receptors | 2010 |
18[F]FDG small animal PET study of sorafenib efficacy in lymphoma preclinical models.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Drug Evaluation, Preclinical; Fluorodeoxyglucose F18; Humans; Lymphoma; Mice; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Pyridines; Radiopharmaceuticals; Sorafenib; Treatment Outcome | 2010 |
Annular leukocytoclastic vasculitis associated with sorafenib administration.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Vasculitis, Leukocytoclastic, Cutaneous | 2010 |
BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Biomarkers, Tumor; Biphenyl Compounds; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Liver; Liver Neoplasms; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Sulfonamides | 2010 |
Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells.
Topics: Annexin A5; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; ras Proteins; Sorafenib; Urinary Bladder Neoplasms | 2010 |
Treatment outcomes of sorafenib for first line or cytokinerefractory advanced renal cell carcinoma in Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Disease Progression; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2010 |
Secondary resistance to sorafenib in two patients with acute myeloid leukemia (AML) harboring FLT3-ITD mutations.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; Fatal Outcome; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Sustained treatment response of metastatic hepatocellular carcinoma with bevacizumab and sorafenib.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
Sorafenib-associated psoriasiform skin changes.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Hand; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Psoriasis; Pyridines; Sorafenib | 2010 |
Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program.
Topics: Animals; Benzenesulfonates; Cell Line, Tumor; Child; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Health-related quality of life and sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality of Life; Sorafenib | 2010 |
Managing patients receiving sorafenib for advanced hepatocellular carcinoma: a case study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Continuity of Patient Care; Diarrhea; Drug Eruptions; Drug Monitoring; Female; Humans; Hypertension; Liver Neoplasms; Niacinamide; Nurse's Role; Oncology Nursing; Patient Care Team; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Safety; Sorafenib | 2010 |
Sorafenib activates CD95 and promotes autophagy and cell death via Src family kinases in gastrointestinal tumor cells.
Topics: Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; Fas Ligand Protein; fas Receptor; Gastrointestinal Neoplasms; Humans; Hydroxamic Acids; Niacinamide; Phenylurea Compounds; Phosphotyrosine; Protein Kinase Inhibitors; Pyridines; Reactive Oxygen Species; Receptor, Platelet-Derived Growth Factor beta; Signal Transduction; Sorafenib; src-Family Kinases; Vorinostat | 2010 |
The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2011 |
Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoradiotherapy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Sorafenib in metastatic renal cell carcinoma with sarcomatoid differentiation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sarcoma; Sorafenib | 2010 |
Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
Topics: Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blood Glucose; Dasatinib; Diabetes Mellitus; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Imatinib Mesylate; Indoles; Linear Models; Male; Middle Aged; Neoplasms; Niacinamide; Pennsylvania; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thiazoles; Time Factors; Treatment Outcome | 2011 |
Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors.
Topics: Adenocarcinoma; Benzenesulfonates; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, Neoplasm; High-Throughput Nucleotide Sequencing; Humans; Indoles; Lung Neoplasms; Mitogen-Activated Protein Kinases; Mutation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Selection, Genetic; Sorafenib; Sunitinib; Tongue Neoplasms | 2010 |
Presurgical targeted therapy with tyrosine kinase inhibitors for advanced renal cell carcinoma: clinical results and histopathological therapeutic effects.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Sorafenib's inhibition of prostate cancer growth in transgenic adenocarcinoma mouse prostate mice and its differential effects on endothelial and pericyte growth during tumor angiogenesis.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Drug Screening Assays, Antitumor; Endothelium, Vascular; Fluorescent Antibody Technique, Direct; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Niacinamide; Pericytes; Phenylurea Compounds; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Pyridines; Sorafenib; Treatment Outcome | 2010 |
From a cancer drug fund to value based pricing of drugs.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; England; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Quality-Adjusted Life Years; Sorafenib; Wales | 2010 |
Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Calcium Channel Blockers; Carcinoma, Hepatocellular; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Felodipine; Humans; Hypertension; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Sorafenib and radiation: a promising combination in colorectal cancer.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Division; Colorectal Neoplasms; Combined Modality Therapy; HT29 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiation Tolerance; Radiotherapy Dosage; Random Allocation; Sorafenib; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2010 |
Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kaplan-Meier Estimate; Kidney Neoplasms; Lapatinib; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2010 |
Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer.
Topics: Administration, Oral; Benzenesulfonates; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Medullary; Clinical Trials, Phase II as Topic; Disease-Free Survival; Humans; Lymph Node Excision; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2010 |
Synergistic cytotoxicity and molecular interaction on drug targets of sorafenib and gemcitabine in human pancreas cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gemcitabine; Humans; MAP Kinase Kinase Kinases; Mitogen-Activated Protein Kinase Kinases; Molecular Targeted Therapy; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphatidylinositol 3-Kinase; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib | 2010 |
Radiologic complete response with sirolimus and sorafenib in a hepatocellular carcinoma patient who relapsed after orthotopic liver transplantation.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Diagnostic Imaging; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sirolimus; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Identification and characterization of novel oncogenes in chronic eosinophilic leukemia and T-cell acute lymphoblastic leukemia.
Topics: Benzenesulfonates; Humans; Hypereosinophilic Syndrome; mRNA Cleavage and Polyadenylation Factors; Niacinamide; Nuclear Pore Complex Proteins; Oncogene Proteins; Oncogene Proteins, Fusion; Phenylurea Compounds; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib | 2010 |
Editorial comment to Treatment outcomes of sorafenib for first line or cytokine-refractory advanced renal cell carcinoma in Japanese patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Disease Progression; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
[Sorafenib].
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Humans; Hypophosphatemia; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2010 |
Risk of arterial thrombosis not increased by sorafenib or sunitinib.
Topics: Angiogenesis Inhibitors; Arterial Occlusive Diseases; Benzenesulfonates; Evidence-Based Medicine; Humans; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Reproducibility of Results; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Thromboembolism | 2010 |
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Ethnicity; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Safety; Sorafenib; Survival Analysis | 2010 |
[Sorafenib in relapsed and refractory FLT3-ITD positive acute myeloid leukemia: a novel treatment option].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Combined Modality Therapy; DNA Mutational Analysis; Dose-Response Relationship, Drug; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Off-Label Use; Phenylurea Compounds; Pyridines; Remission Induction; Retreatment; Sorafenib | 2010 |
The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzenesulfonates; Biphenyl Compounds; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Humans; Liver Neoplasms; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Transplantation; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyridines; RNA, Small Interfering; Sorafenib; Sulfonamides | 2010 |
The multi-targeted kinase inhibitor sorafenib inhibits human cytomegalovirus replication.
Topics: Benzenesulfonates; Cytomegalovirus; DNA Primers; Genes, Immediate-Early; Humans; Immunoblotting; Luciferases; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinase Inhibitors; Pyridines; raf Kinases; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Virus Replication | 2011 |
[Nexavar clinical registry].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Registries; Sorafenib | 2010 |
Complete response after sorafenib therapy for hepatocellular carcinoma in an HIV-HBV co infected patient: Possible synergy with HAART ? A case report.
Topics: Aged; Antiretroviral Therapy, Highly Active; Benzenesulfonates; Carcinoma, Hepatocellular; Coinfection; Drug Synergism; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Resistance, Neoplasm; GPI-Linked Proteins; Humans; Immunomagnetic Separation; Immunotherapy, Adoptive; Indoles; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Linear Models; Nasopharyngeal Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib | 2011 |
Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Movement; Cetuximab; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Sorafenib inhibits cAMP-dependent ERK activation, cell proliferation, and in vitro cyst growth of human ADPKD cyst epithelial cells.
Topics: Benzenesulfonates; Blotting, Western; Cell Proliferation; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Enzyme Activation; Epidermal Growth Factor; Epithelial Cells; Humans; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Polycystic Kidney, Autosomal Dominant; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib | 2010 |
Targeting B-Raf as a treatment strategy for polycystic kidney disease.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Benzenesulfonates; Cell Proliferation; Cells, Cultured; Humans; Niacinamide; Phenylurea Compounds; Polycystic Kidney Diseases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Tolvaptan | 2010 |
Sorafenib enhances the in vitro anti-endothelial effects of low dose (metronomic) chemotherapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Drug Administration Schedule; Endothelial Cells; Etoposide; Humans; In Vitro Techniques; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Sorafenib; Temozolomide | 2010 |
Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Chondrosarcoma; Cyclin D1; Extracellular Signal-Regulated MAP Kinases; Humans; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Signal Transduction; Sorafenib | 2010 |
Sorafenib therapy in patients with hepatocellular carcinoma before liver transplantation.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Liver Transplantation; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
[Therapeutic efficacy of Nexavar on liver cancer and its relation to the expression of Ki-67 and CD34].
Topics: Adult; Aged; Antigens, CD34; Antineoplastic Agents; Female; Humans; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2010 |
Primitive neuroectodermal tumor of the kidney with inferior vena cava tumor thrombus during pregnancy response to sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Kidney Neoplasms; Neuroectodermal Tumors, Primitive; Niacinamide; Phenylurea Compounds; Pregnancy; Pyridines; Radiography; Sorafenib; Thrombosis; Vena Cava, Inferior | 2010 |
Safety and efficacy of the combination of erlotinib and sirolimus for the treatment of metastatic renal cell carcinoma after failure of sunitinib or sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chromatography, Liquid; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Tandem Mass Spectrometry | 2010 |
Sorafenib-induced destructive thyroiditis.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chronic Disease; Hepatitis B, Chronic; Humans; Iodine Radioisotopes; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Propranolol; Protein Kinase Inhibitors; Pyridines; Sorafenib; Technetium; Thyroiditis | 2010 |
Rapid response to sorafenib in metastatic medullary thyroid carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendocrine; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Neoplasms | 2011 |
Monitoring blood-brain barrier status in a rat model of glioma receiving therapy: dual injection of low-molecular-weight and macromolecular MR contrast media.
Topics: Analysis of Variance; Animals; Area Under Curve; Benzenesulfonates; Blood-Brain Barrier; Brain Neoplasms; Contrast Media; Disease Models, Animal; Glioma; Heterocyclic Compounds; Macromolecular Substances; Magnetic Resonance Imaging; Male; Neovascularization, Pathologic; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Pyridines; Random Allocation; Rats; Sorafenib | 2010 |
Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lymphocytes, Tumor-Infiltrating; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; T-Lymphocytes, Regulatory; Treatment Outcome | 2011 |
Combination therapy with sorafenib and S-1 for renal cell carcinoma producing granulocyte colony-stimulating factor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Combinations; Granulocyte Colony-Stimulating Factor; Humans; Kidney Neoplasms; Leukocytosis; Male; Medical Futility; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur | 2011 |
Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyrotropin; Treatment Outcome | 2011 |
[Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Topics: Administration, Oral; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cardiovascular Diseases; Clinical Trials as Topic; Drug Eruptions; Drug Interactions; Drug Monitoring; Gastrointestinal Diseases; Humans; Liver Cirrhosis; Liver Neoplasms; Molecular Targeted Therapy; Neoplasm Proteins; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Radiography; raf Kinases; Sorafenib; Spain | 2010 |
Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Drug Eruptions; Female; Folliculitis; Humans; Keratosis; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinases; Pyridines; Skin; Sorafenib | 2010 |
Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Female; Humans; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Rats; Rats, Nude; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Brachytherapy; Carcinoma, Hepatocellular; Cause of Death; Combined Modality Therapy; Follow-Up Studies; Humans; Iodine Radioisotopes; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Patient Care Planning; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Time Factors | 2010 |
Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Benzenesulfonates; Chromatography, High Pressure Liquid; Humans; Niacinamide; Oxides; Phenylurea Compounds; Pyridines; Sorafenib; Tandem Mass Spectrometry | 2010 |
Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation.
Topics: Apoptosis; Benzenesulfonates; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cell Survival; DNA, Neoplasm; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; src-Family Kinases; STAT3 Transcription Factor | 2011 |
Transient perforating folliculitis induced by sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Folliculitis; Humans; Kidney Neoplasms; Male; Neutrophil Infiltration; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission, Spontaneous; Sorafenib | 2010 |
Hyperkeratotic eruption, hand-foot skin reaction, facial erythema, and stomatitis secondary to multi-targeted kinase inhibitor sorafenib.
Topics: Benzenesulfonates; Carcinoma, Renal Cell; Erythema; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin Diseases, Papulosquamous; Sorafenib; Stomatitis | 2010 |
Atypical linear toxicodermia by sorafenib.
Topics: Adult; Benzenesulfonates; Biopsy; Edema; Female; Hepatolenticular Degeneration; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Skin Diseases, Papulosquamous; Sorafenib | 2010 |
Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Feasibility Studies; Female; Humans; Indoles; Italy; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2010 |
Sorafenib overcomes TRAIL resistance of hepatocellular carcinoma cells through the inhibition of STAT3.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand; Xenograft Model Antitumor Assays | 2010 |
Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis.
Topics: Actins; Animals; Apoptosis; Benzenesulfonates; Caspase 3; Colorimetry; DNA Fragmentation; Hepatic Stellate Cells; Histological Techniques; Hypertension, Portal; Immunohistochemistry; Liver; Liver Cirrhosis, Biliary; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Pyridines; Rats; Sorafenib; Vascular Resistance | 2011 |
Combining functional imaging and interstitial pressure measurements to evaluate two anti-angiogenic treatments.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Contrast Media; Drug Administration Schedule; Extracellular Fluid; Female; Fiber Optic Technology; Melanoma, Experimental; Mice; Neovascularization, Pathologic; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Phospholipids; Pressure; Pyridines; Regional Blood Flow; Sorafenib; Sulfur Hexafluoride; Time Factors; Transducers, Pressure; Ultrasonography, Doppler | 2012 |
Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Follow-Up Studies; Gadolinium DTPA; Humans; Image Enhancement; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome; Tumor Burden | 2011 |
Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique; Humans; Mice; Mice, Transgenic; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Subcellular Fractions; Thyroid Gland; Thyroid Neoplasms | 2011 |
High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid.
Topics: Antineoplastic Agents; Ascitic Fluid; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sensitivity and Specificity; Sorafenib | 2011 |
Clinical management and case reports for the treatment of hepatocellular carcinoma with sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Fatal Outcome; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Treatment Outcome | 2011 |
Impressive efficacy of sorafenib in a patient with an hepatocellular carcinoma and a portal vein thrombosis associated with a metastatic ENT cancer.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Head and Neck Neoplasms; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Sorafenib; Treatment Outcome; Venous Thrombosis | 2011 |
Sorafenib treatment in 13 patients with acute myeloid leukemia and activating FLT3 mutations in combination with chemotherapy or as monotherapy.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Enzyme Activation; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2010 |
The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.
Topics: Antineoplastic Agents; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Benzenesulfonates; Cell Line, Tumor; Endoplasmic Reticulum; Farnesyltranstransferase; Humans; Melanoma; Mitogen-Activated Protein Kinase Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Piperidines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Skin Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factor CHOP | 2011 |
Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transplantation, Homologous | 2010 |
[Tegafur-uracil markedly reduced pulmonary metastasis from renal cell carcinoma refractory to sorafenib, interferon and interleukin 2].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Humans; Interferons; Interleukin-2; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Tomography, X-Ray Computed; Uracil | 2010 |
Enhancing mda-7/IL-24 therapy in renal carcinoma cells by inhibiting multiple protective signaling pathways using sorafenib and by Ad.5/3 gene delivery.
Topics: Adenoviridae; Animals; Apoptosis; bcl-X Protein; Benzenesulfonates; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Culture Media, Conditioned; fas Receptor; Gene Knockdown Techniques; Gene Transfer Techniques; Genetic Therapy; Humans; Interleukins; Kidney Neoplasms; Mice; Mitochondria; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2010 |
The multikinase inhibitor Sorafenib displays significant antiproliferative effects and induces apoptosis via caspase 3, 7 and PARP in B- and T-lymphoblastic cells.
Topics: Antineoplastic Agents; Apoptosis; B-Lymphocytes; Benzenesulfonates; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Humans; Jurkat Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Poly(ADP-ribose) Polymerases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyridines; Sorafenib; T-Lymphocytes | 2010 |
The role of the breast cancer resistance protein (ABCG2) in the distribution of sorafenib to the brain.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Blood-Brain Barrier; Brain; Cell Line; Dogs; Glioma; Humans; Male; Mice; Mice, Knockout; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Bevacizumab for metastatic renal cell carcinoma: a monoclonal antibody in a sea of small molecules.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis | 2010 |
111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Immunohistochemistry; Indium Radioisotopes; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Radionuclide Imaging; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A | 2010 |
Sorafenib prevents human retinal pigment epithelium cells from light-induced overexpression of VEGF, PDGF and PlGF.
Topics: Aged; Angiogenesis Inhibitors; Benzenesulfonates; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; Light; Macular Degeneration; Membrane Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Retinal Pigment Epithelium; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A | 2010 |
Promising efficacy of sorafenib in a relapsed thymic carcinoma with C-KIT exon 11 deletion mutation.
Topics: Antineoplastic Agents; Benzenesulfonates; Exons; Female; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyridines; Sequence Deletion; Sorafenib; Thymus Neoplasms | 2011 |
The low frequency of clinical resistance to PDGFR inhibitors in myeloid neoplasms with abnormalities of PDGFRA might be related to the limited repertoire of possible PDGFRA kinase domain mutations in vitro.
Topics: Amino Acid Sequence; Antineoplastic Agents; Benzamides; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Sequence Data; Mutagenesis, Site-Directed; Mutation; Myeloproliferative Disorders; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Structure-Activity Relationship | 2011 |
Oncogenic RAF: a brief history of time.
Topics: Benzenesulfonates; Drug Screening Assays, Antitumor; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides; Time Factors; Vemurafenib | 2010 |
Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report.
Topics: Adult; Antigens, CD34; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Penile Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Pyrroles; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Mechanism of synergistic antitumor effect of sorafenib and interferon-α on treatment of renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Female; Humans; Immunologic Factors; Interferon-alpha; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Benzenesulfonates; Female; Gene Expression Profiling; Humans; Mice; Mice, Nude; Niacinamide; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Phenylurea Compounds; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2010 |
Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells.
Topics: Animals; Anthracenes; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Binding Sites; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Sp1 Transcription Factor; Transcription Factor AP-1; Transplantation, Heterologous | 2010 |
Analysis of phosphoproteomics data.
Topics: Amino Acid Sequence; Benzenesulfonates; Databases, Protein; Humans; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Proteomics; Pyridines; Signal Transduction; Sorafenib | 2011 |
Efficacy of sorafenib, molecular targeting drug, for advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2010 |
Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Administration Schedule; Feasibility Studies; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Medical Records; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2010 |
Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Retrospective Studies; Severity of Illness Index; Sorafenib; Sunitinib; Treatment Failure; Treatment Outcome | 2010 |
The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primates.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Blood-Brain Barrier; Capillary Permeability; Chromatography, High Pressure Liquid; Half-Life; Infusions, Intravenous; Macaca mulatta; Male; Metabolic Clearance Rate; Models, Animal; Models, Biological; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tandem Mass Spectrometry | 2012 |
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Vascular Endothelial Growth Factors | 2011 |
Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms, Experimental; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tegafur; Time Factors; Treatment Outcome; Uracil; Xenograft Model Antitumor Assays | 2010 |
Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.
Topics: Apoptosis; Benzenesulfonates; Calcium; Cell Survival; Chemokine CXCL12; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Immunoblotting; Intracellular Space; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, CXCR4; Signal Transduction; Sorafenib; Time Factors; Tumor Cells, Cultured; ZAP-70 Protein-Tyrosine Kinase | 2011 |
Sirolimus plus sorafenib in treating HCC recurrence after liver transplantation: a case report.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome | 2010 |
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gastrointestinal Diseases; Graft vs Host Disease; Humans; Inverted Repeat Sequences; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Skin Diseases; Sorafenib; Stem Cell Transplantation; Tandem Repeat Sequences; Transplantation, Homologous; Young Adult | 2011 |
Differential inhibition of transmembrane 4 L six family member 5 (TM4SF5)-mediated tumorigenesis by TSAHC and sorafenib.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Chalcone; Drug Discovery; Humans; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2011 |
Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib | 2010 |
mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Everolimus; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2011 |
Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Deoxycytidine; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Survival Rate; Tumor Cells, Cultured | 2010 |
Kidney cancer: Does hypothyroidism predict clinical outcome?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
[Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma].
Topics: Adult; Aged; Alopecia; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Diarrhea; Disease Progression; Follow-Up Studies; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib; Survival Rate | 2010 |
Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Feasibility Studies; Female; Humans; Liver Neoplasms; Liver Transplantation; Los Angeles; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Marked bone marrow hypoplasia associated with sorafenib-induced marrow blast clearance in two patients with FLT3-ITD acute myeloid leukemia.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Blast Crisis; Bone Marrow Diseases; fms-Like Tyrosine Kinase 3; Humans; Inverted Repeat Sequences; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tandem Repeat Sequences | 2011 |
Systemic immune tuning in renal cell carcinoma: favorable prognostic impact of TGF-β1 mRNA expression in peripheral blood mononuclear cells.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; CD4-Positive T-Lymphocytes; Disease-Free Survival; Flow Cytometry; Forkhead Transcription Factors; Gene Expression; Humans; Immune Tolerance; Interleukin-10; Interleukin-2 Receptor alpha Subunit; Kidney Neoplasms; Leukocytes, Mononuclear; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; RNA, Messenger; Sorafenib; T-Lymphocytes, Regulatory; Transforming Growth Factor beta1; Treatment Outcome | 2011 |
HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lapatinib; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Signal Transduction; Sorafenib; Survivin; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Thyrotropin; Thyroxine; Treatment Outcome; Triiodothyronine | 2011 |
Inhibition of lactic dehydrogenase as a way to increase the anti-proliferative effect of multi-targeted kinase inhibitors.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Synergism; Glycolysis; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Oxamic Acid; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thymidine | 2011 |
Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2010 |
Regional squamous cell carcinomas following systemic sorafenib therapy and isolated limb infusion for regionally advanced metastatic melanoma of the limb.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Squamous Cell; Drug Administration Routes; Follow-Up Studies; Humans; Leg; Male; Melanoma; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Skin Neoplasms; Sorafenib | 2010 |
Clinical outcome of 251 patients with extrahepatic metastasis at initial diagnosis of hepatocellular carcinoma: does transarterial chemoembolization improve survival in these patients?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cause of Death; Chemoembolization, Therapeutic; Chi-Square Distribution; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Prolonged survival in renal transplant recipient with advanced renal cell carcinoma by everolimus and sorafenib.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Kidney Neoplasms; Kidney Transplantation; Lung Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib | 2011 |
PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; Furans; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; raf Kinases; ras Proteins; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2010 |
More than 4 years of progression-free survival in a patient with metastatic renal cell carcinoma treated sequentially with sunitinib, everolimus, sorafenib, and temsirolimus.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Everolimus; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2010 |
RAF kinase activity regulates neuroepithelial cell proliferation and neuronal progenitor cell differentiation during early inner ear development.
Topics: Animals; Benzenesulfonates; Cell Differentiation; Cell Proliferation; Chick Embryo; Ear, Inner; Epithelial Cells; Gene Expression Regulation, Enzymologic; Insulin-Like Growth Factor I; Models, Biological; Neurons; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Stem Cells | 2010 |
How I manage my patients with hepatocellular carcinoma.
Topics: Ablation Techniques; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Management; Evidence-Based Medicine; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate | 2011 |
Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinase; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib | 2011 |
Sorafenib and its tosylate salt: a multikinase inhibitor for treating cancer.
Topics: Antineoplastic Agents; Benzenesulfonates; Crystallography, X-Ray; Enzyme Inhibitors; Humans; Hydrogen Bonding; Molecular Conformation; Molecular Structure; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tosyl Compounds | 2011 |
Immunomodulatory effects of sorafenib on peripheral immune effector cells in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cytokines; Female; Humans; Immunologic Factors; Interleukin-10; Kidney Neoplasms; Leukocytes, Mononuclear; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; RNA, Messenger; Sorafenib; T-Lymphocytes; Transforming Growth Factor beta1 | 2011 |
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.
Topics: Animals; Benzenesulfonates; Benzimidazoles; beta Catenin; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Centrosome; Chromosome Aberrations; DNA Breaks, Double-Stranded; DNA Damage; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Models, Biological; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Polycomb Repressive Complex 2; Proto-Oncogene Proteins c-raf; Pyridines; Rad51 Recombinase; Signal Transduction; Sorafenib; Spheroids, Cellular; Transcription Factors; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2011 |
Myositis due to Sorafenib intake in a patient with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Myositis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Epithelial-Mesenchymal Transition; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Transfection | 2011 |
[Effect of sorafenib on lymphangiogenesis in subcutaneously transplanted human cholangiocarcinoma in nude mice].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Dose-Response Relationship, Drug; Down-Regulation; Humans; Lymphangiogenesis; Lymphatic Vessels; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Random Allocation; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-3 | 2010 |
[The outcome of chemotherapy by sorafenib in advanced hepatocellular carcinoma].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2010 |
[The effect of sorafenib and intermittent hepatic arterial infusion chemotherapy using cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus--a pilot study].
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cisplatin; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Pilot Projects; Portal Vein; Pyridines; Sorafenib; Venous Thrombosis | 2010 |
Sorafenib in unresectable intrahepatic cholangiocellular carcinoma: a case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cholangiocarcinoma; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Complete response for advanced liver cancer during sorafenib therapy: case report.
Topics: Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Treatment Outcome | 2011 |
Invasive squamous cell carcinoma and sorafenib in a black patient.
Topics: Antineoplastic Agents; Benzenesulfonates; Black People; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Drug Eruptions; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib | 2011 |
Splenic infarction associated with sorafenib use in a hepatocellular carcinoma patient.
Topics: Aged; Antineoplastic Agents; Aspirin; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Spleen; Splenic Infarction; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Sorafenib versus cytotoxic chemotherapy for patients with advanced hepatocellular carcinoma: a retrospective, single-institution study.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Cytotoxins; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2012 |
[Cytoprotective and antiangiogenic effects of the multikinase inhibitor sorafenib on human retinal pigmentepithelium].
Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Cytoprotection; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retinal Pigment Epithelium; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2011 |
Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Young Adult | 2011 |
Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts.
Topics: Adamantane; Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Flow Cytometry; Hep G2 Cells; Humans; Liver Neoplasms; Lysophospholipids; Mice; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Pyridines; Sorafenib; Sphingosine; Xenograft Model Antitumor Assays | 2011 |
Complete histologic response induced by sorafenib in advanced hepatocellular carcinoma: a case report.
Topics: alpha-Fetoproteins; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Diffusion Magnetic Resonance Imaging; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Time Factors; Treatment Outcome | 2011 |
FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo.
Topics: Antineoplastic Agents; Benzenesulfonates; Carbazoles; Cells, Cultured; Drug Antagonism; fms-Like Tyrosine Kinase 3; Furans; Humans; Indazoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Membrane Proteins; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Staurosporine; Treatment Outcome | 2011 |
Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Drug Costs; Female; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Markov Chains; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib; Sweden; United States | 2011 |
Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
Topics: Antineoplastic Agents; Benzenesulfonates; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Hydroxylation; Indoles; Liver; Microsomes, Liver; Midazolam; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
Biomarkers in renal cell carcinoma: what next?
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Humans; Kidney Neoplasms; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2011 |
Temsirolimus in metastatic chromophobe renal cell carcinoma after interferon and sorafenib therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Interferons; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Salvage Therapy; Sirolimus; Sorafenib; Treatment Outcome | 2011 |
Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transplantation, Heterologous; Treatment Outcome | 2011 |
Effect of sorafenib on murine liver regeneration.
Topics: Animals; Becaplermin; Benzenesulfonates; Cell Proliferation; Hepatectomy; Hepatocyte Growth Factor; Liver; Liver Regeneration; Male; Mice; Mice, Inbred C57BL; Models, Animal; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-sis; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Atrophy; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Gland; Thyroiditis; Ultrasonography | 2011 |
Sequential treatment with sorafenib and sunitinib in metastatic renal cell carcinoma: clinical outcomes from a retrospective clinical study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors | 2012 |
Sorafenib therapy in patients with advanced hepatocellular carcinoma in advanced liver cirrhosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Young Adult | 2011 |
Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner.
Topics: Acute Disease; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Cytarabine; Disease Models, Animal; DNA Damage; Doxorubicin; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid; Mice; Mice, Inbred C57BL; Mice, Transgenic; Myeloid-Lymphoid Leukemia Protein; Niacinamide; Phenylurea Compounds; Pyridines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Survival Analysis; Tandem Repeat Sequences; Tumor Suppressor Protein p53 | 2011 |
Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA, Small Interfering; Sorafenib; Stromal Cells; Tumor Cells, Cultured | 2011 |
Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell ca
Topics: Academic Medical Centers; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Boston; Carcinoma, Renal Cell; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Observer Variation; Phenylurea Compounds; Predictive Value of Tests; Pyridines; Pyrroles; Reproducibility of Results; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor A | 2011 |
Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Biological Transport; Blood-Brain Barrier; Cells, Cultured; Dogs; Humans; Indoles; Mice; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib; Topoisomerase I Inhibitors; Topotecan | 2011 |
Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Preclincial testing of sorafenib and RAD001 in the Nf(flox/flox) ;DhhCre mouse model of plexiform neurofibroma using magnetic resonance imaging.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Cell Proliferation; Chromatography, High Pressure Liquid; Disease Models, Animal; Drug Evaluation, Preclinical; Everolimus; Female; Hedgehog Proteins; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Integrases; Magnetic Resonance Imaging; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Neurofibroma, Plexiform; Neurofibromin 1; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sirolimus; Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution; Tumor Burden | 2012 |
Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.
Topics: Antineoplastic Agents; Benzenesulfonates; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypophosphatemia; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Kinase inhibitor Sorafenib modulates immunosuppressive cell populations in a murine liver cancer model.
Topics: Animals; Benzenesulfonates; Bone Marrow Cells; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Disease Progression; Immunity, Cellular; Liver Neoplasms; Mice; Mice, Inbred BALB C; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Spleen; T-Lymphocytes, Regulatory | 2011 |
Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Count; Clinical Trials, Phase II as Topic; Dacarbazine; Drug Resistance, Neoplasm; Humans; Melanoma; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Survival Analysis; Temozolomide; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Potent in vitro and in vivo antitumor activity of sorafenib against human intrahepatic cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cholangiocarcinoma; Dose-Response Relationship, Drug; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate; Xenograft Model Antitumor Assays | 2011 |
[Management of hypothyroidism secondary to tyrosine kinase inhibitors: description of treatment in three distinct clinical settings].
Topics: Adult; Benzamides; Benzenesulfonates; Carcinoma, Renal Cell; Choristoma; Female; Gastrointestinal Stromal Tumors; Humans; Hypothyroidism; Imatinib Mesylate; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Pleural Diseases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thymus Gland; Thyroxine | 2011 |
[Squamous cell carcinoma in a patient receiving sorafenib].
Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Cooperative Behavior; Follow-Up Studies; Humans; Interdisciplinary Communication; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Skin; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Doxorubicin; Endpoint Determination; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Randomized Controlled Trials as Topic; Reproducibility of Results; Sorafenib; Treatment Outcome | 2011 |
An approach to meta-analysis of dose-finding studies.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Clinical Trials, Phase I as Topic; Computer Simulation; Dose-Response Relationship, Drug; Drug Combinations; Humans; Maximum Tolerated Dose; Meta-Analysis as Topic; Middle Aged; Models, Statistical; Neoplasms; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Tegafur | 2011 |
Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Fatal Outcome; Humans; Liver Neoplasms; Liver Transplantation; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
B-Raf associates with and activates the NHE1 isoform of the Na+/H+ exchanger.
Topics: Amino Acid Substitution; Animals; Benzenesulfonates; Cation Transport Proteins; Cell Movement; Cell Size; Extracellular Signal-Regulated MAP Kinases; HEK293 Cells; HeLa Cells; Humans; Hydrogen-Ion Concentration; Indoles; Melanoma; Mutation, Missense; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Isoforms; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins B-raf; Pyridines; Rabbits; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfonamides | 2011 |
Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Receptor, Interferon alpha-beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib | 2011 |
Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Topics: Animals; Antifibrinolytic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; In Vitro Techniques; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; raf Kinases; Rats; Sorafenib; Vitamin K | 2010 |
[Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cost-Benefit Analysis; Drug Costs; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2010 |
Functional analysis of microRNAs in human hepatocellular cancer stem cells.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Cluster Analysis; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; MicroRNAs; Neoplasm Transplantation; Neoplastic Stem Cells; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Pluripotent Stem Cells; Pyridines; Sorafenib; Twist-Related Protein 1 | 2012 |
Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells.
Topics: Amides; Antineoplastic Agents; Benzenesulfonates; Binding Sites; Cell Line, Tumor; Computer Simulation; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyridines; raf Kinases; Sorafenib; Structure-Activity Relationship | 2011 |
Surgical outcomes and complications associated with presurgical tyrosine kinase inhibition for advanced renal cell carcinoma (RCC).
Topics: Aged; Carcinoma, Renal Cell; Cohort Studies; Combined Modality Therapy; Female; Humans; Indoles; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Nephrectomy; Niacinamide; Phenylurea Compounds; Postoperative Complications; Preoperative Care; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; Urinary Bladder | 2013 |
Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2011 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Sorafenib inhibits transforming growth factor β1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes.
Topics: Animals; Apoptosis; Benzenesulfonates; Cell Transdifferentiation; Cells, Cultured; Epithelial Cells; Hepatocytes; Mesoderm; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Transforming Growth Factor beta1 | 2011 |
A rare case of metastatic pancreatic hepatoid carcinoma treated with sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Humans; Male; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2012 |
Clinical results and pharmacokinetics of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma in a single center.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Erythropoietin; Feasibility Studies; Hematinics; Hemoglobins; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Sample Size; Sorafenib; Treatment Outcome | 2011 |
SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction.
Topics: Amino Acid Sequence; Animals; Apoptosis; Benzenesulfonates; Biphenyl Compounds; Cell Cycle Proteins; Cell Line, Tumor; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Glycogen Synthase Kinase 3; Humans; Mice; Molecular Sequence Data; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitrophenols; Phenylurea Compounds; Phosphorylation; Piperazines; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Protein Binding; Proto-Oncogene Proteins c-bcl-2; Pyridines; SKP Cullin F-Box Protein Ligases; Sorafenib; Sulfonamides; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Ubiquitination | 2011 |
Eruptive squamous cell carcinomas with keratoacanthoma-like features in a patient treated with sorafenib.
Topics: Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Humans; Keratoacanthoma; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Skin Neoplasms; Sorafenib | 2011 |
Computed tomography findings of sorafenib-treated hepatic tumors in patients with advanced hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Receptors, Vascular Endothelial Growth Factor; Republic of Korea; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2011 |
Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Substrate Specificity; Sunitinib; Swine; Transfection | 2011 |
Management of hepatocellular carcinoma: an update.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatitis B; Hepatitis C; Hepatitis, Autoimmune; Humans; Liver Neoplasms; Mass Screening; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Ultrasonography | 2011 |
Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats.
Topics: Animals; Antihypertensive Agents; Benzamides; Benzenesulfonates; Blotting, Western; Calcium; Disease Models, Animal; Dose-Response Relationship, Drug; Hypertension, Pulmonary; Imatinib Mesylate; Male; Myosin Light Chains; Myosin-Light-Chain Phosphatase; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pulmonary Artery; Pyridines; Pyrimidines; Rats; Rats, Sprague-Dawley; Sorafenib; Vasodilation; Vasodilator Agents; Ventricular Function, Left; Ventricular Function, Right; Ventricular Pressure | 2011 |
[Contribution of microCT structural imaging to preclinical evaluation of hepatocellular carcinoma chemotherapeutics on orthotopic graft in ACI rats].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Deoxycytidine; Disease Models, Animal; Disease Progression; Doxorubicin; Drug Monitoring; Gemcitabine; Liver Neoplasms; Male; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Rats; Rats, Inbred ACI; Sorafenib; Survival Analysis; Tumor Burden; X-Ray Microtomography; Xenograft Model Antitumor Assays | 2011 |
Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer.
Topics: Acute Coronary Syndrome; Benzamides; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Fatal Outcome; Humans; Imatinib Mesylate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Radiography; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2011 |
First-line treatment for advanced pancreatic cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Erlotinib Hydrochloride; Fluorouracil; Gemcitabine; Humans; Lapatinib; Medicine, Chinese Traditional; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Treatment Outcome | 2011 |
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cytochrome P-450 CYP3A; Female; Glucuronosyltransferase; Humans; Liver Neoplasms; Male; Middle Aged; Models, Theoretical; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Statistics as Topic; UDP-Glucuronosyltransferase 1A9 | 2011 |
Prognostic prediction in patients with metastatic renal cell carcinoma treated with sorafenib based on expression levels of potential molecular markers in radical nephrectomy specimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Kidney Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2013 |
Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Down-Regulation; Humans; Kidney Neoplasms; Male; Mice; Mice, SCID; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Which treatment modality should we choose for advanced hepatocellular carcinoma?
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Fluorouracil; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate | 2010 |
[11C]sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Brain; Carbon Radioisotopes; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Radiopharmaceuticals; Sorafenib | 2011 |
Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Hep G2 Cells; Humans; Liver Neoplasms; Melanoma; Mice; Mice, SCID; Niacinamide; Oncolytic Virotherapy; Phenylurea Compounds; Pyridines; Sorafenib; Vaccinia virus; Xenograft Model Antitumor Assays | 2011 |
Design, synthesis and evaluation of novel rhodanine-containing sorafenib analogs as potential antitumor agents.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; HT29 Cells; Humans; Inhibitory Concentration 50; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Rhodanine; Sorafenib; Structure-Activity Relationship | 2011 |
Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Fatigue; Female; Humans; Indoles; Italy; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Oncology Service, Hospital; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Activity of Sorafenib against desmoid tumor/deep fibromatosis.
Topics: Adolescent; Adult; Benzenesulfonates; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome; Watchful Waiting; Young Adult | 2011 |
Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Binding, Competitive; Clinical Trials, Phase II as Topic; Cytarabine; Drug Synergism; Eukaryotic Initiation Factor-4E; Humans; Idarubicin; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Ribavirin; RNA Caps; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2011 |
Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Pyridines; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2011 |
Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Longitudinal Studies; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2011 |
All that glitters: sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tumor Lysis Syndrome | 2011 |
Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Cancer Care Facilities; Carcinoma, Renal Cell; Community Health Services; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Practice Patterns, Physicians'; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; United States | 2012 |
Erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Blood Sedimentation; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Kinetics; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Pyridines; Sorafenib | 2011 |
A painful cranial bulge.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Female; Humans; Lung Neoplasms; Middle Aged; Niacinamide; Occipital Bone; Pain; Parietal Bone; Phenylurea Compounds; Pyridines; Skull Neoplasms; Sorafenib; Temporal Bone; Thyroglobulin; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2011 |
Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carrier Proteins; Cell Proliferation; Drug Synergism; Everolimus; Extracellular Signal-Regulated MAP Kinases; Intracellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphoproteins; Pyridines; Random Allocation; Rats; Sirolimus; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A | 2011 |
Activity of the multikinase inhibitor sorafenib in combination with cytarabine in acute myeloid leukemia.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP-Binding Cassette Transporters; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatography, High Pressure Liquid; Confounding Factors, Epidemiologic; Cytarabine; Disease Models, Animal; Drug Administration Schedule; Gene Expression Regulation, Neoplastic; Humans; Interleukin Receptor Common gamma Subunit; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Tandem Mass Spectrometry; Time Factors; Transplantation, Heterologous; Treatment Outcome | 2011 |
Sorafenib-induced acute localized exanthematous pustulosis in a patient with hepatocellular carcinoma.
Topics: Acute Generalized Exanthematous Pustulosis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Eruptions; Female; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Sequential mTOR inhibitor treatment with temsirolimus in metastatic renal cell carcinoma following failure of VEGF receptor tyrosine kinase inhibitors.
Topics: Adult; Aged; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Treatment Failure; Treatment Outcome | 2013 |
BAY 43-9006/Sorafenib blocks CSF1R activity and induces apoptosis in various classical Hodgkin lymphoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Hodgkin Disease; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib | 2011 |
Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Patient Selection; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2011 |
[Sorafenib induces apoptosis of U937 cells via inhibiting WNT signal pathway].
Topics: Apoptosis; Benzenesulfonates; beta Catenin; Cell Proliferation; Cyclin D1; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; U937 Cells; Wnt Signaling Pathway | 2011 |
Oxidative stress and ERK1/2 phosphorylation as predictors of outcome in hepatocellular carcinoma patients treated with sorafenib plus octreotide LAR.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Delayed-Action Preparations; Drug Resistance, Neoplasm; Female; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Nitric Oxide; Octreotide; Oxidative Stress; Phenylurea Compounds; Phosphorylation; Pyridines; Reactive Oxygen Species; Sorafenib; Superoxide Dismutase; Treatment Outcome | 2011 |
Laryngeal metastasis as first presentation of hepatocellular carcinoma.
Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Combined Modality Therapy; Diagnosis, Differential; Diagnostic Imaging; Embolization, Therapeutic; Humans; Laryngeal Neoplasms; Laryngectomy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms; Thyroidectomy | 2011 |
Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Deoxycytidine; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Proto-Oncogene Proteins c-kit; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2011 |
microRNA-1274a, a modulator of sorafenib induced a disintegrin and metalloproteinase 9 (ADAM9) down-regulation in hepatocellular carcinoma.
Topics: ADAM Proteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Down-Regulation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Membrane Proteins; MicroRNAs; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf.
Topics: Amides; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Structure-Activity Relationship; Sulfonamides; Urea | 2011 |
Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma--data from the Czech registry.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
FLT-PET may not be a reliable indicator of therapeutic response in p53-null malignancy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Disease Models, Animal; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Recombinant Proteins; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
Sorafenib augments cytotoxic effect of S-1 in vitro and in vivo through TS suppression.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Combinations; Drug Synergism; E2F1 Transcription Factor; Female; Fluorouracil; Humans; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Oxonic Acid; Phenylurea Compounds; Pyridines; RNA, Messenger; Sorafenib; Tegafur; Thymidylate Synthase | 2011 |
The tyrosine kinase inhibitor sorafenib sensitizes hepatocellular carcinoma cells to taxol by suppressing the HURP protein.
Topics: Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Eukaryotic Initiation Factor-4E; Humans; Leupeptins; Liver Neoplasms; Neoplasm Proteins; NF-kappa B; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-rel; Pyridines; Sorafenib | 2011 |
One-month relative dose intensity of not less than 50% predicts favourable progression-free survival in sorafenib therapy for advanced renal cell carcinoma in Japanese patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2011 |
Sorafenib enhances the antitumor effects of chemoradiation treatment by downregulating ERCC-1 and XRCC-1 DNA repair proteins.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cells, Cultured; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Endonucleases; Endothelial Cells; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, SCID; Neoplasms; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Radiation Tolerance; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tumor Burden; X-ray Repair Cross Complementing Protein 1; Xenograft Model Antitumor Assays | 2011 |
Continuing response to subsequent treatment lines with tyrosine kinase inhibitors in an adolescent with metastatic renal cell carcinoma.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Fatal Outcome; Female; Humans; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sirolimus; Sorafenib | 2011 |
Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Hypothyroidism; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroxine | 2011 |
Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
[Metastatic renal cell cancer in Germany in 2010. Impact of different target therapies].
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Data Collection; Disease Progression; Drug Delivery Systems; Everolimus; Female; Germany; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2011 |
Inhibition of experimental HCC growth in mice by use of the kinase inhibitor DMAT.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Carcinoma, Hepatocellular; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Cell Survival; Enzyme Activation; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; NF-kappaB-Inducing Kinase; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Pyridines; Signal Transduction; Sorafenib; Wnt Proteins; Xenograft Model Antitumor Assays | 2011 |
Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis.
Topics: Animals; Benzenesulfonates; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Mice; Niacinamide; Paracrine Communication; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Rats; Sorafenib | 2011 |
Design and rationale of the HCC BRIDGE study in China: a longitudinal, multicenter cohort trial in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; China; Disease Progression; Humans; Liver Neoplasms; Longitudinal Studies; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sorafenib | 2011 |
Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Erythema; Hemorrhage; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Terminology as Topic | 2011 |
Sorafenib-associated multivessel coronary artery vasospasm.
Topics: Antineoplastic Agents; Benzenesulfonates; Coronary Vasospasm; Electrocardiography; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Design, synthesis, and antiproliferative activity of new 1H-pyrrolo[3,2-c]pyridine derivatives against melanoma cell lines.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Melanoma; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Skin Neoplasms; Sorafenib; Structure-Activity Relationship | 2011 |
Multikinase inhibitor sorafenib transiently promotes necrosis after radiofrequency ablation in rat liver but activates growth signals.
Topics: Alanine Transaminase; Animals; Benzenesulfonates; Catheter Ablation; Cell Proliferation; Epidermal Growth Factor; Fluorescent Antibody Technique; Glutamate Dehydrogenase; Hepatocyte Growth Factor; Image Processing, Computer-Assisted; Liver; Male; Models, Animal; Necrosis; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Constitutive ERK activity induces downregulation of tristetraprolin, a major protein controlling interleukin8/CXCL8 mRNA stability in melanoma cells.
Topics: Animals; Antibodies; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL1; Chemokine CXCL5; Dichlororibofuranosylbenzimidazole; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression; Genes, Reporter; Half-Life; Humans; Immunotherapy, Active; Interleukin-8; Leupeptins; MAP Kinase Kinase Kinases; Melanoma; Membrane Proteins; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins; Pyridines; Receptors, Interleukin-8B; RNA Stability; RNA, Messenger; RNA, Small Interfering; Sorafenib; Transfection; Tristetraprolin; Tumor Cells, Cultured; Vaccination | 2011 |
Clinical roundtable monograph. Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.
Topics: Ablation Techniques; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Postoperative Complications; Pyridines; Risk Factors; Sorafenib | 2010 |
Editorial comment to erythrocyte sedimentation rate kinetics as a marker of treatment response and predictor of prognosis in Chinese metastatic renal cell carcinoma patients treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Blood Sedimentation; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib | 2011 |
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Therapy, Combination; Female; Humans; Indoles; Italy; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2011 |
Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survivin; TOR Serine-Threonine Kinases | 2011 |
Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autocrine Communication; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Knockdown Techniques; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Pyridines; Signal Transduction; Sorafenib; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2012 |
Combination of hypoxia and RNA-interference targeting VEGF induces apoptosis in hepatoma cells via autocrine mechanisms.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Feedback, Physiological; Hypoxia; MAP Kinase Kinase 4; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Receptors, Vascular Endothelial Growth Factor; RNA Interference; RNA, Small Interfering; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Efficacy of temsirolimus after previous treatment with sunitinib, sorafenib or everolimus in advanced renal cell cancer.
Topics: Aged; Aged, 80 and over; Anemia; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Karnofsky Performance Status; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Nausea; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Thrombocytopenia | 2011 |
[New therapeutic options for advanced thyroid cancer].
Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thyroid Neoplasms | 2011 |
Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK.
Topics: Antineoplastic Agents; Benzenesulfonates; Blotting, Western; Bufanolides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Synergism; Gene Expression Regulation, Enzymologic; Humans; Liver Neoplasms; Microscopy, Electron, Transmission; Morpholines; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Line, Tumor; Drug Synergism; Female; Glutamates; Guanine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Distribution | 2011 |
Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition.
Topics: Alanine; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Drug Resistance, Neoplasm; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Mice; Mice, Knockout; Mice, Transgenic; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Fibroblast Growth Factor; Sorafenib; Treatment Outcome; Triazines; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2 | 2011 |
Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Deoxycytidine; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Severe sorafenib-induced hand-foot skin reaction.
Topics: Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Hepatocellular; Clobetasol; Disease Progression; Drug Eruptions; Fatal Outcome; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Fatal Outcome; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Stomach Diseases | 2011 |
[In vitro cytotox icity effects of cocultured DC-C IK cells combined with sorafenib against hepa to cellular carcinoma].
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cytokine-Induced Killer Cells; Cytotoxicity, Immunologic; Dendritic Cells; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
[KIT and KIT: from biology to clinical use].
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib; Thiazoles | 2012 |
An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Chemotherapy, Adjuvant; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Assessment of multiparametric MRI in a human glioma model to monitor cytotoxic and anti-angiogenic drug effects.
Topics: Angiogenesis Inhibitors; Animals; Benzenesulfonates; Blood Volume; Carmustine; Cell Death; Cell Line, Tumor; Glioma; Humans; Magnetic Resonance Imaging; Male; Microvessels; Models, Biological; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Nude; Sorafenib; Staining and Labeling; Survival Analysis | 2011 |
Multikinase inhibitor sorafenib exerts cytocidal efficacy against Non-Hodgkin lymphomas associated with inhibition of MAPK14 and AKT phosphorylation.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Lymphoma, Non-Hodgkin; Mitogen-Activated Protein Kinase 14; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2011 |
Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Endoplasmic Reticulum; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; RNA, Small Interfering; Sorafenib; Time Factors; Treatment Outcome | 2011 |
Functional and clinical evidence of the influence of sorafenib binding to albumin on sorafenib disposition in adult cancer patients.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bilirubin; Female; Humans; Male; Neoplasms; Niacinamide; Orosomucoid; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Pyridines; Serum Albumin; Sorafenib; Young Adult | 2011 |
cAMP-dependent cytosolic mislocalization of p27(kip)-cyclin D1 during quinol-thioether-induced tuberous sclerosis renal cell carcinoma.
Topics: Animals; Benzenesulfonates; Bucladesine; Carcinoma, Renal Cell; Cell Line; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Cytosol; Down-Regulation; Female; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Hydroquinones; Kidney Neoplasms; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Niacinamide; Pentoxifylline; Phenylurea Compounds; Phosphodiesterase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Rats; RNA, Small Interfering; Signal Transduction; Sorafenib; Theophylline; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2011 |
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Rate; Young Adult | 2011 |
Preparation of the albumin nanoparticle system loaded with both paclitaxel and sorafenib and its evaluation in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cattle; Cell Line, Tumor; Drug Carriers; Female; Hemolysis; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Nanoparticles; Neoplasms; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Serum Albumin, Bovine; Sorafenib | 2011 |
[News on melanoma from the 2010 Dermatology Days in Paris].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Biomarkers, Tumor; Chemotherapy, Adjuvant; Dacarbazine; Dermatology; Evidence-Based Medicine; Humans; Melanoma; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Radiotherapy, Adjuvant; Skin Neoplasms; Sorafenib; Temozolomide; Treatment Outcome | 2011 |
Response of ETV6-FLT3-positive myeloid/lymphoid neoplasm with eosinophilia to inhibitors of FMS-like tyrosine kinase 3.
Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Benzenesulfonates; DNA, Neoplasm; Drug Resistance, Neoplasm; Eosinophilia; ETS Translocation Variant 6 Protein; fms-Like Tyrosine Kinase 3; Hematologic Neoplasms; Humans; Indoles; Male; Middle Aged; Molecular Sequence Data; Niacinamide; Oncogene Fusion; Oncogene Proteins, Fusion; Phenylurea Compounds; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ets; Pyridines; Pyrroles; Repressor Proteins; Sorafenib; Sunitinib | 2011 |
Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Mice; Molecular Structure; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Sorafenib; Stereoisomerism; Structure-Activity Relationship; Sulfonamides | 2011 |
Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Targeting STAT3 in hepatocellular carcinoma: sorafenib again….
Topics: Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; STAT3 Transcription Factor | 2011 |
Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2012 |
[Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cooperative Behavior; Cytokines; Disease Progression; Everolimus; Evidence-Based Medicine; Humans; Indazoles; Indoles; Interdisciplinary Communication; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Patient Care Team; Phenylurea Compounds; Platelet-Derived Growth Factor; Pyridines; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2011 |
Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma.
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Female; Humans; Multiple Endocrine Neoplasia Type 2b; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Thyroid Neoplasms | 2012 |
Quinacrine sensitizes hepatocellular carcinoma cells to TRAIL and chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Camptothecin; Carcinoma, Hepatocellular; Cell Death; Cell Nucleus; Cytoplasm; Deoxycytidine; Doxorubicin; Drug Synergism; Etoposide; Female; Fluorouracil; Gemcitabine; Genes, p53; Humans; Irinotecan; Liver Neoplasms; Mice; Microtubule-Associated Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Pyridines; Quinacrine; Receptors, TNF-Related Apoptosis-Inducing Ligand; RNA, Small Interfering; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2011 |
Quinacrine synergizes with 5-fluorouracil and other therapies in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Synergism; Female; Fluorouracil; Humans; Mice; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); Pyridines; Quinacrine; ras Proteins; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
Langerhans cell histiocytosis with central nervous system involvement--complete response to 2-chlorodeoxyadenosine after failure of tyrosine kinase inhibitor therapies with sorafenib and imatinib.
Topics: Adult; Antineoplastic Agents; Benzamides; Benzenesulfonates; Central Nervous System Diseases; Cladribine; Histiocytosis, Langerhans-Cell; Humans; Imatinib Mesylate; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib | 2012 |
c-Met-Akt pathway-mediated enhancement of inhibitory c-Raf phosphorylation is involved in vitamin K1 and sorafenib synergy on HCC growth inhibition.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclic AMP-Dependent Protein Kinases; Diethylnitrosamine; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Liver Neoplasms, Experimental; MAP Kinase Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-raf; Pyridines; Rats; Rats, Inbred F344; Signal Transduction; Sorafenib; Vitamin K 1 | 2011 |
Proteome analysis of the effects of sorafenib on human hepatocellular carcinoma cell line HepG2.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Electrophoresis, Gel, Two-Dimensional; Gene Expression; Hep G2 Cells; Humans; Immunohistochemistry; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteome; Sorafenib; Tandem Mass Spectrometry | 2012 |
Pancreatic endocrine tumors: a report on a patient treated with sorafenib.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Humans; Liver Neoplasms; Male; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Pyridines; Salvage Therapy; Skin Diseases; Sorafenib; Tomography, X-Ray Computed | 2011 |
Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Blood Coagulation Disorders; Carcinoma, Non-Small-Cell Lung; Humans; Hypertension; Indoles; Intestinal Perforation; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Proteinuria; Pyridines; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Sorafenib; Vascular Endothelial Growth Factor A; Wound Healing | 2011 |
Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Republic of Korea; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Young Adult | 2011 |
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Fibroblast growth factor receptors as therapeutic targets in human melanoma: synergism with BRAF inhibition.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Dacarbazine; Drug Screening Assays, Antitumor; Genes, Dominant; Humans; Indoles; Melanocytes; Melanoma; Niacinamide; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Fibroblast Growth Factor; Signal Transduction; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2011 |
Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Time Factors; Treatment Outcome | 2011 |
Coil extrusion from a gastric varice during sorafenib treatment for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Esophageal and Gastric Varices; Female; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Portasystemic Shunt, Transjugular Intrahepatic; Prosthesis Failure; Pyridines; Sorafenib | 2011 |
Sorafenib-induced eruption resembling pityriasis rubra pilaris.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Biopsy, Needle; Diagnosis, Differential; Drug Eruptions; Humans; Immunohistochemistry; Male; Niacinamide; Phenylurea Compounds; Pityriasis Rubra Pilaris; Pyridines; Risk Assessment; Severity of Illness Index; Sorafenib | 2011 |
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Recurrence; Retrospective Studies; Sorafenib; Transplantation, Homologous; Young Adult | 2011 |
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.
Topics: Animals; Animals, Genetically Modified; Benzenesulfonates; Caenorhabditis elegans; Cell Survival; Disease Models, Animal; Dopaminergic Neurons; Drosophila; Enzyme Activation; Humans; Indoles; Motor Activity; Mutation; Niacinamide; Oxidopamine; Parkinson Disease; Phenols; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Sorafenib; Synucleins | 2011 |
Cautions regarding the fitting and interpretation of survival curves: examples from NICE single technology appraisals of drugs for cancer.
Topics: Antineoplastic Agents; Azacitidine; Benzenesulfonates; Biomedical Research; Cost-Benefit Analysis; Humans; Kaplan-Meier Estimate; Models, Economic; Models, Statistical; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Sorafenib; Technology Assessment, Biomedical; United Kingdom | 2011 |
Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Sorafenib; Time Factors; Treatment Outcome; Waiting Lists | 2011 |
Inhibition of doxorubicin-induced autophagy in hepatocellular carcinoma Hep3B cells by sorafenib--the role of extracellular signal-regulated kinase counteraction.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Autophagy; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin D1; Doxorubicin; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitochondria, Liver; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib | 2011 |
Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Humans; Imidazoles; Kidney Neoplasms; Mice; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinolines; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
[Adverse effects of new oncologic therapies].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Cetuximab; Colonic Neoplasms; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Facial Dermatoses; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib; Trastuzumab | 2011 |
Is advanced hepatocellular carcinoma amenable of cure by liver transplantation with sorafenib as a neoadjuvant approach plus m-TOR inhibitors monotherapy?
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepacivirus; Hepatitis C; Humans; Immunosuppressive Agents; Liver Cirrhosis; Liver Transplantation; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome | 2012 |
Sequence therapy in patients with metastatic renal cell carcinoma: comparison of common targeted treatment options following failure of receptor tyrosine kinase inhibitors.
Topics: Academic Medical Centers; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Chi-Square Distribution; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; Everolimus; Female; Germany; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Time Factors; Treatment Failure | 2011 |
Setting up a kinase discovery and development project.
Topics: Adenosine Triphosphate; Animals; Crystallography, X-Ray; Drug Discovery; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Enzyme Activation; Enzyme Assays; Humans; Indoles; Melanoma; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Solubility; Sorafenib; Structure-Activity Relationship; Sulfonamides | 2012 |
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Liver Neoplasms; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Remission Induction; Sorafenib; Survival Rate | 2011 |
Limited clinical activity of nilotinib and sorafenib in FIP1L1-PDGFRA positive chronic eosinophilic leukemia with imatinib-resistant T674I mutation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Benzenesulfonates; Chronic Disease; Drug Resistance, Neoplasm; Humans; Hypereosinophilic Syndrome; Imatinib Mesylate; Male; Middle Aged; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Pyridines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib | 2012 |
Synergistic effects of the combination of β-ionone and sorafenib on metastasis of human hepatoma SK-Hep-1 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Synergism; Focal Adhesion Protein-Tyrosine Kinases; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Norisoprenoids; Phenylurea Compounds; Phosphorylation; Pyridines; rac1 GTP-Binding Protein; rho GTP-Binding Proteins; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2 | 2012 |
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group.
Topics: Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; International Cooperation; Kidney Neoplasms; Logistic Models; Male; Models, Biological; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Reproducibility of Results; Sorafenib; Sunitinib; Survival Analysis; Time Factors | 2011 |
Des-γ-carboxyprothrombin may be a promising biomarker to determine the therapeutic efficacy of sorafenib for hepatocellular carcinoma.
Topics: Aged; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Pyridines; Radiography; Sorafenib; Survival Analysis | 2011 |
The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib; Thyroid Neoplasms; Urokinase-Type Plasminogen Activator | 2011 |
Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Indoles; Liver Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, SCID; Neoplasm Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Random Allocation; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays | 2011 |
[Long-standing differentiated thyroid carcinoma].
Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy, Needle; Carcinoma, Large Cell; Carcinoma, Papillary; Combined Modality Therapy; Delayed Diagnosis; Diagnosis, Differential; Diagnostic Errors; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Niacinamide; Palliative Care; Phenylurea Compounds; Positron-Emission Tomography; Pyridines; Sorafenib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Tuberculosis, Miliary | 2012 |
Bioavailability and pharmacokinetics of sorafenib suspension, nanoparticles and nanomatrix for oral administration to rat.
Topics: Adhesiveness; Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Biological Availability; Hydrogen-Ion Concentration; Male; Nanoparticles; Nanostructures; Niacinamide; Phenylurea Compounds; Polymethacrylic Acids; Porosity; Pyridines; Rats; Rats, Sprague-Dawley; Silicon Dioxide; Solubility; Sorafenib; Suspensions | 2011 |
Glutamatergic pathway targeting in melanoma: single-agent and combinatorial therapies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glutamic Acid; Indoles; Melanoma; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Receptors, Metabotropic Glutamate; Riluzole; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2011 |
Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis.
Topics: Animals; Anisoles; Astrocytes; Benzamides; Benzenesulfonates; Cell Differentiation; Cell Proliferation; Cells, Cultured; Disease Progression; Encephalomyelitis, Autoimmune, Experimental; Female; Humans; Imatinib Mesylate; Macrophages; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Receptor, Macrophage Colony-Stimulating Factor; Receptors, Platelet-Derived Growth Factor; Sorafenib; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2011 |
Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter?
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2012 |
Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 7; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Lysosomes; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Microtubule-Associated Proteins; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Proteins; Pyridines; RNA Interference; RNA, Small Interfering; Sequestosome-1 Protein; Sorafenib; TOR Serine-Threonine Kinases; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2012 |
Course of size and density of metastatic renal cell carcinoma lesions in the early follow-up of molecular targeted therapy.
Topics: Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Kidney; Kidney Neoplasms; Liver; Lung; Lymph Nodes; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Time Factors; Tomography, X-Ray Computed | 2012 |
Polymeric nanoparticle-encapsulated hedgehog pathway inhibitor HPI-1 (NanoHHI) inhibits systemic metastases in an orthotopic model of human hepatocellular carcinoma.
Topics: Adult; Aged; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Hedgehog Proteins; Humans; Immunophenotyping; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Nanocapsules; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Patched Receptors; Patched-1 Receptor; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Receptors, Cell Surface; Recurrence; Signal Transduction; Sorafenib; Transcription Factors; Zinc Finger Protein GLI1 | 2012 |
Sorafenib attenuates p21 in kidney cancer cells and augments cell death in combination with DNA-damaging chemotherapy.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Doxorubicin; Drug Synergism; Hep G2 Cells; Humans; Kidney Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cell Line; Cell Proliferation; Chick Embryo; Chorioallantoic Membrane; Erlotinib Hydrochloride; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Photochemotherapy; Porphyrins; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Verteporfin; Wet Macular Degeneration | 2012 |
Characterization of kinase inhibitors using different phosphorylation states of colony stimulating factor-1 receptor tyrosine kinase.
Topics: Animals; Benzamides; Benzenesulfonates; Binding, Competitive; Cell Line; Dasatinib; Dose-Response Relationship, Drug; Humans; Imatinib Mesylate; Indazoles; Indoles; Kinetics; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptor, Macrophage Colony-Stimulating Factor; Sorafenib; Spodoptera; Staurosporine; Sulfonamides; Sunitinib; Surface Plasmon Resonance; Thiazoles; Transfection | 2012 |
Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Retrospective Studies; Severity of Illness Index; Sorafenib; Statistics as Topic; Survival Rate; Tomography, X-Ray Computed | 2011 |
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Female; Follow-Up Studies; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sorafenib; Survival Analysis | 2011 |
Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation--interactions between calcineurin inhibitor: two case reports.
Topics: Antineoplastic Agents; Benzenesulfonates; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib | 2011 |
Bilateral diffuse uveal melanocytic proliferation with a positive ophthalmoscopic and visual response to plasmapheresis.
Topics: Aged; Autoantibodies; Benzenesulfonates; Carcinoma, Bronchogenic; Cell Proliferation; Eye Proteins; Fatal Outcome; Fluorescein Angiography; Functional Laterality; Humans; Lung Neoplasms; Male; Melanocytes; Niacinamide; Ophthalmoscopy; Paraneoplastic Syndromes; Phenylurea Compounds; Plasmapheresis; Pyridines; Retina; Sorafenib; Tomography, Optical Coherence; Uveal Diseases; Visual Acuity; Visual Fields | 2011 |
Effect of sorafenib on the energy metabolism of hepatocellular carcinoma cells.
Topics: Adenosine Triphosphate; Aerobiosis; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Respiration; Cell Survival; Energy Metabolism; Glycosylation; Humans; Liver Neoplasms; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Donor erythrocytosis induced by sorafenib treatment after allogeneic hematopoietic SCT in a patient with acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Polycythemia; Pyridines; Sorafenib; Transplantation, Homologous; Unrelated Donors | 2012 |
Differential modulatory effects of GSK-3β and HDM2 on sorafenib-induced AIF nuclear translocation (programmed necrosis) in melanoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Nucleus; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Gene Expression; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Indoles; Melanoma; Mice; Mice, Nude; Mitochondria; Necrosis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Transport; Proto-Oncogene Proteins c-mdm2; Pyridines; RNA Interference; Sorafenib; Spiro Compounds; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2011 |
Interstitial granulomatous drug reaction to sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Foot Dermatoses; Granuloma; Hand Dermatoses; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Cell Line, Tumor; Contrast Media; Iohexol; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Rats; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Statistics as Topic; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
[Clinical characteristics, staging and treatment of patients with hepatocellular carcinoma in clinical practice. Prospective study of 136 patients].
Topics: Aged; Alcoholism; Benzenesulfonates; Carcinoma, Hepatocellular; Comorbidity; Diabetes Mellitus; Early Detection of Cancer; Ethanol; Female; Hepatitis, Viral, Human; HIV Infections; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Sclerotherapy; Sorafenib; Spain | 2011 |
Design, synthesis, and antiproliferative activity of 3,4-diarylpyrazole-1-carboxamide derivatives against melanoma cell line.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyridines; Sorafenib; Structure-Activity Relationship | 2011 |
Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Vascular Endothelial Growth Factor A | 2013 |
Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Case-Control Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
Hepatocellular carcinoma presenting with multiple bone and soft tissue metastases and atypical cytomorphological features--a rare case report.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Radiography, Abdominal; Rare Diseases; Soft Tissue Neoplasms; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Clinical outcome and prognostic factors of sorafenib in Japanese patients with advanced renal cell carcinoma in general clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Prognosis; Pyridines; Retrospective Studies; Sorafenib; Survival Rate | 2011 |
Fluvastatin enhances sorafenib cytotoxicity in melanoma cells via modulation of AKT and JNK signaling pathways.
Topics: Anthracenes; Benzenesulfonates; Cell Death; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; JNK Mitogen-Activated Protein Kinases; Melanoma; Morpholines; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Pyridines; Signal Transduction; Sorafenib | 2011 |
Partial Response and Cardiovascular Recovery after Sorafenib Dose Reduction in a Multinodular HCC Patient.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2012 |
Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
Topics: Apoptosis; Benzenesulfonates; Cell Survival; Cells, Cultured; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Pyridines; raf Kinases; Sorafenib; Tumor Cells, Cultured | 2012 |
AFP measurement in monitoring treatment response of advanced hepatocellular carcinoma to sorafenib: case report and review of the literature.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Humans; Image Processing, Computer-Assisted; Liver; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Neoplasm Invasiveness; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2011 |
The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics.
Topics: Abnormal Karyotype; Antineoplastic Agents; Benzenesulfonates; Cytogenetic Analysis; Drug Resistance, Neoplasm; Erythroid Cells; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Erythroblastic, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Tandem Repeat Sequences; Time Factors; Treatment Outcome | 2012 |
[Gastrointestinal hemorrhage associated with concurrent use of sorafenib and warfarin for hepatocellular carcinoma].
Topics: Anticoagulants; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed; Warfarin | 2011 |
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Benzenesulfonates; Cardiotoxins; Cell Survival; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Indoles; Male; Models, Animal; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; Sunitinib; Zebrafish | 2011 |
Nutlin-3 enhances sorafenib efficacy in renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Benzenesulfonates; Carcinoma, Renal Cell; Caspase 3; Cell Line, Tumor; Cell Movement; Humans; Imidazoles; Kidney Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-mdm2; Pyridines; Sorafenib; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
Sorafenib, doesn't it have any competitor in advanced hepatocellular carcinoma?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiogenic Proteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cytokines; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Pyridines; Risk Assessment; Risk Factors; Sorafenib; Survival Rate; Time Factors; Treatment Outcome; Up-Regulation | 2011 |
Structure-based design of isoindoline-1,3-diones and 2,3-dihydrophthalazine-1,4-diones as novel B-Raf inhibitors.
Topics: Benzenesulfonates; Drug Design; Enzyme Activation; Enzyme Inhibitors; Imidazoles; Isoindoles; Models, Molecular; Molecular Structure; Niacinamide; Phenylurea Compounds; Phthalazines; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Structure-Activity Relationship | 2011 |
Sorafenib inhibits growth and metastasis of hepatocellular carcinoma by blocking STAT3.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Enzyme Inhibitors; Extracellular Signal-Regulated MAP Kinases; Humans; Janus Kinase 2; Liver Neoplasms; Male; Mitogen-Activated Protein Kinase Kinases; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyridines; Rats; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2011 |
Reversible cardiomyopathy associated with sunitinib and sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Cardiomyopathies; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma--a pilot study.
Topics: Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Hypertension, Portal; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Portal Pressure; Protein Kinase Inhibitors; Pyridines; Real-Time Polymerase Chain Reaction; Sorafenib; Syndrome; Treatment Outcome | 2012 |
New imidazo[2,1-b]thiazole derivatives: synthesis, in vitro anticancer evaluation, and in silico studies.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Imidazoles; Melanoma; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Structure-Activity Relationship; Thiazoles | 2011 |
Better effect of sorafenib on the rhabdoid component of a clear cell renal cell carcinoma owing to its higher level of vascular endothelial growth factor-A production.
Topics: Antineoplastic Agents; Arthritis, Rheumatoid; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Depression; Female; Humans; Hypertension; Kidney Neoplasms; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2011 |
Sorafenib exposure decreases over time in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Role of sorafenib in renal cell carcinoma: focus on elderly patients.
Topics: Age Factors; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Sorafenib monotherapy gives sustainable suppression of FLT3 clone in untreated patients with FLT3-internal tandem duplication positive acute myeloid Leukaemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Chloracne-like drug eruption associated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chloracne; Drug Eruptions; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Sorafenib as treatment for relapsed or refractory pediatric acute myelogenous leukemia.
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Child; Female; Humans; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Remission Induction; Sorafenib | 2012 |
Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Data Collection; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Pyridines; Remission Induction; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2012 |
Tilting the AXIS towards therapeutic limits in renal cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2011 |
Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Risk Factors; Serum Albumin; Sorafenib; Sunitinib; Survival Rate; Young Adult | 2012 |
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Squamous Cell; Female; Gene Expression Regulation, Neoplastic; Genotype; Humans; Indoles; Male; Mass Spectrometry; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2012 |
Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Butadienes; Cell Survival; Dacarbazine; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fatal Outcome; Female; Genes, ras; Humans; Melanoma; Molecular Targeted Therapy; Mutation; Niacinamide; Nitriles; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Phosphorylation; Precision Medicine; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-kit; Pyridines; Signal Transduction; Sorafenib; Treatment Outcome | 2011 |
Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Survival Rate | 2011 |
Third-line sunitinib following sequential use of cytokine therapy and sorafenib in Japanese patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cells, Cultured; Female; Humans; Keratinocytes; Male; Middle Aged; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins p21(ras); Pyridines; raf Kinases; ras Proteins; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Skin; Skin Neoplasms; Sorafenib; Tumor Suppressor Protein p53; Ultraviolet Rays | 2012 |
Molecular dynamics simulation and free energy calculation studies of the binding mechanism of allosteric inhibitors with p38α MAP kinase.
Topics: Allosteric Regulation; Benzamides; Benzenesulfonates; Catalytic Domain; Humans; Imatinib Mesylate; Indenes; Mitogen-Activated Protein Kinase 14; Molecular Dynamics Simulation; Naphthalenes; Niacinamide; Phenylurea Compounds; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Sorafenib; Thermodynamics | 2011 |
Multiple kinase pathways involved in the different de novo sensitivity of pancreatic cancer cell lines to 17-AAG.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzoquinones; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Mutation; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Suppressor Protein p53 | 2012 |
A new rapid and sensitive LC-MS assay for the determination of sorafenib in plasma: application to a patient undergoing hemodialysis.
Topics: Antineoplastic Agents; Benzenesulfonates; Calibration; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Drug Stability; Fatal Outcome; Humans; Kidney Failure, Chronic; Limit of Detection; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Renal Dialysis; Reproducibility of Results; Solid Phase Extraction; Sorafenib; Spectrometry, Mass, Electrospray Ionization | 2011 |
Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzimidazoles; Carcinoma; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Survival; Drug Synergism; Everolimus; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Sirolimus; Sorafenib; Thyroid Neoplasms; TOR Serine-Threonine Kinases | 2012 |
Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Salvage Therapy; Sorafenib; Treatment Outcome | 2011 |
Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Pyridines; Sorafenib | 2011 |
[Synthesis and biological evaluation of sorafenib thiourea derivatives].
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Molecular Structure; Niacinamide; Phenylurea Compounds; Sorafenib; Thiourea | 2011 |
Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
Topics: Angiogenesis Inhibitors; Antiviral Agents; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Cost-Benefit Analysis; Humans; Indoles; Interferon-alpha; Kidney Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Quality-Adjusted Life Years; Sorafenib; Sunitinib | 2011 |
Erythema multiforme-like drug reaction to sorafenib.
Topics: Adult; Benzenesulfonates; Diagnosis, Differential; Drug Eruptions; Erythema Multiforme; Female; Hand Dermatoses; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC).
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2011 |
[Renal tolerance of targeted therapies].
Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2012 |
SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antibiotics, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; beta Catenin; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Doxorubicin; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gene Expression Regulation, Neoplastic; Half-Life; Humans; Immunoenzyme Techniques; Immunoprecipitation; Liver Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proteolysis; Pyridines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sirtuin 1; Sorafenib; Survival Rate; Young Adult | 2012 |
Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Female; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Neuroblastoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib | 2011 |
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Inhibitory Concentration 50; Mice; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Treatment effects of the multikinase inhibitor sorafenib on hepatoblastoma cell lines and xenografts in NMRI-Foxn1 nu mice.
Topics: alpha-Fetoproteins; Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Survival; Extracellular Signal-Regulated MAP Kinases; Fluorescent Antibody Technique, Indirect; Forkhead Transcription Factors; Hepatoblastoma; In Situ Nick-End Labeling; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tetrazolium Salts; Thiazoles; Transplantation, Heterologous; Transplants | 2012 |
Downsizing a thrombus of advanced renal cell carcinoma in a presurgical setting with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2012 |
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
Topics: Animals; Apoptosis; Benzenesulfonates; Benzimidazoles; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Molecular Structure; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; Quinolones; RNA Interference; Sorafenib; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells.
Topics: Benzenesulfonates; Blotting, Western; Cell Movement; Cell Survival; Chemokines; Chemotaxis; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Real-Time Polymerase Chain Reaction; Receptors, Antigen, B-Cell; RNA, Messenger; Sorafenib; src-Family Kinases; Syk Kinase; Tumor Cells, Cultured; Tumor Microenvironment | 2012 |
Early evaluation of transcatheter arterial chemoembolization-refractory hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Time Factors; Treatment Failure; Treatment Outcome | 2012 |
Sorafenib sensitizes (-)-gossypol-induced growth suppression in androgen-independent prostate cancer cells via Mcl-1 inhibition and Bak activation.
Topics: Androgens; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; bcl-2 Homologous Antagonist-Killer Protein; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Female; Gossypol; Humans; Male; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; Time Factors; Xenograft Model Antitumor Assays | 2012 |
High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Kidney Neoplasms; Mice; Mice, Nude; Microvessels; Niacinamide; Perfusion; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Interleukin-6; Lymphoma, Non-Hodgkin; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Pyridines; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2012 |
[Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2011 |
[Three cases of hepatocellular carcinoma without distant metastasis effectively treated by sorafenib].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2011 |
[The possible role of sorafenib as a part of the multimodal treatment for hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib; Tomography, X-Ray Computed | 2011 |
Multidisciplinary management of nonresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatitis B; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Treatment algorithm for intermediate and advanced stage hepatocellular carcinoma: Korea.
Topics: Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Liver Transplantation; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Republic of Korea; Sorafenib | 2011 |
Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Remission Induction; Sorafenib; Treatment Outcome | 2011 |
Sorafenib: muscle wasting.
Topics: Benzamides; Benzenesulfonates; Humans; Imatinib Mesylate; Indoles; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Rhabdomyolysis; Sorafenib; Sunitinib | 2011 |
Complete response after sequential sunitinib-sorafenib treatment in a patient with renal cell carcinoma: a case report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Radiography; Sorafenib; Sunitinib; Treatment Outcome; Tumor Burden | 2012 |
Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Feasibility Studies; Female; Humans; Indoles; Kidney Neoplasms; Male; Medical Records; Middle Aged; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Remission Induction; Retrospective Studies; Sorafenib; Sunitinib; Surveys and Questionnaires; Treatment Outcome | 2012 |
Efficacy and safety of vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma and poor risk features.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Drug Administration Schedule; Fatigue; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombocytopenia; Treatment Outcome; Young Adult | 2012 |
PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Drug Synergism; Feedback, Physiological; Furans; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Triazines | 2012 |
Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzenesulfonates; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; Crizotinib; Epithelial-Mesenchymal Transition; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Imatinib Mesylate; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Transgenic; Neoplasm Metastasis; Niacinamide; Pericytes; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Tumor Cells, Cultured | 2012 |
Sorafenib sensitizes human colorectal carcinoma to radiation via suppression of NF-κB expression in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Combined Modality Therapy; Electrophoretic Mobility Shift Assay; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, SCID; NF-kappa B; Niacinamide; Phenylurea Compounds; Pyridines; Radiation-Sensitizing Agents; Sorafenib; Xenograft Model Antitumor Assays | 2012 |
Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sirolimus; Sorafenib; Tacrolimus | 2012 |
Blockade of ataxia telangiectasia mutated sensitizes hepatoma cell lines to sorafenib by interfering with Akt signaling.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Benzenesulfonates; Caffeine; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; DNA-Binding Proteins; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyridines; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Suppressor Proteins | 2012 |
Perfusion MRI for monitoring the effect of sorafenib on experimental prostate carcinoma: a validation study.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Contrast Media; Humans; Image Interpretation, Computer-Assisted; Immunoenzyme Techniques; Magnetic Resonance Imaging; Male; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Random Allocation; Rats; Sorafenib | 2012 |
Sorafenib-induced mitochondrial complex I inactivation and cell death in human neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Shape; Cytochromes c; Down-Regulation; Enzyme Activation; Humans; Membrane Potential, Mitochondrial; Mitochondria; NADH Dehydrogenase; Neuroblastoma; Niacinamide; Phenylurea Compounds; Protein Interaction Maps; Proteolysis; Proteome; Pyridines; Reactive Oxygen Species; Signal Transduction; Sorafenib; Superoxide Dismutase | 2012 |
New sorafenib derivatives: synthesis, antiproliferative activity against tumour cell lines and antimetabolic evaluation.
Topics: Animals; Antimetabolites, Antineoplastic; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50; Magnetic Resonance Spectroscopy; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Objective response to sorafenib in advanced clear-cell sarcoma.
Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Humans; Knee; Male; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Pyridines; Sarcoma, Clear Cell; Sorafenib; Transcription Factors | 2012 |
Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Drug Resistance, Neoplasm; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Male; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Primary Cell Culture; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins pp60(c-src); Pyridines; Signal Transduction; Sorafenib | 2012 |
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases.
Topics: Adult; Aged; Benzenesulfonates; Carcinoma, Renal Cell; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib | 2012 |
Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hemorrhage; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Rupture, Spontaneous; Sorafenib | 2011 |
Sorafenib down-regulates c-IAP expression post-transcriptionally in hepatic carcinoma cells to suppress apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Genes, Reporter; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Luciferases; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Pyridines; RNA, Messenger; Sorafenib; Transcription, Genetic | 2012 |
Sorafenib in metastatic thyroid cancer.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Calcitonin; Carcinoembryonic Antigen; Disease-Free Survival; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Thyroglobulin; Thyroid Neoplasms | 2012 |
Phase II studies in soft tissue sarcoma: time for reappraisal.
Topics: Antineoplastic Agents; Benzenesulfonates; Female; Hemangiosarcoma; Humans; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Inhibiting oncogenic signaling by sorafenib activates PUMA via GSK3β and NF-κB to suppress tumor cell growth.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Genes, ras; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; HCT116 Cells; Hep G2 Cells; HT29 Cells; Humans; Mice; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Transcription, Genetic; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Resampling phase III data to assess phase II trial designs and endpoints.
Topics: Benzenesulfonates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sorafenib; Treatment Outcome | 2012 |
Inflammation-based prognostic score for hepatocellular carcinoma patients on sorafenib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Inflammation; Liver Neoplasms; Male; Middle Aged; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Severity of Illness Index; Sorafenib | 2012 |
Metastatic renal cell carcinoma treated sequentially with multiple VEGF receptor-targeted inhibitors--a case report.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib | 2012 |
A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiomyopathies; Coronary Angiography; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Clinical activity of sorafenib in patients with advanced gastrointestinal stromal tumor bearing PDGFRA exon 18 mutation: a case series.
Topics: Antineoplastic Agents; Benzenesulfonates; Exons; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Mutation; Niacinamide; Phenylurea Compounds; Pyridines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib | 2012 |
[Endocrinology].
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Benzenesulfonates; Carcinoma; Carcinoma, Medullary; Clinical Trials as Topic; Endocrine Gland Neoplasms; Endocrinology; Humans; Niacinamide; Phenylurea Compounds; Pituitary ACTH Hypersecretion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Receptors, Somatostatin; Somatostatin; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2012 |
Dasatinib synergizes with both cytotoxic and signal transduction inhibitors in heterogeneous breast cancer cell lines--lessons for design of combination targeted therapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Epothilones; Female; Humans; Morpholines; Niacinamide; Nitriles; Paclitaxel; Phenylurea Compounds; Pyridines; Pyrimidines; Signal Transduction; Sirolimus; Sorafenib; Tamoxifen; Thiazoles | 2012 |
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Bilirubin; Clinical Trials as Topic; Disease-Free Survival; Female; Genotype; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasms; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Pilot Projects; Polymorphism, Genetic; Prostatic Neoplasms; Pyridines; Sorafenib; UDP-Glucuronosyltransferase 1A9 | 2012 |
MCL1 down-regulation plays a critical role in mediating the higher anti-leukaemic activity of the multi-kinase inhibitor Sorafenib with respect to Dasatinib.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Dasatinib; Down-Regulation; Humans; Leukemia, Myeloid, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrimidines; Sorafenib; Thiazoles | 2012 |
Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-ĸB signaling, and synergizes with an ERK inhibitor.
Topics: Amino Acid Chloromethyl Ketones; Antineoplastic Agents; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-Associated Death Protein; Boronic Acids; Bortezomib; Caspase 3; Caspase 9; Cerebellar Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cytochromes c; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Medulloblastoma; NF-kappa B; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Sorafenib; Tumor Cells, Cultured | 2012 |
Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using Drug Eluting Beads. Implications for clinical practice and trial design.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hepatic Artery; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Research Design; Sorafenib | 2012 |
Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis.
Topics: Animals; Anoikis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Disease Models, Animal; Disease Progression; Female; Humans; Immunohistochemistry; Liver; Liver Neoplasms; Liver Neoplasms, Experimental; Lung Neoplasms; Male; Mice; Mice, Knockout; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Random Allocation; Receptors, Androgen; Sorafenib; Tumor Cells, Cultured | 2012 |
Revealing multi-binding sites for taspine to VEGFR-2 by cell membrane chromatography zonal elution.
Topics: Alkaloids; Benzenesulfonates; Binding Sites; Cell Membrane; Chromatography; HEK293 Cells; Humans; Kinetics; Niacinamide; Phenylurea Compounds; Pyridines; Reproducibility of Results; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Combination therapy for hepatocellular carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib.
Topics: Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Benzenesulfonates; Cadherins; Carcinoma, Hepatocellular; Drug Synergism; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Niacinamide; Panobinostat; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; RNA, Messenger; Sorafenib; Survivin; Xenograft Model Antitumor Assays | 2012 |
Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Kidney Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2012 |
Sorafenib rechallenge in patients with metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retreatment; Retrospective Studies; Sorafenib | 2012 |
Sorafenib rechalenge in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Blood-Brain Barrier; Blotting, Western; Breast Neoplasms; Female; Mice; Mice, Mutant Strains; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Case-Control Studies; Chemotherapy, Adjuvant; China; Female; Health Status Indicators; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Statistics as Topic; Time Factors | 2012 |
K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Everolimus; Extracellular Signal-Regulated MAP Kinases; Feedback, Physiological; Female; Humans; Insulin-Like Growth Factor I; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Mutation; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; Pyrimidines; Pyrroles; ras Proteins; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
Sorafenib dose escalation in the treatment of advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
Topics: Animals; Apoptosis; Aurora Kinases; Benzenesulfonates; Benzothiazoles; Blotting, Western; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyridines; Quinazolines; Sorafenib; Tandem Repeat Sequences; Tumor Cells, Cultured | 2012 |
Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Cycle; Cell Division; Cell Line, Tumor; Combined Modality Therapy; Female; Flow Cytometry; G2 Phase; Gamma Rays; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2012 |
Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Benzenesulfonates; Carcinoid Tumor; Carcinoma, Squamous Cell; CD5 Antigens; DNA Mutational Analysis; Enzyme Activation; Female; Genetic Association Studies; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation, Missense; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thymoma; Thymus Neoplasms; Transcription Factors; Treatment Outcome; Tumor Suppressor Proteins | 2012 |
Inhibition of corneal neovascularization in rats by systemic administration of sorafenib.
Topics: Administration, Oral; Animals; Benzenesulfonates; Blotting, Western; Corneal Neovascularization; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Contraindications; Female; Humans; Indoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Renal Dialysis; Retrospective Studies; Sorafenib; Sunitinib | 2012 |
Partial response of angiosarcoma of the scalp to sorafenib: association with decreased expression of vascular endothelial growth factors and their receptors.
Topics: Antineoplastic Agents; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Scalp; Skin Neoplasms; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factors | 2012 |
Intracranial metastasis from pediatric GI stromal tumor.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Brain Neoplasms; Drug Administration Schedule; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Sorafenib; Stomach Neoplasms; Sunitinib; Treatment Outcome | 2012 |
A maxillary mass in a HBV-cirrhotic patient.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Biopsy; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Hepatectomy; Hepatitis B, Chronic; Humans; Immunohistochemistry; Liver Cirrhosis; Liver Neoplasms; Male; Maxillary Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2012 |
Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cohort Studies; Databases as Topic; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Hormones | 2012 |
Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathways.
Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase 2; Down-Regulation; Humans; Male; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, Androgen; RNA, Small Interfering; Signal Transduction; Sorafenib | 2012 |
Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Benzenesulfonates; Cell Proliferation; Cell Survival; Diphenylamine; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; MAP Kinase Kinase 1; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Pyridines; Signal Transduction; Sorafenib; Transcriptome; Tumor Cells, Cultured | 2012 |
TACE with or without systemic therapy?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cohort Studies; Female; Hemodynamics; Humans; Liver; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Prospective Studies; Pyridines; Sorafenib; Treatment Outcome; Ultrasonography, Doppler, Duplex | 2012 |
Effects of the combined administration of propranolol plus sorafenib on portal hypertension in cirrhotic rats.
Topics: Animals; Antihypertensive Agents; Benzenesulfonates; Drug Therapy, Combination; Hypertension, Portal; Liver Cirrhosis, Experimental; Male; Niacinamide; Phenylurea Compounds; Propranolol; Protein Kinase Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib | 2012 |
Sorafenib and HDAC inhibitors synergize to kill CNS tumor cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Survival; Central Nervous System Neoplasms; Drug Synergism; fas Receptor; Histone Deacetylase Inhibitors; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Janus Kinase 2; Lysophospholipids; Mice; Mice, Inbred NOD; Mice, SCID; Mitogen-Activated Protein Kinases; Neuroblastoma; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Signal Transduction; Sorafenib; Sphingosine; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2012 |
Choosing phase II endpoints and designs: evaluating the possibilities.
Topics: Benzenesulfonates; Clinical Trials, Phase III as Topic; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Randomized Controlled Trials as Topic; Research Design; Sorafenib | 2012 |
Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Monitoring; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2012 |
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Division; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Hep G2 Cells; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-3; Sorafenib; Xenograft Model Antitumor Assays | 2012 |
Potential impact of sorafenib on the survival benefit of liver transplantation for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
[Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
Topics: Adrenal Gland Diseases; Adrenal Gland Neoplasms; Adrenal Glands; Antineoplastic Agents; Carcinoma, Hepatocellular; Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Sorafenib | 2012 |
Indian health groups welcome country's first compulsory licence.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Costs; Drug Industry; Drugs, Generic; Humans; India; Licensure; Niacinamide; Patents as Topic; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Paclitaxel; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Pyridines; ras Proteins; Retinoblastoma Protein; Signal Transduction; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2012 |
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy.
Topics: Benzenesulfonates; Biopsy; Carcinoma; Carcinoma, Papillary; Disease Progression; Endoscopy; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Positron-Emission Tomography; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Tomography, X-Ray Computed; Ultrasonography | 2012 |
Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distribution; Contrast Media; Disease Progression; Doxorubicin; Ethiodized Oil; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib.
Topics: Acute Kidney Injury; Animals; Benzenesulfonates; Captopril; Growth Inhibitors; Hypertension; Male; Niacinamide; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzenesulfonates; Cells, Cultured; Drug Synergism; Female; HL-60 Cells; Humans; Indoles; Leukemia, Myeloid; Membrane Proteins; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; Sorafenib; U937 Cells; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
Comparative efficacy of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitor as second-line therapy in patients with metastatic renal cell carcinoma after the failure of first-line VE
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Enzyme Inhibitors; ErbB Receptors; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrroles; Salvage Therapy; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
[Sorafenib and octreotide combination therapy can inhibit proliferation of and induce apoptosis in human hepatoma cells].
Topics: Apoptosis; Benzenesulfonates; Cell Proliferation; Hep G2 Cells; Humans; Niacinamide; Octreotide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Cells, Cultured; Enzyme-Linked Immunosorbent Assay; Humans; Immunohistochemistry; Indazoles; Light; Middle Aged; Neuropilin-1; Neuropilin-2; Neuropilins; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Ranibizumab; Receptors, Vascular Endothelial Growth Factor; Retinal Pigment Epithelium; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Sulfonamides; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients.
Topics: Acinar Cells; Animals; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Cyclin E; Cyclin-Dependent Kinase 2; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Mammary Glands, Animal; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Isoforms; Proto-Oncogene Proteins B-raf; Purines; Pyridines; Retrospective Studies; Roscovitine; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2012 |
The effects of sorafenib on liver regeneration in a model of partial hepatectomy.
Topics: Animals; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Hepatectomy; Hepatocytes; Liver Cirrhosis; Liver Neoplasms; Liver Regeneration; Male; Mice; Mice, Inbred C57BL; Models, Animal; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Design, synthesis and biological activities of thiourea containing sorafenib analogs as antitumor agents.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Structure-Activity Relationship; Thiourea | 2012 |
Sorafenib and bevacizumab for recurrent metastatic hepatoblastoma: stable radiographic disease with decreased AFP.
Topics: alpha-Fetoproteins; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Child, Preschool; Hepatoblastoma; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Sorafenib | 2012 |
Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Breast Neoplasms; Disease Models, Animal; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Humans; Male; MAP Kinase Kinase 1; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proteome; Proto-Oncogene Proteins c-myc; Pyridines; Receptor Protein-Tyrosine Kinases; Sorafenib | 2012 |
High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib | 2012 |
Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.
Topics: Benzenesulfonates; Caco-2 Cells; HCT116 Cells; HT29 Cells; Humans; Indoles; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Sulfonamides | 2012 |
Role of human CYP3A4 in the biotransformation of sorafenib to its major oxidized metabolites.
Topics: Benzenesulfonates; Catalytic Domain; Cytochrome P-450 CYP3A; Humans; Inactivation, Metabolic; Microsomes, Liver; Models, Molecular; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Protein Conformation; Pyridines; Sorafenib | 2012 |
EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; RNA Interference; Sorafenib | 2012 |
The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Young Adult | 2012 |
Vitamin K1 enhances sorafenib-induced growth inhibition and apoptosis of human malignant glioma cells by blocking the Raf/MEK/ERK pathway.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Glioma; Humans; Immunoenzyme Techniques; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; raf Kinases; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Vitamin K 1; Vitamins | 2012 |
Intra-arterial infusion of chemotherapy for advanced hepatocellular carcinoma: an Asian perspective.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Sorafenib in combination with transarterial chemoembolization and bronchial arterial chemoinfusion in the treatment of hepatocellular carcinoma with pulmonary metastasis.
Topics: Antineoplastic Agents; Benzenesulfonates; Bronchial Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2012 |
Applicability of BCLC stage for prognostic stratification in comparison with other staging systems: single centre experience from long-term clinical outcomes of 1717 treatment-naïve patients with hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Child; Female; Hepatitis B; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Republic of Korea; ROC Curve; Sorafenib; Treatment Outcome; Young Adult | 2012 |
The role of hypoxia-inducible factor-1α and -2α in androgen insensitive prostate cancer cells.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Docetaxel; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Insulin-Like Growth Factor I; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-met; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Sunitinib; Taxoids; Zinc Sulfate | 2013 |
Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Databases, Factual; Disease Progression; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Sorafenib; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2013 |
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Indoles; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The anti-tumor role and mechanism of integrated and truncated PDCD5 proteins in osteosarcoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis Regulatory Proteins; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Mice; Mice, Inbred BALB C; Mice, Knockout; Neoplasm Proteins; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; ras Proteins; Signal Transduction; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured | 2012 |
Hyperthyroidism and thyroid autoimmunity induced by sorafenib in metastatic renal cell cancer.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Hyperthyroidism; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Radionuclide Imaging; Sorafenib; Thyroid Function Tests; Thyroid Gland; Thyroiditis, Autoimmune | 2012 |
Clinical course of sorafenib treatment in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Fatigue; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Failure; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Retrospective Studies; Sorafenib; Time Factors | 2012 |
Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors.
Topics: Carcinoma, Neuroendocrine; Humans; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Thyroid Neoplasms | 2013 |
RAIN-Droplet: a novel 3D in vitro angiogenesis model.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Cells, Cultured; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Imaging, Three-Dimensional; Microscopy, Confocal; Microscopy, Electron, Transmission; Microvessels; Models, Biological; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Spheroids, Cellular | 2012 |
Painful leg mass.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Hospice Care; Humans; Kidney Neoplasms; Leg; Liver Neoplasms; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Pain; Palliative Care; Phenylurea Compounds; Prognosis; Pyridines; Skin Neoplasms; Sorafenib; Tomography, X-Ray Computed | 2012 |
Safety and effectiveness of sorafenib in patients with hepatocellular carcinoma in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Pyridines; Radiography; Sorafenib | 2012 |
Multiple cutaneous metastatic chordomas from the sacrum.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Chordoma; Female; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Sacrum; Skin Neoplasms; Sorafenib | 2012 |
Clusterin inhibition using OGX-011 synergistically enhances antitumour activity of sorafenib in a human renal cell carcinoma model.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Clusterin; Disease Models, Animal; Gene Knockdown Techniques; Humans; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Oligonucleotides, Antisense; Phenylurea Compounds; Pyridines; Sorafenib; Thionucleotides; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
New use for an old drug: inhibiting ABCG2 with sorafenib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Intracellular Space; Mitoxantrone; Molecular Conformation; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Binding; Pyridines; Signal Transduction; Sorafenib | 2012 |
Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.
Topics: AC133 Antigen; Adult; Aged; Animals; Antigens, CD; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Female; Glycoproteins; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Niacinamide; Peptides; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib; Transcriptional Activation; Treatment Outcome | 2012 |
Second-line therapy after VEGF targeted therapy in metastatic renal cancer: a law of diminishing returns.
Topics: Angiogenesis Inhibitors; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Imatinib Mesylate; In Vitro Techniques; Indoles; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2012 |
Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Carcinoma, Hepatocellular; Clinical Trials as Topic; Deoxycytidine; Fluorouracil; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Serum; Sorafenib; Tegafur; Treatment Outcome | 2012 |
Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrroles; Sorafenib; Sunitinib; Thyroid Diseases; Thyroid Gland; Thyrotoxicosis | 2012 |
Combined anti-tumor effects of IFN-α and sorafenib on hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Protocols; bcl-X Protein; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Survival; Cyclin A; Cyclin B; Extracellular Signal-Regulated MAP Kinases; Humans; Interferon-alpha; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; STAT1 Transcription Factor; STAT3 Transcription Factor | 2012 |
Erlotinib and sorafenib in an orthotopic rat model of hepatocellular carcinoma.
Topics: Animals; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Movement; Cell Survival; Drug Therapy, Combination; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Rats; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A | 2012 |
Combination of the ERK inhibitor AZD6244 and low-dose sorafenib in a xenograft model of human renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzimidazoles; Carcinoma, Renal Cell; Cell Proliferation; Humans; Kidney Neoplasms; Mice; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Protein Processing, Post-Translational; Pyridines; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Tumor Burden; Tumor Cells, Cultured; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Skin Diseases; Sorafenib | 2012 |
Cyclic AMP/PKA-dependent paradoxical activation of Raf/MEK/ERK signaling in polycystin-2 defective mice treated with sorafenib.
Topics: Animals; Antineoplastic Agents, Hormonal; Benzenesulfonates; Bile Ducts; Caspase 3; Cell Proliferation; Cells, Cultured; Cyclic AMP-Dependent Protein Kinases; Cysts; Drug Therapy, Combination; Epithelial Cells; Ki-67 Antigen; Liver Diseases; MAP Kinase Signaling System; Mice; Mice, Knockout; Niacinamide; Octreotide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Sorafenib; TRPP Cation Channels | 2012 |
Sorafenib inhibits many kinase mutations associated with drug-resistant gastrointestinal stromal tumors.
Topics: Benzamides; Benzenesulfonates; Cell Line, Tumor; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Inhibitory Concentration 50; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-kit; Pyridines; Pyrimidines; Sorafenib | 2012 |
Sorafenib prevents escape from host immunity in liver cirrhosis patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Count; Female; Humans; Immunity; Japan; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; T-Lymphocytes, Regulatory; Th1 Cells; Th2 Cells; Treatment Outcome | 2012 |
Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sarcopenia; Sorafenib; Survival Analysis | 2012 |
Combination of sorafenib and everolimus impacts therapeutically on adrenocortical tumor models.
Topics: Adenoma; Adolescent; Adrenal Cortex Neoplasms; Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; Cell Line, Tumor; Child; Child, Preschool; Everolimus; Female; Humans; Infant; Male; Mice; Mice, Knockout; Mice, SCID; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Sirolimus; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays; Young Adult | 2012 |
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.
Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Endosomes; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Knockdown Techniques; Glutamates; Guanine; Humans; MAP Kinase Signaling System; Niacinamide; Pemetrexed; Phenylurea Compounds; Protein Phosphatase 2; Pyridines; Receptor, Platelet-Derived Growth Factor beta; RNA Interference; Sorafenib; src-Family Kinases | 2012 |
Contrast-enhanced ultrasonography for evaluating antiangiogenic treatment in hepatocellular carcinoma. A long way from research to clinical practice.
Topics: Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Ultrasonography | 2012 |
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Chemical genetic discovery of targets and anti-targets for cancer polypharmacology.
Topics: Animals; Benzenesulfonates; Cell Transformation, Neoplastic; Disease Models, Animal; Drosophila melanogaster; Drosophila Proteins; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Extracellular Signal-Regulated MAP Kinases; Heterocyclic Compounds, 4 or More Rings; Humans; Male; Molecular Targeted Therapy; Multiple Endocrine Neoplasia Type 2b; Niacinamide; Phenylurea Compounds; Polypharmacy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyridines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; src-Family Kinases; Survival Rate; Xenograft Model Antitumor Assays | 2012 |
The different induction mechanisms of growth arrest DNA damage inducible gene 45 β in human hepatoma cell lines.
Topics: Antigens, Differentiation; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Survival; E2F1 Transcription Factor; Hep G2 Cells; Humans; Liver Neoplasms; NF-kappa B; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Pyridines; S-Adenosylmethionine; Sorafenib; Tumor Suppressor Protein p53 | 2012 |
Tumor reoxygenation following administration of Mitogen-Activated Protein Kinase inhibitors: a rationale for combination with radiation therapy.
Topics: Angiogenesis Inducing Agents; Animals; Apoptosis; Benzamides; Blotting, Western; Diphenylamine; Electron Spin Resonance Spectroscopy; Fibrosarcoma; Glutathione; Liver Neoplasms, Experimental; Mice; Neoplasms, Experimental; Niacinamide; Oxygen Consumption; Phenylurea Compounds; Protein Kinase Inhibitors; Radiation Tolerance; Sorafenib | 2012 |
Second-line treatment outcomes after first-line sunitinib therapy in metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
GSK-3 inhibition in vitro and in vivo enhances antitumor effect of sorafenib in renal cell carcinoma (RCC).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Renal Cell; Cell Proliferation; Glycogen Synthase Kinase 3; Humans; Kidney Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Xenograft Model Antitumor Assays | 2012 |
Use of Sorafenib as an effective treatment in an AML patient carrying a new point mutation affecting the Juxtamembrane domain of FLT3.
Topics: Aged; Amino Acid Sequence; Animals; Antineoplastic Agents; Benzenesulfonates; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Point Mutation; Pyridines; Sequence Alignment; Sorafenib | 2012 |
Development of coronary artery stenosis in a patient with metastatic renal cell carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Coronary Angiography; Coronary Stenosis; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Cardiovascular comorbidities for prediction of progression-free survival in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cardiovascular Diseases; Comorbidity; Disease-Free Survival; Female; Humans; Hypertension; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Sorafenib; Treatment Outcome | 2012 |
Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.
Topics: Antineoplastic Agents; Benzenesulfonates; Cyproheptadine; Drug Approval; Drug Discovery; Ketanserin; Molecular Dynamics Simulation; Niacinamide; Phenylurea Compounds; Protein Conformation; Pyridines; Receptors, Serotonin; Sequence Homology, Amino Acid; Serotonin Antagonists; Sorafenib; United States; United States Food and Drug Administration; User-Computer Interface | 2012 |
Sorafenib enhances the therapeutic efficacy of rapamycin in colorectal cancers harboring oncogenic KRAS and PIK3CA.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Cell Cycle; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Colorectal Neoplasms; Drug Synergism; Humans; Male; MAP Kinase Signaling System; Mechanistic Target of Rapamycin Complex 1; Mice; Multiprotein Complexes; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyridines; ras Proteins; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases | 2012 |
First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Decision Making; Female; Humans; Liver Neoplasms; Male; Multicenter Studies as Topic; Niacinamide; Phenylurea Compounds; Professional Practice; Pyridines; Randomized Controlled Trials as Topic; Residence Characteristics; Sorafenib; Specialization | 2012 |
Skin toxicity and efficacy of sunitinib and sorafenib in metastatic renal cell carcinoma: a national registry-based study.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Exanthema; Female; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Registries; Retrospective Studies; Skin; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
[A case of advanced hepatocellular carcinoma with portal vein invasion successfully treated by sorafenib].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Pyridines; Sorafenib | 2012 |
Angiosarcoma of the scalp successfully treated with a single therapy of sorafenib.
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Female; Head and Neck Neoplasms; Hemangiosarcoma; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Scalp; Skin Neoplasms; Sorafenib; Treatment Outcome | 2012 |
The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2012 |
Design, synthesis and antitumor activities of novel bis-aryl ureas derivatives as Raf kinase inhibitors.
Topics: Antineoplastic Agents; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; raf Kinases; Sorafenib; Structure-Activity Relationship; Urea | 2012 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy.
Topics: Antineoplastic Agents; Hand-Foot Syndrome; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Psoriasis; Sorafenib; Ultraviolet Therapy | 2012 |
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Genetic Predisposition to Disease; Hand-Foot Syndrome; Humans; Korea; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Pyridines; Sorafenib; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2013 |
Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzenesulfonates; Chromatography, Liquid; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Toxicity Tests; Treatment Outcome; Young Adult | 2012 |
Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cough; Dyspnea; Female; Fever; Humans; Japan; Liver Neoplasms; Lung; Male; Marketing; Middle Aged; Niacinamide; Phenylurea Compounds; Pulmonary Alveoli; Sorafenib | 2013 |
Treatment Response After Unusual Low Dose Sorafenib: Diagnosis with Perfusion CT and Follow-up in a Patient with Recurrent Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tomography, X-Ray Computed | 2012 |
Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2012 |
Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma.
Topics: 3T3 Cells; Amino Acid Substitution; Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cell Line; Cell Transformation, Neoplastic; Chlorocebus aethiops; COS Cells; DNA, Neoplasm; Humans; Mice; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
The role of PI3K/mTOR inhibition in combination with sorafenib in hepatocellular carcinoma treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Growth Processes; Cell Line, Tumor; Female; Furans; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Pyrimidines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2012 |
[Relationship between sorafenib-associated hand-food skin reaction and efficacy in treatment of advanced hepatocellular carcinoma].
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug Eruptions; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib | 2012 |
Chemosensitivity of conjunctival melanoma cell lines to target-specific chemotherapeutic agents.
Topics: Antineoplastic Agents; Benzophenones; Boronic Acids; Bortezomib; Cell Proliferation; Conjunctival Neoplasms; Drug Screening Assays, Antitumor; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Pyrazines; Ribonucleases; Sorafenib; Tumor Cells, Cultured | 2013 |
Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Erythema Multiforme; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sample Size; Sorafenib; Treatment Outcome | 2012 |
The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; MAP Kinase Signaling System; Niacinamide; Pemetrexed; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2012 |
MCM7 expression predicts post-operative prognosis for hepatocellular carcinoma.
Topics: Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Chemotherapy, Adjuvant; DNA-Binding Proteins; Gene Expression Regulation; Hepatitis B; Humans; Immunohistochemistry; Liver Neoplasms; Minichromosome Maintenance Complex Component 7; Multivariate Analysis; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib | 2012 |
Preparation, in vitro release, and pharmacokinetics in rabbits of lyophilized injection of sorafenib solid lipid nanoparticles.
Topics: Animals; Benzenesulfonates; Chromatography, High Pressure Liquid; Fatty Acids; Female; Freeze Drying; Nanoparticles; Niacinamide; Particle Size; Phenylurea Compounds; Phosphatidylcholines; Powders; Pyridines; Rabbits; Sorafenib | 2012 |
The monoclonal antibody CH12 enhances the sorafenib-mediated growth inhibition of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Benzenesulfonates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2012 |
Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Diagnosis, Differential; Female; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Portal Vein; Sorafenib | 2012 |
[Influence of body surface area on efficacy and safety of sorafenib in advanced hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Sorafenib | 2012 |
Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Female; Humans; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2012 |
Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9.
Topics: Animals; Disease Models, Animal; Down-Regulation; Hepatectomy; Hepatic Veno-Occlusive Disease; Liver; Male; MAP Kinase Kinase 4; Matrix Metalloproteinase 9; Monocrotaline; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sorafenib | 2012 |
Sorafenib for lung cancer: is the "Battle" still open?
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Molecular mechanisms of sorafenib action in liver cancer cells.
Topics: Apoptosis; Benzenesulfonates; Biological Transport; Carcinoma, Hepatocellular; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Repair; DNA Replication; Gene Expression Profiling; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinases; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Transcription, Genetic | 2012 |
Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib.
Topics: Animals; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cluster Analysis; Female; Gene Expression Profiling; Genomics; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reproducibility of Results; Sorafenib; Transforming Growth Factor beta; Wnt Proteins; Wnt Signaling Pathway | 2012 |
Regression of hepatocellular carcinoma with right atrial extension after sorafenib and transarterial chemoembolization.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Radiography, Abdominal; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Sorafenib combined with locoregional therapy prior to liver transplantation for hepatocellular carcinoma: an update on a previous case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; Waiting Lists | 2013 |
Copy number aberrations of BCL2 and CDKN2A/B identified by array-CGH in thymic epithelial tumors.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Aniline Compounds; Animals; Apoptosis Regulatory Proteins; Autophagy; bcl-X Protein; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Comparative Genomic Hybridization; Cyclin-Dependent Kinase Inhibitor p15; Cyclin-Dependent Kinase Inhibitor p16; DNA Copy Number Variations; Female; Humans; Indoles; Male; Mice; Mice, Nude; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Pyrroles; RNA Interference; RNA, Small Interfering; Sorafenib; Sulfonamides; Thymus Neoplasms; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2012 |
From outlier to trendsetter.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Industry; Drugs, Generic; Economic Competition; Global Health; Humans; India; Intellectual Property; Niacinamide; Patents as Topic; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal.
Topics: Adult; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Down-Regulation; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Leukocytes, Mononuclear; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2013 |
Right sided heart mass reveals hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Male; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Sorafenib; Thrombosis | 2012 |
Targeting angiogenesis in metastatic breast cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Capecitabine; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease-Free Survival; Everolimus; Female; Fluorouracil; Humans; Indoles; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Paclitaxel; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2012 |
Heme oxygenase-1 promotes survival of renal cancer cells through modulation of apoptosis- and autophagy-regulating molecules.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Proteins; Beclin-1; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Heme Oxygenase-1; Humans; Intracellular Signaling Peptides and Proteins; Kidney Neoplasms; Membrane Proteins; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Protoporphyrins; Pyridines; Sirolimus; Sorafenib | 2012 |
HDAC inhibitors synergize antiproliferative effect of sorafenib in renal cell carcinoma cells.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Sulfonamides; Von Hippel-Lindau Tumor Suppressor Protein; Vorinostat | 2012 |
Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice?
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Fatigue; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Radiography; Skin Diseases; Sorafenib; Treatment Outcome | 2012 |
Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.
Topics: Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Humans; Lethal Dose 50; Leukemia, Lymphocytic, Chronic, B-Cell; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; Thiazoles; Treatment Outcome; Tumor Cells, Cultured | 2012 |
Rho-kinase-dependent pathway mediates the hepatoprotective effects of sorafenib against ischemia/reperfusion liver injury in rats with nonalcoholic steatohepatitis.
Topics: Animals; Apoptosis; Disease Models, Animal; Fatty Liver; Gene Expression Regulation, Enzymologic; Hemodynamics; Inflammation; Liver; Male; MAP Kinase Signaling System; Necrosis; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Reperfusion Injury; rho-Associated Kinases; RNA, Messenger; Sorafenib; Transplantation, Homologous | 2012 |
Effects of multikinase inhibitors on pressure overload-induced right ventricular remodeling.
Topics: Animals; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Sorafenib; Sunitinib; Ventricular Function, Right; Ventricular Remodeling | 2013 |
Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Favorable effect of sorafenib in a patient with neurofibromatosis-associated pulmonary hypertension.
Topics: Adult; Benzenesulfonates; Cardiac Catheterization; Exercise Test; Female; Humans; Hypertension, Pulmonary; Neurofibromatosis 1; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Vascular Resistance | 2012 |
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
Topics: Animals; Benzenesulfonates; Blotting, Western; Cells, Cultured; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Immunoprecipitation; Leukemia, Erythroblastic, Acute; Mice; Mice, Inbred BALB C; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tandem Repeat Sequences | 2013 |
Impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; C-Reactive Protein; Carcinoma, Renal Cell; Confidence Intervals; Female; Humans; Hyponatremia; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Leukocytosis; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Severity of Illness Index; Sodium; Sorafenib; Sunitinib | 2012 |
Blockade of STAT3 activation by sorafenib derivatives through enhancing SHP-1 phosphatase activity.
Topics: Animals; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Humans; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphoproteins; Protein Kinase Inhibitors; Protein Kinases; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2012 |
Sorafenib use in hepatocellular carcinoma in Japan: early experience and impact on clinical practice.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Japan; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Risk Factors; Sorafenib; Treatment Outcome | 2012 |
Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Japan; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Pyridines; Sorafenib; Time Factors | 2012 |
Closing remarks.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Approval; Hepatic Artery; Humans; Infusions, Intra-Arterial; Japan; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Sorafenib for non-selected patient population with advanced hepatocellular carcinoma: efficacy and safety data according to liver function.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Calcineurin Inhibitors; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Retrospective Studies; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2012 |
[Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation].
Topics: Adolescent; Adult; Aged; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Liver Transplantation; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2012 |
Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; C-Reactive Protein; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib | 2013 |
Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Prognosis; Protein Precursors; Prothrombin; Pyridines; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2012 |
FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA, Neoplasm; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factor 4; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Incidence; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Transplantation, Heterologous; Treatment Outcome | 2013 |
The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinoma.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Comorbidity; Diabetes Mellitus; Humans; Kidney Neoplasms; Liver Neoplasms; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2012 |
The efficacy of bevacizumab, sorafenib, and retinoic acid on rat endometriosis model.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal, Humanized; Bevacizumab; Disease Models, Animal; Endometriosis; Female; Microvessels; Niacinamide; Phenylurea Compounds; Random Allocation; Rats; Rats, Wistar; Sorafenib; Treatment Outcome; Tretinoin | 2013 |
Monitoring anti-angiogenic therapy in colorectal cancer murine model using dynamic contrast-enhanced MRI: comparing pixel-by-pixel with region of interest analysis.
Topics: Angiogenesis Inhibitors; Animals; Colorectal Neoplasms; Contrast Media; Disease Models, Animal; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Transplantation, Heterologous | 2013 |
Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Intestinal Perforation; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Sigmoid Diseases; Sorafenib | 2012 |
Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Size; Ceramides; Erythrocytes; Hemolysis; Humans; Liver Neoplasms; Niacinamide; Oxidative Stress; Phenylurea Compounds; Phosphatidylserines; Protein Kinase Inhibitors; Sorafenib | 2012 |
Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Diarrhea; Female; Genotype; Glucuronosyltransferase; Humans; Hypertension; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Risk Factors; Skin; Sorafenib; UDP-Glucuronosyltransferase 1A9 | 2012 |
Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo.
Topics: Animals; Cells, Cultured; Dose-Response Relationship, Drug; Gene Expression Regulation; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Niacinamide; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; RNA; Sorafenib; Thioacetamide | 2013 |
[Hepatocellular carcinoma - long-term treatable disease].
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2012 |
Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Down-Regulation; Hep G2 Cells; Humans; Janus Kinases; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Repressor Proteins; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Transplantation, Heterologous; Tumor Suppressor Proteins | 2012 |
Focus.
Topics: Animals; Cell Transformation, Neoplastic; Epithelial-Mesenchymal Transition; Hepatic Veno-Occlusive Disease; Hepatitis C; Hepatocytes; Humans; Male; MAP Kinase Kinase 4; Matrix Metalloproteinase 9; Monocrotaline; Niacinamide; Phenylurea Compounds; Sorafenib; Viral Nonstructural Proteins | 2012 |
Mechanism of enhancement of radiation-induced cytotoxicity by sorafenib in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Cell Survival; Chemoradiotherapy; Colorectal Neoplasms; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; HT29 Cells; Humans; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Radiation Dosage; Radiation Tolerance; Sorafenib; Treatment Outcome | 2013 |
Editorial comment from Dr Saito to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2012 |
RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fluorescent Antibody Technique; Hepatectomy; Hepatocytes; Humans; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Liver Regeneration; Molecular Targeted Therapy; Neoplasm Micrometastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; Rats; Sorafenib | 2013 |
Sorafenib inhibits hypoxia-inducible factor-1α synthesis: implications for antiangiogenic activity in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2012 |
Clinicopathological characteristics of hepatocellular carcinoma in Turkey.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alcoholism; alpha-Fetoproteins; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Hepatitis B; Hepatitis C; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Risk Factors; Sorafenib; Turkey; Young Adult | 2012 |
Differential inhibitory effects of two Raf-targeting drugs, sorafenib and PLX4720, on the growth of multidrug-resistant cells.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Caspase 3; Cell Proliferation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Mice; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Kinases; Protein Processing, Post-Translational; raf Kinases; Sorafenib; Sulfonamides; TOR Serine-Threonine Kinases | 2013 |
The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib.
Topics: Antineoplastic Agents; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ret; Real-Time Polymerase Chain Reaction; RNA Interference; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2012 |
[Clinic predictors of efficacy and adverse events of sorafenib therapy for advanced hepatocellular carcinoma patients].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2012 |
Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Base Sequence; Benzenesulfonates; Disease Models, Animal; DNA Primers; Female; Flow Cytometry; Humans; Immunohistochemistry; Male; Mice; Middle Aged; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
Affinity purification of protein kinases that adopt a specific inactive conformation.
Topics: Benzamides; Benzenesulfonates; Imatinib Mesylate; Niacinamide; Phenylurea Compounds; Piperazines; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrimidines; Sorafenib | 2012 |
Bayer challenges India's first compulsory licence for generic version of cancer drug.
Topics: Antineoplastic Agents; Benzenesulfonates; Drug Costs; Drug Industry; Drugs, Generic; Humans; India; Legislation, Drug; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2012 |
FLT3-ITD knockin impairs hematopoietic stem cell quiescence/homeostasis, leading to myeloproliferative neoplasm.
Topics: Animals; Bone Marrow; Bone Marrow Neoplasms; Cell Compartmentation; Cell Cycle; Cell Proliferation; Enzyme Activation; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Gene Expression Regulation, Neoplastic; Gene Knock-In Techniques; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Homeostasis; Male; Mice; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Promoter Regions, Genetic; RNA, Messenger; Side-Population Cells; Signal Transduction; Small Molecule Libraries; Sorafenib; Tandem Repeat Sequences | 2012 |
An adaptive Src-PDGFRA-Raf axis in rhabdomyosarcoma.
Topics: Animals; Benzamides; Benzenesulfonates; Cell Proliferation; Drug Resistance, Neoplasm; Imatinib Mesylate; Mice; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; raf Kinases; Receptor, Platelet-Derived Growth Factor alpha; Rhabdomyosarcoma, Alveolar; Sorafenib; src-Family Kinases; Tumor Cells, Cultured | 2012 |
A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Fibroblast Growth Factor 3; Fibroblast Growth Factor 4; Gene Amplification; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Synthetic lethal screening with small-molecule inhibitors provides a pathway to rational combination therapies for melanoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Diclofenac; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Phospholipases A2, Cytosolic; Signal Transduction; Skin Neoplasms; Small Molecule Libraries; Sorafenib | 2012 |
Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines.
Topics: Adult; AMP-Activated Protein Kinases; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Blotting, Western; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Cell Survival; Drug Synergism; Enzyme Activation; Fluorouracil; Gene Expression Regulation, Enzymologic; Growth Inhibitors; Hep G2 Cells; Hepatic Stellate Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Thymidylate Synthase; Time Factors | 2012 |
Evaluation of changes in the tumor microenvironment after sorafenib therapy by sequential histology and 18F-fluoromisonidazole hypoxia imaging in renal cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Humans; Hypoxia; Kidney Neoplasms; Mice; Mice, Nude; Misonidazole; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Radiopharmaceuticals; Sorafenib; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2012 |
Rationally designed aberrant kinase-targeted endogenous protein nanomedicine against oncogene mutated/amplified refractory chronic myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Benzamides; Blotting, Western; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Flow Cytometry; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloid Cell Leukemia Sequence 1 Protein; Nanomedicine; Nanoparticles; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Conformation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Real-Time Polymerase Chain Reaction; Receptors, Transferrin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serum Albumin; Sorafenib; STAT5 Transcription Factor; Transferrin; Tumor Cells, Cultured | 2012 |
Molecular mechanisms and modulation of key pathways underlying the synergistic interaction of sorafenib with erlotinib in non-small-cell-lung cancer (NSCLC) cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Chromatography, Liquid; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Tandem Mass Spectrometry | 2013 |
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Recurrence; Sorafenib | 2012 |
Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Receptors, TNF-Related Apoptosis-Inducing Ligand; Sorafenib; STAT3 Transcription Factor; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis.
Topics: Adult; Angiogenesis Inhibitors; Benzenesulfonates; Cell Movement; Cell Proliferation; Cells, Cultured; Endometriosis; Endometrium; Female; Humans; Mesenchymal Stem Cells; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome; Young Adult | 2012 |
Influence of the sorafenib patients assistance program on treatment compliance and overall survival of unresectable hepatocellular carcinoma patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Financial Support; Humans; Indonesia; Kaplan-Meier Estimate; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Phenylurea Compounds; Program Evaluation; Proportional Hazards Models; Prospective Studies; Sorafenib; Young Adult | 2012 |
Single-agent therapy with sorafenib or 5-FU is equally effective in human colorectal cancer xenograft--no benefit of combination therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Fluorouracil; Humans; Intercellular Signaling Peptides and Proteins; Ki-67 Antigen; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response.
Topics: Animals; Apoptosis; Caspase 3; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; Female; Humans; Imidazoles; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 14; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Pyridines; Signal Transduction; Sorafenib; Transplantation, Heterologous | 2012 |
Limitations of targeted therapy with sorafenib in elderly high-risk myelodysplastic syndrome and acute myeloid leukemia.
Topics: Female; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Hepatic arterial thrombosis: a critical complication during combination therapy of arterial chemoinfusion and sorafenib.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Hepatocellular; Cisplatin; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thrombosis | 2012 |
Evaluation of the relationship between MR estimates of blood oxygen saturation and hypoxia: effect of an antiangiogenic treatment on a gliosarcoma model.
Topics: Analysis of Variance; Angiogenesis Inhibitors; Animals; Benzenesulfonates; Brain Neoplasms; Dextrans; Gliosarcoma; Hypoxia, Brain; Image Processing, Computer-Assisted; Immunohistochemistry; Linear Models; Magnetic Resonance Imaging; Magnetite Nanoparticles; Male; Niacinamide; Nitroimidazoles; Oxygen; Phenylurea Compounds; Pyridines; Random Allocation; Rats; Rats, Inbred F344; Reproducibility of Results; Sorafenib | 2012 |
Editorial comment from Dr Vázquez-Alonso and Dr Puche-Sanz to impact of hyponatremia on survival of patients with metastatic renal cell carcinoma treated with molecular targeted therapy.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Hyponatremia; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2012 |
Sorafenib-induced tuberculosis reactivation.
Topics: Aged; Antineoplastic Agents; Antitubercular Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Latent Tuberculosis; Male; Niacinamide; Phenylurea Compounds; Secondary Prevention; Sorafenib; Treatment Outcome | 2012 |
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
Topics: Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Retrospective Studies; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2013 |
Thyroid dysfunction in patients treated with sunitinib or sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Gland; Thyroid Hormones | 2012 |
Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Flow Cytometry; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome; Vitamin K 2 | 2012 |
Design, synthesis and biological activities of sorafenib derivatives as antitumor agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Molecular Structure; Niacinamide; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship | 2012 |
Sunitinib- and sorafenib-induced nephrotic syndrome in a patient with gastrointestinal stromal tumor.
Topics: Angiogenesis Inhibitors; Benzenesulfonates; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Middle Aged; Nephrotic Syndrome; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2012 |
Tyrosine kinase inhibitor induced pancreatitis.
Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Pancreatitis; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib | 2013 |
Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Hypoxia; Cellular Microenvironment; Coculture Techniques; Enzyme Inhibitors; fms-Like Tyrosine Kinase 3; Humans; Indazoles; Leukemia, Myeloid, Acute; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-pim-1; Sorafenib; Stromal Cells; Sulfonamides | 2013 |
Sorafenib-mediated targeting of the AAA⁺ ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Line, Tumor; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Secretory Pathway; Sorafenib | 2012 |
Sorafenib treatment improves hepatopulmonary syndrome in rats with biliary cirrhosis.
Topics: Animals; Benzenesulfonates; Common Bile Duct; Disease Models, Animal; Hemodynamics; Hepatopulmonary Syndrome; Ligation; Liver; Liver Cirrhosis, Biliary; Liver Diseases; Lung; Male; Niacinamide; Oxygen; Partial Pressure; Phenylurea Compounds; Pyridines; Rats; Rats, Sprague-Dawley; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2013 |
The placental growth factor as a target against hepatocellular carcinoma in a diethylnitrosamine-induced mouse model.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Hepatocellular; Diethylnitrosamine; Disease Models, Animal; Drug Therapy, Combination; Liver Neoplasms; Mice; Mice, Knockout; Mice, Transgenic; Neoplasm Metastasis; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Placenta Growth Factor; Pregnancy Proteins; Sorafenib; Treatment Outcome | 2013 |
[A case of fatal clinical course with reversible acute cardiac failure and glucose intolerance during sorafenib therapy for metastatic renal cell carcinoma].
Topics: Acute Disease; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Glucose Intolerance; Heart Failure; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2012 |
Sustained complete remission of metastatic hepatocellular carcinoma with single agent sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib; Tomography, X-Ray Computed | 2013 |
Interactions of everolimus and sorafenib in pancreatic cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Interactions; Everolimus; Humans; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sirolimus; Sorafenib | 2013 |
c-KIT: potential predictive factor for the efficacy of sorafenib in metastatic renal cell carcinoma with sarcomatoid feature.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Hepatocellular; Diarrhea; Female; Follow-Up Studies; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyridines; Skin Diseases; Sorafenib; Survival Rate; Treatment Outcome; Vomiting | 2013 |
The influence of sorafenib on hepatic encephalopathy and the mechanistic survey in cirrhotic rats.
Topics: Animals; Disease Models, Animal; Hepatic Encephalopathy; Humans; Hypertension, Portal; Liver Cirrhosis, Experimental; Male; Niacinamide; Oxidative Stress; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sorafenib | 2012 |
Sorafenib modulates the radio sensitivity of hepatocellular carcinoma cells in vitro in a schedule-dependent manner.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; DNA Repair; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Sorafenib | 2012 |
BRAF mutations in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Exons; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Signal Transduction; Sorafenib; Sulfonamides; Treatment Outcome | 2013 |
Long lasting efficacy of sorafenib in a heavily pretreated patient with thymic carcinoma.
Topics: Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Recurrence; Sorafenib; Thymoma; Thymus Neoplasms; Tomography, X-Ray Computed; Tumor Burden | 2012 |
Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2012 |
The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Viral Load | 2013 |
Effects of antiangiogenic therapy.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Cystoscopy; Embolization, Therapeutic; Female; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Stents; Time Factors; Treatment Outcome | 2012 |
The kinase inhibitor Sorafenib impairs the antiviral effect of interferon α on hepatitis C virus replication.
Topics: Antiviral Agents; Cell Line, Tumor; Hepacivirus; Humans; Interferon-alpha; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Sorafenib; Virus Replication | 2013 |
OPA1 downregulation is involved in sorafenib-induced apoptosis in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochromes c; Down-Regulation; Gene Knockdown Techniques; GTP Phosphohydrolases; Humans; Liver; Liver Neoplasms; Mice; Mice, SCID; Mitochondria; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; raf Kinases; ras Proteins; RNA, Small Interfering; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells.
Topics: Androgens; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Proteasome Endopeptidase Complex; Protein Binding; Protein Isoforms; Protein Kinase Inhibitors; Receptors, Androgen; Signal Transduction; Sorafenib | 2012 |
Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth.
Topics: Anilides; Antineoplastic Agents; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Humans; Keratin-19; Liver Neoplasms; Morpholines; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; Vimentin | 2013 |
Conditional survival of patients with metastatic renal-cell carcinoma.
Topics: Carcinoma, Renal Cell; Humans; Indoles; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival Analysis | 2012 |
Sorafenib and TRAIL have synergistic effect on hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Humans; Hypoxia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Cells, Cultured | 2013 |
A novel combination therapy approach for the treatment of acute myeloid leukemia: the multi-kinase inhibitor sorafenib and the HDM2 inhibitor nutlin-3.
Topics: Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Imidazoles; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Piperazines; Sorafenib; Tumor Suppressor Protein p53 | 2012 |
Sorafenib therapy decreases the clearance of thyrotropin.
Topics: Aged; Aged, 80 and over; Carcinoma; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Function Tests; Thyroid Neoplasms; Thyrotropin | 2013 |
Sorafenib is effective in the treatment of pulmonary veno-occlusive disease.
Topics: Aged; Benzamides; Drug Therapy, Combination; Female; Hemodynamics; Humans; Imatinib Mesylate; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pulmonary Veno-Occlusive Disease; Pyrimidines; Sorafenib; Treatment Outcome | 2012 |
Targeting FLIP and Mcl-1 using a combination of aspirin and sorafenib sensitizes colon cancer cells to TRAIL.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenoma; Antineoplastic Agents; Apoptosis; Aspirin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Therapy, Combination; Gene Knockdown Techniques; Humans; Intestinal Mucosa; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Recombinant Proteins; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; Tumor Stem Cell Assay | 2013 |
Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Osteonecrosis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Sorafenib as third- or fourth-line treatment of advanced gastrointestinal stromal tumour and pretreatment including both imatinib and sunitinib, and nilotinib: A retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Chemotherapy, Adjuvant; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Salvage Therapy; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET).
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carbonic Anhydrase IX; Carbonic Anhydrases; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease-Free Survival; Female; Humans; Immunohistochemistry; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; DNA Damage; DNA Repair; Female; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Radiation-Sensitizing Agents; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2013 |
Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2012 |
Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzenesulfonates; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Pyridines; raf Kinases; Risk Factors; Safety; Sorafenib; Survival Rate | 2013 |
Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation.
Topics: Adult; Cell Proliferation; Drug Combinations; Drug Interactions; Everolimus; Female; Humans; Immunosuppressive Agents; Lymphocytes; Male; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sirolimus; Sorafenib | 2013 |
Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1.
Topics: Antineoplastic Agents; Cell Differentiation; Cells, Cultured; Humans; Leukocytes, Mononuclear; Macrophage Colony-Stimulating Factor; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Osteoclasts; Phenylurea Compounds; Protein Kinase Inhibitors; RANK Ligand; Sorafenib | 2013 |
Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Disease Progression; Ferric Compounds; Humans; Iron; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Phenylurea Compounds; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2012 |
The effect of sorafenib in postoperative adhesion formation in a rat uterine horn model.
Topics: Animals; Benzenesulfonates; Disease Models, Animal; Female; Immunohistochemistry; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Rats; Rats, Wistar; Sorafenib; Tissue Adhesions; Uterine Diseases; Uterus; Vascular Endothelial Growth Factor A | 2012 |
Sorafenib is effective for imatinib-resistant FIP1L1/PDGFRA T674I mutation-positive acute myeloid leukemia with eosinophilia.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; mRNA Cleavage and Polyadenylation Factors; Mutation; Niacinamide; Phenylurea Compounds; Piperazines; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Sorafenib; Treatment Outcome | 2013 |
Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Benzimidazoles; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Humans; Immunosuppressive Agents; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-ret; Pyridines; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Thyroid Neoplasms | 2012 |
Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in vitro.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Time Factors | 2013 |
Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.
Topics: Animals; Antineoplastic Agents; Catheter Ablation; Combined Modality Therapy; Disease Progression; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
The impact of patient and tumour baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2013 |
Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Humans; Indoles; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Multitargeted therapies for multiple myeloma.
Topics: Animals; Disease Models, Animal; Humans; Mice; Models, Biological; Molecular Targeted Therapy; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Sorafenib | 2013 |
Durable spontaneous regression of lung metastases from renal cell carcinoma after incomplete use of multiple kinase inhibitor sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Lung; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib | 2013 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
PTEN enhances the sensitivity of human hepatocellular carcinoma cells to sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma, Hepatocellular; Case-Control Studies; Cell Proliferation; Drug Resistance; Flow Cytometry; Humans; Immunoenzyme Techniques; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; PTEN Phosphohydrolase; Pyridines; Sorafenib; Survival Rate; Tumor Cells, Cultured | 2012 |
Sorafenib for the treatment of unresectable hepatocellular carcinoma in HIV-positive patients.
Topics: Adult; Aged; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carcinoma, Hepatocellular; Disease Progression; Female; HIV Infections; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Surgical resection improves the survival of selected hepatocellular carcinoma patients in Barcelona clinic liver cancer stage C.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Humans; Liver Neoplasms; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Taiwan; Treatment Outcome | 2013 |
Do anti-angiogenic therapies prevent brain metastases in advanced renal cell carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Benzenesulfonates; Bevacizumab; Brain Neoplasms; Cancer Care Facilities; Carcinoma, Renal Cell; Everolimus; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyridines; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Immune modulation of effector CD4+ and regulatory T cell function by sorafenib in patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; CD4-Positive T-Lymphocytes; Coculture Techniques; Cytokines; Dose-Response Relationship, Immunologic; Enzyme-Linked Immunosorbent Assay; Humans; Interleukin-2 Receptor alpha Subunit; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocytes, Regulatory | 2013 |
Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Dietary Supplements; Disease Models, Animal; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Hymecromone; Immunoblotting; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Random Allocation; Sensitivity and Specificity; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Drugmakers struggle with Indian patents.
Topics: Antineoplastic Agents; Benzamides; Drug Design; Drug Industry; Humans; Imatinib Mesylate; India; Indoles; Niacinamide; Patents as Topic; Phenylurea Compounds; Piperazines; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2012 |
Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.
Topics: Acute Kidney Injury; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Fatal Outcome; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib | 2012 |
A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma; Carcinoma, Papillary; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Flow Cytometry; Humans; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Thyroid Cancer, Papillary; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Withanolides | 2012 |
Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Topics: Actins; Animals; Antineoplastic Agents; Apoptosis; Caspases; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Cyclin D1; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Mantle-Cell; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Protein Kinase Inhibitors; Protein Multimerization; Proto-Oncogene Proteins c-bcl-2; Receptors, Antigen, B-Cell; Signal Transduction; Sorafenib; Stromal Cells; Transplantation, Heterologous | 2013 |
Pituitary metastasis from a renal cell carcinoma progressed after sorafenib treatment.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Radiotherapy, Conformal; Sorafenib | 2013 |
Targeting late SV40 factor: is the achilles heel of hepatocarcinogenesis revealed?
Topics: Animals; Antineoplastic Agents; Benzodioxoles; Carcinoma, Hepatocellular; Cell Death; Clinical Trials as Topic; DNA-Binding Proteins; Humans; Liver Neoplasms; Niacinamide; Oncogenes; Phenotype; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinolones; Sorafenib; Transcription Factors | 2012 |
Induction of endoplasmic reticulum stress by sorafenib and activation of NF-κB by lestaurtinib as a novel resistance mechanism in Hodgkin lymphoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carbazoles; Cell Line, Tumor; Drug Interactions; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Furans; Hodgkin Disease; Humans; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Reed-Sternberg Cells; Signal Transduction; Sorafenib | 2013 |
Sustained leukemia-free state and molecular response to sorafenib in a patient with chronic myelomonocytic leukemia in transformation driven by homozygous FLT3-ITD malignant hematopoiesis.
Topics: Antineoplastic Agents; fms-Like Tyrosine Kinase 3; Hematopoiesis; Humans; Leukemia, Myelomonocytic, Chronic; Middle Aged; Niacinamide; Nucleic Acid Hybridization; Phenylurea Compounds; Sorafenib | 2013 |
Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Epithelial Cells; Epithelial-Mesenchymal Transition; Female; Gene Expression; Gene Expression Profiling; Humans; Mesoderm; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Piperidines; Protein Interaction Maps; Protein Kinases; Proteome; Proteomics; Quinazolines; Sorafenib | 2013 |
[Side effects of sorafenib and countermeasures].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Treatment with sorafenib and sunitinib in renal cell cancer: a Swedish register-based study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Administration Schedule; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Sweden; Young Adult | 2013 |
Quantification of dynamic contrast-enhanced ultrasound in HCC: prediction of response to a new combination therapy of sorafenib and panobinostat in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Contrast Media; Fatal Outcome; Humans; Hydroxamic Acids; Indoles; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Panobinostat; Phenylurea Compounds; Sorafenib; Ultrasonography | 2012 |
[Successful treatment with sorafenib for primary refractory acute monoblastic leukemia with FLT3-ITD].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Fatal Outcome; fms-Like Tyrosine Kinase 3; Humans; Inverted Repeat Sequences; Leukemia, Monocytic, Acute; Male; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
Effect of sorafenib combined with cytostatic agents on hepatoblastoma cell lines and xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cisplatin; Cytostatic Agents; DNA Adducts; Enzyme Activation; Female; Hepatoblastoma; Humans; Liver Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Glycolysis; Humans; Liver Neoplasms; Mice; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
How to improve treatment outcomes for hepatocellular carcinoma of intermediate and advanced stage.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2012 |
Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Severity of Illness Index; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2012 |
Brain metastases from renal cell carcinoma in the era of tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Mice; Mice, Knockout; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission, Spontaneous; Sorafenib | 2013 |
Treatment patterns: targeted therapies indicated for first-line management of metastatic renal cell carcinoma in a real-world setting.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; United States | 2013 |
[A case of hepatocellular carcinoma treated by resection of metachronous rib metastasis after primary hepatectomy].
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Ribs; Sorafenib | 2012 |
[A case of curative resection for advanced hepatocellular carcinoma with portal vein tumor thrombus after hepatic arterial infusion chemotherapy].
Topics: Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Venous Thrombosis | 2012 |
A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Humans; Indazoles; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; TOR Serine-Threonine Kinases; Treatment Outcome | 2013 |
PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Pregnane X Receptor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Steroid; Sorafenib | 2013 |
[Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Doxorubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Iodized Oil; Liver Neoplasms; Male; Microwaves; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Rate | 2012 |
A novel p21 attenuator which is structurally related to sorafenib.
Topics: Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Humans; Niacinamide; Phenylurea Compounds; raf Kinases; RNA, Messenger; Sorafenib; Tumor Suppressor Protein p53 | 2013 |
Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Drug Costs; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality-Adjusted Life Years; Sorafenib | 2013 |
Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Piperidones; Sorafenib; Treatment Outcome; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2013 |
PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; Glucuronidase; Human Umbilical Vein Endothelial Cells; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mammary Neoplasms, Experimental; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Saponins; Sorafenib | 2012 |
[Effects of sorafenib and liposome doxorubicin on human poorly differentiated thyroid carcinoma xenografts in nude mice].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Liposomes; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Area Under Curve; Carcinoma, Hepatocellular; Contrast Media; Disease-Free Survival; Female; Ferric Compounds; Humans; Iron; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Perfusion Imaging; Phenylurea Compounds; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Reproducibility of Results; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2013 |
Sustained remission over 36 months of advanced hepatocellular carcinoma after short-term sorafenib therapy.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib | 2013 |
Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Survival; Chemoradiotherapy; Female; Gene Expression; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Matrix Metalloproteinase 2; MCF-7 Cells; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib; Spheroids, Cellular | 2013 |
The noncytotoxic dose of sorafenib sensitizes Bel-7402/5-FU cells to 5-FU by down-regulating 5-FU-induced Nrf2 expression.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Fluorouracil; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; NF-E2-Related Factor 2; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib | 2013 |
αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma.
Topics: 14-3-3 Proteins; alpha-Crystallin B Chain; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; MAP Kinase Signaling System; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Proteomics; Proto-Oncogene Proteins c-fos; Snail Family Transcription Factors; Sorafenib; Transcription Factors | 2013 |
A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2013 |
Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2013 |
Clinical value of continuous administration of sorafenib in combination with modified transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Sorafenib selectively depletes human glioblastoma tumor-initiating cells from primary cultures.
Topics: Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Brain Neoplasms; Cell Differentiation; Cell Proliferation; Down-Regulation; Glioblastoma; Humans; Intermediate Filament Proteins; Mitogen-Activated Protein Kinases; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Nerve Tissue Proteins; Nestin; Niacinamide; Oligodendrocyte Transcription Factor 2; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sorafenib; SOXB1 Transcription Factors; STAT3 Transcription Factor; Tumor Cells, Cultured | 2013 |
Quantification of plasma cell-free DNA in predicting therapeutic efficacy of sorafenib on metastatic clear cell renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; DNA; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Real-Time Polymerase Chain Reaction; Sorafenib; Treatment Outcome | 2013 |
Sorafenib induces autophagy and suppresses activation of human macrophage.
Topics: Antineoplastic Agents; Autophagy; B7-1 Antigen; Cells, Cultured; Cytokines; Dendritic Cells; Down-Regulation; Humans; Immunity, Innate; Immunosuppression Therapy; Lipopolysaccharide Receptors; Macrophage Activation; Macrophages; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Reactive Oxygen Species; Sorafenib | 2013 |
Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; Fluorescent Antibody Technique; Humans; In Situ Nick-End Labeling; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyridines; Sorafenib; Sulfonamides | 2013 |
Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide.
Topics: Animals; Antineoplastic Agents; Glucuronic Acid; HEK293 Cells; Humans; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Transgenic; Neoplasms; Niacinamide; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Phenylurea Compounds; Solute Carrier Organic Anion Transporter Family Member 1B3; Sorafenib | 2013 |
Refractory hypoglycemia controlled by sorafenib in solitary fibrous tumor.
Topics: Adult; Gastrointestinal Stromal Tumors; Humans; Hypoglycemia; Male; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Solitary Fibrous Tumors; Sorafenib | 2013 |
Establishment of HRAS(G12V) transgenic medaka as a stable tumor model for in vivo screening of anticancer drugs.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Agents; Melanophores; Niacinamide; Oryzias; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Sorafenib | 2013 |
[Two cases of bowel perforation in patients with metastatic renal cancer treated with a molecularly targeted drug].
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Intestinal Perforation; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2012 |
Sorafenib inhibits tumor growth and improves survival in a transgenic mouse model of pancreatic islet cell tumors.
Topics: Adenoma, Islet Cell; Animals; Antigens, Polyomavirus Transforming; Apoptosis; Disease Progression; Female; Insulin; Islets of Langerhans; Kaplan-Meier Estimate; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Neuroendocrine Tumors; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Promoter Regions, Genetic; Protein Kinase Inhibitors; Rats; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden | 2012 |
Sorafenib induces autophagy in human myeloid dendritic cells and prolongs survival of skin allografts.
Topics: Animals; Antigens; Autophagy; Cell Survival; Dactinomycin; Dendritic Cells; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Mice; Microscopy, Fluorescence; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Skin Transplantation; Sorafenib; Transplantation, Homologous | 2013 |
Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hodgkin Disease; Mice; Mice, Inbred NOD; Mice, SCID; Mitochondria; Mitogen-Activated Protein Kinases; Necrosis; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Inhibition of S6K1 enhances glucose deprivation-induced cell death via downregulation of anti-apoptotic proteins in MCF-7 breast cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Breast Neoplasms; Down-Regulation; Female; Gene Knockdown Techniques; Glucose; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Survivin; TOR Serine-Threonine Kinases | 2013 |
Expression of angiogenesis-related gene profiles and development of resistance to tyrosine-kinase inhibitor in advanced renal cell carcinoma: characterization of sorafenib-resistant cells derived from a cutaneous metastasis.
Topics: Aneuploidy; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Primary Cell Culture; Protein Kinase Inhibitors; Skin Neoplasms; Sorafenib; Transcriptome; Tumor Cells, Cultured | 2013 |
Potent in vitro and in vivo activity of sorafenib in multiple myeloma: induction of cell death, CD138-downregulation and inhibition of migration through actin depolymerization.
Topics: Actins; Aged; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Boronic Acids; Bortezomib; Chemokine CXCL12; Chemotaxis; Dose-Response Relationship, Drug; Down-Regulation; Female; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Multiple Myeloma; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Polymerization; Pyrazines; Sorafenib; Syndecan-1; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Beclin-1; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Hep G2 Cells; Humans; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-bcl-2; RNA Interference; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; Transplantation, Heterologous | 2013 |
Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Precursors; Prothrombin; Retrospective Studies; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2013 |
Pustular eruption induced by sorafenib in a case of psoriasis vulgaris.
Topics: Aged; Asian People; Humans; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Psoriasis; Severity of Illness Index; Skin Diseases, Vesiculobullous; Sorafenib | 2013 |
Taking cancer-drug toxicity to heart.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Doxorubicin; Heart Failure; Heart Function Tests; Humans; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Trastuzumab | 2013 |
Can the tyrosine kinase inhibitors trigger metabolic encephalopathy in cirrhotic patients?
Topics: Aged; Brain Diseases, Metabolic; Carcinoma, Hepatocellular; Cognition Disorders; Electroencephalography; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Mood Disorders; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
A novel role of cytosolic protein synthesis inhibition in aminoglycoside ototoxicity.
Topics: Alanine; Alkynes; Aminoglycosides; Animals; Anti-Bacterial Agents; Apoptosis; Blotting, Western; Cell Count; Chick Embryo; Cytosol; Ear Diseases; Enzyme Activation; Evoked Potentials, Auditory, Brain Stem; Glycine; Hair Cells, Auditory; Immunohistochemistry; JNK Mitogen-Activated Protein Kinases; Mice; Mice, Inbred CBA; Niacinamide; Organ Culture Techniques; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; RNA, Ribosomal; Sorafenib | 2013 |
Sorafenib delays recurrence and metastasis after liver transplantation in a rat model of hepatocellular carcinoma with high expression of phosphorylated extracellular signal-regulated kinase.
Topics: Animals; Apoptosis; Disease Models, Animal; Disease-Free Survival; Extracellular Signal-Regulated MAP Kinases; Liver Neoplasms, Experimental; Liver Transplantation; Male; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Rats, Inbred ACI; Rats, Inbred Lew; Sorafenib; Tissue Array Analysis | 2013 |
Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma.
Topics: Animals; Antigens, CD; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Humans; Immunocompromised Host; Immunosuppressive Agents; K562 Cells; Killer Cells, Natural; Lectins, C-Type; Liver Neoplasms; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Label-retaining liver cancer cells are relatively resistant to sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Profiling; Humans; Liver Neoplasms; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Stem Cells | 2013 |
Fluorinated N,N'-diarylureas as AMPK activators.
Topics: AMP-Activated Protein Kinases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Halogenation; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship; TOR Serine-Threonine Kinases; Urea | 2013 |
Sorafenib suppresses growth and survival of hepatoma cells by accelerating degradation of enhancer of zeste homolog 2.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromatin Immunoprecipitation; Enhancer of Zeste Homolog 2 Protein; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Polycomb Repressive Complex 2; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Transfection | 2013 |
Sorafenib perpetuates cellular anticancer effector functions by modulating the crosstalk between macrophages and natural killer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cytokines; Drug Evaluation, Preclinical; Humans; Killer Cells, Natural; Liver Neoplasms; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; NF-kappa B; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colonic Neoplasms; Crizotinib; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Comorbidity; Disease Progression; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Quality of Life; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2013 |
Is it time to adopt external beam radiotherapy in the NCCN guidelines as a therapeutic strategy for intermediate/advanced hepatocellular carcinoma?.
Topics: Adrenal Gland Neoplasms; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Ethiodized Oil; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Retrospective Studies; Sorafenib; Survival Rate | 2013 |
Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.
Topics: Amino Acid Sequence; Amino Acid Substitution; Benzothiazoles; Cell Line, Tumor; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Molecular Docking Simulation; Molecular Sequence Data; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridazines; Quinolines; Sorafenib | 2013 |
The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Survival; Chick Embryo; Everolimus; Female; Flow Cytometry; Humans; Immunohistochemistry; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Mice; Mice, Inbred NOD; Mice, SCID; Multiprotein Complexes; Neovascularization, Pathologic; Niacinamide; Osteosarcoma; Phenylurea Compounds; Reactive Oxygen Species; RNA Interference; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2013 |
Zinc sensitizes prostate cancer cells to sorafenib and regulates the expression of Livin.
Topics: Actins; Adaptor Proteins, Signal Transducing; Apoptosis; Cell Line, Tumor; Cell Survival; Cytoskeleton; Drug Synergism; Humans; Inhibitor of Apoptosis Proteins; Male; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Sorafenib; Zinc Sulfate | 2013 |
Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Combinations; Drug Synergism; E2F1 Transcription Factor; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Oxonic Acid; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Tegafur; Thymidylate Synthase | 2013 |
Estimation of renal cell carcinoma treatment effects from disease progression modeling.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease Progression; Kidney Neoplasms; Models, Statistical; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
[Evaluation of the management of metastatic renal cell carcinoma in the era of targeted therapies. retrospective clinical study over six years].
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2013 |
Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
Topics: Adenocarcinoma; Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Drug Interactions; Everolimus; Male; Mice; Mice, Inbred BALB C; Mice, SCID; Models, Biological; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sirolimus; Sorafenib; Tandem Mass Spectrometry; Tissue Distribution | 2013 |
Synergistic interactions between sorafenib and everolimus in pancreatic cancer xenografts in mice.
Topics: Animals; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Humans; Mice; Mice, SCID; Models, Biological; Molecular Targeted Therapy; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Liver tumors and loco-regional therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Evidence-Based Medicine; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Sorafenib | 2013 |
[Design, synthesis and antitumor activity of sorafenib analogues containing 2-picolinylhydrazide moiety].
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Niacinamide; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship | 2012 |
Sorafenib inhibits liver regeneration in rats.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Bilirubin; Body Weight; Cell Proliferation; Hepatectomy; Ki-67 Antigen; Liver; Liver Regeneration; Niacinamide; Organ Size; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Wistar; Sorafenib; Time Factors | 2013 |
Sorafenib induces endometrial carcinoma apoptosis by inhibiting Elk-1-dependent Mcl-1 transcription and inducing Akt/GSK3β-dependent protein degradation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Endometrial Neoplasms; ets-Domain Protein Elk-1; Female; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; MAP Kinase Signaling System; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proteolysis; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Transcription, Genetic | 2013 |
Optimal timing of combining sorafenib with locoregional treatments in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiotherapy, Adjuvant; Sorafenib; Yttrium Radioisotopes | 2013 |
Inhibition of extracellular signal-regulated kinase activity by sorafenib increases sensitivity to DNR in K562 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Butadienes; Cell Line, Tumor; Cell Proliferation; Daunorubicin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; K562 Cells; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Signal Transduction; Sorafenib; U937 Cells; Up-Regulation | 2013 |
α-Fetoprotein promoter-driven Cre/LoxP-switched RNA interference for hepatocellular carcinoma tissue-specific target therapy.
Topics: alpha-Fetoproteins; Animals; Autophagy-Related Protein 5; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Gene Order; Gene Silencing; Genetic Vectors; Homologous Recombination; Humans; Liver Neoplasms; Male; Mice; Microtubule-Associated Proteins; Niacinamide; Organ Specificity; Phenylurea Compounds; Promoter Regions, Genetic; RNA Interference; Sorafenib; Tumor Burden | 2013 |
MicroRNA-216a/217-induced epithelial-mesenchymal transition targets PTEN and SMAD7 to promote drug resistance and recurrence of liver cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; In Vitro Techniques; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Smad7 Protein; Sorafenib; Transforming Growth Factor beta; Up-Regulation | 2013 |
Sorafenib enhances radiation-induced apoptosis in hepatocellular carcinoma by inhibiting STAT3.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Chemoradiotherapy; Cyclin D1; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Radiation Tolerance; RNA Interference; Sorafenib; STAT3 Transcription Factor; Survivin | 2013 |
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Topics: Aminopyridines; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Everolimus; Humans; Imidazoles; Indoles; Kidney Neoplasms; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Morpholines; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Pyrimidines; Pyrroles; Quinolines; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2013 |
Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Sorafenib hepatobiliary disposition: mechanisms of hepatic uptake and disposition of generated metabolites.
Topics: Adult; Animals; Cells, Cultured; CHO Cells; Cricetinae; Cricetulus; Female; Hepatocytes; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2013 |
Second line treatment of metastatic renal cell carcinoma: The Institut Gustave Roussy experience with targeted therapies in 251 consecutive patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Cardiovascular Diseases; Disease Progression; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2013 |
Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II.
Topics: Animals; Antimetabolites, Antineoplastic; Apoptosis; Carcinoma, Pancreatic Ductal; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cytokines; Deoxycytidine; Drug Synergism; Female; Gemcitabine; Humans; Mice; Mice, SCID; Neoplasm Proteins; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Random Allocation; RNA-Binding Proteins; Sorafenib; Survival Analysis; Xenograft Model Antitumor Assays | 2013 |
Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Cohort Studies; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Cyclohexylamines; Deferoxamine; Extracellular Signal-Regulated MAP Kinases; Humans; Iron; Iron Regulatory Protein 2; Liver Neoplasms; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Oxidative Stress; Phenylenediamines; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; RNA Interference; Siderophores; Sorafenib | 2013 |
[Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
Topics: Angiogenesis Inhibitors; Astrocytes; Axitinib; Cell Survival; Cornea; Dose-Response Relationship, Drug; Endothelial Cells; Endothelium, Corneal; Humans; Imidazoles; Indazoles; Lens, Crystalline; Microscopy, Phase-Contrast; Niacinamide; Optic Disk; Organ Culture Techniques; Oxidative Stress; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Retinal Pigment Epithelium; Sorafenib; Sulfonamides; Trabecular Meshwork; Wet Macular Degeneration | 2013 |
Sorafenib combined with transarterial chemoembolization for the treatment of advanced hepatocellular carcinoma: a large-scale multicenter study of 222 patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; ROC Curve; Sorafenib; Treatment Outcome; Young Adult | 2013 |
Transarterial sorafenib chemoembolization: preliminary study of technical feasibility in a rabbit model.
Topics: Animals; Antineoplastic Agents; Chemoembolization, Therapeutic; Dose-Response Relationship, Drug; Ethiodized Oil; Liver; Male; Niacinamide; Phenylurea Compounds; Pilot Projects; Rabbits; Sorafenib; Tissue Distribution; Treatment Outcome | 2013 |
Model-based drug development in oncology: what's next?
Topics: Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Kidney Neoplasms; Models, Statistical; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
[Molecular targeted agent for hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2012 |
[¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer.
Topics: Animals; Carbon Radioisotopes; Cell Line, Tumor; Cell Transformation, Neoplastic; Male; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Radioactive Tracers; Radiochemistry; Rats; Sorafenib | 2013 |
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy; Carcinoma, Hepatocellular; Cell Line, Tumor; Cells, Cultured; Cholangiocarcinoma; Female; Humans; In Vitro Techniques; Liver Neoplasms; Molecular Sequence Data; Niacinamide; Oocytes; Organic Cation Transporter 1; Pharmacogenetics; Phenylurea Compounds; Polymorphism, Single Nucleotide; Sorafenib; Treatment Outcome; Xenopus laevis | 2013 |
Clinical activity of sorafenib in a previously treated advanced urothelial cancer patient.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Urothelium | 2013 |
Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Synergism; Humans; Leupeptins; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Oligopeptides; Phenylurea Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2014 |
Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation.
Topics: Carcinoma; Carcinoma, Papillary; Child; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Respiration, Artificial; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2014 |
Comparative efficacy of sunitinib versus sorafenib as first-line treatment for patients with metastatic renal cell carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Young Adult | 2012 |
Selection and management of hepatocellular carcinoma patients with sorafenib: recommendations and opinions from an Italian liver unit.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Dose-Response Relationship, Drug; Fibrosis; Hepatitis B; Hepatitis C; Humans; Hypertension; Italy; Liver Cirrhosis; Liver Neoplasms; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Sorafenib; Weight Loss | 2013 |
Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm.
Topics: Adult; Aged; Aged, 80 and over; Benzhydryl Compounds; Cell Proliferation; Cells, Cultured; Chronic Disease; Dasatinib; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Drug Synergism; Female; Humans; Janus Kinase 2; Janus Kinases; Male; Middle Aged; Myeloproliferative Disorders; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylcholine; Polycythemia Vera; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrrolidinones; Signal Transduction; Sorafenib; STAT5 Transcription Factor; Thiazoles; Thrombocythemia, Essential; Tumor Cells, Cultured | 2013 |
Field practice studies on sorafenib: lessons in systemic treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Disease-Free Survival; Female; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neuropilin-1; Niacinamide; Phenylurea Compounds; Receptor, ErbB-2; Retrospective Studies; Sorafenib | 2013 |
Metabolic response demonstrated by 18F-FDG-PET/CT in metastatic medullary thyroid carcinoma under sorafenib therapy.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Female; Fluorodeoxyglucose F18; Humans; Middle Aged; Multimodal Imaging; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Combining celecoxib with sorafenib synergistically inhibits hepatocellular carcinoma cells in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Proliferation; Dinoprostone; Drug Synergism; Fluorescent Antibody Technique; Humans; In Vitro Techniques; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazoles; Sorafenib; Sulfonamides; Tumor Cells, Cultured | 2013 |
Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragments.
Topics: Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Immunoblotting; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tumor Cells, Cultured | 2013 |
Education and imaging: Hepatobiliary and pancreatic: Volume-perfusion CT for monitoring therapy for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Monitoring; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2013 |
Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence.
Topics: Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Extracellular Signal-Regulated MAP Kinases; Female; Gene Dosage; Genes, myc; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-met; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Innovations in the treatment of melanoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cancer Vaccines; DNA, Antisense; Genetic Therapy; Humans; Immunologic Factors; Melanoma; Niacinamide; Phenylurea Compounds; Proteasome Inhibitors; Sorafenib | 2004 |
Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Neovascularization, Pathologic; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Pilot Projects; Prospective Studies; Regional Blood Flow; Sorafenib; Treatment Outcome | 2013 |
Antiproliferative effects of sorafenib and pegylated IFN‑α2b on human liver cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Microvessels; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Recombinant Proteins; Sorafenib | 2013 |
The evolving landscape of therapeutic drug development for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Therapy, Combination; Epigenesis, Genetic; ErbB Receptors; Fibroblast Growth Factors; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2013 |
New options for second-line therapy of advanced renal cancer.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2013 |
Sorafenib and entecavir: the dioscuri of treatment for advanced hepatocellular carcinoma?
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Female; Guanine; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Disease Progression; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Case of sorafenib-induced thyroid storm.
Topics: Adrenal Gland Neoplasms; Aged; Amiodarone; Anti-Arrhythmia Agents; Antineoplastic Agents; Atrial Fibrillation; Biomarkers; Bone Neoplasms; Carcinoma, Renal Cell; Drug Administration Schedule; Fatal Outcome; Heart Arrest; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Muscle Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Respiratory Aspiration; Sorafenib; Thyroid Crisis; Thyroid Hormones | 2013 |
Prolonged exposure to tyrosine kinase inhibitors or early use of everolimus in metastatic renal cell carcinoma: are the two options alike?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib | 2013 |
Targeted therapy for human hepatic carcinoma cells using folate-functionalized polymeric micelles loaded with superparamagnetic iron oxide and sorafenib in vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Drug Carriers; Drug Delivery Systems; Ferrocyanides; Folic Acid; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Magnetite Nanoparticles; Micelles; Microscopy, Electron, Transmission; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Sorafenib inhibits lymphoma xenografts by targeting MAPK/ERK and AKT pathways in tumor and vascular cells.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Count; Cell Line, Tumor; Cell Proliferation; Cell Survival; Endothelial Cells; Extracellular Signal-Regulated MAP Kinases; Humans; Lymphoma; MAP Kinase Signaling System; Mice; Mice, SCID; Necrosis; Neovascularization, Pathologic; Niacinamide; Pericytes; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Neoadjuvant targeted molecular therapies in patients undergoing nephrectomy and inferior vena cava thrombectomy: is it useful?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Comorbidity; Dose-Response Relationship, Drug; Female; France; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Thrombectomy; Thrombosis; Treatment Outcome; Vena Cava, Inferior | 2014 |
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Axitinib; Cell Line, Tumor; Disease Models, Animal; Humans; Hypoxia; Imidazoles; Indazoles; Male; Neoplastic Stem Cells; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Efficacy of using cancer stem cell markers in isolating and characterizing liver cancer stem cells.
Topics: AC133 Antigen; alpha-Fetoproteins; Antigens, CD; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial Cell Adhesion Molecule; Gene Expression Profiling; Glycoproteins; Humans; Hyaluronan Receptors; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Peptides; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Thy-1 Antigens | 2013 |
Is India ready to lead the battle for fair access to medicines?
Topics: Antineoplastic Agents; Benzamides; Drug and Narcotic Control; Drug Costs; Drug Industry; Drugs, Generic; Government Regulation; Health Policy; Health Services Accessibility; Humans; Imatinib Mesylate; India; Niacinamide; Patents as Topic; Phenylurea Compounds; Piperazines; Pyrimidines; Sorafenib | 2013 |
Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Diphosphonates; Everolimus; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Imidazoles; Indazoles; Indoles; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography, Panoramic; Retrospective Studies; Sirolimus; Sorafenib; Spinal Cord Compression; Sulfonamides; Sunitinib; Survival Rate; Zoledronic Acid | 2013 |
[Drug now immediately available in Germany].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug Approval; Germany; Humans; Kidney Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2006 |
Preclinical evaluation of sorafenib-eluting stent for suppression of human cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Evaluation, Preclinical; Drug-Eluting Stents; Human Umbilical Vein Endothelial Cells; Humans; Male; Matrix Metalloproteinase 2; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Polyesters; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Simultaneous inhibition of aberrant cancer kinome using rationally designed polymer-protein core-shell nanomedicine.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Everolimus; Humans; Leukemia, Myeloid, Acute; Mitogen-Activated Protein Kinases; Models, Molecular; Nanomedicine; Niacinamide; Phenylurea Compounds; Polyglactin 910; Protein Kinase Inhibitors; Sialic Acid Binding Ig-like Lectin 3; Sirolimus; Sorafenib; STAT5 Transcription Factor; TOR Serine-Threonine Kinases | 2013 |
Pharmacokinetic interaction between sorafenib and prednisolone in a patient with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biotransformation; Carcinoma, Hepatocellular; Drug Eruptions; Drug Interactions; Drug Monitoring; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prednisolone; Sorafenib; Stomatitis; Treatment Outcome | 2013 |
Sorafenib and HDAC inhibitors synergize with TRAIL to kill tumor cells.
Topics: Animals; bcl-2-Associated X Protein; bcl-Associated Death Protein; Carcinoma, Hepatocellular; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 9; Cell Line, Tumor; Drug Synergism; fas Receptor; Female; Hep G2 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; TNF-Related Apoptosis-Inducing Ligand; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2013 |
Multiple squamous cell carcinomas following treatment with sorafenib for renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Humans; Kidney Neoplasms; Male; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Skin Neoplasms; Sorafenib | 2013 |
Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Atrophy; Carcinoma; Carcinoma, Papillary; Female; Humans; Kidney; Middle Aged; Niacinamide; Phenylurea Compounds; Renal Artery Obstruction; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2013 |
Radiosensitivity enhancement of human hepatocellular carcinoma cell line SMMC-7721 by sorafenib through the MEK/ERK signal pathway.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; DNA Repair; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents; Sorafenib | 2013 |
Prognostic factors of survival for patients with metastatic renal cell carcinoma with brain metastases treated with targeted therapy: results from the international metastatic renal cell carcinoma database consortium.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Databases, Factual; Humans; Indoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sorafenib; Sunitinib; Survival; Treatment Outcome | 2013 |
Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Graft Survival; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2013 |
Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiography; Sorafenib; Treatment Outcome | 2014 |
[Suppression of the growth of subcutaneous transplanted human liver cancer and lung metastasis in nude mice treated by sorafenib combined with fluorouracil].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; DNA Topoisomerases, Type II; Drug Synergism; Drug Therapy, Combination; Extracellular Signal-Regulated MAP Kinases; Fluorouracil; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Burden | 2013 |
Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma.
Topics: Aged; Antineoplastic Agents; Arginine; Back; Cell Survival; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Imidazoles; Indoles; Leucine; Lung Neoplasms; MAP Kinase Signaling System; Melanoma; Niacinamide; Oximes; Phenylurea Compounds; Point Mutation; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib | 2013 |
Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Blood Transfusion; Carcinoma, Hepatocellular; Case-Control Studies; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Postoperative Complications; Prognosis; Sorafenib; Survival Rate; Young Adult | 2013 |
Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dendritic Cells; Diphosphonates; Heterografts; Humans; Imidazoles; Immunosuppression Therapy; Indoles; Interleukin-12 Subunit p40; Killer Cells, Natural; Liver Neoplasms; Lung Neoplasms; Macrophages; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasm Transplantation; Neoplastic Cells, Circulating; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sunitinib; Zoledronic Acid | 2013 |
Overexpression of p16(INK4a) in urothelial carcinoma in situ is a marker for MAPK-mediated epithelial-mesenchymal transition but is not related to human papillomavirus infection.
Topics: Aged; Carcinoma in Situ; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Epithelial-Mesenchymal Transition; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Niacinamide; Papillomaviridae; Papillomavirus Infections; Phenylurea Compounds; Sorafenib; Transfection; Urokinase-Type Plasminogen Activator; Urothelium; Uterine Cervical Dysplasia; Uterine Cervical Neoplasms | 2013 |
Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Recombinant Proteins; Signal Transduction; Sorafenib; Sphingolipids; Sphingomyelin Phosphodiesterase; Subcutaneous Tissue; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.
Topics: Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epoxide Hydrolases; Human Umbilical Vein Endothelial Cells; Humans; Molecular Structure; Niacinamide; Phenylurea Compounds; Pyridines; Solubility; Sorafenib; Structure-Activity Relationship | 2013 |
Sorafenib prolongs liver regeneration after hepatic resection in rats.
Topics: Animals; Cell Proliferation; Hepatectomy; Hepatocytes; Liver; Liver Regeneration; Male; Models, Animal; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Inbred F344; Signal Transduction; Sorafenib; Time Factors; Transaminases | 2013 |
Sorafenib enhances proteasome inhibitor-mediated cytotoxicity via inhibition of unfolded protein response and keratin phosphorylation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Drug Synergism; Endoplasmic Reticulum Stress; Humans; Keratins; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteasome Inhibitors; Sorafenib; Ubiquitination; Unfolded Protein Response | 2013 |
Anti-proliferative actions of N'-desmethylsorafenib in human breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; Humans; MAP Kinase Signaling System; MCF-7 Cells; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Sorafenib inhibits epithelial-mesenchymal transition through an epigenetic-based mechanism in human lung epithelial cells.
Topics: Acetylation; Alveolar Epithelial Cells; Cell Line; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gene Expression Regulation; Histone Acetyltransferases; Histone Deacetylases; Histones; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Transforming Growth Factor beta1 | 2013 |
Aspirin minimized the pro-metastasis effect of sorafenib and improved survival by up-regulating HTATIP2 in hepatocellular carcinoma.
Topics: Acetyltransferases; Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Disease Models, Animal; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Transcription Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of advanced hepatocellular carcinoma with different types of portal vein tumor thrombosis].
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Hepatic Artery; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Thrombosis | 2013 |
Hepatocellular carcinoma: perspective of an oncologist.
Topics: Antineoplastic Agents; Attitude of Health Personnel; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Medical Oncology; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Sorafenib sensitizes hepatocellular carcinoma cell to cisplatin via suppression of Wnt/β-catenin signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2013 |
Concurrent versus sequential sorafenib therapy in combination with radiation for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Clinical Trials as Topic; Combined Modality Therapy; DNA Breaks, Double-Stranded; Gamma Rays; Gene Expression; Hindlimb; Histones; Humans; Liver Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Sorafenib ameliorates bleomycin-induced pulmonary fibrosis: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation.
Topics: Alveolar Epithelial Cells; Animals; Apoptosis; Bleomycin; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Extracellular Matrix; Female; Fibroblasts; HEK293 Cells; Humans; Idiopathic Pulmonary Fibrosis; Male; Mice; Mice, Inbred C57BL; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Signal Transduction; Smad Proteins; Sorafenib; Transforming Growth Factor beta1 | 2013 |
PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; Humans; Liver Neoplasms; MAP Kinase Signaling System; Morpholines; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); raf Kinases; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Triazines | 2013 |
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Topics: Adenocarcinoma, Follicular; Adult; Boronic Acids; Bortezomib; Female; Humans; Kidney Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazines; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2013 |
Long-term treatment of hepatocellular carcinoma with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors | 2013 |
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Celecoxib; Cell Line, Tumor; Cell Proliferation; DNA Primers; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Liver Neoplasms; Microarray Analysis; Niacinamide; Phenylurea Compounds; Pyrazoles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; Sulfonamides | 2013 |
A wife asks for futile therapy for her husband, a "fighter": how to respond?
Topics: Carcinoma, Renal Cell; Ethics, Medical; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Actionable gene expression-based patient stratification for molecular targeted therapy in hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cluster Analysis; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA, Messenger; Sorafenib; Transcriptome | 2013 |
Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design.
Topics: Aged; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Radiography; Randomized Controlled Trials as Topic; Sorafenib; Survival Analysis; Treatment Outcome | 2013 |
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Synergism; Female; Heterografts; Humans; Mice; Mice, SCID; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Ruthenium; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Off-label use of cetuximab plus sorafenib and panitumumab plus regorafenib to personalize therapy for a patient with V600E BRAF-mutant metastatic colon cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Female; Humans; Middle Aged; Mutation; Neoplasm Metastasis; Niacinamide; Off-Label Use; Panitumumab; Phenylurea Compounds; Precision Medicine; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib | 2013 |
Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2014 |
Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Diethylnitrosamine; Disease Models, Animal; Granulocyte-Macrophage Colony-Stimulating Factor; Heterografts; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Myeloid Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-myc; Sorafenib | 2013 |
Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Time Factors; Young Adult | 2013 |
Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies.
Topics: Aged; Antineoplastic Agents; Body Composition; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Muscle, Skeletal; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Small-intestinal hemorrhage caused by treatment with sorafenib for hepatocellular carcinoma and diagnosed by capsule endoscopy.
Topics: Aged, 80 and over; Antineoplastic Agents; Capsule Endoscopy; Carcinoma, Hepatocellular; Female; Gastrointestinal Hemorrhage; Humans; Intestine, Small; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Cyclin G1 expands liver tumor-initiating cells by Sox2 induction via Akt/mTOR signaling.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Cyclin G1; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Liver Neoplasms; Male; Mice; Mice, SCID; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Transplantation; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; SOXB1 Transcription Factors; TOR Serine-Threonine Kinases | 2013 |
Pharmacologic inhibition of MEK signaling prevents growth of canine hemangiosarcoma.
Topics: Animals; Antineoplastic Agents; Benzamides; Cell Proliferation; Diphenylamine; Disease Models, Animal; Dogs; Drug Screening Assays, Antitumor; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
First experience of active surveillance before systemic target therapy in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Asymptomatic Diseases; Blood Cell Count; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Function Tests; Kidney Neoplasms; Liver Function Tests; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Nephrectomy; Niacinamide; Patient Preference; Phenylurea Compounds; Population Surveillance; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Time Factors | 2013 |
Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzylisoquinolines; Carcinoma, Hepatocellular; Drug Synergism; HCT116 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Reactive Oxygen Species; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |
Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Evaluation; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Failure; Treatment Outcome | 2013 |
Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Endpoint Determination; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prospective Studies; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Ultrasonography | 2013 |
Novel quinolinylaminoisoquinoline bioisosteres of sorafenib as selective RAF1 kinase inhibitors: design, synthesis, and antiproliferative activity against melanoma cell line.
Topics: Cell Line, Tumor; Cell Proliferation; Drug Design; Humans; Isoquinolines; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Sorafenib; Structure-Activity Relationship | 2013 |
Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment.
Topics: Angiogenesis Inhibitors; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Communication; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cholangiocarcinoma; Enzyme Activation; Humans; Indoles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Signal Transduction; Sorafenib; Sunitinib | 2013 |
Ventricular thrombosis during sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Heart Diseases; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Thrombosis; Treatment Outcome; Ultrasonography; Ventricular Dysfunction | 2013 |
Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Flow Cytometry; Liver Neoplasms, Experimental; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Cells, Cultured; Tumor Microenvironment | 2014 |
Potentiating the efficacy of molecular targeted therapy for hepatocellular carcinoma by inhibiting the insulin-like growth factor pathway.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cells, Cultured; Checkpoint Kinase 2; Drug Resistance, Neoplasm; Drug Synergism; Humans; Indoles; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Radiofrequency ablation suppresses distant tumour growth in a novel rat model of multifocal hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; Hepatocyte Growth Factor; Interleukin-10; Liver Neoplasms, Experimental; Macrophages; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; T-Lymphocytes; Transforming Growth Factor beta; Vascular Endothelial Growth Factors | 2014 |
[A case of metastatic renal cell carcinoma with no evidence of disease for a long term after a favorable response to molecular-targeted therapy followed by metastasectomy].
Topics: Adrenalectomy; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Angiogenic and signalling proteins correlate with sensitivity to sequential treatment in renal cell cancer.
Topics: Angiogenesis Inhibitors; Angiogenic Proteins; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Growth Processes; Everolimus; Humans; Indoles; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Random Allocation; Signal Transduction; Sirolimus; Sorafenib; Sunitinib; Xenograft Model Antitumor Assays | 2013 |
Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
Topics: Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain; Dasatinib; DNA, Complementary; Female; Gene Dosage; Half-Life; Indoles; Male; Maternal-Fetal Exchange; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Pregnancy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Real-Time Polymerase Chain Reaction; RNA; Sex Characteristics; Sorafenib; Sunitinib; Thiazoles | 2013 |
Severe hypoglycemia due to possible interaction between glibenclamide and sorafenib in a patient with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Blood Glucose; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Drug Interactions; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Severity of Illness Index; Sorafenib | 2013 |
Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphorylation; Prognosis; PTEN Phosphohydrolase; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2; Young Adult | 2013 |
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.
Topics: Animals; Apoptosis; Benzazepines; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Male; Mice; Mice, Nude; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Sorafenib makes headway on metastatic thyroid cancer.
Topics: Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2013 |
[Analysis of factors affecting the duration of treatment with sorafenib in patients with hepatocellular carcinoma].
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Precursors; Prothrombin; Sorafenib; Time Factors | 2013 |
Curcumin potentiates the ability of sunitinib to eliminate the VHL-lacking renal cancer cells 786-O: rapid inhibition of Rb phosphorylation as a preamble to cyclin D1 inhibition.
Topics: Antineoplastic Agents; CDC2 Protein Kinase; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Survival; Curcumin; Cyclin D1; Cyclin-Dependent Kinase 4; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Indoles; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Retinoblastoma Protein; Signal Transduction; Sorafenib; Sunitinib | 2013 |
In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; British Columbia; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Insurance Coverage; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
MicroRNA-34a targets Bcl-2 and sensitizes human hepatocellular carcinoma cells to sorafenib treatment.
Topics: Adult; Aged; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Sorafenib | 2014 |
[Complete response after sorafenib therapy plus zoledronic acid for advanced hepatocellular carcinoma with bone metastasis - a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Hepatocellular; Diphosphonates; Humans; Imidazoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib; Zoledronic Acid | 2013 |
Sorafenib alone versus sorafenib combined with transarterial chemoembolization for advanced-stage hepatocellular carcinoma: results of propensity score analyses.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells.
Topics: Animals; Cell Communication; Cell Death; Cell Line, Tumor; Drug Synergism; Female; Gonanes; Hep G2 Cells; Humans; Mice; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; Pyridines; Sorafenib; Thymoma; Thymus Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Histone deacetylase 3 participates in self-renewal of liver cancer stem cells through histone modification.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Gene Expression; Gene Knockdown Techniques; Histone Deacetylase Inhibitors; Histone Deacetylases; Histones; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2013 |
Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Health Care Rationing; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; United Kingdom; Young Adult | 2013 |
Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Rate | 2013 |
[The analysis of the efficacy and safety of combined transarterial chemoembolization with sorafenib in patients with large hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
Synthesis and in vitro antitumor activities of novel benzyl urea analogues of sorafenib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; HT29 Cells; Humans; Inhibitory Concentration 50; Molecular Structure; Niacinamide; Phenylurea Compounds; Solubility; Sorafenib; Structure-Activity Relationship; Urea | 2013 |
Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.
Topics: Adolescent; Adult; Child, Preschool; Enzyme Activation; Female; Gene Rearrangement; Humans; Indoles; Male; MAP Kinase Signaling System; Melanocytes; Melanoma; Middle Aged; Molecular Targeted Therapy; Nevus, Epithelioid and Spindle Cell; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Skin Neoplasms; Sorafenib; Sulfonamides; Vemurafenib; Young Adult | 2013 |
Carotid and brachiocephalic arteries stenosis with long term use of sorafenib.
Topics: Angiography; Aorta, Thoracic; Brachiocephalic Trunk; Carotid Arteries; Constriction, Pathologic; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Thigh; Time Factors; Tomography, X-Ray Computed | 2014 |
Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Flow Cytometry; Fluorouracil; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib | 2013 |
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
Topics: Axitinib; Blood Pressure; Clinical Trials as Topic; Combined Modality Therapy; Erythrocyte Count; Erythropoiesis; Erythropoietin; Fluorouracil; Humans; Imidazoles; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
Complete regression following sorafenib in unresectable, locally advanced hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Discovery of novel Src homology region 2 domain-containing phosphatase 1 agonists from sorafenib for the treatment of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Catalytic Domain; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Models, Molecular; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Random Allocation; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |
Flavopiridol synergizes with sorafenib to induce cytotoxicity and potentiate antitumorigenic activity in EGFR/HER-2 and mutant RAS/RAF breast cancer model systems.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinases; Drug Synergism; ErbB Receptors; Female; Flavonoids; Humans; Lung Neoplasms; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Knockout; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; raf Kinases; ras Proteins; Receptor, ErbB-2; Sorafenib; Treatment Outcome; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib.
Topics: Aged; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Portal Vein; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2013 |
Feasibility of sorafenib combined with local radiotherapy in advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Feasibility Studies; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Radiation Dosage; Radiotherapy; Sorafenib | 2013 |
Increased bowel toxicity in patients treated with a vascular endothelial growth factor inhibitor (VEGFI) after stereotactic body radiation therapy (SBRT).
Topics: Abdominal Neoplasms; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antibodies, Monoclonal, Humanized; Bevacizumab; Duodenal Diseases; Humans; Indazoles; Indoles; Intestinal Diseases; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Radiography; Radiosurgery; Radiotherapy Dosage; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Stomach Ulcer; Sulfonamides; Sunitinib; Ulcer | 2013 |
Reciprocal regulation by TLR4 and TGF-β in tumor-initiating stem-like cells.
Topics: AC133 Antigen; Adaptor Proteins, Signal Transducing; Animals; Antigens, CD; Antineoplastic Agents; Base Sequence; Carcinoma, Hepatocellular; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycoproteins; Homeodomain Proteins; Humans; Inhibitory Concentration 50; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Mice, Transgenic; Nanog Homeobox Protein; Neoplastic Stem Cells; Niacinamide; Oncogenes; Peptides; Phenylurea Compounds; Phosphoproteins; RNA-Binding Proteins; RNA, Small Interfering; Signal Transduction; Sirolimus; Smad Proteins; Sorafenib; Spheroids, Cellular; Toll-Like Receptor 4; Transcription Factors; Transcriptional Activation; Transforming Growth Factor beta; Tumor Burden; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2013 |
Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: some enthusiasm with a word of caution.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography | 2013 |
Liver transplantation treating the patient with hepatic failure associated with sorafenib treatment: report of a case.
Topics: Antineoplastic Agents; Humans; Liver Failure; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Female; Gene Expression; Humans; Immunohistochemistry; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-raf; Sorafenib; STAT3 Transcription Factor | 2013 |
Development and validation of a high-performance liquid chromatography ultraviolet method for lapatinib quantification in human plasma.
Topics: Acetonitriles; Administration, Oral; Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Lapatinib; Limit of Detection; Niacinamide; Phenylurea Compounds; Quinazolines; Sorafenib; Spectrophotometry, Ultraviolet | 2013 |
STAT3-mediated attenuation of CCl4-induced mouse liver fibrosis by the protein kinase inhibitor sorafenib.
Topics: Actins; Active Transport, Cell Nucleus; Animals; Carbon Tetrachloride; Cell Nucleus; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Gene Expression; Hepatocytes; Immunoblotting; Immunohistochemistry; Interleukin-6; Kinetics; Kupffer Cells; Liver; Liver Cirrhosis; Mice; Mice, Inbred C57BL; Mice, Knockout; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; STAT3 Transcription Factor; Tissue Inhibitor of Metalloproteinase-1 | 2013 |
Sorafenib sensitizes head and neck squamous cell carcinoma cells to ionizing radiation.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; DNA Repair; Head and Neck Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Radiation-Sensitizing Agents; raf Kinases; Sorafenib; Squamous Cell Carcinoma of Head and Neck | 2013 |
Hand-foot skin reaction is associated with the clinical outcome in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers, Tumor; C-Reactive Protein; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Hemoglobins; Humans; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Retrospective Studies; Risk Assessment; Sorafenib; Treatment Outcome | 2013 |
Synthesis of polymer-lipid nanoparticles for image-guided delivery of dual modality therapy.
Topics: Angiogenesis Inhibitors; Animals; Antibiotics, Antineoplastic; Doxorubicin; Drug Delivery Systems; Female; Human Umbilical Vein Endothelial Cells; Humans; Lactic Acid; Mice; Mice, Nude; Nanoparticles; Neoplasms; Niacinamide; Optical Imaging; Phenylurea Compounds; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Sorafenib | 2013 |
Sorafenib overcomes irinotecan resistance in colorectal cancer by inhibiting the ABCG2 drug-efflux pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Irinotecan; Mice; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); ras Proteins; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Anilides; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; Down-Regulation; Energy Metabolism; Female; Glucose; Glucose Transporter Type 1; Glycolysis; Humans; Inhibitory Concentration 50; Mechanistic Target of Rapamycin Complex 1; Mitochondria; Multiprotein Complexes; Neoplasm Proteins; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2013 |
Stevens-Johnson syndrome induced by sorafenib for metastatic renal cell carcinoma.
Topics: Aged; Betamethasone; Carcinoma, Renal Cell; Fatal Outcome; Humans; Kidney Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prednisolone; Sirolimus; Skin; Sorafenib; Stevens-Johnson Syndrome | 2013 |
Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.
Topics: Adolescent; Alleles; Animals; Antineoplastic Agents; Cell Line, Tumor; Child; Drug Resistance, Neoplasm; Female; fms-Like Tyrosine Kinase 3; Humans; Indoles; Leukemia, Myeloid, Acute; Male; Mice; Models, Molecular; Molecular Conformation; Mutation; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
[Treatment of hemodialyzed patient by targeted therapy in metastatic renal cell carcinoma: a case report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Renal Dialysis; Sirolimus; Sorafenib | 2013 |
[Complete remission by sorafenib for local reccurence of renal cell carcinoma with a tempraly elevation of C-reactive protein: a case report].
Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib | 2013 |
[Sorafenib monotherapy for FLT3-ITD positive acute myeloid leukemia: a case report].
Topics: fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Brivanib and FOLFOX in hepatocellular carcinoma: finding the common themes among negative trials.
Topics: Alanine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Niacinamide; Palliative Care; Phenylurea Compounds; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Triazines | 2013 |
Discovery of potent, orally active compounds of tyrosine kinase and serine/threonine-protein kinase inhibitor with anti-tumor activity in preclinical assays.
Topics: Antineoplastic Agents; Biological Products; Liver Neoplasms; Medicine, Traditional; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Sorafenib | 2012 |
Alteration in the balance of prosurvival and proapoptotic signalling pathways leads to sequence-dependent synergism between docetaxel and sorafenib in human non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Interphase; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Taxoids | 2014 |
[A case of metastatic renal cell carcinoma associated with Birt-Hogg-Dubé syndrome treated with molecular-targeting agents].
Topics: Animals; Antineoplastic Agents; Birt-Hogg-Dube Syndrome; Carcinoma, Renal Cell; Everolimus; Humans; In Vitro Techniques; Indoles; Kidney Neoplasms; Male; Mice, Knockout; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2013 |
[Extracorporeal partial nephrectomy and auto-transplantation after presurgical targeted therapy with tyrosine kinase inhibitors for renal cell cancer].
Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Molecular Targeted Therapy; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Transplantation, Autologous; Treatment Outcome | 2013 |
Improving immunotherapy of hepatocellular carcinoma (HCC) using dendritic cells (DC) engineered to express IL-12 in vivo.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytokines; Cytotoxicity, Immunologic; Dendritic Cells; Humans; Immunotherapy; Interleukin-12; Liver Neoplasms; Mice; Mice, Inbred C3H; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
Topics: Alanine; Animals; Ascites; Cytokines; DNA Primers; Fatty Liver; Fibroblast Growth Factors; Microcirculation; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Platelet-Derived Growth Factor; Positron-Emission Tomography; Rats; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Splanchnic Circulation; Triazines; Vascular Endothelial Growth Factor A | 2014 |
Slow and steady wins the race: practical (and philosophical) considerations of treatment activity evaluation when novel anticancer agents just slow neoplastic progression.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Sirolimus; Sorafenib | 2014 |
Predictors of non-adherence to systemic oral therapy for advanced hepatocellular carcinoma.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Databases, Factual; Female; Humans; Insurance Claim Review; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sex Factors; Sorafenib | 2013 |
Sorafenib induced eruptive melanocytic lesions.
Topics: Antineoplastic Agents; Brachytherapy; Carcinoma, Renal Cell; Drug Eruptions; Fatal Outcome; Humans; Kidney Neoplasms; Lentigo; Lung Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2013 |
Preserving the sanctity of overall survival for drugs approved on the basis of progression-free survival: tivozanib as a case study.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Quinolines; Sorafenib | 2013 |
In vitro demonstration of synergy/additivity between (188)rhenium and sorafenib on hepatoma lines: preliminary results.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Combined Modality Therapy; Humans; In Vitro Techniques; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Radioisotopes; Rhenium; Sorafenib | 2013 |
Complete radiographic remission with 5-fluorouracil and leucovorin after sorafenib failure in hepatocellular carcinoma: is there a role for chemotherapy after targeted agents?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Vitamin B Complex | 2013 |
Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Hepatocellular; Cisplatin; Deoxycytidine; Disease Progression; Disease-Free Survival; Doxorubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Signal Transduction; Sorafenib; Time Factors; Treatment Outcome | 2014 |
Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Angiopoietin-2; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Cytokines; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2013 |
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Sorafenib; Tandem Repeat Sequences; Xenograft Model Antitumor Assays | 2013 |
Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2013 |
Transarterial embolization with sorafenib in animal livers: a pharmacokinetics study.
Topics: Alanine Transaminase; Angiogenesis Inhibitors; Animals; Bilirubin; Chemoembolization, Therapeutic; Chromatography, High Pressure Liquid; Ethiodized Oil; Feasibility Studies; gamma-Glutamyltransferase; Hepatic Artery; Liver; Male; Models, Animal; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Tandem Mass Spectrometry | 2013 |
Expression patterns of RelA and c-mip are associated with different glomerular diseases following anti-VEGF therapy.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Angiogenesis Inhibitors; Animals; Base Sequence; Binding Sites; Biomarkers; Carrier Proteins; Case-Control Studies; Cell Line; Female; Gene Expression Regulation; Glomerulosclerosis, Focal Segmental; Humans; Hypertension; Kidney Diseases; Kidney Glomerulus; Male; Mice; Mice, Knockout; Middle Aged; Molecular Sequence Data; Nephrosis, Lipoid; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proteinuria; Renal Insufficiency; Sorafenib; Thrombotic Microangiopathies; Transcription Factor RelA; Transcription, Genetic; Transfection; Vascular Endothelial Growth Factors; Young Adult | 2014 |
Sorafenib and sunitinib for elderly patients with renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asthenia; Carcinoma, Renal Cell; Disease-Free Survival; Drug Eruptions; Female; Humans; Indoles; Kidney Neoplasms; Male; Neutropenia; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2013 |
Cytotoxic properties of sunitinib and sorafenib on human corneal epithelial cells.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers; Cell Line; Cell Survival; Enzyme-Linked Immunosorbent Assay; Epithelium, Corneal; Humans; Immunohistochemistry; Indoles; Membrane Proteins; Microscopy, Fluorescence; Microscopy, Phase-Contrast; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Sunitinib; Tetrazolium Salts; Thiazoles | 2014 |
Major response with sorafenib in advanced renal cell carcinoma after 14 years of follow-up.
Topics: Adult; Brain Neoplasms; Carcinoma, Renal Cell; Disease Progression; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Lung Neoplasms; Mediastinal Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2013 |
Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Receptors, Vascular Endothelial Growth Factor; Skin; Sorafenib | 2013 |
Sorafenib sensitizes solid tumors to Apo2L/TRAIL and Apo2L/TRAIL receptor agonist antibodies by the Jak2-Stat3-Mcl1 axis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Blotting, Western; Cell Line, Tumor; Drug Synergism; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Janus Kinase 2; Neoplasms; Niacinamide; Phenylurea Compounds; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; Sorafenib; STAT3 Transcription Factor; TNF-Related Apoptosis-Inducing Ligand | 2013 |
Therapeutic potential of the translation inhibitor silvestrol in hepatocellular cancer.
Topics: Analysis of Variance; Animals; Apoptosis; Blotting, Western; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Eukaryotic Initiation Factor-4A; Humans; Inhibitory Concentration 50; Liver Neoplasms; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Niacinamide; Peptide Chain Initiation, Translational; Phenylurea Compounds; Sirolimus; Sorafenib; Survival Analysis; Triterpenes; Xenograft Model Antitumor Assays | 2013 |
Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Female; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Complications; Retrospective Studies; Sirolimus; Sorafenib; Survival Rate; Treatment Outcome | 2013 |
Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
Pancreatic atrophy--a new late toxic effect of sorafenib.
Topics: Atrophy; Diarrhea; Humans; Niacinamide; Pancreas; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib | 2013 |
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Down-Regulation; Drug Synergism; Female; Gene Knockdown Techniques; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Receptor, Notch3; Receptors, Notch; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2013 |
Synthesis and biological evaluation of novel 4-(2-fluorophenoxy)-2-(1H-tetrazol-1-yl)pyridines bearing semicarbazone moieties as potent antitumor agents.
Topics: Antineoplastic Agents; Apoptosis; Cell Survival; Dose-Response Relationship, Drug; HT29 Cells; Humans; Hydrazones; Inhibitory Concentration 50; Molecular Structure; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; Semicarbazones; Sorafenib; Structure-Activity Relationship | 2013 |
Synergistic effect of EMS1-shRNA and sorafenib on proliferation, migration, invasion and endocytosis of SMMC-7721.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Cortactin; Endocytosis; Female; Gene Knockdown Techniques; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Early prediction of treatment response to sorafenib with elastosonography in a mice xenograft model of hepatocellular carcinoma: a proof-of-concept study.
Topics: Animals; Antineoplastic Agents; Disease Models, Animal; Elasticity Imaging Techniques; Female; Heterografts; Liver; Liver Neoplasms, Experimental; Mice; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tumor Burden | 2013 |
Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Exanthema; Female; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2014 |
Sorafenib tosylate as a radiosensitizer in malignant astrocytoma.
Topics: Astrocytoma; Blotting, Western; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Niacinamide; Phenylurea Compounds; Radiation-Sensitizing Agents; Sorafenib | 2014 |
Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Clofarabine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Young Adult | 2014 |
Efficacy of sorafenib monotherapy versus sorafenib-based loco-regional treatments in advanced hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2013 |
Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Humans; MAP Kinase Kinase 4; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinases; raf Kinases; Skin Neoplasms; Sorafenib | 2014 |
Serum response factor induces epithelial to mesenchymal transition with resistance to sorafenib in hepatocellular carcinoma.
Topics: Aged; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Serum Response Factor; Sorafenib; Vimentin | 2014 |
The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2013 |
Template-based de novo design for type II kinase inhibitors and its extented application to acetylcholinesterase inhibitors.
Topics: Cholinesterase Inhibitors; Drug Design; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Structure-Activity Relationship | 2013 |
A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 8; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Gene Expression; Humans; Interferon-gamma; Liver Neoplasms; Male; NF-kappa B; Niacinamide; Phenylurea Compounds; Rats; RNA, Double-Stranded; Sorafenib; Toll-Like Receptor 3; Transcriptional Activation; Tumor Burden | 2013 |
Combination of sorafenib and angiotensin-II receptor blocker attenuates preneoplastic lesion development in a non-diabetic rat model of steatohepatitis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticarcinogenic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Losartan; Male; Neovascularization, Pathologic; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Precancerous Conditions; Rats, Inbred F344; Sorafenib | 2014 |
The role of receptor tyrosine kinase activation in cholangiocytes and pulmonary vascular endothelium in experimental hepatopulmonary syndrome.
Topics: Animals; Common Bile Duct; Disease Models, Animal; Endothelin-1; Endothelium, Vascular; Hepatopulmonary Syndrome; Ligation; Lung; Male; Neovascularization, Pathologic; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
Combination of targeted PDT and anti-VEGF therapy for rat CNV by RGD-modified liposomal photocyanine and sorafenib.
Topics: Animals; Choroidal Neovascularization; Disease Models, Animal; Fluorescein Angiography; Fundus Oculi; Humans; Liposomes; Male; Niacinamide; Oligopeptides; Phenylurea Compounds; Photochemotherapy; Photosensitizing Agents; Rats; Rats, Inbred BN; Receptors, Immunologic; Sorafenib; Vascular Endothelial Growth Factor A | 2013 |
Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma.
Topics: Allografts; Allosteric Regulation; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diphenylamine; Drug Synergism; Female; Heterografts; Humans; Liver Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; Sulfonamides | 2013 |
Letter: Sorafenib hepatotoxicity may be enhanced during treatment of advanced hepatocellular carcinoma in HIV-infected patients.
Topics: Adult; Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Drug Interactions; HIV Infections; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2013 |
Axitinib in advanced renal-cell carcinoma.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Copper-free azide-alkyne cycloaddition of targeting peptides to porous silicon nanoparticles for intracellular drug uptake.
Topics: Alkynes; Antineoplastic Agents; Azides; Cell Line, Tumor; Cell Proliferation; Click Chemistry; Cycloaddition Reaction; Drug Carriers; Humans; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Porosity; Silicon; Sorafenib | 2014 |
Screening of kinase inhibitors targeting BRAF for regulating autophagy based on kinase pathways.
Topics: Autophagy; Cell Line; Cluster Analysis; Databases, Factual; Humans; Niacinamide; Phenylurea Compounds; Protein Interaction Maps; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib | 2014 |
Stimulatory effects of sorafenib on human non‑small cell lung cancer cells in vitro by regulating MAPK/ERK activation.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cyclin D1; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Niacinamide; Nitriles; Phenylurea Compounds; Phosphorylation; Signal Transduction; Sorafenib | 2014 |
Overman rearrangement and Pomeranz-Fritsch reaction for the synthesis of benzoazepinoisoquinolones to discover novel antitumor agents.
Topics: Antineoplastic Agents; Benzazepines; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; HCT116 Cells; Hep G2 Cells; Humans; Indoles; K562 Cells; Melanoma; Molecular Structure; Niacinamide; Phenylurea Compounds; Quinolones; Sorafenib; Structure-Activity Relationship; Sulfonamides; Vemurafenib | 2013 |
The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Gene Deletion; Genotype; Germ-Line Mutation; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Predictive Value of Tests; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Sorafenib; Treatment Outcome | 2013 |
Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cytokines; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2014 |
A retrospective analysis of two different sequences of therapy lines for advanced kidney cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Everolimus; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases | 2013 |
Inhibitory role of the small leucine-rich proteoglycan biglycan in bladder cancer.
Topics: Animals; Biglycan; Gene Expression Regulation, Neoplastic; Humans; Indoles; Leucine; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyrroles; RNA, Messenger; Sorafenib; Sunitinib; Urinary Bladder Neoplasms | 2013 |
Learning from practice: compulsory licensing cases and access to medicines.
Topics: Antineoplastic Agents; Brazil; Canada; Commerce; Developing Countries; Drug Industry; Drugs, Generic; Health Services Accessibility; India; Licensure; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Effects of sorafenib combined with chemoembolization and radiofrequency ablation for large, unresectable hepatocellular carcinomas.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2013 |
SL1122-37, a novel derivative of sorafenib, has greater effects than sorafenib on the inhibition of human hepatocellular carcinoma (HCC) growth and prevention of angiogenesis.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorimetry; Human Umbilical Vein Endothelial Cells; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromal-derived factor 1 alpha/C-X-C receptor type 4 axis and myeloid differentiation antigen-positive myeloid cell infiltration in mice.
Topics: Animals; Carbon Tetrachloride; Carcinoma, Hepatocellular; CD11b Antigen; Cell Line, Tumor; Cell Movement; Chemokine CXCL12; Disease Models, Animal; Hepatocyte Growth Factor; Liver; Liver Cirrhosis; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Mice, Knockout; Myeloid Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Receptors, Chemokine; Receptors, CXCR4; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Sorafenib | 2014 |
The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Heterografts; Humans; Liver Neoplasms; Mice; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib | 2013 |
Angiogenesis inhibitor therapies for advanced renal cell carcinoma: toxicity and treatment patterns in clinical practice from a global medical chart review.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Asia; Bevacizumab; Carcinoma, Renal Cell; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Humans; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome; United States | 2014 |
Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).
Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hand-Foot Syndrome; Humans; Male; Middle Aged; Models, Biological; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Young Adult | 2014 |
High risk of lung metastasis after resection of hepatocellular carcinoma more than 7 cm in diameter.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk; Sorafenib; Survival Rate | 2014 |
Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neovascularization, Pathologic; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sunitinib | 2014 |
SC-60, a dimer-based sorafenib derivative, shows a better anti-hepatocellular carcinoma effect than sorafenib in a preclinical hepatocellular carcinoma model.
Topics: Apoptosis; Carcinoma, Hepatocellular; Catalytic Domain; Cell Line, Tumor; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |
Polymorphic OCT1: a valid biomarker, but for which drugs?
Topics: Biomarkers, Pharmacological; Cations; Humans; Metformin; Morphine; Niacinamide; Organic Cation Transporter 1; Pharmacogenetics; Phenylurea Compounds; Sorafenib | 2013 |
Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
Topics: Aged; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Iopamidol; Liver Neoplasms; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
[A case of tuberculosis that occurred during treatment of hepatocellular carcinoma with sorafenib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Tuberculosis, Pulmonary | 2013 |
Association between hemoglobin, calcium, and lactate dehydrogenase variability and mortality among metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hemoglobin A; Humans; Indazoles; Indoles; Kidney Neoplasms; L-Lactate Dehydrogenase; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Vascular Endothelial Growth Factor A | 2014 |
Multi-kinase inhibition in ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Sorafenib | 2014 |
Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Communication; Cell Line, Tumor; Cell Proliferation; Connexins; Drug Synergism; Gap Junctions; Glycyrrhetinic Acid; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Oleic Acids; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tretinoin | 2014 |
Clinical and laboratory prognostic factors in patients with metastatic renal cell carcinoma treated with sunitinib and sorafenib after progression on cytokines.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cytokines; Disease Progression; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2014 |
Precision-cut liver slices as a model for the early onset of liver fibrosis to test antifibrotic drugs.
Topics: Animals; Becaplermin; Benzamides; Benzylisoquinolines; Cinnamates; Collagen Type I; Connective Tissue Growth Factor; Depsides; Down-Regulation; Gene Expression; HSP47 Heat-Shock Proteins; Imatinib Mesylate; Liver; Liver Cirrhosis; Male; Models, Biological; Niacinamide; Organ Culture Techniques; Perindopril; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-sis; Pyridones; Pyrimidines; Rats; Rats, Wistar; Rosmarinic Acid; Sorafenib; Transforming Growth Factor beta1; Valproic Acid | 2014 |
Pancreatic cancer: Sorafenib: no effect on efficacy of chemotherapy in pancreatic cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gemcitabine; Humans; Neovascularization, Pathologic; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Long-term survival of patients with hepatocellular carcinoma with inferior vena cava tumor thrombus treated with sorafenib combined with transarterial chemoembolization: report of two cases and literature review.
Topics: Carcinoma, Hepatocellular; Catheterization, Peripheral; Chemoembolization, Therapeutic; Combined Modality Therapy; Hepatic Artery; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Thrombosis; Vena Cava, Inferior | 2014 |
Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Head and Neck Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Squamous Cell Carcinoma of Head and Neck | 2014 |
Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sirolimus; Sorafenib; Treatment Outcome | 2014 |
Acne inversa-like lesions associated with the multi-kinase inhibitor sorafenib.
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Hidradenitis Suppurativa; Humans; Leg Dermatoses; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2014 |
Effects of miR-193a and sorafenib on hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib; Urokinase-Type Plasminogen Activator | 2013 |
[Anti-proliferation effect of sorafenib in combination with 5-FU for hepatocellular carcinoma in vitro: antagonistic performance and mechanism].
Topics: Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Antagonism; Fluorouracil; Humans; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2013 |
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Renal Cell; Clinical Trials as Topic; Disease-Free Survival; Eligibility Determination; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Karnofsky Performance Status; Kidney Neoplasms; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Characterization of mechanism involved in acquired resistance to sorafenib in a mouse renal cell cancer RenCa model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Clusterin; Disease Models, Animal; Drug Resistance, Neoplasm; Inhibitory Concentration 50; Kidney Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Transcriptome | 2014 |
Development and validation of an HPLC-UV method for sorafenib quantification in human plasma and application to patients with cancer in routine clinical practice.
Topics: Antineoplastic Agents; Area Under Curve; Calibration; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Drug Monitoring; Humans; Lapatinib; Metabolic Clearance Rate; Neoplasms; Niacinamide; Phenylurea Compounds; Quinazolines; Reproducibility of Results; Sorafenib; Spectrophotometry, Ultraviolet | 2014 |
Quercetin and sorafenib as a novel and effective couple in programmed cell death induction in human gliomas.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Autophagy; Cell Line, Tumor; Drug Therapy, Combination; Glioblastoma; Glioma; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; HSP72 Heat-Shock Proteins; Humans; Membrane Potential, Mitochondrial; Mitochondria; Molecular Chaperones; Necrosis; Niacinamide; Phenylurea Compounds; Quercetin; Sorafenib | 2014 |
VEGFR, RET, and RAF/MEK/ERK pathway take part in the inhibition of osteosarcoma MG63 cells with sorafenib treatment.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Osteoblasts; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2014 |
Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS.
Topics: Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Down-Regulation; Drug Screening Assays, Antitumor; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Oligonucleotide Array Sequence Analysis; Oncogene Proteins v-fos; Osteosarcoma; Phenylurea Compounds; Receptors, CXCR4; S100 Calcium-Binding Protein A4; S100 Proteins; Sorafenib; Transcriptome | 2014 |
In vivo monitoring of sorafenib therapy effects on experimental prostate carcinomas using dynamic contrast-enhanced MRI and macromolecular contrast media.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Contrast Media; Image Enhancement; Immunohistochemistry; Magnetic Resonance Imaging; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Rats; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Tumor Burden | 2013 |
Diarylureas and diarylamides with pyrrolo[2,3-d]pyrimidine scaffold as broad-spectrum anticancer agents.
Topics: Antineoplastic Agents; Benzamides; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Imatinib Mesylate; Niacinamide; Phenylurea Compounds; Piperazines; Pyrimidines; Pyrroles; Sorafenib | 2014 |
BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Sorafenib | 2013 |
[Three cases of recurrent hepatocellular carcinoma treated with laparoscopic hepatectomy after oral administration of sorafenib].
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Hepatectomy; Humans; Laparoscopy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib | 2013 |
[A case of a patient with hepatocellular carcinoma who achieved long-term survival after repeated transcatheter arterial chemoembolization and sorafenib therapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Time Factors; Treatment Outcome | 2013 |
Cost-effectiveness of sorafenib compared to best supportive care in second line renal cell cancer from a payer perspective in Cyprus.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cost-Benefit Analysis; Cyprus; Decision Support Techniques; Humans; Kidney Neoplasms; Markov Chains; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Quality-Adjusted Life Years; Reimbursement Mechanisms; Sorafenib | 2014 |
Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations.
Topics: Animals; Biological Transport; Docetaxel; Drug Interactions; HEK293 Cells; Hepatocytes; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Mice; Mice, Knockout; Niacinamide; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Taxoids | 2014 |
Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer.
Topics: Aged; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroglobulin; Thyroid Neoplasms | 2014 |
ROS-mediated JNK/p38-MAPK activation regulates Bax translocation in Sorafenib-induced apoptosis of EBV-transformed B cells.
Topics: Apoptosis; B-Lymphocytes; bcl-2-Associated X Protein; Herpesvirus 4, Human; Humans; MAP Kinase Signaling System; Membrane Potential, Mitochondrial; Mitochondria; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Reactive Oxygen Species; Sorafenib | 2014 |
Epirubicin, cisplatin, 5-FU combination chemotherapy in sorafenib-refractory metastatic hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease Progression; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2014 |
YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Immunohistochemistry; Indazoles; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2014 |
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.
Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Indoles; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Piperidines; Pleural Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2014 |
Sorafenib for patients with pretreated recurrent or progressive high-grade glioma: a retrospective, single-institution study.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2014 |
Sorafenib-induced tumor response in a patient with metastatic epithelioid angiomyolipoma.
Topics: Adult; Angiomyolipoma; Antineoplastic Agents; Biopsy, Needle; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Nephrectomy; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2014 |
Early prediction of response of sorafenib on hepatocellular carcinoma by CT perfusion imaging: an animal study.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Liver; Liver Neoplasms, Experimental; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Rats; Rats, Wistar; Sorafenib; Tomography, Emission-Computed; Treatment Outcome | 2014 |
Efficiency and side effects of sorafenib therapy for advanced hepatocellular carcinoma: a retrospective study by the anatolian society of medical oncology.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Medical Oncology; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Turkey | 2013 |
Liver abscess in advanced hepatocellular carcinoma after sorafenib treatment.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Clostridium; Clostridium Infections; Humans; Liver Abscess; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2014 |
Olmesartan potentiates the anti-angiogenic effect of sorafenib in mice bearing Ehrlich's ascites carcinoma: role of angiotensin (1-7).
Topics: Angiotensin I; Angiotensin II Type 1 Receptor Blockers; Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Female; Imidazoles; Immunohistochemistry; Insulin-Like Growth Factor I; Mice; Neovascularization, Pathologic; Niacinamide; Peptide Fragments; Phenylurea Compounds; Receptor, IGF Type 1; Sorafenib; Tetrazoles; Tumor Burden; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Pro-apoptotic Sorafenib signaling in murine hepatocytes depends on malignancy and is associated with PUMA expression in vitro and in vivo.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cells, Cultured; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Suppressor Proteins | 2014 |
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Quinazolines; Signal Transduction; Sorafenib; Transforming Growth Factor alpha; Up-Regulation | 2014 |
Simultaneous inhibition of tumor growth and angiogenesis for resistant hepatocellular carcinoma by co-delivery of sorafenib and survivin small hairpin RNA.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle; Drug Resistance, Neoplasm; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Repressor Proteins; RNA, Small Interfering; Sorafenib; Survivin | 2014 |
Electrochemical monitoring of an important biomarker and target protein: VEGFR2 in cell lysates.
Topics: Animals; Biosensing Techniques; Cell Line; Chitosan; Electrochemical Techniques; Endothelial Cells; Graphite; Immunoassay; Macaca mulatta; Niacinamide; Oxidation-Reduction; Phenothiazines; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Quinazolines; Retina; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome.
Topics: ACTH Syndrome, Ectopic; Carcinoma, Neuroendocrine; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pituitary-Adrenal System; Sorafenib; Thyroid Neoplasms | 2014 |
Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2014 |
Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Contrast Media; Drug Carriers; Hep G2 Cells; Histidine; Humans; Hydrogen-Ion Concentration; Lactic Acid; Magnetic Resonance Imaging; Mice; Nanoparticles; Neoplasms; Niacinamide; Particle Size; Phenylurea Compounds; Polyesters; Polyethylene Glycols; Polymers; Radiography; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Transplantation, Heterologous | 2014 |
Multimodality therapy and liver transplantation for hepatocellular carcinoma: a 14-year prospective analysis of outcomes.
Topics: Aged; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Radiopharmaceuticals; Radiotherapy, Adjuvant; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Yttrium Radioisotopes | 2014 |
Perforating folliculitis-like reaction related to sorafenib.
Topics: Antineoplastic Agents; Drug Eruptions; Folliculitis; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2014 |
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: the ALICE-1 study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genotype; Humans; Liver Neoplasms; Lymphangiogenesis; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor C; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2; Vascular Endothelial Growth Factor Receptor-3 | 2014 |
Treatment of collecting duct carcinoma: current status and future perspectives.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Humans; Indazoles; Kidney Neoplasms; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pyrimidines; Sirolimus; Sorafenib; Sulfonamides | 2014 |
Sorafenib and lithium chloride combination treatment shows promising synergistic effects in human glioblastoma multiforme cells in vitro but midkine is not implicated.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cytokines; ErbB Receptors; Glioblastoma; Humans; Lithium Chloride; Midkine; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Maturing of renal cancer therapeutics.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2014 |
Is intra-patient sorafenib dose re-escalation safe and tolerable in patients with advanced hepatocellular carcinoma?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Synergistic interaction between the HDAC inhibitor, MPT0E028, and sorafenib in liver cancer cells in vitro and in vivo.
Topics: Animals; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Overall survival after immunotherapy, tyrosine kinase inhibitors and surgery in treatment of metastatic renal cell cancer: outcome of 143 consecutive patients from a single centre.
Topics: Aged; Algorithms; Carcinoma, Renal Cell; Combined Modality Therapy; Denmark; Enzyme Inhibitors; Female; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Survival Rate; Time Factors; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
Novel sorafenib-based structural analogues: in-vitro anticancer evaluation of t-MTUCB and t-AUCMB.
Topics: Adamantane; Antineoplastic Agents; Apoptosis; Apoptosis Inducing Factor; Autophagy; Benzamides; Caspases; Cell Cycle; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Mitochondrial Membranes; Niacinamide; Oxidative Stress; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Sorafenib; Urea | 2014 |
Preclinical evaluation of AMG 925, a FLT3/CDK4 dual kinase inhibitor for treating acute myeloid leukemia.
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase 4; Dose-Response Relationship, Drug; fms-Like Tyrosine Kinase 3; Heterocyclic Compounds, 3-Ring; Humans; Leukemia, Myeloid, Acute; Mice; Mice, Nude; Naphthyridines; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; U937 Cells; Xenograft Model Antitumor Assays | 2014 |
[Systemic treatment of metastatic renal cell carcinoma: change of paradigms after introduction of targeted therapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Combined Modality Therapy; Female; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2014 |
Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Pyrazoles; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Management; Female; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
Third-line dovitinib in metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Benzimidazoles; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolones; Sorafenib | 2014 |
Therapy of mRCC beyond mTOR-inhibition in clinical practice: results of a retrospective analysis.
Topics: Adult; Aged; Carcinoma, Renal Cell; Clinical Trials as Topic; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; TOR Serine-Threonine Kinases | 2014 |
BIM upregulation and ROS-dependent necroptosis mediate the antitumor effects of the HDACi Givinostat and Sorafenib in Hodgkin lymphoma cell line xenografts.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carbamates; Cell Line, Tumor; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Imidazoles; Indoles; Membrane Proteins; Mice; Mice, SCID; Necrosis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Reactive Oxygen Species; Sorafenib; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
NORE1A sensitises cancer cells to sorafenib-induced apoptosis and indicates hepatocellular carcinoma prognosis.
Topics: Adaptor Proteins, Signal Transducing; Adolescent; Adult; Aged; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Female; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Monomeric GTP-Binding Proteins; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Real-Time Polymerase Chain Reaction; Sorafenib; Young Adult | 2014 |
Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Administration Schedule; Egypt; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: a single institution experience.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indazoles; Kidney Failure, Chronic; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Renal Dialysis; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Treatment Outcome | 2014 |
Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lymphocytes; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2014 |
Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Amino Acid Substitution; Antineoplastic Agents; Cell Transformation, Neoplastic; DNA, Neoplasm; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation, Missense; Niacinamide; Oncogenes; Phenylurea Compounds; Proto-Oncogene Proteins A-raf; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Sorafenib | 2014 |
Novel combination therapy with imiquimod and sorafenib for renal cell carcinoma.
Topics: Adenocarcinoma; Aminoquinolines; Animals; Antineoplastic Agents; Carcinoma, Renal Cell; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Disease Models, Animal; Drug Therapy, Combination; Female; Imiquimod; Kidney Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
Topics: Aniline Compounds; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
Predictors of survival in patients with established cirrhosis and hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Magnetic Resonance Imaging; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Risk Factors; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Management of sorafenib-related adverse events: a clinician's perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue; Gastrointestinal Diseases; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Physicians; Sorafenib | 2014 |
Management of common adverse events in patients treated with sorafenib: nurse and pharmacist perspective.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Disease Management; Fatigue; Gastrointestinal Diseases; Hand-Foot Syndrome; Humans; Hypertension; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Nurses; Patient Education as Topic; Pharmacists; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib | 2014 |
[Efficacy and safety of combination of sorafenib and transarterial chemoembolization in treating primary hepatocellular carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
1082-39, an analogue of sorafenib, inhibited human cancer cell growth more potently than sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Cell Survival; Cytosol; Dose-Response Relationship, Drug; Humans; Membrane Potential, Mitochondrial; Mitochondria; Molecular Structure; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Sorafenib; Structure-Activity Relationship | 2014 |
Involvement of androgen receptor and glucose-regulated protein 78 kDa in human hepatocarcinogenesis.
Topics: Antineoplastic Agents; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cells, Cultured; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Hep G2 Cells; Hepatocytes; Humans; Niacinamide; Phenylurea Compounds; Receptors, Androgen; RNA, Messenger; Sorafenib | 2014 |
[Diagnostics and treatment of hepatocellular carcinoma: trends in the Netherlands in the period 2003-2011].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Embolization, Therapeutic; Female; Hospitalization; Humans; Liver Neoplasms; Male; Middle Aged; Netherlands; Niacinamide; Palliative Care; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2014 |
The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Drug Carriers; Humans; Lipids; Mice; Mice, Inbred BALB C; Mice, Nude; Nanodiamonds; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach; Stomach Neoplasms | 2014 |
[Liver cancer: progress in diagnosis and treatments. Topics: VI. Progress in treatments of liver cancer; 4. Molecularly targeted agent].
Topics: Antineoplastic Agents; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Galactosylated polymeric carriers for liver targeting of sorafenib.
Topics: Animals; Antineoplastic Agents; Biological Availability; Drug Carriers; Ethylenediamines; Female; Galactose; Kidney; Liver; Lung; Mice, Inbred C57BL; Micelles; Niacinamide; Peptides; Phenylurea Compounds; Polyesters; Sorafenib; Spleen | 2014 |
A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD+ AML.
Topics: Animals; Antineoplastic Agents; Calcium-Binding Proteins; Cation Transport Proteins; Cells, Cultured; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Hydrogen-Ion Concentration; Intracellular Space; K562 Cells; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Tandem Repeat Sequences | 2014 |
Sorafenib blocks the HIF-1α/VEGFA pathway, inhibits tumor invasion, and induces apoptosis in hepatoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cobalt; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms; Niacinamide; Phenylurea Compounds; RNA, Messenger; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Disease-Free Survival; Female; Humans; Hypocalcemia; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Pamidronate; Phenylurea Compounds; Prognosis; Pyrroles; Renal Insufficiency; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A; Zoledronic Acid | 2014 |
Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Mutation; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tandem Repeat Sequences | 2014 |
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary, Follicular; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Salvage Therapy; Sorafenib; Thyroid Neoplasms; Treatment Failure | 2014 |
Rhodotorula mucilaginosa skin infection in a patient treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Dermatomycoses; Humans; Liver Neoplasms; Male; Niacinamide; Opportunistic Infections; Phenylurea Compounds; Rhodotorula; Sorafenib | 2015 |
Effect of BZG-4000, a novel multi-targeted kinase inhibitor with potent anticancer activity, on a hepatocellular carcinoma xenograft model.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Administration Schedule; Gene Expression; Hepatocytes; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
Sorafenib inhibition of hepatic stellate cell proliferation in tumor microenvironment of hepatocellular carcinoma: a study of the sorafenib mechanisms.
Topics: Actins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatic Stellate Cells; Humans; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Microenvironment | 2014 |
More effective agents still needed for progressive radioiodine-refractory differentiated thyroid cancer.
Topics: Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2014 |
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Proteomics; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2014 |
Estimating the clinical risk of hypertension from VEGF signal inhibitors by a non-clinical approach using telemetered rats.
Topics: Angiogenesis Inhibitors; Animals; Blood Pressure; Hypertension; Male; Niacinamide; Phenylurea Compounds; Quinazolines; Rats; Rats, Wistar; Risk; Signal Transduction; Sorafenib; Telemetry; Vascular Endothelial Growth Factor A | 2014 |
Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2014 |
Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Leiomyosarcoma; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Soft Tissue Neoplasms; Sorafenib; Young Adult | 2014 |
Activity of anti-cancer protein kinase inhibitors against Leishmania spp.
Topics: Animals; Antineoplastic Agents; Antiprotozoal Agents; Disease Models, Animal; Drug Repositioning; Indoles; Inhibitory Concentration 50; Lapatinib; Leishmania; Leishmaniasis; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Acute generalized exanthematous pustulosis induced by sorafenib.
Topics: Acute Generalized Exanthematous Pustulosis; Antineoplastic Agents; Female; Humans; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Carcinoma, Renal Cell; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Indoles; Kidney Neoplasms; Mice; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Precision Medicine; Pyrroles; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
The multi-targeted kinase inhibitor sorafenib inhibits enterovirus 71 replication by regulating IRES-dependent translation of viral proteins.
Topics: Animals; Antiviral Agents; Cell Line; Cytopathogenic Effect, Viral; Enterovirus A, Human; Humans; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Protein Kinase Inhibitors; Sorafenib; Viral Proteins; Virus Replication | 2014 |
Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma.
Topics: Adenocarcinoma, Follicular; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pleural Effusion, Malignant; Sorafenib; Thyroid Neoplasms; Thyroidectomy; Treatment Outcome | 2014 |
Symptoms from treatment with sunitinib or sorafenib: a multicenter explorative cohort study to explore the influence of patient-reported outcomes on therapy decisions.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Cohort Studies; Decision Making; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Netherlands; Niacinamide; Phenylurea Compounds; Pyrroles; Quality of Life; Self Report; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Female; Hepatocytes; Humans; Liver Neoplasms; Macrophages; Male; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tumor Burden; Vascular Endothelial Growth Factor A | 2014 |
Hepatocellular carcinoma: concomitant sorafenib promotes necrosis after radiofrequency ablation--propensity score matching analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Contrast Media; Female; Humans; Liver Neoplasms; Male; Middle Aged; Necrosis; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Fatal Outcome; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Nuclear Proteins; Nucleophosmin; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tretinoin; Young Adult | 2014 |
Synergistic inhibition of HCC and liver cancer stem cell proliferation by targeting RAS/RAF/MAPK and WNT/β-catenin pathways.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Drug Synergism; Female; Humans; Immunophenotyping; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Mice; Mitogen-Activated Protein Kinases; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins p21(ras); raf Kinases; Signal Transduction; Sorafenib; Sulfonamides; Survivin; Wnt Signaling Pathway | 2014 |
Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation: does mTOR inhibitors association augment toxicity?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Interactions; Everolimus; Humans; Immunosuppressive Agents; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome | 2014 |
RNAi screening with shRNAs against histone methylation-related genes reveals determinants of sorafenib sensitivity in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; DNA Methylation; Drug Resistance, Neoplasm; Hep G2 Cells; High-Throughput Screening Assays; Histones; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Sorafenib | 2014 |
[Metastasized renal cell carcinoma - research subjects needed!].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Drug Administration Schedule; Humans; Indazoles; Kidney Neoplasms; Multicenter Studies as Topic; Neoplasm Metastasis; Niacinamide; Patient Selection; Phenylurea Compounds; Pyrimidines; Randomized Controlled Trials as Topic; Sorafenib; Sulfonamides | 2014 |
Cabozantinib suppresses tumor growth and metastasis in hepatocellular carcinoma by a dual blockade of VEGFR2 and MET.
Topics: Anilides; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Female; Humans; Immunohistochemistry; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Pyridines; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2014 |
Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Skin; Sorafenib | 2014 |
Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
Topics: Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; RNA, Small Interfering; Sorafenib | 2014 |
Impact of surgery on the prognosis of metastatic renal cell carcinoma with IVC thrombus received TKI therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Thrombectomy; Treatment Outcome; Vena Cava, Inferior; Venous Thrombosis | 2014 |
Identification of Zinc Finger, MYM-type 2 (ZMYM2) as a regulator of sorafenib resistance in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gene Library; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; Transcription Factors | 2014 |
Sorafenib cardiotoxicity increases mortality after myocardial infarction.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cats; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship, Drug; Heart; In Vitro Techniques; Male; Metoprolol; Mice; Mice, Inbred C57BL; Myocardial Infarction; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Sorafenib | 2014 |
Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening.
Topics: Antineoplastic Agents; Biomechanical Phenomena; Breast; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Collagen; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2014 |
Poly(lactide-co-glycolide) microspheres for MRI-monitored transcatheter delivery of sorafenib to liver tumors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Cell Line, Tumor; Cell Proliferation; Drug Carriers; Liver; Liver Neoplasms; Magnetic Resonance Imaging; Male; Microspheres; Niacinamide; Phenylurea Compounds; Polyglactin 910; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sorafenib | 2014 |
Response to sorafenib treatment in advanced metastatic thyroid cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Compassionate Use Trials; Female; Follow-Up Studies; Heart Failure; Humans; Iodine Radioisotopes; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Response Evaluation Criteria in Solid Tumors; Sorafenib; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2014 |
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer.
Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Disease-Free Survival; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms | 2014 |
Signal transducer and activator of transcription 3 as molecular therapy for non-small-cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Cell Survival; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-raf; RNA, Small Interfering; Sorafenib; STAT3 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Carbazoles; DNA Mutational Analysis; Female; fms-Like Tyrosine Kinase 3; Furans; Humans; Leukemia, Myeloid, Acute; Male; Medical Records; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2014 |
Development of hypertension within 2 weeks of initiation of sorafenib for advanced hepatocellular carcinoma is a predictor of efficacy.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |
Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Cause of Death; Embolization, Therapeutic; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Yttrium Radioisotopes | 2015 |
Radiation recall reaction causing cardiotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Chemoradiotherapy; Coronary Angiography; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Myocarditis; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Radiation Dosage; Radiation Injuries; Risk Factors; Sorafenib; Whole Body Imaging | 2014 |
New era for treatment in differentiated thyroid cancer.
Topics: Antineoplastic Agents; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2014 |
Response of patients with metastatic uveal melanoma to combined treatment with fotemustine and sorafenib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Neoplasm Staging; Niacinamide; Nitrosourea Compounds; Organophosphorus Compounds; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Uveal Neoplasms | 2014 |
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2014 |
Silencing of PKCη induces cycle arrest of EBV(+) B lymphoma cells by upregulating expression of p38-MAPK/TAp73/GADD45α and increases susceptibility to chemotherapeutic agents.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; DNA-Binding Proteins; Drug Resistance, Neoplasm; Herpesvirus 4, Human; Humans; Membrane Potential, Mitochondrial; NF-kappa B; Niacinamide; Nuclear Proteins; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase C; Pyrazines; RNA Interference; RNA, Small Interfering; Sorafenib; Tumor Protein p73; Tumor Suppressor Proteins; Up-Regulation | 2014 |
Therapeutic effects of sorafenib on the A549/DDP human lung adenocarcinoma cell line in vitro.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors | 2014 |
A preclinical evaluation of a novel multikinase inhibitor, SKLB-329, as a therapeutic agent against hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Evaluation, Preclinical; Endothelial Cells; Female; Human Umbilical Vein Endothelial Cells; Humans; Inhibitory Concentration 50; Liver; Liver Neoplasms; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Signal Transduction; Sorafenib; Zebrafish | 2014 |
Sequential targeted therapy after pazopanib therapy in patients with metastatic renal cell cancer: efficacy and toxicity.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2014 |
Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cytochrome P-450 CYP3A; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glucuronosyltransferase; Humans; Liver; Liver Neoplasms; Male; Microsomes, Liver; Middle Aged; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sorafenib; UDP-Glucuronosyltransferase 1A9 | 2014 |
Safety and efficacy of preoperative sorafenib therapy in facilitating cytoreductive surgery in renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Cytoreduction Surgical Procedures; Humans; Niacinamide; Phenylurea Compounds; Preoperative Period; Safety; Sorafenib; Treatment Outcome | 2014 |
Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
Topics: Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2014 |
Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Female; Gene Expression; Humans; Liver; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis | 2014 |
Sorafenib increases efficacy of vorinostat against human hepatocellular carcinoma through transduction inhibition of vorinostat-induced ERK/NF-κB signaling.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Humans; Hydroxamic Acids; Liver Neoplasms; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Nude; NF-kappaB-Inducing Kinase; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Sorafenib; Vorinostat; Xenograft Model Antitumor Assays | 2014 |
Inhibition of the vacuolar ATPase induces Bnip3-dependent death of cancer cells and a reduction in tumor burden and metastasis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Butadienes; Cell Hypoxia; Enzyme Inhibitors; Gene Knockdown Techniques; Heterografts; Humans; Hydrogen-Ion Concentration; Macrolides; MAP Kinase Signaling System; MCF-7 Cells; Membrane Proteins; Mice; Neoplasm Metastasis; Niacinamide; Nitriles; Phenylurea Compounds; Proto-Oncogene Proteins; Sorafenib; Tumor Burden; Vacuolar Proton-Translocating ATPases | 2014 |
Sorafenib continuation after first disease progression could reduce disease flares and provide survival benefits in patients with hepatocellular carcinoma: a pilot retrospective study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Analysis; Withholding Treatment | 2014 |
Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Female; Humans; Lapatinib; MCF-7 Cells; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diarrhea; Female; Gastrointestinal Hemorrhage; Hepatic Encephalopathy; Humans; Hypertension; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Retrospective Studies; Skin Diseases; Sorafenib | 2014 |
Valproic acid overcomes transforming growth factor-β-mediated sorafenib resistance in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Transforming Growth Factor beta; Treatment Failure; Treatment Outcome; Valproic Acid | 2014 |
Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Female; Humans; Indoles; Kidney Neoplasms; Male; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Important role of CYP2J2 in protein kinase inhibitor degradation: a possible role in intratumor drug disposition and resistance.
Topics: Benzamides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1B1; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dasatinib; Hep G2 Cells; Humans; Imatinib Mesylate; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Sunitinib; Thiazoles | 2014 |
Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.
Topics: Acetylation; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; Sorafenib; Transfection; Tumor Suppressor Protein p53; Vorinostat | 2014 |
Postoperative but not preoperative treatment with sorafenib inhibits liver regeneration in rats.
Topics: Animals; Body Weight; Cell Proliferation; Hepatectomy; Hepatocytes; Liver Regeneration; Niacinamide; Organ Size; Phenylurea Compounds; Postoperative Period; Protein Kinase Inhibitors; Rats; Rats, Wistar; Sorafenib | 2014 |
Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Japan; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Metastatic involvement of the maxillary antrum from an uncommon source.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chemoradiotherapy, Adjuvant; Embolization, Therapeutic; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Maxillary Sinus Neoplasms; Nephrectomy; Niacinamide; Palatal Neoplasms; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2014 |
Hand, foot and scrotal blisters in a patient with cancer receiving oral chemotherapy.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aged; Blister; Carcinoma, Hepatocellular; Drug Eruptions; Foot Dermatoses; Hand Dermatoses; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Scrotum; Severity of Illness Index; Sorafenib; Syndrome; Treatment Outcome | 2014 |
Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis.
Topics: 20-Hydroxysteroid Dehydrogenases; Amino Acid Transport System y+; Apoptosis; Biomarkers; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cystine; Endoplasmic Reticulum Stress; Glutamic Acid; Humans; Iron; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Sequence Analysis, RNA; Sorafenib; Structure-Activity Relationship; Transcriptome; Up-Regulation | 2014 |
The emerging questionable benefit of sorafenib as a neo-adjuvant in HCC patients treated with Y-90 radioembolization pending liver transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2014 |
Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Autocrine Communication; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Heterografts; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Tiam1 siRNA enhanced the sensitivity of sorafenib on esophageal squamous cell carcinoma in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Guanine Nucleotide Exchange Factors; Humans; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; T-Lymphoma Invasion and Metastasis-inducing Protein 1; Xenograft Model Antitumor Assays | 2014 |
ETV6-FLT3 fusion gene-positive, eosinophilia-associated myeloproliferative neoplasm successfully treated with sorafenib and allogeneic stem cell transplant.
Topics: Adult; Cytogenetics; Eosinophilia; ETS Translocation Variant 6 Protein; Female; fms-Like Tyrosine Kinase 3; Humans; Mutation; Myeloproliferative Disorders; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-ets; Repressor Proteins; Sorafenib; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2014 |
Enhanced therapeutic efficacy of combined use of sorafenib and transcatheter arterial chemoembolization for treatment of advanced hepatocellular carcinoma.
Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Severity of Illness Index; Sorafenib; Venous Thromboembolism | 2014 |
Novel investigational approaches for inhibiting angiogenesis in recurrent glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Female; Glioma; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
JUNB promotes the survival of Flavopiridol treated human breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Female; Flavonoids; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Sorafenib; Transcription Factors; Treatment Outcome | 2014 |
Sarcomatoid dedifferentiation in metastatic clear cell renal cell carcinoma and outcome on treatment with anti-vascular endothelial growth factor receptor tyrosine kinase inhibitors: a retrospective analysis.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Differentiation; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Disease-Free Survival; Eosinophils; Female; Hemoglobins; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Multivariate Analysis; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2014 |
A quantitative HPLC-UV method for determination of serum sorafenib and sorafenib N-oxide and its application in hepatocarcinoma patients.
Topics: Acetonitriles; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Drug Stability; Humans; Ions; Liver Neoplasms; Mass Spectrometry; Niacinamide; Oxides; Phenylurea Compounds; Reference Standards; Solubility; Solutions; Sorafenib; Ultraviolet Rays | 2014 |
Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blood Platelets; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Enzyme Activation; Epidermal Growth Factor; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Time Factors | 2014 |
Multikinase inhibitor sorafenib prevents pressure overload-induced left ventricular hypertrophy in rats by blocking the c-Raf/ERK1/2 signaling pathway.
Topics: Animals; Becaplermin; Blood Pressure; Blotting, Western; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Gene Expression Regulation; Heart Ventricles; Hypertrophy, Left Ventricular; Male; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins c-sis; Rats; Rats, Inbred Lew; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; RNA; Signal Transduction; Sorafenib; Transforming Growth Factor beta1 | 2014 |
Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Propensity Score; Proportional Hazards Models; Radiotherapy; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2014 |
Pilot study of sorafenib in relapsed or refractory peripheral and cutaneous T-cell lymphoma.
Topics: Antineoplastic Agents; Humans; Lymphoma, T-Cell, Cutaneous; Lymphoma, T-Cell, Peripheral; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pilot Projects; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2014 |
VEGFA genomic amplification tailors treatment of HCCs with sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2014 |
Hyponatremia as a powerful prognostic predictor for Japanese patients with clear cell renal cell carcinoma treated with a tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Hyponatremia; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Risk Factors; Serum Albumin; Sodium; Sorafenib; Sunitinib; Survival Rate | 2015 |
Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.
Topics: Adult; Aged; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Remission Induction; Retreatment; Retrospective Studies; Sorafenib; Tandem Repeat Sequences; Treatment Outcome | 2014 |
Multidisciplinary management of hepatocellular carcinoma in clinical practice.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Severity of Illness Index; Sorafenib | 2014 |
Evaluation of the impact of transient interruption of antiangiogenic treatment using ultrasound-based techniques in a murine model of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Humans; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Transferrin targeted core-shell nanomedicine for combinatorial delivery of doxorubicin and sorafenib against hepatocellular carcinoma.
Topics: Apoptosis; Carcinoma, Hepatocellular; Doxorubicin; Drug Carriers; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms; Nanomedicine; Niacinamide; Phenylurea Compounds; Sorafenib; Transferrin | 2014 |
Expression and function analysis of mitotic checkpoint genes identifies TTK as a potential therapeutic target for human hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genes, cdc; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Sorafenib | 2014 |
An inducible hepatocellular carcinoma model for preclinical evaluation of antiangiogenic therapy in adult mice.
Topics: Angiogenesis Inhibitors; Animals; Disease Models, Animal; Humans; Liver Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Mice, Transgenic; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Sorafenib/regorafenib and lapatinib interact to kill CNS tumor cells.
Topics: Anoikis; Antineoplastic Agents; Apoptosis Regulatory Proteins; Autophagy-Related Protein 5; bcl-X Protein; Beclin-1; Brain Neoplasms; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 9; Cell Line, Tumor; Drug Synergism; ErbB Receptors; fas Receptor; Fas-Associated Death Domain Protein; Glioblastoma; Humans; Lapatinib; Lysosomal-Associated Membrane Protein 2; MAP Kinase Kinase 1; Membrane Proteins; Microtubule-Associated Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Quinazolines; Sorafenib; TOR Serine-Threonine Kinases; Unfolded Protein Response | 2015 |
Use of sorafenib in a corticotropin-secreting pancreatic neuroendocrine carcinoma.
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Carcinoma, Neuroendocrine; Humans; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
B-Raf regulation of integrin α4β1-mediated resistance to shear stress through changes in cell spreading and cytoskeletal association in T cells.
Topics: Cell Adhesion; Cytoskeleton; Gene Knockdown Techniques; Humans; Integrin alpha4beta1; Jurkat Cells; Lymphocyte Function-Associated Antigen-1; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptors, Vitronectin; Shear Strength; Sorafenib; Stress, Physiological; T-Lymphocytes; Vascular Cell Adhesion Molecule-1 | 2014 |
Sorafenib and triptolide as combination therapy for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes; Drug Synergism; Epoxy Compounds; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Mice; Mice, Nude; Models, Biological; NF-kappa B p50 Subunit; Niacinamide; Organophosphates; Phenanthrenes; Phenylurea Compounds; Prodrugs; Signal Transduction; Sincalide; Sorafenib; Translational Research, Biomedical; Xenograft Model Antitumor Assays | 2014 |
Development of chronic myeloid leukaemia in patients treated with anti-VEGF therapies for clear cell renal cell cancer.
Topics: Adult; Aged; Bone Marrow Cells; Carcinoma, Renal Cell; Humans; Indoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Synergistic inhibitory effect of hyperbaric oxygen combined with sorafenib on hepatoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Synergism; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hyperbaric Oxygenation; Liver Neoplasms; MicroRNAs; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Sorafenib; Tumor Stem Cell Assay | 2014 |
Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Genetic Engineering; Humans; Liver Neoplasms; Niacinamide; Oncolytic Virotherapy; Phenylurea Compounds; Sorafenib; Vaccinia virus; Viral Plaque Assay; Virus Replication | 2014 |
Feasibility of global miRNA analysis from fine-needle biopsy FFPE material in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Feasibility Studies; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Markers; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Retrognathia; Sorafenib; Treatment Outcome | 2015 |
[Prognostic value of toxicities induced by targeted therapies in patients treated for a metastatic renal cell carcinoma].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2014 |
Distinct antifibrogenic effects of erlotinib, sunitinib and sorafenib on rat pancreatic stellate cells.
Topics: Actins; Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Indoles; Male; Matrix Metalloproteinase 2; Niacinamide; Pancreas; Pancreatic Stellate Cells; Phenotype; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Rats, Inbred Lew; RNA, Messenger; Signal Transduction; Sorafenib; Sunitinib; Time Factors; Transforming Growth Factor beta1 | 2014 |
Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient antimalarial agent.
Topics: Animals; Antineoplastic Agents; Artemisinins; Artesunate; Carcinoma, Hepatocellular; Cell Death; Dose-Response Relationship, Drug; Drug Repositioning; Drug Resistance, Neoplasm; Drug Therapy, Combination; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Unfolded Protein Response | 2014 |
Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Palliative Care; Phenylurea Compounds; Pilot Projects; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2014 |
Differential combined effect of COX inhibitors on cell survival suppressed by sorafenib in the HepG2 cell line.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cell Proliferation; Cell Survival; Cyclooxygenase Inhibitors; Drug Synergism; Flow Cytometry; Hep G2 Cells; Humans; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Invasive hepatocellular carcinoma with recurrent pulmonary embolism: use of AngioVac cannula thrombectomy device for mechanical aspiration.
Topics: Adult; Angiography; Anticoagulants; Antineoplastic Agents; Carcinoma, Hepatocellular; Enoxaparin; Fatal Outcome; Heart Atria; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pulmonary Embolism; Sorafenib; Suction; Thrombectomy; Vena Cava, Inferior | 2014 |
Earlier presentation and application of curative treatments in hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Child; Child, Preschool; Comorbidity; Early Diagnosis; Female; Humans; Incidence; Infant; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; SEER Program; Sorafenib; United States; Young Adult | 2014 |
Targeted polytherapy in small cell sarcoma and its association with doxorubicin.
Topics: Apoptosis; Benzoquinones; Cell Cycle; Cell Line, Tumor; Doxorubicin; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Niacinamide; Phenylurea Compounds; Sarcoma, Small Cell; Sorafenib; Vorinostat | 2014 |
[Two cases of successful sorafenib retreatment with the addition of steroid therapy following sorafenib-induced erythema multiforme in two patients with hepatocellular carcinoma].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Erythema Multiforme; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prednisolone; Sorafenib | 2014 |
The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenib.
Topics: Acetyltransferases; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Microvessels; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Transcription Factors; Young Adult | 2014 |
Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3).
Topics: Antineoplastic Agents; Cell Line, Transformed; Cell Proliferation; Cyclic S-Oxides; Gene Expression Regulation; Humans; Indoles; Inhibitor of Apoptosis Proteins; Keratinocytes; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyrroles; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Sunitinib; Survivin; Tetrazolium Salts | 2014 |
Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect.
Topics: Antineoplastic Agents; Bone Marrow; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Retreatment; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome | 2014 |
Both sunitinib and sorafenib are effective treatments for pheochromocytoma in a xenograft model.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Angiogenesis Inhibitors; Animals; Apoptosis; Cell Survival; Dose-Response Relationship, Drug; Heterografts; Indoles; Male; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; PC12 Cells; Phenylurea Compounds; Pheochromocytoma; Protein Kinase Inhibitors; Pyrroles; Rats; Sorafenib; Sunitinib; Time Factors; Tumor Burden | 2014 |
Blocking lipid synthesis overcomes tumor regrowth and metastasis after antiangiogenic therapy withdrawal.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Disease Progression; Fatty Acid Synthases; Homeodomain Proteins; Humans; Indoles; Lipids; Metabolomics; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proteomics; Pyrroles; RNA Interference; Sorafenib; Sunitinib; Transplantation, Heterologous | 2014 |
Genetic screen identifies suppressor of morphogenesis in genitalia-1 (SMG-1) as a modulator of sorafenib resistance in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Genome, Human; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; RNA, Small Interfering; Signal Transduction; Sorafenib | 2014 |
Extensive Squamous Cell Carcinoma of the Skin Related to Use of Sorafenib for Treatment of FLT3-Mutant Acute Myeloid Leukemia.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Skin Neoplasms; Sorafenib | 2016 |
A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Disease Progression; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis | 2015 |
Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib.
Topics: 3' Untranslated Regions; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Genes, Reporter; Hep G2 Cells; Hepatitis B virus; Humans; Liver Neoplasms; MicroRNAs; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Transfection | 2014 |
Two death pathways induced by sorafenib in myeloma cells: Puma-mediated apoptosis and necroptosis.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Blotting, Western; Caspase Inhibitors; Caspases; Cell Proliferation; Flow Cytometry; Humans; Mitochondria; Multiple Myeloma; Necrosis; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sorafenib; Tumor Cells, Cultured | 2015 |
MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Case-Control Studies; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Mucoepidermoid; Cell Proliferation; Disease Models, Animal; Down-Regulation; Female; Heterografts; Humans; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Random Allocation; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Salivary Gland Neoplasms; Sensitivity and Specificity; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2015 |
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2015 |
SC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; DNA-Binding Proteins; Drug Resistance, Neoplasm; Drug Synergism; Humans; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Regulatory Factor X Transcription Factors; Regulatory Factor X1; Sorafenib; STAT3 Transcription Factor; Transcription Factors; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2014 |
A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Hep G2 Cells; Humans; Hyaluronan Receptors; Liver Neoplasms, Experimental; Mice, Nude; Niacinamide; Phenotype; Phenylurea Compounds; Sorafenib; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2015 |
Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Coculture Techniques; Culture Media; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Hepatic Stellate Cells; Humans; Janus Kinase 2; Ligands; Liver Neoplasms; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2014 |
Network features suggest new hepatocellular carcinoma treatment strategies.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Signal Transduction; Sorafenib; Systems Biology; Transcriptome | 2014 |
Activation of phosphatidylinositol 3-kinase/Akt signaling mediates sorafenib-induced invasion and metastasis in hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms, Experimental; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Real-Time Polymerase Chain Reaction; Signal Transduction; Snail Family Transcription Factors; Sorafenib; Transcription Factors | 2014 |
Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases.
Topics: Adult; Antineoplastic Agents; Axilla; Combined Modality Therapy; Dioxoles; Epirubicin; Fatal Outcome; Humans; Ifosfamide; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sarcoma, Synovial; Sorafenib; Tetrahydroisoquinolines; Trabectedin | 2014 |
Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Contrast Media; Humans; Liver Neoplasms; Mice; Microbubbles; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Random Allocation; Software; Sorafenib; Treatment Outcome; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Early changes in apparent diffusion coefficient as an indicator of response to sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Hep G2 Cells; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Xenograft Model Antitumor Assays | 2014 |
Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.
Topics: Angiogenesis Inhibitors; Animals; Cancer Vaccines; Cell Line, Tumor; Combined Modality Therapy; Female; Flow Cytometry; Humans; Indoles; Lymphocytes, Tumor-Infiltrating; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Sorafenib; Sunitinib; Vaccines, Synthetic | 2014 |
miR‑222 regulates sorafenib resistance and enhance tumorigenicity in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; MAP Kinase Signaling System; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
Topics: Analysis of Variance; Binding, Competitive; Blotting, Western; Cell Movement; Dimerization; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Gene Knockdown Techniques; HEK293 Cells; Humans; Indenes; MAP Kinase Kinase 1; MAP Kinase Signaling System; Models, Molecular; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins A-raf; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyrazoles; RNA, Small Interfering; Sorafenib; Time-Lapse Imaging; Tumor Cells, Cultured | 2014 |
Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib | 2014 |
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Clofarabine; DNA Damage; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tandem Repeat Sequences; Vidarabine | 2014 |
Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Delayed onset perforating folliculitis associated with sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Eruptions; Folliculitis; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Time Factors | 2014 |
Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autocrine Communication; Benzamides; Cell Line, Tumor; Cell Survival; Diphenylamine; Drug Resistance, Neoplasm; Female; Humans; Interleukin-6; MAP Kinase Signaling System; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation, Missense; Niacinamide; Oncogenes; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Xenograft Model Antitumor Assays | 2014 |
Sorafenib regulating ERK signals pathway in gastric cancer cell.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Microcystis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Sorafenib; Stomach Neoplasms | 2014 |
Survival trends among patients with advanced renal cell carcinoma in the United States.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; SEER Program; Sorafenib; Survival Analysis; Survival Rate; Time Factors; Treatment Outcome; United States; Young Adult | 2015 |
MiR-200c sensitizes clear-cell renal cell carcinoma cells to sorafenib and imatinib by targeting heme oxygenase-1.
Topics: Antineoplastic Agents; Benzamides; Carcinoma, Renal Cell; Cell Line, Tumor; DNA Methylation; Heme Oxygenase-1; Humans; Imatinib Mesylate; Kidney Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Piperazines; Promoter Regions, Genetic; Pyrimidines; Sorafenib | 2014 |
[Synthesis and in vitro cytotoxic activities of sorafenib derivatives].
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Inhibitory Concentration 50; Molecular Structure; Niacinamide; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship | 2014 |
Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Humans; Immunologic Factors; Interferon-gamma; Lenalidomide; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocyte Subsets; Thalidomide | 2014 |
Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor α.
Topics: Breast Neoplasms; Cell Proliferation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 3-alpha; Humans; MCF-7 Cells; Niacinamide; Nuclear Receptor Coactivator 3; Phenylurea Compounds; Pyrimidines; Sorafenib; Tamoxifen | 2014 |
Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Knockout Techniques; Genetic Vectors; Hep G2 Cells; Humans; In Vitro Techniques; Liver Neoplasms; Membrane Proteins; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Plasmids; RNA, Small Interfering; Sorafenib | 2014 |
Reproducible complete remission of advanced hepatocellular carcinoma with sorafenib in combination with clopidogrel.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Platelet Aggregation Inhibitors; Receptors, Vascular Endothelial Growth Factor; Remission Induction; Sorafenib; Ticlopidine; Time Factors; Tomography, X-Ray Computed | 2014 |
The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Enzyme-Linked Immunosorbent Assay; Female; Genotype; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Tolerability of single-agent sorafenib in the treatment of elderly patients with hepatocellular carcinoma (HCC).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2014 |
BIRC6 promotes hepatocellular carcinogenesis: interaction of BIRC6 with p53 facilitating p53 degradation.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Humans; Inhibitor of Apoptosis Proteins; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Tumor Suppressor Protein p53; Ubiquitination | 2015 |
Synergistic effects of β-catenin inhibitors and sorafenib in hepatoma cells.
Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib | 2014 |
Sorafenib efficacy in thymic carcinomas seems not to require c-KIT or PDGFR-alpha mutations.
Topics: Aged; Antineoplastic Agents; DNA Mutational Analysis; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Receptor, Platelet-Derived Growth Factor alpha; Retrospective Studies; Sorafenib; Thymoma; Thymus Neoplasms; Treatment Outcome | 2014 |
S-Adenosyl-L-methionine-competitive inhibitors of the histone methyltransferase EZH2 induce autophagy and enhance drug sensitivity in cancer cells.
Topics: Adenosine; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line, Tumor; Cell Survival; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Gene Knockdown Techniques; Hep G2 Cells; Histone Methyltransferases; Histone-Lysine N-Methyltransferase; Humans; Indazoles; Niacinamide; Phenylurea Compounds; Polycomb Repressive Complex 2; Pyridones; S-Adenosylmethionine; Sorafenib | 2015 |
Acquired perforating dermatosis associated with sorafenib therapy.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Biopsy; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Skin; Skin Diseases; Sorafenib | 2016 |
In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cerebellar Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Indazoles; Male; Medulloblastoma; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2014 |
In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer.
Topics: Activating Transcription Factor 2; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 14; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; RNA, Small Interfering; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2014 |
Sorafenib overcomes the chemoresistance in HBx-expressing hepatocellular carcinoma cells through down-regulation of HBx protein stability and suppresses HBV gene expression.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cisplatin; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Viral; Hep G2 Cells; Hepatitis B virus; Humans; Interferon-alpha; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Proteasome Endopeptidase Complex; Protein Stability; Sorafenib; Trans-Activators; Transfection; Viral Regulatory and Accessory Proteins | 2014 |
2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Topics: 2-Methoxyestradiol; Active Transport, Cell Nucleus; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin D1; Dose-Response Relationship, Drug; Drug Synergism; Estradiol; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Isoenzymes; L-Lactate Dehydrogenase; Lactate Dehydrogenase 5; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; RNA Interference; Signal Transduction; Sorafenib; Time Factors; Transfection; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2014 |
The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; G1 Phase Cell Cycle Checkpoints; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Resting Phase, Cell Cycle; Sorafenib; Stomach Neoplasms | 2014 |
Combination of macrophage inflammatory protein 1 alpha with existing therapies to enhance the antitumor effects on murine hepatoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemokine CCL3; Chemoradiotherapy; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Sorafenib; Treatment Outcome | 2015 |
Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Drug Resistance, Neoplasm; Female; Hepatic Artery; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
Comparison of standard-dose and half‑dose sorafenib therapy on clinical outcome in patients with unresectable hepatocellular carcinoma in field practice: A propensity score matching analysis.
Topics: Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Sorafenib; Treatment Outcome | 2014 |
The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells.
Topics: Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; DNA Damage; Humans; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Sorafenib | 2014 |
Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNK-mediated NF-κB-dependent pathway that reduces uPA and MMP-9 expression.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MAP Kinase Kinase 4; Matrix Metalloproteinase 9; Metformin; Neoplasm Invasiveness; NF-kappa B; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Urokinase-Type Plasminogen Activator | 2014 |
Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden | 2014 |
Flavonoid-enriched apple fraction AF4 induces cell cycle arrest, DNA topoisomerase II inhibition, and apoptosis in human liver cancer HepG2 cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle Checkpoints; Cell Proliferation; Cell Survival; DNA Fragmentation; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Flavonoids; Hep G2 Cells; Humans; Liver Neoplasms; Malus; Niacinamide; Phenylurea Compounds; Sorafenib; Topoisomerase II Inhibitors | 2014 |
The isothiocyanate erucin abrogates telomerase in hepatocellular carcinoma cells in vitro and in an orthotopic xenograft tumour model of HCC.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA Damage; Gene Expression; Hep G2 Cells; Humans; Immunoblotting; Isothiocyanates; Kidney; Liver; Liver Neoplasms; Mice, Nude; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Sorafenib; Telomerase; Tumor Burden; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2014 |
Novel approach of MALDI drug imaging, immunohistochemistry, and digital image analysis for drug distribution studies in tissues.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Immunohistochemistry; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Sarcoma; Sorafenib; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tissue Distribution | 2014 |
Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients: Applicability of the BCLC Staging System.
Topics: Ablation Techniques; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Humans; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Tumor Burden | 2016 |
Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Risk Assessment; Sorafenib; Survival Rate | 2017 |
Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Republic of Korea; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2014 |
Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Stroke Volume; Thyroid Neoplasms; Treatment Outcome | 2014 |
Combination of individualized local control and target-specific agent to improve unresectable liver cancer managements: a matched case-control study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2015 |
Anti-proliferative but not anti-angiogenic tyrosine kinase inhibitors enrich for cancer stem cells in soft tissue sarcoma.
Topics: Aldehyde Dehydrogenase 1 Family; Angiogenesis Inhibitors; Animals; Antigens, CD; Cell Line, Tumor; Cell Proliferation; Cell Survival; Female; Humans; Indazoles; Isoenzymes; Liver Neoplasms; Lung Neoplasms; Mice, Inbred NOD; Neoadjuvant Therapy; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Retinal Dehydrogenase; Sarcoma; Sorafenib; Sulfonamides; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2014 |
The molecular mechanisms of a novel multi-kinase inhibitor ZLJ33 in suppressing pancreatic cancer growth.
Topics: Animals; beta Catenin; Blotting, Western; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Hydrazines; Immunoprecipitation; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2015 |
Prognostic factors in renal cell carcinoma patients treated with sorafenib: results from the Czech registry.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Czech Republic; Databases, Factual; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Registries; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2015 |
Safety and efficacy of transarterial chemoembolization plus sorafenib for hepatocellular carcinoma with portal venous tumour thrombus.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Dermatitis; Diarrhea; Fatigue; Female; Fever; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Venous Thrombosis | 2014 |
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib.
Topics: Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Indoles; Iodine Radioisotopes; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Thyroid Neoplasms; Treatment Failure | 2015 |
Molecular ultrasound imaging using contrast agents targeting endoglin, vascular endothelial growth factor receptor 2 and integrin.
Topics: Animals; Biomarkers, Tumor; Cell Line, Tumor; Contrast Media; Endoglin; Female; Integrin alphaV; Intracellular Signaling Peptides and Proteins; Melanoma; Mice; Mice, Nude; Molecular Imaging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Ultrasonography; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Binding interaction between sorafenib and calf thymus DNA: spectroscopic methodology, viscosity measurement and molecular docking.
Topics: Animals; Cattle; Circular Dichroism; DNA; Hydrogen Bonding; Kinetics; Molecular Conformation; Molecular Docking Simulation; Niacinamide; Osmolar Concentration; Phenylurea Compounds; Protein Binding; Sorafenib; Spectrometry, Fluorescence; Spectrophotometry, Ultraviolet; Thermodynamics; Viscosity | 2015 |
Synergistic anti-tumor effects of the combination of a benzofuroxan derivate and sorafenib on NCI-H460 human large cell lung carcinoma cells.
Topics: Antineoplastic Agents; Benzoxazoles; Carcinoma, Non-Small-Cell Lung; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Occurrence of hepatocellular carcinoma upon advanced liver fibrosis thirteen years after achieving sustained virological response to hepatitis C: how long surveillance should be maintained?
Topics: Antineoplastic Agents; Antiviral Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; RNA, Viral; Severity of Illness Index; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Viral Load | 2015 |
RFX-1-dependent activation of SHP-1 inhibits STAT3 signaling in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Chromatin Immunoprecipitation; DNA-Binding Proteins; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Liver Neoplasms; Luciferases; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyrroles; Real-Time Polymerase Chain Reaction; Regulatory Factor X Transcription Factors; Regulatory Factor X1; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
Arabidopsis putative MAP kinase kinase kinases Raf10 and Raf11 are positive regulators of seed dormancy and ABA response.
Topics: Abscisic Acid; Arabidopsis; Arabidopsis Proteins; Gene Expression Regulation, Plant; Germination; MAP Kinase Kinase Kinases; Models, Biological; Mutation; Niacinamide; Phenylurea Compounds; Plant Dormancy; Plant Growth Regulators; Plants, Genetically Modified; Protein Kinase Inhibitors; Recombinant Proteins; Seeds; Sorafenib; Transcription Factors | 2015 |
FLT3 and CDK4/6 inhibitors: signaling mechanisms and tumor burden in subcutaneous and orthotopic mouse models of acute myeloid leukemia.
Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Disease Models, Animal; fms-Like Tyrosine Kinase 3; Leukemia, Myeloid, Acute; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tumor Burden | 2014 |
Sprouty2 protein is downregulated in human squamous cell carcinoma of the head and neck and suppresses cell proliferation in vitro.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression; Head and Neck Neoplasms; Humans; Hyperplasia; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Tumor Burden | 2015 |
Serial low doses of sorafenib enhance therapeutic efficacy of adoptive T cell therapy in a murine model by improving tumor microenvironment.
Topics: Animals; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Drug Administration Schedule; Immunosuppressive Agents; Immunotherapy, Adoptive; Lymphoma; Mice; Mice, Transgenic; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Microenvironment | 2014 |
[Effects of sorafenib on proliferation and apoptosis of human multiple myeloma cell RPMI 8226].
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Humans; Multiple Myeloma; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sorafenib | 2014 |
Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Coupled variable selection for regression modeling of complex treatment patterns in a clinical cancer registry.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Confounding Factors, Epidemiologic; Data Interpretation, Statistical; Decision Support Techniques; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Registries; Regression Analysis; Sorafenib | 2014 |
Can 111In-RGD2 monitor response to therapy in head and neck tumor xenografts?
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cell Line, Tumor; Female; Head and Neck Neoplasms; Humans; Indium; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Oligopeptides; Phenylurea Compounds; Radioisotopes; Sorafenib; Time Factors; Tissue Distribution; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2014 |
Possible Role of Raf-1 Kinase in the Development of Cerebral Vasospasm and Early Brain Injury After Experimental Subarachnoid Hemorrhage in Rats.
Topics: Animals; Basilar Artery; Blood-Brain Barrier; Brain Damage, Chronic; Brain Edema; Cyclooxygenase 2; Disease Models, Animal; Down-Regulation; Interleukin-1beta; Interleukin-6; Male; MAP Kinase Kinase Kinases; Matrix Metalloproteinase 9; Mitogen-Activated Protein Kinase Kinases; Nerve Tissue Proteins; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-raf; Rats; Rats, Sprague-Dawley; RNA, Messenger; Signal Transduction; Sorafenib; Subarachnoid Hemorrhage; Vascular Endothelial Growth Factor A; Vasospasm, Intracranial | 2015 |
Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Humans; L-Lactate Dehydrogenase; Necrosis; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured | 2014 |
Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity.
Topics: Adult; Animals; Antineoplastic Agents; Cardiotoxicity; Down-Regulation; Glycoproteins; Heart; Humans; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib; Ventricular Dysfunction; Zebrafish | 2015 |
Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma.
Topics: Animals; Antibodies, Monoclonal; B7-H1 Antigen; Carcinoma, Hepatocellular; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Disease Models, Animal; Humans; Immunotherapy; Killer Cells, Natural; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |
Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Hospitals, University; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Assessment; Sorafenib; Statistics, Nonparametric; Survival Analysis; Survival Rate; Treatment Outcome | 2014 |
Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Circulation; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2014 |
Multiple mechanisms mediate resistance to sorafenib in urothelial cancer.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Urinary Bladder; Urinary Bladder Neoplasms; Urothelium | 2014 |
To treat or not to treat: developments in the field of advanced differentiated thyroid cancer.
Topics: Adenocarcinoma, Follicular; Aged; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Female; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2014 |
NSK-01105 inhibits proliferation and induces apoptosis of prostate cancer cells by blocking the Raf/MEK/ERK and PI3K/Akt/mTOR signal pathways.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; HCT116 Cells; Hep G2 Cells; HT29 Cells; Humans; Male; MAP Kinase Kinase Kinases; MCF-7 Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Quinazolines; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2015 |
Combination therapy with sorafenib and radiofrequency ablation for BCLC Stage 0-B1 hepatocellular carcinoma: a multicenter retrospective cohort study.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2014 |
Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma.
Topics: Activities of Daily Living; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Female; Humans; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Analysis; Thyroid Neoplasms; Thyroidectomy; Treatment Failure; Treatment Outcome; Young Adult | 2015 |
Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
Topics: Animals; Apoptosis; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Neoplasm Proteins; Niacinamide; Oxides; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2015 |
Generation of a murine hepatic angiosarcoma cell line and reproducible mouse tumor model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Hemangiosarcoma; Immunohistochemistry; Liver; Liver Neoplasms; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, Knockout; Mice, SCID; Microscopy, Electron; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Receptor, Notch1; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Tumor Burden | 2015 |
[Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement].
Topics: Antineoplastic Agents; Chemoradiotherapy; Evidence-Based Medicine; Germany; Humans; Iodine Radioisotopes; Medical Oncology; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Radiopharmaceuticals; Sorafenib; Thyroid Neoplasms; Treatment Failure; Treatment Outcome | 2015 |
Preparation and structure of drug-carrying biodegradable microspheres designed for transarterial chemoembolization therapy.
Topics: Absorbable Implants; Animals; Antineoplastic Agents; Cell Line, Tumor; Chemoembolization, Therapeutic; Cisplatin; Drug Delivery Systems; Drug Interactions; Drug Liberation; Human Umbilical Vein Endothelial Cells; Humans; Lactic Acid; Mice, Inbred BALB C; Microscopy, Electron, Scanning; Microspheres; Niacinamide; Phenylurea Compounds; Polyesters; Polymers; Porosity; Radiography; Sorafenib | 2015 |
Inhibition of c-Kit by tyrosine kinase inhibitors.
Topics: Aminopyridines; Antineoplastic Agents; Benzothiazoles; Biomarkers; Bone Marrow; Cell Line, Tumor; Clinical Trials as Topic; Dasatinib; fms-Like Tyrosine Kinase 3; Gene Expression; Hair; Hematopoietic Stem Cells; Humans; Indazoles; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Pigmentation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Thiazoles | 2015 |
Validation of the criteria of transcatheter arterial chemoembolization failure or refractoriness in patients with advanced hepatocellular carcinoma proposed by the LCSGJ.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hepatic Artery; Hepatitis C; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Reproducibility of Results; Retrospective Studies; Risk Factors; Sorafenib; Treatment Failure | 2014 |
Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Administration Schedule; Hepatectomy; Humans; Japan; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib; Survivors; Tomography, X-Ray Computed; Treatment Outcome | 2014 |
Measurement of sorafenib plasma concentration by high-performance liquid chromatography in patients with advanced hepatocellular carcinoma: is it useful the application in clinical practice? A pilot study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chromatography, High Pressure Liquid; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Sorafenib | 2015 |
Distinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3.
Topics: Animals; Antineoplastic Agents; Cachexia; Carcinoma, Lewis Lung; Colon; Colonic Neoplasms; Lung; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; STAT3 Transcription Factor; Wasting Syndrome | 2014 |
Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Everolimus; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Sunitinib | 2015 |
Sorafenib treatment of advanced renal cell carcinoma patients in daily practice: the large international PREDICT study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ambulatory Care Facilities; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2015 |
The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Female; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Necrosis; Niacinamide; Oxidative Stress; Phenylurea Compounds; Reactive Oxygen Species; Retinoblastoma Protein; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma.
Topics: Adult; Animals; beta Catenin; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Child; Epithelial-Mesenchymal Transition; Female; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Early treatment response to sorafenib for rabbit VX2 orthotic liver tumors: evaluation by quantitative contrast-enhanced ultrasound.
Topics: Animals; Contrast Media; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Tumor Burden; Ultrasonography | 2015 |
A rare primary liver tumor that responded to sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cholangiocarcinoma; Eukaryotic Initiation Factor-3; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Sorafenib | 2014 |
Correlation between LDH levels and response to sorafenib in HCC patients: an analysis of the ITA.LI.CA database.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Kaplan-Meier Estimate; L-Lactate Dehydrogenase; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; ROC Curve; Sorafenib; Treatment Outcome | 2015 |
Oncogenic c-Myc and prothymosin-alpha protect hepatocellular carcinoma cells against sorafenib-induced apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; DNA-Binding Proteins; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Precursors; Sorafenib; Thymosin; Transcription Factors | 2015 |
Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Hep G2 Cells; Humans; Imidazoles; MCF-7 Cells; Mice; Mice, Nude; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridines; Sorafenib; Structure-Activity Relationship | 2015 |
Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer.
Topics: Administration, Metronomic; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Female; Humans; Letrozole; Middle Aged; Niacinamide; Nitriles; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Triazoles | 2015 |
Sorafenib inhibits macrophage-induced growth of hepatoma cells by interference with insulin-like growth factor-1 secretion.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Macrophage Activation; Macrophage Colony-Stimulating Factor; Macrophages; Niacinamide; Phenylurea Compounds; raf Kinases; Receptors, Cell Surface; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2015 |
Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; China; Embolization, Therapeutic; Feasibility Studies; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Rupture, Spontaneous; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2014 |
Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Comorbidity; Drug Interactions; Drug Monitoring; Female; Follow-Up Studies; France; Hemorrhage; Humans; Incidence; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Platelet Aggregation Inhibitors; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Tumor Burden; Venous Thrombosis | 2015 |
Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Necrosis; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Regional Blood Flow; Sorafenib; Vascular Access Devices | 2015 |
Hypoxia promotes 786-O cells invasiveness and resistance to sorafenib via HIF-2α/COX-2.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Cadherins; Cyclooxygenase 2; Drug Resistance, Neoplasm; Humans; Hypoxia; Kidney Neoplasms; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Snail Family Transcription Factors; Sorafenib; Transcription Factors; Tumor Cells, Cultured | 2015 |
Cytochrome P450-Mediated Biotransformation of Sorafenib and Its N-Oxide Metabolite: Implications for Cell Viability and Human Toxicity.
Topics: Antineoplastic Agents; Biotransformation; Cell Cycle; Cell Survival; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Hep G2 Cells; Humans; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
Differential sensitivity of prostate tumor derived endothelial cells to sorafenib and sunitinib.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Endothelial Cells; Humans; Indoles; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2014 |
Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weighting.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Drug Evaluation; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Failure | 2015 |
[Percutaneous ablation of hepatocellular carcinoma in older patients in clinical practice].
Topics: Aged; Aged, 80 and over; Alcoholism; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Diabetes Complications; Ethanol; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Prospective Studies; Remission Induction; Sorafenib | 2015 |
Addition of local hepatic therapy to sorafenib in patients with advanced hepatocellular carcinoma (stage BCLC C).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Chemoembolization, Therapeutic; Combined Modality Therapy; Embolization, Therapeutic; Epirubicin; Ethiodized Oil; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tumor Burden | 2014 |
Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2015 |
Thyroid carcinoma, version 2.2014.
Topics: Adenocarcinoma; Anilides; Carcinoma, Neuroendocrine; Guidelines as Topic; Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Thyroid Neoplasms | 2014 |
[Clinical observation of transcatheter arterial chemoembolization plus sorafenib in the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Topics: Antineoplastic Agents; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Venous Thrombosis | 2014 |
Sorafenib therapy for hepatocellular carcinoma with extrahepatic spread: treatment outcome and prognostic factors.
Topics: Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis B, Chronic; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Radiography; Republic of Korea; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-treated hepatocellular carcinoma in mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immunotherapy; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Protein Kinase Inhibitors; Receptors, CXCR4; Sorafenib; Tumor Microenvironment | 2015 |
MiR-338-3p inhibits hepatocarcinoma cells and sensitizes these cells to sorafenib by targeting hypoxia-induced factor 1α.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Fluorescent Antibody Technique; Gene Expression Regulation, Neoplastic; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoenzyme Techniques; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2014 |
RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward?
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Denosumab; Drug Resistance, Neoplasm; Humans; Male; Niacinamide; Osteosarcoma; Phenylurea Compounds; Prognosis; RANK Ligand; Remission Induction; Salvage Therapy; Sorafenib | 2015 |
Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Angiogenesis Inhibitors; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Costs and Cost Analysis; Denmark; Drug Costs; Efficiency; Employment; Everolimus; Female; Fluorouracil; Health Care Costs; Hospitalization; Humans; Immunologic Factors; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Radiography; Radiotherapy; Registries; Sirolimus; Sorafenib; Sunitinib | 2015 |
Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation.
Topics: Adult; Antineoplastic Agents; Combined Modality Therapy; fms-Like Tyrosine Kinase 3; Gene Duplication; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Niacinamide; Off-Label Use; Phenylurea Compounds; Retrospective Studies; Sorafenib; Transplantation, Homologous; Treatment Outcome | 2015 |
Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Models, Animal; Injections, Intra-Arterial; Iodized Oil; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Treatment Outcome | 2014 |
NSK-01105, a novel sorafenib derivative, inhibits human prostate tumor growth via suppression of VEGFR2/EGFR-mediated angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Discovery; Enzyme Activation; ErbB Receptors; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Quinazolines; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2014 |
Sorafenib inhibits proliferation and invasion of human hepatocellular carcinoma cells via up-regulation of p53 and suppressing FoxM1.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Forkhead Box Protein M1; Forkhead Transcription Factors; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Knockout; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Suppressor Protein p53; Up-Regulation | 2015 |
The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Depsipeptides; Dose-Response Relationship, Drug; Drug Synergism; Female; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, SCID; Niacinamide; Phenylurea Compounds; Sorafenib; T-2 Toxin; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Expression of pERK and VEGFR-2 in advanced hepatocellular carcinoma and resistance to sorafenib treatment.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Resistance, Neoplasm; eIF-2 Kinase; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Sorafenib-induced severe urticaria in a patient with hepatocellular cancer.
Topics: Aged; Antineoplastic Agents; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Severity of Illness Index; Sorafenib; Urticaria | 2016 |
Cutaneous metastasis from hepatocellular carcinoma after a percutaneous interventional procedure.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Diathermy; Ethanol; Fatal Outcome; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Needles; Neoplasm Seeding; Niacinamide; Phenylurea Compounds; Radiofrequency Therapy; Sclerosing Solutions; Skin Neoplasms; Sorafenib | 2015 |
Comparison of sorafenib-loaded poly (lactic/glycolic) acid and DPPC liposome nanoparticles in the in vitro treatment of renal cell carcinoma.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Chemistry, Pharmaceutical; Chitosan; Dose-Response Relationship, Drug; Drug Carriers; Humans; Hydrophobic and Hydrophilic Interactions; Kidney Neoplasms; Kinetics; Lactic Acid; Liposomes; Nanoparticles; Nanotechnology; Niacinamide; Phenylurea Compounds; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Solubility; Sorafenib; Technology, Pharmaceutical | 2015 |
Sorafenib reverses resistance of gastric cancer to treatment by cisplatin through down-regulating MDR1 expression.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; Blotting, Western; Cell Line, Tumor; Cisplatin; Down-Regulation; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Hepatitis B viral load predicts survival in hepatocellular carcinoma patients treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; DNA, Viral; Drug Therapy, Combination; Female; Forecasting; Hepatitis B virus; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Survival Rate; Viral Load; Virus Activation | 2015 |
Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Comorbidity; Female; Humans; Incidence; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiography; Republic of Korea; Risk Assessment; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2015 |
Cyclophilin D-mediated apoptosis attributes to sorafenib-induced cytotoxicity in clear cell-renal cell carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cell Survival; Cyclophilins; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Kidney Neoplasms; Male; Membrane Potential, Mitochondrial; Middle Aged; Niacinamide; Peptidyl-Prolyl Isomerase F; Phenylurea Compounds; Sorafenib | 2015 |
The proteomic 2D-DIGE approach reveals the protein voltage-dependent anion channel 2 as a potential therapeutic target in epithelial thyroid tumours.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Cell Line, Tumor; Female; Humans; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Niacinamide; Phenylurea Compounds; Proteomics; Sorafenib; Thyroid Neoplasms; Two-Dimensional Difference Gel Electrophoresis; Up-Regulation; Voltage-Dependent Anion Channel 2; Young Adult | 2015 |
Paracrine factors of human fetal MSCs inhibit liver cancer growth through reduced activation of IGF-1R/PI3K/Akt signaling.
Topics: Carcinoma, Hepatocellular; Cell Proliferation; Culture Media, Conditioned; Fetus; Gene Knockdown Techniques; Humans; Indoles; Liver Neoplasms; Mesenchymal Stem Cells; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib; Sunitinib | 2015 |
Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biopharmaceutics; Cell Line, Tumor; Cell Proliferation; Curcumin; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms, Experimental; Mice; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Tissue Distribution; Xenograft Model Antitumor Assays | 2015 |
[Five-year therapeutic experience of sorafenib for patients with advanced renal cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Fatigue; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Sorafenib | 2014 |
MicroRNA-93 activates c-Met/PI3K/Akt pathway activity in hepatocellular carcinoma by directly inhibiting PTEN and CDKN1A.
Topics: 3' Untranslated Regions; Adult; Aged; Aged, 80 and over; Apoptosis; Binding Sites; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Female; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinase; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Pyrrolidinones; Quinolines; Sorafenib; Time Factors; Transfection; Up-Regulation | 2015 |
Dual-drug delivery by porous silicon nanoparticles for improved cellular uptake, sustained release, and combination therapy.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Delayed-Action Preparations; Drug Delivery Systems; Endocytosis; Humans; Methotrexate; Nanoparticles; Niacinamide; Particle Size; Phenylurea Compounds; Porosity; Silicon; Sorafenib; Spectroscopy, Fourier Transform Infrared; Static Electricity | 2015 |
Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Topics: Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nucleosides; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Reduction Behavior; Sorafenib; Survival Rate | 2015 |
Adjuvant sorafenib reduced mortality and prolonged overall survival and post-recurrence survival in hepatocellular carcinoma patients after curative resection: a single-center experience.
Topics: Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Care; Retrospective Studies; Sorafenib; Survival Analysis | 2014 |
Surgical resection versus transarterial chemoembolization for BCLC stage C hepatocellular carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Proportional Hazards Models; Serum Albumin; Sorafenib; Taiwan | 2015 |
Predictors of survival in patients with advanced hepatocellular carcinoma who permanently discontinued sorafenib.
Topics: Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Predictive Value of Tests; Prospective Studies; Reproducibility of Results; Risk Assessment; Sorafenib; Survival Analysis; Withholding Treatment | 2015 |
Cyproheptadine significantly improves the overall and progression-free survival of sorafenib-treated advanced HCC patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Case-Control Studies; Cyproheptadine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |
Sorafenib neoadjuvant therapy in the treatment of high risk renal cell carcinoma.
Topics: Adult; Aged; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Preoperative Period; Risk; Sorafenib; Treatment Outcome | 2015 |
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Neoplasm, Residual; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tandem Repeat Sequences | 2015 |
Sorafenib induces paradoxical phosphorylation of the extracellular signal-regulated kinase pathway in acute myeloid leukemia cells lacking FLT3-ITD mutation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Leukemia, Myeloid, Acute; Mice; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Signal Transduction; Sorafenib; Tandem Repeat Sequences | 2015 |
Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib.
Topics: Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Indazoles; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Tandem Mass Spectrometry | 2015 |
Survival Outcome Between Hepatic Resection and Transarterial Embolization for Hepatocellular Carcinoma More Than 10 cm: A Propensity Score Model.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Survival Rate; Tumor Burden | 2015 |
A high baseline HBV load and antiviral therapy affect the survival of patients with advanced HBV-related HCC treated with sorafenib.
Topics: Adult; Aged; Antiviral Agents; Carcinoma, Hepatocellular; DNA, Viral; Female; Hepatectomy; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Factors; Sorafenib; Survival Analysis; Viral Load | 2015 |
Personalized dosimetry with intensification using 90Y-loaded glass microsphere radioembolization induces prolonged overall survival in hepatocellular carcinoma patients with portal vein thrombosis.
Topics: Aged; Carcinoma, Hepatocellular; Embolization, Therapeutic; Europe; False Positive Reactions; Female; Glass; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiometry; Retrospective Studies; Sorafenib; Thrombosis; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes | 2015 |
Sorafenib ameliorates renal fibrosis through inhibition of TGF-β-induced epithelial-mesenchymal transition.
Topics: Actins; Animals; Apoptosis; Cadherins; Cell Line; Disease Models, Animal; Epithelial-Mesenchymal Transition; Fibrosis; Immunohistochemistry; Kidney Diseases; Male; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Smad3 Protein; Sorafenib; Transforming Growth Factor beta; Ureteral Obstruction | 2015 |
Antiproliferative activity of long chain acylated esters of quercetin-3-O-glucoside in hepatocellular carcinoma HepG2 cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Proliferation; Cisplatin; DNA Fragmentation; DNA Topoisomerases, Type II; Drug Screening Assays, Antitumor; Esters; Fatty Acids; Flavonoids; Glucosides; Hep G2 Cells; Humans; Liver Neoplasms; Microscopy, Fluorescence; Niacinamide; Phenylurea Compounds; Quercetin; Sorafenib | 2015 |
Long-lasting tumour response to sorafenib therapy in advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-2-Associated X Protein; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retinoids; Sorafenib; Tetrahydronaphthalenes; Tretinoin | 2015 |
Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; MAP Kinase Signaling System; Metformin; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Sorafenib; Spheroids, Cellular; Thyroid Neoplasms; Tumor Stem Cell Assay | 2015 |
PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation.
Topics: Animals; beta Catenin; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; HEK293 Cells; Homeodomain Proteins; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Sorafenib; Transcription, Genetic; Tumor Suppressor Proteins; Up-Regulation; Wnt Proteins | 2015 |
Predictive value of serum insulin-like growth factor-1 in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Humans; Insulin-Like Growth Factor I; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Rate | 2015 |
[Mechanisms of sorafenib induced NB4 cell apoptosis].
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; Down-Regulation; Humans; Leukemia, Promyelocytic, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocytes, Helper-Inducer | 2015 |
Comparison of treatment safety and patient survival in elderly versus nonelderly patients with advanced hepatocellular carcinoma receiving sorafenib combined with transarterial chemoembolization: a propensity score matching study.
Topics: Age Factors; Aged; Antineoplastic Agents; Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Safety; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
miR-27b synergizes with anticancer drugs via p53 activation and CYP1B1 suppression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cytochrome P-450 CYP1B1; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Inactivation, Metabolic; Kidney Neoplasms; Liver Neoplasms; Mice; MicroRNAs; Niacinamide; Phenylurea Compounds; RNA, Messenger; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Multifunctional porous silicon nanoparticles for cancer theranostics.
Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Humans; Male; Mice, Nude; Nanoparticles; Neoplasms; Niacinamide; Phenylurea Compounds; Silicon; Sorafenib; Theranostic Nanomedicine | 2015 |
Fulminant hepatitis in a patient with hepatocellular carcinoma related to nonalcoholic steatohepatitis treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Fatal Outcome; Humans; Jaundice; Liver Failure, Acute; Liver Neoplasms; Male; Muscle Weakness; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed; Tremor | 2015 |
Nexavar/Stivarga and viagra interact to kill tumor cells.
Topics: Apoptosis; Cell Proliferation; Cyclic Nucleotide Phosphodiesterases, Type 5; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Signal Transduction; Sildenafil Citrate; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2015 |
Education and imaging. Hepatology: Complete regression of locally advanced hepatocellular carcinoma following Sorafenib monotherapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Remission Induction; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Deoxycytidine; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Prospective Studies; Sorafenib | 2015 |
MiRNA-30a-mediated autophagy inhibition sensitizes renal cell carcinoma cells to sorafenib.
Topics: Aged; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 5; Beclin-1; Carcinoma, Renal Cell; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Kidney Neoplasms; Male; Membrane Proteins; MicroRNAs; Microtubule-Associated Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; RNA, Neoplasm; RNA, Small Interfering; Signal Transduction; Sorafenib; Up-Regulation | 2015 |
MiRNA153 Reduces Effects of Chemotherapeutic Agents or Small Molecular Kinase Inhibitor in HCC Cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Sorafenib | 2015 |
Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model.
Topics: Animals; Chaperonin 60; Diet, High-Fat; Diethylnitrosamine; Disease Models, Animal; Fibrillar Collagens; Glutathione Transferase; HSP90 Heat-Shock Proteins; Interleukin-10; Interleukin-6; Liver Cirrhosis; Matrix Metalloproteinase 9; Mitochondria, Liver; Niacinamide; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phenylurea Compounds; Polarography; Protein Kinase Inhibitors; Rats, Sprague-Dawley; RNA, Messenger; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transcription Factors | 2015 |
Combination of Matrine and Sorafenib Decreases the Aggressive Phenotypes of Hepatocellular Carcinoma Cells.
Topics: Alkaloids; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver Neoplasms; Matrines; Niacinamide; Phenotype; Phenylurea Compounds; Quinolizines; Sorafenib | 2014 |
[A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2014 |
Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Female; G1 Phase; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Osteosarcoma; Phenylurea Compounds; Phosphorylation; Reactive Oxygen Species; Resting Phase, Cell Cycle; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Complete remission of advanced hepatocellular carcinoma by radiofrequency ablation after sorafenib therapy.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Catheter Ablation; Humans; Liver Neoplasms; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography, Interventional | 2015 |
Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Keratin-18; Liver Neoplasms; Male; Necrosis; Niacinamide; Phenylurea Compounds; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2015 |
Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge.
Topics: Antineoplastic Agents; Female; Humans; Iodine Radioisotopes; Liver; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Sorafenib; Thyroid Neoplasms | 2015 |
Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer.
Topics: Anilides; Antineoplastic Agents; Apoptosis; Autoantigens; Carcinoma, Papillary; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Glucose Transporter Type 3; Humans; Iodide Peroxidase; Iron-Binding Proteins; Microfilament Proteins; Muscle Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-ret; Pyridines; Receptors, Thyrotropin; Signal Transduction; Sorafenib; Symporters; Thyroid Neoplasms | 2015 |
The multikinase inhibitor Sorafenib enhances glycolysis and synergizes with glycolysis blockade for cancer cell killing.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Cell Respiration; Cell Survival; Deoxyglucose; Energy Metabolism; Glycolysis; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Reactive Oxygen Species; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2015 |
Relationship of pathologic factors to efficacy of sorafenib treatment in patients with metastatic clear cell renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Grading; Neoplasm Staging; Nephrectomy; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Sorafenib | 2015 |
Regulation of multidrug resistance proteins by genistein in a hepatocarcinoma cell line: impact on sorafenib cytotoxicity.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Genistein; Humans; Liver Neoplasms; Membrane Transport Proteins; MicroRNAs; Niacinamide; Phenylurea Compounds; Phytoestrogens; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib; Tumor Cells, Cultured | 2015 |
Pneumothorax as a complication of combination antiangiogenic therapy in children and young adults with refractory/recurrent solid tumors.
Topics: Adolescent; Adult; Angiogenesis Inhibitors; Bevacizumab; Bone Neoplasms; Child; Child, Preschool; Female; Humans; Infant; Male; Neoplasm Recurrence, Local; Niacinamide; Osteosarcoma; Phenylurea Compounds; Pneumothorax; Sarcoma, Ewing; Sarcoma, Synovial; Sorafenib; Wilms Tumor; Young Adult | 2015 |
Sneddon-Wilkinson disease induced by sorafenib in a patient with advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Skin Diseases, Vesiculobullous; Sorafenib | 2015 |
Growth-factor-driven rescue to receptor tyrosine kinase (RTK) inhibitors through Akt and Erk phosphorylation in pediatric low grade astrocytoma and ependymoma.
Topics: Apoptosis; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Movement; Crizotinib; Dasatinib; Ependymoma; Extracellular Signal-Regulated MAP Kinases; Humans; Intercellular Signaling Peptides and Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Signal Transduction; Sorafenib | 2015 |
Synthesis and broad-spectrum antiproliferative activity of diarylamides and diarylureas possessing 1,3,4-oxadiazole derivatives.
Topics: Amides; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Niacinamide; Oxadiazoles; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship; Urea | 2015 |
Effects of Antitumor Drug Sorafenib on Chick Embryo Development.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Movement; Chick Embryo; Embryonic Development; Epithelial-Mesenchymal Transition; Gastrulation; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study.
Topics: Adult; Aged, 80 and over; Canada; Cardiovascular Diseases; Female; Humans; Indoles; Male; Middle Aged; Myocardial Ischemia; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2015 |
PHY906(KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Drugs, Chinese Herbal; Humans; Liver Neoplasms; Medicine, Chinese Traditional; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Plant Extracts; Scutellaria baicalensis; Sorafenib; Tumor Microenvironment | 2015 |
Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Cell Line, Tumor; Drug Administration Schedule; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Expression; Humans; Leukemia, Myeloid, Acute; Mice; Monocytes; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Survival Analysis; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro.
Topics: Antiviral Agents; Cells, Cultured; Hepacivirus; Hepatocytes; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Virus Internalization; Virus Replication | 2015 |
Decreased miR122 in hepatocellular carcinoma leads to chemoresistance with increased arginine.
Topics: Animals; Apoptosis; Arginine; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; MicroRNAs; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Radiation-induced hemorrhagic duodenitis associated with sorafenib treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Duodenitis; Gastrointestinal Hemorrhage; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiation Injuries; Radiotherapy; Receptor Protein-Tyrosine Kinases; Sorafenib | 2015 |
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Silybin; Silymarin; Sorafenib | 2015 |
Low-dose steroid-induced tumor lysis syndrome in a hepatocellular carcinoma patient.
Topics: Acute Kidney Injury; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Creatinine; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Steroids; Tomography, X-Ray Computed; Tumor Lysis Syndrome | 2015 |
Professor Shukui Qin: patient reported outcomes in study of axitinib or sorafenib in Asian patients with metastatic renal cell carcinoma.
Topics: Asia; Asian People; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Time Factors; Treatment Outcome | 2015 |
Sorafenib enhances the antitumor effects of anti-CTLA-4 antibody in a murine cancer model by inhibiting myeloid-derived suppressor cells.
Topics: Animals; Antibodies, Anti-Idiotypic; CD8-Positive T-Lymphocytes; CTLA-4 Antigen; Humans; Kidney Neoplasms; Lymphocyte Activation; Mice; Myeloid Cells; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Survival in relation to hospital type after resection or sorafenib treatment for hepatocellular carcinoma in The Netherlands.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Hepatectomy; Hospitals; Humans; Liver Neoplasms; Male; Middle Aged; Netherlands; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate | 2015 |
GRP78/Dna K Is a Target for Nexavar/Stivarga/Votrient in the Treatment of Human Malignancies, Viral Infections and Bacterial Diseases.
Topics: Animals; Bacterial Infections; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Escherichia coli; Heat-Shock Proteins; Humans; Indazoles; Neoplasms; Niacinamide; Phenylurea Compounds; Polynucleotide 5'-Hydroxyl-Kinase; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; Sulfonamides; Virus Diseases | 2015 |
Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Taiwan; Treatment Failure | 2015 |
Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Complement System Proteins; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Niacinamide; Phenylurea Compounds; Rituximab; Sorafenib | 2015 |
Sorafenib treatment in Child-Pugh A and B patients with advanced hepatocellular carcinoma: safety, efficacy and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2015 |
Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure.
Topics: Administration, Metronomic; Aged; Antineoplastic Agents; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Failure | 2015 |
Enhanced sensitivity to sorafenib by inhibition of Akt1 expression in human renal cell carcinoma ACHN cells both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression; Gene Silencing; Humans; Kidney Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Sorafenib; Tumor Cells, Cultured | 2015 |
Targeting mTOR and AREG with everolimus, sunitinib and sorafenib in HPV-positive and -negative SCC.
Topics: Amphiregulin; Carcinoma, Squamous Cell; EGF Family of Proteins; Everolimus; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Indoles; Molecular Targeted Therapy; Niacinamide; Papillomaviridae; Phenylurea Compounds; Pyrroles; Sirolimus; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Sunitinib; TOR Serine-Threonine Kinases | 2015 |
Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Topics: Carcinoma, Hepatocellular; Cell Movement; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib | 2015 |
Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
Topics: Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Drug Synergism; Hep G2 Cells; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vitamin K | 2015 |
Sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombus.
Topics: Aged; Carcinoma, Hepatocellular; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Retrospective Studies; Sorafenib; Thrombosis; Treatment Outcome | 2015 |
PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Disease Progression; Humans; Liver Neoplasms; MAP Kinase Signaling System; Mice; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Prognosis; Protein Tyrosine Phosphatase, Non-Receptor Type 11; raf Kinases; Sorafenib | 2015 |
Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Female; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Niacinamide; Nitrogen Mustard Compounds; Phenylurea Compounds; Prodrugs; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition.
Topics: Cell Culture Techniques; Cell Line, Tumor; Cell Movement; Collagenases; Humans; Hydrogels; Indoles; Melanoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Tissue Scaffolds; Vemurafenib | 2015 |
A novel approach using sorafenib in alpha fetoprotein-producing hepatoid adenocarcinoma of the lung.
Topics: Adenocarcinoma; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Fatal Outcome; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Sorafenib | 2015 |
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Atrophy; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreas; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Survival; Humans; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2015 |
Identification of a unique hepatocellular carcinoma line, Li-7, with CD13(+) cancer stem cells hierarchy and population change upon its differentiation during culture and effects of sorafenib.
Topics: Animals; Carcinoma, Hepatocellular; CD13 Antigens; Cell Differentiation; Cell Line, Tumor; Cell Lineage; Gene Expression Regulation, Neoplastic; Genetic Heterogeneity; Humans; Liver Neoplasms; Mice; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome | 2015 |
Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Liberation; Folic Acid; Humans; Iron; Liver Neoplasms; Magnetic Phenomena; Nanoparticles; Niacinamide; Phenylurea Compounds; Polyesters; Polyethylene Glycols; Sorafenib | 2015 |
Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Remission Induction; Sorafenib | 2015 |
Sorafenib and DE605, a novel c-Met inhibitor, synergistically suppress hepatocellular carcinoma.
Topics: Aminopyridines; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoxazoles; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Real-Time Polymerase Chain Reaction; Sorafenib; Transfection; Xenograft Model Antitumor Assays | 2015 |
Sorafenib in the treatment of recurrent hepatocellular carcinoma after liver transplantation: a report of four cases.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Sorafenib; Tomography, X-Ray Computed | 2015 |
Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer.
Topics: Administration, Metronomic; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
RACK1 modulates apoptosis induced by sorafenib in HCC cells by interfering with the IRE1/XBP1 axis.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; DNA-Binding Proteins; Endoribonucleases; Gene Expression Regulation, Neoplastic; GTP-Binding Proteins; Humans; Liver Neoplasms; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Serine-Threonine Kinases; Receptors for Activated C Kinase; Receptors, Cell Surface; Regulatory Factor X Transcription Factors; Signal Transduction; Sorafenib; Transcription Factors; Unfolded Protein Response; X-Box Binding Protein 1 | 2015 |
Nuclear factor kappa B-mediated CD47 up-regulation promotes sorafenib resistance and its blockade synergizes the effect of sorafenib in hepatocellular carcinoma in mice.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; CD47 Antigen; Disease Models, Animal; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, SCID; Molecular Targeted Therapy; NF-kappa B; Niacinamide; Phenylurea Compounds; Random Allocation; Signal Transduction; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Epidermal Growth Factor; Erlotinib Hydrochloride; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyridines; Quinazolines; Sorafenib | 2015 |
Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Mice, SCID; Niacinamide; Phenylurea Compounds; Random Allocation; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
[CLAG regimen in combination with sorafenib in the treatment of refractory acute myeloid leukemia:a case report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Cost-Benefit Analysis; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
Different survival of Barcelona clinic liver cancer stage C hepatocellular carcinoma patients by the extent of portal vein invasion and the type of extrahepatic spread.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis B; Humans; Liver Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Prospective Studies; Risk Factors; Sorafenib; Survival Analysis; Terminology as Topic | 2015 |
Skeletal muscle depletion predicts the prognosis of patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aging; Carcinoma, Hepatocellular; Demography; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Linear Models; Liver Neoplasms; Male; Multivariate Analysis; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Risk Factors; Sorafenib; Withholding Treatment | 2015 |
Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b.
Topics: Animals; Female; Glucuronidase; Glucuronides; Hepatocytes; Humans; Intestines; Mice; Mice, Inbred C57BL; Mice, Knockout; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Niacinamide; Organic Cation Transport Proteins; Phenylurea Compounds; Rats; Sf9 Cells; Sorafenib | 2015 |
The combination of sorafenib and everolimus shows antitumor activity in preclinical models of malignant pleural mesothelioma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cytoskeletal Proteins; Drug Synergism; Everolimus; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Mesothelioma; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Pleural Neoplasms; Sorafenib; TOR Serine-Threonine Kinases; Treatment Outcome; Xenograft Model Antitumor Assays | 2015 |
Evaluation of in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Disease Models, Animal; Everolimus; Genetic Engineering; Homozygote; Immunohistochemistry; In Situ Nick-End Labeling; Male; Mice; Mice, Knockout; Neoplasms, Experimental; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; PTEN Phosphohydrolase; Signal Transduction; Sorafenib | 2015 |
Sorafenib-induced hand-foot syndrome.
Topics: Aged; Antineoplastic Agents; Hand-Foot Syndrome; Humans; Male; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Cost-effectiveness analysis of axitinib through a probabilistic decision model.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Markov Chains; Models, Economic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Sorafenib; Uncertainty | 2015 |
Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; bcl-2-Associated X Protein; Cell Proliferation; Disease Models, Animal; Endometriosis; Endometrium; Female; Indazoles; Indoles; Niacinamide; Ovarian Reserve; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2015 |
Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Sorafenib; Tandem Repeat Sequences; Treatment Outcome | 2015 |
NFATc1 as a therapeutic target in FLT3-ITD-positive AML.
Topics: Apoptosis; Biomarkers, Tumor; Blotting, Western; Cell Proliferation; Cyclosporine; Drug Resistance, Neoplasm; Flow Cytometry; fms-Like Tyrosine Kinase 3; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; NFATC Transcription Factors; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Sorafenib; Survival Rate; Tandem Repeat Sequences; Tumor Cells, Cultured | 2015 |
High Serum Transforming Growth Factor-β1 Levels Predict Outcome in Hepatocellular Carcinoma Patients Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; RNA, Messenger; Sorafenib; Transforming Growth Factor beta1; Treatment Outcome | 2015 |
Corosolic Acid Inhibits Hepatocellular Carcinoma Cell Migration by Targeting the VEGFR2/Src/FAK Pathway.
Topics: Actins; Adenosine Triphosphate; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Down-Regulation; Drug Synergism; Focal Adhesion Kinase 1; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; src-Family Kinases; Triterpenes; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Binding interaction of sorafenib with bovine serum albumin: Spectroscopic methodologies and molecular docking.
Topics: Animals; Binding Sites; Cattle; Circular Dichroism; Energy Transfer; Kinetics; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Conformation; Serum Albumin, Bovine; Sorafenib; Spectrophotometry, Ultraviolet; Thermodynamics | 2015 |
Combination of oxaliplatin and S-1 versus sorafenib alone in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Disease-Free Survival; Drug Combinations; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Phenylurea Compounds; Sorafenib; Tegafur; Treatment Outcome | 2014 |
[Therapeutic decisions and treatment with sorafenib in hepatocellular carcinoma: final analysis of GIDEON study in Italy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib | 2015 |
Model Matters: Differences in Orthotopic Rat Hepatocellular Carcinoma Physiology Determine Therapy Response to Sorafenib.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Comparative Genomic Hybridization; Disease Models, Animal; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Male; Neoplasm Grading; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Sorafenib | 2015 |
Results of the first trial assessing adjuvant tyrosine kinase inhibitors in renal cell carcinoma do not reASSURE.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Early Termination of Clinical Trials; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Treatment Outcome | 2015 |
Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blood Loss, Surgical; Carcinoma, Hepatocellular; Combined Modality Therapy; Diagnostic Imaging; Disease-Free Survival; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Operative Time; Phenylurea Compounds; Sorafenib; Thrombosis; Vena Cava, Inferior | 2015 |
Baseline chronic kidney disease is associated with toxicity and survival in patients treated with targeted therapies for metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Chronic Disease; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Diseases; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate | 2015 |
Poly(lactide-co-glycolide) microspheres for MRI-monitored delivery of sorafenib in a rabbit VX2 model.
Topics: Animals; Antineoplastic Agents; Capsules; Cell Line, Tumor; Contrast Media; Diffusion; Drug Monitoring; Ferric Compounds; Liver Neoplasms; Magnetic Resonance Imaging; Niacinamide; Particle Size; Phenylurea Compounds; Polyglactin 910; Rabbits; Sorafenib | 2015 |
Effects of sorafenib on lung metastasis in rats with hepatocellular carcinoma: the role of microRNAs.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Rats; Sorafenib | 2015 |
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System.
Topics: Aged; Antineoplastic Agents; Arteries; Blood Pressure; Carcinoma, Renal Cell; Female; Heart; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pulse Wave Analysis; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Neoplasms; Vascular Stiffness | 2016 |
CSN5 silencing reverses sorafenib resistance of human hepatocellular carcinoma HepG2 cells.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; COP9 Signalosome Complex; Cyclin D1; Cyclin-Dependent Kinase 6; Drug Resistance, Neoplasm; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Integrin beta1; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; NF-kappa B; Niacinamide; Peptide Hydrolases; Phenylurea Compounds; RNA, Small Interfering; Signal Transduction; Sorafenib; Transforming Growth Factor beta1 | 2015 |
Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 9; Cell Proliferation; DNA Transposable Elements; Drug Synergism; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylcholine; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins p21(ras); RNA, Small Interfering; Sorafenib; Tumor Suppressor Protein p53 | 2015 |
Active Targeting of Sorafenib: Preparation, Characterization, and In Vitro Testing of Drug-Loaded Magnetic Solid Lipid Nanoparticles.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Dextrans; Drug Carriers; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Magnetic Resonance Imaging; Magnetite Nanoparticles; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition.
Topics: Animals; Cell Line; Hepatic Stellate Cells; Humans; Liver Cirrhosis; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; STAT3 Transcription Factor | 2015 |
Evaluation of sorafenib treatment and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a comparative study using the propensity score matching method.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Propensity Score; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2015 |
Characterization of interactions and pharmacophore development for DFG-out inhibitors to RET tyrosine kinase.
Topics: Aminopyridines; Binding Sites; Humans; Indoles; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Naphthalenes; Niacinamide; Oligonucleotides; Phenylurea Compounds; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Pyrazoles; Sorafenib; Structural Homology, Protein; Thermodynamics; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
miR-494 promotes cell proliferation, migration and invasion, and increased sorafenib resistance in hepatocellular carcinoma by targeting PTEN.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; PTEN Phosphohydrolase; Sorafenib | 2015 |
Interaction of key pathways in sorafenib-treated hepatocellular carcinoma based on a PCR-array.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Polymerase Chain Reaction; Signal Transduction; Sorafenib | 2015 |
Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Biomarkers; Biomarkers, Tumor; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Female; Formaldehyde; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; High-Throughput Nucleotide Sequencing; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Neuregulin-1; Niacinamide; Paraffin Embedding; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Sequence Analysis, DNA; Sequence Analysis, RNA; Sorafenib; Transforming Growth Factor alpha; Treatment Outcome; Tumor Suppressor Protein p53 | 2015 |
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Cell Proliferation; Female; Hep G2 Cells; Humans; Immunohistochemistry; Indoles; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Pyrazoles; Pyrroles; Quinolines; Signal Transduction; Sorafenib; Sunitinib; Transforming Growth Factor beta1 | 2015 |
Activation of RAF1 (c-RAF) by the Marine Alkaloid Lasonolide A Induces Rapid Premature Chromosome Condensation.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; Chromatin; Chromosomes; Embryo, Mammalian; Fibroblasts; Humans; Macrolides; Mice; Niacinamide; Phenylurea Compounds; Phosphorylation; Porifera; Proto-Oncogene Proteins c-raf; Sorafenib | 2015 |
Integration of Hedgehog and mutant FLT3 signaling in myeloid leukemia.
Topics: Animals; Cell Compartmentation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Hedgehog Proteins; Humans; Kruppel-Like Transcription Factors; Leukemia, Myeloid, Acute; Mice; Mutant Proteins; Myeloproliferative Disorders; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Receptors, G-Protein-Coupled; Signal Transduction; Smoothened Receptor; Sorafenib; STAT5 Transcription Factor; Stem Cells; Veratrum Alkaloids; Zinc Finger Protein Gli2 | 2015 |
Prolonging survival in metastatic renal cell carcinoma patients treated with targeted anticancer agents: a single-center experience of treatment strategy modifications.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease-Free Survival; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Life Style; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Pyrroles; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2015 |
Early decline in serum phospho-CSE1L levels in vemurafenib/sunitinib-treated melanoma and sorafenib/lapatinib-treated colorectal tumor xenografts.
Topics: Animals; Antibodies, Neoplasm; Cell Line, Tumor; Cell Proliferation; Cellular Apoptosis Susceptibility Protein; Colorectal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Lapatinib; Male; Melanoma; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Pyrroles; Quinazolines; Sorafenib; Sulfonamides; Sunitinib; Vemurafenib; Xenograft Model Antitumor Assays | 2015 |
1118-20, an indazole diarylurea compound, inhibits hepatocellular carcinoma HepG2 proliferation and tumour angiogenesis involving Wnt/β-catenin pathway and receptor tyrosine kinases.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Indazoles; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptor Protein-Tyrosine Kinases; Sorafenib; Wnt Signaling Pathway | 2015 |
[Systemic therapy of soft tissue sarcomas].
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Dacarbazine; Deoxycytidine; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Female; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Ifosfamide; Indazoles; Indoles; Male; Molecular Targeted Therapy; Neoadjuvant Therapy; Niacinamide; Palliative Care; Phenylurea Compounds; Polyethylene Glycols; Pyrimidines; Pyrroles; Radiography; Sarcoma; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome | 2015 |
Comparative Metabolomic Profiling of Hepatocellular Carcinoma Cells Treated with Sorafenib Monotherapy vs. Sorafenib-Everolimus Combination Therapy.
Topics: Annexin A5; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Drug Synergism; Everolimus; Fluorescein-5-isothiocyanate; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Spectroscopy; Metabolic Networks and Pathways; Metabolomics; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Sorafenib; Tetrazolium Salts; Thiazoles | 2015 |
Sorafenib continuation or discontinuation in patients with unresectable hepatocellular carcinoma after a complete response.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Quality of Life; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
Novel Cancer Therapeutics with Allosteric Modulation of the Mitochondrial C-Raf-DAPK Complex by Raf Inhibitor Combination Therapy.
Topics: Aged; Animals; Apoptosis; Cell Line, Tumor; Death-Associated Protein Kinases; Disease-Free Survival; Drug Synergism; Female; Gene Knockout Techniques; Humans; Indoles; Kidney Neoplasms; Male; Mice; Middle Aged; Mitochondria; Niacinamide; Phenols; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-raf; Reactive Oxygen Species; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Development of a Drug-Response Modeling Framework to Identify Cell Line Derived Translational Biomarkers That Can Predict Treatment Outcome to Erlotinib or Sorafenib.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Models, Statistical; Neoplasms; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Survival Analysis | 2015 |
Long-term therapy with sorafenib is associated with pancreatic atrophy.
Topics: Aged; Antineoplastic Agents; Atrophy; Carcinoma, Hepatocellular; China; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Pancreas; Pancreatic Diseases; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Carcinoma, Hepatocellular; Cisplatin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2015 |
Abdominal Distension in a Patient With Hepatocellular Carcinoma. Benign Pneumatosis Intestinalis and Pneumoperitoneum Associated With Sorafenib Therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Jejunum; Liver Neoplasms; Male; Niacinamide; Peritoneal Cavity; Phenylurea Compounds; Pneumatosis Cystoides Intestinalis; Pneumoperitoneum; Sorafenib; Tomography, X-Ray Computed | 2015 |
Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Renal Cell; Contrast Media; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Feasibility Studies; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2015 |
2-Deoxy-d-Glucose Can Complement Doxorubicin and Sorafenib to Suppress the Growth of Papillary Thyroid Carcinoma Cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxyglucose; Dose-Response Relationship, Drug; Doxorubicin; Drug Combinations; Drug Synergism; Gene Expression; Glycolysis; Humans; Lactic Acid; Mutation; Niacinamide; Oxygen Consumption; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Thyroid Gland | 2015 |
Sustained complete remission of advanced hepatocellular carcinoma with sorafenib therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Remission Induction; Sorafenib | 2015 |
Sorafenib in the treatment of thyroid cancer.
Topics: Animals; Antineoplastic Agents; Disease-Free Survival; Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2015 |
Comparison of Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Study.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2014 |
Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Risk Assessment; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Young Adult | 2014 |
MiR-101 targets DUSP1 to regulate the TGF-β secretion in sorafenib inhibits macrophage-induced growth of hepatocarcinoma.
Topics: Adult; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Dual Specificity Phosphatase 1; Enzyme Activation; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Immunohistochemistry; Lipopolysaccharides; Liver Neoplasms; Macrophages; Male; MicroRNAs; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; Transforming Growth Factor beta1 | 2015 |
Systemic Treatment: Expecting Further Success.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A | 2015 |
Efficacy and safety of sorafenib for treatment of Japanese metastatic renal cell carcinoma patients undergoing hemodialysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Renal Dialysis; Retrospective Studies; Risk Assessment; Sorafenib; Survival Rate; Treatment Outcome | 2016 |
Inhibition of MAPK and VEGFR by Sorafenib Controls the Progression of Endometriosis.
Topics: Adult; Animals; Apoptosis; Case-Control Studies; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Endometriosis; Endometrium; Extracellular Signal-Regulated MAP Kinases; Female; Heterografts; Humans; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Stromal Cells; Time Factors; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Next Generation of Preclinical Liver Cancer Models.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Comparative Genomic Hybridization; Disease Models, Animal; Genetic Heterogeneity; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Protein Kinase Inhibitors; Sorafenib | 2015 |
Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma.
Topics: Aged; Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Proteins; Cell Cycle Proteins; Cell Line, Tumor; Chromatin Immunoprecipitation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Middle Aged; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Sorafenib; Transfection; Xenograft Model Antitumor Assays | 2015 |
The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2014 |
[Hepatocellular Carcinoma: therapeutic options 2015].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy; Combined Modality Therapy; Evidence-Based Medicine; Humans; Internationality; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Sorafenib-Sunitinib Sequence: The Jury Is Out.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2015 |
Adaptive GPU-accelerated force calculation for interactive rigid molecular docking using haptics.
Topics: Algorithms; Animals; Aprotinin; Benchmarking; Binding Sites; Cattle; Chaperonin 10; Chaperonin 60; Computer Graphics; Epidermal Growth Factor; ErbB Receptors; Humans; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Binding; Proto-Oncogene Proteins B-raf; Sorafenib; Trypsin; User-Computer Interface | 2015 |
Hepatocellular Carcinoma with Cervical Spine and Pelvic Bone Metastases Presenting as Unknown Primary Neoplasm.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Cervical Cord; Chemoembolization, Therapeutic; Gamma Rays; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasms, Unknown Primary; Niacinamide; Pelvic Bones; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2015 |
[Two Patients with Recurrence of Hepatocellular Carcinoma after Liver Resection Who Achieved Long-Term Stable Disease with Small Doses of Sorafenib Therapy].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Japan; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Sorafenib Action in Hepatitis B Virus X-Activated Oncogenic Androgen Pathway in Liver through SHP-1.
Topics: Age Factors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Enzyme Activation; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hepatitis B; Hepatitis B virus; Incidence; Liver Neoplasms; Male; Mice; Mice, Transgenic; Niacinamide; Orchiectomy; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Signal Transduction; Sorafenib; Trans-Activators; Viral Regulatory and Accessory Proteins | 2015 |
Visceral fat area predicts survival in patients with advanced hepatocellular carcinoma treated with tyrosine kinase inhibitors.
Topics: Aged; Alanine; alpha-Fetoproteins; Carcinoma, Hepatocellular; Female; France; Hand-Foot Syndrome; Humans; Intra-Abdominal Fat; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sarcopenia; Sorafenib; Survival Rate; Tomography, X-Ray Computed; Triazines | 2015 |
Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
Topics: Antineoplastic Agents; Caprylates; Cell Survival; Chromatography, High Pressure Liquid; Delayed-Action Preparations; Drug Carriers; Drug Liberation; Hemolysis; Hep G2 Cells; Humans; Lipids; Microscopy, Electron, Scanning; Nanoparticles; Niacinamide; Particle Size; Phenylurea Compounds; Sorafenib; Triglycerides | 2015 |
CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer.
Topics: Animals; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Resistance, Neoplasm; Endocytosis; Human Umbilical Vein Endothelial Cells; Humans; Lactic Acid; Lipids; Liver Neoplasms; Male; Mice; Nanoparticles; Neoplasm Metastasis; Niacinamide; Phenotype; Phenylurea Compounds; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Receptors, CXCR4; Sorafenib; Survival Analysis; Tumor Microenvironment | 2015 |
Sorafenib combined with percutaneous radiofrequency ablation for the treatment of medium-sized hepatocellular carcinoma.
Topics: Antineoplastic Agents; Catheter Ablation; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Engineering Melanin Nanoparticles as an Efficient Drug-Delivery System for Imaging-Guided Chemotherapy.
Topics: Animals; Antineoplastic Agents; Drug Carriers; Engineering; Hep G2 Cells; Humans; Melanins; Mice; Nanoparticles; Niacinamide; NIH 3T3 Cells; Phenylurea Compounds; Photoacoustic Techniques; Positron-Emission Tomography; Solubility; Sorafenib; Water | 2015 |
Bowel Perforation After Treatment with Sorafenib: A Case Report and Review of Literature.
Topics: Antineoplastic Agents; Humans; Intestinal Perforation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.
Topics: Adult; Aged; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Remission Induction; Retrospective Studies; Risk Factors; Sorafenib; Tandem Repeat Sequences; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2015 |
Regulation of cell death receptor S-nitrosylation and apoptotic signaling by Sorafenib in hepatoblastoma cells.
Topics: Antineoplastic Agents; Caspase 3; Caspase 8; Caspase 9; Cell Death; Cysteine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Niacinamide; Nitric Oxide; Nitric Oxide Donors; Nitric Oxide Synthase Type III; Phenylurea Compounds; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor, Type I; S-Nitrosothiols; Signal Transduction; Sorafenib | 2015 |
NMR-Based Metabolic Profiling Reveals Neurochemical Alterations in the Brain of Rats Treated with Sorafenib.
Topics: Amino Acids; Animals; Antioxidants; Brain; Cell Membrane; Energy Metabolism; Magnetic Resonance Imaging; Male; Metabolomics; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Sprague-Dawley; Sorafenib | 2015 |
A significant response to sorafenib in a woman with advanced lung adenocarcinoma and a BRAF non-V600 mutation.
Topics: Adenocarcinoma; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib | 2015 |
The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.
Topics: Animals; Cell Line, Tumor; Cells, Cultured; Dose-Response Relationship, Drug; Flow Cytometry; Gene Expression; Humans; Immunoblotting; Interferon-alpha; Interleukin-2; Janus Kinase 1; K562 Cells; Leukocytes, Mononuclear; Lymphocytes; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; raf Kinases; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; STAT1 Transcription Factor; STAT5 Transcription Factor; Thyroid Neoplasms | 2015 |
Improving Drug Penetrability with iRGD Leverages the Therapeutic Response to Sorafenib and Doxorubicin in Hepatocellular Carcinoma.
Topics: Administration, Intravenous; Amino Acid Motifs; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Drug Delivery Systems; Evans Blue; Gadolinium DTPA; Hep G2 Cells; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Mice, Nude; Mice, Transgenic; Niacinamide; Oligopeptides; Phenylurea Compounds; Sorafenib; Tissue Distribution | 2015 |
Regulation of ADAM10 and ADAM17 by Sorafenib Inhibits Epithelial-to-Mesenchymal Transition in Epstein-Barr Virus-Infected Retinal Pigment Epithelial Cells.
Topics: ADAM Proteins; ADAM10 Protein; ADAM17 Protein; Amyloid Precursor Protein Secretases; Cell Movement; Cells, Cultured; DNA; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; Gene Expression Regulation; Herpesvirus 4, Human; Humans; Immunoblotting; Membrane Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Vascular Endothelial Growth Factor; Retinal Pigment Epithelium; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sorafenib; Tumor Necrosis Factor-alpha; Vitreoretinopathy, Proliferative | 2015 |
Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Hepatic Veins; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Venous Thrombosis | 2015 |
Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Meloxicam; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Thiazines; Thiazoles; Xenograft Model Antitumor Assays | 2015 |
A model of neuropathic pain induced by sorafenib in the rat: Effect of dimiracetam.
Topics: Analgesics; Analysis of Variance; Animals; Antineoplastic Agents; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperalgesia; Imidazoles; Male; Neuralgia; Niacinamide; Pain Measurement; Pain Threshold; Phenylurea Compounds; Pyrroles; Rats; Rats, Sprague-Dawley; Reaction Time; Sorafenib; Time Factors | 2015 |
High-Dose Vitamin C Promotes Regression of Multiple Pulmonary Metastases Originating from Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Ascorbic Acid; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Lung Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
Sorafenib enriches epithelial cell adhesion molecule-positive tumor initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Disease Progression; Epithelial Cell Adhesion Molecule; Humans; Liver Neoplasms; Mice; Neoplastic Stem Cells; Niacinamide; Oncogene Protein v-akt; Phenylurea Compounds; Sorafenib; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins | 2015 |
High rate of hematological responses to sorafenib in FLT3-ITD acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplantation.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retreatment; Retrospective Studies; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome | 2016 |
Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2015 |
Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer.
Topics: Angiogenesis Inhibitors; Animals; Benzylamines; Carcinoma, Hepatocellular; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Disease Progression; Genetic Therapy; Heterocyclic Compounds; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred C3H; Nanoparticles; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Receptors, CXCR4; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2015 |
TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboxymethylcellulose Sodium; Carcinoma, Hepatocellular; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Extracellular Signal-Regulated MAP Kinases; Humans; Immune System; Immunosuppressive Agents; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Niacinamide; Phenylurea Compounds; Phosphorylation; Poly I-C; Polylysine; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Toll-Like Receptor 3 | 2015 |
Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules.
Topics: Adenosine Triphosphate; Adenylyl Imidodiphosphate; Cell Line, Tumor; Cell Survival; Deuterium Exchange Measurement; Humans; Indoles; Isotope Labeling; MAP Kinase Signaling System; Mass Spectrometry; Molecular Dynamics Simulation; Mutation; Niacinamide; Peptides; Phenylurea Compounds; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Protein Structure, Secondary; Protein Structure, Tertiary; Proteolysis; Proteomics; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Trypsin; Vemurafenib | 2015 |
Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia.
Topics: Azacitidine; Cell Line, Tumor; Decitabine; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Survival Analysis | 2015 |
Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner.
Topics: Activating Transcription Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biphenyl Compounds; Cell Line, Tumor; Cell Survival; Cytochromes c; Gene Knockdown Techniques; Glioma; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Nitrophenols; Peptide Hydrolases; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Pyridines; Sorafenib; STAT3 Transcription Factor; Sulfonamides; Tyrphostins | 2015 |
[Molecular targeting treatment for thyroid cancer].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Quinolines; Sorafenib; Thyroid Neoplasms | 2015 |
Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Curcumin; Dose-Response Relationship, Drug; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Thyroid Neoplasms | 2016 |
Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Flavonoids; Flavonols; Humans; Immunohistochemistry; Melanoma; Mice, Nude; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Female; fms-Like Tyrosine Kinase 3; Gene Expression; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Remission Induction; Retrospective Studies; Sorafenib; Survival Analysis; Transplantation, Homologous; Treatment Outcome | 2015 |
LincRNA-p21 activates endoplasmic reticulum stress and inhibits hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Endoplasmic Reticulum Stress; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; RNA, Long Noncoding; Sorafenib; Transplantation, Heterologous; Tumor Burden | 2015 |
MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Niacinamide; Oligonucleotides; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sorafenib; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; raf Kinases; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Child, Preschool; Female; Gene Expression Profiling; Humans; Infant; Male; Middle Aged; Molecular Targeted Therapy; Neoplasms; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyridones; Pyrimidinones; Sorafenib; Transcriptome; Treatment Outcome; Young Adult | 2016 |
Incomplete Dll4/Notch signaling inhibition promotes functional angiogenesis supporting the growth of skin papillomas.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Calcium-Binding Proteins; Disease Progression; Down-Regulation; Gene Deletion; Intracellular Signaling Peptides and Proteins; Male; Membrane Proteins; Mice; Neovascularization, Pathologic; Niacinamide; Papilloma; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Signal Transduction; Skin Neoplasms; Sorafenib; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Multilayer-Coated Liquid Crystalline Nanoparticles for Effective Sorafenib Delivery to Hepatocellular Carcinoma.
Topics: Animals; Apoptosis; Calorimetry, Differential Scanning; Carcinoma, Hepatocellular; Cell Survival; Drug Carriers; Drug Liberation; Erythrocytes; Hemolysis; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liquid Crystals; Liver Neoplasms; Male; Microscopy, Atomic Force; Microscopy, Electron, Transmission; Nanoparticles; Niacinamide; Phenylurea Compounds; Polymers; Rats; Rats, Sprague-Dawley; Sorafenib; Spectroscopy, Fourier Transform Infrared | 2015 |
Combinatorial high-throughput experimental and bioinformatic approach identifies molecular pathways linked with the sensitivity to anticancer target drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Computational Biology; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genomics; HeLa Cells; Hep G2 Cells; Humans; Indazoles; Indoles; Inhibitory Concentration 50; Jurkat Cells; MCF-7 Cells; Neoplasms; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Pyrimidines; Pyrroles; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Transcriptome | 2015 |
[Efficacy of Sorafenib versus Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2015 |
Inhibition of FOXP3/NFAT Interaction Enhances T Cell Function after TCR Stimulation.
Topics: Animals; Antineoplastic Agents; CD40 Ligand; Cell Proliferation; CTLA-4 Antigen; Female; Forkhead Transcription Factors; Humans; Immunotherapy; Interferon-gamma; Interleukin-17; Interleukin-2; Interleukin-2 Receptor alpha Subunit; Interleukin-6; Jurkat Cells; Lymphocyte Activation; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Transgenic; Neoplasms; NFATC Transcription Factors; Niacinamide; Ovalbumin; Peptide Fragments; Phenylurea Compounds; Promoter Regions, Genetic; Receptors, Antigen, T-Cell; Sorafenib; T-Lymphocytes, Regulatory; Transforming Growth Factor beta | 2015 |
An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
Topics: AC133 Antigen; Antibiotics, Antineoplastic; Antigens, CD; Antineoplastic Agents; Aporphines; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Doxorubicin; Drug Resistance, Neoplasm; Female; Glycoproteins; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Peptides; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; RNA-Binding Proteins; Sorafenib; Survival Analysis; Time Factors; Transfection | 2015 |
Clinical Trial Participants With Metastatic Renal Cell Carcinoma Differ From Patients Treated in Real-World Practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Female; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Patients; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Severity of Illness Index; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer.
Topics: Aged; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Sorafenib; Thrombocytopenia; Thyroid Neoplasms; Thyroidectomy | 2015 |
Early Tumor Shrinkage Under Treatment with First-line Tyrosine Kinase Inhibitors as a Predictor of Overall Survival in Patients with Metastatic Renal Cell Carcinoma: a Retrospective Multi-Institutional Study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Japan; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Treatment of intermediate-stage hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
Hepatocellular carcinoma: current questions and future directions.
Topics: Antineoplastic Agents; Biomarkers; Biopsy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Diagnostic Imaging; Drug Discovery; Humans; Image Interpretation, Computer-Assisted; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2015 |
The role of sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Hypophosphatemia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Research; Sorafenib; Treatment Failure; Treatment Outcome | 2015 |
Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentr
Topics: Adult; Antineoplastic Agents; Aortic Aneurysm; Aortic Dissection; Carcinoma, Medullary; Cushing Syndrome; Diabetes Insipidus; Fatal Outcome; Humans; Hydrocortisone; Intussusception; Jejunal Diseases; Male; Niacinamide; Paraneoplastic Polyneuropathy; Phenylurea Compounds; Primary Dysautonomias; Sorafenib; Thyroid Neoplasms | 2015 |
Promotion of Cancer Stem-Like Cell Properties in Hepatitis C Virus-Infected Hepatocytes.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cyclic S-Oxides; Dasatinib; Epithelial-Mesenchymal Transition; Female; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Imatinib Mesylate; Liver Neoplasms; Mice; Neoplasm Transplantation; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; RNA, Messenger; Sorafenib; Spheroids, Cellular; STAT3 Transcription Factor; Transplantation, Heterologous; Tumor Cells, Cultured | 2015 |
NDRG1 promotes growth of hepatocellular carcinoma cells by directly interacting with GSK-3β and Nur77 to prevent β-catenin degradation.
Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Doxycycline; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Hep G2 Cells; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Mice, Nude; Microscopy, Fluorescence; Niacinamide; Nuclear Receptor Subfamily 4, Group A, Member 1; Phenylurea Compounds; Protein Binding; Proteolysis; RNA Interference; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Feasibility of Using Volumetric Contrast-Enhanced Ultrasound with a 3-D Transducer to Evaluate Therapeutic Response after Targeted Therapy in Rabbit Hepatic VX2 Carcinoma.
Topics: Animals; Antineoplastic Agents; Contrast Media; Disease Models, Animal; Feasibility Studies; Image Enhancement; Imaging, Three-Dimensional; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rabbits; Reproducibility of Results; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2015 |
Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
Topics: Apoptosis; Bufanolides; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2015 |
Absence of Significant Correlation of Adverse Events Between First- and Second-Line Tyrosine Kinase Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Female; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib | 2016 |
The Eltrombopag antitumor effect on hepatocellular carcinoma.
Topics: Apoptosis; Benzoates; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Drug Synergism; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Hydrazines; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazoles; Receptors, Thrombopoietin; Sorafenib | 2015 |
A Proteometric Analysis of Human Kinome: Insight into Discriminant Conformation-dependent Residues.
Topics: Animals; Binding Sites; Crystallography, X-Ray; Humans; Imatinib Mesylate; Least-Squares Analysis; Models, Molecular; Niacinamide; Phenylurea Compounds; Protein Conformation; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Sorafenib | 2015 |
CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Disease Progression; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; Receptors, Interleukin-8B; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
Sorafenib-induced defective autophagy promotes cell death by necroptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Blotting, Western; Cells, Cultured; Drug Resistance, Neoplasm; Embryo, Mammalian; Fibroblasts; Flow Cytometry; Humans; Immunoenzyme Techniques; Immunoprecipitation; Male; Mice; Mice, Knockout; Microtubule-Associated Proteins; Necrosis; Niacinamide; Phagosomes; Phenylurea Compounds; Prostatic Neoplasms; Receptor-Interacting Protein Serine-Threonine Kinases; RNA-Binding Proteins; Sorafenib; Tissue Array Analysis | 2015 |
Celecoxib enhances [sorafenib + sildenafil] lethality in cancer cells and reverts platinum chemotherapy resistance.
Topics: Antineoplastic Agents; Carboplatin; Celecoxib; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; Female; Humans; Inhibitory Concentration 50; Niacinamide; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Phenylurea Compounds; Sildenafil Citrate; Sorafenib | 2015 |
Initial Experience of Sorafenib Neoadjuvant Therapy Combined with Retroperitoneoscopy in Treating T2 Large Renal Carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Laparoscopy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Niacinamide; Perioperative Care; Peritoneum; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2015 |
Sorafenib-Induced Eruption Mimicking Erythema Multiforme.
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Erythema Multiforme; Humans; Male; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Targeted therapy for advanced or metastatic differentiated thyroid carcinoma.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2015 |
Cardiovascular toxicity after antiangiogenic therapy in persons older than 65 years with advanced renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cardiovascular Diseases; Female; Humans; Incidence; Indoles; Kidney Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Pyrroles; Risk Factors; SEER Program; Sorafenib; Sunitinib; Survival Analysis; United States | 2016 |
Cyclodextrin-Modified Porous Silicon Nanoparticles for Efficient Sustained Drug Delivery and Proliferation Inhibition of Breast Cancer Cells.
Topics: Animals; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclodextrins; Drug Delivery Systems; Drug Liberation; Female; Flow Cytometry; Humans; Kidney; Liver; Nanoparticles; Niacinamide; Particle Size; Phenylurea Compounds; Porosity; Rats; Silicon; Sorafenib; Spectroscopy, Fourier Transform Infrared | 2015 |
The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes.
Topics: Humans; Indazoles; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Protein Binding; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Sorafenib; Sulfonamides | 2015 |
Efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in Japan: a retrospective analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Humans; Japan; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
Selective internal radiation therapy compared with sorafenib for hepatocellular carcinoma with portal vein thrombosis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Radiopharmaceuticals; Sorafenib; Venous Thrombosis; Yttrium Radioisotopes | 2016 |
[Prognostic factors for metastatic renal cell carcinoma treated with second-line targeted therapies].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Everolimus; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Prognosis after recurrence of hepatocellular carcinoma in liver transplantation: predictors for successful treatment and survival.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Combined Modality Therapy; Follow-Up Studies; Graft Survival; Humans; Liver Neoplasms; Liver Transplantation; Lymphocytes; Multivariate Analysis; Neoplasm Recurrence, Local; Neutrophils; Niacinamide; Phenylurea Compounds; Postoperative Complications; Prognosis; Retrospective Studies; Risk Factors; Sirolimus; Sorafenib; Survival Rate | 2015 |
Sorafenib Inhibition of Mcl-1 Accelerates ATRA-Induced Apoptosis in Differentiation-Responsive AML Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Differentiation; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-bcl-2; RNA, Small Interfering; Sorafenib; Tretinoin; Xenograft Model Antitumor Assays | 2016 |
Sorafenib inhibits cancer side population cells by targeting c‑Jun N‑terminal kinase signaling.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Fluorouracil; Humans; MAP Kinase Signaling System; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-jun; Sorafenib | 2015 |
[A Case of Wilson's Disease with Psoriasis Vulgaris, Complicated with Hepatocellular Carcinoma and Successfully Treated with Sorafenib].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Hepatolenticular Degeneration; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Psoriasis; Recurrence; Sorafenib | 2015 |
[Successful Multimodal Treatment for Aggressive Extrahepatic Metastatic Hepatocellular Carcinoma - A Case Report].
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Hepatectomy; Humans; Liver Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Sorafenib | 2015 |
Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Patient Compliance; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2015 |
Clinicopathological and prognostic factors for long-term survival in Chinese patients with metastatic renal cell carcinoma treated with sorafenib: a single-center retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2015 |
Monitoring Serum Levels of Sorafenib and Its N-Oxide Is Essential for Long-Term Sorafenib Treatment of Patients with Hepatocellular Carcinoma.
Topics: Aged; Aged, 80 and over; Area Under Curve; Carcinoma, Hepatocellular; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Monitoring; Female; Half-Life; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Phenylurea Compounds; Proportional Hazards Models; ROC Curve; Sorafenib; Time Factors; Withholding Treatment | 2015 |
Growth inhibitory effect of an injectable hyaluronic acid-tyramine hydrogels incorporating human natural interferon-α and sorafenib on renal cell carcinoma cells.
Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Humans; Hyaluronic Acid; Hydrogels; Interferon-alpha; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Tyramine; Xenograft Model Antitumor Assays | 2016 |
A polymeric nanoparticle formulation of curcumin in combination with sorafenib synergistically inhibits tumor growth and metastasis in an orthotopic model of human hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Curcumin; Diffusion; Drug Synergism; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nanocapsules; Niacinamide; Phenylurea Compounds; Polymers; Sorafenib; Treatment Outcome | 2015 |
Azacitidine and Sorafenib Therapy in a Pediatric Patient With Refractory Acute Myeloid Leukemia With Monosomy 7 and Somatic PTPN11 Mutation.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Azacitidine; Child, Preschool; Chromosome Deletion; Chromosomes, Human, Pair 7; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Sorafenib; Stem Cell Transplantation | 2016 |
Synergistic Effect of Sorafenib and Radiation on Human Oral Carcinoma in vivo.
Topics: Animals; Apoptosis; Bone Neoplasms; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality Therapy; Gene Expression Regulation, Neoplastic; Humans; Mice; Mouth Neoplasms; NF-kappa B; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Real-Life Clinical Practice with Sorafenib in Advanced Hepatocellular Carcinoma: A Single-Center Experience Second Analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2015 |
pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cations; Cell Proliferation; Chitosan; Drug Delivery Systems; Female; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liposomes; Mice; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib | 2015 |
[Three Patients with Acute Myocardial Infarction Associated with Targeted Therapy of Sorafenib for Metastatic Renal Cell Carcinoma : Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Myocardial Infarction; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
The STORM trial and beyond: narrowing the horizon of adjuvant sorafenib for postoperative hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis | 2015 |
Metformin synergistically sensitizes FLT3-ITD-positive acute myeloid leukemia to sorafenib by promoting mTOR-mediated apoptosis and autophagy.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Antineoplastic Agents; Apoptosis; Autophagy; Biomarkers; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Synergism; Enzyme Activation; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Metformin; Microtubule-Associated Proteins; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sorafenib; Tandem Repeat Sequences; TOR Serine-Threonine Kinases | 2015 |
Design, Synthesis, Activity and Docking Study of Sorafenib Analogs Bearing Sulfonylurea Unit.
Topics: Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Humans; Hydrogen Bonding; Inhibitory Concentration 50; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Structure, Secondary; Protein Structure, Tertiary; Sorafenib; Structure-Activity Relationship; Sulfonylurea Compounds; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Drug Resistance, Neoplasm; Humans; Hypoglycemic Agents; Liver Neoplasms; Metformin; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2015 |
Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma.
Topics: Adipose Tissue; Adult; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Survival; Exosomes; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mesenchymal Stem Cells; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Microscopy, Confocal; Niacinamide; Phenylurea Compounds; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Real Life Treatment of Hepatocellular Carcinoma: Impact of Deviation from Guidelines for Recommended Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Egypt; Female; Guideline Adherence; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Practice Guidelines as Topic; Prospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2015 |
Identification of the β-catenin/JNK/prothymosin-alpha axis as a novel target of sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Precursors; Sorafenib; Thymosin; Transfection | 2015 |
Fisetin, a dietary flavonoid, augments the anti-invasive and anti-metastatic potential of sorafenib in melanoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cadherins; Cell Line, Tumor; Cell Movement; Cells, Cultured; Drug Synergism; Epithelial-Mesenchymal Transition; Female; Flavonoids; Flavonols; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Melanoma; Mice, Nude; Mutation; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Murine colitis treated with multitargeted tyrosine kinase inhibitors.
Topics: Animals; Axitinib; Colitis; Imidazoles; Indazoles; Indoles; Male; Mice; Mice, Inbred C57BL; Microvessels; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Quantification of Sorafenib in Human Serum by Competitive Enzyme-Linked Immunosorbent Assay.
Topics: Animals; Antibodies; Antigens; Antineoplastic Agents; Drug Monitoring; Enzyme-Linked Immunosorbent Assay; Female; Horseradish Peroxidase; Humans; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Serum Albumin, Bovine; Sorafenib | 2015 |
Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyrroles; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatitis B, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Remission Induction; Republic of Korea; Retrospective Studies; Sorafenib | 2015 |
Nanoassemblies Based on Supramolecular Complexes of Nonionic Amphiphilic Cyclodextrin and Sorafenib as Effective Weapons to Kill Human HCC Cells.
Topics: Adamantane; Antineoplastic Agents; Binding, Competitive; Cell Line, Tumor; Cell Survival; Cyclodextrins; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Erythrocytes; Hemolysis; Hepatocytes; Humans; Kinetics; Nanostructures; Niacinamide; Phenylurea Compounds; Sorafenib; Surface-Active Agents | 2015 |
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcin
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Databases, Factual; Diarrhea; Drug Administration Schedule; Fatigue; Female; Hand-Foot Syndrome; Humans; Imidazoles; Indazoles; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Models, Statistical; Molecular Targeted Therapy; Mucositis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pyrimidines; Pyrroles; Retrospective Studies; Risk Assessment; Risk Factors; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Female; Fluorescent Antibody Technique; Follow-Up Studies; Humans; Immunoenzyme Techniques; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Sorafenib; Survival Rate; Tumor Cells, Cultured | 2016 |
Convection-enhanced delivery of sorafenib and suppression of tumor progression in a murine model of brain melanoma through the inhibition of signal transducer and activator of transcription 3.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Convection; Heterografts; Humans; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib; STAT3 Transcription Factor; Transcriptional Activation | 2016 |
Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenib.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Homeostasis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proteins; Regulatory Factor X Transcription Factors; Sorafenib; Transcription Factors; Unfolded Protein Response | 2016 |
A case series of anal melanoma including the results of treatment with imatinib in selected patients.
Topics: Adult; Aged; Aged, 80 and over; Anal Canal; Antineoplastic Agents; Anus Neoplasms; Dacarbazine; Digestive System Surgical Procedures; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Retrospective Studies; Sorafenib; Survival Rate | 2016 |
Sorafenib and novel multikinase inhibitors in AML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myeloid, Acute; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
Nilotinib reduced the viability of human ovarian cancer cells via mitochondria-dependent apoptosis, independent of JNK activation.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Fragmentation; Female; Humans; Imatinib Mesylate; JNK Mitogen-Activated Protein Kinases; Membrane Potential, Mitochondrial; Mitochondria; Niacinamide; Ovarian Neoplasms; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyrimidines; Reactive Oxygen Species; Sorafenib | 2016 |
Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis.
Topics: Animals; Carbon Tetrachloride; Drug Carriers; Human Umbilical Vein Endothelial Cells; Lactic Acid; Liver; Liver Cirrhosis; Male; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Polyglactin 910; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Protein Kinase Inhibitors; Sorafenib | 2016 |
In vitro and in vivo activity of a novel sorafenib derivative SC5005 against MRSA.
Topics: Animals; Anti-Bacterial Agents; Caenorhabditis elegans; Cell Line; Cell Survival; Disease Models, Animal; Female; Humans; Inhibitory Concentration 50; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred C57BL; Microbial Sensitivity Tests; Niacinamide; Phenylurea Compounds; Sorafenib; Staphylococcal Infections; Staphylococcus epidermidis; Survival Analysis; Treatment Outcome | 2016 |
Sorafenib, a multikinase inhibitor, induces formation of stress granules in hepatocarcinoma cells.
Topics: Activating Transcription Factor 4; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytoplasmic Granules; Drug Resistance, Neoplasm; Eukaryotic Initiation Factor-2; Fluorescent Antibody Technique; Humans; In Situ Hybridization, Fluorescence; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Biosynthesis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Signal Transduction; Sorafenib; Stress, Physiological; Transfection | 2015 |
Oct4 is a reliable marker of liver tumor propagating cells in hepatocellular carcinoma.
Topics: Animals; Biomarkers, Tumor; Carcinogenesis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; Flow Cytometry; Green Fluorescent Proteins; Humans; Liver Neoplasms; Mice, Inbred BALB C; Neoplastic Stem Cells; Niacinamide; Octamer Transcription Factor-3; Phenylurea Compounds; Sorafenib; Spheroids, Cellular | 2015 |
Surface bioengineering of diatomite based nanovectors for efficient intracellular uptake and drug delivery.
Topics: Antineoplastic Agents; Biocompatible Materials; Cell Line, Tumor; Cell Survival; Cell-Penetrating Peptides; Diatomaceous Earth; Drug Carriers; Drug Delivery Systems; Erythrocytes; Hemolysis; Humans; Hydrogen-Ion Concentration; MCF-7 Cells; Microscopy, Confocal; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Nanoparticles; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Propylamines; Silanes; Solubility; Sorafenib; Spectroscopy, Fourier Transform Infrared; Water | 2015 |
Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Female; Heparin; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Niacinamide; Phenylurea Compounds; Poloxamer; Sorafenib; Stomach Neoplasms | 2016 |
Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats.
Topics: Angiogenic Proteins; Animals; Anti-Inflammatory Agents; Cytokines; Dimethylnitrosamine; Drug Therapy, Combination; Gadolinium; Hepatic Stellate Cells; Hepatocytes; Hydroxyproline; Kupffer Cells; Liver; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Rats, Wistar; Sorafenib | 2015 |
Non-invasive in vivo imaging of early metabolic tumor response to therapies targeting choline metabolism.
Topics: Animals; Antineoplastic Agents; Choline Kinase; Diffusion Magnetic Resonance Imaging; Female; Heterografts; Humans; Isoquinolines; Magnetic Resonance Spectroscopy; Mammary Neoplasms, Experimental; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protons; Sorafenib; Sulfonamides | 2016 |
Gemcitabine and Oxaliplatin, but Not Sorafenib or Paclitaxel, Have a Synergistic Effect with Yttrium-90 in Reducing Hepatocellular Carcinoma and Cholangiocarcinoma Cell Line Viability.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Cholangiocarcinoma; Deoxycytidine; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Synergism; Gemcitabine; Humans; Niacinamide; Organoplatinum Compounds; Paclitaxel; Phenylurea Compounds; Pyridines; Radiation Tolerance; Radiopharmaceuticals; Sorafenib; Yttrium Radioisotopes | 2015 |
Derivate isocorydine inhibits cell proliferation in hepatocellular carcinoma cell lines by inducing G2/M cell cycle arrest and apoptosis.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Aporphines; Carcinoma, Hepatocellular; CCAAT-Enhancer-Binding Protein-beta; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Disease Models, Animal; Female; G2 Phase Cell Cycle Checkpoints; Humans; Liver Neoplasms; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Efficacy of sorafenib correlates with Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification and bone metastasis in Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Bone Neoplasms; Carcinoma, Renal Cell; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Risk Factors; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin E; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Oncogene Proteins; Phenylurea Compounds; Protein Kinase Inhibitors; RNA, Messenger; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
Down-regulation of SDF1-α expression in tumor microenvironment is associated with aspirin-mediated suppression of the pro-metastasis effect of sorafenib in hepatocellular carcinoma.
Topics: Animals; Aspirin; Benzylamines; Carcinoma, Hepatocellular; Cell Proliferation; Chemokine CXCL12; Cyclams; Down-Regulation; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Heterocyclic Compounds; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Receptors, CXCR4; Sorafenib; Tumor Microenvironment | 2015 |
Sorafenib suppresses the epithelial-mesenchymal transition of hepatocellular carcinoma cells after insufficient radiofrequency ablation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Movement; Cell Survival; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2015 |
Sorafenib induces autophagic cell death and apoptosis in hepatic stellate cell through the JNK and Akt signaling pathways.
Topics: Animals; Apoptosis; Autophagy; Cell Line; Hepatic Stellate Cells; Humans; JNK Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Rats; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2016 |
Complete radiological response after sorafenib treatment for advanced hepato-cellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Radiography; Remission Induction; Sorafenib; Treatment Outcome | 2015 |
Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Topics: Aged; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comorbidity; Disease-Free Survival; Dose-Response Relationship, Drug; Everolimus; Fees, Pharmaceutical; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2016 |
MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Apoptosis; Binding Sites; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Neoplastic Stem Cells; Niacinamide; Oligonucleotide Array Sequence Analysis; Phenylurea Compounds; Protein Kinase Inhibitors; raf Kinases; ras Proteins; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Sorafenib; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2016 |
The Relationship Between the Adverse Events and Efficacy of Sorafenib in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study from Northwest China.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; China; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2015 |
Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma.
Topics: Aged; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Female; Fibroblast Growth Factors; Gene Expression; Gene Expression Profiling; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Receptor, Fibroblast Growth Factor, Type 1; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Somatomedins; Sorafenib; Spheroids, Cellular; Survival Rate; Xenograft Model Antitumor Assays | 2017 |
Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, Hepatocellular; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Poly(ADP-ribose) Polymerase Inhibitors; Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Tumor Suppressor Protein p53 | 2016 |
Synergistic effect of fisetin combined with sorafenib in human cervical cancer HeLa cells through activation of death receptor-5 mediated caspase-8/caspase-3 and the mitochondria-dependent apoptotic pathway.
Topics: Animals; Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; Drug Synergism; Female; Flavonoids; Flavonols; HeLa Cells; Humans; Membrane Potential, Mitochondrial; Mitochondria; Niacinamide; Phenylurea Compounds; Receptors, TNF-Related Apoptosis-Inducing Ligand; Signal Transduction; Sorafenib; Tumor Burden; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2016 |
LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Drug Synergism; Gene Expression Regulation, Neoplastic; Genes, bcl-2; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Phosphatase 2; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Random Allocation; Smad3 Protein; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
Multikinase Inhibitors Induce Cutaneous Toxicity through OAT6-Mediated Uptake and MAP3K7-Driven Cell Death.
Topics: Animals; Cell Death; Cell Line, Tumor; Female; Hep G2 Cells; Humans; Keratinocytes; MAP Kinase Kinase Kinases; Mice; Mice, Inbred C57BL; Niacinamide; Nuclear Receptor Subfamily 2, Group C, Member 2; Organic Anion Transporters; Phenylurea Compounds; Protein Kinase Inhibitors; Random Allocation; Skin; Skin Diseases; Sorafenib; Transfection | 2016 |
A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Activation; Enzyme Activators; Humans; Liver Neoplasms; Mice, Nude; Niacinamide; Phenyl Ethers; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Predictive factors for sorafenib-induced hand-foot skin reaction using ordered logistic regression analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Hand-Foot Syndrome; Humans; Logistic Models; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Retrospective Studies; Sorafenib; Young Adult | 2016 |
Inhibition of mutant KrasG12D-initiated murine pancreatic carcinoma growth by a dual c-Raf and soluble epoxide hydrolase inhibitor t-CUPM.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzoates; Carcinoma, Pancreatic Ductal; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Epoxide Hydrolases; Extracellular Signal-Regulated MAP Kinases; Genes, ras; Genetic Predisposition to Disease; Male; Mice, Inbred C57BL; Mice, Mutant Strains; Mutation; Niacinamide; Oxylipins; Pancreatic Neoplasms; Phenotype; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; Tumor Burden; Urea | 2016 |
Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease Progression; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Time Factors; Withholding Treatment | 2016 |
Sorafenib: osteonecrosis of the jaw.
Topics: Antineoplastic Agents; Humans; Jaw; Niacinamide; Osteonecrosis; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2015 |
Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study.
Topics: Aged; Algorithms; Angiogenesis Inhibitors; Area Under Curve; Carcinoma, Hepatocellular; Chi-Square Distribution; Decision Support Techniques; Female; France; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; ROC Curve; Sorafenib; Treatment Outcome | 2016 |
Sorafenib treatment during partial hepatectomy reduces tumorgenesis in an inflammation-associated liver cancer model.
Topics: Animals; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Sub-Family B Member 4; Carcinoma, Hepatocellular; Cell Proliferation; Cell Transformation, Neoplastic; Disease Models, Animal; Hepatectomy; Hepatitis; Immunoenzyme Techniques; Inflammation; Liver Neoplasms; Liver Regeneration; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Array Analysis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sorafenib | 2016 |
Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Time Factors; Treatment Outcome | 2016 |
Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Hepatitis C, Chronic; Hepatocyte Growth Factor; Humans; Interferon-alpha; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Polyethylene Glycols; Protein Precursors; Prothrombin; Recombinant Proteins; Sorafenib; Survival Rate; Vascular Endothelial Growth Factor A | 2016 |
Tyrosine kinase inhibitors target cancer stem cells in renal cell cancer.
Topics: Axitinib; Carcinoma, Renal Cell; Cell Communication; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Humans; Imidazoles; Indazoles; Indoles; Neoplastic Stem Cells; Niacinamide; Oxygen; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; Tumor Microenvironment | 2016 |
Improving Oral Bioavailability of Sorafenib by Optimizing the "Spring" and "Parachute" Based on Molecular Interaction Mechanisms.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Chemistry, Pharmaceutical; Dogs; Male; Niacinamide; Phenylurea Compounds; Polymers; Solubility; Sorafenib; Spectroscopy, Fourier Transform Infrared; Tablets; Tissue Distribution | 2016 |
Inducing tolerability of adverse events increases sorafenib exposure and optimizes patient's outcome in advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Sorafenib; Time Factors; Withholding Treatment; Young Adult | 2016 |
[Efficacy and safety of sorafenib in patients with advanced renal cell carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Fatigue; Humans; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2015 |
MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 3-Ring; Humans; Immunoenzyme Techniques; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
[Anticancer effect of SN-38 combined with sorafenib on hepatocellular carcinoma in vitro and its mechanism].
Topics: Apoptosis; Camptothecin; Carcinoma, Hepatocellular; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Histones; Humans; Irinotecan; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Sorafenib; Tumor Suppressor Protein p53 | 2015 |
A mixed DFT-MD methodology for the in silico development of drug releasing macrocycles. Calix and thia-calix[N]arenes as carriers for Bosutinib and Sorafenib.
Topics: Aniline Compounds; Calixarenes; Computer Simulation; Drug Carriers; Drug Liberation; Molecular Dynamics Simulation; Molecular Structure; Niacinamide; Nitriles; Phenylurea Compounds; Quantum Theory; Quinolines; Sorafenib | 2016 |
CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
A Case of Pancreatic Side Effects Resulting from Sorafenib and Axitinib Treatment of Stage IV Renal Cell Carcinoma.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Pancreatitis; Phenylurea Compounds; Sorafenib | 2015 |
Design, Synthesis and Antiproliferative Activity of Novel Benzothiazole Derivatives Conjugated with Semicarbazone Scaffold.
Topics: Antineoplastic Agents; Benzothiazoles; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; Hydrazones; Molecular Structure; Niacinamide; Phenylurea Compounds; Piperazines; Semicarbazones; Sorafenib | 2016 |
Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Topics: Aged; Animals; Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Comparative Effectiveness Research; Disease-Free Survival; Everolimus; Female; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Treatment Outcome; United States | 2016 |
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Treatment Outcome | 2016 |
The Efficacy of Continued Sorafenib Treatment after Radiologic Confirmation of Progressive Disease in Patients with Advanced Hepatocellular Carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Radiography; Sorafenib; Treatment Outcome | 2016 |
JAMA PATIENT PAGE. Treatment of Liver Cancer.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Embolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate | 2016 |
Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Receptors, Vascular Endothelial Growth Factor; Registries; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Treatment Outcome; Withholding Treatment | 2016 |
Metformin inhibits the prometastatic effect of sorafenib in hepatocellular carcinoma by upregulating the expression of TIP30.
Topics: Acetyltransferases; Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Lung Neoplasms; Metformin; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Thioredoxins; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
Early Radiation Toxicity from Yttrium-90 Radioembolization for Advanced Hepatocellular Carcinoma.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Hepatocellular; Comorbidity; Dyspnea; Embolization, Therapeutic; Hepatitis B virus; Humans; Liver Cirrhosis; Liver Neoplasms; Lung Injury; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Radiation Exposure; Sorafenib; Ytterbium | 2016 |
Singapore Cancer Network (SCAN) Guidelines for Systemic Therapy of Metastatic Renal Cell Carcinoma (mRCC).
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Interleukin-2; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Singapore; Sirolimus; Sorafenib; Sulfonamides; Sunitinib | 2015 |
B-Raf Inhibition in the Clinic: Present and Future.
Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; MAP Kinase Signaling System; Melanoma; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Oximes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sorafenib; Sulfonamides; Thyroid Neoplasms; Vemurafenib | 2016 |
DCT015, a new sorafenib derivate, inhibits tumor growth and angiogenesis in gastric cancer models.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; HCT116 Cells; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Stomach Neoplasms; Tumor Burden | 2016 |
MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2016 |
Bufalin enhances anti-angiogenic effect of sorafenib via AKT/VEGF signaling.
Topics: Angiogenesis Inhibitors; Animals; Aorta; Apoptosis; Bufanolides; Cell Cycle; Cell Movement; Cell Proliferation; Cell Survival; Chick Embryo; Cytokines; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Random Allocation; Rats; Signal Transduction; Sorafenib; Vascular Endothelial Growth Factor A | 2016 |
Hypothyroidism Side Effect in Patients Treated with Sunitinib or Sorafenib: Clinical and Structural Analyses.
Topics: Carcinoma, Renal Cell; Female; Humans; Hypothyroidism; Indoles; Kidney Neoplasms; Male; Models, Molecular; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Receptors, Retinoic Acid; Retinoic Acid Receptor gamma; Retinoid X Receptor alpha; Sorafenib; Sunitinib | 2016 |
Heart failure associated with small molecule tyrosine kinase inhibitors.
Topics: Aged; Aged, 80 and over; Dasatinib; Female; Heart Failure; Humans; Indoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk Factors; Sorafenib; Sunitinib | 2016 |
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
Topics: Aged; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Sorafenib; Thyroid Neoplasms | 2016 |
The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
Topics: Celecoxib; Cell Differentiation; Cells, Cultured; Dasatinib; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Humans; Immune Tolerance; Indoles; Monocytes; Myeloid Cells; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sunitinib | 2016 |
Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patient.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Proteomics; Sorafenib | 2016 |
Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
Topics: Antibodies, Neutralizing; Apoptosis; Autocrine Communication; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Indoles; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib; Sulfonamides | 2016 |
Effects of RAF inhibitors on PI3K/AKT signalling depend on mutational status of the RAS/RAF signalling axis.
Topics: Apoptosis; Benzimidazoles; Blotting, Western; Cell Proliferation; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2016 |
Inhibition of tumor growth and metastasis by photoimmunotherapy targeting tumor-associated macrophage in a sorafenib-resistant tumor model.
Topics: Animals; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Female; Immunotherapy; Macrophages; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Phototherapy; RAW 264.7 Cells; Sorafenib | 2016 |
[Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Treatment Outcome | 2015 |
[Survival after Sorafenib Treatment for Advanced Recurrent Hepatocellular Carcinoma with Tumor Thrombus in the Inferior Vena Cava].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Recurrence; Sorafenib; Thrombosis; Treatment Outcome; Vena Cava, Inferior | 2015 |
[Complete Surgical Resection of a Huge Hepatocellular Carcinoma Invading the Diaphragm and Lung after Transcatheter Arterial Chemoembolization (TACE) and Sorafenib--A Case Report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Diaphragm; Hepatectomy; Humans; Liver Neoplasms; Lung; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib | 2015 |
[A Case of Multiple HCC with Vp2 and Vv3 Invasion Controlled by Multidisciplinary Treatment Including Surgery].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Cisplatin; Combined Modality Therapy; Hepatectomy; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Sorafenib | 2015 |
[Combination Chemotherapy Using Sorafenib and Hepatic Arterial Infusion with a Fine-Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis--A Case Report].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Embolization, Therapeutic; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Powders; Sorafenib; Venous Thrombosis | 2015 |
Transketolase counteracts oxidative stress to drive cancer development.
Topics: Animals; Base Sequence; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Proliferation; Female; Gene Knockdown Techniques; Glucose; Glutathione; Glycolysis; Humans; Liver Neoplasms; Male; Metabolome; Mice, Nude; Molecular Sequence Data; Niacinamide; Oxidative Stress; Pentose Phosphate Pathway; Peroxides; Phenylurea Compounds; Reactive Oxygen Species; RNA, Messenger; Sorafenib; Transketolase; Up-Regulation | 2016 |
Targeting glucosylceramide synthase upregulation reverts sorafenib resistance in experimental hepatocellular carcinoma.
Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Ceramides; Drug Resistance, Neoplasm; Fatty Acids, Monounsaturated; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glucosyltransferases; Humans; Immunoenzyme Techniques; Immunosuppressive Agents; Liver Neoplasms, Experimental; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Drug Carriers; Drug Delivery Systems; Fluorescent Antibody Technique, Indirect; Humans; Male; Maleates; Micelles; Niacinamide; Phenylurea Compounds; Polystyrenes; Prostatic Neoplasms, Castration-Resistant; Pyrimidines; Sorafenib; Tumor Cells, Cultured | 2016 |
Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment.
Topics: Antineoplastic Agents; Commerce; Drug Industry; Erlotinib Hydrochloride; Global Health; Humans; Imatinib Mesylate; Lapatinib; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sorafenib | 2016 |
Tyrosine receptor kinase B silencing inhibits anoikis‑resistance and improves anticancer efficiency of sorafenib in human renal cancer cells.
Topics: Anoikis; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Membrane Glycoproteins; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Receptor, trkB; Signal Transduction; Sorafenib | 2016 |
An improved approach for predicting drug-target interaction: proteochemometrics to molecular docking.
Topics: Aldehyde Reductase; Anthracyclines; Antineoplastic Agents; Colchicine; Databases, Protein; Demecolcine; Drug Interactions; Models, Biological; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Proteomics; Reproducibility of Results; Sorafenib; Support Vector Machine | 2016 |
Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study.
Topics: Aged; Algorithms; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; raf Kinases; Remission Induction; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2016 |
Widespread morbilliform rash due to sorafenib or vemurafenib treatment for advanced cancer; experience of a tertiary dermato-oncology clinic.
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Exanthema; Female; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Steroids; Sulfonamides; Vemurafenib | 2016 |
Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Male; Mice; Models, Molecular; Niacinamide; p120 GTPase Activating Protein; Paired Box Transcription Factors; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Sorafenib | 2016 |
Sorafenib and gadolinium co-loaded liposomes for drug delivery and MRI-guided HCC treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Contrast Media; Drug Delivery Systems; Drug Liberation; Female; Gadolinium; Hep G2 Cells; Humans; Liposomes; Liver Neoplasms, Experimental; Magnetic Resonance Imaging; Mice; Microscopy, Electron, Transmission; Niacinamide; Phenylurea Compounds; Sorafenib; Tissue Distribution; Treatment Outcome; Tumor Burden | 2016 |
Combined Treatment of Tyrosine Kinase Inhibitor-Labeled Gold Nanorod Encapsulated Albumin With Laser Thermal Ablation in a Renal Cell Carcinoma Model.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Coumarins; Drug Compounding; Gold; Humans; Kidney Neoplasms; Lasers; Nanotubes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Serum Albumin; Solubility; Sorafenib | 2016 |
Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatment.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cation Transport Proteins; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Organic Cation Transporter 1; Phenylurea Compounds; RNA, Messenger; Sorafenib | 2016 |
Upregulation of the oncoprotein SET determines poor clinical outcomes in hepatocellular carcinoma and shows therapeutic potential.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Female; Gene Expression Regulation, Neoplastic; Histone Chaperones; Humans; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Prognosis; Quinazolines; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
Multi-kinase inhibitors can associate with heat shock proteins through their NH2-termini by which they suppress chaperone function.
Topics: Antineoplastic Agents; Cell Line, Tumor; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Indazoles; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Sorafenib; Sulfonamides | 2016 |
[Treatment of refractory pulmonary metastases from hepatocellular carcinoma by transcatheter arterial chemoembolization using arsenic trioxide in combination with sorafinib].
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Oxides; Phenylurea Compounds; Sorafenib | 2015 |
Sec6/8 regulates Bcl-2 and Mcl-1, but not Bcl-xl, in malignant peripheral nerve sheath tumor cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Cell Line, Tumor; Doxorubicin; Gene Expression Regulation, Neoplastic; Humans; Membrane Potential, Mitochondrial; Myeloid Cell Leukemia Sequence 1 Protein; Nerve Sheath Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Transcription, Genetic; Vesicular Transport Proteins | 2016 |
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Electrolytes; Female; Follow-Up Studies; Humans; Hypertension; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate | 2016 |
Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease-Free Survival; Fatigue; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Sorafenib treatment for patients with RET fusion-positive non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Grading; Neoplasm Staging; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Management; Drug-Related Side Effects and Adverse Reactions; Early Detection of Cancer; Europe; Female; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Pacific Islands; Phenylurea Compounds; Registries; Sorafenib; Young Adult | 2016 |
Multidisciplinary Approach in Hepatocellular Carcinoma in a Level II Hospital: The First Decade of Hospital Universitario Fundacion Alcorcon.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Cohort Studies; Embolization, Therapeutic; Female; Hepatectomy; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Liver Diseases, Alcoholic; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Staging; Niacinamide; Patient Care Team; Phenylurea Compounds; Prospective Studies; Secondary Care Centers; Sorafenib; Treatment Outcome; Tumor Burden | 2015 |
Sorafenib-induced Posterior Reversible Encephalopathy Syndrome in a Child With FLT3-ITD-positive Acute Myeloid Leukemia.
Topics: Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Posterior Leukoencephalopathy Syndrome; Salvage Therapy; Sorafenib | 2016 |
Adverse reactions in mRCC patients documented in routine practice by German office-based oncologists and uro-oncologists.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Renal Cell; Diarrhea; Documentation; Fatigue; Female; Germany; Humans; Indoles; Interferons; Kidney Neoplasms; Male; Medical Oncology; Middle Aged; Nausea; Niacinamide; Phenylurea Compounds; Prospective Studies; Pyrroles; Registries; Sirolimus; Sorafenib; Stomatitis; Sunitinib | 2017 |
Real-Life Experience of Sorafenib Treatment for Hepatocellular Carcinoma in Korea: From GIDEON Data.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Republic of Korea; Sorafenib; Treatment Outcome | 2016 |
A comparison of survival in patients with hepatocellular carcinoma and portal vein invasion treated by radioembolization or sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Logistic Models; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Propensity Score; Radiopharmaceuticals; Retrospective Studies; Sorafenib; Spain; Survival Analysis; Yttrium Radioisotopes | 2016 |
Resveratrol attenuates constitutive STAT3 and STAT5 activation through induction of PTPε and SHP-2 tyrosine phosphatases and potentiates sorafenib-induced apoptosis in renal cell carcinoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Movement; Cell Survival; Humans; Kidney Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Receptor-Like Protein Tyrosine Phosphatases, Class 4; Resveratrol; S Phase Cell Cycle Checkpoints; Signal Transduction; Sorafenib; STAT3 Transcription Factor; STAT5 Transcription Factor; Stilbenes | 2016 |
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.
Topics: Adaptor Proteins, Signal Transducing; Axitinib; Cell Line, Tumor; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imidazoles; Indazoles; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Niacinamide; Phenylurea Compounds; Point Mutation; Protein Interaction Maps; Protein Kinase Inhibitors; Sorafenib; src-Family Kinases | 2016 |
AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin.
Topics: AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Apoptosis; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Sorafenib; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Macrophages; Mice; Neutrophil Infiltration; Neutrophils; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocytes, Regulatory | 2016 |
Biological Validation of Novel Polysubstituted Pyrazole Candidates with in Vitro Anticancer Activities.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; Humans; In Vitro Techniques; Molecular Structure; Niacinamide; Phenylurea Compounds; Pyrazoles; Sorafenib; Structure-Activity Relationship | 2016 |
Anti-VEGF-related thrombotic microangiopathy in a child presenting with nephrotic syndrome.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Bone Neoplasms; Cisplatin; Doxorubicin; Humans; Ifosfamide; Male; Methotrexate; Nephrotic Syndrome; Niacinamide; Osteosarcoma; Phenylurea Compounds; Proteinuria; Remission, Spontaneous; Sorafenib; Thrombotic Microangiopathies; Vascular Endothelial Growth Factor A; Withholding Treatment | 2016 |
Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemical and Drug Induced Liver Injury; Child; Diarrhea; Disease Progression; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; Hypertension; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Patient Acuity; Phenylurea Compounds; Product Surveillance, Postmarketing; Prospective Studies; Sex Factors; Sorafenib; Survival Rate; Withholding Treatment; Young Adult | 2016 |
Targeting Androgen Receptor (AR)→IL12A Signal Enhances Efficacy of Sorafenib plus NK Cells Immunotherapy to Better Suppress HCC Progression.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Cytotoxicity, Immunologic; Disease Models, Animal; Disease Progression; Gene Expression Regulation, Neoplastic; Humans; Immunotherapy, Adoptive; Interleukin-12 Subunit p35; Killer Cells, Natural; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Receptors, Androgen; Signal Transduction; Sorafenib; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; Fluorodeoxyglucose F18; Glucose Transporter Type 1; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-bcl-2; Quercetin; Sorafenib; Tumor Suppressor Protein p53 | 2016 |
Trends and Patterns of Hepatocellular Carcinoma Treatment in Korea.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Cross-Sectional Studies; Databases, Factual; Female; Humans; Insurance Claim Review; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prevalence; Protein Kinase Inhibitors; Republic of Korea; Sorafenib | 2016 |
Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.
Topics: Adamantane; Apoptosis; Autophagy; Bile Duct Neoplasms; Cell Proliferation; Cholangiocarcinoma; Drug Synergism; Drug Therapy, Combination; Humans; Niacinamide; Phenylurea Compounds; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Pyridines; Sorafenib; Tumor Cells, Cultured | 2016 |
Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Basic Helix-Loop-Helix Transcription Factors; Blotting, Western; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Metformin; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays | 2016 |
SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Carrier Proteins; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Membrane Proteins; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Sorafenib; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Xenograft Model Antitumor Assays | 2016 |
iRGD decorated lipid-polymer hybrid nanoparticles for targeted co-delivery of doxorubicin and sorafenib to enhance anti-hepatocellular carcinoma efficacy.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Hepatocellular; Doxorubicin; Humans; Lipids; Liver Neoplasms; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Polymers; Sorafenib | 2016 |
Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.
Topics: Adult; Aged; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Niacinamide; Phenylurea Compounds; RNA, Messenger; Signal Transduction; Sorafenib | 2016 |
In vitro and in vivo evaluation of drug-eluting microspheres designed for transarterial chemoembolization therapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Delivery Systems; Drug Liberation; Embolization, Therapeutic; Female; Fibroblasts; Human Umbilical Vein Endothelial Cells; Mice, Inbred BALB C; Microspheres; Neoplasms; Niacinamide; Phenylurea Compounds; Polyesters; Sorafenib; Tumor Burden | 2016 |
Inhibition of Autophagy by Chloroquine Enhances the Antitumor Efficacy of Sorafenib in Glioblastoma.
Topics: Animals; Apoptosis; Autophagy; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Glioblastoma; Male; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib | 2016 |
Continuous molecular remission and regression of side effects after discontinuation of salvage therapy with sorafenib and donor lymphocyte infusions in a young patient with relapsed AML.
Topics: Alopecia; Antineoplastic Agents; Child, Preschool; Female; Humans; Leukemia, Myeloid, Acute; Lymphocyte Transfusion; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib; Tissue Donors | 2016 |
Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Leukocyte Count; Lymphocyte Count; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
Topics: Adult; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Hepatitis B; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Metastasis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Period; Proto-Oncogene Proteins c-raf; Recurrence; Retrospective Studies; Sorafenib | 2016 |
Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Propensity Score; Radiotherapy; Retrospective Studies; Sorafenib; Venous Thrombosis | 2016 |
Epigastric Distress Caused by Esophageal Candidiasis in 2 Patients Who Received Sorafenib Plus Radiotherapy for Hepatocellular Carcinoma: Case Report.
Topics: Aged; Aged, 80 and over; Antifungal Agents; Antineoplastic Agents; Candidiasis; Carcinoma, Hepatocellular; Dose Fractionation, Radiation; Esophagitis; Fluconazole; Heartburn; Hiccup; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Proton Pump Inhibitors; Sorafenib; Stomach Ulcer | 2016 |
Complete Remission of Unresectable Hepatocellular Carcinoma After Combined Sorafenib and Adjuvant Yttrium-90 Radioembolization.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Portal Vein; Radiopharmaceuticals; Radiotherapy, Adjuvant; Remission Induction; Sorafenib; Thrombosis; Treatment Outcome; Yttrium Radioisotopes | 2016 |
pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Endothelial Cells; Female; Gene Expression; Humans; Immunohistochemistry; Male; Middle Aged; Mutation; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2016 |
Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib | 2016 |
Intracellular interactions of electrostatically mediated layer-by-layer assembled polyelectrolytes based sorafenib nanoparticles in oral cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Calcium Carbonate; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dextran Sulfate; DNA Fragmentation; Drug Carriers; Drug Compounding; Drug Liberation; Epithelial Cells; Humans; Kinetics; Mouth Mucosa; Nanoparticles; Niacinamide; Peptides; Phenylurea Compounds; Polyelectrolytes; Protein Kinase Inhibitors; Sorafenib; Static Electricity | 2016 |
Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Morpholines; Mutation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Triazines; Xenograft Model Antitumor Assays | 2016 |
Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Metallothionein; Mice, Nude; NF-E2-Related Factor 2; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Effect of sorafenib on cisplatin-based chemoradiation in head and neck cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Cycle; Cell Movement; Cell Proliferation; Chemoradiotherapy; Cisplatin; Head and Neck Neoplasms; Humans; Niacinamide; Phenylurea Compounds; Radiation Tolerance; Radiation-Sensitizing Agents; Sorafenib; Tumor Cells, Cultured; X-Rays | 2016 |
[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; NF-kappa B; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
Kidney cancer: No advantage of adjuvant sunitinib or sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indoles; Kidney Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Sorafenib; Sunitinib | 2016 |
[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Remission Induction; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2016 |
Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
Topics: Antineoplastic Agents; Female; Humans; Middle Aged; Niacinamide; Perivascular Epithelioid Cell Neoplasms; Phenylurea Compounds; Sirolimus; Sorafenib; TOR Serine-Threonine Kinases; Uterine Neoplasms | 2016 |
Optimal combination of gemcitabine, sorafenib, and S-1 shows increased efficacy in treating cholangiocarcinoma in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; Drug Combinations; Drug Screening Assays, Antitumor; Gemcitabine; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Statistical; Niacinamide; Oxonic Acid; Phenylurea Compounds; Random Allocation; Sorafenib; Tegafur; Xenograft Model Antitumor Assays | 2016 |
Synergistic effects of ascorbate and sorafenib in hepatocellular carcinoma: New insights into ascorbate cytotoxicity.
Topics: Apoptosis; Ascorbic Acid; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Hep G2 Cells; Humans; Hydrogen Peroxide; Liver Neoplasms; Mitochondria; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Early sorafenib-related adverse events predict therapy response of TACE plus sorafenib: A multicenter clinical study of 606 HCC patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2016 |
Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival.
Topics: Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Thyroid Neoplasms | 2016 |
Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Rate; Treatment Outcome; Venous Thrombosis | 2016 |
Sorafenib metabolism, transport, and enterohepatic recycling: physiologically based modeling and simulation in mice.
Topics: Animals; Antineoplastic Agents; Computer Simulation; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Glucuronosyltransferase; Liver; Mice; Mice, Knockout; Models, Biological; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Sorafenib; Tissue Distribution; UDP-Glucuronosyltransferase 1A9 | 2016 |
Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemotherapy, Adjuvant; Chi-Square Distribution; Female; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplastic Cells, Circulating; Niacinamide; Odds Ratio; Phenylurea Compounds; Portal Vein; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Venous Thrombosis | 2016 |
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Case-Control Studies; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Genotype; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nitric Oxide Synthase Type III; Phenylurea Compounds; Polymorphism, Single Nucleotide; Retrospective Studies; Sorafenib | 2016 |
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Actins; Animals; Antigens, CD34; Antineoplastic Agents; Blood Vessels; Carcinoma, Hepatocellular; Contrast Media; Disease Models, Animal; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Homeodomain Proteins; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, SCID; MicroRNAs; Neoplasm Invasiveness; Neoplasm Transplantation; Neovascularization, Pathologic; Niacinamide; Osteopontin; Phenylurea Compounds; Repressor Proteins; Sequence Analysis, RNA; Signal Transduction; Sorafenib; Ultrasonography; Up-Regulation; Vascular Endothelial Growth Factor A; Vimentin; Zinc Finger E-box Binding Homeobox 2; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
[Evaluation of Sorafenib for Hepatocellular Carcinoma with Low α-Fetoprotein by Arrival Time Parametric Imaging Using Contrast-Enhanced Ultrasonography with Sonazoid].
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; Ferric Compounds; Humans; Iron; Liver Neoplasms; Male; Middle Aged; Niacinamide; Oxides; Phenylurea Compounds; Sorafenib; Time Factors; Ultrasonography | 2016 |
Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease Progression; Fatal Outcome; Humans; Jaw; Liver Neoplasms; Male; Niacinamide; Osteonecrosis; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tomography, X-Ray Computed | 2016 |
The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities.
Topics: Animals; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Echocardiography; Electrocardiography; Heart Defects, Congenital; Heart Rate; Hemodynamics; Male; Mice; Myocardial Contraction; Niacinamide; Organ Size; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Tadalafil; Thyroxine | 2016 |
Sorafenib effect on liver neoplastic changes in rats: more than a kinase inhibitor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; beta Catenin; Cell Proliferation; Cyclin D1; Disease Models, Animal; Glutathione; Histocytochemistry; Liver; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Rats; Sorafenib; Treatment Outcome | 2017 |
Iron depletion enhances the effect of sorafenib in hepatocarcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Proliferation; Disease Models, Animal; Female; Humans; Iron; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis | 2016 |
HDAC6-mediated EGFR stabilization and activation restrict cell response to sorafenib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Stability; Signal Transduction; Sorafenib | 2016 |
Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Inhibitory Concentration 50; Liver Neoplasms; Male; Mice, SCID; MicroRNAs; Niacinamide; Paclitaxel; Phenylurea Compounds; Protein Kinase Inhibitors; Quercetin; Receptor, Notch1; Signal Transduction; Sorafenib; Transfection; Xenograft Model Antitumor Assays | 2016 |
Cytochrome P450 1A2 Metabolizes 17β-Estradiol to Suppress Hepatocellular Carcinoma.
Topics: 2-Methoxyestradiol; Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 CYP1A2; Estradiol; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Humans; Liver; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Receptors, Estrogen; Sorafenib; Tumor Suppressor Protein p53 | 2016 |
[Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].
Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Retrospective Studies; Salvage Therapy; Sorafenib; Treatment Outcome | 2016 |
Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
Topics: Administration, Oral; Adult; Carcinoma, Hepatocellular; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2016 |
CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors.
Topics: Animals; Carcinoma, Hepatocellular; Cell Differentiation; Cell Lineage; Chromatin; DNA Helicases; DNA-Binding Proteins; High-Throughput Nucleotide Sequencing; Liver Neoplasms; Mice; Mice, Inbred C57BL; Niacinamide; Phenylurea Compounds; Receptors, Estrogen; Sorafenib; Transcription Factors | 2016 |
Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Focal Adhesion Kinase 1; Galectin 1; Humans; Integrin alphaVbeta3; Liver Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Morpholines; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; RNA Interference; Signal Transduction; Sorafenib; Survival Rate | 2016 |
All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo.
Topics: Animals; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Myeloid, Acute; Mice; Mutant Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Tandem Repeat Sequences; Tretinoin; Xenograft Model Antitumor Assays | 2016 |
Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution.
Topics: Adult; Afatinib; Aged; Antineoplastic Agents; Asian People; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Everolimus; Feasibility Studies; Female; Genetic Predisposition to Disease; High-Throughput Nucleotide Sequencing; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Pilot Projects; Precision Medicine; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Republic of Korea; Sorafenib; Young Adult | 2016 |
Downregulation of amplified in breast cancer 1 contributes to the anti-tumor effects of sorafenib on human hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Down-Regulation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Nuclear Receptor Coactivator 3; Phenylurea Compounds; Signal Transduction; Sorafenib | 2016 |
Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Dose-Response Relationship, Drug; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Product Surveillance, Postmarketing; Prospective Studies; Sorafenib; Treatment Outcome; Young Adult | 2016 |
Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Dose-Response Relationship, Drug; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib; Treatment Outcome | 2016 |
Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; China; Cost-Benefit Analysis; Disease Progression; Disease-Free Survival; Drug Costs; Female; Hepatitis B; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Middle Aged; Models, Economic; Niacinamide; Phenylurea Compounds; Quality of Life; Quality-Adjusted Life Years; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Multicentric survey on dose reduction/interruption of cancer drug therapy in 12.472 patients: indicators of suspected adverse reactions.
Topics: Antineoplastic Agents; Capecitabine; Docetaxel; Drug Administration Schedule; Humans; Neoplasms; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Pharmacovigilance; Phenylurea Compounds; Retrospective Studies; Sorafenib; Taxoids; Treatment Outcome | 2016 |
A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; CD13 Antigens; Cell Cycle; Cell Line, Tumor; Cisplatin; Drug Synergism; Fluorouracil; Gene Expression Regulation, Neoplastic; Humans; Leucine; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib | 2016 |
Sorafenib-resistant hepatocellular carcinoma stratified by phosphorylated ERK activates PD-1 immune checkpoint.
Topics: Animals; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Hep G2 Cells; Humans; K562 Cells; Liver Neoplasms; Mice; Mice, Nude; Mice, Transgenic; Niacinamide; Phenylurea Compounds; Phosphorylation; Programmed Cell Death 1 Receptor; Signal Transduction; Sorafenib | 2016 |
Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3/ITD mutation.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; G2 Phase Cell Cycle Checkpoints; Genetic Predisposition to Disease; Glycolysis; Humans; Leukemia, Myeloid, Acute; Mice; Mitochondria; Mutation; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Pyruvates; Signal Transduction; Sorafenib; Tandem Repeat Sequences; Time Factors | 2016 |
Actionable pathways: interactive discovery of therapeutic targets using signaling pathway models.
Topics: Antineoplastic Agents; Breast Neoplasms; Computer Graphics; Computer Simulation; Drug Discovery; Gene Expression Regulation, Neoplastic; Gene Knockout Techniques; Humans; Information Storage and Retrieval; Internet; Metabolic Networks and Pathways; Models, Statistical; Molecular Targeted Therapy; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Signal Transduction; Software; Sorafenib | 2016 |
Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Embolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Microspheres; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Propensity Score; Radiopharmaceuticals; Republic of Korea; Retrospective Studies; Sorafenib; Treatment Outcome; Venous Thrombosis; Yttrium Radioisotopes | 2016 |
[Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia].
Topics: Cytarabine; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Sorafenib; Treatment Outcome | 2016 |
Inhibition of Cell Proliferation in an NRAS Mutant Melanoma Cell Line by Combining Sorafenib and α-Mangostin.
Topics: Cell Line, Tumor; Cell Proliferation; Genes, ras; Humans; Melanoma; Niacinamide; Phenylurea Compounds; Receptors, Retinoic Acid; Sorafenib; Xanthones | 2016 |
ADRB2 signaling promotes HCC progression and sorafenib resistance by inhibiting autophagic degradation of HIF1α.
Topics: Animals; Autophagy; Carcinoma, Hepatocellular; Disease Progression; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Receptors, Adrenergic, beta-2; Signal Transduction; Sorafenib | 2016 |
The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Ablation Techniques; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chemoradiotherapy, Adjuvant; Chi-Square Distribution; Female; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Proportional Hazards Models; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Acidic pH-Triggered Drug-Eluting Nanocomposites for Magnetic Resonance Imaging-Monitored Intra-arterial Drug Delivery to Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Delivery Systems; Hydrogen-Ion Concentration; Liver Neoplasms; Magnetic Resonance Imaging; Nanocomposites; Niacinamide; Phenylurea Compounds; Rats; Sorafenib | 2016 |
Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Outcome | 2016 |
Des-gamma-carboxy prothrombin antagonizes the effects of Sorafenib on human hepatocellular carcinoma through activation of the Raf/MEK/ERK and PI3K/Akt/mTOR signaling pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Antagonism; Hep G2 Cells; Humans; Liver Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphotransferases; Protein Precursors; Prothrombin; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2016 |
Prognostic value of pathological features of primary lesion in metastatic renal cell carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Sorafenib | 2016 |
Metastatic renal cell carcinoma: the first report of unilateral fundus hemorrhage induced by sorafenib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Renal Cell; Eye Hemorrhage; Fundus Oculi; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Identification of a germline F692L drug resistance variant in cis with Flt3-internal tandem duplication in knock-in mice.
Topics: Animals; Benzothiazoles; Drug Resistance; fms-Like Tyrosine Kinase 3; Gene Knock-In Techniques; Germ-Line Mutation; Humans; Leukemia, Myeloid, Acute; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Tumor Cells, Cultured | 2016 |
Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiodized Oil; Feasibility Studies; Hypoxia-Inducible Factor 1, alpha Subunit; Liver Neoplasms, Experimental; Male; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rabbits; Sorafenib; Tissue Distribution; Vascular Endothelial Growth Factor A | 2016 |
Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Cysteine; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Metallothionein; NF-E2-Related Factor 2; Niacinamide; Oxidation-Reduction; Oxidative Stress; Phenylurea Compounds; Prognosis; Promoter Regions, Genetic; Protein Kinase Inhibitors; Sorafenib; Transcription, Genetic | 2016 |
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Clinical Trials, Phase III as Topic; Disease-Free Survival; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kaplan-Meier Estimate; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
Simultaneous multitarget radiotherapy using helical tomotherapy and its combination with sorafenib for pulmonary metastases from hepatocellular carcinoma.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cohort Studies; Combined Modality Therapy; Disease-Free Survival; Feasibility Studies; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Radiotherapy, Intensity-Modulated; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma.
Topics: Aged; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Decision Making; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Markov Chains; Monte Carlo Method; Niacinamide; Phenylurea Compounds; Probability; Quality-Adjusted Life Years; Radiosurgery; Randomized Controlled Trials as Topic; Sorafenib; Taiwan | 2016 |
Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cell Line, Tumor; Combined Modality Therapy; Cytotoxicity, Immunologic; Disease Models, Animal; Humans; Immunophenotyping; Immunotherapy; Immunotherapy, Adoptive; Killer Cells, Natural; Liver Neoplasms; Lymphocyte Activation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
Sorafenib inhibits macrophage-mediated epithelial-mesenchymal transition in hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Epithelial-Mesenchymal Transition; Humans; Liver Neoplasms; Macrophages; Male; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib | 2016 |
Identification of a thalidomide derivative that selectively targets tumorigenic liver progenitor cells and comparing its effects with lenalidomide and sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Lenalidomide; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Stem Cells; Thalidomide | 2016 |
Little Impact on Renal Function in Advanced Renal Cell Carcinoma Patients Treated with Sorafenib--Analyses of Postmarketing Surveillance in Japan in over 3,200 Consecutive Cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Glomerular Filtration Rate; Humans; Kidney; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2016 |
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular Carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Female; France; Humans; Liver Neoplasms; Lung; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Serum Albumin; Severity of Illness Index; Sorafenib; Survival Analysis; United Kingdom; Young Adult | 2016 |
Innovations and Improvements in Pharmacokinetic Models Based on Physiology.
Topics: Animals; Humans; Liver; Mice; Models, Biological; Niacinamide; Phenylurea Compounds; Piperidines; Remifentanil; Sorafenib | 2017 |
[Effective Prevention of Hand-Foot Syndrome by the Consumption of Dried Bonito Broth].
Topics: Aged; Antineoplastic Agents; Female; Fish Products; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Remission Induction; Retrospective Studies; Sirolimus; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden | 2016 |
Potential efficacy of therapies targeting intrahepatic lesions after sorafenib treatment of patients with hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Salvage Therapy; Sorafenib; Treatment Outcome | 2016 |
Integrin alphavbeta3 enhances β-catenin signaling in acute myeloid leukemia harboring Fms-like tyrosine kinase-3 internal tandem duplication mutations: implications for microenvironment influence on sorafenib sensitivity.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis; beta Catenin; Cell Line, Tumor; Cell Survival; Female; fms-Like Tyrosine Kinase 3; Gene Expression Regulation, Leukemic; Humans; Integrin alphaVbeta3; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Niacinamide; Osteopontin; Phenylurea Compounds; Prognosis; Risk; Signal Transduction; Sorafenib; Tumor Microenvironment | 2016 |
Sorafenib treatment in children with relapsed and refractory neuroblastoma: an experience of four cases.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Drug Resistance, Neoplasm; Fatal Outcome; Female; Humans; Male; Neuroblastoma; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Retreatment; Sorafenib; Treatment Outcome | 2016 |
Aggressive Treatment of Performance Status 1 and 2 HCC Patients Significantly Improves Survival - an Egyptian Retrospective Cohort Study of 524 Cases.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate | 2016 |
Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Portal Vein; Retrospective Studies; Sorafenib; Survival Analysis; Survival Rate; Treatment Outcome; Venous Thrombosis | 2017 |
Synthesis of thermosensitive magnetic nanocarrier for controlled sorafenib delivery.
Topics: Acrylamides; Delayed-Action Preparations; Epoxy Compounds; Hot Temperature; Humans; Hydrogen-Ion Concentration; Magnetite Nanoparticles; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Prognostic Value of SETD2 Expression in Patients with Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Gene Expression Regulation, Neoplastic; Histone-Lysine N-Methyltransferase; Humans; Indoles; Kidney Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Young Adult | 2016 |
Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Endometrial Neoplasms; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Pyridines; Sorafenib; Thyroid Neoplasms | 2016 |
Silk-Elastinlike Protein Polymer Liquid Chemoembolic for Localized Release of Doxorubicin and Sorafenib.
Topics: Doxorubicin; Drug Liberation; Microscopy, Electron, Scanning; Niacinamide; Phenylurea Compounds; Polymers; Rheology; Silk; Sorafenib; Spectroscopy, Fourier Transform Infrared | 2016 |
Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Diffusion Magnetic Resonance Imaging; Image Enhancement; Image Interpretation, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Angiography; Male; Mice; Mice, Inbred BALB C; Motion; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2017 |
Clinical Trial Simulations From a Model-Based Meta-Analysis of Studies in Patients With Advanced Hepatocellular Carcinoma Receiving Antiangiogenic Therapy.
Topics: Aged; Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Computer Simulation; Female; Humans; Liver Neoplasms; Male; Middle Aged; Network Meta-Analysis; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Overexpression of DLX2 is associated with poor prognosis and sorafenib resistance in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Homeodomain Proteins; Humans; Immunohistochemistry; Ki-67 Antigen; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Analysis; Transcription Factors | 2016 |
Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Humans; Mice; Mice, Inbred C57BL; Myeloid Cell Leukemia Sequence 1 Protein; NF-kappa B; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Quinacrine; Sorafenib; Thyroid Carcinoma, Anaplastic; Thyroid Gland; Thyroid Neoplasms; Transcription Factor RelA | 2016 |
In vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancer.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Biocompatible Materials; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Survival; Drug Liberation; Female; Hemolysis; Humans; Inhibitory Concentration 50; Lipids; Liver Neoplasms; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib; Suspensions; Tissue Distribution; Treatment Outcome; Veins | 2016 |
Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2016 |
Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Time; Treatment Outcome | 2016 |
Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors.
Topics: Animals; Cell Line, Tumor; Enzyme Activation; Fingolimod Hydrochloride; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein Phosphatase 2; Sorafenib | 2016 |
NUPR1, a new target in liver cancer: implication in controlling cell growth, migration, invasion and sorafenib resistance.
Topics: Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Movement; Cell Proliferation; Cell Survival; Computational Biology; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Gene Silencing; Humans; Liver Neoplasms; Male; Membrane Proteins; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib; Transcription Factor RelB; Transcriptome; Young Adult | 2016 |
Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways.
Topics: Adult; Cell Cycle; Cell Movement; Cell Proliferation; Cells, Cultured; Female; Fibroblasts; Humans; Keloid; Male; Middle Aged; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sincalide; Smad Proteins; Sorafenib; Transforming Growth Factor beta; Young Adult | 2016 |
Last line therapy with sorafenib in colorectal cancer: A retrospective analysis.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Male; Neoplasm Staging; Niacinamide; Off-Label Use; Phenylurea Compounds; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Sorafenib; Withholding Treatment | 2016 |
Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Patients with Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug Resistance, Neoplasm; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Interferons; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Retrospective Studies; Sorafenib; Treatment Outcome | 2016 |
[Endovascular implantation of iodine-125 seeds strand and portal vein stenting followed by transcatheter arterial chemoembolization combined therapy with sorafenib for hepatocellular carcinoma with main portal vein tumor thrombus].
Topics: Arteries; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Endovascular Procedures; Humans; Iodine Radioisotopes; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Stents; Thrombosis; Treatment Outcome | 2016 |
Receptor-targeted, drug-loaded, functionalized graphene oxides for chemotherapy and photothermal therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Cell Death; Drug Carriers; Endocytosis; Folate Receptors, GPI-Anchored; Folic Acid; Graphite; Hemolysis; Humans; Hyperthermia, Induced; KB Cells; Male; Nanomedicine; Niacinamide; Phenylurea Compounds; Phototherapy; Rats; Sorafenib; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2016 |
Sirtuin 3 enhanced drug sensitivity of human hepatoma cells through glutathione S-transferase pi 1/JNK signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Separation; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Glutathione; Glutathione S-Transferase pi; Glycogen Synthase Kinase 3; Humans; Liver Neoplasms; MAP Kinase Kinase 4; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; RNA, Messenger; Signal Transduction; Sirtuin 3; Sorafenib | 2016 |
Severe adverse skin reaction and desensitization to sorafenib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Growth Processes; Desensitization, Immunologic; Drug Hypersensitivity; Female; Humans; Immune Tolerance; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Urticaria; Young Adult | 2016 |
Ablative Focused Ultrasound Synergistically Enhances Thermally Triggered Chemotherapy for Prostate Cancer in Vitro.
Topics: Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Cryoelectron Microscopy; Drug Delivery Systems; High-Intensity Focused Ultrasound Ablation; Humans; Liposomes; Male; Microscopy, Confocal; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Sorafenib | 2016 |
Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Case-Control Studies; Disease Progression; Female; Fibroblast Growth Factors; Gene Dosage; High-Throughput Nucleotide Sequencing; Humans; Liver Neoplasms; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, Fibroblast Growth Factor; Remission Induction; Retrospective Studies; Sequence Analysis, DNA; Sorafenib; Treatment Outcome | 2016 |
miR-181a induces sorafenib resistance of hepatocellular carcinoma cells through downregulation of RASSF1 expression.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; RNA Interference; Sorafenib; Tumor Suppressor Proteins | 2016 |
Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case report.
Topics: Aged; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Humans; Liver Neoplasms; Lung Neoplasms; Male; Mutation; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Sorafenib; Treatment Outcome | 2016 |
Efficacy of lenvatinib in treating thyroid cancer.
Topics: Biomarkers; Calcitonin; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Half-Life; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroglobulin; Thyroid Neoplasms | 2016 |
FBW7 mutations mediate resistance of colorectal cancer to targeted therapies by blocking Mcl-1 degradation.
Topics: Animals; Cell Cycle Proteins; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; F-Box Proteins; F-Box-WD Repeat-Containing Protein 7; Female; Gene Knockout Techniques; HCT116 Cells; Heterografts; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Mutation, Missense; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Transfection; Ubiquitin-Protein Ligases | 2017 |
Discovery of a Nanomolar Multikinase Inhibitor (KST016366): A New Benzothiazole Derivative with Remarkable Broad-Spectrum Antiproliferative Activity.
Topics: Animals; Antineoplastic Agents; Benzothiazoles; Cell Line, Tumor; Discoidin Domain Receptor 1; Drug Screening Assays, Antitumor; Humans; Male; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Receptor, trkA; Sorafenib; Vascular Endothelial Growth Factor Receptor-2 | 2016 |
Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; beta Catenin; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidinones; RNA Interference; RNAi Therapeutics; Sorafenib; Transfection; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2016 |
[Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2016 |
Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sirolimus; Sorafenib | 2016 |
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission.
Topics: Adult; Aged; Antineoplastic Agents; Combined Modality Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Remission Induction; Retrospective Studies; Sorafenib; Tandem Repeat Sequences; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2016 |
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network.
Topics: Aged; Antineoplastic Agents; Bevacizumab; Carcinoma, Renal Cell; Chemical and Drug Induced Liver Injury; Cohort Studies; Computer Communication Networks; Female; Follow-Up Studies; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Vascular Endothelial Growth Factor A | 2016 |
Small-molecule inhibitor sorafenib regulates immunoreactions by inducing survival and differentiation of bone marrow cells.
Topics: Animals; Bone Marrow Cells; Cell Differentiation; Cytokines; Dendritic Cells; Female; Humans; Immunomodulation; Liver Neoplasms; Liver Transplantation; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Sorafenib; T-Lymphocytes | 2016 |
Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?
Topics: Adult; Aged; Aged, 80 and over; Anorexia; Antineoplastic Agents; Carcinoma, Renal Cell; Developing Countries; Disease-Free Survival; Fatigue; Female; Follow-Up Studies; Hand-Foot Syndrome; Humans; India; Indoles; Kidney Neoplasms; Male; Middle Aged; Mucositis; Niacinamide; Phenylurea Compounds; Pigmentation Disorders; Prospective Studies; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sirolimus; Sorafenib; Sunitinib; Survival Rate; White People; Young Adult | 2016 |
Microwave coagulation/ablation in combination with sorafenib suppresses the overgrowth of residual tumor in VX2 liver tumor model.
Topics: Animals; Catheter Ablation; Cell Line, Tumor; Chemotherapy, Adjuvant; Contrast Media; Diffusion Magnetic Resonance Imaging; Immunohistochemistry; Liver; Liver Neoplasms, Experimental; Microwaves; Necrosis; Neoplasm, Residual; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rabbits; Sorafenib; Ultrasonography | 2016 |
Is radioembolization or sorafenib the best option for patients with hepatocellular carcinoma and portal vein invasion?
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib | 2016 |
Leukocyte trafficking is not affected by multikinase inhibitors sunitinib or sorafenib in mice.
Topics: Animals; Cell Movement; Female; Indoles; Leukocytes; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, SCID; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib; T-Lymphocytes, Regulatory; Transendothelial and Transepithelial Migration | 2016 |
Synergistic inhibition of characteristics of liver cancer stem-like cells with a combination of sorafenib and 8-bromo-7-methoxychrysin in SMMC-7721 cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Drug Synergism; Flavonoids; Flow Cytometry; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Drug Substitution; Female; Humans; Japan; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Retreatment; Sorafenib; Time Factors; Treatment Outcome | 2016 |
A case report: delayed high fever and maculopapules during Sorafenib treatment of ectopic hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Drug Eruptions; Fever; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prednisone; Sorafenib; Treatment Outcome | 2016 |
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline.
Topics: Antineoplastic Agents; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; Humans; Imidazoles; Indazoles; Indoles; Interferon-alpha; Kidney Neoplasms; Logistic Models; Multivariate Analysis; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrroles; Randomized Controlled Trials as Topic; Sorafenib; Sunitinib; Time Factors | 2016 |
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Child; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Registries; Sorafenib | 2016 |
Novel combination of sorafenib and biochanin-A synergistically enhances the anti-proliferative and pro-apoptotic effects on hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Genistein; Hepatocytes; Humans; Inhibitory Concentration 50; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
[Prediction and preventive strategies for recurrence after surgery for hepatocellular carcinoma].
Topics: Biopsy; Carcinoma, Hepatocellular; Embolization, Therapeutic; Humans; Immunotherapy; Interferons; Liver Neoplasms; MicroRNAs; Neoplasm Recurrence, Local; Niacinamide; Osteopontin; Phenylurea Compounds; Sorafenib; Tumor Microenvironment | 2016 |
Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphoproteins; Prognosis; Protein Transport; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2016 |
Capecitabine in advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis | 2016 |
Krüppel-like factor 8 promotes cancer stem cell-like traits in hepatocellular carcinoma through Wnt/β-catenin signaling.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Kruppel-Like Transcription Factors; Liver; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Prognosis; Repressor Proteins; Sorafenib; Wnt Proteins; Wnt Signaling Pathway | 2017 |
[The efficacy of sorafenib to prevent relapse in patients with FLT3-ITD mutation positive acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation].
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Recurrence; Retrospective Studies; Secondary Prevention; Sorafenib; Survival Rate; Treatment Outcome | 2016 |
A retrospective study of predictive factors for unexpectedly prolonged or shortened progression-free survival and overall survival among patients with metastatic renal cell carcinoma who received first-line targeted therapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; Retrospective Studies; Sirolimus; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2016 |
Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.
Topics: Apoptosis; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Melatonin; Mitophagy; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib | 2016 |
FOLFOX4 or sorafenib as the first-line treatments for advanced hepatocellular carcinoma: A cost-effectiveness analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; China; Cohort Studies; Cost-Benefit Analysis; Female; Fluorouracil; Humans; Leucovorin; Liver Neoplasms; Male; Middle Aged; Monte Carlo Method; Niacinamide; Organoplatinum Compounds; Phenylurea Compounds; Quality-Adjusted Life Years; Sorafenib | 2016 |
The effect of radiotherapy in liver-confined but non-resectable Barcelona Clinic Liver Cancer stage C large hepatocellular carcinoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Child; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Registries; Regression Analysis; Republic of Korea; Retrospective Studies; Sorafenib; Time Factors; Treatment Outcome; Young Adult | 2016 |
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Clinical Decision-Making; Clinical Trials as Topic; Combined Modality Therapy; Disease Management; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2016 |
Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
Topics: Adult; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Biomarkers, Tumor; Carbonic Anhydrase IX; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Nephrectomy; Niacinamide; Phenylurea Compounds; Platelet Endothelial Cell Adhesion Molecule-1; Prognosis; Prospective Studies; Pyrroles; Receptor, Platelet-Derived Growth Factor beta; Sorafenib; Sunitinib; Tissue Array Analysis; Vascular Endothelial Growth Factor Receptor-1 | 2016 |
Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Genes, myc; Humans; Liver Neoplasms; Mice; Niacinamide; Nuclear Proteins; Oligopeptides; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; raf Kinases; ras Proteins; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors; Transcription Initiation Site; Xenograft Model Antitumor Assays | 2016 |
68Ga DOTATATE PET/CT in Differentiated Thyroid Carcinoma With Fibular Metastasis and Mixed Response to Sorafenib.
Topics: Female; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Organometallic Compounds; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Sorafenib; Thyroid Neoplasms; Treatment Outcome | 2016 |
Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Complications; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Treatment Outcome | 2017 |
Response to Successful liver transplantation for hepatocellular carcinoma following down-staging using sorafenib single therapy by Borentain et al.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
The Limonoids TS3 and Rubescin E Induce Apoptosis in Human Hepatoma Cell Lines and Interfere with NF-κB Signaling.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Humans; Limonins; Liver Neoplasms; NF-kappa B; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib | 2016 |
Angiopoietin-like protein 1 antagonizes MET receptor activity to repress sorafenib resistance and cancer stemness in hepatocellular carcinoma.
Topics: Angiopoietin-Like Protein 1; Angiopoietin-like Proteins; Angiopoietins; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Female; Humans; Liver Neoplasms; Male; Mice; Middle Aged; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-met; Sorafenib | 2016 |
Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.
Topics: Adult; Aged; Antineoplastic Agents; Female; Genotype; Glucuronosyltransferase; Humans; Liver Neoplasms; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Retrospective Studies; Sorafenib | 2016 |
Analysis of Sorafenib Outcome: Focusing on the Clinical Course in Patients with Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2016 |
Overall prognostic impact of C-reactive protein level in patients with metastatic renal cell carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate | 2016 |
Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate | 2017 |
Sorafenib inhibits cell growth but fails to enhance radio- and chemosensitivity of glioblastoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Radiation; Drug Resistance, Neoplasm; Glioblastoma; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Radiation Tolerance; Signal Transduction; Sorafenib; X-Rays | 2016 |
Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Caspase Inhibitors; Cell Death; Cell Line, Tumor; Cell Survival; DNA Fragmentation; Drug Synergism; Enzyme Activation; Free Radical Scavengers; Humans; Liver Neoplasms; Niacinamide; Oleanolic Acid; Oxidative Stress; Phenylurea Compounds; Proteolysis; Reactive Oxygen Species; Sorafenib | 2016 |
Effect of the timing of best tumor shrinkage on survival of patients with metastatic renal cell carcinoma who received first-line tyrosine kinase inhibitor therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Response Evaluation Criteria in Solid Tumors; Sorafenib; Sulfonamides; Sunitinib; Survival Rate; Time Factors | 2017 |
Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2016 |
Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordoma.
Topics: Antineoplastic Agents; Chordoma; Graves Disease; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2016 |
Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Chi-Square Distribution; China; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Curative therapies are superior to standard of care (transarterial chemoembolization) for intermediate stage hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Standard of Care; Survival Analysis; Treatment Outcome | 2017 |
Sorafenib Therapy for Pediatric Acute Myeloid Leukemia with FMS-like Tyrosine Kinase 3-internal Tandem Duplication Mutations: 2 Case Reports.
Topics: Child; Child, Preschool; Drug Administration Schedule; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Mutation; Niacinamide; Phenylurea Compounds; Salvage Therapy; Sorafenib; Tandem Repeat Sequences; Treatment Outcome | 2017 |
Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Cadherins; Cell Movement; Colorectal Neoplasms; Dose-Response Relationship, Drug; Enzyme Activation; Epithelial-Mesenchymal Transition; Female; HCT116 Cells; HT29 Cells; Humans; Lung Neoplasms; Male; Mice, Nude; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Pyridines; RNA Interference; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Time Factors; Transfection; Transforming Growth Factor beta1; Xenograft Model Antitumor Assays | 2016 |
The interaction of sorafenib and regorafenib with membranes is modulated by their lipid composition.
Topics: Antineoplastic Agents; Ascorbic Acid; Cell Membrane; Cell Membrane Permeability; Cholesterol; Dithionite; Kinetics; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Phosphatidylcholines; Phosphatidylethanolamines; Pyridines; Sorafenib; Spin Labels; Staining and Labeling; Unilamellar Liposomes | 2016 |
A simple, rapid and sensitive RP-HPLC-UV method for the simultaneous determination of sorafenib & paclitaxel in plasma and pharmaceutical dosage forms: Application to pharmacokinetic study.
Topics: Animals; Calibration; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Dosage Forms; Niacinamide; Paclitaxel; Phenylurea Compounds; Piroxicam; Rabbits; Reproducibility of Results; Sorafenib; Ultraviolet Rays | 2016 |
Indole-3- carbinol enhances sorafenib cytotoxicity in hepatocellular carcinoma cells: A mechanistic study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; NADPH Oxidase 1; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Topics: Amino Acid Transport System y+; Animals; Antineoplastic Agents, Alkylating; Apoptosis; Astrocytes; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Dacarbazine; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Gene Knockdown Techniques; Glioma; Humans; Mice; Niacinamide; Phenylurea Compounds; Piperazines; Pyramidal Cells; Rats; Sorafenib; Temozolomide | 2016 |
Substituted 2-hydroxy-N-(arylalkyl)benzamide sensitizes cancer cells to metabolic stress by disrupting actin cytoskeleton and inhibiting autophagic flux.
Topics: Actin Cytoskeleton; Antineoplastic Agents; Apoptosis; Autophagy; Benzamides; Cell Cycle; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; Niacinamide; Phenylalanine; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Stress, Physiological; Wound Healing | 2016 |
Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Humans; Inflammation; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib | 2016 |
IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibodies, Neutralizing; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Case-Control Studies; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA Methylation; Epigenesis, Genetic; Female; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Insulin-Like Growth Factor II; Liver Neoplasms; Male; Mice, Inbred C57BL; MicroRNAs; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Receptor, IGF Type 1; Receptors, Somatomedin; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sorafenib; Tumor Stem Cell Assay; Up-Regulation | 2016 |
Sorafenib plus cisplatin for hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Clinical Trials, Phase II as Topic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2016 |
Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; Fever; Humans; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chi-Square Distribution; Disease Progression; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Logistic Models; London; Male; Middle Aged; Multivariate Analysis; Niacinamide; Odds Ratio; Patient Selection; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome | 2017 |
Sorafenib potentiates ABT-737-induced apoptosis in human oral cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Biphenyl Compounds; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Therapy, Combination; Humans; Mouth Neoplasms; Niacinamide; Nitrophenols; Phenylurea Compounds; Piperazines; Sorafenib; Staining and Labeling; Sulfonamides | 2017 |
In vitro and in vivo evaluation of redox-responsive sorafenib carrier nanomicelles synthesized from poly (acryic acid) -cystamine hydrochloride-D-α-tocopherol succinate.
Topics: Acrylic Resins; alpha-Tocopherol; Animals; Cell Line, Tumor; Chemistry Techniques, Synthetic; Cystamine; Drug Carriers; Drug Liberation; Hemolysis; Humans; Hydrophobic and Hydrophilic Interactions; Male; Micelles; Nanostructures; Niacinamide; Oxidation-Reduction; Particle Size; Phenylurea Compounds; Rabbits; Rats; Sorafenib; Stereoisomerism | 2016 |
Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the laminin-332/α3 integrin axis recovery of focal adhesion kinase ubiquitination.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Focal Adhesion Protein-Tyrosine Kinases; Hepatic Stellate Cells; Humans; Integrin alpha3; Laminin; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Cells, Cultured; Ubiquitination | 2016 |
Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Chordoma; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Male; Membrane Proteins; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A | 2016 |
Eosinophil percentage elevation as a prognostic factor for overall survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Enzyme Inhibitors; Eosinophils; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Leukocyte Count; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Protein-Tyrosine Kinases; Sorafenib; Young Adult | 2016 |
Response of Malignant Thymoma to Sorafenib.
Topics: Adult; Antineoplastic Agents; Female; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Thymoma; Thymus Neoplasms; Treatment Outcome | 2016 |
mRECIST response combined with sorafenib-related adverse events is superior to either criterion alone in predicting survival in HCC patients treated with TACE plus sorafenib.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome | 2017 |
The miR-367-3p Increases Sorafenib Chemotherapy Efficacy to Suppress Hepatocellular Carcinoma Metastasis through Altering the Androgen Receptor Signals.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Models, Animal; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; MicroRNAs; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Receptors, Androgen; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Genetic Vectors; Humans; Liver Neoplasms; Male; Mice; MicroRNAs; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA Interference; RNA, Long Noncoding; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Exosomes; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Signal Transduction; Sorafenib; Tumor Microenvironment | 2016 |
Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antineoplastic Agents; Cell Adhesion; Cell Movement; Chemokine CCL2; Chemokine CXCL11; Disease Models, Animal; Fibrosis; Gene Expression Regulation; Humans; Kidney Tubules; Macrophages; Male; Mice; Mice, Inbred C57BL; Myofibroblasts; Niacinamide; Phenylurea Compounds; Receptors, CXCR3; RNA, Messenger; Signal Transduction; Sorafenib; Transforming Growth Factor beta1; Ureter; Ureteral Obstruction | 2016 |
Sorafenib-induced Thyroiditis in FMS-like Tyrosine Kinase 3-internal Tandem Duplication-mutated Acute Myeloid Leukemia.
Topics: Adult; Female; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib; Tandem Repeat Sequences; Thyroiditis | 2016 |
Overexpression of PCBP2 contributes to poor prognosis and enhanced cell growth in human hepatocellular carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; RNA-Binding Proteins; Sorafenib; Young Adult | 2016 |
Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Erythrocyte Indices; Erythrocytes, Abnormal; Female; Hematologic Diseases; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib; Treatment Outcome | 2016 |
Ginkgo biloba extract in combination with sorafenib is clinically safe and tolerable in advanced hepatocellular carcinoma patients.
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Hepatocellular; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; Ginkgo biloba; Humans; Liver Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Phenylurea Compounds; Plant Extracts; Prospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2016 |
Successful molecular targeted treatment of AML in pregnancy with Azacitidine and Sorafenib with no adverse fetal outcomes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Female; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pregnancy; Pregnancy Complications, Neoplastic; Sorafenib; Treatment Outcome | 2018 |
Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Databases, Factual; Female; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Medicare; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; SEER Program; Sorafenib; Survival Rate; United States | 2017 |
Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Imidazoles; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyridazines; Retrospective Studies; Sorafenib; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Diffusion Magnetic Resonance Imaging; Drug Monitoring; Early Detection of Cancer; Female; Humans; Image Interpretation, Computer-Assisted; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Multimodal Imaging; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome | 2017 |
C2-ceramide enhances sorafenib-induced caspase-dependent apoptosis via PI3K/AKT/mTOR and Erk signaling pathways in HCC cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Flow Cytometry; Humans; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sorafenib; Sphingosine; TOR Serine-Threonine Kinases | 2017 |
Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
Topics: Androgen Antagonists; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Nitriles; Phenylthiohydantoin; Phenylurea Compounds; Prostatic Neoplasms, Castration-Resistant; Protein Kinase Inhibitors; Receptors, Androgen; Signal Transduction; Sorafenib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Ubenimex attenuates acquired sorafenib resistance in renal cell carcinoma by inhibiting Akt signaling in a lipophagy associated mechanism.
Topics: Adenine; Animals; Autophagy; Carcinoma, Renal Cell; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Leucine; Lipid Metabolism; Mice; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2016 |
[Lenvatinib in radioiodine refractory thyroid carcinomas].
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Clinical Trials as Topic; Compassionate Use Trials; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Thyroid Neoplasms | 2016 |
[Implementation of a nurse-driven educational program improves management of sorafenib's toxicities in hepatocellular carcinoma].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Asthenia; Carcinoma, Hepatocellular; Diarrhea; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Niacinamide; Patient Education as Topic; Phenylurea Compounds; Practice Patterns, Nurses'; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib | 2016 |
The antitumor activity of a lactosaminated albumin conjugate of doxorubicin in a chemically induced hepatocellular carcinoma rat model compared to sorafenib.
Topics: Animals; Antibiotics, Antineoplastic; Biomarkers, Tumor; Carcinoma, Hepatocellular; Diethylnitrosamine; Doxorubicin; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms, Experimental; Male; Niacinamide; Phenylurea Compounds; Rats; Rats, Wistar; Serum Albumin; Sorafenib; Survival Rate | 2017 |
Painful Rashes on the Palms and Soles.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Neoplasms, Multiple Primary; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Longitudinal alterations in health-related quality of life and its impact on the clinical course of patients with advanced hepatocellular carcinoma receiving sorafenib treatment.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Longitudinal Studies; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Quality of Life; Social Behavior; Sorafenib; Treatment Outcome | 2016 |
Evaluation of sorafenib for advanced hepatocellular carcinoma with low α-fetoprotein in arrival time parametric imaging using contrast-enhanced ultrasonography.
Topics: Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2017 |
Potential biomarkers for the therapeutic efficacy of sorafenib, sunitinib and everolimus.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Cycle Proteins; Cell Line, Tumor; Disease-Free Survival; Everolimus; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphoproteins; Protein Kinase Inhibitors; Pyrroles; Ribosomal Protein S6 Kinases, 70-kDa; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma.
Topics: Biomarkers, Tumor; Carcinoma, Renal Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Gene Expression Profiling; Humans; Interleukin-6; Kidney Neoplasms; Microarray Analysis; Niacinamide; Phenylurea Compounds; RNA, Long Noncoding; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2017 |
Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Drug Evaluation, Preclinical; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Retinoblastoma Binding Proteins; Sorafenib; Ubiquitin-Protein Ligases | 2017 |
ABCC2 (1249G > A) polymorphism implicates altered transport activity for sorafenib.
Topics: Antineoplastic Agents; HEK293 Cells; Humans; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Sorafenib | 2017 |
Synthesis, Biological Evaluation and Docking Studies of Sorafenib Derivatives N-(3-fluoro-4-(pyridin-4-yloxy)phenyl)-4(5)-phenylpicolinamides.
Topics: Amides; Antineoplastic Agents; Drug Design; Drug Screening Assays, Antitumor; Humans; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Picolinic Acids; Protein Conformation; Sorafenib; Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
TGFβ signaling confers sorafenib resistance via induction of multiple RTKs in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyrazoles; Quinolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Transforming Growth Factor beta | 2017 |
NT1721, a novel epidithiodiketopiperazine, exhibits potent in vitro and in vivo efficacy against acute myeloid leukemia.
Topics: Animals; Cell Line, Tumor; Cytarabine; DNA (Cytosine-5-)-Methyltransferase 1; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Mice; Niacinamide; Phenylurea Compounds; Piperazines; Polycomb Repressive Complex 1; Sorafenib | 2016 |
Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Survival; Chemoradiotherapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; MAP Kinase Kinase Kinases; Mice, Inbred BALB C; Mice, Nude; NF-kappa B; Niacinamide; Phenylurea Compounds; Phosphorylation; Promoter Regions, Genetic; Signal Transduction; Sorafenib; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Resveratrol enhances the efficacy of sorafenib mediated apoptosis in human breast cancer MCF7 cells through ROS, cell cycle inhibition, caspase 3 and PARP cleavage.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caspase 3; Cell Cycle Checkpoints; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Humans; MCF-7 Cells; Niacinamide; Phenylurea Compounds; Poly(ADP-ribose) Polymerases; Reactive Oxygen Species; Resveratrol; Sorafenib; Stilbenes; Treatment Outcome | 2016 |
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib | 2017 |
Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; GTPase-Activating Proteins; Humans; Liver Neoplasms; Male; Mice, Nude; Niacinamide; Phenylurea Compounds; RNA, Long Noncoding; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatitis B; Humans; L-Lactate Dehydrogenase; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2016 |
Inhibition of acquired-resistance hepatocellular carcinoma cell growth by combining sorafenib with phosphoinositide 3-kinase and rat sarcoma inhibitor.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diphenylamine; Drug Resistance, Neoplasm; Heterocyclic Compounds, 3-Ring; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib | 2016 |
Adjuvant therapies in advanced hepatocellular carcinoma: moving forward from the STORM.
Topics: Angiogenesis Inhibitors; Carcinoma, Hepatocellular; Catheter Ablation; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topic; Sorafenib; Time Factors; Treatment Outcome | 2016 |
Blocking preferential glucose uptake sensitizes liver tumor-initiating cells to glucose restriction and sorafenib treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Glucose; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Complete response with sorafenib and transcatheter arterial chemoembolization in unresectable hepatocellular carcinoma.
Topics: Aged; Angiography, Digital Subtraction; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Phlebography; Portal Vein; Protein Kinase Inhibitors; Sorafenib; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Venous Thrombosis | 2016 |
Texture analysis of intermediate-advanced hepatocellular carcinoma: prognosis and patients' selection of transcatheter arterial chemoembolization and sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Young Adult | 2017 |
CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemokine CXCL12; Chemotherapy, Adjuvant; Female; Hepatectomy; Humans; Hypoxia; Immunohistochemistry; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Sorafenib; Survival Analysis; Tissue Array Analysis; Young Adult | 2017 |
Neurotensin regulation induces overexpression and activation of EGFR in HCC and restores response to erlotinib and sorafenib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Neoplasms; Neurotensin; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Transfection | 2017 |
Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
Topics: Animals; Caco-2 Cells; Cell Cycle Checkpoints; Colorectal Neoplasms; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Mutation; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Sorafenib | 2016 |
Contrary influence of clinically applied sorafenib concentrations among hepatocellular carcinoma patients.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Cells, Cultured | 2017 |
Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production.
Topics: Adenosine Triphosphate; AMP-Activated Protein Kinases; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Deoxyglucose; Drug Synergism; G1 Phase; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Resting Phase, Cell Cycle; Sorafenib | 2017 |
Genome-Wide CRISPR Screen Identifies Regulators of Mitogen-Activated Protein Kinase as Suppressors of Liver Tumors in Mice.
Topics: Animals; Benzimidazoles; Blotting, Western; Butadienes; Carcinoma, Hepatocellular; Cell Line, Tumor; CRISPR-Cas Systems; Cytoskeletal Proteins; DNA, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; Genes, Neurofibromatosis 1; Genome-Wide Association Study; Hepatocytes; High-Throughput Nucleotide Sequencing; HMGA Proteins; HMGA2 Protein; Humans; Immunohistochemistry; Liver Neoplasms; Liver Neoplasms, Experimental; Membrane Glycoproteins; Mice; Mice, Knockout; Mice, Nude; Mitogen-Activated Protein Kinases; Nerve Tissue Proteins; Niacinamide; Nitriles; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Pyridones; Pyrimidinones; ras Proteins; Real-Time Polymerase Chain Reaction; Receptors, Cell Surface; Sequence Analysis, DNA; Sorafenib; Survival Analysis; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2017 |
Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mechanistic Target of Rapamycin Complex 2; Metformin; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Sorafenib for the Treatment of Advanced Hepatocellular Cancer - a UK Audit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Audit; Databases, Factual; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; United Kingdom; Young Adult | 2017 |
Activated p53 with Histone Deacetylase Inhibitor Enhances L-Fucose-Mediated Drug Delivery through Induction of Fucosyltransferase 8 Expression in Hepatocellular Carcinoma Cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; Drug Synergism; Fucose; Fucosyltransferases; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone Deacetylase Inhibitors; Humans; Liposomes; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2016 |
Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Modality Therapy; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
MicroRNA-125a-5p Is a Downstream Effector of Sorafenib in Its Antiproliferative Activity Toward Human Hepatocellular Carcinoma Cells.
Topics: Base Sequence; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Proto-Oncogene Mas; Reproducibility of Results; Sorafenib; Up-Regulation | 2017 |
Internal Structure and Preferential Protein Binding of Colloidal Aggregates.
Topics: Bacterial Proteins; beta-Lactamases; Colloids; Coloring Agents; Congo Red; DNA; Dynamic Light Scattering; Estradiol; Fluoresceins; Fulvestrant; Niacinamide; Peptides; Phenylurea Compounds; Protein Binding; Protein Folding; Proteins; Ribosomal Proteins; Scattering, Small Angle; Sorafenib; Trypsin; Trypsin Inhibitors; X-Ray Diffraction | 2017 |
Ilexgenin A exerts anti-inflammation and anti-angiogenesis effects through inhibition of STAT3 and PI3K pathways and exhibits synergistic effects with Sorafenib on hepatoma growth.
Topics: Angiogenesis Inhibitors; Animals; Anti-Inflammatory Agents; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphorylation; Sorafenib; STAT3 Transcription Factor; Triterpenes | 2017 |
Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Animals; Consciousness; Hemodynamics; Indazoles; Losartan; Male; Niacinamide; Phenylurea Compounds; Piperidines; Propranolol; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor Protein-Tyrosine Kinases; Regional Blood Flow; Sorafenib; Sulfonamides | 2017 |
Synergistic Combination for Chemoprevention of Hepatocellular Carcinoma: An In Silico and In Vitro Approach.
Topics: Alanine Transaminase; Antineoplastic Combined Chemotherapy Protocols; Aspartate Aminotransferases; Carcinoma, Hepatocellular; Chalcone; Chemoprevention; Drug Synergism; Hep G2 Cells; Humans; Liver Neoplasms; Molecular Docking Simulation; Niacinamide; Oxidative Stress; Phenylurea Compounds; Protein Interaction Maps; Sorafenib; Vitamin K 1 | 2017 |
Moving beyond sorafenib alone in advanced hepatocellular carcinoma: is hepatic arterial infusion chemotherapy the best option?
Topics: Carcinoma, Hepatocellular; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Matrix Metalloproteinase Responsive Nanoparticles for Synergistic Treatment of Colorectal Cancer via Simultaneous Anti-Angiogenesis and Chemotherapy.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Liberation; HT29 Cells; Humans; Male; Matrix Metalloproteinase 2; Mice, Inbred BALB C; Nanoparticles; Niacinamide; Phenylurea Compounds; Photoacoustic Techniques; Rats, Sprague-Dawley; Sorafenib; Tissue Distribution; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |
Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Hep G2 Cells; Hepatocyte Growth Factor; Humans; Insulin; Interleukin-1beta; Liver Neoplasms; Niacinamide; Phenotype; Phenylurea Compounds; Phosphorylation; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Rabbits; Signal Transduction; Sorafenib; Time Factors; Vascular Endothelial Growth Factor A | 2017 |
Tumor-targeting Salmonella typhimurium A1-R regresses an osteosarcoma in a patient-derived xenograft model resistant to a molecular-targeting drug.
Topics: Adolescent; Animals; Antineoplastic Agents; Biological Therapy; Bone Neoplasms; Drug Resistance, Neoplasm; Humans; Male; Mice, Nude; Molecular Targeted Therapy; Necrosis; Niacinamide; Osteosarcoma; Phenylurea Compounds; Protein Kinase Inhibitors; Salmonella typhimurium; Sorafenib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Digitoxin synergizes with sorafenib to inhibit hepatocelluar carcinoma cell growth without inhibiting cell migration.
Topics: Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cardiotonic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Digitoxin; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2017 |
Pituitary Metastasis from Renal Cell Carcinoma: Description of a Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Disease Progression; Everolimus; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Neurosurgical Procedures; Niacinamide; Phenylurea Compounds; Pituitary Neoplasms; Pyrroles; Radiotherapy, Adjuvant; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Liver cancer drug is rejected for routine NHS use but will remain in Cancer Drugs Fund.
Topics: Advisory Committees; Antineoplastic Agents; Cost-Benefit Analysis; Humans; Liver; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Sorafenib; United Kingdom | 2017 |
An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Down-Regulation; Female; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Sorafenib; Survival Rate; Up-Regulation | 2017 |
Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer.
Topics: Animals; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Disease Progression; Endometrial Neoplasms; Endoplasmic Reticulum Stress; Enzyme Activation; Female; Humans; Mice, Nude; Mitogen-Activated Protein Kinases; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Sorafenib versus sunitinib as first-line treatment agents in Chinese patients with metastatic renal cell carcinoma: the largest multicenter retrospective analysis of survival and prognostic factors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
Topics: Amino Acid Transport System y+; Animals; Antioxidants; Apoptosis; Aspirin; Cell Line, Tumor; Cisplatin; DNA Damage; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Glutathione; Head and Neck Neoplasms; Humans; Mice; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
CDK4/6 inhibition and sorafenib: a ménage à deux in HCC therapy?
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Advantage of sorafenib combined with radiofrequency ablation for treatment of hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Liver Neoplasms; Male; Mice; Necrosis; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia.
Topics: Bilirubin; Catalysis; Enzyme Inhibitors; Glucuronosyltransferase; Humans; Hyperbilirubinemia; Indazoles; Kinetics; Lapatinib; Microsomes, Liver; Niacinamide; Phenylurea Compounds; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Sulfonamides | 2017 |
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Fibroblast Growth Factors; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Receptor, Fibroblast Growth Factor, Type 4; Signal Transduction; Sorafenib; Up-Regulation | 2017 |
FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
Topics: Animals; Binding Sites; Blotting, Western; Carbazoles; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Furans; Gene Duplication; Humans; Mice, Inbred BALB C; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Tandem Repeat Sequences | 2017 |
Receptor tyrosine kinase inhibition by regorafenib/sorafenib inhibits growth and invasion of meningioma cells.
Topics: Animals; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cell Survival; Depsipeptides; Disease Models, Animal; Humans; Meningeal Neoplasms; Meningioma; Mice; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2017 |
Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Cell Line, Tumor; Docetaxel; Drug Synergism; Female; Humans; Mice, Nude; Niacinamide; Phenylurea Compounds; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Taxoids; Triple Negative Breast Neoplasms | 2017 |
Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?
Topics: Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Humans; Indoles; Kidney Neoplasms; Nephrectomy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Risk; Risk Assessment; Sorafenib; Sunitinib; Survival Rate; Treatment Outcome | 2017 |
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Drug Synergism; Humans; Lung Neoplasms; Mice; Neoplasms, Experimental; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Combination of Everolimus with Sorafenib for Solid Renal Tumors in Tsc2
Topics: Animals; ATP-Binding Cassette Transporters; Cell Death; Cell Line, Tumor; Disease Models, Animal; Drug Synergism; Everolimus; GTPase-Activating Proteins; Kidney Neoplasms; Mice; Mice, Knockout; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Tuberous Sclerosis | 2017 |
In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.
Topics: Aged; Aged, 80 and over; Animals; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Caspase 3; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Protein Serine-Threonine Kinases; Sorafenib | 2017 |
Chronic myelomonocytic leukemia with double-mutations in DNMT3A and FLT3-ITD treated with decitabine and sorafenib.
Topics: Azacitidine; Decitabine; DNA (Cytosine-5-)-Methyltransferases; DNA Methyltransferase 3A; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
The albumin-bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development.
Topics: Adult; Aged; Aged, 80 and over; Albumins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Databases, Factual; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Prospective Studies; Sorafenib | 2017 |
Synergy with interferon-lambda 3 and sorafenib suppresses hepatocellular carcinoma proliferation.
Topics: Animals; Apoptosis; Carcinogenesis; Carcinoma, Hepatocellular; Caspase 3; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Drug Synergism; Female; Humans; Interferons; Interleukins; Liver Neoplasms; Membrane Potential, Mitochondrial; Mice, Nude; Niacinamide; Phenylurea Compounds; Reactive Oxygen Species; Sorafenib | 2017 |
Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; N-Acetylgalactosaminyltransferases; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Polypeptide N-acetylgalactosaminyltransferase; Prognosis; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2017 |
Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Observer Variation; Phenylurea Compounds; Pyrroles; Reproducibility of Results; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; ROC Curve; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
[Treatment Experience with Sorafenib for Lung Metastases of Hepatocellular Carcinoma Complicated with Interstitial Pneumonia].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Diseases, Interstitial; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2016 |
[A Case of Advanced Hepatocellular Carcinoma, Its Disease Progression Could Be Controlled by Multimodal Treatment].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Combined Modality Therapy; Disease Progression; Hepatectomy; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2016 |
Reply to the Letter to the editor 'Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus Sorafenib for advanced hepatocellular carcinoma: randomized phase II trial' by Fornaro et al.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cisplatin; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Activity of bevacizumab-containing regimens in recurrent low-grade serous ovarian or peritoneal cancer: A single institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Bevacizumab; Carboplatin; Cyclophosphamide; Databases, Factual; Deoxycytidine; Disease-Free Survival; Female; Gemcitabine; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Niacinamide; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Phenylurea Compounds; Retrospective Studies; Sorafenib; Young Adult | 2017 |
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Grading; Nephrectomy; Niacinamide; Phenylurea Compounds; Prognosis; Pyrimidines; Pyrroles; SEER Program; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Carcinoma, Renal Cell; Caspase 8; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Flow Cytometry; Humans; Kidney Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Conformation; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Sorafenib; TNF-Related Apoptosis-Inducing Ligand | 2017 |
Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Delivery Systems; Female; Glucans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Overall survival in response to sorafenib with transarterial chemoembolization for BCLC stage B hepatocellular carcinoma: propensity score analysis
.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Propensity Score; Sorafenib | 2017 |
Intracellular responsive dual delivery by endosomolytic polyplexes carrying DNA anchored porous silicon nanoparticles.
Topics: Antineoplastic Agents; Cell Line; Click Chemistry; Cross-Linking Reagents; Delayed-Action Preparations; DNA; Drug Liberation; Fluoresceins; Fluorescent Dyes; Humans; Maleic Anhydrides; Nanocomposites; Nanoparticles; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Polyethyleneimine; Polyvinyls; Porosity; Silicon; Sorafenib | 2017 |
Mathematical modelling unveils the essential role of cellular phosphatases in the inhibition of RAF-MEK-ERK signalling by sorafenib in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Dual Specificity Phosphatase 1; Dual Specificity Phosphatase 6; Extracellular Signal-Regulated MAP Kinases; Humans; Liver Neoplasms; MAP Kinase Kinase Kinases; Models, Biological; Niacinamide; Phenylurea Compounds; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Kinase Inhibitors; Protein Phosphatase 2; raf Kinases; Signal Transduction; Sorafenib; Time Factors | 2017 |
Abdominal aortic dissection during sorafenib therapy for hepatocellular carcinoma.
Topics: Antineoplastic Agents; Aortic Aneurysm, Abdominal; Aortic Dissection; Carcinoma, Hepatocellular; Endovascular Procedures; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Stents; Treatment Outcome | 2017 |
Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver; Liver Neoplasms; Male; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; PTEN Phosphohydrolase; Signal Transduction; Sorafenib | 2017 |
Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Delivery Systems; Female; Humans; Lactose; Male; Methylcellulose; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamines; Polyethylene Glycols; Polymers; Random Allocation; Rats; Rats, Sprague-Dawley; Sorafenib; Tumor Burden | 2017 |
Pharmacoepidemiology of Clinically Relevant Hypothyroidism and Hypertension from Sunitinib and Sorafenib.
Topics: Cohort Studies; Female; Humans; Hypertension; Hypothyroidism; Indoles; Male; Middle Aged; Niacinamide; Pharmacoepidemiology; Phenylurea Compounds; Pyrroles; Sorafenib; Sunitinib | 2017 |
Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma.
Topics: Anthracenes; Carcinoma, Hepatocellular; Caspase 3; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; MAP Kinase Kinase 4; Melatonin; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib | 2017 |
The lack of the organic cation transporter OCT1 at the plasma membrane of tumor cells precludes a positive response to sorafenib in patients with hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cell Membrane; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Octamer Transcription Factor-1; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib | 2017 |
Sorafenib and FH535 in combination act synergistically on hepatocellular carcinoma by targeting cell bioenergetics and mitochondrial function.
Topics: Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Energy Metabolism; Humans; Liver Neoplasms; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sorafenib; Sulfonamides | 2017 |
Surgical Resection for Lymph Node Metastasis After Liver Transplantation for Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoradiotherapy; Feasibility Studies; Female; Humans; Liver; Liver Neoplasms; Liver Transplantation; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Pretreatment Serum Prealbumin as an Independent Prognostic Indicator in Patients With Metastatic Renal Cell Carcinoma Using Tyrosine Kinase Inhibitors as First-Line Target Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prealbumin; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Serum Albumin, Human; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Cell Line; Cell Transformation, Neoplastic; Deoxyglucose; fms-Like Tyrosine Kinase 3; Glycolysis; Hematopoietic Stem Cells; Hexokinase; Humans; Hydrocarbons, Brominated; Leukemia, Experimental; Mice; Mice, Inbred BALB C; Microsatellite Repeats; Mitochondria; Molecular Targeted Therapy; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Propionates; Proto-Oncogene Proteins c-akt; Sorafenib | 2017 |
Treatment of Post-transplant Relapse of FLT3-ITD Mutated AML Using 5-Azacytidine and Sorafenib Bitherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Postoperative Care; Recurrence; Retreatment; Sorafenib; Treatment Outcome | 2017 |
MUC13 overexpression in renal cell carcinoma plays a central role in tumor progression and drug resistance.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Renal Cell; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Humans; Immunoenzyme Techniques; Indoles; Kidney Neoplasms; Mucins; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Tumor Cells, Cultured | 2017 |
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Inflammation; Liver Neoplasms; Lymphocytes; Male; Middle Aged; Neoplasm Staging; Neutrophils; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Retrospective Studies; Risk; Sorafenib; Survival Analysis | 2017 |
Multikinase inhibitors sorafenib and sunitinib as radiosensitizers in head and neck cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Biopsy, Needle; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Disease-Free Survival; Head and Neck Neoplasms; Humans; Immunohistochemistry; Indoles; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Radiation-Sensitizing Agents; Risk Assessment; Sorafenib; Squamous Cell Carcinoma of Head and Neck; Sunitinib | 2017 |
Vascular CXCR4 Expression Promotes Vessel Sprouting and Sensitivity to Sorafenib Treatment in Hepatocellular Carcinoma.
Topics: Adult; Aged; Animals; Biomarkers, Tumor; Blood Vessels; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Liver; Liver Neoplasms; Male; Mice; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Receptors, CXCR4; Signal Transduction; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Prostaglandin E
Topics: Alprostadil; Antineoplastic Agents; Cell Line; Cell Proliferation; Cyclic AMP Response Element-Binding Protein; Hand-Foot Syndrome; Humans; Keratinocytes; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Signal Transduction; Skin; Sorafenib; STAT3 Transcription Factor | 2017 |
Impact of Hepatitis C Virus Eradication on the Clinical Outcome of Patients with Hepatitis C Virus-Related Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antiviral Agents; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Time-to-Treatment; Treatment Outcome | 2017 |
Acquired Resistance with Epigenetic Alterations Under Long-Term Antiangiogenic Therapy for Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Disease Models, Animal; DNA Methylation; Drug Resistance, Neoplasm; Epigenesis, Genetic; Gene Expression Profiling; Gene Expression Regulation; Histones; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Analysis | 2017 |
Increased expression of HOXB9 in hepatocellular carcinoma predicts poor overall survival but a beneficial response to sorafenib.
Topics: Angiogenesis Inducing Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Disease-Free Survival; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Homeodomain Proteins; Humans; Liver Neoplasms; Male; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome; Up-Regulation | 2017 |
Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Renal Cell; Disease-Free Survival; Drug Monitoring; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Receptors, Cell Surface; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Cohort Studies; Cytokines; Disease Progression; Disease-Free Survival; Female; Hepatitis B; Humans; Interleukin-17; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Risk Factors; Sorafenib | 2017 |
Polyphosphoester nanoparticles as biodegradable platform for delivery of multiple drugs and siRNA.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Delivery Systems; Drug Screening Assays, Antitumor; Humans; Injections, Intravenous; Mice; Molecular Structure; Nanoparticles; Niacinamide; Organophosphorus Compounds; Paclitaxel; Phenylurea Compounds; Polymers; RNA, Small Interfering; Sorafenib; Structure-Activity Relationship; Survival Rate | 2017 |
Early Sorafenib-related Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; China; Combined Modality Therapy; Contrast Media; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
Timing of multikinase inhibitor initiation in differentiated thyroid cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Salvage Therapy; Sorafenib; Thyroid Neoplasms; Time Factors; Treatment Failure | 2017 |
Primary Tumor Characteristics Are Important Prognostic Factors for Sorafenib-Treated Patients with Metastatic Renal Cell Carcinoma: A Retrospective Multicenter Study.
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Demography; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib | 2017 |
Intravoxel incoherent motion MRI for monitoring the therapeutic response of hepatocellular carcinoma to sorafenib treatment in mouse xenograft tumor models.
Topics: Animals; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Heterografts; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Female; Humans; Liver Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Sorafenib; TOR Serine-Threonine Kinases | 2017 |
Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors.
Topics: Animals; Benzimidazoles; Carcinoma, Hepatocellular; Cell Line; Drug Delivery Systems; Humans; Liver Neoplasms; Mice; Nanoparticles; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Receptors, CXCR4; Sorafenib | 2017 |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Proliferation; Chaperonins; Computational Biology; Computer Simulation; Databases, Genetic; Dose-Response Relationship, Drug; Drug Discovery; Drug Repositioning; Ethanolamine; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Hep G2 Cells; HSP90 Heat-Shock Proteins; Humans; Liver Neoplasms; Male; Molecular Chaperones; Niacinamide; Niclosamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Time Factors; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Carcinoma, Hepatocellular; DNA; Drug Monitoring; Female; Genotype; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome | 2017 |
Real-World Data for the Evaluation of Transarterial Radioembolization versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Topics: Aged; Antineoplastic Agents; Cancer Care Facilities; Carcinoma, Hepatocellular; Cohort Studies; Cost-Benefit Analysis; Embolization, Therapeutic; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Markov Chains; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Quality-Adjusted Life Years; Sorafenib; Survival | 2017 |
Albumin-Bilirubin grade predicts prognosis of HCC patients with sorafenib use.
Topics: Aged; Albuminuria; Antineoplastic Agents; Bilirubin; Biomarkers; Carcinoma, Hepatocellular; Female; Humans; Liver Function Tests; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Rate; Treatment Failure | 2017 |
Patient-specific blood pressure correction technique for arterial stiffness: evaluation in a cohort on anti-angiogenic medication.
Topics: Adult; Aged; Algorithms; Angiogenesis Inhibitors; Blood Pressure; Carotid Arteries; Cohort Studies; Cross-Sectional Studies; Female; Humans; Indoles; Male; Manometry; Middle Aged; Models, Biological; Neoplasms; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Pulse Wave Analysis; Pyrroles; Sorafenib; Sunitinib; Vascular Stiffness | 2017 |
Sorafenib as a potential strategy for refractory pulmonary arterial hypertension.
Topics: Adolescent; Adult; Arterial Pressure; Dose-Response Relationship, Drug; Familial Primary Pulmonary Hypertension; Female; Heart Failure; Humans; Hypertension, Pulmonary; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Severity of Illness Index; Sorafenib; Treatment Outcome | 2017 |
Sorafenib use for recurrent hepatocellular cancer after resection or transplantation: Observations from a US regional analysis of the GIDEON registry.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Registries; Sorafenib | 2017 |
Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Cycle Proteins; Cell Line; Cell Line, Tumor; Cell Proliferation; Cytokines; Diethylnitrosamine; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Hepatocytes; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Rats, Wistar; Scorpions; Signal Transduction; Sorafenib; Spider Venoms; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Overexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Caspase 3; Caspase 7; Cell Line, Tumor; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Liver Neoplasms; Niacinamide; Osteopontin; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Mas; RNA Interference; RNA, Small Interfering; Sorafenib | 2017 |
Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Portal Vein; Prognosis; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Treatment Failure; Treatment Outcome | 2017 |
Rational drug design of indazole-based diarylurea derivatives as anticancer agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Computer-Aided Design; Drug Design; Drug Screening Assays, Antitumor; HCT116 Cells; Humans; Indazoles; Molecular Docking Simulation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-kit; Sorafenib; Structure-Activity Relationship; Urea | 2017 |
Selective effects of oral antiangiogenic tyrosine kinase inhibitors on an animal model of hereditary hemorrhagic telangiectasia.
Topics: Activin Receptors, Type I; Activin Receptors, Type II; Administration, Oral; Administration, Topical; Anemia; Angiogenesis Inhibitors; Animals; Arteriovenous Malformations; Disease Models, Animal; Erlotinib Hydrochloride; Gastrointestinal Hemorrhage; Hemoglobins; Image Processing, Computer-Assisted; Indazoles; Mice; Mice, Knockout; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Skin; Sorafenib; Sulfonamides; Sulfones; Telangiectasia, Hereditary Hemorrhagic; Tyrosine; Vascular Endothelial Growth Factor A; Wound Healing | 2017 |
Biomacromolecule/lipid hybrid nanoparticles for controlled delivery of sorafenib in targeting hepatocellular carcinoma therapy.
Topics: Animals; Carcinoma, Hepatocellular; Cell Survival; Drug Delivery Systems; Hep G2 Cells; Humans; Lipids; Liver Neoplasms; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Painful skin reaction.
Topics: Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Emergency Service, Hospital; Hand-Foot Syndrome; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Skin Diseases; Sorafenib | 2017 |
TP53 and RET may serve as biomarkers of prognostic evaluation and targeted therapy in hepatocellular carcinoma.
Topics: Adult; Aged; Biomarkers, Tumor; Carcinoma, Hepatocellular; Exome; Female; High-Throughput Nucleotide Sequencing; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Niacinamide; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins c-ret; Sequence Analysis, DNA; Sorafenib; Survival Analysis; Tumor Suppressor Protein p53 | 2017 |
Upregulation of miR-137 reverses sorafenib resistance and cancer-initiating cell phenotypes by degrading ANT2 in hepatocellular carcinoma.
Topics: 3' Untranslated Regions; Adenine Nucleotide Translocator 2; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; High-Intensity Focused Ultrasound Ablation; Humans; Liver Neoplasms; Male; MicroRNAs; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Sorafenib; Up-Regulation | 2017 |
3-bromopyruvate and buthionine sulfoximine effectively kill anoikis-resistant hepatocellular carcinoma cells.
Topics: Anoikis; Antineoplastic Agents; Buthionine Sulfoximine; Carcinoma, Hepatocellular; Epithelial-Mesenchymal Transition; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Pyruvates; Reactive Oxygen Species; Sorafenib | 2017 |
Sorafenib and 2,3,5-triiodobenzoic acid-loaded imageable microspheres for transarterial embolization of a liver tumor.
Topics: Animals; Antineoplastic Agents; Biocompatible Materials; Chemoembolization, Therapeutic; Disease Models, Animal; Drug Carriers; Drug Delivery Systems; Drug Liberation; Liver Neoplasms; Magnetic Resonance Imaging; Male; Materials Testing; Microspheres; Niacinamide; Phenylurea Compounds; Rats; Sorafenib; Tissue Distribution; Tomography, X-Ray Computed; Treatment Outcome; Triiodobenzoic Acids; Xenograft Model Antitumor Assays | 2017 |
Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoates; Carcinoma, Hepatocellular; Cell Line, Tumor; Cyclopropanes; Drug Resistance, Neoplasm; Histone Demethylases; Humans; Liver Neoplasms; Male; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Niacinamide; Pargyline; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; RNA Interference; Sorafenib; Time Factors; Transfection; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2017 |
Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Sorafenib; Sulfonamides; Sunitinib; Young Adult | 2017 |
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Feasibility Studies; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Response to the article "Sorafenib as a potential strategy for refractory pulmonary arterial hypertension".
Topics: Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Rate; Treatment Outcome | 2017 |
Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Topics: Adult; Aged; alpha-Fetoproteins; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Phenylurea Compounds; Retrospective Studies; Severity of Illness Index; Sorafenib; Survival Analysis; Taiwan; Time Factors; Treatment Outcome | 2018 |
Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Liver Neoplasms; Mice; Niacinamide; NIMA-Interacting Peptidylprolyl Isomerase; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
In-vivo relation between plasma concentration of sorafenib and its safety in Chinese patients with metastatic renal cell carcinoma: a single-center clinical study.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Renal Cell; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Pharmacogenomic Variants; Phenylurea Compounds; Polymorphism, Genetic; Protein Kinase Inhibitors; Sorafenib; Tandem Mass Spectrometry; Treatment Outcome; Young Adult | 2017 |
Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models.
Topics: Animals; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Disease Models, Animal; DNA; Doxorubicin; Drug Synergism; Female; Humans; Lung Neoplasms; Mice; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Osteosarcoma; Phenylurea Compounds; RNA; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Synergistic anti-tumor efficacy of sorafenib and fluvastatin in hepatocellular carcinoma.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Fatty Acids, Monounsaturated; Female; Fluvastatin; Hep G2 Cells; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Rats; Rats, Wistar; Signal Transduction; Sorafenib | 2017 |
Secreted GRP78 activates EGFR-SRC-STAT3 signaling and confers the resistance to sorafeinib in HCC cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Gene Expression Regulation, Neoplastic; Heat-Shock Proteins; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins pp60(c-src); Signal Transduction; Sorafenib; STAT3 Transcription Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Immune oncology in hepatocellular carcinoma-hype and hope.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2017 |
Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cohort Studies; Disease Models, Animal; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice; Mice, Inbred BALB C; Middle Aged; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Disulfide-Isomerases; Random Allocation; RNA, Messenger; Sorafenib; Statistics, Nonparametric; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2017 |
Barcelona clinic liver cancer-stage C hepatocellular carcinoma: A novel approach to subclassification and treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib; Tumor Burden | 2017 |
Phosphoproteome Analysis Reveals Differential Mode of Action of Sorafenib in Wildtype and Mutated FLT3 Acute Myeloid Leukemia (AML) Cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; fms-Like Tyrosine Kinase 3; Gene Regulatory Networks; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Phosphoproteins; Protein Kinase Inhibitors; Proteomics; Sorafenib | 2017 |
Management of hepatocellular carcinoma recurrence after liver transplant is far from perfect.
Topics: Adult; Carcinoma, Hepatocellular; Child; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Registries; Sorafenib | 2018 |
Ferroptosis and Cell Death Analysis by Flow Cytometry.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Dactinomycin; Flow Cytometry; Humans; Indicators and Reagents; Iron; Necrosis; Niacinamide; Phenylurea Compounds; Piperazines; Propidium; Rats; Sorafenib | 2017 |
Dysfunction of IKZF1/MYC/MDIG axis contributes to liver cancer progression through regulating H3K9me3/p21 activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Dioxygenases; Disease Progression; Histone Demethylases; Histones; Humans; Ikaros Transcription Factor; Liver Neoplasms; Methylation; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Promoter Regions, Genetic; Proto-Oncogene Proteins c-myc; Signal Transduction; Sorafenib; Transplantation, Heterologous | 2017 |
Fasting inhibits hepatic stellate cells activation and potentiates anti-cancer activity of Sorafenib in hepatocellular cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; Dose-Response Relationship, Drug; Fasting; Gene Expression Regulation, Neoplastic; Glucose; Hep G2 Cells; Hepatic Stellate Cells; Humans; Lipopolysaccharides; Liver Cirrhosis, Experimental; Liver Neoplasms; Mice, Inbred C57BL; Niacinamide; Non-alcoholic Fatty Liver Disease; Phenylurea Compounds; Sorafenib; Time Factors | 2018 |
Editorial: sorafenib toxicity, a biomarker of effect?
Topics: Antineoplastic Agents; Benzenesulfonates; Biomarkers; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib | 2017 |
Editorial: sorafenib toxicity, a biomarker of effect? Authors' reply.
Topics: Biomarkers; Humans; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Upregulated expression of Nucleostemin/GNL3 is associated with poor prognosis and Sorafenib Resistance in Hepatocellular Carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; GTP-Binding Proteins; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Prognosis; Proto-Oncogene Proteins c-bcl-2; Sorafenib; Survival Rate; Up-Regulation; Young Adult | 2017 |
Prescription Patterns of Sorafenib and Outcomes of Patients with Advanced Hepatocellular Carcinoma: A National Population Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2017 |
Advanced chordoma treated by first-line molecular targeted therapies: Outcomes and prognostic factors. A retrospective study of the French Sarcoma Group (GSF/GETO) and the Association des Neuro-Oncologues d'Expression Française (ANOCEF).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Child; Chordoma; Erlotinib Hydrochloride; Female; France; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Pyrroles; Retrospective Studies; Sirolimus; Skull Base Neoplasms; Sorafenib; Sunitinib; Treatment Outcome; Young Adult | 2017 |
Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Topics: Aged; Antineoplastic Agents; Cell Differentiation; Clinical Trials, Phase III as Topic; Controlled Clinical Trials as Topic; Cost-Benefit Analysis; Drug Costs; Female; Health Care Costs; Humans; Male; Middle Aged; Models, Economic; Monte Carlo Method; Neoplasm Grading; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quality of Life; Quinolines; Sorafenib; Survival Analysis; Thyroid Neoplasms; Tumor Burden; United States | 2017 |
Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS.
Topics: Chromatography, Liquid; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tandem Mass Spectrometry | 2017 |
[Tumor-associated macrophages promote the proliferation and migration as well as invasion of sorafenib-resistant hepatocellular carcinoma cells].
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Macrophages; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Immortal time bias or sorafenib effect in elderly patients with HCC?
Topics: Aged; Antineoplastic Agents; Bias; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Carboxyamidotriazole Synergizes with Sorafenib to Combat Non-Small Cell Lung Cancer through Inhibition of NANOG and Aggravation of Apoptosis.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Lewis Lung; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Synergism; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Nanog Homeobox Protein; Niacinamide; Phenylurea Compounds; Sorafenib; Triazoles; Xenograft Model Antitumor Assays | 2017 |
Sub-classification of Advanced-Stage Hepatocellular Carcinoma: A Cohort Study Including 612 Patients Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2018 |
Midostaurin Gets FDA Nod for AML.
Topics: Drug Approval; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Sorafenib; Staurosporine; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.
Topics: Antineoplastic Agents; Cell Proliferation; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Imidazoles; Mutation; Niacinamide; Oximes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
NRAS mutations in cutaneous T cell lymphoma (CTCL) sensitize tumors towards treatment with the multikinase inhibitor Sorafenib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; GTP Phosphohydrolases; Humans; Hydroxamic Acids; Lymphoma, T-Cell, Cutaneous; MAP Kinase Signaling System; Membrane Proteins; Molecular Targeted Therapy; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vorinostat | 2017 |
Korean Red Ginseng Extract Enhances the Anticancer Effects of Sorafenib through Abrogation of CREB and c-Jun Activation in Renal Cell Carcinoma.
Topics: Apoptosis; Carcinoma, Renal Cell; Cell Line, Tumor; Cyclic AMP Response Element-Binding Protein; Humans; Niacinamide; Panax; Phenylurea Compounds; Phosphorylation; Plant Extracts; Proto-Oncogene Proteins c-jun; Sorafenib; Vascular Endothelial Growth Factor A | 2017 |
The inhibition of FGF receptor 1 activity mediates sorafenib antiproliferative effects in human malignant pleural mesothelioma tumor-initiating cells.
Topics: Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Survival; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Fibroblast Growth Factor 2; Humans; Lung Neoplasms; Mesothelioma; Mesothelioma, Malignant; Mice, Inbred NOD; Mice, SCID; Models, Biological; Myeloid Cell Leukemia Sequence 1 Protein; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Pleural Neoplasms; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Sorafenib; Time Factors | 2017 |
Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Liver Transplantation; Living Donors; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Proportional Hazards Models; Protein Kinase Inhibitors; Sorafenib; Survival Analysis; Time Factors; Treatment Outcome | 2017 |
Prediction of Response to Sorafenib in Hepatocellular Carcinoma: A Putative Marker Panel by Multiple Reaction Monitoring-Mass Spectrometry (MRM-MS).
Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Carcinoma, Hepatocellular; Carrier Proteins; Female; Glycoproteins; Humans; Immunoglobulin J-Chains; Liver Neoplasms; Male; Mass Spectrometry; Middle Aged; Niacinamide; Phenylurea Compounds; Precision Medicine; Proteomics; Receptors, Scavenger; Retrospective Studies; Scavenger Receptors, Class B; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
Sorafenib induces variations of the DNA methylome in HA22T/VGH human hepatocellular carcinoma-derived cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; DNA Methylation; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2017 |
The Collagen Gel Droplet-embedded Culture Drug Sensitivity Test in Relapsed Hepatoblastoma.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Child; Child, Preschool; Collagen; Drug Screening Assays, Antitumor; Drug Synergism; Female; Hepatoblastoma; Humans; Indoles; Infant; Inhibitory Concentration 50; Irinotecan; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Recurrence; Sorafenib; Sunitinib | 2017 |
Sorafenib-Induced Changes in Thyroid Hormone Levels in Patients Treated for Hepatocellular Carcinoma.
Topics: Aged; Amino Acid Transport Systems, Neutral; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Chlorocebus aethiops; Cohort Studies; COS Cells; Female; Humans; In Vitro Techniques; Liver Neoplasms; Male; Middle Aged; Monocarboxylic Acid Transporters; Niacinamide; Phenylurea Compounds; Prospective Studies; Sorafenib; Symporters; Thyrotropin; Thyroxine; Triiodothyronine | 2017 |
Value-Based pricing and the end of pharmaceutical pricing as we know it? A case study on sorafenib and axitinib.
Topics: Axitinib; Humans; Imidazoles; Indazoles; Niacinamide; Pharmaceutical Preparations; Phenylurea Compounds; Sorafenib | 2017 |
Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels.
Topics: Animals; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Survival; Deubiquitinating Enzyme CYLD; Dose-Response Relationship, Drug; Drug Combinations; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Inhibitor of Differentiation Protein 1; Kidney Neoplasms; Male; Mice; Mice, SCID; Naphthoquinones; Niacinamide; Phenylurea Compounds; Primary Cell Culture; Signal Transduction; Sorafenib; Survivin; Tumor Suppressor Proteins; Von Hippel-Lindau Tumor Suppressor Protein; Xenograft Model Antitumor Assays | 2017 |
Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study.
Topics: Blood Volume; Carcinoma, Hepatocellular; Feasibility Studies; Humans; Liver Neoplasms; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Sorafenib; Tomography, Spiral Computed | 2017 |
PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Glutamine; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; PPAR delta; Random Allocation; Sorafenib; Transfection; Xenograft Model Antitumor Assays | 2017 |
Temozolomide and sorafenib as programmed cell death inducers of human glioma cells.
Topics: Antineoplastic Agents; Apoptosis; Astrocytoma; Cell Line, Tumor; Dacarbazine; Gene Expression Regulation, Neoplastic; Humans; Niacinamide; Phenylurea Compounds; RNA Interference; Sorafenib; Temozolomide | 2017 |
Anti-tumor Effects of Sorafenib Administered at Different Time Points in Combination with Transarterial Embolization in a Rabbit VX2 Liver Tumor Model.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Disease Models, Animal; Drug Administration Schedule; Embolization, Therapeutic; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rabbits; Sorafenib | 2017 |
Evaluation of First-Line Sorafenib Treatment for Metastatic Renal Cell Carcinoma in Kidney Transplant Patients: A Single-Center Experience With Four Cases.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Kidney Neoplasms; Kidney Transplantation; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2017 |
Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; France; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib | 2017 |
Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Humans; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Sorafenib; Thyroid Neoplasms; TOR Serine-Threonine Kinases | 2017 |
Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers.
Topics: Asialoglycoprotein Receptor; Dendrimers; Disaccharides; Drug Carriers; Fluorescein-5-isothiocyanate; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Mechanisms of Paradoxical Activation of AMPK by the Kinase Inhibitors SU6656 and Sorafenib.
Topics: Allosteric Regulation; AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Binding Sites; Catalytic Domain; Cell-Free System; Enzyme Activation; HEK293 Cells; HeLa Cells; Humans; Indans; Indoles; Mutagenesis, Site-Directed; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Isoforms; Protein Serine-Threonine Kinases; Pyrimidines; Sorafenib; src-Family Kinases; Sulfonamides | 2017 |
Sorafenib controls the epithelial‑mesenchymal transition of ovarian cancer cells via EGF and the CD44‑HA signaling pathway in a cell type‑dependent manner.
Topics: Basigin; Cell Line, Tumor; Cell Movement; Down-Regulation; Epidermal Growth Factor; Epithelial-Mesenchymal Transition; Female; Humans; Hyaluronan Receptors; Hyaluronan Synthases; Hyaluronic Acid; MAP Kinase Signaling System; Neoplasm Invasiveness; Niacinamide; Ovarian Neoplasms; Phenotype; Phenylurea Compounds; RNA, Small Interfering; Signal Transduction; Sorafenib | 2017 |
Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
Topics: Apoptosis; B7-H1 Antigen; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA (Cytosine-5-)-Methyltransferase 1; DNA Methylation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Liver Neoplasms; Molecular Targeted Therapy; NF-kappa B; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2017 |
The significance of TIMD4 expression in clear cell renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Expression; Humans; Kidney Neoplasms; Male; Membrane Proteins; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; RNA, Small Interfering; Sorafenib | 2017 |
Herb-Drug Interaction between the Traditional Hepatoprotective Formulation and Sorafenib on Hepatotoxicity, Histopathology and Pharmacokinetics in Rats.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Herb-Drug Interactions; Liver; Male; Medicine, Chinese Traditional; Niacinamide; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Sorafenib | 2017 |
Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma.
Topics: Aged; Axitinib; Carcinoma, Renal Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Interactions; Female; Gastrointestinal Diseases; Humans; Imidazoles; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proton Pump Inhibitors; Pyrroles; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2017 |
Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; Jagged-1 Protein; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proteolysis; Quassins; Sorafenib; Time Factors; Transcription, Genetic; Transfection; Tumor Burden; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2017 |
Stearoyl-CoA desaturase regulates sorafenib resistance via modulation of ER stress-induced differentiation.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Hong Kong; Humans; Liver Neoplasms; Niacinamide; Pharmacogenomic Testing; Phenylurea Compounds; Sorafenib; Stearoyl-CoA Desaturase; Survival Analysis | 2017 |
Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Risk Factors; ROC Curve; Severity of Illness Index; Sorafenib; Survival Rate; Withholding Treatment | 2017 |
Combination of sorafenib and cytokine-induced killer cells in metastatic renal cell carcinoma: a potential regimen.
Topics: Carcinoma, Renal Cell; Cytokine-Induced Killer Cells; Humans; Immunotherapy; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Desmoid Tumors and Celecoxib with Sorafenib.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2017 |
Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury.
Topics: Animals; Apoptosis; Cell Death; Disease Models, Animal; Humans; Inflammation; Mice; Necrosis; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinases; Receptor-Interacting Protein Serine-Threonine Kinases; Reperfusion Injury; Sorafenib; Tumor Necrosis Factor-alpha | 2017 |
Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response.
Topics: Cells, Cultured; Electron Transport; Electron Transport Complex II; Electron Transport Complex III; HEK293 Cells; Humans; Mitochondria; Mitochondrial Proton-Translocating ATPases; Niacinamide; Phenylurea Compounds; Protein Kinases; Sorafenib; Ubiquitin-Protein Ligases | 2017 |
Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Humans; Liver Neoplasms; Male; Metabolic Syndrome; Middle Aged; Multivariate Analysis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Natural History of T1N0M0 Hepatocellular Carcinoma: Large-Scale Study in the United States.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Hepatectomy; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome; United States | 2017 |
Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition.
Topics: Adaptor Proteins, Signal Transducing; AMP-Activated Protein Kinases; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Apoptosis; Aspirin; Carcinoma, Hepatocellular; Cell Proliferation; Cells, Cultured; Drug Therapy, Combination; Embryo, Mammalian; Fibroblasts; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Knockout; Multiprotein Complexes; Niacinamide; Phenylurea Compounds; Regulatory-Associated Protein of mTOR; Sorafenib; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2017 |
Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Disease Progression; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib | 2017 |
Increased matrix stiffness promotes tumor progression of residual hepatocellular carcinoma after insufficient heat treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Combined Modality Therapy; Disease Progression; Enzyme Activation; Extracellular Matrix; Extracellular Signal-Regulated MAP Kinases; Humans; Hyperthermia, Induced; Liver Neoplasms, Experimental; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm, Residual; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Vitamin K 1; Xenograft Model Antitumor Assays | 2017 |
Tolerance and outcomes of sorafenib in elderly patients treated for advanced hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diarrhea; Female; France; Hand-Foot Syndrome; Humans; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2017 |
Chronic inflammation-elicited liver progenitor cell conversion to liver cancer stem cell with clinical significance.
Topics: Animals; Antigens, Differentiation; Antineoplastic Agents; Cell Self Renewal; Cell Transformation, Neoplastic; Chromosomal Instability; Chronic Disease; Female; Humans; Inflammation; Interleukin-6; Keratin-19; Liver; Liver Neoplasms; Macrophages; Male; Mice; Middle Aged; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Rats, Wistar; Sorafenib; src-Family Kinases; STAT3 Transcription Factor; Tumor Necrosis Factor-alpha | 2017 |
Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Renal Cell; Disease-Free Survival; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Registries; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2017 |
Liver transplantation using the otherwise-discarded partial liver resection graft with hepatic benign tumor: Analysis of a preliminary experience on 15 consecutive cases.
Topics: Adult; Aged; Antineoplastic Agents; Blood Vessel Prosthesis; End Stage Liver Disease; Female; Hepatectomy; Hepatic Veins; Humans; Liver Neoplasms; Liver Transplantation; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Postoperative Complications; Sorafenib; Treatment Outcome; Young Adult | 2017 |
Interleukin-27 augments the inhibitory effects of sorafenib on bladder cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Synergism; Humans; Interleukin-27; Niacinamide; Phenylurea Compounds; Sorafenib; Urinary Bladder Neoplasms | 2017 |
Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axitinib; Carcinoma, Renal Cell; Cohort Studies; Databases, Factual; Disease-Free Survival; Everolimus; Female; France; Humans; Imidazoles; Indazoles; Indoles; Insurance, Health; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pyrimidines; Pyrroles; Retrospective Studies; Sorafenib; Sulfonamides; Sunitinib | 2017 |
Non-invasive monitoring of the therapeutic response in sorafenib-treated hepatocellular carcinoma based on photoacoustic imaging.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Humans; Liver Neoplasms, Experimental; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Photoacoustic Techniques; Sorafenib | 2018 |
A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.
Topics: Abies; Animals; Binding Sites; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Hep G2 Cells; Humans; Immunosuppression Therapy; Liver Neoplasms; Macrophages; Mice; Niacinamide; Phenylurea Compounds; Plant Extracts; Receptors, CCR2; Sorafenib; THP-1 Cells; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
Simultaneous inhibition of growth and metastasis of hepatocellular carcinoma by co-delivery of ursolic acid and sorafenib using lactobionic acid modified and pH-sensitive chitosan-conjugated mesoporous silica nanocomplex.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chitosan; Delayed-Action Preparations; Disaccharides; Drug Synergism; Humans; Hydrogen-Ion Concentration; Liver Neoplasms; Lung Neoplasms; Male; Mice; Nanoparticles; Niacinamide; Phenylurea Compounds; Porosity; Rats; Silicon Dioxide; Sorafenib; Triterpenes; Ursolic Acid | 2017 |
Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Survival; Dose-Response Relationship, Drug; Haloperidol; Humans; Iron; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Receptors, sigma; Sigma-1 Receptor; Sorafenib; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Phosphorylation-dependent signaling controls degradation of DNA mismatch repair protein PMS2.
Topics: Blotting, Western; Enzyme Inhibitors; HEK293 Cells; Humans; Marine Toxins; Mismatch Repair Endonuclease PMS2; Mutation; MutL Protein Homolog 1; MutL Proteins; Niacinamide; Oxazoles; Phenylurea Compounds; Phosphorylation; Proteolysis; Serine; Signal Transduction; Sorafenib; Threonine | 2017 |
Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Retrospective Studies; Sorafenib | 2017 |
Molecular profiling and targeted inhibitor therapy in atypical chronic myeloid leukaemia in blast crisis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Blast Crisis; DNA Mutational Analysis; High-Throughput Nucleotide Sequencing; Humans; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Liver; Liver Neoplasms; Male; Mice; Niacinamide; Phenylurea Compounds; Proteasome Endopeptidase Complex; Protein Tyrosine Phosphatase, Non-Receptor Type 6; Proto-Oncogene Proteins; Sorafenib; STAT3 Transcription Factor; Survival Analysis; Up-Regulation; Vascular Endothelial Growth Factor A | 2017 |
Comparison of efficacy, safety, and quality of life between sorafenib and sunitinib as first-line therapy for Chinese patients with metastatic renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; China; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Quality of Life; Sorafenib; Sunitinib; Treatment Outcome | 2017 |
Down-Regulation of TGF-β Expression Sensitizes the Resistance of Hepatocellular Carcinoma Cells to Sorafenib.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Death; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Mice, Inbred BALB C; Mice, Nude; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphorylation; RNA, Small Interfering; Signal Transduction; Sorafenib; Transforming Growth Factor beta; Xenograft Model Antitumor Assays | 2017 |
Fluorescence imaging of bombesin and transferrin receptor expression is comparable to 18F-FDG PET in early detection of sorafenib-induced changes in tumor metabolism.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Fluorescent Dyes; Fluorodeoxyglucose F18; Humans; Mice, Transgenic; Molecular Imaging; Neoplasm Transplantation; Niacinamide; Optical Imaging; Phenylurea Compounds; Positron-Emission Tomography; Radiopharmaceuticals; Random Allocation; Receptors, Bombesin; Receptors, Transferrin; Sorafenib; Treatment Outcome; Tumor Burden | 2017 |
A data mining approach for identifying pathway-gene biomarkers for predicting clinical outcome: A case study of erlotinib and sorafenib.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Cluster Analysis; Data Mining; Databases, Factual; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Humans; Linear Models; Microarray Analysis; Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2017 |
Sorafenib Impedes Rift Valley Fever Virus Egress by Inhibiting Valosin-Containing Protein Function in the Cellular Secretory Pathway.
Topics: Adenosine Triphosphatases; Animals; Carcinoma, Hepatocellular; Cell Cycle Proteins; Chlorocebus aethiops; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rift Valley Fever; Rift Valley fever virus; Secretory Pathway; Sorafenib; Tumor Cells, Cultured; Valosin Containing Protein; Vero Cells; Virion; Virus Release; Virus Replication | 2017 |
Supramolecular alleviation of cardiotoxicity of a small-molecule kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Bridged-Ring Compounds; Cardiotoxicity; Cell Line, Tumor; Cell Survival; Embryo, Nonmammalian; Humans; Imidazoles; Macromolecular Substances; Magnetic Resonance Spectroscopy; Molecular Structure; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Sorafenib; Zebrafish | 2017 |
Survival benefit of transarterial chemoembolization in patients with metastatic hepatocellular carcinoma: a single center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Regression Analysis; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
An internally validated new clinical and inflammation-based prognostic score for patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Hepatocellular; Diarrhea; Female; Humans; Inflammation; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Neutrophils; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Retrospective Studies; ROC Curve; Severity of Illness Index; Sorafenib; Treatment Outcome | 2018 |
Questiomycin A stimulates sorafenib-induced cell death via suppression of glucose-regulated protein 78.
Topics: Animals; Antineoplastic Agents; Cell Death; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Chaperone BiP; Heat-Shock Proteins; Humans; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Oxazines; Phenylurea Compounds; Sorafenib; Structure-Activity Relationship | 2017 |
6-Methoxyethylamino-numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib.
Topics: Alanine Transaminase; Animals; Antineoplastic Agents; Apoptosis; Aspartate Aminotransferases; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Naphthalimides; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Association between Skeletal Muscle Depletion and Sorafenib Treatment in Male Patients with Hepatocellular Carcinoma: A Retrospective Cohort Study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Female; Humans; Liver Neoplasms; Male; Middle Aged; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sex Factors; Sorafenib | 2017 |
Nodular-cystic eruption in course of sorafenib administration for hepatocarcinoma: An unconventional skin reaction requiring unconventional treatment.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Photochemotherapy; Photosensitizing Agents; Protein Kinase Inhibitors; Sorafenib | 2017 |
Does Sorafenib Fit for All?
Topics: Humans; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
A typical presentation of a hepatocellular carcinoma in a middle-aged patient.
Topics: Antineoplastic Agents; Biopsy, Fine-Needle; Bone Neoplasms; Carcinoma, Hepatocellular; Clavicle; Fatal Outcome; Fractures, Bone; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.
Topics: Analysis of Variance; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MicroRNAs; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; RNA, Small Interfering; Signal Transduction; Sorafenib | 2018 |
Sorafenib stimulates human skin type mast cell degranulation and maturation.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Antineoplastic Agents; Apoptosis; Biopsy; Cell Count; Cell Degranulation; Cell Proliferation; Drug Eruptions; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; Humans; Male; Mast Cells; Middle Aged; Niacinamide; Organ Culture Techniques; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Signal Transduction; Skin; Sorafenib; Stem Cell Factor; Vascular Endothelial Growth Factor A; Wortmannin; Young Adult | 2017 |
Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.
Topics: A549 Cells; Apoptosis; Betulinic Acid; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Combined Modality Therapy; Drug Synergism; Flow Cytometry; Humans; Mutation; Niacinamide; Pentacyclic Triterpenes; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Sorafenib; Triterpenes | 2017 |
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; RNA, Neoplasm; Signal Transduction; Sorafenib; Stathmin; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells.
Topics: Adenylyl Cyclases; Cell Differentiation; Cell Proliferation; Colforsin; Cyclic AMP; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; Thyroid Neoplasms; Tumor Cells, Cultured | 2017 |
By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.
Topics: Animals; Aspirin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Glycolysis; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphofructokinase-2; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Effects of Ascorbyl-2-phosphate Magnesium on Human Keratinocyte Toxicity and Pathological Changes by Sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Ascorbic Acid; Cell Line; Hand-Foot Syndrome; Humans; Keratinocytes; Magnesium; Niacinamide; Phenylurea Compounds; Phosphorylation; Reactive Oxygen Species; RNA, Small Interfering; Signal Transduction; Skin; Sorafenib; STAT3 Transcription Factor | 2017 |
Might Sorafenib combined with radiotherapy be better option for treating hepatocellular carcinoma with portal vein tumour thrombosis?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Venous Thrombosis | 2018 |
Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Dose-Response Relationship, Drug; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2017 |
The impact of FLT3 mutations on treatment response and survival in Chinese de novo AML patients.
Topics: Acute Disease; Adult; Asian People; China; Drug Therapy; Female; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Middle Aged; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Sorafenib; Tandem Repeat Sequences; Transplantation, Homologous; Treatment Outcome; Young Adult | 2018 |
Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Lymphocyte Count; Male; Middle Aged; Neoadjuvant Therapy; Nephrectomy; Neutrophils; Niacinamide; Nutritional Status; Phenylurea Compounds; Preoperative Period; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate; Young Adult | 2017 |
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma.
Topics: Adult; Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis B Surface Antigens; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib; Treatment Outcome | 2017 |
Nanoparticles of a polyaspartamide-based brush copolymer for modified release of sorafenib: In vitro and in vivo evaluation.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Drug Delivery Systems; Drug Liberation; Humans; Liver Neoplasms; Male; Mice, Nude; Nanoparticles; Niacinamide; Peptides; Phenylurea Compounds; Polymethacrylic Acids; Protein Kinase Inhibitors; Sorafenib | 2017 |
Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Diphenylamine; Female; HL-60 Cells; Humans; K562 Cells; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Random Allocation; Sorafenib; Xenograft Model Antitumor Assays | 2017 |
Synthesis of piperazine-based thiazolidinones as VEGFR2 tyrosine kinase inhibitors inducing apoptosis.
Topics: Apoptosis; Binding Sites; Caspases; Cell Line, Tumor; Hep G2 Cells; Humans; Molecular Docking Simulation; Niacinamide; Phenylurea Compounds; Piperazine; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Sorafenib; Staurosporine; Thiazolidines; Vascular Endothelial Growth Factor Receptor-2 | 2017 |
Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Follow-Up Studies; Humans; Liver; Liver Neoplasms; Longitudinal Studies; Male; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Prognosis; Prospective Studies; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Design, synthesis and antitumor activity of Novel Sorafenib derivatives bearing pyrazole scaffold.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Delivery Systems; Drug Design; Drug Screening Assays, Antitumor; Humans; Inhibitory Concentration 50; Microscopy, Fluorescence; Molecular Structure; Niacinamide; Phenylurea Compounds; Pyrazoles; Sorafenib; Structure-Activity Relationship | 2017 |
Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Heterocyclic Compounds, 3-Ring; Humans; Liver Neoplasms; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib | 2017 |
Human mesenchymal stromal cells as cellular drug-delivery vectors for glioblastoma therapy: a good deal?
Topics: Administration, Intranasal; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Glioblastoma; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
The SIRveNIB and SARAH trials and the role of SIR-Spheres® Y-90 resin microspheres in the management of hepatocellular carcinoma.
Topics: Brachytherapy; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Disease Management; Humans; Liver Neoplasms; Microspheres; Multicenter Studies as Topic; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Treatment Outcome; Yttrium Radioisotopes | 2017 |
Effects of the kinase inhibitor sorafenib on heart, muscle, liver and plasma metabolism in vivo using non-targeted metabolomics analysis.
Topics: Animals; Heart; Liver; Metabolomics; Mice; Mice, Inbred Strains; Muscle, Skeletal; Niacinamide; Phenylurea Compounds; Plasma; Protein Kinase Inhibitors; Sorafenib; Tissue Distribution | 2017 |
High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Cohort Studies; Disease-Free Survival; Humans; Interleukin-6; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2017 |
Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report.
Topics: Acrylamides; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Fibroblast Growth Factors; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Nitric Oxide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; Receptor, Fibroblast Growth Factor, Type 4; Sorafenib | 2018 |
Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats.
Topics: Administration, Oral; Animals; Biological Availability; Drug Carriers; Female; Lipids; Liver; Nanoparticles; Niacinamide; Particle Size; Phenylurea Compounds; Rats; Rats, Sprague-Dawley; Sorafenib; Suspensions | 2018 |
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Databases, Factual; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Interactions; Drug Resistance, Neoplasm; Female; Humans; Hypoglycemic Agents; Immunohistochemistry; Insulin; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Male; Metformin; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sirtuin 3; Sorafenib; Time Factors; Treatment Outcome | 2017 |
Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Decision Support Techniques; Disease-Free Survival; Female; France; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors; Serum Albumin, Human; Sorafenib; Time Factors; Treatment Outcome; Tumor Burden; United Kingdom | 2017 |
Alpha mangostin Inhibits Hepatic Stellate Cells Activation Through TGF-β/Smad and Akt Signaling Pathways: An in vitro Study in LX2.
Topics: Actins; Animals; Biomarkers; Cell Proliferation; Cells, Cultured; Collagen Type I; Collagen Type I, alpha 1 Chain; Dose-Response Relationship, Drug; Hepatic Stellate Cells; Ki-67 Antigen; Male; Niacinamide; Phenylurea Compounds; Plasminogen Activator Inhibitor 1; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; Smad3 Protein; Sorafenib; Tissue Inhibitor of Metalloproteinase-1; Transforming Growth Factor beta; Xanthones | 2018 |
Cost-effectiveness analysis of transcatheter arterial chemoembolization with or without sorafenib for the treatment of unresectable hepatocellular carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analysis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Quality-Adjusted Life Years; Sorafenib | 2017 |
Cost-effectiveness analysis of treatment with non-curative or palliative intent for hepatocellular carcinoma in the real-world setting.
Topics: Aged; Aged, 80 and over; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Cost-Benefit Analysis; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Palliative Care; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2017 |
Increasing AR by HIF-2α inhibitor (PT-2385) overcomes the side-effects of sorafenib by suppressing hepatocellular carcinoma invasion via alteration of pSTAT3, pAKT and pERK signals.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Hep G2 Cells; Humans; Indans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Promoter Regions, Genetic; Proto-Oncogene Proteins c-akt; Receptors, Androgen; Sorafenib; STAT3 Transcription Factor; Sulfones | 2017 |
Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Female; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Histone-Lysine N-Methyltransferase; Humans; Liver Neoplasms; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Sorafenib; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
The treatment path in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Clinical Trials as Topic; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Sorafenib; Survival Rate | 2017 |
Rhabdomyosarcoma cells are susceptible to cell death by LDK378 alone or in combination with sorafenib independently of anaplastic lymphoma kinase status.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Drug Synergism; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Rhabdomyosarcoma; Sorafenib; Sulfones | 2017 |
Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Recepto
Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Cells, Cultured; Dose-Response Relationship, Drug; Echocardiography; ErbB Receptors; Erlotinib Hydrochloride; Fatty Acids; Female; Gene Expression Profiling; Heart; Heart Diseases; Indoles; Mice; Molecular Targeted Therapy; Myocardial Contraction; Myocardium; Myocytes, Cardiac; Niacinamide; Oxidation-Reduction; Phenylurea Compounds; Protein Interaction Maps; Protein Kinase Inhibitors; Proteomics; Pyrroles; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; STAT3 Transcription Factor; Sunitinib; Time Factors | 2017 |
Predominance of regorafenib over sorafenib: Restoration of membrane-bound MICA in hepatocellular carcinoma cells.
Topics: ADAM Proteins; ADAM10 Protein; Amyloid Precursor Protein Secretases; Carcinoma, Hepatocellular; Depression, Chemical; Gene Expression; Hep G2 Cells; Hepatitis C, Chronic; Histocompatibility Antigens Class I; Humans; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Pyridines; RNA, Messenger; Solubility; Sorafenib | 2018 |
Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Germany; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Recurrence; Remission Induction; Retrospective Studies; Risk Factors; Sorafenib; Stem Cell Transplantation; Tandem Repeat Sequences; Time Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Child; Drug Resistance, Neoplasm; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Phosphoproteins; Sorafenib; Transfection; Young Adult | 2017 |
Reply to: "Predictors of sorafenib benefit in patients with hepatocellular carcinoma".
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2018 |
Predictors of sorafenib benefit in patients with hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2018 |
Leg ulcers associated with cutaneous vascular degeneration in a patient receiving pazopanib chemotherapy.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Indazoles; Kidney Neoplasms; Leg Ulcer; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides | 2017 |
Liver resection for hepatocellular carcinoma in patients with hematological malignancies.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Biomarkers; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Disease-Free Survival; Female; Hematologic Neoplasms; Hepacivirus; Hepatectomy; Hepatitis B; Hepatitis B virus; Hepatitis C; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Niacinamide; Patient Selection; Phenylurea Compounds; Postoperative Complications; Prognosis; Retrospective Studies; Serologic Tests; Sorafenib; Survival Rate; Young Adult | 2017 |
Use of Ultrasmall Superparamagnetic Iron Oxide Enhanced Susceptibility Weighted Imaging and Mean Vessel Density Imaging to Monitor Antiangiogenic Effects of Sorafenib on Experimental Hepatocellular Carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Hepatocellular; Ferric Compounds; Heterografts; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Mice; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib | 2017 |
Codelivery of sorafenib and GPC3 siRNA with PEI-modified liposomes for hepatoma therapy.
Topics: Animals; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Combined Modality Therapy; Drug Delivery Systems; Drug Resistance, Neoplasm; Gene Transfer Techniques; Glypicans; Hep G2 Cells; Humans; Liposomes; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib | 2017 |
Co-delivery of sorafenib and siVEGF based on mesoporous silica nanoparticles for ASGPR mediated targeted HCC therapy.
Topics: Antineoplastic Agents; Apoptosis; Asialoglycoprotein Receptor; Carcinoma, Hepatocellular; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Liberation; Humans; Liver Neoplasms; Nanoparticles; Niacinamide; Phenylurea Compounds; RNA Interference; RNA, Small Interfering; Silicon Dioxide; Sorafenib; Vascular Endothelial Growth Factor A | 2018 |
Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Combined Modality Therapy; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pneumonectomy; Sorafenib; Survival Rate; Time Factors; Treatment Outcome | 2018 |
Potential Visualization of Sorafenib-Induced Acidosis Using 11C-Acetate PET/CT in Patients With Hepatocellular Carcinoma.
Topics: Acetates; Acidosis; Aged, 80 and over; Carbon Radioisotopes; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Sorafenib | 2018 |
Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cell Nucleus; Cell Survival; Cetuximab; Colorectal Neoplasms; Curcumin; Dasatinib; Drug Resistance, Neoplasm; Fatty Acids, Unsaturated; Female; Fluorouracil; Gene Silencing; HCT116 Cells; HT29 Cells; Humans; Leucovorin; Male; Middle Aged; Molecular Chaperones; Molecular Targeted Therapy; Niacinamide; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Phenylurea Compounds; Protein Inhibitors of Activated STAT; Protein Transport; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; Sorafenib | 2017 |
Topics: Carcinoma, Hepatocellular; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Retrospective Studies; Sorafenib; Treatment Outcome | 2018 |
Utility of Cremophor RH 40 as a micellar improvement for spectrofluorimetric estimation of sorafenib in pure form, commercial preparation, and human plasma.
Topics: Antineoplastic Agents; Fluorescence; Humans; Limit of Detection; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Sorafenib; Spectrometry, Fluorescence | 2018 |
Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Decision-Making; Disease Progression; Disease-Free Survival; Egypt; Female; Hand-Foot Syndrome; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Risk Factors; Sorafenib; Time Factors; Treatment Outcome; Young Adult | 2018 |
Evaluation of renal function change during first-line tyrosine kinase inhibitor therapy for metastatic renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Disease-Free Survival; Female; Glomerular Filtration Rate; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrroles; Sorafenib; Sunitinib | 2017 |
ABCG2-mediated suppression of chlorin e6 accumulation and photodynamic therapy efficiency in glioblastoma cell lines can be reversed by KO143.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Cell Survival; Chlorophyllides; Diketopiperazines; Doxycycline; Gene Expression; Glioblastoma; Heterocyclic Compounds, 4 or More Rings; Humans; Light; Niacinamide; Phenylurea Compounds; Photosensitizing Agents; Porphyrins; Sorafenib | 2018 |
Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Expression Regulation, Neoplastic; Ginsenosides; Hep G2 Cells; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Signal Transduction; Sorafenib | 2018 |
A biomaterial screening approach reveals microenvironmental mechanisms of drug resistance.
Topics: Animals; Antineoplastic Agents; Benzamides; Biocompatible Materials; Cell Communication; Cell Line, Tumor; Diphenylamine; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Extracellular Matrix; Female; Humans; Hydrogels; Hydrogen; Linear Models; MAP Kinase Kinase Kinases; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Niacinamide; Phenylurea Compounds; Phosphoproteins; Phosphorylation; Plastics; Sorafenib; Spheroids, Cellular; Systems Biology; Transcriptome; Tumor Microenvironment | 2017 |
miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Humans; Mice, Nude; MicroRNAs; Nanoparticles; Niacinamide; Phenylurea Compounds; Sorafenib; Stomach Neoplasms; Tretinoin | 2017 |
Association of liver cirrhosis severity with type 2 diabetes mellitus in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Diabetes Mellitus, Type 2; Female; Humans; Incidence; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Severity of Illness Index; Sorafenib | 2018 |
Functional Characterization of VEGF- and FGF-induced Tumor Blood Vessel Models in Human Cancer Xenografts.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Deoxycytidine; Dose-Response Relationship, Drug; Fibroblast Growth Factors; Gemcitabine; Humans; Immunohistochemistry; Mice; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2017 |
Capsaicin enhances the antitumor activity of sorafenib in hepatocellular carcinoma cells and mouse xenograft tumors through increased ERK signaling.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Capsaicin; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Female; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Transcatheter arterial chemoembolization after stopping sorafenib therapy for advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome | 2017 |
Augmentation of Anticancer Drug Efficacy in Murine Hepatocellular Carcinoma Cells by a Peripherally Acting Competitive N-Methyl-d-aspartate (NMDA) Receptor Antagonist.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Discovery; Drug Resistance, Multiple; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Receptors, N-Methyl-D-Aspartate; Sorafenib | 2017 |
Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer.
Topics: Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Cell Line, Tumor; Chloroquine; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Differential effects of hepatic cirrhosis on the intrinsic clearances of sorafenib and imatinib by CYPs in human liver.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Female; Humans; Imatinib Mesylate; Infant; Infant, Newborn; Liver Cirrhosis; Male; Metabolic Clearance Rate; Microsomes, Liver; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2018 |
Development of a validated liquid chromatographic method for quantification of sorafenib tosylate in the presence of stress-induced degradation products and in biological matrix employing analytical quality by design approach.
Topics: Chromatography, High Pressure Liquid; Drug Stability; Humans; Hydrolysis; Limit of Detection; Linear Models; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sorafenib | 2018 |
High mobility group box 1 promotes sorafenib resistance in HepG2 cells and in vivo.
Topics: Animals; Carcinoma, Hepatocellular; Cytosol; Down-Regulation; Drug Resistance, Neoplasm; Gene Knockdown Techniques; Hep G2 Cells; HMGB1 Protein; Humans; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitochondria; Niacinamide; Phenylurea Compounds; Protein Transport; RNA, Small Interfering; Sorafenib; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.
Topics: Administration, Metronomic; Aged; Antimetabolites, Antineoplastic; Capecitabine; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Retrospective Studies; Sorafenib; Survival Rate | 2018 |
Survival pathway of cholangiocarcinoma via AKT/mTOR signaling to escape RAF/MEK/ERK pathway inhibition by sorafenib.
Topics: Bile Duct Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Resistance, Neoplasm; Drug Synergism; Everolimus; Forkhead Box Protein O1; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2018 |
Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cytokines; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2017 |
Wild type Kirsten rat sarcoma is a novel microRNA-622-regulated therapeutic target for hepatocellular carcinoma and contributes to sorafenib resistance.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Culture Techniques; Humans; Liver Neoplasms; MicroRNAs; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins p21(ras); Sorafenib | 2018 |
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Axitinib; Carcinoma, Papillary; Disease-Free Survival; Female; Humans; Imidazoles; Indazoles; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Sorafenib; Survival Rate; Thyroid Neoplasms; Treatment Outcome | 2018 |
The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Female; Fibroblast Growth Factor 4; Hepatectomy; Hepatitis B; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Salvage Therapy; Sorafenib; Survival Rate | 2018 |
The Safety and Efficacy of Combination Therapy of Sorafenib and Radiotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Radiation Dosage; Radiotherapy, Conformal; Retrospective Studies; Sorafenib; Survival Analysis | 2018 |
A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs.
Topics: Angiogenesis Inhibitors; Biological Assay; Blood Vessels; Gene Knockdown Techniques; Human Umbilical Vein Endothelial Cells; Humans; Indoles; Microvessels; Models, Biological; Neovascularization, Physiologic; Niacinamide; Phenylurea Compounds; Pyrroles; Signal Transduction; Sorafenib; Sunitinib; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A | 2018 |
Glycaemic adverse drug reactions from anti-neoplastics used in treating pancreatic cancer.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Blood Glucose; China; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Female; Gemcitabine; Humans; Hyperglycemia; Incidence; Male; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Registries; Sorafenib | 2017 |
The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow.
Topics: Antineoplastic Agents; Bone Marrow Cells; CD8 Antigens; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocytes; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Programmed Cell Death 1 Receptor; Recurrence; Sorafenib; Transplantation, Homologous | 2018 |
miR‑378a enhances the sensitivity of liver cancer to sorafenib by targeting VEGFR, PDGFRβ and c‑Raf.
Topics: Adult; Antagomirs; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Female; Hep G2 Cells; Humans; Liver Neoplasms; Male; Matrix Metalloproteinase 2; MicroRNAs; Middle Aged; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Receptor, Platelet-Derived Growth Factor beta; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib | 2018 |
Effect of histidine on sorafenib-induced vascular damage: Analysis using novel medaka fish model.
Topics: Animals; Antineoplastic Agents; Blood Flow Velocity; Blood Vessels; Carcinoma, Hepatocellular; Histidine; Humans; Liver Neoplasms; Niacinamide; Oryzias; Phenylurea Compounds; Sorafenib | 2018 |
Mechanisms of mitochondrial toxicity of the kinase inhibitors ponatinib, regorafenib and sorafenib in human hepatic HepG2 cells.
Topics: Adenosine Triphosphate; Animals; Apoptosis; Cytochromes c; Electron Transport; Hep G2 Cells; Humans; Imidazoles; Lysosomes; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Mitophagy; Necrosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridazines; Pyridines; Sorafenib | 2018 |
Wee1 inhibitor MK1775 sensitizes KRAS mutated NSCLC cells to sorafenib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Humans; Lung Neoplasms; Mutation; Niacinamide; Nuclear Proteins; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyrimidines; Pyrimidinones; Sorafenib | 2018 |
Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer.
Topics: Carcinoma, Hepatocellular; Cell Survival; Elastic Modulus; Exome; Fluorescent Antibody Technique; Humans; Hydrogels; Liver Neoplasms; Niacinamide; Organoids; Phenylurea Compounds; Porosity; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma: A retrospective, multi-institutional cohort study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Costs; Drug Prescriptions; Female; Gastroenterologists; Humans; Liver Neoplasms; Male; Medical Oncology; Middle Aged; Niacinamide; Phenylurea Compounds; Practice Patterns, Physicians'; Retrospective Studies; Sorafenib; United States | 2018 |
Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Mice, SCID; Niacinamide; Phenylurea Compounds; Pregnane X Receptor; Protein Kinase Inhibitors; Receptors, Steroid; RNA Interference; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
CXCR1 expression predicts benefit from tyrosine kinase inhibitors therapy in patients with metastatic renal cell carcinoma.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Renal Cell; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Pyrroles; Receptors, Interleukin-8A; Retrospective Studies; Sorafenib; Sunitinib; Survival Rate | 2018 |
Sorafenib and fluvastatin synergistically alleviate hepatic fibrosis via inhibiting the TGFβ1/Smad3 pathway.
Topics: Animals; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Fatty Acids, Monounsaturated; Fluvastatin; Hepatic Stellate Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kupffer Cells; Liver Cirrhosis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rats; Real-Time Polymerase Chain Reaction; Smad3 Protein; Sorafenib; Transforming Growth Factor beta1 | 2018 |
Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin.
Topics: Animals; Antineoplastic Agents; Carcinogenesis; Carcinoma, Hepatocellular; Glycolysis; Hep G2 Cells; Hexokinase; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Mechanistic Target of Rapamycin Complex 1; Metabolic Flux Analysis; Metformin; Mice, Nude; Molecular Targeted Therapy; Niacinamide; Oxidative Phosphorylation; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Disease Progression; Female; Follow-Up Studies; Hepatectomy; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome; Young Adult | 2018 |
Early prediction of survival in hepatocellular carcinoma patients treated with transarterial chemoembolization plus sorafenib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Patient Selection; Phenylurea Compounds; Portal Vein; Prognosis; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Thrombosis; Young Adult | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2018 |
Negative phase 3 study of
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Sorafenib; Yttrium Radioisotopes | 2018 |
Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Transport; Dogs; Drug Interactions; Drug Resistance, Neoplasm; Flavonoids; LLC-PK1 Cells; Madin Darby Canine Kidney Cells; Male; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Swine; Tissue Distribution | 2018 |
Comparison of Outcome of Hepatic Arterial Infusion Chemotherapy Combined with Radiotherapy and Sorafenib for Advanced Hepatocellular Carcinoma Patients with Major Portal Vein Tumor Thrombosis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Female; Fluorouracil; Hepatic Artery; Humans; Infusions, Intra-Arterial; Interferons; Liver Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Niacinamide; Phenylurea Compounds; Portal Vein; Radiotherapy, Conformal; Retrospective Studies; Sorafenib; Survival Rate | 2018 |
Downregulation of secreted clusterin potentiates the lethality of sorafenib in hepatocellular carcinoma in association with the inhibition of ERK1/2 signals.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Clusterin; Gene Silencing; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; RNA, Small Interfering; Sorafenib | 2018 |
Strong enhancement by IGF1-R antagonists of hepatocellular carcinoma cell migration inhibition by Sorafenib and/or vitamin K1.
Topics: Actin Cytoskeleton; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Extracellular Signal-Regulated MAP Kinases; Humans; Imidazoles; Insulin-Like Growth Factor I; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Pyrroles; Sorafenib; Vitamin K 1 | 2018 |
Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Propensity Score; Retrospective Studies; Sorafenib; Survival Rate; Treatment Outcome | 2018 |
Skull Base Metastasis From Occult Renal Cell Carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Everolimus; Humans; Immunotherapy; Indoles; Kidney Neoplasms; Male; Neoplasms, Unknown Primary; Nephrectomy; Niacinamide; Phenylurea Compounds; Pyrroles; Skull Base Neoplasms; Sorafenib; Sunitinib | 2018 |
Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Retrospective Studies; Safety; Sorafenib; Treatment Outcome | 2018 |
Is Sorafenib an Optimal Treatment for Hepatocellular Carcinoma With Macrovascular Invasion or Metastatic Disease?
Topics: Adult; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2018 |
Determinants of survival following hepatocellular carcinoma in Egyptian patients with untreated chronic HCV infection in the pre-DAA era.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Comorbidity; Egypt; Female; Hepatitis C, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Risk Factors; Sorafenib; Survival Analysis | 2018 |
Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Homeodomain Proteins; Immunity, Cellular; Lymphocytes; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Polyesters; Polyethylene Glycols; Sorafenib | 2018 |
Effectiveness and the strategy to treat the side effects of sorafenib administration after transarterial chemoembolization in advanced hepatocellular carcinoma patients.
Topics: Adult; Aftercare; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis; Treatment Outcome | 2018 |
Treatment of advanced hepatocellular carcinoma: beyond sorafenib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Controlled Clinical Trials as Topic; Disease Progression; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Survival Analysis | 2018 |
Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Butadienes; Cell Survival; Drug Carriers; Drug Liberation; Erythrocytes; Hemolysis; Hep G2 Cells; Humans; Inhibitory Concentration 50; Male; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Polyethylene; Protein Kinase Inhibitors; Sorafenib | 2018 |
Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Disease Progression; Female; Follow-Up Studies; Humans; Liver Neoplasms; Male; Middle Aged; Models, Statistical; Niacinamide; Phenylurea Compounds; Prognosis; Prospective Studies; Sorafenib; Survival Rate | 2018 |
Trials that say "maybe": the disconnect between exploratory and confirmatory testing after drug approval.
Topics: Antineoplastic Agents; Calcium Channel Blockers; Clinical Trials as Topic; Drug Approval; Drug Industry; Humans; Indoles; Niacinamide; Phenylurea Compounds; Pregabalin; Pyrroles; Sorafenib; Sunitinib | 2018 |
Treatment of hepatocellular carcinoma: a cost analysis of yttrium-90 transarterial radioembolization versus sorafenib.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cost-Benefit Analysis; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Yttrium Radioisotopes | 2018 |
Advanced Hepatocellular Carcinoma: Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Liver; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Predictive Value of Tests; Radiographic Image Enhancement; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Amentoflavone Enhances the Therapeutic Efficacy of Sorafenib by Inhibiting Anti-apoptotic Potential and Potentiating Apoptosis in Hepatocellular Carcinoma
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biflavonoids; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Humans; Liver Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Evaluation of survival of patients with hepatocellular carcinoma: A comparative analysis of prognostic systems.
Topics: Aged; alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Survival Rate; Tomography, X-Ray Computed | 2018 |
Synergistic anti-hepatoma effect of bufalin combined with sorafenib via mediating the tumor vascular microenvironment by targeting mTOR/VEGF signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bufanolides; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; Drug Synergism; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2018 |
Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Competence; Diagnostic Errors; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Observer Variation; Phenylurea Compounds; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Sorafenib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2018 |
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheterization, Peripheral; Chemoembolization, Therapeutic; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver Neoplasms; Male; Microvessels; Neoplasm Invasiveness; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2018 |
Enhanced oral absorption of sorafenib via the layer-by-layer deposition of a pH-sensitive polymer and glycol chitosan on the liposome.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Caco-2 Cells; Cell Survival; Chitosan; Humans; Hydrogen-Ion Concentration; Intestinal Absorption; Liposomes; Male; Niacinamide; Phenylurea Compounds; Polymethacrylic Acids; Protein Kinase Inhibitors; Rats, Sprague-Dawley; Sorafenib | 2018 |
Monocarboxylate transporters MCT1 and MCT4 are independent prognostic biomarkers for the survival of patients with clear cell renal cell carcinoma and those receiving therapy targeting angiogenesis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Renal Cell; Cohort Studies; Female; Follow-Up Studies; Humans; Indoles; Kidney Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Monocarboxylic Acid Transporters; Muscle Proteins; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyrroles; Sorafenib; Sunitinib; Survival Rate; Symporters; Vascular Endothelial Growth Factor A | 2018 |
Molecular Interaction and Computational Analytical Studies of Pinocembrin for its Antiangiogenic Potential Targeting VEGFR-2: A Persuader of Metastasis.
Topics: Angiogenesis Inhibitors; Asteraceae; Benzamides; Flavanones; HSP90 Heat-Shock Proteins; Ligands; Molecular Docking Simulation; Molecular Dynamics Simulation; Niacinamide; Phenylurea Compounds; Picolinic Acids; Protein Binding; Sorafenib; Thermodynamics; Vascular Endothelial Growth Factor Receptor-2 | 2018 |
Rupture of a Small Hepatocellular Carcinoma in a Stable Disease State in a Patient Receiving Sorafenib Treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Rupture; Sorafenib; Treatment Outcome | 2018 |
Medium or Large Hepatocellular Carcinoma: Sorafenib Combined with Transarterial Chemoembolization and Radiofrequency Ablation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Catheter Ablation; Chemoembolization, Therapeutic; Combined Modality Therapy; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2018 |
Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bufanolides; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Humans; Male; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells.
Topics: Activating Transcription Factor 2; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gene Silencing; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase 10; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; RNA, Small Interfering; Sorafenib; Tumor Necrosis Factor-alpha | 2018 |
Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinoma, Hepatocellular; Diterpenes; Endoplasmic Reticulum Chaperone BiP; Humans; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Phosphoproteins; Sorafenib; Transcription Factors; YAP-Signaling Proteins | 2018 |
Comparison of clinical outcomes between sorafenib and hepatic artery infusion chemotherapy in advanced hepatocellular carcinoma: A STROBE-compliant article.
Topics: Adult; Antineoplastic Agents; Bilirubin; Carcinoma, Hepatocellular; Disease-Free Survival; Female; Hepatic Artery; Humans; Infusions, Intra-Arterial; International Normalized Ratio; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Risk Factors; Sorafenib; Treatment Outcome | 2018 |
Cost-Effectiveness of Sorafenib Monotherapy and Selected Combination Therapy with Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Combined Modality Therapy; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Liver Neoplasms; Male; Middle Aged; Models, Statistical; Niacinamide; Phenylurea Compounds; Quality-Adjusted Life Years; Sorafenib; Taiwan | 2018 |
Preparation of an efficient and safe polymeric-magnetic nanoparticle delivery system for sorafenib in hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Biological Availability; Cell Survival; Drug Delivery Systems; Hep G2 Cells; Humans; Liver Neoplasms; Liver Neoplasms, Experimental; Magnetite Nanoparticles; Male; Neoplasm Proteins; Niacinamide; Particle Size; Phenylurea Compounds; Polyvinyl Alcohol; Rats; Rats, Wistar; Sorafenib | 2018 |
Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Treatment Outcome | 2018 |
[Sorafenib combined with chemotherapy and donor lymphocyte infusion as salvage therapy in patients with FLT3-positive acute myeloid leukemia relapse after allogeneic hematopoietic stem cell transplantation].
Topics: Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Recurrence; Remission Induction; Salvage Therapy; Sorafenib; Transplantation, Homologous; Treatment Outcome | 2018 |
Hand-foot-skin reaction related to use of the multikinase inhibitor sorafenib and hard orthotics.
Topics: Child; Diagnosis, Differential; Fluocinolone Acetonide; Glucocorticoids; Hand-Foot Syndrome; Humans; Male; Niacinamide; Orthotic Devices; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib | 2018 |
Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Topics: Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Self Renewal; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Humans; Kruppel-Like Factor 4; Liver Neoplasms; Neoplastic Stem Cells; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-akt; Signal Transduction; Silybin; Silymarin; Sorafenib; STAT3 Transcription Factor | 2018 |
Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer.
Topics: Antineoplastic Agents; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Male; Neoadjuvant Therapy; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Cancer, Papillary; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed; Treatment Outcome; Young Adult | 2018 |
[Hepatocellular Carcinoma: New multimodal therapy concepts].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Clinical Trials as Topic; Combined Modality Therapy; Humans; Liver Neoplasms; Liver Transplantation; Niacinamide; Phenylurea Compounds; Sorafenib | 2018 |
Niclosamide Exhibits Potent Anticancer Activity and Synergizes with Sorafenib in Human Renal Cell Cancer Cells.
Topics: Carcinoma, Renal Cell; Cell Cycle; Drug Synergism; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Kidney Neoplasms; Neoplasm Proteins; Niacinamide; Niclosamide; Phenylurea Compounds; PTEN Phosphohydrolase; Sorafenib | 2018 |
Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Phosphatidylethanolamine Binding Protein; Protein Kinase Inhibitors; Sorafenib; Tumor Cells, Cultured | 2018 |
Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cyclin D1; Diethylnitrosamine; Fosinopril; Liver Neoplasms, Experimental; Losartan; Male; Matrix Metalloproteinase 2; Mice; NF-kappa B; NF-KappaB Inhibitor alpha; Niacinamide; Perindopril; Phenylurea Compounds; Phosphorylation; Renin-Angiotensin System; Signal Transduction; Sorafenib; Time Factors; Transcription Factor RelA; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha; Vascular Endothelial Growth Factor A | 2018 |
[Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Diarrhea; Disease Progression; Disease-Free Survival; Hand-Foot Syndrome; Humans; Indoles; Kidney Neoplasms; Multivariate Analysis; Neutropenia; Niacinamide; Phenylurea Compounds; Prognosis; Proportional Hazards Models; Pyrroles; Retrospective Studies; Risk Factors; Sorafenib; Sunitinib; Thrombocytopenia; Treatment Outcome | 2018 |
[Evaluation of cryptotanshinone inhibition of angiogenesis in human hepatic sinusoidal endothelial cells].
Topics: Animals; Animals, Genetically Modified; Cell Proliferation; Cells, Cultured; Down-Regulation; Drugs, Chinese Herbal; Endothelial Cells; Humans; Neovascularization, Pathologic; Niacinamide; Nitric Oxide; Phenanthrenes; Phenylurea Compounds; Salvia miltiorrhiza; Sorafenib; von Willebrand Factor; Zebrafish | 2016 |
Sequence‑dependent effect of sorafenib in combination with natural phenolic compounds on hepatic cancer cells and the possible mechanism of action.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; Drug Therapy, Combination; Fibroblasts; Humans; Inhibitory Concentration 50; Liver Neoplasms; Membrane Potential, Mitochondrial; Niacinamide; Phenols; Phenylurea Compounds; Sorafenib | 2018 |
Anti-GPC3 antibody-modified sorafenib-loaded nanoparticles significantly inhibited HepG2 hepatocellular carcinoma.
Topics: Animals; Antibodies; Antineoplastic Agents; Caproates; Carcinoma, Hepatocellular; Cell Line, Tumor; Glypicans; Hep G2 Cells; Humans; Lactones; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Niacinamide; Phenylurea Compounds; Polyethylene Glycols; Polymers; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
The excellent antitumor effect of apatinib alone as second-line therapy in a patient with sorafenib-refractory hepatocellular carcinoma: A case report.
Topics: Adult; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Disease Progression; Fatal Outcome; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tomography, X-Ray Computed | 2018 |
Sorafenib and praziquantel synergistically attenuate Schistosoma japonicum-induced liver fibrosis in mice.
Topics: Actins; Animals; Collagen Type I; Collagen Type III; Female; Liver; Liver Cirrhosis; Mice; Mice, Inbred BALB C; Niacinamide; Phenylurea Compounds; Platelet-Derived Growth Factor; Praziquantel; Receptor, Platelet-Derived Growth Factor beta; Schistosoma japonicum; Schistosomiasis japonica; Sorafenib | 2018 |
Melatonin Synergizes with Sorafenib to Suppress Pancreatic Cancer via Melatonin Receptor and PDGFR-β/STAT3 Pathway.
Topics: Cell Line, Tumor; Drug Synergism; Humans; Melatonin; Neoplasm Proteins; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Receptor, Platelet-Derived Growth Factor alpha; Receptors, Melatonin; Signal Transduction; Sorafenib; STAT3 Transcription Factor | 2018 |
Efficacy and Safety of Sorafenib in a Racially Diverse Patient Population with Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Disease Progression; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Population Groups; Retrospective Studies; Sorafenib; Survival Analysis; Treatment Outcome | 2018 |
Retrospective analysis on the efficacy of sunitinib/sorafenib in combination with dendritic cells-cytokine-induced killer in metastasis renal cell carcinoma after radical nephrectomy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Renal Cell; Combined Modality Therapy; Cytokine-Induced Killer Cells; Dendritic Cells; Female; Humans; Immunotherapy, Adoptive; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Postoperative Care; Pyrroles; Retrospective Studies; Sorafenib; Sunitinib; Survival Analysis; Treatment Outcome | 2018 |
[Simultaneous determination of donafenib and its N-oxide metabolite in human plasma by liquid chromatography-tandem mass spectrometry].
Topics: Antineoplastic Agents; Chromatography, Liquid; Humans; Niacinamide; Oxides; Phenylurea Compounds; Plasma; Protein Kinase Inhibitors; Reproducibility of Results; Sorafenib; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2017 |
Sorafenib for Advanced Hepatocellular Carcinoma: A Real-Life Experience.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Female; Humans; Kaplan-Meier Estimate; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Probability; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome | 2018 |
Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Berberine; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Drug Therapy, Combination; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Tumor Cells, Cultured | 2018 |
Multikinase inhibitor-associated hand-foot skin reaction as a predictor of outcomes in patients with hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Eruptions; Female; Foot; Hand; Humans; Incidence; Liver Neoplasms; Male; Medication Adherence; Middle Aged; Niacinamide; Pharmacists; Phenylurea Compounds; Protein Kinase Inhibitors; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Skin; Sorafenib; Survival Analysis; Treatment Failure | 2018 |
Inhibition of cFLIP overcomes acquired resistance to sorafenib via reducing ER stress‑related autophagy in hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Biomarkers, Tumor; Carcinoma, Hepatocellular; CASP8 and FADD-Like Apoptosis Regulating Protein; Cell Proliferation; Drug Resistance, Neoplasm; Endoplasmic Reticulum Stress; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; Tumor Cells, Cultured | 2018 |
Effects of toceranib compared with sorafenib on monocrotaline-induced pulmonary arterial hypertension and cardiopulmonary remodeling in rats.
Topics: Animals; Antihypertensive Agents; Arterial Pressure; Autophagy; Disease Models, Animal; Dose-Response Relationship, Drug; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Indoles; Male; Monocrotaline; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pulmonary Artery; Pyrroles; Rats, Wistar; Signal Transduction; Sorafenib; Vascular Remodeling; Ventricular Function, Right; Ventricular Remodeling | 2018 |
Aortic Dissection and Cardiac Dysfunction Emerged Coincidentally During the Long-Term Treatment with Angiogenesis Inhibitors for Metastatic Renal Cell Carcinoma.
Topics: Aged; Angiogenesis Inhibitors; Aortic Dissection; Axitinib; Carcinoma, Renal Cell; Heart Diseases; Humans; Imidazoles; Indazoles; Kidney Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Vascular Endothelial Growth Factor A | 2018 |
Influence of Sorafenib, Sunitinib and Capecitabine on the Antioxidant Status of the Skin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antioxidants; Capecitabine; Carotenoids; Female; Hand-Foot Syndrome; Humans; Indoles; Male; Middle Aged; Neoplasms; Niacinamide; Phenylurea Compounds; Pyrroles; Skin; Sorafenib; Sunitinib | 2018 |
Extracellular matrix collagen I promotes the tumor progression of residual hepatocellular carcinoma after heat treatment.
Topics: Animals; Carcinoma, Hepatocellular; Catheter Ablation; Cell Line, Tumor; Cell Movement; Cell Proliferation; Collagen Type I; Disease Progression; Epithelial-Mesenchymal Transition; Extracellular Matrix; Humans; Hyperthermia, Induced; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |
[Sustained Complete Response of Hepatocellular Carcinoma with Multiple Intrahepatic Metastases following the Discontinuation of Sorafenib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2019 |
Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor.
Topics: Carcinoma, Hepatocellular; Humans; Leukemia; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2019 |
[E26 transformation-specific variant 4 promotes sorafenib and cisplatin resistance in hepatocellular carcinoma cells
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Resistance, Neoplasm; Humans; Liver Neoplasms; Membrane Proteins; Niacinamide; Phenylurea Compounds; Sorafenib | 2019 |
A Prospective Study of Peritransplant Sorafenib for Patients with FLT3-ITD Acute Myeloid Leukemia Undergoing Allogeneic Transplantation.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Transplantation, Homologous | 2020 |
Sorafenib for Patients with Hepatocellular Carcinoma and Child-Pugh B Liver Cirrhosis: Lessons Learned from a Terminated Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2020 |
Design And Characterisation Of Novel Sorafenib-Loaded Carbon Nanotubes With Distinct Tumour-Suppressive Activity In Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Body Weight; Carcinoma, Hepatocellular; Cell Proliferation; Drug Compounding; Drug Design; Hep G2 Cells; Humans; Hydrogen-Ion Concentration; Liver; Liver Neoplasms; Male; Nanotubes, Carbon; Niacinamide; Rats, Wistar; Sorafenib; Spectroscopy, Fourier Transform Infrared; Static Electricity | 2019 |
Quercetin improves the effects of sorafenib on growth and migration of thyroid cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Niacinamide; Phenylurea Compounds; Quercetin; Sorafenib; Thyroid Neoplasms | 2020 |
Letter: are sorafenib-related adverse events associated with prolonged survival?
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2020 |
Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2020 |
Response to: Prognostication of HCC patients under sorafenib is not always possible.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2020 |
Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms.
Topics: Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2020 |
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Europe; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Renal Dialysis; Sorafenib; Treatment Outcome | 2020 |
The efficacy and safety of sorafenib in older adults with advanced hepatocellular carcinoma: An analysis of a majority Hispanic cohort.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Hispanic or Latino; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2020 |
s-HBEGF/SIRT1 circuit-dictated crosstalk between vascular endothelial cells and keratinocytes mediates sorafenib-induced hand-foot skin reaction that can be reversed by nicotinamide.
Topics: Aged; Aged, 80 and over; Animals; Disease Models, Animal; Endothelial Cells; Female; Foot; HaCaT Cells; Hand; Heparin-binding EGF-like Growth Factor; Humans; Keratinocytes; Keratosis; Male; Mice, Inbred ICR; Middle Aged; Mitogen-Activated Protein Kinase 9; Models, Biological; Niacinamide; Phosphorylation; Protein Stability; Sirtuin 1; Skin; Sorafenib | 2020 |
Exacerbation of psoriasis vulgaris by sorafenib treatment for hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Psoriasis; Sorafenib; Treatment Outcome | 2020 |
Association of Gastric Acid Suppression and Sorafenib Efficacy in Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Gastric Acid; Humans; Liver Neoplasms; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome; United Kingdom | 2021 |
Pancreatic Insufficiency in Patients Under Sorafenib Treatment for Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Exocrine Pancreatic Insufficiency; Female; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2021 |
Outcomes of sorafenib therapy in advanced hepatocellular carcinoma in a single center in Ethiopia.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Ethiopia; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2020 |
Bismuth-Based Mesoporous Nanoball Carrying Sorafenib for Computed Tomography Imaging and Synergetic Chemoradiotherapy of Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bismuth; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chemoradiotherapy; Liver Neoplasms; Mice; Niacinamide; Sorafenib | 2020 |
Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Pharmacogenetics; Phenylurea Compounds; Sorafenib | 2020 |
Topics: Adult; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Sorafenib | 2021 |
Predictive factors for long-term survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Male; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.
Topics: Antineoplastic Agents; Cell Line, Tumor; Clustered Regularly Interspaced Short Palindromic Repeats; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; TOR Serine-Threonine Kinases; Transcription Factors | 2022 |
Penile and scrotal infundibular cysts in an adolescent treated with sorafenib.
Topics: Adolescent; Carcinoma, Squamous Cell; Humans; Male; Niacinamide; Phenylurea Compounds; Skin Neoplasms; Sorafenib | 2021 |
Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Sorafenib | 2021 |
Evaluation of cardiovascular events in patients with hepatocellular carcinoma treated with sorafenib in the clinical practice. The CARDIO-SOR study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cardiovascular Diseases; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Fibrinogen-Like Protein 1 Modulates Sorafenib Resistance in Human Hepatocellular Carcinoma Cells.
Topics: Apoptosis; Autophagy; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Fibrinogen; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Liver Neoplasms; MAP Kinase Signaling System; Niacinamide; Phenylurea Compounds; Signal Transduction; Sorafenib | 2021 |
Valuable insights from real-life experiences of advanced thyroid cancer treatment with sorafenib in Latin America.
Topics: Antineoplastic Agents; Humans; Latin America; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms | 2021 |
Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Treatment Outcome | 2021 |
Sorafenib-related generalized eruptive keratoacanthomas (Grzybowski syndrome): a case report.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Exanthema; Humans; Keratoacanthoma; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Skin Diseases; Sorafenib | 2021 |
Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Female; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sirtuin 2; Sorafenib; Synthetic Lethal Mutations; Xenograft Model Antitumor Assays | 2022 |
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Hepatectomy; Humans; Liver Neoplasms; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2022 |
Antitumor effects of rhamnazinon sorafenib-treated human hepatocellular carcinoma cell lines via modulation of VEGF signaling and PI3K/NF-κB p38/caspase-3 axes cross talk.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Caspase 3; Cell Line; Cell Line, Tumor; Cell Proliferation; Humans; Liver Neoplasms; NF-kappa B; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Sorafenib; Vascular Endothelial Growth Factor A | 2022 |
Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Line, Tumor; Dog Diseases; Dogs; Fibrosarcoma; Mice; Mice, Nude; Neovascularization, Pathologic; Niacinamide; Rodent Diseases; Sorafenib; Tumor Microenvironment; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prospective Studies; Retrospective Studies; Sorafenib; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2022 |
The Cost-Effectiveness of Selective Internal Radiation Therapies Compared With Sorafenib for Treating Advanced Unresectable Hepatocellular Carcinoma in the United Kingdom.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; United Kingdom | 2022 |
Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Nivolumab; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2023 |
Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
Topics: Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Combined Modality Therapy; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib | 2022 |
The Efficacy of Combined Therapy of Regorafenib with Detoxicating and Stasis Softening Chinese Herbal Spleen Tonics in Mid-/Late-Stage Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; China; Humans; Liver Neoplasms; Mice; Niacinamide; Phenylurea Compounds; Pyridines; Retrospective Studies; Sorafenib; Spleen; Vascular Endothelial Growth Factor A | 2022 |
Metformin Enhances the Anti-Cancer Efficacy of Sorafenib via Suppressing MAPK/ERK/Stat3 Axis in Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Liver Neoplasms; Metformin; Mice; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2022 |
Sorafenib maintenance after hematopoietic stem cell transplantation improves outcome of FLT3-ITD-mutated acute myeloid leukemia.
Topics: fms-Like Tyrosine Kinase 3; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Recurrence; Retrospective Studies; Sorafenib; Transplantation, Homologous | 2022 |
S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cysteine; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Lipoylation; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Phosphatidylinositol 3-Kinases; Proprotein Convertase 9; Proto-Oncogene Proteins c-akt; Sorafenib | 2022 |
FXYD5 promotes sorafenib resistance through the Akt/mTOR signaling pathway in hepatocellular carcinoma.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Ion Channels; Liver Neoplasms; Microfilament Proteins; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Signal Transduction; Sorafenib; TOR Serine-Threonine Kinases | 2022 |
[Sorafenib regulates vascular endothelial growth factor by runt-related transcription factor-3 to inhibit angiogenesis in hepatocellular carcinoma].
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Core Binding Factor Alpha 3 Subunit; Humans; Liver Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Sorafenib; Vascular Endothelial Growth Factor A | 2022 |
Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib; Treatment Outcome | 2022 |
Therapeutic efficacy of nivolumab plus sorafenib therapy in patients with unresectable hepatocellular carcinoma.
Topics: alpha-Fetoproteins; Antineoplastic Agents; Carcinoma, Hepatocellular; Humans; Immune Checkpoint Inhibitors; Liver Neoplasms; Niacinamide; Nivolumab; Phenylurea Compounds; Sorafenib | 2022 |
Ramucirumab combination with sorafenib enhances the inhibitory effect of sorafenib on HepG2 cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bevacizumab; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Hep G2 Cells; Humans; Liver Neoplasms; Matrix Metalloproteinase 9; Niacinamide; Panitumumab; Phenylurea Compounds; Ramucirumab; Sorafenib | 2022 |
Simultaneous treatment with sorafenib and glucose restriction inhibits hepatocellular carcinoma in vitro and in vivo by impairing SIAH1-mediated mitophagy.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Glucose; Humans; Liver Neoplasms; Mitophagy; Niacinamide; Sorafenib | 2022 |
Effect of Novel AKT Inhibitor Vevorisertib as Single Agent and in Combination with Sorafenib on Hepatocellular Carcinoma in a Cirrhotic Rat Model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Liver Cirrhosis; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats; Sorafenib | 2022 |
Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Liver Neoplasms; MAP Kinase Signaling System; Mice; Niacinamide; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Signal Transduction; Sorafenib | 2023 |
Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Prognosis; Retrospective Studies; Sorafenib; Treatment Outcome; Vascular Endothelial Growth Factor A | 2022 |
A Single Nucleotide Polymorphism rs1010816 Predicts Sorafenib Therapeutic Outcomes in Advanced Hepatocellular Carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Genome-Wide Association Study; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Single Nucleotide; Retrospective Studies; Sorafenib; Treatment Outcome | 2023 |
[The clinical safety and efficacy of the patients of acute myeloid leukemia with FLT3-ITD positive treated with sorafenib in combination with venetoclax and azactitidine regimen].
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Sulfonamides | 2022 |
Ca
Topics: Antineoplastic Agents; Apoptosis; Astrocytes; Cell Line, Tumor; Glioblastoma; Humans; Niacinamide; Phenylurea Compounds; Selenium; Sorafenib | 2023 |
Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Fibromatosis, Aggressive; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2023 |
Low Pi stress enhances the sensitivity of hepatocellular carcinoma to sorafenib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; Liver Neoplasms; Mice; Mice, Inbred Strains; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Sorafenib | 2023 |
Efficacy and safety analysis of TACE + Donafenib + Toripalimab versus TACE + Sorafenib in the treatment of unresectable hepatocellular carcinoma: a retrospective study.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Retrospective Studies; Sorafenib | 2023 |